,id,ticker,title,category,content,date,provider,url,article_id
141200,362715,HUM,Health insurers under pressure as Sanders takes lead in Iowa,news,"Health insurers are under modest pressure in apparent reaction to the news that Presidential candidate Bernie Sanders  I VT  has taken the lead in Iowa according to a poll conducted by CNN and The Des Moines Register 
Mr  Sanders was favored by 20  of would be caucusgoers followed by Elizabeth Warren  17    Pete Buttigieg  16   and Joe Biden  15   
Mr  Sanders  along with Ms  Warren  are advocates for a single payer U S  health system dubbed  Medicare for All  which would decimate the private health insurance market 
Selected tickers  eHealth  EHTH  1 9    WellCare Health Plans  WCG  0 8    UnitedHealth Group  UNH  1    Humana  HUM  1 1    Cigna  CI  2    Centene  CNC  1 8    Anthem  ANTM  2    CVS Health  CVS  0 7  ",2020-01-13,Seeking Alpha,https://invst.ly/phevi,2058098
141201,362716,HUM,Health Insurers Hit With Bernie Sanders Leading in Iowa,news,"Investing com   Health insurance stocks bucked the overall market trend Monday  falling as a recent poll of the Democratic field in Iowa showed Sen  Bernie Sanders in the lead 
On Friday  Selzer   Co  released a poll of likely voters in the Iowa caucuses that showed Sanders in the lead at 20  
Sanders was followed by Sen  Elizabeth Warren at 17   Pete Buttigieg at 16  and former Vice President Joe Biden at 15  
Sanders is a harsh critic of private health insurers and is running on a promise to provide a Medicare for All healthcare program 
That would be a  single payer  national health insurance program to provide everyone in America with comprehensive health care coverage  free at the point of service  with   n o networks  no premiums  no deductibles  no copays  no surprise bills   according to the candidate s website 
Among the insurers  Cigna  NYSE CI  fell 3 7   UnitedHealth  NYSE UNH  lost 3 1   Humana  NYSE HUM  was down 2 6  and Anthem  NYSE ANTM  dropped 3 2  
The iShares U S  Healthcare ETF  NYSE IYH  fell 1 7  ",2020-01-13,Investing.com,https://www.investing.com/news/stock-market-news/health-insurers-hit-with-bernie-sanders-leading-in-iowa-2058297,2058297
141202,362717,HUM,Should Value Investors Pick Humana  HUM  Stock Right Now ,opinion,"Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put  Humana  Inc    NYSE HUM   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Humana has a trailing twelve months PE ratio of 20 04  as you can see in the chart below  This level actually compares pretty favorably with the market at large  as the PE for the S P 500 compares in at about 20 83  If we focus on the stock s long term PE trend  the current level Humana puts current PE ratio below its midpoint  which is 22 38  over the past five years  Also  the stock s PE compares favorably with the Zacks Medical sector s trailing twelve months PE ratio  which stands at 23 54  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers  We should also point out that Humana has a forward PE ratio  price relative to this year s earnings  of 19 62  so it is fair to say that a slightly more value oriented path may be ahead for the stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  the stock has a P S ratio of about 0 78  This is a bit lower than the S P 500 average  which comes in at 3 60 right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years  If anything  this suggests some level of undervalued trading at least compared to historical norms    Broad Value OutlookIn aggregate  Humana currently has a Value Style Score of A  putting it into the top 20  of all stocks we cover from this look  This makes HUM a solid choice for value investors What About the Stock Overall 
Though Humana might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of A and a Momentum score of F  This gives HUM a VGM score or its overarching fundamental grade of A    You can read more about the Zacks Style Scores   Meanwhile  the company s recent earnings estimates have been mixed  The current quarter has seen two estimates go higher in the past sixty days compared to none lower  while current year estimate has seen two upward and one downward revision in the same time period This has had a noticeable impact on the consensus estimate as the current quarter consensus estimate has inched up 0 9  in the past two months  while current year estimate has not shown any earnings movement in the same time period  You can see the consensus estimate trend and recent price action for the stock in the chart below   Humana Inc  Price and Consensus   This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term Bottom LineHumana is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Moreover  a strong industry rank  Top 18  out of more than 250 industries  further supports the growth potential of the stock  In fact  over the past one year  the sector has clearly underperformed the broader market  as you can see below  So  value investors might want to wait for estimates  analyst sentiment and industry trend to turn favorable in this name first  but once that happen  this stock could be a compelling pick Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ",2020-01-21,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-pick-humana-hum-stock-right-now-200500536,200500536
141203,362718,HUM,What s In Store For HCA Healthcare s  HCA  Q4 Earnings ,opinion,HCA Healthcare  Inc    NYSE HCA   is scheduled to release fourth quarter 2019 results on Jan 28  In the last reported quarter  the company reported adjusted earnings of  2 23 per share  surpassing the Zacks Consensus Estimate by 4 2   Moreover  the bottom line inched up 3 2  year over year on the back of higher revenues Let s see  how things are shaping up prior to this announcement The company s fourth quarter earnings are likely to have been supported by a solid revenue stream on higher admissions and licensed beds  These factors have been driving its results over the last few quarters  a trend that most likely continued in the to be reported quarter The Zacks Consensus Estimate for earnings in the quarter to be reported is pegged at  3 06  indicating a 2 3  increase from the year ago reported figure The company s top line is expected to have been boosted by growth in admissions in the fourth quarter  The Zacks Consensus Estimate for revenues stands at  13 3 billion  suggesting an 8 5  rise from the prior year reported number The consensus mark for the total number of hospitals implies a 2 8  improvement from the year earlier reported figure  attributable to strategic acquisitions made by HCA Healthcare The Zacks Consensus Estimate for admissions and equivalent admissions hints at respective growth of 7  and 5 8  from the year ago reported numbers  driven by network expansion moves by HCA Healthcare The consensus estimate for fourth quarter patient days indicates a 6 6  upside from the year ago reported number The Zacks Consensus Estimate for the licensed number of beds is pegged at 48 6 million  implying a 3  improvement from the prior year reported figure  This uptrend might have been boosted by the rising number of hospitals Share repurchases made by the company in the to be reported quarter are likely to have aided its bottom line HCA Healthcare s steady generation of cash flow is also likely to be seen in the to be reported results However  the company might have slightly taken a hit from elevated expenses because of growth related investments and operating costs What the Quantitative Model StatesOur proven model doesn t conclusively predict an earnings beat for HCA Healthcare this time around  This is because the stock needs to have the right combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to increase the odds of a positive surprise  You can see Earnings ESP  HCA Healthcare has an Earnings ESP of 0 00   This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at  3 06  You can uncover the best stocks to buy or sell before they are reported with our  HCA Healthcare  Inc  Price and EPS Surprise   Zacks Rank  HCA Healthcare has a Zacks Rank of  3  which increases the predictive power of ESP  However  its 0 00  Earnings ESP makes surprise prediction difficult Stocks to ConsiderSome stocks worth considering from the medical sector with the perfect mix of elements to surpass estimates in the next releases are as follows Humana Inc    NYSE HUM   has an Earnings ESP of  0 15  and a Zacks Rank of 3  The company is set to report fourth quarter earnings numbers on Feb 5 Molina Healthcare  Inc   NYSE MOH   has an Earnings ESP of  0 48   This Zacks  3 Ranked company is set to report fourth quarter earnings performance on Feb 10 Teladoc Health  Inc    NYSE TDOC   is slated to release fourth quarter financial figures on Feb 26  The stock has an Earnings ESP of  17 56  and is  3 Ranked The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2020-01-22,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-hca-healthcares-hca-q4-earnings-200501071,200501071
141204,362719,HUM,Goldman Sachs  3 Healthcare Stocks to Snap Up Now,opinion,Stuck for fresh investing inspiration  You re not alone  After the stock market s record breaking performance in 2019  plenty of uncertainty lingers on Wall Street as we go forward into 2020  The U S  presidential election coupled with new fears related to the spread of the coronavirus  which pushed the S P 500 down 1 6  yesterday  have driven concerns that 2020 will see its fair share of volatility Against this backdrop  investment banking giant Goldman Sachs published a report containing valuable insights  Highlighting the healthcare services sector in particular  the firm notes that while it anticipates fourth quarter results will fall in line with expectations  the key area to watch is 2020 guidance  We believe 2020 outlooks will matter more  and see some potential for these updates to be overshadowed by political developments   speci cally  upcoming Democratic primaries  where investors seem braced for a win  or two  by Senator Sanders  a Democratic candidate who supports the elimination of private health insurance   analyst Stephen Tanal explained To this end  the analyst argues that any weakness in the firm s Buy rated managed care organizations  MCOs  will present investors with an attractive entry point Bearing this in mind   we ve pulled up three of Goldman s recent stock picks  and run them through TipRanks  Stock Comparison tool to confirm that Goldman is in the majority on Wall Street in recommending these equities   Based on the information provided by the platform  each of the names has also garnered substantial support from other analysts  enough to earn a  Strong Buy  consensus rating Humana Inc   HUM Healthcare is at the core of everything for medical insurance company Humana  whose goal is to not only improve healthcare  but also make it more accessible  While the company is off to a rocky start in 2020  Goldman Sachs believes several positives are in store Tanal points to the permanent repeal of the health insurance fee  HIF   which will go into effect in 2021  as standing to benefit HUM  According to the analyst  the repeal  will have a disproportionately positive impact on HUM s earnings given its group high exposure to Medicare Advantage   He added   We expect out year estimates to rise post 4Q and in the coming n months  as it appears that most sell side analysts have undershot the likely bene t of the repeal of the HIF  Even though Tanal acknowledges that the company could face headwinds related to higher reimbursement rates for dialysis patients on Medicare Advantage plans  he estimates that the repeal will cover the headwind by a double digit multiple Adding to the good news  Humana s fourth quarter results are expected to be favorable   We are comfortable with 4Q  too  At our recent healthcare CEO conference  HUM s CEO noted that investors should not be overly concerned by the potential impact of the most widespread  u season in years   Tanal wrote With the stock trading at a 9  discount to the S P 500  it seals the deal for Tanal  Given all that HUM has going for it  the analyst not only kept the rating as a Buy  but also added the name to the firm s Conviction List  In addition  the  425 price target implies that shares could climb 23  higher in the next twelve months   To watch Tanal s track record  click here Turning now to the rest of the Street  analysts are generally on board with HUM  14 Buy ratings and 4 Holds assigned in the last three months add up to a Strong Buy Street consensus  Based on the  392 56 average price target  the upside potential lands at 13    See Humana stock analysis on TipRanks Cigna Corporation  CI  Another health insurance name  Cigna s approach has integrated the physical  emotional  financial  social and environmental aspects of health and well being  Even after a solid six month performance in which 16  was ticked on to the share price  Tanal thinks that there s still plenty of room for CI to grow As 2019 marked the first full year since its acquisition of Express Scripts  the Goldman Sachs analyst is expecting the company to post strong fourth quarter numbers  According to his projections  2020 adjusted EPS guidance could fall within the range of  18 05 to  18 55  This figure  should leave room for  beat and raise  quarters  in part because guidance typically excludes future capital deployment and any favorable prior period development  The analyst cites three possible catalysts that could propel shares higher in 2020  First and foremost  the ramp of synergies from Express Scripts could have a significant impact  with the year over year step up previously expected to be  273 million  or 3  of the midpoint of current 2019 guidance  On top of this  he points out that its deleveraging could generate a  154 million step down in interest expense year over year and the earn back of stranded costs related to the Anthem transition in 2019 stand to add  100 million to earnings Tanal added   Between the specialty launch pipeline  the Prime deal  the HIF repeal  proposed incremental capital deployment post the announced divestiture of the Group Disability and Life business and bigger than expected buybacks in 1Q 3Q 2019  we see a clear path to 2021 targeted adjusted EPS of  20 to  21  In line with his optimistic take on CI  the analyst maintained a Buy rating and  245 price target  Should the target be met  shares could be in for a 24  twelve month gain What do other analysts have to say  As it turns out  the rest of the Street generally sides with the bulls  A Strong Buy consensus rating breaks down into 10 Buys  1 Hold and 1 Sell  In addition  the  232 75 average price target indicates 16  upside potential   See Cigna stock analysis on TipRanks HCA Healthcare Inc   HCA  Focusing on a different segment of the healthcare space  HCA operates hundreds of hospitals and clinics located throughout the U S  Thanks to its performance exiting the third quarter  the Goldman Sachs analyst has high hopes for the healthcare name Despite the investor concern ahead of its fourth quarter earnings release due to the volatility of the fundamentals in the  rst three quarters of 2019  Tanal notes that his bullish thesis is very much intact  Out of all the hospital and dialysis stocks he covers  HCA lands among the top two names expected to deliver the most potential upside compared to the adjusted EBITDA consensus estimate  Same facility adjusted upside could be the source of the beat For HCA  management s outlook for 2020 will be essential  in the analyst s view  He thinks the full year 2020 guidance will come in at around  10 260 million to  10 540 million  versus the Street s  10 354 million forecast  Labor costs are likely to be a focus heading into 2020 given continued robust job growth and low unemployment levels  Further  we will also be interested in any updated commentary on not for pro t M A opportunities  as recent acquisitions such as North Carolina based Mission Health have delivered strong performance vs  the company s initial expectations   Tanal wrote It also doesn t hurt that admissions could see an increase as a result of the current flu season  It should come as no surprise  then  that the Goldman Sachs analyst reiterated his bullish call and  165 price target  This target conveys his confidence in HCA s ability to surge 17  in the coming twelve months Looking at the consensus breakdown  it appears that other analysts are on the same page  With 12 Buys compared to a single Hold  the word on the Street is that HCA is a Strong Buy  At  161 45  the average price target brings the potential twelve month gain to 14    See HCA Healthcare stock analysis on TipRanks ,2020-01-28,TipRanks,https://invst.ly/pnymq,200502182
141205,362720,HUM,Analysts Estimate Humana  HUM  To Report A Decline In Earnings  What To Look Out For,opinion,"Wall Street expects a year over year decline in earnings on higher revenues when Humana  HUM  reports results for the quarter ended December 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on February 5  2020  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This health insurer is expected to post quarterly earnings of  2 19 per share in its upcoming report  which represents a year over year change of  17 4  
Revenues are expected to be  16 13 billion  up 13 9  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1 31  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Humana 
For Humana  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  1 02  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Humana will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Humana would post earnings of  4 58 per share when it actually produced earnings of  5 03  delivering a surprise of  9 83  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Humana doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2020-01-29,Zacks Investment Research,https://www.investing.com/analysis/analysts-estimate-humana-hum-to-report-a-decline-in-earnings-what-to-look-out-for-200502796,200502796
141206,362721,HUM,Is A Beat In The Cards For Humana s  HUM  Earnings In Q4  ,opinion,Humana Inc  s   NYSE HUM   fourth quarter 2019 results are scheduled to be reported on Feb 5  2019 The Zacks Consensus Estimate for earnings is pegged at  2 20  indicating a decline of 17  from the year ago reported figure The consensus mark for revenues of  16 1 billion suggests an uptick of 14  from the prior year reported number Factors to Impact Q4 ResultsThe company s top line is likely to have witnessed an upside during the fourth quarter on the back of growth in premiums  and its strong Medicaid and Medicare lines of businesses However  the overall earnings might have been affected by lower number of members due to consequent decline in Prescription Drug Plan  PDP  enrolment  The consensus mark for Speciality membership hints at a fall of 26 8  from the year ago reported figure Humana s fourth quarter earnings performance might also reflect escalating growth related investments The company is expected to have enjoyed healthy operating cash flow in the quarter to be reported on the back of excellent operating efficiency and solid working capital Additionally  total investment income for the to be reported quarter might have noticed an uptrend  The consensus estimate for the same implies a 28 6  rise from the year ago reported figure Per its last earnings call  management had supposedly made certain incremental investments in the fourth quarter  which include higher Medicare annual election period marketing spend plus increased sales and service costs related to the PDP plan changes  etc  An elevation in such expenditures might weigh down the company s margins What the Quantitative Model StatesOur proven model predicts an earnings beat for Humana this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of beating estimates  which you can see below  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Humana has an Earnings ESP of  0 15   You can see Humana Inc  Price and EPS Surprise   Zacks Rank  Humana carries a Zacks Rank  3  which increases the predictive power of ESP  Plus  its positive ESP makes us hopeful of a positive surprise in the upcoming quarterly release Highlights of Q3 Earnings and Surprise HistoryHumana s third quarter 2019 operating earnings per share of  5 03 beat both the Zacks Consensus Estimate and the year over year figure by 9 8   This positivity can primarily be attributed to Medicare Advantage membership growth and higher revenues The company boasts a stellar earnings record  having delivered a positive surprise in all the trailing four quarters  the average being 8 6  Other Stocks to ConsiderSome other stocks worth considering from the medical sector with the perfect combination of elements to also surpass estimates in the next releases are as follows Change Healthcare Inc    NASDAQ CHNG   has an Earnings ESP of  1 83  and a Zacks Rank of 1  The company is set to report fourth quarter earnings on Feb 12 Clovis Oncology  Inc    NASDAQ CLVS   has an Earnings ESP of  3 56  and a Zacks Rank  2  The company is set to report fourth quarter earnings performance on Feb 24 Tandem Diabetes Care  Inc    NASDAQ TNDM   is slated to release fourth quarter financial figures on Feb 24  The stock has an Earnings ESP of  27 59  and is Zacks  1 Ranked Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2020-02-02,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-humanas-hum-earnings-in-q4-200503932,200503932
141207,362722,HUM,Cigna  CI  To Report Q4 Earnings  What s In The Offing ,opinion,"Cigna Corp    NYSE CI   will release fourth quarter 2019 results on Feb 6  before market open In the last reported quarter  Cigna s earnings of  4 54 per share beat the Zacks Consensus Estimate by 3 89   led by accretion from the Express Scripts  NASDAQ ESRX  acquisition Factors at PlayThe Zacks Consensus Estimate for the company s earnings per share is pegged at  4 19  indicating an increase of 70 33  from the year ago reported figure  The consensus mark for revenues stands at  35 3 billion  suggesting a 156 7  rise from the year ago reported figure Cigna s Integrated Medical segment is likely to have driven revenues on customer growth  strengthening of customer relationships  premium rise reflecting underlying cost trends  and the inclusion of Express Scripts and Medicare Part D business  The segment is likely to have seen an increase in global medical customers  backed by growth in select and middle market segments In the company s Health Services segment  earnings are likely to have benefited from organic growth owing to the addition of new pharmacy customers  strong volumes of adjusted pharmacy scripts fulfilled and a continued improvement in specialty pharmacy  The Zacks Consensus Estimate for Health Services revenues stands at  26 3 billion The company s International business is expected to have benefited from business growth and strong margins  partially offset by an unfavorable foreign currency impact Cigna s debt levels are likely to have declined in the fourth quarter as it prioritizes to repay debt that was incurred to fund the purchase of Express Scripts  Share repurchases made by the company during the to be reported quarter are likely to have aided the bottom line 2019 Guidance  For the full year  the company expects earnings per share in the range of  16 6  16 9 and revenues within  136  137 billion while medical customers are projected to grow by approximately 200 000  Medical care ratio is expected in the band of 80 8 81 2  Earnings SurpriseThe company boasts a decent earnings surprise history  having surpassed estimates in three of the trailing four quarters  the average positive surprise being 5 17   This is depicted in the graph below Cigna Corporation Price and EPS Surprise   What Our Model SaysOur proven model does not conclusively predict an earnings beat for Cigna this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of a positive surprise  But that s not the case here Earnings ESP  Cigna has an Earnings ESP of  0 31   You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Currently  Cigna carries a Zacks Rank  2 Stocks Worth a LookHere are a few healthcare stocks worth considering as these have the right combination of elements to beat on earnings in the upcoming quarterly results Humana Inc    NYSE HUM   has an Earnings ESP of  0 15  and a Zacks Rank  3 
 You can see  Teladoc Health  Inc    NYSE TDOC   has an Earnings ESP of  11 70  and a Zacks Rank of 3 Molina Healthcare  Inc    NYSE MOH   has an Earnings ESP of  0 48  and is Zacks  3 Ranked 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 7  per year  So be sure to give these hand picked 7 your immediate attention ",2020-02-03,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-to-report-q4-earnings-whats-in-the-offing-200504453,200504453
141208,362723,HUM,Stocks making the biggest moves in the premarket  Disney  Snap  Tesla  Merck  Ford   more,news,Check out which companies are making headlines before the bell Disney  DIS    Disney shares dipped 0 8  after the media giant failed to update the guidance for its online streaming service  Disney   The company had previously forecast subscriber growth between 60 million and 90 million by fiscal 2024  The subscriber growth overshadowed better than expected earnings and revenue for the company Snap  SNAP    Shares of the social media company dropped more than 9  on the back of disappointing quarterly revenue  Snap reported sales of  561 million for the previous quarter  Analysts polled by Refinitiv expected revenue of  563 million  The company s average revenue per user  ARPU    a key metric for social media companies   also missed analysts  expectations Chipotle Mexican Grill  CMG    The fast casual food chain posted earnings for the previous quarter that beat analysts  expectations  sending the stock up more than 1   Chipotle reported an adjusted profit of  2 86 per share  topping a Refinitiv estimate of  2 75 per share  The burrito chain also had same store sales growth   a key metric for restaurant chains   that beat estimates Ford Motor  F    Ford dropped more than 7  in the premarket after reporting a loss of  1 7 billion for the fourth quarter and issuing disappointing guidance for 2020  The company s quarterly loss was driven in part by higher pension contributions and increasing labor and warranty costs Gilead Sciences  GILD    Gilead reported earnings per share of  1 30  missing a Refinitiv estimate of  1 67 per share  The biotechnology company also issued full year earnings guidance ranging between  6 05 per share and  6 45 per share   that s below a Refinitiv estimate of  7 01 per share  Gilead shares were down 0 7  in the premarket Humana  HUM    Humana shares traded 2 1  higher in the premarket on the back of better than expected quarterly results  The managed care company earned  2 28 per share on revenue of  16 295 billion  Analysts polled by Refinitiv expected earnings of  2 20 per share on sales of  16 19 billion  Humana also issued better than expected earnings guidance for 2020 Merck  MRK    Merck reported a weaker than expected revenue for the previous quarter and announced it will spin off its women s health business to focus on oncology  vaccines  hospitals and animal health  The company posted sales of  11 868 billion for the previous quarter  missing a Refinitiv estimate of  11 982 billion Tesla  TSLA    An analyst at Canaccord downgraded the high flying electric car maker to hold from buy  The analyst said investors will  likely get a more attractive entry point  in the future after the stock s recent run higher Pinterest  PINS    A Loop Capital analyst initiated Pinterest with a buy rating and a price target of  29 per share  The target implies a 29  upside from Tuesday s close of  22 46 per share  The analyst cited a  great potential as an advertising and eCommerce platform  for Pinterest ,2020-02-06,CNBC,https://invst.ly/pre4v,2076655
141209,362724,HUM,How Humana Beat Expectations Again in Q4,news,"Humana  NYSE HUM  beat Wall Street s estimates on both the top and bottom lines when it reported its 2019 third quarter results in November  Investors were hoping for a repeat performance with the health insurer s fourth quarter numbers 
Those hopes were fulfilled when Humana announced its 2019 fourth quarter and full year results before the market opened on Wednesday  Here are the highlights from Humana s Q4 update 

By the numbers
Humana announced Q4 revenue of  16 3 billion  a 15  increase from the  14 2 billion reported in the same quarter of the previous year  This result topped analysts  average revenue estimate of  16 19 billion 
The company reported net income in the fourth quarter of  593 million  or  3 84 per share  based on generally accepted accounting principles  GAAP   This was big jump from Humana s net income of  436 million  or  2 58 per share  recorded in the prior year period 
Humana s adjusted non GAAP net income in the fourth quarter was  2 28 per share  down from adjusted net income of  2 65 per share posted in the same quarter of 2018  However  the company s Q4 adjusted net income was well above the consensus Wall Street estimate of  2 20 per share 
Behind the numbers
The brightest spot in Humana s Q4 update was the performance of its retail segment  which focuses primarily on Medicare plans  Revenue for the segment jumped 18  year over year to  14 2 billion  The retail segment s earnings  though  fell nearly 19  to  275 million on a GAAP basis and  279 million on an adjusted basis as medical costs rose 
Humana s healthcare services segment  which includes its pharmacy services business  delivered Q4 revenue of  6 7 billion  up 8  year over year  The segment s earnings rose 11  on a GAAP basis to  178 million and 8  on an adjusted basis to  241 million 
It wasn t as good of a picture for Humana s group and specialty segment  which markets health insurance products to employer groups and the military  plus specialty insurance products including dental and vision insurance  Revenue for the segment slipped nearly 2  year over year to  1 9 billion  The segment also generated a loss of  146 million on a GAAP basis and a loss of  145 million on an adjusted basis  
Looking ahead
Humana anticipates full year 2020 GAAP earnings per share  EPS  will be between  17 76 and  18 26  Non GAAP EPS is expected to be between  18 25 and  18 75  The company reaffirmed its 2020 individual Medicare Advantage membership year over year growth projection of between 7 5  and 9 2   It also changed its estimate for stand alone prescription drug program membership to a decline of around 550 000 members from its previous guidance of a decline of around 600 000 members 
CFO Brian Kane said   We enter 2020 with positive momentum from strong 2019 results and industry leading individual Medicare Advantage membership growth   He added   We expect 2020 to be another good year for the company with solid top and bottom line growth notwithstanding the return of the health insurance industry fee  
Perhaps the biggest unknown is the impact that the presidential election this year will have on healthcare stocks  Humana and other health insurers would be significantly impacted if a candidate advocating single payer healthcare is elected president ",2020-02-06,The Motley Fool,https://invst.ly/prj76,2077043
141210,362725,HUM,The Zacks Analyst Blog Highlights  Amazon com  Procter   Gamble  Pfizer  Southwest Airlines And Humana,opinion,For Immediate ReleaseChicago  IL   February 4  2020   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Amazon com  Inc    NASDAQ AMZN    The Procter   Gamble Company   NYSE PG    Pfizer Inc    NYSE PFE    Southwest Airlines Co    NYSE LUV   and Humana Inc    NYSE HUM   Here are highlights from Monday s Analyst Blog  Q4 Earnings Scorecard   Analyst Reports for Amazon  Pfizer   OthersThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Amazon com  Inc   The Procter   Gamble Company and Pfizer Inc  These research reports have been hand picked from the roughly 70 reports published by our analyst team today  We have also included a real time update on the ongoing Q4 earnings season  You can see Q4 Earnings Season ScorecardWe now have Q4 results from 228 S P 500 members  Total earnings for these companies are down  0 5  from the same period last year on  2 3  higher revenues  with 71 4  beating EPS estimates and 67  beating revenue estimates  This is a better showing than we saw from the same group of 228 index members in the first three quarters of 2019  Looking at Q4 as a whole  combining the actual results that have come out with estimates for the still to come companies  total earnings are expected to be down  0 6  from the same period last year on  4  higher revenues  You can find more details about the ongoing earnings season in our weekly Earnings Preview report Amazon s shares have outperformed the Zacks Internet   Commerce industry over the past one year period   22 9  vs   16 8   and the Zacks analyst expects the momentum continuing on the back of the company s aggressive retail strategies and distribution strength  Rapid adoption of Prime driven by customer benefits and strengthening grocery services is aiding its top line  Further  Prime is driving its holiday sales growth  Also  expanding content portfolio is encouraging Prime membership  Furthermore  strengthening AWS services and its growing adoption rate are aiding Amazon s dominance in the cloud space However  rising transportation cost related to its free one day shipping service remains an overhang and is likely to increase further  Also  Amazon expects foreign exchange headwinds to continue impacting its top line Shares of Procter   Gamble have gained 27 1  in the past one year period against the Zacks Soap and Cleaning Materials industry s rise of 17 8   The Zacks analyst believes that the company s solid second quarter fiscal 2020 earnings mark the continuation of its positive surprise trend  Further  earnings and sales improved year over year in the reported quarter on gains from productivity efforts  robust volume  favorable mix and pricing  Total productivity cost savings aided core currency neutral gross and operating margin by 120 bps and 220 bps  respectively However  currency fluctuations remain concerning  Nevertheless  gains from acquisitions and divestitures are likely to partly offset the currency headwinds Pfizer s shares have underperformed the Zacks Large Cap Pharmaceuticals over the past two year period   7 4  vs   17 9    But the Zacks analyst believes that the company s Consumer Healthcare joint venture with Glaxo  the Array acquisition and the pending merger of Upjohn unit with Mylan  NASDAQ MYL   if successful  will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines  The smaller Pfizer should see better revenue growth as the Lyrica LOE cliff will go away Pfizer expects continued strong growth of key brands like Ibrance  Xeljanz and Eliquis to drive sales in 2020  Pfizer also has a strong portfolio of new drugs  which will accelerate growth in 2020 and beyond  However  Lyrica generic erosion  currency headwinds and pricing pressure are the key near term top line headwinds Other noteworthy reports we are featuring today include Southwest Airlines Co  and Humana Inc Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2020-02-04,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-amazoncom-procter--gamble-pfizer-southwest-airlines-and-humana-200504292,200504292
141211,362726,HUM,Humana  HUM  Beats Q4 Earnings And Revenue Estimates,opinion,"Humana  HUM  came out with quarterly earnings of  2 28 per share  beating the Zacks Consensus Estimate of  2 20 per share  This compares to earnings of  2 65 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 3 64   A quarter ago  it was expected that this health insurer would post earnings of  4 58 per share when it actually produced earnings of  5 03  delivering a surprise of 9 83  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Humana  which belongs to the Zacks Medical   HMOs industry  posted revenues of  16 30 billion for the quarter ended December 2019  surpassing the Zacks Consensus Estimate by 0 87   This compares to year ago revenues of  14 17 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Humana shares have lost about 6 5  since the beginning of the year versus the S P 500 s gain of 2 1  
What s Next for Humana 
While Humana has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Humana was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  4 76 on  17 88 billion in revenues for the coming quarter and  18 68 on  71 39 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   HMOs is currently in the top 15  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2020-02-06,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-beats-q4-earnings-and-revenue-estimates-200504691,200504691
141212,362727,HUM,Humana Inc  HUM  Q4 2019 Earnings Call Transcript,news,"Humana Inc  NYSE HUM Q4 2019 Earnings CallFeb 5  2020  9 00 a m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorLadies and gentlemen  thank you for standing by and welcome to the Humana Fourth Quarter Earnings Call   Operator Instructions  Thank you I would now like to hand the call over to your first speaker Amy Smith  Vice President of Investor Relations  Ma am  please go ahead Amy Smith    Vice President of Investor RelationsThank you and good morning  In a moment  Bruce Broussard  Humana s President and Chief Executive Officer and Brian Kane  Chief Financial Officer  will discuss our fourth quarter 2019 results and our updated financial outlook for 2020  Following these prepared remarks  we will open up the lines for a question and answer session with industry analysts  Our Chief Legal Officer  Joe Ventura will also be joining Bruce and Brian for the Q A session  We encourage the investing public and media to listen to both management s prepared remarks and the related Q A with analysts  This call is being recorded for replay purposes  That replay will be available on the Investor Relations page of Humana s website  humana com later today Before we begin our discussion  I need to advise call participants of our cautionary statements  Certain of the matters discussed in this conference call are forward looking and involve a number of risks and uncertainties  Actual results could differ materially  Investors are advised to read the detailed risk factors discussed in our fourth quarter 2019 earnings press release as well as in our filings with the Securities and Exchange Commission  Today s press release  our historical financial news releases and our filings with the SEC are all also available on our Investor Relations site Call participants should note that today s discussion includes financial measures that are not in accordance with Generally Accepted Accounting Principles or GAAP  Management s explanation for the use of these non GAAP measures and reconciliations of GAAP to non GAAP financial measures are included in today s press release  Finally  any references to earnings per share or EPS made during this conference call refer to diluted earnings per common share With that  I ll turn the call over to Bruce Broussard Bruce D  Broussard    President and Chief Executive OfficerThank you  Amy  Good morning and thank you for joining us  Today  we reported adjusted earnings per share of  2 28 for the fourth quarter of 2019 and  17 80 for the full year  above our previous estimate of  17 75  We are pleased with our 2019 performance  particularly our success in balancing and executing on multiple priorities as we grew membership  improved the quality and productivity of our operations and continued to invest in the long term During 2019  we experienced significant membership growth in both Medicare Advantage and Medicaid  where we were able to serve our country s sickest and most vulnerable population in need of quality care and better health outcomes  For individual Medicare Advantage  we saw the highest growth we ve seen in a decade  with over 0 5 million seniors choosing Humana MA plans In addition  we have a record number of MA members in 4 Star and higher plans  Our Medicaid membership grew nearly 38  with our statewide Florida win for 2019  and we added approximately 140 000 members on January 1st  2020 under our Kentucky Medicaid contract that was previously fully ceded to CareSource  We also demonstrated the strength of our Medicaid capabilities through procurements  expanded our senior focused payer agnostic primary care centers  significantly advanced our home health capabilities  expanded our pharmacy operations and took significant initial steps toward creating an interoperable health ecosystem via technology partnerships As we begin to scale our clinical solutions in 2020  we are continuing to balance our strategic initiatives across five key areas of influence on a member s health journey  primary care  home  pharmacy  social determinants of health and behavior  Let me give you an update on the recent progression in some of these areas  In 2019  we opened 29 senior focused primary care centers under our wholly owned alliance and JV model bringing our center total to 262  and we continue to see the maturity of our value based care platform resulting in more providers in surplus and improve the operating performance of our legacy Conviva operations We are now evolving from proof of concept to scaling these senior focused value based primary care assets and just this week we announced an exciting strategic partnership with Welsh  Carson  Anderson   Stowe that will accelerate our payer agnostic center expansion giving more seniors access to quality  primary care built around their unique health needs  especially in geographies that lack the access today WCAS is an important strategic partner in Humana s journey of building an omni channel senior focused consumer platform and this new arrangement is a capital efficient approach to rapid expansion  WCAS together with Humana has committed approximately  600 million to create a joint venture that is expected to open a minimum of 50 payer agnostic senior focused primary care centers over three years beginning in 2020  WCAS will maintain majority ownership and Partners in Primary Care will manage the centers for a management fee  Similar to our innovative deal to acquire Kindred at Home  put in call options to provide Partners in Primary Care with a path to full ownership of the centers in 5 to 10 years We are excited to being able to work with WCAS to facilitate faster entry into additional community in need of senior focused primary care  We re also expanding our JV and alliance model and expect to add 35 centers in 2020 with these important partners  Today  we serve over a quarter of a million of our individual MA members in our owned  JV and alliance model  Our goal is to double the number of members served in this model over the next several years Our pharmacy operations just completed the acquisition of Enclara Healthcare  one of the nation s largest hospital benefit pharmacy and benefit management organizations  This acquisition provides Humana pharmacy the opportunity to expand our comprehensive care continuum strategy to cover the pharmacy related needs associated with hospice care  simplify the mail order pharmacy experience and advance the technology stack for in home pharmacy through areas such as enhanced mobile medication management and improved electronic medical record connectivity In the home  we advanced our transformational home health initiative with Kindred at Home and Curo through the implementation of a Companywide EMR and the extrapolation of best practices for  Technical Issues  to over 20 000 home health episodes  The next phase beginning in 2020 is to provide more care services in the home  including acute care and primary care in the home  so that we may begin to generate meaningful trend benders for our health plans in the future while improving clinical outcomes for our seniors We remain committed to improving the life of those we serve through our social determinants capabilities  which positions us strongly to serve the vulnerable populations Medicare and Medicaid and provide us with the experience needed to meaningfully participate in the MA value based insurance design program and Medicaid procurements  In 2019  we scaled social determinants of health screenings to over 1 million  more than doubled the number of screenings in 2018 and connected those in need to community resources  We will continue to expand our outreach and services around social determinants of health in 2020 and beyond Lastly  recognizing that healthcare continues to evolve and technology will be at the forefront of the evolution  we announced two key strategic partnerships in 2019 with Microsoft and Epic to leverage technology to develop a health ecosystem and enable a seamless and integrated experience  Our focus in 2020 will be migration to the cloud to enable interoperability and agility In addition  we are seeing nice uptick in provider engagement Encompass  our population health delivery platform and a higher direct to consumer sales completions in our digital  virtual  intelligent plan recommendation tool as compared to our standard online enrollment tool  We ve also seen that members use the virtual recommendation tool are significantly more likely to share their health information with us in ways that could improve their decision making and help us better onboard and engage clinically once they are enrolled  As a Company  we continue to emphasize the enduring need to drive efficiency and productivity across the organization while not losing focus on the key themes of providing a simpler experience for our customers and delivering better health outcomes As we discussed last quarter  the return of the health insurance industry fee in 2020 posed a significant headwind for the industry  reinforcing this need to drive productivity  As Brian will describe  we worked diligently to identify ways to improve our cost structure by leveraging technology to streamline processes and executing a reduction in our workforce including redeployment of individuals to open positions  which impacted approximately 2 000 jobs  While we were able to drive meaningful savings  it was not an easy task and there are still members who enhance    who experience an increase in premium or reduction in benefits for 2020 given the magnitude of the HIF  Given the significance of the headwind  particularly the  2 10 headwind from the non deductibility of the HIF  we are pleased to provide the ability    the initial adjusted EPS guidance in the range of  18 25 to  18 75  representing reasonable growth while also delivering solid expected MA membership growth  We expect to add 270 000 to 330 000 individual MA members in 2020  representing growth of approximately 7 5  to 9 2   which we believe at a minimum will be in line with the industry growth  These expected results reflect balanced growth across all segments with each segment projected to deliver meaningful pre tax or EBITDA growth in 2020 Brian will provide more detailed segment level guidance in his remarks  As we have discussed previously  given the HIF is a premium based fee  beneficiaries of Medicare Advantage and Medicaid  the sicker and most vulnerable populations are disproportionately taxed  Despite that seniors continue to increasingly choose Medicare Advantage over original Medicare with compelling individual MA industry growth of 8 7  in 2019  excluding the impact of cost plans  compared to 7 2  in 2018 and 6 1  in 2017 MA penetration continues to increase  reaching 34  in 2019 and 2020 industry growth is expected to keep pace for 2019 even with the return of the HIF  a testament to the value the MA program provides and a model for other potential public private partnerships for additional populations needing affordable healthcare  Accordingly  we are pleased that Congress waived the fee beginning in 2021 recognizing that the imposition of the HIF falls disproportionately on Medicare beneficiaries and reduces affordability  The permanent repeal of the HIF is a significant win for consumers and we appreciate    are appreciative of the strong bipartisan support to repealing Looking ahead  we are committed to delivering strong short term performance while investing in transformative capabilities for the long term sustainability of the Company  To that end  we will continue to stay focused on three key priorities  expanding our local presence with primary care centers  the home and value based partnership models  modernizing our digital and analytics infrastructure including cloud migration  interoperability and the creation of a longitudinal health record and developing an enterprise clinical operating model built on technology and analytics to integrate our clinical assets focused on patient centered care and disease specific best practices In closing  I want to thank    personally thank our associates for their dedication to our strategy and operational excellence  We are pleased that because of their exemplary efforts in our success in 2019  including improved net promoter score  significantly individual MA membership growth and adjusted EPS growth in excess of our long term target  we are able to reward our associates with higher incentive based compensation  Our associates continued to demonstrate world class engagement which manifest in a better experience for our customers leading to a long term sustainability for the Company Over the next year  we expect political discussion to continue to focus on healthcare and results in market volatility  However  we are confident in the Medicare Advantage program which has significant bipartisan support and our opportunity to be part of the solution to both addressing the rising cost of healthcare and the need for quality outcomes With that  I ll turn the call over to Brian Brian A  Kane    Chief Financial OfficerThank you  Bruce  and good morning everyone  Today we reported adjusted EPS of  2 28 for the fourth quarter of 2019 and  17 87 for the full year  ahead of our previous expectations  This represents 23  increase in adjusted EPS year over year  These 2019 results led by industry leading individual Medicare Advantage membership growth and better than expected MA utilization  provide positive momentum going into 2020  We expect 2020 to be another strong year for the Company with solid top and bottom line growth notwithstanding the return of the health insurance fee or HIF which is not deductible for tax purposes  As I discuss our 2019 results and our expectations for 2020 this morning  I encourage you to reference the waterfall slide provided on our Investor Relations website with the webcast materials As outlined in the waterfall  we expect 2020 adjusted EPS range of  18 25 to  18 75  which is consistent with our commentary last quarter  We believe we struck the appropriate balance between top and bottom line growth while investing for long term sustainability as we contemplated our 2020 pricing  recognizing the significant impact of the return of the non deductible health insurance fee  of which the after tax portion alone is worth  2 10 for the year  Our strong Medicare Advantage growth in both individual and group MA is driving our 2020 consolidated revenue growth of approximately 14  at the midpoint of our revenue guidance of  73 9 billion to  74 5 billion and we are forecasting strong and balanced pre tax and EBITDA growth across our three reporting segments  Additionally  as we contemplate the quarterly progression of earnings in 2020  we expect the first quarter to contribute a bit more than 24  of the annual total which contemplates unusually high workday seasonality in the quarter primarily due to 2020 being a leap year Before discussing the segment results  I would like to echo what Bruce said in his remarks regarding the exemplary performance of our associates this past year  We are pleased that we were able to reward our associates with higher incentive based compensation given the outperformance in 2019 aligning our associates  compensation with the exceptional value they provide for our customers  providers and shareholders  An important part of the work our team accomplished during 2019 was to drive significant productivity savings which took a great deal of effort and necessitated difficult decisions These important initiatives are part of our longer journey to drive cost efficiency over the last number of years  In fact  when you exclude approximately 170 basis points for the impact of the HIF in 2020  the midpoint of our guidance range for the operating cost ratio is 10 3   down 110 basis points versus last year  Even when you exclude the incremental investments made in 2019 that increased our operating cost ratio  the 2020 midpoint adjusted to exclude the HIF still demonstrates 70 basis points of improvement over the 11  midpoint of our initial guide for 2019  This improvement continues the compelling efficiency gains driven over the last five years  freeing up resources to help mitigate the impact on premiums and benefits for our members due to the return of the HIF  while also driving solid earnings growth and enabling us to invest in critical strategic areas I will now turn to segment results  And as I do  I will touch briefly on 2019 and then transition to how we are improving operating results in 2020  I will begin with the Retail segment  In 2019  we saw industry leading individual Medicare Advantage growth of approximately 525 000 members  the highest growth we have seen in a decade  We also experienced considerably lower utilization in Medicare Advantage than our expectations  which allowed us to end 2019 with a benefit ratio for the Retail segment  70 basis points below the midpoint of our initial guidance for the year  We have now experienced multiple years of declining inpatient admissions for 1 000 members or APTs in Medicare Advantage  driven primarily by better health outcomes from our clinical programs coupled with well controlled outpatient physician and pharmacy trends  The 2019 improvement allowed us to invest this outperformance into our 2020 bids which when coupled with our productivity efforts will enable us to grow our individual MA book at the market growth rate at a minimum  This is something we are quite proud of given the material headwinds we faced in 2020 and after coming off an exceptional growth year in 2019 Our Group MA business continues to perform well and we expect to grow Group MA membership by approximately 90 000 members or 17  in 2020  primarily driven by the addition of a large Group account from a competitor  As you know  Group MA membership growth can vary widely from year to year based on the pipeline of opportunities  particularly larger accounts going out to bid  We believe we are well positioned to capture these opportunities as they arise  For our stand alone PDP business  in 2019  we experienced a second consecutive year of significant declines in membership as we no longer were the low price plan in any market  As we ve discussed previously  this business is exceedingly price competitive with a win or take all dynamic  Accordingly  as you are aware  we made important changes in 2020 repositioning our PDP products to allow us to once again have the low price offering in most markets Our new low price Humana Walmart Value Rx Plan is seeing nice growth in 2020  in line with expectations  However  this growth is not enough to overcome the significant losses we are seeing in our Premier Rx Plan where most members experienced a significant increase in premium in 2020 because of our plan design changes caused by the 3 plan limit imposed by CMS and an aging population with more chronic conditions and higher pharmacy costs  Based on the final results of AEP  our expectations for 2020 PDP membership losses have improved relative to our prior guidance and we now expect to lose approximately 550 000 members compared to our previous estimate of approximately 600 000  While these losses are modestly higher than initially expected at the time of bids  the plan changes we made in 2020 were necessary to attract a balanced risk pool and stem the membership losses in our book going forward Lastly  our Medicaid business continues to perform well and we are excited about the opportunities ahead for this business  Effective 01 012020  we added approximately 140 000 members under the existing Kentucky Medicaid contract previously ceded to CareSource  We are pleased to be serving Medicaid members in Kentucky  Florida and Illinois in 2020  We look forward to the final resolution of both the Kentucky and Louisiana procurements where the award of both contracts demonstrated our strong Medicaid capabilities  All in  the Retail segment is expected to show strong operating improvement as demonstrated in the waterfall contributing an incremental  1 66 to adjusted EPS when you adjust for the reinvestment of approximately  0 70 of Retail outperformance from the first half of 2019 in the bids for 2020 to help offset the impact of the HIF While our Retail segment outperformed in 2019  our Group and Specialty segment did not perform well and we are taking the opportunity to significantly reposition the segment in 2020 and beyond  The segment faced a number of pressures  including membership migration out of our community rated product into a level funded ASO which drove unexpected adverse selection in our community rated block resulting in significant negative prior period development  Note that this negative prior period development also adversely impacted the starting cost baseline for 2020 given the unanticipated morbidity mix  Using our consistent historical reserving practices for the Group and Specialty segment  we acknowledged the negative prior year claims development we experienced in 2019 as we contemplated the adequacy of reserves as of December 31st  2019 The segment also experienced large numbers of provider settlements  IT system upgrades for the insurance and specialty businesses and investments in market infrastructure  Our core trend remained stable and we believe the investments we are making in systems and people will position the segment for growth in 2020 and beyond  Accordingly  we expect the segment to contribute approximately  0 55 of incremental adjusted EPS to the enterprise for 2020 For healthcare services  we had a strong year  as we saw growth in our pharmacy business  solid performance of Kindred at Home and continued improvement in our Conviva operations  partially offset by the cost incurred to continue to expand our owned  JV and alliance senior focused primary care centers  Notwithstanding the significant PDP membership losses  our pharmacy script volume grew year over year primarily due to higher Medicare Advantage and state based contract membership  For 2020  despite the expected PDP membership decline we anticipate strong EBITDA growth in the pharmacy business  As Bruce mentioned  we recently closed the Enclara transaction expanding our hospice pharmacy capabilities Our home business is also anticipated to perform well led by Kindred at Home in which the conversion to Homecare Homebase across home health and hospice in 2019 weighed on results due to the significant required one time investment but will drive EBITDA in 2020 notwithstanding the adoption of a new payment methodology PDGM  And in our provider businesses as Bruce described  we are working to meaningfully scale this opportunity and are very excited about the recently announced innovative venture with Welsh  Carson to open a minimum of 50 additional payer agnostic senior focused primary care centers over the next three years which will be managed by our Partners in Primary Care team under the Partners in Primary Care brand Finally  our Conviva primary care business is expected to continue improving its core operating performance  As a result of all these efforts  we expect meaningful year over year healthcare services adjusted EBITDA growth to contribute an incremental  1 03 to adjusted EPS Turning to cash flow and capital deployment  Our operating cash flow was a record  5 3 billion in 2019  reflecting strong earnings and the benefit of a significant membership growth we experienced for individual Medicare Advantage  In periods of increasing enrollment  operating cash flows are positively impacted because premiums are collected in advance of claims by a period of up to several months  While we expect solid MA membership growth in 2020  due to the significant membership increase we experienced in 2019 and timing of the related premium collections and claim payments as well as other working capital items  we expect our operating cash flows for 2020 to be in the range of  3 2 billion to  3 6 billion  Additionally  as we ve demonstrated through the various transactions we have pursued  we will continue to deploy our capital in an efficient manner with a target debt to capitalization ratio of 35  in order to maintain our investment grade credit rating with the ability to move higher than that for strategic M A Finally  our initial guidance for 2020 includes an assumption of some share repurchase in the back half of 2020 and our strategic M A priorities remain the same including the continued build out of our healthcare services capabilities to drive our integrated care model as well as tactical health plan acquisitions to the extent they become actionable With that we will open the lines up for your questions   Operator Instructions  Operator  please introduce the first caller Questions and Answers Operator Operator Instructions  Your first question comes from the line of Charles Rhyee from Cowen  Your line is open Charles Rhyee    Cowen and Company    AnalystHey  thanks for taking the questions  As we think further out maybe  obviously you ve given us the outlook here for  20  growth remains strong here and you continue to look further to invest  maybe two questions real quick  First in Retail  as we think about investing the HIF money in the future  how do you think    how much do you think that  that should we consider either being really driven for growth versus maybe some of that coming back into earnings And then secondly  you were talking about extending your primary care footprint here  can you give us a little bit more color on how your Partners in Primary Care efforts are going  say sort of not going to be really impactful to 2020  but when would you expect that to really start to have a more meaningful impact to the bottom line  Thanks Bruce D  Broussard    President and Chief Executive OfficerWell  good morning  Charles  So let me take them in order  First  with regard to the HIF in 2021  As we ve said in prior settings  it s obviously early to be commenting on 2021  We do believe that the health insurance fee repeal will be a significant benefit to our customers and we would expect them to see increased benefits on account of that  But we will balance as we always do membership growth with EPS as well as making sure we invest for long term sustainability  And so you ll see us continue to invest in our integrated care model as we balance top and bottom line growth I would also say  as we think about 2021 and I know this has been a topic of conversation  we ll make sure we understand the impact of ESRD  We need to obviously see where the rate notice ultimately comes out and that s something that we re obviously eagerly anticipating and also will need to gain theory out what we think our competitors do with respect to the HIF repeal in 2021  But overall  we obviously are bullish on 2021 but it s really too early to provide specifics On the second question with regard to primary care  we feel very good about our primary care capabilities  In fact  both our Conviva operations  which are performing nicely and we re seeing good operational turnaround  but also the business we re expanding partners in primary care  we believe has an operating model that can be replicable and scalable across multiple markets in the US and so it s really a function of how do you fund this expansion  There is a significant J curve in these clinics  meaning that for the first few years they lose EBITDA  they lose money and then over time  they begin to make money and actually earn a nice return on investment and so how do we bridge that gap And so partnering with Welsh  Carson  who is an expert in healthcare and very  very good at what they do  we believe that we ll be able to scale this model very efficiently and really get us the capital we need to tie us over between for the J curve period where we re losing money  so where we can bring these back on balance sheet if we decide to do that when they re more profitable Joseph C  Ventura    Chief Legal OfficerJust to add to Brian s comment  We do see benefit from the clinics early on the insurance side  So if you think about the contribution to the Company  there is really two parts to it  One is the actual centers themselves and then the second part is enhancing and moving members more and more to value based payment models  which we see better star score  we see lower MER and we also see a better satisfaction there So in the    as Brian articulated in the J curve side  you ll see it more on the insurance side  As it grows  it continues to be on the insurance side  but then it becomes more on the clinic side  So in 2020  we will see benefits from these clinics and in the 200 some we have we ve seen benefits all along  but you ll see it more on the insurance side and more in the as we reference in trend benders as opposed to see it in the actual profitability of the centers themselves Charles Rhyee    Cowen and Company    AnalystSo basically you re able to direct your members to the primary care centers that you have and is that    when you re recruiting physicians for these centers  is it    are you bringing positions that already have full patient panels themselves or you kind of recruiting doctors who are interested in changing the way they practice in general and   Joseph C  Ventura    Chief Legal OfficerMost of these are exceptions  we will bring some physicians that have patients but the majority of them will be starting from scratch  And that s really the reason for the J curve as what Brian was talking about  In reference to steering the patients there we really    our design plans to make it affordable for people to choose the clinics  but obviously it s their choice and they from    to choose their physician  But we do find in areas where we locate and where they don t have primary care or hospital that we are the sort of the community choice there  So I would just emphasize both from plan and where we locate them is an important part of how our members choose them Amy Smith    Vice President of Investor RelationsAnd Charles  was a great example of getting a lot of questions and please remember to limit yourself to one question  Introduce the next question please OperatorYour next question comes from the line of AJ Rice from Credit Suisse  Your line is open AJ Rice    Credit Suisse    AnalystHi  everybody  I might just continue to just trying to flush out the strategy around these Partners in Primary Care  With this deal  will the growth all be in this joint venture or can you continue to do ones on your own or with other third parties and is there any restriction around the risk sharing  I know that s been a big part of the long term targeted savings for the health plan is to do risk sharing with these  Is there any restrictions given it s payer agnostic or what you can do there  And then maybe another thing you didn t mention is once you get to 50 up and running  how much of your Humana MA book will be covered by one of the    or have access to one of these clinics Brian A  Kane    Chief Financial OfficerYeah  let me try to go in reverse order  It will still be a relatively small portion of our MA book which is the reason why for what Bruce said we want to scale these up as quickly as we can  but still be a relatively small portion of our book  Remember from a risk perspective  each or from risk member perspective each clinic has about 2 200 or so risk members kind of varies  depending on the size  it could be as low 1 500  it could go to 2 500 members  And so you can do the math  It s still relatively small  which is why it s important that we take a balanced approach to our growth really getting to your first question We have partnerships with a number of players  They re very valuable partners that  that we will continue to expand with  Some we have equity investments in  some we do not  but we will look to continue to expand those joint venture and alliance models  But we have  I would say  the ability to expand as we see fit to continue to grow this footprint which we will do  We re obviously very mindful of the impacts on the income statement when we do this  So we re trying to be created with the use of our capital  But I would tell you that we have flexibility to execute our business plan And then on the risk sharing side  being payer agnostic is really important  It s important so that we can actually fill up these clinics  It s important so we can attract physicians  It s important to be able to really create the best in class experience for our members and to give them the ultimate    the patients to give them the ultimate choice what they need in their lives  But there is no restrictions with respect to risk sharing or the like  Obviously each risk contract is different and sometimes there are path to risk contract  So we may not go full risk day one but generally we sign at least path to risk deals with the various payers  but we re encouraged by the reception that we ve  that we ve seen from other payers and we re committed to making this payer agnostic Amy Smith    Vice President of Investor RelationsThank you  Next question OperatorYour next question comes from the line of Peter Costa from Wells Fargo  Your line is open Peter Costa    Wells Fargo    AnalystGood morning everybody  sort of on the same line  focusing on the Partners in Primary Care transaction  one of your competitors    one of your large competitors buys larger practices  physician practices and other    your larger competitors doesn t buy practices at all or run them and use contracts and there is smattering of that across the board  you guys seem to be the ones trying to grow practices  yet you ve had    you ve struggled with that  whether it be Conviva that has gone through a turnaround  Concentra  which never really grew the way you wanted to and now with Partners in Primary Care  it seems like you re pushing that off your books from an earnings perspective here in the short term while it grows  Can you explain why you still think this is the right strategy versus what your competitors are doing Bruce D  Broussard    President and Chief Executive OfficerI would maybe try to put those in boxes  Let me start with Concentra  I think Concentra was an urgent care model that had a small primary care part to it  But we ended up doing actually the genesis of Partners in Primary Care is out of Concentra and so we    what we did is we bought the company  then pulled the primary care out of it and then began this    the Partners in Primary Care  So that transaction we didn t want to be in the urgent care business going forward  Conviva  actually is interesting because Conviva today is probably one of the larger organizations in the country that has pure clinics with senior focused  It s got some 200 000 some Medicare Advantage lives in it and is performing well And when we talk about turnaround  it s really more bringing in the various different brands that were in South Florida and creating a brand of one of which that brand  some of those brands have been within the organization since 2008  2009 in that arena  So what you see is more making at a better brand  a holistic brand and growing and continuing to serve the organization well on the insurance side  has good Star scores  it has good MER  good satisfaction and growth  So I wouldn t make either one of those as the organization is sort of shunning or in and out of this I would say there is a philosophy difference between us and others in the country that you re referencing and our philosophy is the buying primary care and trying to convert them to Medicare Advantage value based care model is a highly risky proposition and we ve seen over the years that organizations that have tried to do that have not been totally successful  Now if you re going to keep them fee for service  you re going to keep them commercial  if you re going to keep them in that vein  I think you re going to be quite  quite successful in not having to deal with the change management  What you do see the organization doing is going through sort of stages with that  I think the first stage was around does this work for Partners in Primary Care and we ve been testing and learning that for the last few years and we ve come to the conclusion seeing the results that we ve had in the markets we ve opened that  that this is really working  We re seeing great Star scores  As I mentioned  we re seeing great satisfaction scores  we re being able to recruit doctors into it  we re able to fill them up in the time that we thought So the real question is how do we scale it and so we ve tried to scale out over the years through joint venture partnerships and you ve seen today we have 260  some clinics and serving about 10  or so about our    of our members and now it s just a question of scaling  And so what we chose is to scale it in a way that we can utilize a capital efficient way to be able to do it  Be able to set it as an independent entity but still have control over it over a period of time and be able to use that as a growth vehicle for us  But at the same time continuing to scale through our joint venture and alliance partners that we ve done in the past So I think what you ll see is  is more of a scale question as opposed to anything else and it s a question of how do we build a great base for this and I feel that the Company has matured in a way that is very bullish on this  but at the same time matured in a way to test and learn because of you articulating in different ways  owning and operating physicians is a very  very difficult task at times and it is also a risky task and we ve tried to navigate through this to ensure that the organization is able to both succeed but more importantly  scale this because of the end results Amy Smith    Vice President of Investor RelationsNext question please OperatorYour next question comes from the line of Justin Lake  Your line is open Justin Lake    Wolfe Research    AnalystThanks  good morning  A couple of questions on margins  Just first  can you give us an idea of where Medicare Advantage kind of settles out  I know you don t want to give specifics  but just relative to the 4 5  to 5   how close are we there  And also kind of how should we think about it in 2021 if you are going to reinvest some of the HIF as the next move downward in those margins  And then just in terms of the healthcare services business  same thing margins  really strong there looking like in the guide  is that all just improvement in those ancillary businesses that you kind of outlined and if so where do you kind of see the trajectory of those going forward from here  Thanks Brian A  Kane    Chief Financial OfficerGood morning  Justin  On the MA side  I would say for 2019  we finished a little bit below our 4 5  to 5  margin  obviously a really strong year given where we started the year  For 2020  as I mentioned in my remarks and we ve discussed in the past  we invested some of that outperformance into    in 2019 into our 2020 bids and so obviously that s going to impact margins  But then we obviously improved the operations as well  So  all in  I would say the margins are relatively flat year over year 2020 versus 2019 and so we re still bit below the 4 5  to 5   With respect to 2021 again  really we re too early to give 2021  but it s fair to say whenever there is that tax impact on the after tax line  you can see the geography of where the earning shows up changes a little bit  So it s conceivable that  that we do have a decrease in margins for 2021 while obviously still growing EPS very nicely  So that s something we would have to work through  but typically  that is a dynamic that s at play when we ve seen tax rates change dramatically  whether because of the HIF or because of tax reform that occurred in 2018 On the healthcare services side  I would describe it as balanced growth  I think we feel very good about really all segments  The pharmacy side is showing a really nice improvement year over year  They continue to drive penetration on the mail order side  on the specialty side as well as we think this Enclara opportunity on the hospice side  will give them some runway as well  Kindred at Home is also performing well  We hope to continue to see strong EBITDA growth notwithstanding the change in the payment model  As you know we ve embraced this payment model because it gets us closer to chronic nursing versus solely focused on therapy But I think the team is doing a really nice job of mitigating any impacts there and also leveraging the benefits of implementing Homecare Homebase and  as Bruce discussed on our primary care business both Conviva and Partners in Primary Care  we see a nice turnaround there particularly in Conviva which is entirely on balance sheet  where we re seeing real improvement in the EBITDA performance  So really I think it s a real positive story on healthcare services and we hope that continues in the years ahead Amy Smith    Vice President of Investor RelationsThank you  Next question please OperatorYour next question comes from the line of Dave Windley from Jefferies  Your line is open David Styblo    Jefferies    AnalystThanks  good morning  It s Dave Styblo in for Dave Windley  I wanted to ask a question about the Group and Specialty business  just kind of looking at the bridge here  it looks like there s about  0 55 tailwind for 2020 that you called out  I m curious how much of that is from the absence of one time costs that happened in 2019 or settlements versus improvements in the core business  And then more broadly related to that business  how does commercial fit into the broader portfolio just given the fits and challenges that  that business has gone through Brian A  Kane    Chief Financial OfficerI would say it s on your first question  it s really a balance  Clearly  we don t have the repetition of one time items  but some of it is also improving in the core business  Some of the pricing actions that we ve taken  I think it s important  and we expect to hope to have gotten the baseline right  As I mentioned in my remarks  the adverse selection we saw in our book really hurt the 2019 performance because 2018 backed up  You sort of have a double whammy there  you have the  18 hit and then you have a    you re trending off the wrong baseline for 2019  So I think we ve    I m hopeful we ve gotten that right  We ll obviously see what happens in the coming months here  So I think it s really a combination of core improvement as well as the one timers not repeating Really to your second question  we continue to invest in this business  that s also weighing on the results for 2020  In other words  the results would have been higher were it not for that  We believe that there is a real opportunity to grow this business  become more of a player  a significant player in particular markets where we re strong in Medicare and where we think really number one  there is an opportunity to drive more relevance with our providers and we think when we have a commercial presence  particularly moving upmarket away solely from the small group and moving into the mid group and sort of larger group side not the jumbo side but more large group  gives us the attention of the providers in the local markets We also think there is a significant cross sell opportunity as members age into Medicare and also on the Group MA side  it s an area where our competitors have done a very nice job leveraging their commercial business  Because we don t have that same commercial business  it s hard for us to get those synergies and so we think there are opportunities there And then the final thing I would say is our specialty business is something that we don t talk a lot about but we re bullish on it and we really hope to grow it both on the Group side and also on the individual side  It s a business that is low capital requirements and good margins and so we think we can continue to grow that and cross sell that product  So for those reasons  we re committed to the business and we re hopeful for a better year this year in 2020 Bruce D  Broussard    President and Chief Executive OfficerJust to add to Brian  I think just emphasize we realize that having a national strategy in commercial is just not the right direction here and so we are picking markets where today we are strong and utilizing those markets to continue to build our local presence and commercial is one of those along with the other assets that we have and so you see a much more concentrated effort  Obviously as what Brian has talked about in 2019 was a rough year for the commercial business for a whole host of reasons  but we do believe in certain markets that makes sense to have a commercial product and that s what you see the team oriented to  but we need to make sure our infrastructure is prepared for that and that s what you see a lot of the investments and the work going on in 2019 Amy Smith    Vice President of Investor RelationsThank you  Next question OperatorYour next question comes from the line of Sarah James from Piper Sandler  Your line is open Sarah James    Piper Sandler    AnalystThank you  Thank you  So just wanted to get a little bit better understanding of some of the non repeat items that are going on here  So you guys talked about negative prior period development related to the Group business but you can t tell on the press release it looks like for total Co  it s net positive  so how much negative group development was there and what would MLR have been without it  And then as we think about other non repeating items that are occurring in  20  is there any carrying costs related to Louisiana and then is there any start up costs related to what you guys are doing on the provider JV side that wouldn t continue as we think about run rate earnings Brian A  Kane    Chief Financial OfficerGood morning Sarah  So I would  and it s    you could see in our press release  there is a breakout between Group PPD and Retail  So Group has gotten hit for the reasons I talked about  Retail was modestly positive  I think it was a good year for PPD  For Retail obviously less so for Group    so that is a    I would call that a one time item and I hope it s a one time item on the negative PPD side for Group  So I think that s one example  There are some modest start up cost in Louisiana  We have to plan for that  So that is in our numbers  in our costs  so we ve obviously scaled up to be ready for that  Again  it s something we re very proud of  The Medicaid team has done just a fabulous job winning that contract and we ll see where it goes  but we feel good about that And so it s important that we make sure we are ready to implement that contract when and if we get    we get that finalized and officially awarded  There are a few other things on the JV side  but a lot of those costs are going to come off our 2020 income statement because of the partnership that we announced  There is still some of that does not    not all that s coming off and we still have some assets on balance sheet  some assets off balance sheet  But really the opportunity here is to be able to scale as Bruce said to scale that business and be able to grow it more quickly so that we don t have additional losses going forward  The idea is to remove those losses  So hopefully  that answers your question Amy Smith    Vice President of Investor RelationsNext question please OperatorYour next question comes from the line of George Hill from Deutsche Bank  Your line is open George Hill    Deutsche Bank    AnalystGood morning  guys  And I appreciate you taking the questions  Maybe switching gears for a second  talk a little bit about pharmacy  You ve seen some of your competitors kind of pursue some interesting partnership strategies and you guys have had the decline in Med D enrollment  I guess  do you feel like you need to partner up with somebody either on the rebate aggregation side or the pharmacy network side to get better economics out of your pharmacy business  And do you feel like the current partnerships that you have right now are delivering the rates that you need in net book Bruce D  Broussard    President and Chief Executive OfficerI would first say we are always looking for ways to bring a lower cost to our members  So whether it s in    and we do have some generic partnerships today that we buy with and through  So I would say the recent announcement that you re referring to is something that others do but I wouldn t say we are not    we are not exempt from that  but we just don t broadcast it  But we do orient to how do we have a cost of goods and we constantly are checking that and what we find is that we are very  very competitive in the marketplace  The Part D decline is not so much of a cost of goods conversation  it s more around just the pricing of the product itself and as Brian articulated with the unique aspect of Part D is you can start a plan without removing a plan and it gets complicated to do that and that s what you see happening  So I would say it s more on the plan design side for Part D than it is on the side of the cost of goods And related to the pharmacy  I d    we re constantly looking for ways to expand our capabilities whether that s from a delivery point of view to care and clinical point of view  like in specialty pharmacy and in addition in areas that are more oriented to rebates  I would just say that we are content today  but I wouldn t say that content is something that we are going to continue  We will continue as we did with Enclara and other things that we ve done this past year to like to advance that  But again I think the emphasis to the question is  I would not connect the Part D decline to capabilities within our pharmacy as a whole Amy Smith    Vice President of Investor RelationsThank you  Next question OperatorNext question comes from the line of Kevin Fischbeck from Bank of America  Your line is open Kevin Fischbeck    Bank of America Merrill Lynch    AnalystGreat  I wanted to go back to the commercial conversation  I don t remember if you actually gave it but what was commercial trend in 2019  Just    I understand the concept of risk converting into ASO but you raised your MLR guidance multiple times through the year and then the fact that you experienced negative development almost every quarter through the year implies that in fact trend is rising and just trying to understand why that s not the case and I heard your comments about why you feel better about next year  but given that consistent MLR guidance increase and given the consistent negative development  how much confidence I guess do you really have in your visibility into that book right now Brian A  Kane    Chief Financial OfficerGood morning  Kevin  So again I would distinguish between core trend and sort of the net trend that we re seeing on account of sort of the morbidity mix in our book  Our core trends are relatively stable  I would say just like last year  6  plus or minus the 50 is    50 basis points is sort of a reasonable place to be  We ended up in that range for 2019  It s really the net trend once it sort of filters through and the membership that we have and our morbidity mix that s driving that  Obviously our commercial book is small and as a consequence  it s hard to extrapolate broader for those with larger books whatever it may be and since ours is very focused  it s almost entirely small group based  Well north of 50  of our premium it comes from lives under 100 or groups under 100 and so we re in this interesting part of the marketplace that I think is just been going through a lot of change with respect to the ACA community rated block the 250 block the migration to LFP  the grandmother  grandfather products  It s just    there s just been a lot of churn in that market and so that s really been where we ve been focused As Bruce said  we want to  we want to move upmarket a little bit into the    more mid Group  larger Group space to be more relevant in certain key markets and where it is a strategic objective of ours to do that  I would say we re always mindful of trend and where it s going  but we re less focused on the core trend side than we are in the business mix that we re attracting  So hopefully that distinction makes sense Amy Smith    Vice President of Investor RelationsThank you  Next question OperatorNext question comes from the line of Josh Raskin from Nephron Research Your line is open Josh Raskin    Nephron Research    AnalystHi  thanks  Good morning  thanks for taking the question  Wanted to just get back to the primary care conversation and maybe just take a step back  you ve got a whole bunch of different assets and strategies around this broad strategy of physician enablement and I guess I want to understand what s the ultimate goal  Is this about growing your market share in Medicare Advantage  is this about improving the core profitability of your MA book or is this about controlling medical cost spend and sort of creating a new sort of business segment  business line that over time can kind of augment the overall Humana  I m just curious about sort of where this all starts in terms of and what the end game is Bruce D  Broussard    President and Chief Executive OfficerYeah  Let me try to take that and put it in a few elements  It originates out we feel that this is a very effective care model and I think as Peter asked a while back  we ve been doing this for some time and we have a lot of proven results from this  And when you look at our members in these programs  as all the results there  the one thing I didn t mention is also retention is higher and so we see wonderful performance out of there  And if we could wave a magic wand we would want 100  of our members in these programs for all the reasons we ve talked about  The challenge we find in today s world is  is that the fee for service payment model and the model    the operating model within that is sort of what dominates the healthcare system and our ability to put seniors in these types of clinics is very    there isn t a lot of supply  I mean  as you well know  DaVita was probably the one and only that had more of scale there and so over the last few years we ve tried to find a way to scale it through joint ventures and alliances is what Brian was talking about And in addition to have our proprietary product because what we want to make sure of is  is over time  we have a product that when we re in a market that we have stability in our network and that we re able to fulfill that in these particular products allow us to both if we have ownership and other contractual rights that allows us to control our destiny in markets that we want to ensure our members have the proper providers to and that    so the first is great performance Second is the ability to have in the markets  protection around the    we call it the supply chain  And then the third is  is once you begin to go those two routes  then there is the question  how do you optimize that  that the performance of that business  And what you see us doing is saying it needs to be agnostic  it needs to be a business upon itself  it needs to be able to grow and serve the community there  which benefits us as both as an owner of the product  but also it benefits our plan because our plan is also being able to have a lower cost serving there and more effective And so  and then it turns into how do we maximize the business on itself but it originates from what s best for our member and then goes to how do we control and ensure that we have stability in the marketplace for our supply chain  And then the third thing it moves to is now how do we maximize the business there  Where it ultimately ends up is I think you re going to see as Brian said  we want to double our membership in this particular area over the next few years and you re seeing the Welsh  Carson is one of them  Along with our affiliates are another way to do that  But over time I think the investors will see that this will be another part of our business no different than when we started pharmacy years ago and it became part of that and no different than what you ll see with the home that it will be a business that will be profitable  It will be value    valuable from a shareholder point of view  but it also will be valuable for our members point of view Amy Smith    Vice President of Investor RelationsThank you  Next question OperatorNext question comes from the line of Ricky Goldwasser from Morgan Stanley  Your line is open Ricky Goldwasser    Morgan Stanley    AnalystYeah  hi  good morning  My question focuses on the partnership with Microsoft and Epic  What are your kind of like the timelines on deploying Epic in patient EMR  it really captures the data  the member data across the Humana enterprise  And then as we think about this longer term  does this really become sort of a pre requisite for clinic partnerships outside can affect the Humana homegrown base Bruce D  Broussard    President and Chief Executive OfficerYeah  I ll take that  Interoperability is at a core what we see enables value based payment models and the ability for us to manage complex patients  just because of the complexity of the system and the complexity of people s conditions  So to answer your first question  just where are we in that journey  Microsoft and Epic are really two different journeys but both are well along the way  In the Microsoft approach  we really have three different horizons  One is the cloud and moving everything to cloud and allowing a much more agile environment and at the same time  building a longitudinal health record that allows to use FHIR and interoperability inside the organization and outside the organization and both of those things are well on their way  We have  I think we announced last year    last quarter some partners that we ve already rolled out part of the longitudinal record and so that is now in structurally there  we just have to continue to add our partners to it This year we ll be bringing on all of Kindred and that relationship as a result of them completing their EMR install  There is a number of providers through the Compass product that we have that are using the longitudinal record along with some of our pharmacy areas including Enclara and that we just acquired  So we have a  a really good progress going on in both the cloud conversion I think cloud conversion is going to take about five years but what you see and most of that is the traditional technology that s been around for a long period of time taking the longest On the Epic side  what you see is we are in    we just really we have a number of hospitals today that we are now passing information back and forth through in the Epic conversion  I mean the Epic connection  That is in used case only  we re not really announcing what those used cases are but we are in market with a number of hospitals  These are integrated systems that we are passing information back and forth with the Epic area  But these are    these are the beginning of a long process no different than what we are talking with the clinics about the ability to have interoperability  which leads me to the third It is a standard we will imply employ and with our clinics of having interoperability  most of our clinics today already have that interoperability  you ll just see us continue to do it more  But more importantly through any kind of deep partnership  we are looking for interoperability to be a part of that partnership no different than the value based payment models and other mechanisms that we use but interoperability will be an important part of that Amy Smith    Vice President of Investor RelationsThank you  Next question please OperatorNext question comes from the line of Steve Tanal from Goldman Sachs  Your line is open Steve Tanal    Goldman Sachs    AnalystGood morning  guys  thanks for the question  Wanted to go back to the HIF repeal in  21  Obviously it s sort of all in worth over  9 00 EPS before any offsets and kind of a uniform magnitude impact to MAOs across the industry which tends to be concentrated at the local level  So I guess is there any reason to think that MA plans won t act rationally to use a portion of the pre tax tailwind to absorb any headwind the rule change on ESRD patients creates  And relatedly  if you could maybe comment on any advocacy efforts with CMS on this front  whether the agency has been receptive and gets the issue and your expectations for what we ll see there whether they will provide actuarially sound rates for ESRD patients in  21 on the advance notice that s tomorrow  kind of curious if this risk factor could actually turn into an earnings opportunity Brian A  Kane    Chief Financial OfficerHi  good morning  Steve  So I think it s fair to say obviously  the HIF tailwind would certainly help offset any ESRD headwind  And I think what we re trying to just understand is the magnitude of that headwind and over the coming months we re doing lots of modeling and various scenarios that would drive different levels of penetration in ESRD  which would will obviously impact the 2021 earnings profile  It won t be crazy to think that  that ESRD penetration could get to Medicare Advantage levels we ll see  We re modeling that  There s been a bunch of commentary on the Street about that by various analysts and so we are working through that  I think it s important to really break the population into two buckets  one  being duals  one being non duals to really understand the impact On the dual side  MA could have some appeal to them  just because of the supplementary benefits  particularly around transportation and some over the counter benefits and so that s one of the things we re looking at  And on the non dual side  particularly the under 65 ESRD population  you really need to look at where Med Sup is and understand what the Med Sup availability is for these various folks and in some states it s not available where it s not required to be available or there is significant premiums  And so  it s certainly a premium for someone to buy it  And so that s what we re really trying to understand what the impact will be Again  we feel good about where we are for 2021  Obviously the health insurance fee is a big positive  And on the advocacy side  clearly rates is one factor and we ll see where CMS comes out  I think it s just important for people to understand why the benchmark maybe understated and that s a function of the fact that there is not a maximum amount of pocket in fee for service while there is an MA and so that impacts the cost and also typically people    HMOs pay higher rates than original Medicare to the  to the large dialysis providers and so that also impacts the cost So obviously rate is one element  Making sure that there is competition in the marketplace is another in terms of the provision of dialysis care and so we re working with CMS on that both in terms of some of the CONs  state CON requirements around what  what people can build in terms of getting  getting the CON loss  getting  getting through those as well as basic conditions for coverage and what sort of innovative capabilities can we bring to bear in the ESRD space  whether it s around the home  whether it s around micro clinics  various alternative sites of care to provide dialysis But regardless  we re working very hard on it  We re standing up clinical teams  take these members and over the long term  we understand why it makes sense to bring ESRD into this population  We just need to manage the short term transition  So long winded answer to your question  We re taking it from multiple angles  modeling it appropriately  doing appropriate advocacy and then preparing the clinical side and working with our dialysis partners to come up with creative risk sharing mechanisms to help drive outcomes  Hopefully that s helpful Amy Smith    Vice President of Investor RelationsAll right  thank you  Next question please OperatorYour next question comes from the line of Ralph Giacobbe from Citi  Your line is open Ralph Giacobbe    Citigroup    AnalystThanks  good morning  Just wanted to ask on the individual MA membership  you added almost 230 000 members during AEP  When I look at last year  you had almost 10  of total enrollment in OEP and then you saw further growth in sort of the AGN and D SNP  So I guess when I look at that 270 000 to 330 000 range  seems like you re trending closer to higher end if not even above that  Is that fair or help us with other consideration sort of this year versus last year that may not make that be the case  Thanks Brian A  Kane    Chief Financial OfficerWell  obviously we hope you re right  but there s a lot of  lot of game up the play  I would say that we feel good about the 270 000 to 330 000 that we put out there  We finished AEP at around 229 000 for the January    the January lives and I think this year is different than last year and that are on a relative basis  we re not as strong from a benefit design as we were in a relative basis in 2019 and so you have to see what are the sales are going to be and what are the terms going to be  Obviously the sales opportunities are a little bit  a little bit less in the in the post AEP than the pre    than during AEP and you saw the terminations in your book and we have a larger book  And so if you have a similar term rate you actually lose more lives right  And so  so those are the types of things we re working through  We re closely monitoring OEP  it seems to be going well  we ll see where it ultimately shakes out  But I would just say we feel good about the 270 000 to 330 000 that we put out Amy Smith    Vice President of Investor RelationsThank you  Next question please OperatorNext question comes from the line of Frank Morgan from RBC Capital Markets  Your line is open Frank Morgan    RBC Capital Markets    AnalystGood morning  I want to go back to the healthcare side of the business  I think you said  I want to confirm you said you had completed the Homecare Homebase conversions  so the    I m assuming that means the drag from that conversion should be completed and then what are sort of your early reads on PDG in the    on the home healthcare side  Are you seeing your rates higher or lower or flat  And then finally just what s the    what kind of financial drag would you be removing from your income statement and balance sheet with moving those assets into this partnership in primary care  Thanks Brian A  Kane    Chief Financial OfficerOkay  So on Homecare Homebase  it is completed  It was a herculean effort  I think the team did it faster than any conversion that s happened before  Just the magnitude of an EMR conversion on both the home and hospice side is very significant  The team did an extraordinary job and so we re very excited about that and so that drag is no longer there for 2020  although it was meaningful for 2019 and that s part of the increase in EBITDA that you re seeing in the healthcare services side I think it s still too early to comment on PDGM  I think things are going as we planned and as expected  they were adjusting to the change in the payment model  The impacts of that are reflected in our 2020 numbers but I think the team feels good about mitigating the EBITDA impact of that  The important side for us in particular is the clinical side and we re excited about the movement of the model to much more as I said earlier  to much more of a chronic nursing model and so that s positive  But it does change the operating model when you have a payment model like this that is focused on these chronic conditions and so they re working through that and I think doing a very nice job We haven t called out the specific financial drag on the clinics  Broadly  depending on the size of the clinic to get to profitability  you re talking sort of high single  digits  million EBITDA to get to profitability over a several year period including the capex  so you can  you can multiply through and see some of the impact  I mean  ultimately the size of the facility  the  600 million facility is effectively over a period of P L burn that we re taking off our income statement  That the purpose of the facility is to fund those losses and so I think that gives you the order of magnitude over the life cycle of the investment what the impact is and typically by year four  year five  these things are really starting to breakeven and drive profitability  So I think that gives you a broad sense of the impact  which is why it s so important that we did this so we could scale the opportunity Bruce D  Broussard    President and Chief Executive OfficerYeah Frank and I know your question wasn t inferring this  but I d just like to emphasize it  The main reason why we re doing this with WCAS is to scale the business and that s really what Brian was articulating because we feel it s a great addition to the organization and the organization is ready to scale it  Some other things that Brian was talking about were some barriers to do it  so at the end of the day  we want to scale this and begin to start getting more and more members in our proprietary product Brian A  Kane    Chief Financial OfficerI would just add one more point  We get this question all the time  and want to make sure investors have this  There is    in terms of where the EBITDA per clinic can go because we get asked that all the time and it really can vary  so some of the smaller clinics could be  2 million   3 million   4 million  Some of the bigger clinics could be  6 million   7 million   8 million  So it really depends on the size of the clinic in terms of the EBITDA but when you look at the economics  just a return on capital on individual clinic  when these gets to profitability  it s a really good model Amy Smith    Vice President of Investor RelationsThank you  Next question please OperatorNext question comes from the line of Steven Valiquette from Barclays  Your line is open Steven Valiquette    Barclays    AnalystGreat  thanks  Good morning  Bruce and Brian  So two questions around the first quarter of 2020  First  for the Group and Specialty segment  you re targeting 84  to 84 5  benefit ratio for the full year  but given that the jump off point in 4Q  19 is in the 95  range  I guess I m curious will that gradually trend back down throughout 2020 or will your improvement show up immediately such that 1Q  20 for the segment maybe in line with the full year range  somewhere in that mid 80  range  that s question one And question two  also around 1Q  I mean the stock is at  20 right now  so it s a focus on the slight negative but the    I mean the adjusted tax rate in 4Q  19 I think came somewhere in the mid single digits  probably due to the Group and Specialty segment results  but just given your comment around 1Q  20 earnings being 24  of the full year  should we assume the overall tax rate normalizes back to    call it 30  or so in 1Q  20  Thanks Brian A  Kane    Chief Financial OfficerSure  So fair questions  We don t give quarterly MER guidance by segment  as you know  but I think it s fair to say the Group    the way the Group segment works is the MER is low in the first part of the year and then it increases as people get through their deductibles  So I think in terms of the way you think about the sort of quarterly progression of MERs  you can look at historical patterns and see what it is for the Group business and just use our annual number and frac it out accordingly  But just the way the benefit design works  it s lower MER at the beginning and then it ramps up through the year as people go through their deductibles and we start covering the cost On the tax rate side  really two drivers  one is  what s I guess known as the windfall tax  which is we have stock vestings in December  it s where when our stocks    stock annually vest and we had a big run up in our stock  And so the tax deduction is larger and that drives the improved tax rate  As you know  the stock moved a lot in the last few months and has been volatile  but when it occurred  when the vest incurred  we had the windfall benefit  We also saw profitability show up in different states  little somewhere lower tax states than we expected  So small moves in that can impact the tax rate a bit and so that was also driving it  So it s really for those two reasons that we had a lower tax rate Bruce D  Broussard    President and Chief Executive OfficerBut in general when you look at the tax rate on an annual basis  it remained relatively the same  I mean there is a 50 basis points change  So when you look at an annual side  it s    it had minimum impact on it Amy Smith    Vice President of Investor RelationsAll right  thank you  Next question OperatorYour next question comes from the line of Gary Taylor from J P  Morgan  Your line is open Gary Taylor    J P  Morgan    AnalystHi  good morning  Most of my questions answered  I ll just be real quick  When we go to the healthcare services EBITDA growth  I think 17  at the midpoint  I know you ve covered some of the one time investments you re lapping etc  Is it possible to help us think about organic versus acquisition  is it contemplated that any of the trailing acquisitions or any forward acquisitions are in that number or is that a pretty pure organic growth for 2020 Brian A  Kane    Chief Financial OfficerGood morning  Gary  There is some acquisition in there from the Enclara deal though I would say it s relatively small  so that would be acquisition  I do think there are some  as you said lapping investments on Homecare Homebase which helps  I would say most is organic improvement but if you re sort of trying to model beyond 2020 I wouldn t expect that kind of EBITDA growth beyond 2020  I think it will more normalize to a lower level  So I think that s a fair question  There are some good guys in there but the business organically is growing very nicely  I mean  really all elements  pharmacy  home and primary care are growing nicely organically  So it s    I would say it s a balanced EBITDA growth but there are some good guys in there for 2020 Gary Taylor    J P  Morgan    AnalystAll right  Okay  thanks Brian A  Kane    Chief Financial OfficerYou bet Amy Smith    Vice President of Investor RelationsThank you  Next question OperatorYour next question comes from the line of Whit Mayo from UBS  Your line is open Whit Mayo    UBS    AnalystHey  thanks  Just a quick one on D SNP  the performance has been pretty impressive  Brian  maybe just any color around benefits  design plan strategy anything that s contributed to the recent performance and any expectations for the rest of the year  Is this a one time boost through open enrollment or do you see the momentum continuing throughout the year  Thanks Brian A  Kane    Chief Financial OfficerHey  good morning Whit  So we re certainly hopeful that the D SNP growth continues  we ll see where it goes  We are proud of the D SNP growth that we ve achieved  I think on the benefit side  we continue to emphasize some of the over the counter benefits and a few other things  I would say there wasn t anything dramatically different this year  I think it s really a focus of the organization  leveraging some of our distribution channels to make sure we are appealing to the D SNP population  It s also frankly offering D SNPs in more counties as well and so expanding that as well and so it s really a combination of things  But I would just say that it s certainly important  an organizational focus of ours and in driving the distribution and sales of that product Amy Smith    Vice President of Investor RelationsThank you  Next question OperatorNext question comes from the line of Scott Fidel from Stephens  Your line is open Scott Fidel    Stephens    AnalystHi  good morning  Just wanted to toggle back over to Group and Specialty and definitely it sounds like you re still committed to the business in terms of the investments that you re making and hoping for brighter days ahead  When we look at the 2020 guide  it still is implying pre tax margin still sub 2  and top line growth sub 2  as well  So if we think that some of these bets that you re making around the investments do ultimately pay off  what type of growth rates do you think in pre tax margins are reasonable to think about being sustainable in the longer term Brian A  Kane    Chief Financial OfficerYeah  it s a fair question  Scott  I m really not prepared today to give details on margin and growth  I do think the margins are clearly not nearly where they need to be  We haven t given a margin target on Group and I m not prepared to do that today  but I would tell you that we do expect margins to improve  The ASO level funded margins are much better and we ll continue to get better as we mature in that product  And hopefully  as we move up market will also see some margin improvement as we leverage some of the unit cost benefits we can get by being a bigger presence in the marketplace  And again  we hope we can continue to grow with level funded product but also grow upmarket as well in terms of the top line And so the goal would be to start growing that top line in addition to getting the PMPM benefits that you get in the Group space  So we do think there s an opportunity there  but I wouldn t expect significant growth  I d just    we re hopeful that we can really turn it around and start getting measured growth as we move forward here on both frankly top end and bottom line  And also importantly  just a cross sell benefit that I mentioned on the Specialty side and on the Medicare side  that s an important part of this as well  That won t show up directly in the segment results Amy Smith    Vice President of Investor RelationsThank you  Next question OperatorNext question comes from the line of Michael Newshel from Evercore  Your line is open Michael Newshel    Evercore    AnalystThanks  Maybe just going back to the HIF repeal and I appreciate you re not committing to anything in 2021  but I just wanted to confirm that long term  since you re still targeting that 4 5  to 5  pre tax margin  that s ultimately a higher net margin once HIF is gone  So is it just fair to say that the non deductible headwind will still drop back to margins eventually  but maybe just not all immediately if you favor enrollment growth more instead for a period of time  is that the right way to frame it Brian A  Kane    Chief Financial OfficerI think that s fair  We re committed to 4 5  to 5   Similarly  on the tax reform  we did the same thing  where it went below and then it came back up and so  yes  we re committed to 4 5  to 5  Amy Smith    Vice President of Investor RelationsGreat  Thank you  I think that was our last question Bruce D  Broussard    President and Chief Executive OfficerOkay  I ll just close it out  Again  thanks for our investors and especially today considering it lasted for an hour and a half  so we have lot of engaged investors  so we appreciate that  And as importantly  thanks to the 50 000 people that get up every day and help our members to achieve their best health there  So everyone have a great week and we will talk to you next quarter Operator Operator Closing Remarks Duration  85 minutesCall participants Amy Smith    Vice President of Investor RelationsBruce D  Broussard    President and Chief Executive OfficerBrian A  Kane    Chief Financial OfficerJoseph C  Ventura    Chief Legal OfficerCharles Rhyee    Cowen and Company    AnalystAJ Rice    Credit Suisse    AnalystPeter Costa    Wells Fargo    AnalystJustin Lake    Wolfe Research    AnalystDavid Styblo    Jefferies    AnalystSarah James    Piper Sandler    AnalystGeorge Hill    Deutsche Bank    AnalystKevin Fischbeck    Bank of America Merrill Lynch    AnalystJosh Raskin    Nephron Research    AnalystRicky Goldwasser    Morgan Stanley    AnalystSteve Tanal    Goldman Sachs    AnalystRalph Giacobbe    Citigroup    AnalystFrank Morgan    RBC Capital Markets    AnalystSteven Valiquette    Barclays    AnalystGary Taylor    J P  Morgan    AnalystWhit Mayo    UBS    AnalystScott Fidel    Stephens    AnalystMichael Newshel    Evercore    Analyst
More HUM analysis
All earnings call transcripts",2020-02-06,The Motley Fool,https://invst.ly/projp,2077430
141229,362744,HUM,Cigna Lags Industry In  19  Can Efforts Aid Recovery In 2020 ,opinion,"Cigna Corp    NYSE CI   had a volatile 2019  with the stock losing 17  in the first half of the year and gaining 7 6  in the second half Year to date  the stock has gained 7 6  compared with its  s growth of 18 6   Other stocks in the same space such as UnitedHealth Group Inc    NYSE UNH    Anthem Inc    NYSE ANTM   and Humana Inc    NYSE HUM   have gained 18 7   16  and 29   respectively  over the same time frame 

 
Though Cigna performed well in 2019 and closed the acquisition of Express Scripts  NASDAQ ESRX   which expanded its healthcare offering  the stock seems to have taken a beating from the broader market and sector volatility 
Cigna expects to benefit from its strong business fundamentals  The company s current valuation also seems reasonable 
The stock is trading at a forward 12 month price to earnings  P E  of 10 99X  which is lower than its 5 year median level of 14 19X 
We believe Cigna s stock with a VGM Score of A is poised for gains in 2020 
Factors to Drive Growth in 2020
Business Streamlining  This month  Cigna announced to sell its Group Life and Disability insurance business for  6 3 billion  which is expected to fetch  5 3 billion  This move is in line with the company s efforts to reduce its debt level  Part of the fund will also be used for share repurchases 
This deal also gives a positive signal to investors regarding the company s commitment to work on deleveraging its balance sheet  Also  Cigna s priority is to focus on its core business related to healthcare  which expanded further after the purchase of Express Scripts  The company desires to strengthen its Medicare business  which presents a huge business opportunity on the back of its ever increasing demand from the baby boomer population 
Acquisition of Express Scripts  Cigna acquired the largest pharmacy benefit manager Express Scripts holding for  67 billion  including  15 billion in debt  The merged company is now a one stop shop for customers  healthcare needs  ranging from sale of drugs to insurance cover 
It would benefit consumers by bringing together medical care and pharmacy benefits under one roof to improve treatment and lower costs  The combined company has improved its ranking in the health insurance industry  strengthening its competitive position 
Cigna expects the deal to increase earnings per share from  18 to  20  21 in 2021  The merged company will generate free cash flow of at least  6 billion in 2021 
International Operations Provide Diversification  In the first quarter of 2019  Cigna acquired OnePath Life Insurance from ANZ Bank in New Zealand  This acquisition will enable Cigna to delve deeper into an existing geography  with an expanded set of solutions and capabilities to create more value for its customers and exemplify its continued focus on effective capital deployment to drive long term growth 
This will also expand its international operations  which have been boosting revenues over the years  Also  the company s broadening international business provides proliferation and shields against stiff regulations governing its businesses in the United States 
We believe that the aforementioned factors will  help the stock to gain momentum in the New Year Cigna carries a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-12-27,Zacks Investment Research,https://www.investing.com/analysis/cigna-lags-industry-in-19-can-efforts-aid-recovery-in-2020-200495240,200495240
141230,362745,HUM,Will UnitedHealth Exhibit Strong Share Price Gains In 2020 ,opinion,UnitedHealth Group Inc    NYSE UNH   maintained its strong operating performance trend of the past many years in 2019 However  its shares failed to reflect the same In 2019  the stock has rallied 17 5   underperforming the  s growth of 18 4   Other companies in the same space include Humana Inc    NYSE HUM    Anthem Inc    NYSE ANTM   and Molina Healthcare  Inc    NYSE MOH    which have gained 28 4   16 3  and 16 9  in the past year  respectively The stock of  UnitedHealth was exposed to volatility  as investors shied away from its industry due to regulatory uncertainties emanating from various political proposals  the most prominent being  Medicare For All   proposed by Bernie Sanders  to reform the healthcare system The company s fundamental strength is  nevertheless  reflected by its superior segmental performances and a solid balance sheet position  Its earnings consistently surpassed estimates in each of the past 24 quarters UnitedHealth maintains its leadership position in the health insurance industry by virtue of its two complementary business platforms  namely Optum for health services and UnitedHealth for health benefits In 2020  its segment  UnitedHealthcare is poised to grow on the back of its vast Medicare and expanding Medicaid business  Total enrollment is expected to reach 49 8 50 4 million in 2020  led by Medicare Advantage growth as management expects to further extend the company s market share  In Medicare  margins will be somewhat under pressure year over year by the return of the Health Insurance Tax in 2020  The Medicaid business should gain from expansion of Medicaid in 15 states in 2020 Its Optum segment provides a good revenue diversification  It transformed UnitedHealth from a health insurance company into a healthcare company by opening a number of allied businesses  such as  data and analytics  care delivery  population health management and engagement  health financial services  health IT  benefit and care operations and pharmacy care services under its subsegments OptumHealth  OptumInsight and OptumRx   The aforementioned segment has grown over the years on the back of a slew of mergers and acquisitions  Recently  its sub segment Optum Rx announced that it will acquire Diplomat  a provider of specialty pharmacy and infusion services In 2020  Optum s revenues will be primarily driven by a strong contribution from OptumHealth  up 27 30   followed by OptumInsight  up 11 16   and Optum RX  up 7 9   For next year  management expects revenues of  260 262 billion  representing a 7 8  upside from its upwardly revised 2019 guidance of  242 billion  UnitedHealth s top line is expected between  208 billion and  210 billion while Optum s revenues are estimated between  127 billion and  128 billion  Operating earnings are envisioned to in the range of  21 7 22 3 billion  implying a nearly 8 5  margin at the mid point  Adjusted EPS of  16 25 16 55 indicates 9  growth from the updated 2019 outlook of nearly  15 00 Though the company will continue to perform well in 2020  regulatory instability from various proposals to reform the healthcare will continue through the 2020 presidential elections  This is most likely to expose the stock to volatile swings UnitedHealth carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-12-30,Zacks Investment Research,https://www.investing.com/analysis/will-unitedhealth-exhibit-strong-share-price-gains-in-2020-200495749,200495749
141231,362746,HUM,Goldman Sachs  These 3 S P 500 Stocks Are Poised to Move Higher,opinion,Investors are always on the lookout for a stock that primed to rise   and skill is measured by success  Goldman Sachs  the international investment bank  has achieved that success  by a combination of capital access  institutional savvy  and attracting the right people  The bank s investment arm doesn t just rely on current trends  they work to understand the markets and adjust strategies accordingly To wit  the bank is using new data analysis methods to choose potentially winning stocks  G S financial experts have begun looking at revenue projection adjustments as leading indicators  and testing those predictions against actual performance The results have been interesting  Goldman s hypothetical portfolio  using their new projections  showed an annualized gain of 7   The experiment showed that there is a high potential benefit to crunching numbers and calibrating investment decisions based on real world data The banking giant sees several S P 500 stock plays for investors to consider in coming months  Running each stock through the Stock Screener tool at TipRanks  we ve confirmed that Goldman Sachs is in the majority on Wall Street in recommending these equities  Here s what you need to know about them State Street Corporation  STT While not a household name  State Street  name for the famous street on Boston  is a fixture of the US financial sector  In fact  it can trace its company history back to 1792  and only US financial institution which is older is the Bank of New York  State Street is also one of the world s largest asset managers  with over  2 5 trillion in assets under management  and an additional  31 trillion in its custody For Q3 2019  the most recent reported  the company showed a top line of  2 9 billion and EPS of  1 51  While both numbers were down year over year  they both beat the analysts  forecasts   a good sign  Investors are clearly not worried by year over year declines  as the stock is up nearly 30  since the Q3 report was released Writing on STT for Goldman  4 star analyst Alexander Blostein said   We see the stock as a  self help  story into 2020 as STT s ongoing expense initiatives and significantly improving capital flexibility are likely to amplify benefits from stronger revenues conditions  boosting EPS growth well ahead of the Street s current expectations  Our 2020 2021 EPS is  7 22  8 18 or  12   16  above consensus   The analyst added   Historically  STT has had one of the highest correlations in the group with EPS revisions  67  R squared   and given our significantly above the Street s EPS view   14  on average   we think the stock has more room to run  Blostein upgraded his firm s stance on STT  bumping it to a Buy rating  His  95 price target suggests a robust 17  upside potential for the stock   To watch Blostein s track record  click here Overall  STT holds a Moderate Buy rating from the analyst consensus  based on 8  buy   3  hold   and 1  sell  ratings  Shares are selling for  80 79  and the average price target of  83 31 implies a decidedly modest upside  But  as Blostein s comments indicate  there may be much better potential here than first meets the eye  It also should be noted that STT earns a 9 Smart Score on TipRanks   See State Street s stock analysis at TipRanks Humana  Inc   HUM Humana is another fixture of the financial scene  this time of the health insurance industry  The company is a top provider of Medicare Advantage plans  with over 6 million members enrolled  Sales in the Medicare Advantage segment have pushed the company s success in recent months Rising revenues and earnings are clear from the most recent quarterly release  In Q3 last year  HUM beat both the estimates and year over year numbers on revenues and EPS  The top line number was an impressive  16 24 billion  on the bottom line  EPS came in at  5 03  The strong revenues reflected 2019 generally   the stock grew 32  last year  slightly outpacing the general markets Also positive for investors  Humana has been reliable about the dividend  At 55 cents per quarter  the payment is small  and the yield  at just 0 6   is nothing to write home about  but the company has a 9 year history of growing the dividend payment  The dividend has been increased 3 times since 2016 Goldman s Stephen Tanal added HUM to the firm s Conviction List  saying   We are adding shares of Buy rated HUM to the Conviction List given our expectation of meaningful upward estimate revisions to consensus estimates for 2021 and beyond that we expect will occur due to the recent repeal of the health insurer industry fee  HIF   signed into law by President Trump on 12 20 2019   The analyst continued   We hike our 2021 adjusted EPS estimate by  10  to  24 10 from  21 95  capturing only the benefit associated with a smaller tax burden  which HUM sized at   2 15 per share at its March 2019 Investor Day  Tanal s Buy rating on the stock is backed by a  425 price target  implying an upside of 14    To watch Tanal s track record  click here Humana stock s recent gains have pushed the trading price right through the average price target  and analysts have not yet had time to adjust their sights  Tanal s rating shows that there is likely still upside here  Wall Street appears to agree   HUM has a Moderate Buy consensus rating  with Buys outnumbering Holds buy 9 to 4   See Humana s stock analysis at TipRanks Citigroup  Inc   C Citigroup is the third largest American banking firm  and part of the Big Four industry giants who set the tone for smaller players  With revenues of  72 8 billion in the 2018 calendar year  Citi is clearly doing well  and is on track to bring in higher revenues in 2019  Improvements in the bank s currency and commodities trading division  as well as the corporate and investor clients  pushed C shares to a 12 8  gain in 2019 While C underperformed the broader markets last year  it made up for that with an above average 2 6  dividend yield  The annualized payment stands at  2 04 per share  Better yet  in the last three years C has increased the dividend payment from 16 cents quarterly to 51 cents Quarterly earnings are also steady  In Q3 2019  the top and bottom lines both beat of the forecasts  albeit modestly  Total revenues hit  18 6 billion  while EPS came in at  1 97  As mentioned above  the currency and commodity trading division is doing particularly well  and beat expectations by 4  Like Humana  Citigroup now sits on Goldman s Conviction List  placed there by 4 star analyst Richard Ramsden  Ramsden opined   The market is overly pessimistic on Citi s revenue growth inflection  targeted expense savings  and outlook for credit costs  given the improvement in the risk profile of its international loan book  Citi s path to higher returns is clearer than the market currently ascribes value to  Ramsden backed his Buy rating with an  88 price target  implying an upside of 10  from current levels   To watch Ramsden s track record  click here With 10 Buy ratings against just a single Hold  Citi get a Strong Buy from the analyst consensus  The stock currently trades at  79 45  and the average price target indicates an upside potential of 11    See Citigroup s stock analysis at TipRanks ,2020-01-07,TipRanks,https://invst.ly/pex24,200496890
141232,362747,HUM,Will Humana  HUM  Beat Estimates Again In Its Next Earnings Report ,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering Humana  HUM   which belongs to the Zacks Medical   HMOs industry 
This health insurer has an established record of topping earnings estimates  especially when looking at the previous two reports  The company boasts an average surprise for the past two quarters of 12 64  
For the last reported quarter  Humana came out with earnings of  5 03 per share versus the Zacks Consensus Estimate of  4 58 per share  representing a surprise of 9 83   For the previous quarter  the company was expected to post earnings of  5 24 per share and it actually produced earnings of  6 05 per share  delivering a surprise of 15 46  
Price and EPS Surprise

With this earnings history in mind  recent estimates have been moving higher for Humana  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the company is positive  which is a great sign of an earnings beat  especially when you combine this metric with its nice Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Humana has an Earnings ESP of  0 66  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  3  Hold   it shows that another beat is possibly around the corner  The company s next earnings report is expected to be released on February 5  2020 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2020-01-08,Zacks Investment Research,https://www.investing.com/analysis/will-humana-hum-beat-estimates-again-in-its-next-earnings-report-200497371,200497371
141233,362748,HUM,UnitedHealth  UNH  To Post Q4 Earnings  What s In The Cards     ,opinion,"UnitedHealth Group Inc    NYSE UNH   is set to release fourth quarter and 2019 earnings on Jan 15  before market open The Zacks Consensus Estimate for the company s earnings per share is pegged at  3 77  indicating an increase of 14 94  year over year  The consensus mark for revenues is pegged at  60 98 billion  indicating a rise of 4 38  Factors at PlayRevenues at the UnitedHealthcare segment are likely to have gained from higher enrollment and increase in pricing  The Zacks Consensus Estimate for this segment s revenues is currently pegged at  48 7 billion  indicating growth of 5 1  from the year ago quarter s reported figure  Its business groups   Employer and Individual  Medicare and Retirement  and Global   are expected to have contributed to earnings  Also  revenue growth and cost control are likely to have aided the segment s earnings Revenues at Optum segment are likely to have improved on strong contributions across each of its sub segments  OptumHealth  OptumInsight and OptumRx  The Zacks Consensus Estimate for this segment s revenues is currently pegged at  30 4 billion  suggesting growth of 10 5  from year ago quarter s reported figure The company is likely to have experienced an increase in total medical membership driven by growth in members served in the Commercial and Medicare Advantage  partially offset by lower Medicaid and International membership Share repurchases made by UnitedHealth in the to be reported quarter is likely to have benefited its bottom line 2019 GuidanceThe company expects 2019 adjusted EPS of  14 90  15 Earnings Surprise HistoryThe company boasts an attractive earnings surprise history  It beat estimates in each of the last four quarters  the surprise being 3 41   on average  This is depicted in the chart below UnitedHealth Group Incorporated Price and EPS Surprise

   What Our Model SaysOur proven model predicts an earnings beat for UnitedHealth this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  UnitedHealth has an Earnings ESP of  0 43  as the Zacks Consensus Estimate is pegged at  3 77 per share and the Most Accurate Estimate stands at  3 79 per share 
Zacks Rank  UnitedHealth has a Zacks Rank  3  You can see  Other Stocks That Warrant a LookHere are some other companies in the healthcare sector that you may consider as our model shows that these too have the right combination of elements to post an earnings beat this quarter Humana Inc    NYSE HUM   has an Earnings ESP of  0 15  and a Zacks Rank  2 Centene Corp    NYSE CNC   has an Earnings ESP of  0 91  and a Zacks Rank  3 Medtronic PLC   NYSE MDT   has an Earnings ESP of  0 03  and a Zacks Rank  2 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2020-01-12,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-unh-to-post-q4-earnings-whats-in-the-cards-200498309,200498309
141234,362749,HUM,Stocks   CVS  Humana  HP Rise Premarket  Match Tumbles,news,"Investing com   Stocks in focus in premarket trading on Wednesday 
  CVS Health  NYSE CVS  stock was up 3 2  in premarket trade by 8 20 AM ET  11 20 GMT  after its earnings and revenue beat forecasts  due to strong results from its Aetna  NYSE AET  health insurance business and pharmacy benefit division 
  HP Inc  NYSE HPQ  stock surged 8 2  on reports that Xerox  NYSE XRX  is considering a  27 billion takeover bid in a consolidation move in the face of falling demand for printed products 
  Match Group  NASDAQ MTCH  stock tumbled 12 6  after the dating site owner gave weak guidance for the fourth quarter  citing stronger competition  The Tinder app owner said it expects to incur a loss of about  25 million in the fourth quarter due to long term investments and legal costs 
    CenturyLink    NYSE CTL  stock fell 4 1  after the network operator agreed to pay  400 000 to settle Federal Communications Commission violations over a 911 service outage 
  Humana  NYSE HUM  stock rose 3 1  after the health insurer beat on its bottom and top line and raised its full year forecast 
  Coty  NYSE COTY  stock jumped 4 3  after its earnings came in slightly above forecasts  even as slower sales caused revenue to dip below expectations ",2019-11-06,Investing.com,https://www.investing.com/news/stock-market-news/stocks--cvs-humana-hp-rise-premarket-match-tumbles-2013376,2013376
141235,362750,HUM,U S  Supreme Court justices lean toward insurers on  12 billion Obamacare claims,news,"By Lawrence Hurley WASHINGTON  Reuters    U S  Supreme Court justices on Tuesday appeared sympathetic to claims made by health insurers seeking  12 billion from the federal government under a program set up by the Obamacare law aimed at encouraging them to offer medical coverage to previously uninsured Americans  The justices considered a challenge by a group of insurers of a lower court s ruling that Congress had suspended the government s obligation to make such payments  The insurers have said that ruling constituted a  bait and switch  that would enable the government to withhold money the companies were promised  The court s four liberal justices  in addition to Chief Justice John Roberts and Justice Brett Kavanaugh  all asked questions indicating they are inclined to vote for the insurers   Why doesn t the government have to pay its contracts just like everybody else   said Justice Stephen Breyer  Moda Health Plan Inc and other insurers sued in an effort to compel the Department of Health and Human Services  HHS  to make the payments  The program in question was designed to help insurers recover from early losses they suffered after the 2010 passage of the Affordable Care Act  ACA  under Democratic former President Barack Obama  The law  dubbed Obamacare  has enabled millions of Americans who previously had no medical coverage to obtain insurance  including those with pre existing medical conditions  Unlike other court cases involving Obamacare  this dispute before the justices concerns only payments to insurers and does not directly challenge the law itself  Conservative Justice Samuel Alito seemed most supportive of the government   Has there ever been a case where this court has  in effect  required Congress to appropriate     billions of dollars for private businesses   he asked the insurers  lawyer  Paul Clement  Other insurers involved in the case include Blue Cross and Blue Shield of North Carolina  Maine Community Health Options and Land of Lincoln Mutual Health Insurance Company  If the Supreme Court sides with the insurers  it could result in a significant one time cash infusion for major companies such as  Humana Inc   N HUM   Anthem Inc  N ANTM  and  Centene  Corp  N CNC   according to a note by Evercore ISI  Shares of all three were up slightly on Tuesday  Payments would have come through the law s risk corridor program designed to mitigate insurers  risks from 2014 to 2016  when they sold coverage to previously uninsured people through exchanges established under the ACA  Under the program  insurers that paid out significantly less in claims on policies sold through the exchanges than they took in from premiums provided some of their gains to the government  Insurers that paid out more were entitled to government compensation for part of their losses  Roberts questioned whether any of the insurers would have participated in the program if the payments were not available    Its a good business opportunity for them because the government promised to pay   he said  Republicans  who have opposed Obamacare from the outset and numerous times sought to repeal it in Congress  have called the risk corridor program a  bailout  for the insurance industry  From 2015 through 2017  Congress each year passed appropriations bills that included language barring HHS from using general funds to pay the government s risk corridor obligations  
The U S  Court of Appeals for the Federal Circuit ruled 2 1 in 2018 that Congress effectively repealed its obligation to pay the insurers ",2019-12-10,Reuters,https://www.investing.com/news/stock-market-news/us-supreme-court-justices-lean-toward-insurers-on-12-billion-obamacare-claims-2038109,2038109
141236,362751,HUM,U S  watchdog finds  6 7 billion in questionable Medicare payments to insurers,news,"By Chad Terhune  Reuters    A U S  government watchdog is raising fresh concerns that health insurers are exaggerating how sick Medicare patients are  receiving billions of dollars in improper payments as a result  Health insurers selling Medicare Advantage plans to seniors and the disabled received an estimated  6 7 billion in 2017 after adding diagnoses to patients  files that were not supported by their medical records  according to a report released on Thursday by the U S  Health and Human Services  HHS  Inspector General s Office   Inspectors found that Medicare Advantage insurers had added diagnoses for diabetes  heart disease and other conditions in 99 3  of chart reviews of patient information  even though they did not appear in records from doctors  hospitals or other medical providers  Insurers deleted incorrect diagnoses less than 1  of the time  they found  The additional diagnoses boosted government payments to insurers by an estimated  6 9 billion  while the deleted information trimmed payouts by nearly  200 million  producing a net benefit of  6 7 billion for the companies   We could not see any services with the diagnosis and that raised a number of concerns   Linda Ragone  a regional inspector general in Philadelphia and co author of the report  said in a phone interview   There is a vulnerability here that needs to be addressed   The report highlighted a group of 4 616 Medicare Advantage enrollees for whom insurers added a diagnosis that resulted in a higher payment  even though there was no record of the person receiving any medical services during the year under review  Medicare Advantage plans are privately run alternatives to traditional Medicare  They served 22 million people   or 1 in 3 of those eligible for the government healthcare program   at a cost of  210 billion in 2018   The report did not identify specific insurers  UnitedHealth Group Inc  N UNH    Humana Inc   N HUM  and CVS Health Corp  N CVS  through its ownership of Aetna  NYSE AET   are among the biggest sellers of Medicare Advantage plans  Together  the three companies have 54  of the market  according to the Kaiser Family Foundation  America s Health Insurance Plans  AHIP   an industry trade group  said the rate of improper payments in the Medicare Advantage program has been decreasing   Everyone agrees that Medicare Advantage payments must be fair and accurate  and we continue to work with  Medicare  to improve payment accuracy   said AHIP spokeswoman Kristine Grow  The U S  government pays Medicare Advantage insurers based on a risk score for each enrollee  The formula pays more for sicker patients  creating a financial incentive for insurers to inflate risk scores  The U S  Centers for Medicare and Medicaid Services  CMS  should be doing more to prevent insurers from exploiting this vulnerability  the inspector general said  In a Nov  1 letter to the inspector general s office cited in the report  CMS challenged the  6 7 billion estimate of payments linked to chart reviews as too high  The agency agreed with the report s recommendations for increased oversight and audits  CMS in a statement said it is  committed to ensuring that Medicare Advantage plans submit accurate information to CMS so that payments to plans are appropriate   
Prior to these findings  Medicare estimated it had made  40 billion in overpayments to insurers from 2013 to 2016 due to diagnoses submitted by health plans not supported by medical records ",2019-12-12,Reuters,https://www.investing.com/news/stock-market-news/us-watchdog-finds-67-billion-in-questionable-medicare-payments-to-insurers-2039671,2039671
141238,362753,HUM,Why Should You Retain MEDNAX  MD  Stock In Your Portfolio ,opinion,MEDNAX Inc    NYSE MD   has been in investors  good books on the back of its healthy revenue stream and strategic initiatives The company has also been adopting measures to boost its portfolio and enhance its capabilities Its   of A is also impressive  Here V stands for Value  G for Growth and M for Momentum with the score being a weighted combination of all three factors Now let s see what makes this stock an investor favorite Riding high on operational efficiency and inorganic growth story  MEDNAX has been witnessing solid revenue growth over the past many years  The company saw a CAGR of 12 3  between 2012 and 2018  In the first nine months of 2019  its top line inched up 1 6  year over year  We expect MEDNAX to witness revenue growth in the coming quarters on strategic initiatives Acquisitions and divestitures have been a major catalyst  Significant buyouts including that of vRad in 2015 helped the company expand its services in telemedicine  In 2018  the entity acquired nine physician group practices  Following this trend  in the first nine months of 2019  MEDNAX closed the transactions of two neonatology physician practices  two maternal fetal medicine physician practices and two other pediatric subspecialty practices MEDNAX has been affiliated to Boca Radiology Group  P A   a private radiology physician group based in Boca Raton  FL  This move is in line with the company s strategy to widen its radiology practices  thereby cementing its position as one of the leading players in the nation  Notably  MEDNAX reads 11 8 million studies per year through its chain of more than 825 board certified or eligible radiologists In October 2019  MEDNAX divested its MedData business to Frazier Healthcare Partners  The divestiture is expected to further strengthen the company  both financially and strategically as well as help it concentrate more on its core business  This strategic action will also likely aid it to pay down debt However  the company has been enduring elevated debt levels for the past many years  Long term debt piled up at 45   on average  from 2014 to 2018  Moreover  interest expenses have been escalating since 2015  The company s high debt level and decreased interest servicing capability raise its financial risk In the past year  shares of this Zacks Rank  3  Hold  company have shed 24 3  of value against its  s growth of 13  Stocks to ConsiderInvestors interested in the medical sector might consider some better ranked stocks like Humana Inc    NYSE HUM    WellCare Health Plans  Inc    NYSE WCG   and The Joint Corp    NASDAQ JYNT   Humana operates as a health and well being company in the United States  For the trailing four quarters  the company delivered an earnings beat of 8 6   on average  It currently holds a Zacks Rank  2  Buy   You can seeWellCare Health offers managed care services to government sponsored health care programs  The company came up with a positive surprise of 17 3   on average  for the preceding four quarters  It currently sports a Zacks Rank  1 The Joint Corp  develops  owns  operates  supports and manages chiropractic clinics  For the last four quarters  the company has an earnings beat of 175 8   on average  The stock is presently Zacks  1 Ranked Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2020-01-14,Zacks Investment Research,https://www.investing.com/analysis/why-should-you-retain-mednax-md-stock-in-your-portfolio-200498879,200498879
141239,362754,HUM,Goldman likes Humana in premarket analyst action,news,"Kodiak Sciences  NASDAQ KOD  initiated with Buy rating and  100  47  upside  price target at Jefferies  Shares up 1  premarket 
Tivity Health  NASDAQ TVTY  initiated with Neutral rating and  22  6  upside  price target at Credit Suisse 
Endo International  NASDAQ ENDP  upgraded to Overweight with a  7  56  upside  price target at Piper Jaffray  Shares up 4  premarket 
Humana  NYSE HUM  added to Conviction Buy List at Goldman Sachs 
Zimmer Biomet Holdings  NYSE ZBH  named a Top Pick at BTIG Research 
Incyte  NASDAQ INCY  downgraded to Neutral with a  79  8  downside risk  price target at Mizuho Securities  Shares down 12  premarket after failed itacitinib study in GvHD 
MEDNAX  NYSE MD  downgraded to Neutral with a  29  5  upside  price target at Citigroup  Shares down 2  premarket 
Novo Nordisk  NYSE NVO  downgraded to Neutral at Guggenheim  Shares down 1  premarket ",2020-01-03,Seeking Alpha,https://invst.ly/pd1fx,2051798
141240,362755,HUM,Managed care providers could see healthy 2020 on repeal of insurance tax,news,"Goldman s Stephen Tanal and JPMorgan s Gary Taylor are bullish on Humana s  NYSE HUM  growth prospects on the basis of the expected permanent repeal of the health insurance tax  HIT  associated with the Affordable Care Act  ACA   Mr  Tanal has raised his price target to  425  17  upside  from  397 and raised in non GAAP EPS target  10  to  24 10  Mr  Taylor has raised his price target to  448 from  437 and maintains his  Top Pick  tag on the stock 
The tax on providers  enacted by the Obama administration  was intended to subsidize the cost of insurance for uninsured families and individuals  Companies have been lobbying to kill the tax for years since they have had to absorb part of the expense in order to remain competitive in the Medicare Advantage market 
In its year end spending deal  Congress appears ready to do just that  the House passed the package on Tuesday  December 31   If the Senate goes along  a virtual certainty  the tax would be repealed in 2021 
In 2018  UnitedHealth Group  NYSE UNH  paid  2 60B  the highest HIT tab  followed by Anthem  NYSE ANTM    1 54B   Humana   1 04B  and Centene  NYSE CNC    709M  
Related tickers  Cigna  NYSE CI   WellCare Health Plans  NYSE WCG   Molina Healthcare  NYSE MOH   CVS Health  NYSE CVS  ",2020-01-03,Seeking Alpha,https://invst.ly/pd33l,2051883
141256,362771,HUM,Here s Why Select Medical  SEM  Stock Looks Attractive,opinion,"Select Medical Holdings Corporation   NYSE SEM   has been in investors  good books  owing to its consistently strong operating performance 
In the last reported quarter  the company beat estimates by 50   Annual estimates for Select Medical have been northward bound over the past 30 days  reflecting analysts  confidence in the stock  Over this period  the Zacks Consensus Estimate for current year earnings climbed 4 7  to  1 12 
The stock carries a Zacks Rank  1  Strong Buy  and a Value Style Score of A  Our research shows that stocks with a Value Style Score of A or B when combined with a Zacks Rank  1 or 2  Buy  offer the best opportunities in the value investing space 
You can see 
Factors Favoring the Stock
Strong Earnings Guidance  The company raised its earlier provided guidance for 2019  It now expects consolidated net operating revenues for 2019 to be in the range of  5 375  5 475 billion  versus earlier guidance of  5 2  5 4 billion   adjusted EBITDA between  685 million and  700 million  versus  660 million and  700 million expected earlier   diluted earnings per share in the range of  1 00 and  1 06  versus  1 00 to  1 16 as per the earlier guidance   adjusted earnings per common share to be in the range of  1 07  1 13  versus  0 97 to  1 13 projected earlier  
Increasing Top Line  The company s revenues have been increasing over the years  Its revenues witnessed a CAGR of 13 5   2014 2018  and was up 7  in the first nine months of 2019  This growth has been achieved on the back of its leadership position and reputation as a high quality  cost effective healthcare provider in each of its business segments  which allow it to attract patients and employees  aid in marketing efforts to referral sources  and helps to negotiate payor contracts  For 2019  the company expects net revenues to be in the range of  5 375 billion to  5 475 billion  up 6 7  year over year  calculated at the mid point  
Acquisitions  A number of acquisitions made by the company over the years have aided its inorganic growth  It is well positioned to capitalize on consolidation opportunities within each of its business segments  which operate in a highly fragmented market and selectively augment the company s internal growth  With its geographically diversified portfolio of facilities in the United States  its footprint provides a wide ranging perspective on multiple potential acquisition opportunities 
Concentra Segment Poised to Grow  The acquisition of U S  HealthWorks in 2018 has driven growth in the company s Concentra segment led by increased visits  decreased patient turnaround times and enhanced staffing efficiencies  Concentra is the nation s largest provider of occupational health services  This segment s expanded national footprint  coupled with its focus on quality care and patient client satisfaction  gives the company a distinct competitive advantage and will drive growth opportunities for the rest of 2019 and beyond  The segment s revenues grew 5  year over year in the first nine months of 2019 
Year to date  the stock has gained 44  compared with the  s growth of 12 3    The company has performed better than other stocks in the same space such as Cigna Corp    NYSE CI    Anthem Inc    NYSE ANTM   and Humana Inc    NYSE HUM    which were up 2 8   8 9  and 19 3   respectively 
 
 
7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2019-12-04,Zacks Investment Research,https://www.investing.com/analysis/heres-why-select-medical-sem-stock-looks-attractive-200490102,200490102
141257,362772,HUM,Why Is Humana  HUM  Up 9 5  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Humana  HUM   Shares have added about 9 5  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Humana due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Humana s Q3 Earnings Surpass Estimates  Improve Y YHumana s third quarter 2019 operating earnings per share of  5 03 beat both the Zacks Consensus Estimate and the year over year figure by 9 8   This upside can primarily be attributed to Medicare Advantage membership growth and higher revenues Operational UpdateRevenues of  16 2 billion were up nearly 14 3  year over year  Moreover  the top line surpassed the Zacks Consensus Estimate by 0 5   Adjusted consolidated pre tax income of  869 million decreased 5 7  year over year due to weekday seasonality Benefit ratio expanded 300 basis points  bps  to 85  Operating cost ratio contracted 210 bps to 11 4  Segmental ResultsRetailRevenues from the Retail segment were  14 09 billion  up 17  year over year  This can primarily be attributed to Medicare Advantage membership strength and higher per member premium along with improved state based contracts membership  Benefit ratio of 85 9  expanded 270 bps year over year due to 2019 HIF suspension  unfavorable impact from weekday seasonality  lower favorable prior period development  in the segment and the shift in Medicare membership mix  The segment s operating cost ratio of 9 3  contracted 190 bps year over year on the suspension of the health insurance industry fee  HIF  in 2019  better scale efficiencies related to its Medicare Advantage membership and operating cost efficiencies Group and SpecialtyRevenues from the Group and Specialty segment were  1 89 billion  down 0 3  from the prior year quarter due to a reduction in fully insured group commercial and specialty membership  the impact of a few contractual incentives and also adjustments related to the TRICARE contract of 2018 Benefit ratio expanded 560 bps year over year to 86 3   due to the impact of weekday seasonality in the quarter under review  effect of HIF suspension in 2019  lower prior period development  effect of the continued migration of fully insured group members  and dental network contracted rates  Operating cost ratio contracted 170 bps year over year to 21 9  Healthcare ServicesRevenues of  6 6 billion increased 11  year over year  primarily owing to Medicare Advantage membership growth  Operating cost ratio expanded 10 bps year over year to 96 2  Individual CommercialHumana exited this business effective Jan 1  2018 Financial UpdateAs of Sep 30  2019  the company had cash  cash equivalents and investment securities of  16 36 billion  Debt to total capitalization ratio as of Sep 30  2019 was 34 3   contracting 310 bps from Dec 31  2018  Operating cash inflow totaled  2 4 billion at third quarter end  up 8 3  year over year Capital DeploymentThe company paid out cash dividends worth  74 million in the quarter under review  In October 2019  it declared a cash dividend of 55 cents per share  payable Jan 31  2020 to its shareholders of record as of Dec 31  2019  In July 2019  its board of directors approved a share repurchase plan worth  3 billion  set to expire Jun 30  2022  It also entered into an agreement in July this year with a third party financial institution to implement a  1 00 billion ASR program under the authorization  In the quarter under review  the company repurchased around 2 695 900 shares under this plan  As of Nov 5  2019  it had remaining share repurchase authorization of  2 billion 2019 GuidanceAfter third quarter results  the company revised its 2019 guidance  Adjusted EPS is now expected to be approximately  17 75  The 2019 individual Medicare Advantage membership is anticipated to be around 530 000 members 
How Have Estimates Been Moving Since Then 
It turns out  estimates review have trended downward during the past month  The consensus estimate has shifted  13 06  due to these changes 
VGM Scores
At this time  Humana has a great Growth Score of A  though it is lagging a lot on the Momentum Score front with a D  However  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Humana has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-12-05,Zacks Investment Research,https://www.investing.com/analysis/why-is-humana-hum-up-95-since-last-earnings-report-200490800,200490800
141258,362773,HUM,UnitedHealth  UNH  To Buy Diplomat  Expand Pharmacy Services,opinion,"UnitedHealth Group Inc  s   NYSE UNH   health service segment Optum s pharmacy care services  OptumRx will acquire Diplomat  a provider of specialty pharmacy and infusion services 
The agreement includes buying Diplomat s outstanding common stock for  4 per share through a cash tender offer and takeover of existing debt 
Diplomat is a perfect fit for OptumRx given the former company s niche in treating patients with complex diseases  such as oncology and immunology  It also provides specialized infusion therapies in convenient and clinically appropriate settings with a vast presence in all 50 states and Washington  D C 
The deal will aid the segment s margin by lowering total cost of care  which will be achieved by improved health outcomes and reduced prescription drug costs 
Through OptumRx  the company aims to provide a full spectrum of pharmacy care services by making drugs more affordable and creating a better experience for consumers   
OptumRx promotes the lowest net cost prescription drugs through negotiated discounts and outcomes based contracts with drug manufacturers   The company continues to focus on new ways to drive cost savings across the pharmacy supply chain 
Optum Rx s services include Pharmacy Care  specialty pharmacy  infusion pharmacy  home delivery  community pharmacies  physician and consumer digital tools  It is one of the fastest growing businesses with more than 56 million people served  1 3 billion of adjusted scripts processed annually and approximately  96 billion in total prescription spend managed annually  Last year  to expand business  it acquired specialty pharmacy company  Avella  and Genoa Healthcare  which run pharmacies in behavioral health clinics 
Over the long term  management expects OptumRx revenues to grow at an average annual rate of 5  to 8  with operating margins of 3 5  
The pharmacy benefit management  PBM  space is witnessing tough competition and health insurers are foraying into this market to control drug cost  which forms a significant part of their medical cost  While some insurers have acquired PBM players  others are developing their in house PBMs 
For instance  Humana Inc    NYSE HUM   and Anthem  NYSE ANTM  have their in house PBMs named Humana Pharmacy Solutions and IngenioRx  respectively  Last year  Cigna Corp    NYSE CI   merged with  Express Scripts  NASDAQ ESRX   the leading PBM player and Aetna  NYSE AET  got acquired by CVS Heath Corporation   NYSE CVS   Year to date  the stock of UnitedHealth has gained 11 4   compared with the  s growth of 12 8  

 
UnitedHealth carries a Zacks Rank  3  Hold  
You can see  
Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ",2019-12-10,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-unh-to-buy-diplomat-expand-pharmacy-services-200491645,200491645
141259,362774,HUM,Resurgent health insurer stocks face test at Democratic debates,news,"By Lewis Krauskopf NEW YORK  Reuters    Shares of U S  health insurers that have rebounded in the past two months could come under pressure this week as Democrats square off in their first presidential debates  with healthcare policy reform potentially high on the agenda  Support for government run  Medicare for All  plans from U S  Senator Bernie Sanders and other left leaning politicians and candidates shook the stocks earlier this year  and has contributed to the overall sector s underperformance  despite the recent recovery   The debates take place on Wednesday and Thursday in Florida   with 10 candidates taking part each night   as Democrats vie for their party s nomination for president in 2020  Other debates are expected in July and later in the fall  The stocks have also faced uncertainty because of changes proposed by the Trump administration involving how the industry uses drug discounts and policies regarding disclosure of hospital and physician pricing   Of all healthcare companies  insurer stocks have  the most to win or lose  from the debates  said Martin Jarzebowski  sector head of healthcare for Federated Investors    They have already been hit the hardest when you looked at all of the different Medicare for All proposals   Jarzebowski said  With a variety of healthcare reform ideas   some more radical than others   clouding their prospects  health insurer stocks have lagged this year  The S P 1500 managed care sub index is up barely over 1  in 2019  That trails a 7 5  rise for the broader S P 500 healthcare sector and the 16 5  gain for the S P 500  a common barometer of the overall stock market  Since mid April  however  the S P 1500 managed care index has climbed over 15   through Tuesday s close  nearly doubling the increase of the overall healthcare sector over that time  while the S P 500 has barely gained  Among health insurer stocks over that time  Anthem  NYSE ANTM  climbed 20   UnitedHealth Group  NYSE UNH  rose 14  and Molina Healthcare increased nearly 25   Investors seem more confident that the chances are small that the 2020 elections will result in a government run healthcare system that eliminates the role of private insurers  according to analysts   The markets are pretty comfortable that something like a single payer system isn t going to happen  anytime soon    said Ipsita Smolinski  managing director at healthcare research and consulting firm Capitol Street   For a graphic on  Rebounding health insurer shares  click   BIDEN BOUNCE Jarzebowski also noted that the rebound in insurer shares came as former Vice President Joe Biden  who is seen as likely to favor more moderate healthcare reforms  officially entered the race and has been leading in polls  The companies also  printed solid numbers  in their first quarter results  said Sahak Manuelian  head of equity trading at Wedbush Securities   The weakness had been more political risk than any kind of fundamental risk to their business   Manuelian said  Democrats will likely focus on three healthcare policy themes  Bernstein analyst Lance Wilkes wrote in a note ahead of the debates  expanding access to coverage  improving affordability  and attacking prescription drug costs  How the health insurer stocks perform following the debates may depend on which candidates are perceived as having done well  said Michael Newshel  an analyst with Evercore ISI   If someone that is pounding the table for Medicare for All  no compromise  are they getting rewarded for that in the polls   said Newshel   Or is there clearly some room for some candidates to talk about incrementalism and not get punished for that    Indeed  some candidates might be more likely to embrace improvements to the Affordable Care Act  ACA   a change that could be viewed more favorably than wholesale system reform  One candidate whose position may be closely watched  according to Wilkes  is U S  Senator Elizabeth Warren  who has gained some steam in recent polls    Is she for Medicare for All or does she support building upon and expanding the ACA   Wilkes said  And some proposals could benefit insurers  such as the ability for adults 55 years old or younger to  buy in  to Medicare  the federal government health plan for which people now must be at least 65 to be eligible  That could particularly help insurers such as  Humana Inc   NYSE HUM   which specializes in private Medicare Advantage plans  Newshel said  
 As these stocks sold off  there hasn t be any differentiation  in terms of their product mix   he said ",2019-06-26,Reuters,https://www.investing.com/news/stock-market-news/resurgent-health-insurer-stocks-face-test-at-democratic-debates-1908383,1908383
141260,362775,HUM,Humana s  HUM  Alliances To Offer Relief To Members With CKD,opinion,Humana Inc    NYSE HUM   entered into agreements with Monogram Health and Somatus to boost its care management portfolio  The two specialized care management companies would help Humana provide customized services to its Humana Medicare Advantage and Commercial members  who suffer kidney disease and reside in four states  While Monogram Health operates in Louisiana and Mississippi  Somatus is located in Georgia and Virginia This unique tie up would allow Humana to diagnose and manage kidney disease much better  which in turn  will likely improve overall health outcomes and quality of life  Many Americans suffer kidney diseases and with proper intervention  the same can be controlled  Chronic kidney disease  CKD  is the nation s ninth leading cause for death  Per Centers for Disease Control  CKD impacts more than 30 million Americans Humana expects to serve members with this condition and provide them with coordinated care to cure the same  Patients would also be given access to tools that would help in managing their health  The members would be able to get care within the comforts of their own homes  The services would also be delivered to members with chronic kidney and end stage renal disease Teams from both companies include clinicians  such as nephrologists  nurses  dietitians and social workers  The range of services would consist of care coordination with an individual s primary care physician and nephrologist  in house health and medication evaluation  patient education about treatment choices as well as counselling sessions  Services through Monogram Health are already available while those via Somatus will commence on Jan 1  2020 This comprehensive approach to healthcare is in line with the company s commitment to improve health outcomes through high quality care while keeping costs under control Humana has constantly taken up initiatives to boost its network and offer value based customized care options  As of Sep 30  2019  it had more than 2 3 million individual Medicare Advantage members and approximately 115 000 commercial members   Shares of this Zacks Rank  3  Hold  company have gained 10 3  in a year s time  outperforming its  s 2 4  growth Stocks to ConsiderInvestors interested in the medical sector might consider some better ranked stocks like Select Medical Holdings Corporation   NYSE SEM    WellCare Health Plans  Inc    NYSE WCG   and Genesis Healthcare  Inc    NYSE GEN    You can see Select Medical Holdings operates critical illness recovery hospitals  rehabilitation hospitals  outpatient rehabilitation clinics and occupational health centers  In the trailing four quarters  the company s average beat was 11 07   The stock sports a Zacks Rank  1 WellCare Health offers managed care services to government sponsored health care programs  The company pulled off average positive surprise of 17 32  in the preceding four quarters  It carries a Zacks Rank  2  Buy  Genesis Healthcare operates skilled nursing facilities and assisted senior living facilities  In the last four quarters  the company delivered average beat of 80 96   It has a Zacks Rank of 1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-12-11,Zacks Investment Research,https://www.investing.com/analysis/humanas-hum-alliances-to-offer-relief-to-members-with-ckd-200492110,200492110
141261,362776,HUM,New frontier in health fraud  Genetic tests of the elderly,news,"By Sarah N  Lynch
LAWRENCEVILLE  Ga   Reuters    The genetic screening sales reps turn out at health fairs  houses of religion  parks and elder enclaves  offering seniors a chance to learn if they or their loved ones are at risk of developing cancer  All they need  the reps say  is a free cheek swab 
In truth  U S  federal investigators say  some of the sales representatives are part of a burgeoning industry that threatens to become what multiple government investigators call the next big frontier in healthcare fraud  genetic testing  which is reaping millions of dollars from unnecessary tests that target senior citizens 
Shimon Richmond  assistant inspector general for investigations with the Office of Inspector General for the Department of Health and Human Services  said his office has seen a steady stream of complaints into genetic testing  In 2018  the inspector general s office received about one or two complaints per week  Now  he said  the fraud hotline burns with as many as 50 calls weekly 
 We have investigations going on in this space across the country  It is not limited to one geographic region   Richmond said in an interview   This is touching every corner  
In all  more than 300 federal investigations  conducted by multiple law enforcement agencies  are examining genetic testing fraud schemes  said a law enforcement official who spoke on condition of anonymity because the inquiries are not yet public  The investigative crush was sparked in part by unusual Medicare billing data patterns that started to emerge in 2015 
In the United States  genetic testing has skyrocketed  For Medicare  the public insurance program for elderly and disabled Americans  payouts for genetic tests jumped from  480 million in 2015 to  1 1 billion in 2018  a Reuters analysis found  Those figures do not include invoices for spending by state Medicaid programs  which serve the poor  or supplemental Medicare insurance programs offered by private insurers 
The investigations are examining billings submitted to federal health insurance programs  By law  all diagnostic lab tests must be ordered by a doctor treating a patient for a specific condition 
In the cases under review  investigators and patients told Reuters  marketers get elderly residents to turn over their Medicare or Medicaid information  along with their driver s license and other identifying information  and tell them they will take a free cheek swab that can help them understand their risks of developing cancer or whether their genetics could unlock clues about how they will respond to drug treatments  They then get a doctor to sign off and approve the test and ship the swab off to a lab  which seeks Medicare payouts 
But many of the lab tests are not relevant to the patient s history  and some of the doctors sign off on the results without conferring with the patient  said investigators familiar with the operations and patients interviewed by Reuters  Suspect companies pocket thousands  with a cut going to doctors  but the seniors get little  if any  benefit  investigators say 
Brian Benczkowski  the assistant attorney general for the U S  Department of Justice s Criminal Division  estimated that fraudulent billings submitted over the last few years are expected to total  north of  1 billion   He called genetic testing of the elderly  the next big frontier in federal healthcare fraud enforcement  
 There is a huge pot of money that entrepreneurial criminals are trying to figure out how to access   Benczkowsi told Reuters 
Investigators say genetic testing became a ready target thanks to advances in medical technology and a rise in the technique s popularity  Companies such as 23 Me  which offers health and ancestry genetic tests directly to consumers for  199  have entered the mainstream  Their success  federal investigators say  has drawn the attention of scamsters looking to capitalize on the trend 
Rebecca Kinney  the acting director for the Office of Healthcare Information and Counseling  part of HHS  said seniors should be on the lookout for red flags and any genetic tests should be ordered by their own doctors   The thing that we really try to tell people to pay attention to in any kind of marketing scheme or fraud scheme are the phrases  Free to you  or  Free if you have Medicare     she said 
TARGETING SENIOR CITIZENS
In Delray Beach  Florida  Janet Putrah participated in a cheek swabbing event hosted by her condo building s social committee in February 2018 
She said none of the tests  which were sent to a lab called Clio Laboratories  made any sense to her  She was stunned to learn the lab billed her Medicare Part B insurance plan more than  30 000 and was paid more than  12 000 
The test results  were useless   she wrote in a complaint to the condo board   There were pages and pages with information about drugs  It listed 12 drugs that I may have an  unfavorable  response to  I don t take any of the drugs listed  
Putrah said she only participated because her grandmother had died of colon cancer and she was told the test would be paid for by Medicare  In July 2018  she contacted Medicare to raise concerns about her billing statement  and then in December 2018 she called the inspector general s fraud hotline and forwarded supporting documents 
 It s my money you re taking from me in taxes   she said   This is just insane  
Jean Stone  a Medicare fraud specialist who worked for the federal Centers for Medicare   Medicaid Services and now often testifies as an expert witness  said the test results Putrah received appear  useless  
 They paid  12 000 they shouldn t have paid   Stone said of Medicare  calling the test  wasted taxpayer dollars  
 Who gets the test results   she asked   They don t even know who the woman s doctor is  
Another condo resident  Arlene Pallack  said her Humana  NYSE HUM  Medicare Advantage plan in 2018 paid for  2 225 17 of the  4 625 42 Clio charged for her cheek swab  Humana is concerned about the  growing health care issue  of testing fraud  a spokeswoman said  and targets misuse 
Until she was interviewed by Reuters this August  Pallack had never received the results  She only got them after calling the lab to inquire 
A spokesperson for the Centers for Medicare and Medicaid Services said it uses an  aggressive  approach to address fraud prevention 
Janet Shaver  the current treasurer of the condo board where Putrah and Pallack participated in the cheek swabbing event  said the board s leadership has since changed  but that she intends to follow up  to make as many people as possible aware of this  
Victoria Nemerson  Clio s general counsel  said in a statement that the company s testing is proper and that it has  extensive experience providing important testing and laboratory services for physicians and patients   She added   We commit substantial time and resources to meeting our legal duties  
Other companies are also riding the genetic testing wave 
In California  Jean Reeves  Lura Tamm and Patti Falkenberg said they had their cheeks swabbed at a free event in February 2019 by a pleasant woman named Ronda Butman  a sales representative who later told Reuters she worked on contract with two different marketing companies  One of those businesses was called MyDNACancerTesting  the other marketing company went by MedMolecular 
The women said Butman told them the genetic test could help predict if they were at risk of developing cancer and tell them how their genetics could impact the way their bodies metabolize their medications   a scientific field known as  pharmacogenetics  
All three recall being told the cancer and pharmacogenetic screenings would only cost Medicare a few thousand dollars  All they needed to provide  they said they were told  was a swab of their DNA  their Medicare card number  and other sensitive information  which they shared 
But Medicare explanation of benefits statements  reviewed by Reuters  revealed that a lab in Arlington  Texas  called Spectrum Diagnostic Labs LLC had in two cases tried to charge Medicare more than  15 000 per patient  and received around  5 000 
 I m worried about my Medicare information and my Social Security out there  I thought  My gosh  they ve got all of this information     Falkenberg said 
The tests were approved  records show  by a physician the women say they never met  Dr  Cornelius J  O Leary  Before taking part in genetic testing  public records show  he had filed for bankruptcy in 2012  had been convicted of misdemeanor battery in 2015  and in two lawsuits in 2012 and 2014 had alleged law enforcement officials were harassing him and using counter terrorism units to sleep deprive him 
O Leary could not be reached for comment  He did not respond to emails or calls seeking an interview at multiple numbers listed for him  A relative declined to help Reuters get in touch with him 
Butman  the sales rep  said she later quit her job at MyDNACancerTesting  MedMolecular  the other company  later shut down its genetic testing business 
Butman has since gone back to those from whom she collected cheek swabs to warn them the billings for the tests might be improper  She said she has filed complaints with several state attorneys general against MyDNACancerTesting and some of the labs she fears were overbilling 
 I feel like a victim   said Butman  who said she got involved to help those at risk of cancer 
Jerry Pfeister  the founder of MyDNACancerTesting  told Reuters he contracted with a different company which dealt with the labs  but his company did not interact with labs or doctors  He said MyDNACancerTesting severed ties and stopped collecting cheek swabs for the company that dealt with the labs in April   We never had any interactions with any doctors or labs   Pfeister said 
Monique Deckter  formerly vice president of operations at the other company  MedMolecular  said her small marketing firm contracted with a larger distributor that helped facilitate the tests  which were later shipped to Spectrum Diagnostic  She said she closed MedMolecular in April 2019 amid concerns the telemedicine company she was told to use was not strictly following Medicare rules 
Justo M ndez  an attorney for Spectrum Diagnostic Labs  said every sample it receives comes with a medical order signed by a doctor and a patient consent form   Spectrum has processes in place to ensure compliance with the required documentation needed from the referring physician   he said 
The amounts billed are handled by a third party  he said  and the company has no financial relationships with doctors 
Perry Holloway  a company principal  said he was unaware of any problems  His attorney Samy Khalil said his client  did not know of or intentionally participate in any fraud  
In a common trend nationwide  sales reps were enticed by some marketing firms through ads on recruitment websites  with the promise they could earn from anywhere from  200 to more than  1 000 for every swab collected and sent to the lab  said investigators and several sales reps interviewed by Reuters 
In some cases  investigators warn  such payments could be construed as a kickback  Anti kickback laws prohibit medical referrals in exchange for a reward or anything of value in connection with federal healthcare programs  In 2018  Congress doubled the maximum prison term in such cases to 10 years per offense 
TANGLED TESTING WEB
A little explored world surrounds the marketing companies  laboratories and telemedicine companies involved in elder genetic testing  Among them is Spectrum  Another is Clio Laboratories  the Georgia based lab that is part of an interconnected network of labs  medical billing operations  a telemedicine firm and other healthcare related limited liability companies  company records show 
Several patients said they filed complaints with state or federal agencies against Clio and Spectrum  either by phone or through written complaints seen by Reuters 
In a handful of cases  the patients who had DNA samples sent to Clio or Spectrum said they never spoke with a doctor about why the cancer or pharmacogenetic tests were medically necessary  Moreover  when test results were completed  they were mailed directly to patients  homes  That is not the norm  say doctors and medical experts  Usually  the ordering physician receives results first  then reviews them with the patient 
Nemerson  the Clio lawyer  declined to comment on these specifics  citing her statement to Reuters that the company diligently follows testing rules 
Spectrum s lawyer said the company has not been contacted by the government concerning any patient complaints 
In 2017  the most recent data available  Clio billed Medicare  8 6 million for genetic testing and was paid about  4 6 million 
Clio Laboratories and a cluster of companies   including Elite Medical Laboratories  360 Laboratories and billing company Laboratory Experts   are connected to Jordan Satary  an entrepreneur in his mid twenties whose father once ran a lab that went bust  records show 
His father  Khalid Ahmed Satary  had earlier founded and led Confirmatrix  a Georgia toxicology lab  Satary started that company after his April 2008 release from federal prison  he had pleaded guilty to charges filed in 2003 involving fraud  trafficking in counterfeit products and copyright infringement related to a compact disc company he operated 
Confirmatrix was raided by federal investigators in 2016  media reports say  as part of a probe into a kickback scheme involving opioid pain clinic owners who were routing urine drug tests to toxicology labs  The lab was accused  but not charged  with being part of the scheme in a 2017 indictment filed in Tennessee  The investigation is ongoing 
Confirmatrix filed for bankruptcy November 4  2016  Some of the former employees of the defunct company now work for multiple other labs with ties to the Satary family 
Elite Medical Laboratories  for instance  lists its lab director as Stanley Wu  the former Confirmatrix lab director  Wu hung up on Reuters when it sought his comment and did not respond to an email seeking comment 
Reuters journalists stopped by Elite s office last month  From outside the offices through large front windows  they saw UPS and FedEx  NYSE FDX  boxes stacked inside  with cheek swabs and other DNA samples spilling out  Two men stood at a table sorting them 
Elite has  a long history of providing valuable services  and is  committed to upholding  its legal obligations  Nemerson said in a statement 
Khalid Satary did not respond to text messages or emails seeking comment  An attorney who previously represented Satary told Reuters he could not comment 
Son Jordan is listed in an April 2019 document as the CEO and CFO of a medical billing operation  GNOS Medical  which is located in the same business plaza with Elite and Clio  It has since changed its name to Laboratory Experts  public records show 
Jordan Satary lists Laboratory Experts as belonging to him on his own corporate website  He was separately listed in 2018 as a registered agent for Clio s Florida based location  which later merged with the Georgia office  The contact information on the website for Elite Medical Labs contained an email address as recently as August for his media company  Shufe Media  The reference was later removed  after Reuters inquiries 
Jordan Satary could not be reached for comment  When a reporter stopped by Clio Laboratories in August  the office said he was out of town and referred Reuters to Nemerson  the company s general counsel  He did not respond to subsequent emails listed for his various companies  or to a text message 
DISCIPLINED DOCTORS
Some of the doctors involved in the genetic testing wave also have checkered pasts 
One California doctor was signing off on genetic tests for patients even as two states had disciplined him or were preparing to do so after he was criminally convicted in Los Angeles 
Orthopedic surgeon Dr  Mitchell G  Cohen pleaded guilty in November 2015 to filing a false tax return in connection with an illegal kickback scheme  cooperated with the government s investigation  and later served more than eight months in a halfway house in central California through March 2019  court records show  Cohen was not charged with making an illegal kickback  but pleaded guilty to making a false tax return in a case federal authorities said involved kickbacks 
New York and California each took disciplinary action based on the conviction  with both placing him on probation in June 2018 and June 2019  respectively 
Cohen was approving genetic tests for Medicare patients during his stint in the halfway house and after his probation period ended  He approved the medical necessity of genetic tests handled by labs including BioConfirm in Georgia and Elite Medical Laboratories  lab records show 
He signed off on the genetic test for Elite in September 2018  as he was serving his sentence in the halfway house  records show  He approved the medical necessity of tests sent to Bioconfirm on May 10  2019 
Scott Grubman  an attorney for BioConfirm  said his client  relies in good faith on the information submitted to it by the ordering provider   complies with its legal obligations and is not aware of any issues related to Dr  Cohen 
Contacted by Reuters  Cohen said he was in surgery and hung up  Mark Werksman  his attorney  said Cohen stopped working for several telemedicine companies authorizing genetic tests for Medicare patients on May 20  2019  after the government suspended his Medicare billing privileges  an action that typically occurs after a doctor is convicted 




Under the probation terms  he said Cohen was allowed to work during the day while spending nights in the halfway house  He said Cohen consulted with patients before the tests and followed up to discuss the results 
 He believes he was providing a medically necessary and important service to his patients   Werksman said ",2019-09-25,Reuters,https://www.investing.com/news/world-news/special-report-new-frontier-in-health-fraud--genetic-tests-of-the-elderly-1986202,1986202
141262,362777,HUM,HMO Industry Outlook  Multiple Levers To Drive Growth,opinion,"The Health Maintenance Organization  HMO  industry comprises entities  either private or public  that take care of the basic and supplemental health services of its subscribers  Companies in this space primarily assume the risks involved and assign premiums for health and medical insurance policies  Industry participants also provide administrative and managed care services for self funded insurance Services are generally provided by a network of approved care providers  called in network   which include primary care physicians  clinical facilities  hospitals and specialists  However  out of network exceptions are made in emergencies or when medically necessary  Health insurance plans can be availed by ways such as private purchase  social insurance or social welfare programs such as Medicare and Medicaid  funded by the government Let us take a look at the industry s three major themes      As life expectancy continues to increase in the United States and seniors account for a higher percentage of the total population  overall demand for health insurance for seniors will increase  According to the 2018 U S  Census  between 2010 and 2030  the number of individuals aged 65  is projected to nearly double from 39 million to 73 million  a growth rate nearly 5 times faster than the 17  increase expected for the total population  The census estimates this group to grow from 13  to 21  by 2030   one of the fastest growing within U S  population  This senior population has fueled demand for Medicare Advantage  MA   the private version of the government Medicare program  Medicare Advantage continues to be a popular choice  serving 35  of individuals eligible for Medicare  up from 25  since 2010  These plans have also led to considerable revenue growth for the likes of UnitedHealth Group Inc   NYSE UNH   Humana Inc   NYSE HUM  and Anthem Inc   NYSE ANTM  among other health insurers  The overall Medicare market is forecast to expand from  860 billion annually in 2020 to nearly  1 3 trillion in 2025  According to UnitedHealth  the market for Medicare Advantage could expand from roughly 35  of all seniors today to more than 50  by 2027      The HMO industry is rapidly consolidating with mergers and acquisitions  The most common takeovers in recent years have been in the nature of horizontal expansion in the areas of Medicare and Medicaid as the players seek to garner a greater share of the attractive MA market  Lately  however  the companies have shown interest in expanding vertically and add capabilities to its supply chain through mergers and acquisitions  The mega mergers of Aetna  NYSE AET  with CVS Health Corp  NYSE CVS    CVS  and Cigna Corp   CI  with Express Scripts  NASDAQ ESRX  are the best examples of inter industry deals that led to the union of a health insurer and a pharmacy benefit manager An increase in scale and size will place strong players to serve the health insurance market which is still underserved  According to UnitedHealth  with an estimated 85 million people representing approximately  900 billion in annual health care spending still not served in managed care inthe United States alone  players are well positioned for continued growth      The industry has also witnessed development in ancillary business to diversify revenue sources in the wake of tough regulations laid  via the ACA  on health insurance business  These businesses  mostly in the form of health care services  are growing rapidly  opening up avenues of growth and forming an increased proportion of the industry s total revenues  Health services business is an important growth area for HMOs as these provide unregulated cash flows and enable players to become comprehensive healthcare providers  Ample opportunities of growth exist in the health service business and continued investments are being made in this area  A poster child for the same is UnitedHealth s Optum  which provides a range of healthcare related services  including pharmacy benefit management  physician services  data analytics and more Zacks Industry Rank Indicates Bright ProspectsThe group s   which is basically the average of the Zacks Rank of all the member stocks  indicates upbeat prospects in the near term  The Zacks   which is a 16 stock group within the broader Zacks  sector  currently carries a Zacks Industry Rank  21  which places it at the top 21  of 253 Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperforms the bottom 50  by a factor of more than 2 to 1 The industry s positioning in the top 50  of the Zacks ranked industries is a result of positive earnings outlook for the constituent companies in aggregate  In a year s time  the industry s earnings estimate for the current year has gone up by 4 5  One Year Price PerformanceBefore we present a few HMO stocks that you may want to consider for your portfolio  let s take a look at the industry s recent stock market performance and valuation picture Industry Return Underperformed S P 500 but Betters SectorThe Zacks Medical HMO industry has underperformed both the Zacks S P 500 composite but outperformed its own sector over the past year We see that the stocks in this industry have collectively gained 9 7  over the past year  while the Zacks S P 500 composite and Zacks Medical Sector have rallied 23 7  and 4 1   respectively HMO Industry s Current ValuationOn the basis of forward 12 month price to earnings  P E  ratio  which is commonly used for valuing HMO stocks  the industry is currently trading at 15 87X compared with the S P 500 s 18 29X and the sector s 21 02X Over the past five years  the industry has traded as high as 20 68X  as low as 12 59X and at a median of 16 25X Price to Earnings  P E  Ratio  F12M Price to Earnings  P E  Ratio  F12M Bottom LineDespite earnings outperformance by the companies  the industry has underperformed the S P in a year s time due to various regulatory issues and uncertainty in policy changes in case a new president gets elected  These may have kept investors away from the industry   Shrugging aside the intermittent political disruptions  players in the industry will continue to ride on technological investment and upgrade  application of blockchain technology  growth of new business units  international expansion  better claims handling  medical cost management  mergers and acquisitions  and a healthy balance sheet HMO Stocks to ConsiderTwo stocks in the Zacks Medical HMO space currently carry a Zacks Rank  1  Strong Buy  and  2  Buy   You can see  Select Medical Holdings Corporation  SEM   This stock with a Zacks Rank  1 surpassed earnings estimates in the last reported quarter by 50   It witnessed an upward revision in 2019 and 2020 earnings estimates by 6 7  and 8   respectively  over the past 60 days Price and Consensus  SEMWellCare Health Plans  Inc   WCG   This stock with a Zacks Rank  2 surpassed earnings estimates in the last reported quarter by 40   It witnessed an upward revision in 2019 and 2020 earnings estimates by 13 3  and 2 5   respectively  over the past 60 days Price and Consensus  WCGAnthem Inc   ANTM   The stock surpassed earnings estimates in the last reported quarter by 0 62   The Zacks Consensus Estimate for this Minnetonka  MI based company s 2019 earnings went up 0 4  over the past 60 days Price and Consensus  ANTMMolina Healthcare  Inc   MOH   The Zacks Consensus Estimate for 2019 bottom line of this Louisville  KY based company increased 0 7  over the past 60 days  The stock surpassed earnings estimates by 3 32  in the last reported quarter Price and Consensus  MOH 
Today s Best Stocks from Zacks  Would you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9    This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ",2019-12-16,Zacks Investment Research,https://www.investing.com/analysis/hmo-industry-outlook-multiple-levers-to-drive-growth-200492807,200492807
141266,362781,HUM,Humana  HUM  To Take Over Enclara For Enriched Healthcare,opinion,Humana Inc    NYSE HUM   recently entered into a definitive agreement to purchase the privately held Enclara Healthcare  Enclara   a leading hospice pharmacy and benefit management provider  from Consonance Capital Partners and Enclara management  Expected to close in the first half of 2020  the deal will likely have an immaterial impact on 2020 earnings  However  financial terms of the transaction were not disclosed A Few Details About EnclaraEnclara  one of the nation s largest hospice pharmacy and benefit management providers  aims at easing care delivery for patients resorting to complex care  It serves more than 450 hospice providers and 97 000 hospice patients daily  The transaction includes the acquisition of Enclara Pharmacia  GuidantRx and Avanti Health Care Services and is subject to certain closing conditions Rationale Behind the DealWith this strategic move  Humana would be able to enhance its wide ranging care package to serve pharmacy based requirements associated with hospice care  Additionally  the company would also be able to simplify the mail order pharmacy experience and upgrade its technology stack for in house pharmacy via better mobile medication management and electronic medical record  EMR  connectivity Humana looks forward to utilizing Enclara s clinical management expertise and its trusted relationship with customers that it has built over the past 20 years  The move is in line with its commitment to provide enriched healthcare to individuals Moreover  the deal would allow it to boost its PBM game  which is necessary as other insurers are also putting in concentrated efforts to solidify their presence in the pharmacy benefit management space  For example  Anthem  Inc    NYSE ANTM   launched its own PBM  IngenioRx Other Significant AcquisitionsAcquisitions have always been the company s major growth trajectory  Some most significant ones are the purchase of Family Physicians Group  Your Home Advantage  Curo and a share in Kindred at Home  which helped the company deepen its toes in the home health and hospice market  These tactical initiatives paved way for the company s growth Zacks Rank and Share Price MovementShares of this Zacks Rank  3  Hold  company have gained 25 3  in a year s time  outperforming its  s growth of 12 3  Stocks to ConsiderInvestors interested in the medical sector might consider some better ranked stocks like Select Medical Holdings Corporation   NYSE SEM   and WellCare Health Plans  Inc    NYSE WCG    You can see Select Medical Holdings operates critical illness recovery hospitals  rehabilitation hospitals  outpatient rehabilitation clinics and occupational health centers  In the trailing four quarters  the company s average beat was 11 07   The stock sports a Zacks Rank  1 WellCare Health offers managed care services to government sponsored health care programs  The company pulled off average positive surprise of 17 32  in the preceding four quarters  It carries a Zacks Rank  2  Buy  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  SherazMian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-12-16,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-to-take-over-enclara-for-enriched-healthcare-200493184,200493184
141268,362783,HUM,Humana  HUM  Grows On Strong Medicare Business Expansion ,opinion,Humana Inc    NYSE HUM   is well poised for growth on the back of its robust Medicare business  The company has been constantly taking up initiatives to boost this line of business  which bodes well for the long term Impressive uptick in the Medicare Advantage business is owing to its operating initiatives  evident from the 54  surge in Medicare membership from 2013 to 2018  Higher enrollment and a better offering led to this outperformance Demand for this business line is expected to bump up  riding on complex patient populations who are constantly looking for value based care For 2019  Individual Medicare Advantage membership is predicted to be around 530000  above the previous projection of 415 000 440 000 The company has been making concerted efforts to boost its network of Medicare Advantage members  Recently  it announced the upgrade of health plan choices for its Medicare beneficiaries in New Jersey by adding numerous counties to its network Last month  it entered into a partnership with Hawaii Senior Medical Group to provide coordinated and enriched experience for Medicare Advantage members in Hawaii  Several strategic alliances have been made by the company of late in order to enhance this business line Humana has also been chosen as one of the health plans to provide Florida s Medicare retirees with Medicare coverage effective Jan 1  2020  The company recently announced the launch of Humana Honor Medicare Advantage plans for 2020  designed to complement the Veterans Affairs program Earlier  management stated that it plans to add 270 000 330 000 members to its Medicare Advantage plans for individuals in 2020  As of Sep 30  2019  the company had more than 2 3 million individual Medicare Advantage members Other companies in the same space like Anthem  Inc    NYSE ANTM   has also been working on its Medicare Advantage network  Also  Centene Corporation   NYSE CNC   is on course to acquire WellCare Health Plans  Inc    NYSE WCG    which is expected to close by the first half of 2020  This combined entity will have a wider scale and diversification with more than 12 million Medicaid and nearly 5 million Medicare members Shares of this Zacks Rank  3  Hold  company have surged 30 9   outperforming its  s rally of 20 5   You can see Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-12-27,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-grows-on-strong-medicare-business-expansion-200495222,200495222
141275,362790,HUM,Exclusive  Hedge funds target Centene  may oppose WellCare deal   sources,news,"By Carl O Donnell and Svea Herbst Bayliss  Reuters    Hedge funds Corvex Management LP and Sachem Head Capital Management LP have built stakes in U S  health insurer  Centene   NYSE CNC  Corp and are exploring challenging its planned  17 3 billion acquisition of WellCare Health Plans Inc  people familiar with the matter said on Monday  The hedge funds believe that Centene may be able to do more to find out if another company such as  Humana Inc   NYSE HUM  would be interested in acquiring it  the sources said   The hedge funds are seeking to take advantage of the fact that Centene needs to secure approval from its shareholders for the WellCare deal  according to the sources  who asked not to be identified because the matter is confidential  There is no certainty that the funds will agitate against the deal  the sources added   We remain as committed to our combination with WellCare today as we did when we announced it on March 27   said Marcela Hawn  Centene s chief communications officer   Corvex and Sachem Head declined to comment  WellCare and Humana did not immediately respond to requests for comment  It was unclear whether Humana would take an interest in an acquisition of Centene  When asked during a May 1 earnings conference call with analysts about his view on Medicaid growth in light of Centene s acquisition of WellCare  Humana s chief executive  Bruce Broussard  said the company was  confident in our organic direction   but that its strategy involved always looking at the market for M A possibilities   Centene shares rose 5 percent to  55 23 on the news  WellCare shares dropped 1 4 percent to  256 07  Centene s acquisition of WellCare would create a major new player in government sponsored healthcare  serving 22 million members across 50 states  It would allow it to bulk up its government backed Medicare and Medicaid businesses  while reducing exposure to Obamacare healthcare exchanges  Centene s chief executive officer  Michael Neidorff  76  recently extended his contract to run Centene for another five years  and in a conference call with analysts said he is in good health and looking forward to continuing to run the business   An acquisition of Centene would give Humana control over the largest Medicaid managed care organization in the country and its extensive portfolio of Medicare Advantage customers   Centene has nearly 400 000 customers in Medicare related plans  8 6 million customers in Medicaid related plans and 2 5 million commercial customers including those enrolled in Obamacare health insurance plans  Humana is the second largest Medicare Advantage provider  with 3 7 million Medicare Advantage members and another 4 5 million in Medicare drug plans  It has about 460 000 members in state based contracts that include programs for people eligible for Medicare and Medicaid  temporary assistance and long term support services  It has about 1 5 million commercial customers and nearly 6 million in U S  military plans  including in dental  vision and other supplementary insurance  
A Humana tie up with Centene would face limited antitrust hurdles because there is relatively little overlap in the markets that the two companies operate in ",2019-05-06,Reuters,https://www.investing.com/news/stock-market-news/exclusive-hedge-funds-target-centene-may-oppose-wellcare-deal--sources-1857911,1857911
141276,362791,HUM,Supreme Court to hear insurers  bid for  12 billion in Obamacare money,news,"By Nate Raymond  Reuters    The U S  Supreme Court on Monday agreed to decide whether insurers can seek  12 billion from the federal government under a program set up by the Obamacare law aimed at encouraging them to offer medical coverage to previously uninsured Americans  The justices will hear an appeal by a group of insurers of a lower court s ruling that Congress had suspended the government s obligation to make such payments  The insurers have said that ruling  if allowed to stand  would let the government pull a  bait and switch  and withhold money the companies were promised  Moda Inc unit Moda Health Plan Inc and other insurers that sued to try to compel the Department of Health and Human Services  HHS  to make the payments have said the government was supposed to help them recover from early losses they suffered after the 2010 passage of the Affordable Care Act under Democratic former President Barack Obama  The law  dubbed Obamacare  has enabled millions of Americans who previously had not medical coverage to obtain insurance  Other insurers involved in the case include Blue Cross and Blue Shield of North Carolina  Maine Community Health Options and Land of Lincoln Mutual Health Insurance Company  If the Supreme Court sides with the insurers  it could result in a significant one time cash infusion for major companies such as  Humana Inc   NYSE HUM   Anthem  NYSE ANTM  Inc and  Centene   NYSE CNC  Corp  according to a note by Evercore ISI  The insurers had previously written off the value of the payments  Payments would have come through the law s so called risk corridor program that was designed to mitigate insurers  risks from 2014 to 2016 when they sold coverage to previously uninsured people who bought insurance on exchanges established under the Affordable Care Act  Robert Gootee  chief executive of Moda Inc  said he was encouraged that the Supreme Court agreed to hear the case   We remain confident that the court will ultimately hold the government to its promise to pay those companies  including Moda  who answered the government s call to provide access to affordable health care for the neediest of Americans   Gootee said in a statement  HHS declined to comment  Under the risk corridor program  insurers that paid out significantly less in claims on policies sold through the exchanges than they took in from premiums provided some of their gains to the government  Insurers that paid out more were entitled to government compensation for part of their losses  Republicans  who have opposed Obamacare from the outset and sought numerous times to repeal it in Congress  have called the risk corridor program a  bailout  for the insurance industry  In December 2014  Congress passed an appropriations bill for the 2015 fiscal year that included a rider barring HHS from using general funds to pay the government s risk corridor obligations  As a result  the government could compensate insurers only with the money it collected from insurance companies that paid less than they took in from premiums  Congress enacted identical riders for fiscal years 2016 and 2017  Payments from insurers  though  could not fund all of the claimed risk corridor payments  In November 2017  HHS published statistics indicating that payments from insurers for the three year period fell short of claimed payments by  12 billion  The U S  Court of Appeals for the Federal Circuit ruled 2 1 last year that Congress  in passing the appropriations riders  implicitly repealed its statutory obligation to pay the insurers  The insurers appealed  arguing that Supreme Court precedents require much more explicit legislative language to eliminate a previously adopted payment obligation  
For a graphic on major Supreme Court rulings  click ",2019-06-24,Reuters,https://www.investing.com/news/world-news/us-supreme-court-takes-up-insurers-12-billion-obamacare-dispute-1905777,1905777
141280,362795,HUM,Week Ahead  Volatility To Rise After Robust Risk Rally But No Trade Accord,opinion,"Friday s record equity index trifecta resulted from U S  trade rhetoric  but conflicting weekend reports could pressure stocks lower
VIX near lowest levels since 2018
The dollar dropped on Friday along with safe havens but nervous investors could jump back in on Monday
It s unclear how much more risk investors will be willing to take on  after Friday s astounding trifecta of all time highs  The Dow  S P 500 and NASDAQ all finished the week at new records  with each benchmark closing at the very highest point of the session 
However  with any sort of trade resolution still unclear notwithstanding reports out of China on Saturday that  constructive talks  via a high level call had occurred with the U S  market volatility will likely intensify  Though reports on Friday cited a top White House official saying a signature was forthcoming  news over the weekend wasn t as encouraging 

Even with  constructive talks  being signaled by the Asian nation  both sides haven t been able to actually get past significant roadblocks  with some officials even indicating they re  not on the same page   Though the latest news provides a more optimistic tone  with numerous reversals in the ongoing trade resolution narrative having already occurred  how much longer will investors buy the encouraging news  which never actually leads to a significant conclusion  While the path to a trade deal has been a windy one  it has  nevertheless been the key market driver for risk during the past month 
Equities Jump  Safe Havens Slump
U S  equities bounced higher to close the trading week  vaulting into uncharted territory  The dollar fell  along with safe havens Treasurys  gold and the yen 
Global economic data remains mixed  with softer October retail sales and industrial production in China  but firmer than expected eurozone GDP  The global slump in manufacturing appears to be improving  the global manufacturing PMI has moved higher for three straight months  albeit from low levels  We believe underlying fundamentals could support further gains in stocks  but we don t expect the recent low volatility to persist indefinitely 

The VIX has reached its lowest point since Apr  12  which tends to make contrarian investors nervous 
The S P 500 rose 0 77  on Friday  with Health Care doing most of the lifting    2 13    after President Donald Trump talked about a new transparency in healthcare plan he d like to implement  forcing hospitals to reveal discounts they receive from insurers  Shares of insurers such as UnitedHealth Group  NYSE UNH   Humana  NYSE HUM   Anthem  NYSE ANTM  and Cigna  NYSE CI  initially enjoyed a boost but closed off session highs  as the plan is expected to be challenged in Congress  For the day  trade sensitive Materials was the only sector that slipped into the red    0 08   
On a weekly basis  the SPX climbed 0 89   with Healthcare once again in the lead    2 45    Energy underperformed    1 01    even as oil advanced on trade hopes  Financials were also in negative territory    0 3   
The benchmark index advanced for the sixth straight week its longest streak in two years  It hit another all time high alongside the NASDAQ    0 73   and the Dow Jones Industrial Average   0 8    which moved past 28 000 for the first time  The market hat trick was also a stunning a show of force  as no one dared take the opposite side of the trade 
Only the small cap Russell 2000 closed off its highs  though it too finished the week higher   0 47    as well  the index has hit no new record since August 

Technically  the small cap index may be forming a bullish pennant or falling flag  

Yields on the U S  10 year Treasury note advanced on Friday  even as they struggled at the crossroads of a rising channel since the September bottom and the long term downtrend line since November 2018  For the week  yields trimmed half of the previous week s gains 

The USD fell for a second day  on Friday  slipping for the week as well  Technically  it found support at the neckline of a small double bottom 

The yen slumped both on Friday and for the week  as it found resistance by the highs since August  nearing the downtrend line since the October 2018 high 
Gold fell for the first time in four sessions  on the way back from a falling channel bottom  edging higher for the week 
Crude jumped on Friday  ending the week higher for the second day in a row  after White House economic adviser Larry Kudlow s comments late on Thursday that a partial trade agreement with China was close to being signed overshadowed supply concerns raised by the International Energy Agency on Friday 
Week AheadAll times listed are EST
Monday
19 30  Australia   RBA Meeting Minutes
Tuesday8 30  U S    Building Permits  expected to fall from 1 391M in September to 1 383 in October 
20 30   China   PboC Interest Rate Decision 
Wednesday
8 30  Canada    Core CPI  YoY measure expected to remain flat at 1 9  
10 30  U S    Crude Oil Inventories  seen to have slipped to 1 649M from 2 219M 
14 00  U S    FOMC Meeting Minutes  Always anticipated look into Fed thinking on the recent cut and future rate decisions 
Thursday
8 30  U S    Philadelphia Fed Manufacturing Index  likely to rise to 7 0 from 5 6 
10 00  U S    Existing Home Sales  probably rose to 5 48M in October from 5 38M 
Friday2 00  Germany   GDP  forecast to remain steady at 0 1  QoQ  while plunging to 0 5  from 1 0  YoY 
3 30  Germany   Manufacturing PMI  likely to rise to 43 0 from 42 1 

3 30  Eurozone   ECB President Lagarde Speaks  the first public event for the eurozone s new central bank president 
4 30  UK   Manufacturing and Services PMIs  previous results 49 6 for manufacturing  50 0 for services 
8 30  Canada   Retail Sales  expected to come in at 0 1  from  0 1  previously ",2019-11-17,Pinchas Cohen/Investing.com,https://www.investing.com/analysis/week-ahead-volatility-to-rise-after-robust-risk-rally-but-no-trade-accord-200485832,200485832
141282,362797,HUM,Humana  HUM  Scales New 52 Week High On Solid Q3 Earnings,opinion,Shares of Humana Inc    NYSE HUM   hit a fresh 52 week high of  340 48 on Nov 15  before closing the day at  335 55  Impressive earnings performance in the third quarter and solid Medicare business contributed to this rally Over the past year  the Zacks Rank  3  Hold  stock has gained 8 1   significantly outperforming the  s growth of 2 4  Let s delve deeper and analyze the factors responsible for the stock s upsurge Driving FactorsThe company retained investors  favorable sentiments surrounding the stock with an earnings beat in all the last four quarters  the average being 8 6  Humana s third quarter 2019 earnings per share of  5 03 surpassed both the Zacks Consensus Estimate and the year over year figure by 9 8   This upside can primarily be attributed to its Medicare Advantage  MA  membership growth and higher revenues The company s Medicare business has been performing strongly over the last many quarters  Impressive growth in the Medicare Advantage business is owing to its operating initiatives  evident from the 54  rise in Medicare membership from 2013 to 2018  Humana has been chosen as one of the health plans to provide Florida s Medicare retirees with Medicare coverage effective Jan 1  2020  The company recently announced the launch of Humana Honor Medicare Advantage plans for 2020  designed to complement the Veterans Affairs program The company has also been progressing well on the back of its strategic initiatives  The buyouts of Family Physicians Group  Your Home Advantage  Curo and a share in Kindred at Home poise it well for long term growth Humana has been efficiently deploying excess capital for the past several years  which continues to instill investor s confidence in the stock  The company has been witnessing steady operating cash flows over the last many quarters  except 2018   In February 2019  it raised dividend by 10  to 55 cents per share  This initiative further reflects the company s strong liquidity and it not only retains the existing investors  optimism but also attracts new ones Stocks to ConsiderInvestors interested in the medical sector might consider some better ranked stocks like Select Medical Holdings Corporation   NYSE SEM    WellCare Health Plans  Inc    NYSE WCG   and Genesis Healthcare  Inc    NYSE GEN    You can see Select Medical Holdings operates critical illness recovery hospitals  rehabilitation hospitals  outpatient rehabilitation clinics and occupational health centers  In the trailing four quarters  the company s average beat was 11 07   The stock sports a Zacks Rank  1 WellCare Health offers managed care services to government sponsored health care programs  The company pulled off average positive surprise of 17 32  in the preceding four quarters  It carries a Zacks Rank  2  Buy  Genesis Healthcare operates skilled nursing facilities and assisted senior living facilities  In the last four quarters  the company delivered average beat of 80 96   It has a Zacks Rank of 1 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 5  per year  So be sure to give these hand picked 7 your immediate attention ,2019-11-17,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-scales-new-52week-high-on-solid-q3-earnings-200486057,200486057
141285,362800,HUM,UnitedHealth Group To Enhance Its Medicare Advantage Network,opinion,UnitedHealth Group Incorporated s   NYSE UNH   health benefits business UnitedHealthcare along with Walgreens will open 14 UnitedHealthcare Medicare services centers within Walgreens stores in five metropolitan areas  This is part of a multi year pact between the companies  The UnitedHealthcare Medicare services centers will open up from January 2020 at Walgreens stores across the markets of Las Vegas  Phoenix  Cleveland  Denver and Memphis With this agreement  members will benefit from better access to their UnitedHealthcare Medicare Advantage  MA  plans along with strong customer service and information they need within Walgreens  These centers will help educate Walgreen customers about Medicare  enable them to meet service advocates to talk about their UnitedHealthcare plan benefits and even get enrolled in plans  This apart  the members can also make an appointment for an in store annual wellness visit at the Medicare services center of Walgreens via UnitedHealthcare s HouseCalls program Meanwhile  Walgreens look forward to providing comprehensive services  suitable to address the particular needs of communities Both companies are also collaborating on formation of the new AARP Medicare Advantage Walgreens plans from UnitedHealthcare to provide reasonably priced prescription drugs and an easy access to medications  These new plans under Medicare Part D prescription drug coverage will help people get convenient access to medications through the plan s preferred retail pharmacy of Walgreens Additionally  multiple plans will feature premiums and  0 copays on primary care visits  preventive care and common generic drugs  which will allow savings for members  The new plans boast a wide health care network  dental and vision coverage  and access to Renew Active  UnitedHealthcare s Medicare fitness program for the mind and body AARP Medicare Advantage Walgreens plan members will also gain other advantages  such as filling prescriptions at many retail pharmacies or via mail order from OptumRx  receiving higher discounts through the Walgreens Balance Rewards program and accessing simple digital tools via Walgreens The package of 46 plans will be available at 24 states where 16 2 million people  eligible for Medicare  are present  UnitedHealthcare s Medicare plans cater to the requirements of more than 12 million Medicare beneficiaries Other companies  such as Humana Inc    NYSE HUM   is also making efforts to enhance its Medicare Advantage network Shares of this Zacks Rank  3  Hold  have gained 4 3  in a year s time  outperforming its  s growth of 2 6   Stocks to ConsiderInvestors interested in the medical sector might consider some better ranked stocks like Select Medical Holdings Corporation   NYSE SEM   and WellCare Health Plans  Inc    NYSE WCG    You can see Select Medical Holdings operates critical illness recovery hospitals  rehabilitation hospitals  outpatient rehabilitation clinics and occupational health centers  In the trailing four quarters  the company s average beat was 11 1   The stock sports a Zacks Rank  1 WellCare Health offers managed care services to government sponsored health care programs  The company pulled off average positive surprise of 17 3  in the preceding four quarters  It carries a Zacks Rank  2  Buy  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-11-25,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-group-to-enhance-its-medicare-advantage-network-200488191,200488191
141288,362803,HUM,Humana  Epione Tie Up To Aid Medicare Advantage Members,opinion,Humana Inc    NYSE HUM   recently reached a value based agreement with Epione Health of Oklahoma  LLC to provide coordinated  enriched healthcare for Humana Medicare Advantage members in the state  With this unique partnership  the local Humana Medicare Advantage members will be able to achieve better health outcomes The deal will allow Humana s Medicare Advantage HMO and PPO plan members in a number of counties of Oklahoma to gain access to Epione s physicians and facilities across the region This strategic move is an extension of Humana s long term commitment to provide value based care including personal time with health professionals and customized care that will meet an individual s personal health situation  It also features access to proactive health screenings and programs  better care for patients with chronic health situations  usage of advanced technologies  etc This relationship will help Humana Medicare Advantage HMO and PPO plan patients benefit from the support offered by the company  This is likely to assist Epione s doctors to concentrate on improved patient care  Epione  which provides a model for care in Oklahoma City and southern Oklahoma  is a perfect partner for such endeavor  Epione s model places primary care physicians right at the center of healthcare and its strong network of like minded hospitals and specialty providers facilitates quality patient care The company has been taking up various initiatives to strengthen its Medicare Advantage business by increasing members  It recently entered into a partnership with Hawaii Senior Medical Group to provide coordinated and enriched experience for Medicare Advantage members in Hawaii  It also announced the upgrade of health plan choices for its Medicare beneficiaries in New Jersey by adding numerous counties to its network  Humana has also been chosen as one of the health plans to provide Florida s Medicare retirees with Medicare coverage effective Jan 1  2020 As of Sep 30  2019  the company had more than 2 3 million individual Medicare Advantage members and approximately 115 000 commercial members  We expect the company s Medicare business to continue performing well and keep contributing to its top line Shares of this Zacks Rank  3  Hold  company have gained 11 3  in a year s time  outperforming its  s growth of 2 6  Stocks to ConsiderInvestors interested in the medical sector might consider some better ranked stocks like Select Medical Holdings Corporation   NYSE SEM    WellCare Health Plans  Inc    NYSE WCG   and Genesis Healthcare  Inc    NYSE GEN    You can see Select Medical Holdings operates critical illness recovery hospitals  rehabilitation hospitals  outpatient rehabilitation clinics and occupational health centers  In the trailing four quarters  the company s average beat was 11 1   The stock sports a Zacks Rank  1 WellCare Health offers managed care services to government sponsored health care programs  The company pulled off average positive surprise of 17 3  in the preceding four quarters  It carries a Zacks Rank  2  Buy  Genesis Healthcare operates skilled nursing facilities and assisted senior living facilities  In the last four quarters  the company delivered average beat of 80 9   It has a Zacks Rank of 1 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-11-26,Zacks Investment Research,https://www.investing.com/analysis/humana-epione-tie-up-to-aid-medicare-advantage-members-200488186,200488186
141291,362806,HUM,Centene  CNC  Divests IlliniCare As Part Of Merger Agreement,opinion,Centene Corporation   NYSE CNC   and CVS Health   NYSE CVS   have inked a deal under which CVS Health will buy Medicaid and Medicare Advantage lines of business owned by Centene in Illinois  The financial terms of this transaction have been kept under wraps The divestiture of IlliniCare Health Plan is necessary for Centene to win approval for its WellCare Health Plans   NYSE WCG   acquisition given business overlap in the region Centene had agreed to buy WellCare for  17 3 billion in March 2019  The merger will create a premier healthcare enterprise and a leader in Medicaid  Medicare and the Health Insurance Marketplace  The combined entity will have a wider scale and diversification with more than 12 million Medicaid and around 5 million Medicare members  In total  it will have around 22 million members across 50 U S  states The pending transaction has already received approvals from insurance and health care departments from 26 states though it is still subject to state regulatory approvals and other conditions  The transaction is expected to be completed in the first half of 2020 The divestiture of the IlliniCare Health plan is the latest development for Centene and the subsequent step in the process of completing the merger with Tampa based WellCare The acquisition of IlliniCare will aid CVS as the latter competes with UnitedHealth Group  NYSE UNH   Humana  NYSE HUM  and others in the Medicare Advantage business  Last year  it purchased Aetna  NYSE AET   which gave it access to the latter s health insurance business The latest buyout will provide CVS with an opportunity to expand its Medicaid and Medicare Advantage presence in Illinois Shares of this Zacks Rank  3  Hold  company have rallied 39 1  quarter to date  outperforming the  s increase of 27 7  Stock to ConsiderA better ranked stock from the medical sector is Select Medical Holdings Corporation   NYSE SEM    which sports a Zacks Rank  1  Strong Buy   You can see Select Medical Holdings operates critical illness recovery hospitals  rehabilitation hospitals  outpatient rehabilitation clinics  and occupational health centers in the United States  The company delivered positive surprise in three of the last four reported quarters  the average being 11 07  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-12-02,Zacks Investment Research,https://www.investing.com/analysis/centene-cnc-divests-illinicare-as-part-of-merger-agreement-200489679,200489679
141292,362807,HUM,Humana  HUM  Vs  Anthem  ANTM   Which Is Better Placed  ,opinion,A strong U S  economy  aging population and boom in Medicaid and Medicare business bode well for health insurers in the long run  The last few quarters also witnessed active mergers and acquisitions in the industry  leading to a series of consolidations  Despite frequent political interference  the industry remains a promising platform for investment owing to rising demand for value based health plans  increasing number of baby boomers and better health outcomes through usage of analytics  artificial intelligence plus other advanced technologies The healthcare insurance industry is poised for sustained growth across markets  mainly by enhancing government programs  The changing U S  demography  product modifications and medical cost management also contribute to the progress of industry players Further  consolidations led to market share wins and business diversification for the players involved   One pending mega merger is that of Centene Corporation   NYSE CNC   with WellCare Health Plans  Inc    NYSE WCG    which is expected to close by the first half of 2020 The overall bullish scenario makes us believe that growth will be consistent in this industry  which should boost prospects of companies with strong business fundamentals  The buoyancy in the health insurance space is confirmed by its  within the top 24   61 of 253    Against this backdrop  let s look at the two leading health insurers  namely Anthem Inc    NYSE ANTM   and Humana Inc    NYSE HUM   with respective market capitalization of  73 1 billion and  45 2 billion  Each stock has a Zacks Rank  3  Hold   You can see Shares of Humana and Anthem have gained 9 4  and 18 1  year to date  respectively  The industry has rallied 12 6  year to date compared with the S P 500 Index s 24  increase Let s analyze certain other parameters to find out which company is better positioned Earnings Surprise HistoryA stock s earnings surprise track helps investors get an idea about its performance in the previous quarters Both companies boast a decent earnings surprise record  having surpassed the Zacks Consensus Estimate in each of the last four quarters Humana managed to pull off average four quarter beat of 8 56  while the same for Anthem reads 3 77   This proves that Humana has an edge over Anthem here Return on EquityReturn on equity is a profitability measure  which accounts for profits generated on shareholders  equity  Hence  higher ROE reflects the company s efficiency in using shareholders  funds and is preferred by all equity investors The ROE of 22 3  for Humana compares favorably with Anthem s ROE of 15 6  ValuationPrice to earnings value is one of the multiples used for valuing health insurers  Compared with the health insurance industry s forward 12 month P E ratio of 15 78  Anthem is undervalued with a reading of 12 81 while Humana s shares are expensive with a P E ratio of 18 18 Debt to EquityBoth companies have lower debt to equity ratio than the industry average of 65 8  However  Humana s leverage ratio of 52 3 betters Anthem s ratio of 62 3  Therefore  Humana is at an advantage over Anthem on this front Estimate MovementFor 2019  the Zacks Consensus Estimate for Anthem has moved 0 1  north to  19 43 in the past 30 days while the same for Humana has been revised 0 6  upward to  17 77 Bottom LineOur comparative analysis shows that Humana is better positioned than Anthem with respect to earnings surprise  return on equity  estimate revision and leverage  Meanwhile  Anthem scores higher in terms of price performance and valuation  As the scale is tilted in favor of Humana  the stock discernibly makes a more promising investment proposition 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-12-02,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-vs-anthem-antm-which-is-better-placed-200489573,200489573
141296,362811,HUM,U S  Congress invites pharmacy benefit managers to third drug pricing hearing,news," Reuters    The U S  Senate Finance Committee has invited executives from five pharmacy benefit managers to testify on April 3 on the rising costs of prescription medicines  in Congress s latest effort to question industry officials directly over an issue voters consistently cite as a top concern   Pharmacy benefit managers  PBMs  administer drug benefits for employers and health plans and also run large mail order pharmacies  Drugmakers say they are under pressure to provide rebates to the handful of PBMs dominating the market to get their products included on preferred coverage lists   PBMs have come under increased scrutiny both by President Donald Trump s administration and lawmakers who say there needs to be more transparency about how drug prices get so high  The effect of rebates to PBMs are of particular concern  The committee s chairman  Republican Senator Chuck Grassley  and its top Democrat  Senator Ron Wyden  on Tuesday invited executives from UnitedHealth  NYSE UNH  Group s Optum   Cigna Corp   NYSE CI    Humana Inc   NYSE HUM   CVS Health Corp  NYSE CVS   CVS Caremark and Prime Therapeutics LLC to the hearing  the third in a series examining rising prescription drug costs   There s far too much bureaucracy and too little transparency getting in the way of affordable  quality health care   Grassley and Wyden said  calling for the executives to provide real information and discuss real solutions  
The committee last month heard from seven pharmaceutical company executives  Its first hearing on Jan  29 focused on insulin affordability ",2019-03-12,Reuters,https://www.investing.com/news/stock-market-news/us-congress-invites-pharmacy-benefit-managers-to-third-drug-pricing-hearing-1805641,1805641
141297,362812,HUM,UnitedHealth beats first quarter profit view  raises 2019 forecast,news," Reuters    UnitedHealth Group Inc  NYSE UNH  on Tuesday reported a quarterly profit above estimates and raised its 2019 earnings forecast on increased prescription volumes at its pharmacy benefits unit  sending shares of the largest U S  health insurer up 3 percent  The results eased some pressure on the health insurance sector where stocks have taken a beating in the past few weeks over policy related uncertainty  Shares of rivals Anthem  NYSE ANTM  Inc   Centene   NYSE CNC  Corp   Humana Inc   NYSE HUM  and  Cigna Corp   NYSE CI  were also up in light trading  The uncertainty has largely resulted from proposals to change the drug rebate system under which drugmakers refund money to insurers and pharmacy benefit managers  Analysts said the industry bellwether s quarterly results reinforce that underlying fundamentals for the sector remain fully on track  despite the recent slump in share prices  Optum  UnitedHealth s fastest growing unit which houses its pharmacy benefits business  brought in sales of  26 36 billion in the quarter  a jump of nearly 12 percent from a year earlier due to higher prescription volumes  UnitedHealth on Tuesday also raised its full year adjusted earnings forecast to between  14 50 and  14 75 per share from its prior view of  14 40 to  14 70   We find this notable  as UnitedHealth has historically been conservative in adjusting guidance early in the year   Cantor Fitzgerald analyst Steven Halper said  Last year  rivals Cigna Corp and Aetna  NYSE AET  combined with Optum s two largest rivals  Express Scripts  NASDAQ ESRX  Holding and CVS Health Corp  NYSE CVS   In its health insurance business  UnitedHealth s medical care ratio  which compares premiums with the cost of delivering medical care  worsened to 82 percent  from 81 4 percent last year  on deferral of the health insurance tax  the company said  Analysts on average were expecting 82 2 percent  In the quarter ended March 31  net earnings rose 22 2 percent to  3 47 billion  or  3 56 per share  The company reported adjusted earnings of  3 73 per share  beating estimates of  3 60 per share  according to IBES data from Refinitiv  Total revenue rose 9 3 percent to  60 31 billion  ahead of estimates of  59 71 billion  Evercore ISI analyst Michael Newshel said UnitedHealth continues to deliver consistent performance and fundamentals still look good    But now the question is whether any rebound in the shares can be sustained amid the political overhang that has plagued the managed care group   
UnitedHealth s shares were up 2 66 percent at  236 32 in pre market trading  As of Monday s close  the stock is down nearly 8 percent in 2019 ",2019-04-16,Reuters,https://www.investing.com/news/stock-market-news/unitedhealth-reports-222-percent-rise-in-quarterly-profit-1837122,1837122
141298,362813,HUM,StockBeat   UnitedHealth Tumbles After CEO Sounds Alarm on Medicare for All,news,"Investing com   UnitedHealth fell Tuesday  giving up early post earnings gains as political concerns overshadowed solid results 
Among Democratic presidential hopefuls   healthcare for all  has proved a popular narrative  Proponents of a universal Medicare plan  where people could be guaranteed coverage without using private insurance  argue that a government led measure would iron out the administrative creases currently bedeviling the U S  health care system  But UnitedHealth Group CEO David Wichmann warned that a Medicare for All system would destabilize the health care system and ultimately fail to expand access to care 
The measures proposed by Democrats would  surely jeopardize the relationship people have with their doctors  destabilize the nation s health system and limit the ability of clinicians to practice medicine at their best   Wichmann said   And the inherent cost burden would surely have a severe impact on the economy and jobs    all without fundamentally increasing access to care  
Wichmann s remarks served as a reminder that health care will likely continue to remain a focal point and stocks will be vulnerable to negative headline risk as the 2020 presidential race heats up  In recent weeks  the sector has been pressured as lawmakers considered plans to curb drug prices 
UnitedHealth  NYSE UNH  fell 5 6  even as the company delivered above consensus earnings and raised its 2019 earnings per share guidance to  14 50 to  14 75 from  14 40 to  14 70  The earnings beat and raise led to some bullish calls from analysts on Wall Street 
But UnitedHealth s shares hit a 52 week low after the Wichmann comments and subtracted more than 80 points from the Dow Jones Industrial Average  The shares are off more than 12  this year 
 We think UNH s strong growth in Q1 demonstrates its value to stakeholders across the health care system  and reinforces our view that any future reforms will still allow UNH to continue making its customers happy   CFRA said in a note 
Other healthcare insurers including  Community Health   NYSE CYH   Humana  NYSE HUM  and Molina Healthcare  NYSE MOH  also slumped  leaving the wider healthcare sector nursing a 1  loss ",2019-04-16,Investing.com,https://www.investing.com/news/stock-market-news/stockbeat--unitedhealth-tumbles-after-ceo-sounds-alarm-on-medicare-for-all-1837685,1837685
141305,362820,HUM,Humana  HUM  Reports Next Week  What To Expect,opinion,"Humana  HUM  is expected to deliver flat earnings compared to the year ago quarter on higher revenues when it reports results for the quarter ended September 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on November 6  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This health insurer is expected to post quarterly earnings of  4 58 per share in its upcoming report  which represents no change from the year ago quarter 
Revenues are expected to be  16 15 billion  up 13 7  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Humana 
For Humana  the Most Accurate Estimate is the same as the Zacks Consensus Estimate  suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate  This has resulted in an Earnings ESP of 0  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Humana will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Humana would post earnings of  5 24 per share when it actually produced earnings of  6 05  delivering a surprise of  15 46  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Humana doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-10-29,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-reports-next-week-what-to-expect-200480174,200480174
141307,362822,HUM,Which Healthcare Fund To Buy  FSHCX Or JAGLX ,opinion,Investors often rely on the healthcare sector to safeguard their investments  This is because demand for healthcare services does not vary so much with market conditions and investments in the sector provide sufficient protection to the capital invested So far this year  mega scale healthcare mergers  corporate restructuring as well as FDA approvals have buoyed gains for the space  As a matter of fact  America s healthcare sector is being anticipated to experience a major revolution in the days to come  With an uptick in over the counter drug sales coupled with major breakthroughs in the treatment of rare conditions  the healthcare space is deemed to gain big The U S  healthcare sector has performed decently so far this year  The Health Care Select Sector SPDR Fund  XLV  has gained 9 5  year to date despite fears related to a slowdown in the global economy and trade tensions Mutual funds are perfect choices for investors looking to enter this sector since they possess the advantages of wide diversification and analytical insight  However  choosing the right mutual funds for your portfolio can become cumbersome  Let us  therefore  discuss which of these two funds are better for you Fidelity Select Health Care Services Portfolio    This fund seeks long term growth of capital and invests a bulk of its shares in securities of companies involved in the ownership and management of hospitals  nursing homes and health maintenance organizations  FSHCX also invests in companies that provide direct healthcare services  This non diversified fund invests in common stocks of both U S  and non U S  companies This Sector Health product has a history of positive total returns for over 10 years  Specifically  the fund s returns are 10 1  over the 3 year and 9 4  of the 5 year period  To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds     The Fidelity Select Health Care Services Portfolio fund  as of the last filing  allocates its assets in top two major groups   Large Value and Small Growth  Further  as of the last filing  Unitedhealth Group Inc  Cigna Corp  NYSE CI  and Humana Inc  NYSE HUM  were the top holdings for FSHCX This product with a Zacks Mutual Fund Rank  1  Strong Buy  was incepted in June 1986 and is managed by   FSHCX carries an expense ratio of 0 76  and requires a minimal initial investment of  0 Janus Henderson Global Life Sciences Fund Class T   The fund invests in securities of companies that have a life science orientation  JAGLX invests a minimum of one fourth of its assets in securities issued by companies that are categorized in the  life sciences  sector This Sector Health product has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3 and 5 year benchmarks are 8 4  and 7 8   respectively  To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds     Janus Henderson Global Life Sciences Fund Class T  as of the last filing  allocates its assets in the top two major groups   Small Growth and Foreign Bond  Further  as of the last filing  Merck   Co and Abbott Laboratories  NYSE ABT  were the top holdings for JAGLX This product with a Zacks Rank  2  Buy  was incepted in December 1998 and is managed by   JAGLX carries an expense ratio of 0 92  and requires a minimal initial investment of  2 500 To ConcludeWhile both FSHCX and JAGLX are recommended buys  upon having a closer look  we find that the former is a clear winner  JAGLX is much more expensive compared to FSHCX  it has a minimum initial investment  2 500 compared to FSHCX s  0   Further  its administrative and other operating expenses are also higher compared to FSHCX  So  one should clearly bet on FSHCX for higher returns on low investments Want key mutual fund info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ,2019-10-31,Zacks Investment Research,https://www.investing.com/analysis/which-healthcare-fund-to-buy-fshcx-or-jaglx-200481411,200481411
141308,362823,HUM,J J Asbestos Report Pulls Health Care Stocks Down Midday,news,"Investing com   Health care stocks were struggling in midday trading on  that Johnson   Johnson  NYSE JNJ  knew for decades that talcum baby powder contained asbestos pushed that major sector component lower 
The consumer goods and medical company slumped about 7   wiping off  24 billion from its market capitalization  after Reuters reported that it knew about the presence of asbestos as early as 1971 and hired ghostwriters to redraft studies of its baby powder 
 Simply put  the Reuters story is an absurd conspiracy theory  in that it apparently has spanned over 40 years  orchestrated among generations of global regulators  the world s foremost scientists and universities  leading independent labs  and J J employees themselves   the company said in a statement 
The company faces around 6 000 lawsuits that allege its talc products cause ovarian cancer 
The S P 500 Health Care index fell about 1  
Other health care companies were also down  with  Universal Health Services   NYSE UHS  falling 4 8   Humana  NYSE HUM  dipping 2 9  and Cigna  NYSE CI  decreasing 2 5  
Walgreens Boots Alliance  NASDAQ WBA  was also lower  falling 3 7  after Goldman Sachs  NYSE GS  downgraded the stock  Reuters reported ",2018-12-14,Investing.com,https://www.investing.com/news/stock-market-news/jj-asbestos-report-pulls-health-care-stocks-down-midday-1722059,1722059
141310,362825,HUM,Humana s  HUM  Q3 Earnings Surpass Estimates  Improve Y Y,opinion,Humana Inc  s   NYSE HUM   third quarter 2019 operating earnings per share of  5 03 beat both the Zacks Consensus Estimate and the year over year figure by 9 8   This upside can primarily be attributed to Medicare Advantage membership growth and higher revenues Operational UpdateRevenues of  16 2 billion were up nearly 14 3  year over year  Moreover  the top line surpassed the Zacks Consensus Estimate by 0 5  Adjusted consolidated pre tax income of  869 million decreased 5 7  year over year due to weekday seasonality Benefit ratio expanded 300 basis points  bps  to 85  Operating cost ratio contracted 210 bps to 11 4  Humana Inc  Price  Consensus and EPS Surprise   Segmental ResultsRetailRevenues from the Retail segment were  14 09 billion  up 17  year over year  This can primarily be attributed to Medicare Advantage membership strength and higher per member premium along with improved state based contracts membership Benefit ratio of 85 9  expanded 270 bps year over year due to 2019 HIF suspension  unfavorable impact from weekday seasonality  lower favorable prior period development  in the segment and the shift in Medicare membership mix The segment s operating cost ratio of 9 3  contracted 190 bps year over year on the suspension of the health insurance industry fee  HIF  in 2019  better scale efficiencies related to its Medicare Advantage membership and operating cost efficiencies Group and SpecialtyRevenues from the Group and Specialty segment were  1 89 billion  down 0 3  from the prior year quarter due to a reduction in fully insured group commercial and specialty membership  the impact of a few contractual incentives and also adjustments related to the TRICARE contract of 2018 Benefit ratio expanded 560 bps year over year to 86 3   due to the impact of weekday seasonality in the quarter under review  effect of HIF suspension in 2019  lower prior period development  effect of the continued migration of fully insured group members  and dental network contracted rates Operating cost ratio contracted 170 bps year over year to 21 9  Healthcare ServicesRevenues of  6 6 billion increased 11  year over year  primarily owing to Medicare Advantage membership growth Operating cost ratio expanded 10 bps year over year to 96 2  Individual CommercialHumana exited this business effective Jan 1  2018 Financial UpdateAs of Sep 30  2019  the company had cash  cash equivalents and investment securities of  16 36 billion Debt to total capitalization ratio as of Sep 30  2019 was 34 3   contracting 310 bps from Dec 31  2018 Operating cash inflow totaled  2 4 billion at third quarter end  up 8 3  year over year Capital DeploymentThe company paid out cash dividends worth  74 million in the quarter under review  In October 2019  it declared a cash dividend of 55 cents per share  payable Jan 31  2020 to its shareholders of record as of Dec 31  2019 In July 2019  its board of directors approved a share repurchase plan worth  3 billion  set to expire Jun 30  2022  It also entered into an agreement in July this year with a third party financial institution to implement a  1 00 billion ASR program under the authorization  In the quarter under review  the company repurchased around 2 695 900 shares under this plan As of Nov 5  2019  it had remaining share repurchase authorization of  2 billion 2019 Guidance After third quarter results  the company revised its 2019 guidance  Adjusted EPS is now expected to be approximately  17 75  The 2019 individual Medicare Advantage membership is anticipated to be around 530 000 members Zacks RankHumana carries a Zacks Rank  3  Hold   You can see Performance of Other PlayersAmong other players from the medical sector  having already reported third quarter earnings  the bottom line results of UnitedHealth Group Incorporated   NYSE UNH    Anthem Inc    NYSE ANTM   and Centene Corporation   NYSE CNC   topped the respective Zacks Consensus Estimate Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 5  per year These 7 were selected because of their superior potential for immediate breakout ,2019-11-05,Zacks Investment Research,https://www.investing.com/analysis/humanas-hum-q3-earnings-surpass-estimates-improve-yy-200482975,200482975
141311,362826,HUM,Day Ahead  Top 3 Things to Watch,news,"Investing com   Here s a preview of the top 3 things that could rock markets tomorrow 
1  Fed Day Part 2  The Overanalyzing
Expect plenty of Monday  Thursday  morning quarterbacking following today s Federal Reserve rate hike 
At its face it appears that the market got what it expected  another boost of 25 basis points  and what it wanted  signs from the dot plot the Fed won t be as aggressive next year  
But  as often happens  the market decided what it wants isn t what it wanted in the first place  Investors were apparently hoping for much more dovish projections for 2019 and more dovish comments from Fed chief Jay Powell at his Q A 
The Dow swung from up 300 points shortly before the decision to close down about 350 
Traders will be looking closely at the Treasury yield curve tomorrow for more signs of flattening  with many saying that the Fed s decision to keep its policy of quantitative tightening  QT  by  50 billion per month on autopilot spooked equity investors 
The spread between the 10 Year and 2 Year yields was 11 basis points at the time of writing 
And for those burned out on the Fed  hey  the chances it keeps rates steady next month are currently 100  



2  Philly Fed and Jobless Claims Arrive
While the Fed is  somewhat  in the rearview mirror  the economic numbers keep rolling in 
At 8 30 AM ET  13 30 GMT   there will be the figures on weekly jobless claims 
Economists expect that claims for first time unemployment benefits rose to 219 000 last week 
At the same time the Philadelphia Fed will release its measure of December manufacturing activity  with economists forecasting the Philly Fed index to climb to 15 6 
3  Walgreen s Set to Report
Dow component Walgreens Boots Alliance  NASDAQ WBA  reports earnings before the bell tomorrow 
On average  analysts expect the drugstore chain to report a profit of  1 43 per share on sales of about  33 8 billion 
Shares looked to be on a roll in late November when there was speculation of a deal with Humana  NYSE HUM  that sparked a rally  but the stock joined the rest of the market in the recent selloff and is little changed in the last three months and the year 
Investors will be looking for details on its partnerships with companies like Kroger  NYSE KR  and  Alibaba   NYSE BABA   according to Briefing com ",2018-12-19,Investing.com,https://www.investing.com/news/stock-market-news/day-ahead-top-3-things-to-watch-1726833,1726833
141313,362828,HUM,Humana  HUM  Q3 Earnings And Revenues Top Estimates,opinion,"Humana  HUM  came out with quarterly earnings of  5 03 per share  beating the Zacks Consensus Estimate of  4 58 per share  This compares to earnings of  4 58 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 9 83   A quarter ago  it was expected that this health insurer would post earnings of  5 24 per share when it actually produced earnings of  6 05  delivering a surprise of 15 46  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Humana  which belongs to the Zacks Medical   HMOs industry  posted revenues of  16 24 billion for the quarter ended September 2019  surpassing the Zacks Consensus Estimate by 0 55   This compares to year ago revenues of  14 21 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Humana shares have added about 2 9  since the beginning of the year versus the S P 500 s gain of 22 7  
What s Next for Humana 
While Humana has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Humana was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  2 51 on  16 13 billion in revenues for the coming quarter and  17 67 on  64 62 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   HMOs is currently in the top 21  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-11-06,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-q3-earnings-and-revenues-top-estimates-200482817,200482817
141314,362829,HUM,Trade Deal Delay Unlikely To Hit U S  Healthcare  4 Picks,opinion,The protracted United States and China trade war is unlikely to ease any time soon  In early October  deputy level officials from both countries had agreed to a  phase one  deal and strike off a tariff hike due in mid October America s move to halt the imposition of a fresh round of tariffs on Chinese products and China s promise to buy more agricultural products from the United States brought about broad based gains for the stock markets However  the phase one trade deal  which was to be signed at APEC Summit in Chile  got delayed after the summit got canceled The three major benchmarks   the Dow  S P 500 and Nasdaq Composite   hit record highs on Nov 4 after investors got hopeful of a U S  China trade deal  In an interview with Bloomberg  U S  Commerce Secretary Wilbur Ross had expressed optimism over a trade deal But on Nov 6  the Trump administration confirmed that the signing of the interim deal would potentially be pushed into December  Additionally  President Donald Trump s administration official said  it was still possible the  phase one  agreement would not be reached  but a deal was more likely than not   This has kept investors on tenterhooks as a trade deal seems far out of sight Such developments have weighed on the benchmark indexes lately  However  healthcare seems unperturbed by delays in a trade deal Should You Invest in Healthcare Healthcare stocks are considered as a defensive as they are need based and stay in constant demand just like utilities and consumer staples Investors often rely on the healthcare sector to safeguard their investments  This is because demand for healthcare services does not vary so much with market conditions and investments in the sector provide sufficient protection to the capital invested Many pharmaceutical companies also offer regular dividends  Companies that pay out consistent dividends are financially stable and generate consistent cash flows irrespective of market conditions The S P 500 Health Care Sector index  XLV  has gained 10 6  on a year to date basis  Furthermore  a spate of healthcare mergers in the pipeline has also boosted the space  Bristol Myers Squibb  NYSE BMY  merged with Celgene  NASDAQ CELG  in a  74 billion deal in January  Further  the  8 billion merger of Eli Lilly  NYSE LLY  and Loxo Oncology in February also paved way for gains in healthcare This apart  the sector has also been on a hiring spree  Per the Institute for Supply Management s  ISM  non manufacturing index latest data  healthcare employment continued the northward movement in October also by adding 15 000 payrolls  Overall the health care sector has added 402 000 jobs in the past 12 months Notably  healthcare earnings have also remained largely unaffected by trade war woes  At a time when trade sensitive sectors like tech have been battered by trade war woes  healthcare companies have raked in gains Companies like Humana  NYSE HUM   CVS Health Corp  NYSE CVS   DaVita have posted stellar third quarter earnings and their shares have jumped 3 5   5 6  and 12 9   respectively  since reporting earnings Our Top 4 PicksU S  healthcare has remained largely unaffected by trade related worries  Big names from the space have posted better than expected earnings over the last few quarters  Given such positives  investing in healthcare seems prudent  We have  thus  selected four stocks that should boost your portfolio  These stocks flaunt a Zacks Rank  1  Strong Buy  or 2  Buy  LHC Group  Inc    NASDAQ LHCG   is a publicly traded health care company that specializes in post acute continuum of care primarily for Medicare beneficiaries in the United States  The company s expected earnings growth rate for the current year is 22 3   which is above the  industry s projected rally of 12 1   The Zacks Consensus Estimate for current year earnings has improved 0 5  over the past 90 days LHC Group flaunts a Zacks Rank  1  You can see the complete list of today s Zacks  1 Rank stocks here Retrophin  Inc    NASDAQ RTRX   is a publicly traded biopharmaceutical company that focuses on the identification  development  acquisition  and commercialization of therapies for the treatment of rare diseases  The company s expected earnings growth rate for the current year is 169 5   which is above the  industry s projected rally of 6 4  The Zacks Consensus Estimate for current year earnings has improved 14 4  over the past 60 days  Retrophin sports a Zacks Rank  1 Dermira  Inc    NASDAQ DERM   is a publicly traded biopharmaceutical company that develops and commercializes therapies for patients with dermatologic diseases in the United States  The company s expected earnings growth rate for the current quarter is 21 8   which is above the  industry s decline of 107 4  The Zacks Consensus Estimate for current year earnings has improved 14 4  over the past 60 days  Dermira carries a Zacks Rank  1 Merck   Co   Inc    NYSE MRK   is a publicly traded biopharmaceutical company that focuses on the identification  development  acquisition  and commercialization of therapies for the treatment of rare diseases  The company s expected earnings growth rate for the current year is 16 6   which is above the  industry s projected rally of 2 5  The Zacks Consensus Estimate for current year earnings has improved 3 5  over the past 60 days  Merck   Co  carries a Zacks Rank  2 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-11-06,Zacks Investment Research,https://www.investing.com/analysis/trade-deal-delay-unlikely-to-hit-us-healthcare-4-picks-200483400,200483400
141315,362830,HUM,Aetna  other health insurers team up with IBM on blockchain project,news," Reuters    CVS Health  NYSE CVS  Corp s Aetna  NYSE AET  and a host of other health insurers said on Thursday they have partnered with  IBM   NYSE IBM  Corp to create a blockchain network aimed at cutting costs in the healthcare industry  The companies intend to use blockchain technology  which allows the sharing of databases across a network of computers  for processing claims and payments and to maintain directories  they said in a joint statement  Blockchain  the technology that underpins crypto currencies such as bitcoin  is being increasingly adopted across varied industries  Financial services firms too note the distributed ledger technology has the potential to generate wide ranging savings  Other companies involved in the project are health insurers Anthem  NYSE ANTM  Inc  Health Care Service Corp and financial services company PNC Bank   Using this technology  we can remove friction  duplication  and administrative costs that continue to plague the industry   Chris Ward  an executive at PNC Bank s treasury management unit said  New members  including technology companies and healthcare providers  are expected to join the collaboration in the coming months  according to the statement   Another blockchain alliance was formed in April between several healthcare firms including insurers  Humana Inc   NYSE HUM  and UnitedHealthcare Group to explore how the technology could be used to make the most current healthcare provider information available in directories  
Aetna and Ascension  the largest U S  non profit health system  are also partners in the other project ",2019-01-24,Reuters,https://www.investing.com/news/cryptocurrency-news/aetna-other-health-insurers-team-up-with-ibm-on-blockchain-project-1756807,1756807
141316,362831,HUM,The Zacks Analyst Blog Highlights  LHC  Retrophin  Dermira And Merck   Co,opinion,For Immediate ReleaseChicago  IL   November 8  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  LHC Group  Inc    NASDAQ LHCG    Retrophin  Inc    NASDAQ RTRX    Dermira  Inc    NASDAQ DERM   and Merck   Co   Inc    NYSE MRK   Here are highlights from Thursday s Analyst Blog  Trade Deal Delay Unlikely to Hit U S  Healthcare  4 PicksThe protracted United States and China trade war is unlikely to ease any time soon  In early October  deputy level officials from both countries had agreed to a  phase one  deal and strike off a tariff hike due in mid October America s move to halt the imposition of a fresh round of tariffs on Chinese products and China s promise to buy more agricultural products from the United States brought about broad based gains for the stock markets However  the phase one trade deal  which was to be signed at APEC Summit in Chile  got delayed after the summit got canceled The three major benchmarks   the Dow  S P 500 and Nasdaq Composite   hit record highs on Nov 4 after investors got hopeful of a U S  China trade deal  In an interview with Bloomberg  U S  Commerce Secretary Wilbur Ross had expressed optimism over a trade deal But on Nov 6  the Trump administration confirmed that the signing of the interim deal would potentially be pushed into December  Additionally  President Donald Trump s administration official said  it was still possible the  phase one  agreement would not be reached  but a deal was more likely than not   This has kept investors on tenterhooks as a trade deal seems far out of sight Such developments have weighed on the benchmark indexes lately  However  healthcare seems unperturbed by delays in a trade deal Should You Invest in Healthcare Healthcare stocks are considered as a defensive as they are need based and stay in constant demand just like utilities and consumer staples Investors often rely on the healthcare sector to safeguard their investments  This is because demand for healthcare services does not vary so much with market conditions and investments in the sector provide sufficient protection to the capital invested Many pharmaceutical companies also offer regular dividends  Companies that pay out consistent dividends are financially stable and generate consistent cash flows irrespective of market conditions The S P 500 Health Care Sector index  XLV  has gained 10 6  on a year to date basis  Furthermore  a spate of healthcare mergers in the pipeline has also boosted the space  Bristol Myers Squibb  NYSE BMY  merged with Celgene  NASDAQ CELG  in a  74 billion deal in January  Further  the  8 billion merger of Eli Lilly  NYSE LLY  and Loxo Oncology in February also paved way for gains in healthcare This apart  the sector has also been on a hiring spree  Per the Institute for Supply Management s  ISM  non manufacturing index latest data  healthcare employment continued the northward movement in October also by adding 15 000 payrolls  Overall the health care sector has added 402 000 jobs in the past 12 months Notably  healthcare earnings have also remained largely unaffected by trade war woes  At a time when trade sensitive sectors like tech have been battered by trade war woes  healthcare companies have raked in gains Companies like Humana  NYSE HUM   CVS Health Corp  NYSE CVS   DaVita have posted stellar third quarter earnings and their shares have jumped 3 5   5 6  and 12 9   respectively  since reporting earnings Our Top 4 PicksU S  healthcare has remained largely unaffected by trade related worries  Big names from the space have posted better than expected earnings over the last few quarters  Given such positives  investing in healthcare seems prudent  We have  thus  selected four stocks that should boost your portfolio  These stocks flaunt a Zacks Rank  1  Strong Buy  or 2  Buy  LHC Group  Inc is a publicly traded health care company that specializes in post acute continuum of care primarily for Medicare beneficiaries in the United States  The company s expected earnings growth rate for the current year is 22 3   which is above the  industry s projected rally of 12 1   The Zacks Consensus Estimate for current year earnings has improved 0 5  over the past 90 days LHC Group flaunts a Zacks Rank  1  You can see the complete list of today s Zacks  1 Rank stocks here Retrophin  Inc is a publicly traded biopharmaceutical company that focuses on the identification  development  acquisition  and commercialization of therapies for the treatment of rare diseases  The company s expected earnings growth rate for the current year is 169 5   which is above the  industry s projected rally of 6 4  The Zacks Consensus Estimate for current year earnings has improved 14 4  over the past 60 days  Retrophin sports a Zacks Rank  1 Dermira  Inc is a publicly traded biopharmaceutical company that develops and commercializes therapies for patients with dermatologic diseases in the United States  The company s expected earnings growth rate for the current quarter is 21 8   which is above the  industry s decline of 107 4  The Zacks Consensus Estimate for current year earnings has improved 14 4  over the past 60 days  Dermira carries a Zacks Rank  1 Merck   Co   Inc is a publicly traded biopharmaceutical company that focuses on the identification  development  acquisition  and commercialization of therapies for the treatment of rare diseases  The company s expected earnings growth rate for the current year is 16 6   which is above the  industry s projected rally of 2 5  The Zacks Consensus Estimate for current year earnings has improved 3 5  over the past 60 days  Merck   Co  carries a Zacks Rank  2 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-11-07,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-lhc-retrophin-dermira-and-merck--co-200483856,200483856
141324,362839,HUM,Humana Earnings beat  Revenue misses In Q3,news,"Investing com   Humana  NYSE HUM  reported third quarter earnings  that beat analyst s expectations on Wednesday and revenue that fell short of forecasts 
The firm reported earnings per share of  4 58 on revenue of  13 91B  Analysts polled by Investing com forecast EPS of  4 27 on revenue of  13 92B  That compared to EPS of  3 39 on revenue of  13 28B in the same period a year earlier  The company had reported EPS of  3 96 on revenue of  14 26B in the previous quarter 
For the year  Humana shares are up 40 74   outperforming the S P 500 which is up 4 23  year to date 
Humana follows other major Healthcare sector earnings this month
 On October 16  J J reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 05B 
Pfizer earnings beat analyst s expectations on October 30  with third quarter EPS of  0 78 on revenue of  13 3B  Investing com analysts expected EPS of  0 75 on revenue of  13 5B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-11-07,Investing.com,https://www.investing.com/news/stock-market-news/humana-earnings-beat-revenue-misses-in-q3-1678298,1678298
141328,362843,HUM,Wall Street rallies on U S  elections  tech  health stocks lead,news,"By Sin ad Carew NEW YORK  Reuters    Wall Street rose 2 percent on Wednesday  led by the technology and healthcare sectors as investors breathed a sigh of relief following the U S  midterm elections and made bets that a divided Congress would be good news for equities  Democrats won control of the House of Representatives on Tuesday  while President Donald Trump s Republican party expanded its Senate majority  pointing to the likelihood of political gridlock in Washington  The S P s biggest boosts came from the S P technology sector and the healthcare stocks  with both indexes gaining 2 9 percent  The consumer discretionary sector climbed 3 1 percent  spurred by a 6 9 percent rise in Amazon com  NASDAQ AMZN  shares  Amazon provided the single biggest boost to the S P 500   Now we re in an environment that people can understand again so they ll be willing to put some money back on the table  There was a little fear out there   said Peter Tuz  president at Chase Investment Counsel Corp in Charlottesville  Virginia   The Dow Jones Industrial Average rose 545 29 points  or 2 13 percent  to 26 180 3  the S P 500 gained 58 44 points  or 2 12 percent  to 2 813 89  and the Nasdaq Composite added 194 79 points  or 2 64 percent  to 7 570 75  The CBOE Volatility Index  the most widely followed gauge of expected near term gyrations for the S P 500  finished down 3 55 points at 16 36  its lowest close in about a month  While a divided Congress will make it harder for President Donald Trump to push through new legislation such as additional tax cuts  investors were not expecting a reversal of tax cuts and deregulation already enacted under Trump   This outcome probably provides the most paralysis for new policies   said Brian Nick  chief investment strategist for Nuveen Asset Management in New York  adding that growth sectors such as tech and healthcare would continue to be strong    In a scenario where there s no  additional  fiscal stimulus and we re not experiencing severe growth concerns in terms of contraction  they re the best bet   he said   Some strategists said Democratic control of the House means that Trump will have a harder time gaining support for efforts to impose new regulations on Amazon com  But even as technology and healthcare stocks soared  several investors questioned whether the sectors could now be at risk of additional regulatory scrutiny  Even after Wednesday s gains  the S P 500 was 4 percent below its record close in September  as investors kept their eyes on rising interest rates and the U S  China trade war  The Federal Reserve began a two day monetary policy meeting on Wednesday  but no rate increase was expected when it releases its policy decision on Thursday  The Fed is expected to raise rates in December  at its last policy meeting of the year  Health insurers  Humana Inc   NYSE HUM   Anthem  NYSE ANTM  Inc and UnitedHealth Group Inc  NYSE UNH  jumped to record highs as voters in three states approved expanding Medicaid programs for low income people  DaVita Inc jumped 10 9 percent after California rejected a proposal to limit the rates that dialysis clinics can charge commercially insured patients  Anadarko Petroleum Corp  NYSE APC  rose 5 7 percent and  Noble Energy  Inc  NYSE NBL  gained 4 percent after Colorado voters rejected a tougher rule on oil and gas drilling  which spurred shares of companies operating in the state  Advancing issues outnumbered declining ones on the NYSE by a 3 27 to 1 ratio  on Nasdaq  a 2 31 to 1 ratio favored advancers  The S P 500 posted 35 new 52 week highs and three new lows  the Nasdaq Composite recorded 67 new highs and 71 new lows   
On U S  exchanges 8 0 billion shares changed hands compared with the 8 64 billion average for the last 20 sessions ",2018-11-07,Reuters,https://www.investing.com/news/stock-market-news/futures-lower-as-us-midterm-elections-kick-off-1675699,1675699
141329,362844,HUM,Take a look inside Walgreens  futuristic store where it s plotting new ways to take on Amazon and CVS,news,We took a look at a  store where the drugstore giant pilots some of its new strategies to see what the future of the pharmacy might look like   Inside  we saw a makeup counter  shelves of over the counter medication and toiletries  and medical services like an eyeglasses store   One big goal is to create new reasons for customers to shop in stores  as more and more shopping moves online to competitors like    We re in transformation mode   Richard Ashworth  Walgreens  president of operations  told Business Insider   On the edge of a suburban lot in the Chicago area  next to a Whole Foods and across the way from a Barnes   Noble  NYSE BKS   sits a Walgreens   At first glance  it seems like any other drugstore  But upon closer look there are some differences  For one  there s a large beauty section right at the front of the store  For another  candy and other tempting snacks have been relegated to the back  along with seasonal decorations  There s more over the counter medications  supplements  and toiletries in the first few aisles  too   Another big change  the store offers lots of health services  such as hearing screenings    and    is using this store   not more than half a mile from its corporate headquarters   as its pilot for what future pharmacies might look like around the US  In a world where more and more shopping happens online  Walgreens is  what it ll take to get you to visit one of its 9 560 US stores   We re in transformation mode   Richard Ashworth  Walgreens  president of operations told Business Insider   Ashworth is doing all this to keep up with customer behavior  which has been changing much faster than it has in past decades  From 2010 2018  he said   Everything has changed    Ashworth says customers want to be able to shop more quickly and conveniently  And they re making lots of their purchases online  and having them delivered  Walgreens is up against stiff competition for customers  facing off against the  which is getting into the pharmacy business through its     which is making a big bet on the healthcare aspect of its business through the pending acquisition of insurer Aetna  NYSE AET   and of course retail giant   For its part  Walgreens might be looking to strike up a closer relationship with a health insurer as well  On Tuesday   that Walgreens and Humana  NYSE HUM  were considering taking equity stakes in one another  Walgreens is already partnering with Humana to run primary care clinics out of some of its stores in the     The pharmacy business model is under more direct attack from disruptive players than are health plans   Jefferies analyst Brian Tanquilut noted Wednesday  A stronger partnership with Humana  he said  could help Walgreens with its market share  while Humana could benefit from better branding and marketing that comes from being seen inside the retail pharmacy   Read more   The pharmacy giant is hanging on   the stock of its parent company is up  But same store sales of things like snacks  toothbrushes and laundry detergent were down 1 9  in the company s fiscal fourth quarter  Prescription drug sales did better  up 1 3   As competition heats up  Ashworth has faith that going to an actual store will still be a part of that picture    I think customers very much will enjoy brick and mortar retailing if we make it modern and experiential   Ashworth said   How Walgreens is trying to improve your experience in the store On the left side of the store as I walked in  I was greeted by a make up display presenting kits filled with bath bombs  brushes  and lip balm  There s a designated beauty consultant who staffs the section  Across they US  Walgreens has hired 3 500 beauty consultants  Ashworth said   On the right side  next to a FedEx  NYSE FDX  counter  was an optical store  There  I could browse for eyeglasses or pop into an eye exam room  The optometrist had previously worked at the  in Niles  Illinois  That Sears is among the locations  it would close    There was a place to get lab results as well  In October  Walgreens made an agreement with lab testing giant    All of the health services   including lab services  the pharmacy  and optical   are nestled under what Walgreens calls its health corner alongside a hearing station  Within the hearing station is a room built to test how well people can hear  which could dictate whether they might need a hearing aid   The pharmacy counter is in the back right corner  which looked standard apart from the express lane  Through the Walgreens app  you re able to check out remotely and then scan the QR code for a quicker check out process  Here s a closer look at the counter  As for whether it ll all look like the storefront in Deerfield  Illinois   Jury s not out on that   Ashworth said  What works for one community might not work for another ,2018-11-21,Business Insider,https://www.investing.com/news/stock-market-news/take-a-look-inside-walgreens039-futuristic-store-where-it039s-plotting-new-ways-to-take-on-amazon-and-cvs-1696724,1696724
141330,362845,HUM,Humana s  HUM  Medicare Business Aids  High Costs Persist,opinion,Humana Inc    NYSE HUM   is well poised for growth on the back of its solid Medicare Advantage plans The company delivered a positive earnings surprise in all the last four quarters  the average being 7 79  Humana s Medicare business has been performing strongly over the last many quarters  The Medicare Advantage business is consistently delivering solid returns owing to the company s operating efforts It recently announced expanding its footprint in New Jersey by offering Medicare Advantage plans across Cumberland  Hunterdon  Mercer  Salem  Somerset  Sussex and Warren Counties Apart from widening its network  the company has concentrated on assisting its customers by tying up with local providers  This is evident from its August tie up with Baptist Health Care via which Humana Medicare Advantage members will gain in network access to Baptist Hospital  Gulf Breeze Hospital and Jay Hospital  In the same month  it entered into an agreement with McLaren Physician Partners through which Humana Medicare Advantage members can avail of eight additional McLaren Health Care hospitals and outpatient facilities In September 2019  it inked a partnership deal with Iora Health to add 11 Iora Primary care practices to its Medicare Advantage network in areas like Texas  Georgia and Arizona  With this pact  Humana Medicare Advantage members can experience an impactful  relationship based primary care On Oct 1  2019  Humana announced its plans for Medicare Advantage in 2020  The proposals will include fitness program memberships  dental  hearing and eye coverage  home support for caregivers  etc  The company s efforts to enrich member s experience are mainly aimed at catering to certain social determinants of health that are food insecurity  conveyance  and social isolation All these measures bode well for the business line  Medicare membership surged 54  from 2013 to 2018  The company expects Individual Medicare Advantage membership in the band of 480 000 500 000  up from the previous projection of 415 000 440 000 However  Humana has been witnessing a rise in the operating expenses since 2010  Although during 2017  the same declined 6   it again increased 8 7  and 13   each during 2018 and the first half 2019  The company expects to witness an elevation in benefit expenses  which will induce overall higher operating expenses  This is likely to hurt the bottom line Stocks That Warrant a LookSome stocks worth a look from the medical sector are HCA Healthcare  Inc    NYSE HCA    Molina Healthcare  Inc    NYSE MOH   and Anthem  Inc    NYSE ANTM   HCA provides health care services  In the last four quarters  the company delivered average beat of 15 74  Molina offers Medicaid related solutions to meet the healthcare needs of low income families and individuals  In the trailing four quarters  the company s average beat was 66 9  Anthem works as a health benefits company in the United States  In the preceding four quarters  the company pulled off average beat of 4 57  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-10-07,Zacks Investment Research,https://www.investing.com/analysis/humanas-hum-medicare-business-aids-high-costs-persist-200471512,200471512
141331,362846,HUM,UnitedHealth Expands Medicare Offerings In New Counties,opinion,UnitedHealth Group Inc    NYSE UNH   has announced to offer more than 100 new Medicare plans as it expands its offerings to reach an additional 1 2 million people in 100 new counties This expanded  product offering will enable 90  of people eligible for Medicare to choose UnitedHealthcare Medicare Advantage  MA  plans  nationwide in 2020 UnitedHealthcare is also collaborating with Walgreens to introduce the new its AARP Medicare Advantage Walgreens plans   The company is providing supplemental health benefits such as virtual visits  House Calls and Navigate4Me  a personal concierge support program UnitedHealth currently serves nearly 6 million people via its MA plans and holds  highest share of the MA market The MA enrollment is expected to grow from 46 million in 2019 to 72 million in 2025  MA has become the most attractive business for health insurers after the recent policy changes for Medicare Advantage and Part D programs by the Centers for Medicare   Medicaid Services  CMS   These policy changes include opportunities to offer broadened supplemental benefits packages and expanded telehealth services Supplemental benefits may include meal delivery  transportation for non medical needs  pest control  indoor air quality equipment and services  benefits to address social needs  and structural improvements such as ramps or the widening of hallways In tandem with this  insurers are offering various benefits suited to the medical condition of the customers  These benefits are expected to increase competition between MA plan offerings Recently  many insurers have announced expansion of MA offerings for 2020  Humana Inc    NYSE HUM   announced health plan choices for Medicare beneficiaries in New Jersey by more than doubling the number of counties to 13  in which Humana Medicare Advantage plans are offered  Cigna Corp    NYSE CI   is expanding its Medicare Advantage  MA  plans across 17 states and 80 counties  Centene Corp    NYSE CNC   and Anthem  NYSE ANTM  have also made similar announcements In the first nine months of 2019  UnitedHealth s stock was down 12 8   almost matching the  decline of 12   For the current year  the company s earnings are expected to grow 15 2  compared with the industry s rally of 22 1  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-10-08,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-expands-medicare-offerings-in-new-counties-200471386,200471386
141332,362847,HUM,What s In The Cards For UnitedHealth  UNH  Earnings In Q3 ,opinion,"UnitedHealth Group Inc  s   NYSE UNH   third quarter 2019 earnings  scheduled on Oct 15 before the opening bell  are likely to have showcased well balanced revenue and earnings growth across its different businesses  thereby retaining the positive trend of several previous quarters For the to be reported quarter  the Zacks Consensus Estimate for earnings is pegged at  3 75  indicating an increase of 9 97  from the year ago reported figure on revenues of  56 2 billion  which implies an improvement of 5 42  from the prior year reported number In the last reported quarter  higher revenues  strength in both segments   UnitedHealthcare and Optum   and membership growth led to the outperformance Factors Likely to Affect Q3Within the UnitedHealthcare segment in the quarter to be reported  fee based commercial group business is likely to have increased  primarily owing to an acquisition  Medicare Advantage is also expected to have gained from growth in people served through individual and employer sponsored group Medicare Advantage plans However  we expect a decrease in people served through Medicaid and this is attributable to states adding carriers to the existing programs  reduced enrollment from state efforts to manage eligibility status and the sale of New Mexico Medicaid plan in 2018  Meanwhile  all these are partially offset by uptrends in Dual Special Needs Plans In the third quarter  UnitedHealthcare s revenues and earnings from operations are likely to rise from growth in the number of individuals served through several Medicare products  a higher revenue membership mix and rate hikes for underlying medical cost trends  However  revenue strength might be partially offset by the moratorium on the Health Insurance Industry Tax in 2019 Meanwhile  earnings from operations are expected to be favorably impacted by efficient operating cost management in the to be reported quarter  The Zacks Consensus Estimate for UnitedHealthcare revenues stands at  47 6 billion  suggesting a 3 6  climb from the year earlier count Optum revenues are likely to grow on the back of solid contribution from OptumHealth  OptumInsight and OptumRx in the third quarter  The Zacks Consensus Estimate for segmental revenues is pegged at  28 2 billion  hinting at an 11  ascent from the year ago reported figure OptumHealth revenues are expected to increase from strength and diversity of growth across care delivery  behavioral health services and complex care management in the impending quarterly results  The Zacks Consensus Estimate for this segmental revenues stands at  7 8 billion  suggesting an improvement of 28 7  from the figure reported in the comparable quarter last year Optum Insight revenues are likely to be driven by health care operations and technology  revenue management  and payer and advisory services  The Zacks Consensus Estimate for revenues at this segment is pinned at  2 5 billion  implying a rise of 12 9  from the year ago reported number OptumRx revenues are expected to ride on the traction from market share gains and continued diversification of services provided including a higher mix of specialty pharmacy care services  Moreover  we expect to see higher fulfilled adjusted scripts in the third quarter  The Zacks Consensus Estimate for revenues in this segment stands at  17 9 billion  denoting a 2 9  climb from the year earlier reported number Earnings Surprise HistoryThe company boasts an attractive earnings surprise history  having surpassed estimates in the trailing four reported quarters  the average being 3 27   This is depicted in the chart below UnitedHealth Group Incorporated Price and EPS Surprise   Here is What Our Quantitative Model Predicts The proven Zacks model does not conclusively show that UnitedHealth is likely to beat on earnings this reporting cycle because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as elaborated below Earnings ESP  UnitedHealth has an  of  0 50   You can uncover the best stocks to buy or sell before they re reported with our Earnings ESP FilterZacks Rank  UnitedHealth carries a Zacks Rank  3  which increases the predictive power of ESP  However  its  0 50  ESP in the combination leaves surprise prediction inconclusive Stocks That Warrant a LookHere are some companies worth considering in the healthcare sector as our model shows that these have the right combination of elements to beat estimates this earnings season Cigna Corp    NYSE CI   has an Earnings ESP of  1 53  and a Zacks Rank  2  You can see  Anthem Inc    NYSE ANTM   has an Earnings ESP of  3 98 and a Zacks Rank of 3 Humana Inc    NYSE HUM   has an Earnings ESP of  1 21  and is Zacks  3 Ranked 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-10-10,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-unitedhealth-unh-earnings-in-q3-200472800,200472800
141334,362849,HUM,Humana Lifts Health Care Midday  Wayfair Soars,news,"Investing com   Health care stocks were among the biggest gainers in midday trading led by Humana  NYSE HUM   which announced a buyback and reaffirmed its guidance for next year 
The S P 500 Health Care index rose about 0 6  at 11 30 AM ET  16 30 GMT  
Humana announced it is buying back  750 million in stock and said it still expects adjusted earnings of  14 40 per share for 2018 
Shares jumped about 4  
Humana is also expecting to add 350 000 to 400 000 members to its Medicare Advantage health plan in 2019  Reuters reported  The program  which is offered to people older than 65 or with disabilities  has helped the company grow in the past few quarters 
Also rising in the sector were UnitedHealth  NYSE UNH   increasing about 2 5   WellCare  NYSE WCG   which gained about 3  and Johnson   Johnson  NYSE JNJ   which climbed 1  
Meanwhile  retailer Wayfair  NYSE W  soared about 14  on bullish holiday sales numbers 
Wayfair said direct retail gross sales rose 58  from Thanksgiving to Cyber Monday  compared with the year ago period  Briefing com reported ",2018-11-28,Investing.com,https://www.investing.com/news/stock-market-news/humana-lifts-health-care-midday-wayfair-soars-1703578,1703578
141337,362852,HUM,UnitedHealth  UNH  Q3 Earnings And Revenues Beat  Guidance Up,opinion,"UnitedHealth Group Inc  s   NYSE UNH   third quarter 2019 earnings of  3 88 per share surpassed the Zacks Consensus Estimate by 3 5   The same was up 13 8  year over year 
Higher revenues  strength in both segments   UnitedHealthcare and Optum   plus membership growth led to this outperformance 
UnitedHealth has a tradition of guiding conservatively and then surpassing its own estimates to surprise investors  The reported quarter was not an exception 
UnitedHealth Group Incorporated Price  Consensus and EPS Surprise
    
Strong Operating Performance
UnitedHealth posted revenues of  60 4 billion  beating the Zacks Consensus Estimate by 1 3   The same was up 7  year over year  led by double digit growth at UnitedHealthcare Medicare   Retirement  OptumRx and OptumHealth 
Total operating cost of  55 3 billion was up 6 3  year over year  led by higher medical costs and operating cost     
The operating cost ratio of 14 8  improved 20 basis points year over year due to the deferral of the health insurance tax and continued effect of operating cost productivity improvements 
Strong Performance Across Segments
In the reported quarter  the company s health benefits segment  UnitedHealthcare  generated revenues of  48 1 billion  up 4 7  year over year  Revenue growth was driven by higher enrollment and increase in pricing 
Its business groups   Employer and Individual  Medicare and Retirement and Global   contributed to the growth  Earnings from operations were up 3 8  year over year to  2 7 billion  led by revenue growth and cost control 
Revenues from Optum improved 13 4  year over year to  28 8 billion  reflecting strong contributions from the sub segments   OptumHealth  up 34 4    OptumInsight  16 1   and OptumRx  5 8    Earnings from operations jumped 20  year over year to  2 4 billion  Steady focus on accelerating growth as well as improving margins and productivity through enhanced integration and business alignment led to the segment s overall improvement 
Increase in Membership Enrollment
The company served 49 39 million people in the quarter  up 0 8  year over year  It was led by growth in members  served in the Commercial and Medicare Advantage and partially offset by lower Medicaid and International membership 
Capital Position Update
Cash flow from operations declined 8  year over year to  12 2 billion in the first nine month of 2019 
Cash and short term investments at quarter end were  15 8 billion  up 10 4  year over year 
Share Buyback and Dividend Payout
During the third quarter  dividend payout grew 20  year over year to  1 billion and  600 million of shares were repurchased 
2019 Guidance Raised
Following a strong third quarter 2019 performance  UnitedHealth raised its 2019 adjusted earnings per share guidance to  14 90  15 from  14 7 14 9 guided earlier 
Our Take    
UnitedHealth s vast and diversified business operations  spanning from health benefit to health services  and a number of accretive acquisitions that have driven its performance over the years  will be the growth catalysts this year too 
Moreover  a solid balance sheet will enable acquisitions that should drive inorganic growth  Good command on controlling medical cost should aid its margins 
Zacks Rank and Stocks That Warrant a Look
UnitedHealth  with a Zacks Rank  4  Sell   has got this reporting cycle off to a flying start 
Some better ranked stocks in the same space are Molina Healthcare  Inc    NYSE MOH    Humana Inc    NYSE HUM    and Cigna Corp    NYSE CI    While Molina Healthcare sports a Zacks Rank  1  Strong Buy   Humana and Cigna Corp  carry a Zacks Rank  2  Buy   You can see  
Humana  Molina Healthcare and Cigna are expected to reported earnings growth by 21    8 4   and 18   respectively 
Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-15,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-unh-q3-earnings-and-revenues-beat-guidance-up-200473642,200473642
141354,362869,HUM,Humana eyes stronger ties with Walmart despite Walgreens partnership,news,By Tamara Mathias and Ankur Banerjee  Reuters     Humana Inc   N HUM  said it was looking to expand its tie up with Walmart  N WMT   easing concerns that the insurer s agreement with drugstore chain Walgreens Boots Alliance  O WBA  would prevent it from broadening its partnership with the retailer  Humana s shares rose about 4 percent to a record high of  326 97 after Chief Executive Bruce Broussard s comments on a call discussing the company s better than expected earnings   We still value and have a strong relationship with Walmart   Broussard said  adding that the insurer is looking at ways to expand the partnership  Walmart currently has a co branded Medicare drug plan with Humana that steers patients to Walmart stores  The partnership offers a prescription drug plan that can save up to 20 percent in drug costs for customers  In June  the insurer announced it would partner with Walgreens  with its unit operating senior focused primary care clinics inside two Walgreens stores in Kansas  a move some analysts said at the time ended any speculation over a deal with Walmart  Reuters reported in March that Walmart was in early talks with Humana about developing closer ties  with a possible acquisition on the table   Both of them  ties to Walmart and Walgreens  are complementary   Broussard said  adding partnering with one does not restrict the other deal  Unlike its rivals  Humana has said it will focus on partnerships and smaller deals while cementing its dominance in the Medicare Advantage business  which powered a better than  expected second quarter profit  Humana  in the past few months  has joined hands with private equity firms to buy health care services companies  creating the largest hospice operator in the United States  RAISES FORECAST Humana also raised its 2018 adjusted earnings forecast to about  14 15 per share from its previous forecast of  13 70 to  14 10 per share  The company s adjusted consolidated benefit ratio  the percentage of premiums spent on claims  deteriorated to 84 3 percent in the quarter  missing consensus estimate of 83 9 percent according to brokerage Evercore ISI  Over the past few quarters  insurers have kept a tight leash on medical costs and even a slight slip has weighed on stocks  Earlier this month  the largest U S  health insurer UnitedHealth Group  N UNH  reported quarterly medical costs slightly higher than expected  overshadowing a second quarter profit beat  Excluding items  Humana earned  3 96 per share  beating analysts  average estimate of  3 77  according to Thomson Reuters I B E S  Revenue rose 5 4 percent to  14 26 billion  above the average estimate of  14 16 billion ,2018-08-01,Reuters,https://www.investing.com/news/stock-market-news/humana-eyes-stronger-ties-with-walmart-despite-walgreens-partnership-1555610,1555610
141355,362870,HUM,U S  to boost drug price negotiation in Medicare Advantage health plans,news, Reuters    The Trump administration said on Tuesday it would give Medicare Advantage health plans for the elderly new tools to negotiate for lower prescription drug prices  The Centers for Medicare and Medicaid Services  CMS  said Medicare Advantage plans will be allowed to require that patients first try certain lower cost drugs before moving to a more expensive alternative if the first treatment is not effective   Medicare Advantage plans are administered by private health insurers  such as  Aetna Inc   N AET  and  Humana Inc   N HUM   and cover medical benefits for some 20 million seniors  Until now  such requirements could not be made on drugs covered by Medicare Part B  which are administered in a hospital or doctor s office  The changes also affect Medicare Part D drugs that patients get at the pharmacy  The Medicare Advantage plans would be allowed to require patients try alternatives covered within Part D before moving on to physician administered drugs  that are typically much more expensive  In 2017  Medicare Advantage plans spent  11 9 billion on Medicare Part B drugs  These types of changes in the private market have generally resulted in savings of about 15 percent to 20 percent  according to the Department of Health and Human Services  More than half of the savings will be required to be passed on to patients  CMS said  U S  President Donald Trump has made lowering prescription drug costs for U S  consumers a top priority  He announced a blueprint for lower healthcare costs in May and his administration has been announcing new initiatives this summer  The changes announced on Tuesday can take effect as early as 2019  Medicare Advantage plans that choose to implement the so called step therapy will be required to disclose the change to patients  They would be allowed to switch to another Medicare Advantage plan or to fee for service by March 31 ,2018-08-07,Reuters,https://www.investing.com/news/stock-market-news/us-to-boost-drug-price-negotiation-in-medicare-advantage-health-plans-1564292,1564292
141356,362871,HUM,Anthem ties up with Walmart for over the counter drugs,news," Reuters    Anthem Inc  N ANTM  said on Monday it has partnered with Walmart Inc  N WMT  to launch a program in January 2019 that will allow its Medicare Advantage plan customers to purchase over the counter medications from the retailer s stores and website  Anthem said the program will provide OTC drugs and health related items  such as first aid supplies  support braces  and pain relievers at reduced costs  The Medicare Advantage plan  which competes with the traditional Medicare fee for service program  provides healthcare coverage to about 17 million Americans and is offered by insurers including UnitedHealth Group Inc  N UNH   and  Aetna Inc   N AET    Leerink analyst Ana Gupte said the collaboration emphasizes Anthem s increasing focus and success on Medicare Advantage growth post the margin turnaround  adding the tie up modestly dampens the likelihood of a near term Humana deal or JV with Walmart   Earlier this month  insurer  Humana Inc   N HUM   which has a co branded Medicare drug plan with Walmart  said it was looking to expand its tie up with the retailer  
The Walmart Humana partnership offers a prescription drug plan that saves up to 20 percent in drug costs for customers ",2018-08-20,Reuters,https://www.investing.com/news/stock-market-news/anthem-tiesup-with-walmart-for-overthecounter-drugs-1580116,1580116
141357,362872,HUM,Strategic Acquisitions Aid Revenue Growth At Ensign Group,opinion,The Ensign Group  Inc    NASDAQ ENSG   boasts a strong inorganic growth story with several acquisitions made in the past decade  Its historical growth has been mainly driven by its expertise in acquiring real estate or leasing post acute care operations and transforming the same into market leaders Recently  The Ensign Group made a series of buyouts  such as the real estate and operations of Temple View Transitional Care Center in Rexburg  ID  the real estate and operations of Surprise Health and Rehabilitation Center in Surprise  AZ  the operations of Mainplace Senior Living  a 91 unit assisted living community in Orange  CA  the assets of Agape Hospice and Palliative Care and the real estate and operations of The Terrace at Mt  Ogden in UT All these buyouts are expected to boost the company s capabilities and add to its revenue growth  With the most recent purchase  Ensign Group now has a portfolio of 202 skilled nursing hubs  of which 27 consist of assisted living operations  57 assisted and independent living operations  26 home health agencies  28 hospice agencies and nine home care businesses across 16 states  The company owns the real estate at 80 of its 259 healthcare facilities The Ensign Group s acquisition strategy comprises application of its core operating expertise to improve the above operations both clinically and financially  It continues to seek transactions to acquire real estate properties and lease both well performing and struggling skilled nursing  assisted living and other healthcare related businesses in the new and the existing markets Moreover  the company s recent announcement of the separation of its home health and hospice business plus all its senior living operations from the parent company into a publicly traded entity will not slow down its acquisitions at all Ensign Group s growth plans and integrations have driven its top line  which has been growing since 2012  This uptick is evident from its 2012 2018 CAGR of 16 3   We expect these growth policies and acquisitions to further bolster the revenue stream  The company also anticipates annual revenues between  2 34 billion and  2 40 billion  the mid point indicating a rise of 16 2  from the 2018 figure Shares of this Zacks Rank  2  Buy  company have surged 31 9  in a year s time  outperforming the s rise of 3 9  Other Stocks to ConsiderInvestors interested in the medical sector can also take a look at some other top ranked stocks like Molina Healthcare  Inc   NYSE MOH    Centene Corporation   NYSE CNC   and Humana Inc    NYSE HUM    each carrying the same solid Zacks Rank as Ensign Group  You can see  Molina offers Medicaid related solutions to meet the health care needs of low income families and individuals  In the trailing four quarters  the company came up with average beat of 66 9  Centene works as a diversified and multi national healthcare enterprise in the United States In the preceding four quarters  the company delivered average beat of 4 6  Humana works as a health and well being company in the United States  The company pulled off average positive surprise of 7 79  in the last four quarters 5 Stocks Set to DoubleZacks experts released their picks to gain  100  or more in 2020  One is a famous cutting edge food company that is  hiding in plain sight   Swamped with competitors and ignored by Wall Street  its stock price floundered  Now  suddenly  it acquired a company that gives it an advantage none of its peers have ,2019-09-16,Zacks Investment Research,https://www.investing.com/analysis/strategic-acquisitions-aid-revenue-growth-at-ensign-group-200465430,200465430
141360,362875,HUM,Cigna deal gets antitrust nod  positive sign for CVS Aetna,news,"By Caroline Humer  Reuters    Health insurer Cigna Corp s  N CI   52 billion acquisition of pharmacy benefits manager Express Scripts Holding Co has passed U S  antitrust scrutiny  the companies said on Monday  allowing them to proceed with a combination they say will lead to lower costs by better coordinating pharmacy and medical benefits  Wall Street analysts had expected antitrust approval as the companies have little overlap in their businesses  The decision bodes well for the pending U S  antitrust review of CVS Health Corp s  N CVS  proposed  69 billion acquisition of health insurer  Aetna Inc   N AET   The new company will marry Cigna s business of managing health plans for corporations and the government with Express Scripts   O ESRX  role handling pharmacy benefits for those same customers  Express Scripts also owns specialty pharmacies that distribute pricey drugs   We are pleased that the Department of Justice has cleared our transaction and that we are another step closer to completing our merger   Cigna Chief Executive David Cordani said in a statement  The Justice Department review of CVS s planned purchase of Aetna may conclude this month  but will take longer because of divestitures needed to resolve competitive concerns  a source familiar with the matter told Reuters  CVS spokeswoman Carolyn Castel said the company continues to expect to close its deal late in the third quarter or in the fourth quarter  a forecast it gave investors on Aug  8 during a conference call  The Justice Department in 2016 successfully blocked a pair of large health insurance mergers it believed would limit competition in the industry  Those were Aetna s plan to acquire smaller U S  health insurer  Humana Inc   N HUM  for  37 billion  and a planned  54 billion combination of insurers Anthem Inc  N ANTM  and Cigna  Aetna and Cigna  however  were determined to seek growth through deals while responding to a changing healthcare landscape  eventually targeting mergers with the nation s largest pharmacy benefit managers  PBMs    We believe these two transactions add more pressure on Humana to move further down the path of vertical integration   William Blair analyst John Kreger said   We suspect other health plans will look to follow suit    FEELING THE PRESSURE Antitrust experts have described the current deals as vertical combinations that present fewer issues than the failed insurer mergers  That view was bolstered after the Justice Department lost its case to stop AT T s  N T  acquisition of media company Time Warner  The department is appealing the decision   Everyone is feeling the pressure right now     to react to disruption in the healthcare industry   said Brad Haller  a director in West Monroe Partners  mergers   acquisitions practice  That disruption includes Amazon com Inc s  O AMZN  moves into healthcare  The world s largest online retailer purchased online pharmacy PillPack  which Wall Street analysts say can help it undercut traditional prescription drug sales  Amazon has also aligned itself with JPMorgan Chase   Co  N JPM  and Warren Buffett s  Berkshire Hathaway Inc   N BRKa  to experiment with new business models for employee healthcare   one of Cigna s target markets  Cigna s purchase of Express Scripts comes as PBMs  role in prescription drug costs has come under scrutiny  The administration of U S  President Donald Trump has said it is looking at how so called industry middlemen and pharmacies such as Express Scripts and CVS impact drug costs for U S  consumers  The administration is looking at implementing a rule that could change or eliminate the use of rebates from drugmakers to PBMs that critics say contribute to higher drug prices  Cigna and Express Scripts said they have already obtained clearances for the deal from departments of insurance in 16 states and are working with regulators in remaining jurisdictions to obtain clearance for the merger   States could still conduct a public hearing     though it is very unlikely that they do not align with the U S  Department of Justice s decision   Leerink analyst Ana Gupte said   The companies continue to expect the deal to close by the end of the year  subject to the satisfaction of all closing conditions  
Cigna shares closed up 1 4 percent at  197 84  while Express Scripts shares closed up 3 7 percent at  95 23  CVS and Aetna shares also rose  closing up 1 5 percent and 1 percent  respectively ",2018-09-17,Reuters,https://www.investing.com/news/stock-market-news/cignaexpress-scripts-deal-gets-us-antitrust-approval-1613368,1613368
141361,362876,HUM,CVS  Aetna win U S  approval for  69 billion deal,news,"By Diane Bartz and Caroline Humer WASHINGTON NEW YORK  Reuters    Pharmacy chain CVS Health Corp  N CVS  won U S  antitrust approval for its  69 billion acquisition of health insurer  Aetna Inc   N AET   the Justice Department said on Wednesday  paving the way for a combination with potential to cut U S  healthcare costs for consumers  The companies have said they will save administrative and patient care costs when they combine  in part by steering Aetna customers to walk in clinics in CVS stores for less expensive medical services  CVS could offer more preventive care services and screenings in its clinics  such as enabling patients with diabetes to monitor blood sugar levels  avoiding higher cost visits to doctors or emergency rooms  CVS aims to cut costs by  750 million annually by the end of the second year after the deal closes   It is the second large recent healthcare deal to win U S  Justice Department approval  The agency gave the green light to health insurer Cigna Corp s  N CI   52 billion acquisition of the nation s largest pharmacy benefit manager  PBM   Express Scripts Holding Co  O ESRX   on Sept  17  Shares of CVS and Aetna each rose about 1 percent on Wednesday  a day when the broader market was sharply lower  with CVS trading at  80 20 and Aetna at  206 48  The deal was approved on the condition that the companies sell Aetna s standalone Medicare prescription drug plan business  known as Medicare Part D  the Justice department said   Aetna last month said it would sell all of those standalone plans for prescription drugs that are part of the Medicare program for Americans aged 65 and older and the disabled to WellCare Health Plans Inc  N WCG   paving the way for the deal s approval   Without the sale the two companies would have owned more than a 30 percent share of those standalone Medicare drug plans  creating concern about the amount of control the new CVS would have had over this part of the Medicare insurance market  Drugs administered by doctors and hospitals are covered under a separate Medicare benefit  Together Aetna and CVS have 6 8 million members in standalone Medicare drug plans  the Justice Department said  CVS also has a large PBM business   The divestitures required here allow for the creation of an integrated pharmacy and health benefits company that has the potential to generate benefits by improving the quality and lowering the costs of the healthcare services that American consumers can obtain   Makan Delrahim  head of the department s Antitrust Division  said in a statement  ON TRACK TO CLOSE THIS YEAR California  Florida  Hawaii  Mississippi and Washington also joined the antitrust review   We know that over consolidation is bad for healthcare and leaves millions of Californians with fewer options  We will keep close watch to ensure that the terms of this settlement are met   California Attorney General Xavier Becerra said in a statement  CVS Chief Executive Larry Merlo said in a statement that the deal is on track to close early in the fourth quarter  CVS first announced plans to buy Aetna last December  Since then  online retailer Amazon com Inc  O AMZN  stepped into the healthcare market with the purchase of online pharmacy PillPack  which Wall Street analysts say can help it expand further in healthcare and undercut major players across the prescription drugs supply chain  Amazon has also aligned itself with  JP Morgan Chase    Co  N JPM  and Berkshire Hathaway  NYSE BRKa  Inc  to experiment with new models for employee healthcare   one of Aetna s target markets for health insurance  The decision comes as the Trump administration intensifies pressure on healthcare industry  middlemen   such as PBMs  over practices it says increase the cost of prescription medicines for U S  consumers  After the deals were announced  antitrust experts described them as  vertical  combinations that were less troublesome from a competitive standpoint than a previous round of proposed consolidation deals among insurers  which were blocked  
The Justice Department sued and won its case to stop Aetna s  37 billion plan to acquire smaller U S  health insurer  Humana Inc   N HUM   It also blocked a combination of health insurers Anthem Inc  N ANTM  and Cigna ",2018-10-10,Reuters,https://www.investing.com/news/stock-market-news/justice-department-expected-to-approve-cvs-deal-for-aetna-as-soon-as-wednesday-source-1638771,1638771
141362,362877,HUM,Here s How Cigna  CI  Is Poised Amid Political Uncertainty,opinion,"Cigna Corp    NYSE CI   is more immune to the uncertainty from the ensuing changes in health care regulations following the  2020 presidential election  given its large book of administrative services only business and sizable international business The company is also mulling to sell off its Group Disability and Life business in order to focus on medical care provider area  All the major health insurers such as UnitedHealth Group  Inc    NYSE UNH    Humana Inc    NYSE HUM    and CVS Health Corporation   NYSE CVS   have invested to grow in the medical care provider line Factors Driving Growth Strong Growth in Health Services Business  The company s Health Services segment  which consists of Express Scripts  NASDAQ ESRX   the pharmacy benefits management business  should gain from growth in pharmacy scripts insourcing  The acquisition provides Cigna with cross selling opportunities  The company expects adjusted scripts insourcing in the range of  1 17 billion to 1 19 billion in 2019 and the same to be nearly  1 4 billion in 2021 Government Business to Grow in 2020 and Beyond   Cigna is poised to grow its Medicare Advantage business in 2020 and beyond The company expects membership growth of 10  15  in this line of business over the long term  driven by product and geographic market expansion beginning in 2020 International Markets  Cigna s international market spanning more than 30 countries are well positioned for growth given secular increase in middle class population  proven local market capabilities  continuous innovation and rise of chronic disease  The CAGR of this segment s revenues has been 8  from 2015 2018  The company s deep customer insights  local talent and operating model  global provider network  continuous innovation and a local license base should further help in the growth of this segment Capital Efficient Business  Consistent cash flow from operations should allow the company to deleverage its capital structure and achieve debt to capital ratio of less than 40   Significant financial flexibility also enables it to reinvest in business  pursue mergers and acquisitions and return capital to shareholders  It expects cash flow of operations to be more than  8 billion in 2019 and north of  8 5 billion in 2021 Cigna s core businesses  health services  government and international markets  provide path for sustained growth in a dynamic marketplace and regulatory environment The company remains on track to deliver EPS of  20 to  21 in 2021 and 10  to 13  average annual EPS growth over the long term Year to date  the stock has fallen 12 86  compared with its  s decline of 5 96  Cigna carries a Zacks Rank  3  Hold    You can see  
5 Stocks Set to DoubleZacks experts released their picks to gain  100  or more in 2020  One is a famous cutting edge food company that is  hiding in plain sight   Swamped with competitors and ignored by Wall Street  its stock price floundered  Now  suddenly  it acquired a company that gives it an advantage none of its peers have ",2019-09-17,Zacks Investment Research,https://www.investing.com/analysis/heres-how-cigna-ci-is-poised-amid-political-uncertainty-200465272,200465272
141363,362878,HUM,Cigna Expands Health Care Exchange Offerings To New Markets,opinion,Cigna Corporation   NYSE CI   has extended its health care exchange offerings to new locations for 2020  The plans will be accessible in 19 markets across 10 states  including Kansas  South Florida and Utah The new initiative will encourage better health outcomes of individuals by providing quality medical care as well as reducing overall expenses  Cigna s patients will now be able to get preventive care services as well as enjoy online help from doctors via its advanced telehealth service  With the company s Patient Assurance Program  eligible patients will receive their preferred branded insulin for 30 days in  25 or less  starting from 2020 Moreover  the company will offer gym memberships  nutrition support and loyalty plan in certain markets  etc  to motivate customers to take better care of their health  Additional around the clock support as well as access to health and wellness resources via Cigna com  and the myCigna application would aid customers  Patients with complicated health issues will be given personalized support through the My Personal Champion program Customers in Phoenix will be able to use Cigna Medical Group that comprises more than 140 primary care and specialty doctors at 20 regions  hearing and vision centers  and additional specialty services  urgent care centers  and onsite drug stores The move is in line with the company s commitment to provide quality healthcare to customers  Cigna has been constantly putting in effort to increase its membership as well as quality of care over the past few quarters  We expect the company to witness rise in membership going forward  given its diversified product portfolio  a wide agent network and superior service Shares of this Zacks Rank  3  Hold  company have lost 20 3  in a year  wider than its  s decline of 3 7    Stocks to ConsiderInvestors interested in the same space can also take a look at some better ranked stocks like Molina Healthcare  Inc    NYSE MOH    CVS Health Corporation   NYSE CVS   and Humana Inc    NYSE HUM   Molina offers Medicaid related solutions to meet the healthcare needs of low income families and individuals  In the trailing four quarters  the company s average beat was 66 9   The company currently sports a Zacks Rank  1  Strong Buy   You can see  CVS Health provides health services in the United States  In the preceding four quarters  the company delivered average beat of 5 9   The company currently carries a Zacks Rank of 2  Buy  Humana works as a health and well being company in the United States  The company pulled off average positive surprise of 7 79  in the last four quarters  Presently  it is also a Zacks  2 Ranked player 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-09-19,Zacks Investment Research,https://www.investing.com/analysis/cigna-expands-health-care-exchange-offerings-to-new-markets-200466107,200466107
141364,362879,HUM,UnitedHealth To Offer Medicare Advantage Plan In Bay Area,opinion,UnitedHealth Group Incorporated   NYSE UNH   will unveil a Medicare Advantage Plan named UnitedHealthcare Canopy Health Medicare Advantage to more than 63 000 Medicare beneficiaries in Contra Costa  Alameda and San Francisco counties  This new co branded plan in Bay Area will feature Centene Corporation s   NYSE CNC   subsidiary Canopy Health  The plan is expected to be effective Jan 1  2020 Canopy Health s affiliated members in the above mentioned region will be able to gain access to a wide  comprehensive and advanced network of caregivers  leading to better health outcomes  Additionally  the new plan is expected to reduce overall expenses and enrich patient experience The combination of Canopy Health provider s quality of care and the strength of UnitedHealthcare Medicare Advantage plan will surely lead to advanced healthcare at affordable rates  People will now have more choices in acquiring healthcare benefits   Canopy Health is the perfect partner for this move as it already has an alliance with the company regarding the employer sponsored health insurance This move is in line with the company s constant efforts and commitment toward improving the quality of care provided to individuals  Its Medicare membership has also been increasing and currently caters to more than 3 million people in California including 1 2 million Medicare beneficiaries Medicare Advantage members grew over the past five years and currently comprise more than one third of all Medicare beneficiaries  This is why most industry players are making efforts to boost their membership as well as the quality of care that they provide in this highly competitive market Shares of this Zacks Rank  3  Hold  company have lost nearly 12 6  in a year s time  narrower than its  s decline of 15 1  Stocks to ConsiderInvestors interested in the same space can also take a look at some better ranked stocks like Molina Healthcare  Inc    NYSE MOH   and Humana Inc    NYSE HUM   Molina offers Medicaid related solutions to meet the healthcare needs of low income families and individuals  In the trailing four quarters  the company s average beat was 66 9   The company currently sports a Zacks Rank  1  Strong Buy   You can see  Humana works as a health and well being company in the United States  The company pulled off average positive surprise of 7 79  in the last four quarters  Presently  it is also a Zacks  2 Ranked player Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ,2019-09-19,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-to-offer-medicare-advantage-plan-in-bay-area-200466611,200466611
141365,362880,HUM,UnitedHealth To Offer New Medicare Advantage Plan In Bay Area  Revised ,opinion,UnitedHealth Group Incorporated   NYSE UNH   will offer a new Medicare Advantage Plan  named UnitedHealthcare Canopy Health Medicare Advantage plan  to more than 63 000 Medicare beneficiaries in Contra Costa  Alameda and San Francisco counties  This new co branded plan in Bay Area will feature Canopy Health and is expected to be effective Jan 1  2020 Canopy Health s affiliated members in the above mentioned region will be able to gain access to a wide  comprehensive and advanced network of caregivers  leading to better health outcomes  Additionally  the new plan is expected to reduce overall expenses and enrich patient experience The combination of Canopy Health provider s quality of care and the strength of UnitedHealthcare Medicare Advantage plan will surely lead to advanced healthcare at affordable rates  People will now have more choices in acquiring healthcare benefits   Canopy Health is the perfect partner for this move as it already has an alliance with the company regarding the employer sponsored health insurance This move is in line with the company s constant efforts and commitment toward improving the quality of care provided to individuals  Its Medicare membership has also been increasing and currently caters to more than 3 million people in California including 1 2 million Medicare beneficiaries Medicare Advantage members grew over the past five years and currently comprise more than one third of all Medicare beneficiaries  This is why most industry players are making efforts to boost their membership as well as the quality of care that they provide in this highly competitive market Shares of this Zacks Rank  3  Hold  company have lost 14 4  in a year s time  narrower than its  s decline of 14 7  Stocks to ConsiderInvestors interested in the same space can also take a look at some better ranked stocks like Molina Healthcare  Inc    NYSE MOH    Anthem  Inc    NYSE ANTM   and Humana Inc    NYSE HUM   Molina offers Medicaid related solutions to meet the healthcare needs of low income families and individuals  In the trailing four quarters  the company s average beat was 66 9   The company currently sports a Zacks Rank  1  Strong Buy   You can see  Humana works as a health and well being company in the United States  The company pulled off average positive surprise of 7 8  in the last four quarters  Presently  it is also a Zacks  2 Ranked player Anthem provides network based managed care health benefit plans to individuals  small and large groups  Medicaid  and Medicare markets  With a Zacks Rank  2  Buy   the company managed to deliver an average beat of 4 6  in the last four quarters  We are reissuing this article to correct a mistake  The original article  issued on September 20  2019  should no longer be relied upon  ,2019-09-24,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-to-offer-new-medicare-advantage-plan-in-bay-area-revised-200467344,200467344
141366,362881,HUM,3 Health Insurance Stocks Poised To Beat On Earnings In Q3,opinion,The health insurance industry delivered a stellar operating performance in the first six months of 2019 with most players reporting higher top and the bottom line numbers from the year ago quarter as well as beating estimates on both counts An increase in membership and premiums was the main catalyst for top line growth  leading to gains in the first two quarters of 2019  Medical cost management  better claims handling and cost saving initiatives among others contributed to the bottom line Leading players including the likes of Humana  UnitedHealth Group Inc    NYSE UNH    Cigna and Anthem also upped their respective earnings guidance for 2019  This reflects the companies  continued optimism on the operating environment Nevertheless  year to date  the health insurance  has declined 9 7  against the Zacks S P 500 composite s rise of 17 7   The industry s decrease was due to investors  supposed concern for various political uncertainties Factors to Influence Third Quarter EarningsProgress in Government Business  Medicare Advantage  MA  and Medicaid  Although MA remains one of the most attractive markets  it is underpenetrated and provides enough scope for expansion  These insurance plans are in huge demand from the baby boomers  which are rising by the day  Most health insurance giants  namely United Health  Humana  Aetna  NYSE AET  Anthem and Well Care Health have witnessed a secular uptrend in their MA business and the trend is expected to continue in the to be reported quarter Per The Centers for Medicare   Medicaid Services  CMS   Medicaid expenditures will exceed  540 billion by 2025 of which nearly 60  is expected to be serviced by managed care as state Medicaid programs increasingly turn to health insurers to take responsibility for the care of their most complex and chronically ill beneficiaries This shift toward managed Medicaid presents a growth opportunity for the industry players  Medical enrollment historically  from 2013 to 2018  has augmented for UnitedHealth  Centene  NYSE CNC   Anthem  WellCare Health Plans and is likely to shoot up further Gains From Pharmacy Benefit Management Business  The healthcare sector witnessed a transition in recent years with a string of mergers between entities from the two major industries  such as Pharmacy Benefit Managers  PBM  and Health insurers The integration of PBMs and Payors started with UnitedHealth building its own PBM business  Optum Rx  and other insurers following suit Last year  Cigna acquired the PBM major Express Scripts  NASDAQ ESRX   Also  Aetna was bought by another PBM major CVS while Anthem is developing its own PBM platform called IngenioRx  Further  Humana functions through its own in house PBM Humana Pharmacy Solutions In the second quarter  revenues from the respective PBM businesses under UnitedHealth  CVS Health  NYSE CVS  and Humana ascended 11 7   4 2  and 7   respectively  Players expect a spurt in adjusted scripts  which should aid revenues from this line of business   Share Buybacks  Given the surplus capital resource available at their disposal  major health insurers have been actively repurchasing their shares  Except Cigna and CVS  other players inclusive of UnitedHealth  Anthem and Humana bought back shares  only to bump up the bottom line in turn  Given the fact that the share repurchase authorizations of most companies are still pending  we expect more buybacks in the ensuing quarters   We are thus upbeat about an overall positive performance from the sector in absence of any significant headwind Stocks to Bet on for Q3 Earnings BeatBelow we pick up three stocks that are likely to deliver a third quarter positive earnings surprise These are the stocks with the perfect combination of a favorable Earnings ESP and a top Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  You can see Our research shows that for stocks with this ideal mix  chances of a positive earnings surprise are as high as 70  Notably   provides the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate  You can uncover the best stocks to buy or sell before they re reported with our  Cigna Corp    NYSE CI   has an Earnings ESP of  0 25  and a Zacks Rank  2  For the to be reported quarter  the company s earnings are expected to grow 13 8   The stock surpassed estimates in three of the last four quarters  the average positive surprise being 7 02   You can see the complete list of today s Zacks  1 Rank stocks here Anthem Inc    NYSE ANTM   has an Earnings ESP of  4 31  and a Zacks Rank of 2  For the quarter to be reported  the company s earnings are estimated to jump 26 5   The stock outpaced estimates over the trailing four quarters  the average being 4 57  Humana Inc    NYSE HUM   has an Earnings ESP of  1 77  and is Zacks  2 Ranked  For the impending quarterly results  earnings for the company are anticipated to inch up 0 22    The stock trumped earnings estimates in all the preceding four quarters  the average being 7 79  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-09-27,Zacks Investment Research,https://www.investing.com/analysis/3-health-insurance-stocks-poised-to-beat-on-earnings-in-q3-200468740,200468740
141367,362882,HUM,S P  Dow Still Positive For September,opinion,"SPECIAL NOTE  We ve just released this quarter s Ultimate Four report which includes four stocks our team believes have the greatest upside potential over the upcoming quarter  This latest report features favorite stocks from Brian Bolan  Ben Rains  Dan Laboe and Tracey Ryniec  Log on to Zacks com to see these stocks today The major indices just finished a second straight week of losses  as the latest trade headline had investors nervous about next month s U S    China meetings 
	A strong Friday session could have gotten stocks onto the plus side for the week  The announcement that high level talks would resume in two weeks was hoped to provide that extra boost into the green 
	But that s not what happened 
	Instead  we got reports that the White House is thinking about limiting U S  investment in China  perhaps even delisting Chinese companies from U S  exchanges 
	This consideration is in the very early stages and may never come to fruition  but this skittish market doesn t need much to selloff these days 
	The NASDAQ took the brunt of this news and plunged 1 13   or about 91 points  to 7939 63  The S P was down 0 53  to 2961 79 and the Dow slipped 0 26   or nearly 71 points  to 26 820 25 
	All of the indices started the session in the green before dipping lower  However  they all came off their lows as well 
	The most important thing for the market in the short term is to get to those meetings next month  As long as they re still happening  then these day to day headline driven moves are just noise 
	Earnings season is also coming up in the next few weeks  Investors will be watching to see what kind of an impact the trade conflict and global economic weakness is having on companies 
	But first things first  We ve got one more day of September and of the third quarter on Monday   
	The S P and Dow go into the final session with gains for the month  which is impressive given how tough this time is for stocks  However  today s slump has pulled the NASDAQ into the red for the month   
	And then we start the fourth quarter  Let s hope its better than last year s Today s Portfolio Highlights Value Investor  The market is not a big fan of drugstores right now  but Tracey is willing to be patient with industry staple Walgreens Boots Alliance  NASDAQ WBA   Shares are down 21  this year  but it has come off of recent lows  This Zacks Rank  2  Buy  is  a classic value stock by all measures   according to the editor  She appreciates WBA s shareholder friendly ways  including a dividend that currently yields 3 4   Through its partnership with Humana  NYSE HUM   the company continues to roll out medical clinics and new services to compete with CVS Aetna  Read the full write up for a lot more on this new addition TAZR Trader  Rumors that President Trump may delist Chinese equities has Kevin looking to get even more defensive in this seasonally weak period for the market  On Friday  he sold Alteryx  AYX  while he can still get a nice 22 9  profit in this data analytics software company  He also sold Elatic  ESTC   And for those of you feeling a little aggressive  the editor thinks this is a good time to add ProShares UltraPro Short QQQ ETF  SQQQ   Read the full write up for a lot more on today s news and action 
	Have a Great Weekend 
	Jim Giaquinto 
Recommendations from Zacks  Private Portfolios   Believe it or not  this article is not available on the Zacks com website  The commentary is a partial overview of the daily activity from Zacks  private recommendation services  If you would like to follow our Buy and Sell signals in real time  we ve made a special arrangement for readers of this website  Starting today you can see all the recommendations from all of Zacks  portfolios absolutely free for 7 days  Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises  which we ve predicted with an astonishing 80   accuracy    Click here to  test drive  Zacks Ultimate for FREE   ",2019-09-27,Zacks Investment Research,https://www.investing.com/analysis/sp-dow-still-positive-for-september-200468878,200468878
141371,362886,HUM,WellCare s Unit To Divest Medicaid Health Plans To Anthem,opinion,WellCare Health Plans  Inc    NYSE WCG   has announced that it will be selling its Missouri and Nebraska Medicaid plans to Anthem  Inc    NYSE ANTM    This move is related to the  17 billion pending merger of Centene Corporation   NYSE CNC   and WellCare  which is expected to close in the first half of 2020  However  this sale is subject to certain closing conditions Notably  Anthem  which is at the helm of implementing Blue Cross and Blue Shield plans across 14 states  will win around 300000 Medicaid members through this deal  The company has been actively collaborating and acquiring units for enhancing its expansion process  With this buyout  it is looking to serve the Medicaid members in Missouri and Nebraska and help them achieve improved health outcomes As previously declared  Centene has agreed to purchase WellCare  which will leverage its position as the largest Medicaid managed care organization in the country  The merged entity  post closure  will have a wider scale and diversification with more than 12 million Medicaid and around 5 million Medicare members  In total  it will have almost 22 million members across 50 US states  making it one of the biggest providers of government insurance The deal has got regulatory nod in 19 states The transaction is expected to generate adjusted earnings per share accretion of approximately mid single digits in the year two following its completion with long term growth opportunities and cost reduction efforts across markets and products This government business line remains attractive for Centene because of the growth opportunity it holds for the players  The rise in the number of baby boomers makes the business lucrative for the companies as more people would opt for the plans that provide an enriched value based care  Per CMS  Medicare spending is expected to grow on average of 7 6  per year from 2020 to 2027  Whereas Medicaid spending is projected to increase 6  every year over the same time frame  This is the reason why market leaders like UnitedHealth Group Inc    NYSE UNH   and Humana Inc  NYSE HUM   are making concerted efforts to make the most of this business The deal will push the merged entity into the fastest growing segment of the industry Shares of WellCare  a Zacks Rank  2  Buy  player  have lost 19 5  in a year s time  narrower than its  s decline of 21 2   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-09-29,Zacks Investment Research,https://www.investing.com/analysis/wellcares-unit-to-divest-medicaid-health-plans-to-anthem-200469229,200469229
141372,362887,HUM,The Zacks Analyst Blog Highlights  UnitedHealth  Cigna  Anthem And Humana,opinion,For Immediate ReleaseChicago  IL   September 30  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  UnitedHealth Group Inc    NYSE UNH    Cigna Corp    NYSE CI    Anthem Inc    NYSE ANTM   and Humana Inc    NYSE HUM   Here are highlights from Friday s Analyst Blog  3 Health Insurance Stocks Poised to Beat Q3 EarningsThe health insurance industry delivered a stellar operating performance in the first six months of 2019 with most players reporting higher top and the bottom line numbers from the year ago quarter as well as beating estimates on both counts An increase in membership and premiums was the main catalyst for top line growth  leading to gains in the first two quarters of 2019  Medical cost management  better claims handling and cost saving initiatives among others contributed to the bottom line Leading players including the likes of Humana  UnitedHealth Group Inc   Cigna and Anthem also upped their respective earnings guidance for 2019  This reflects the companies  continued optimism on the operating environment Nevertheless  year to date  the health insurance industry has declined 9 7  against the Zacks S P 500 composite s rise of 17 7   The industry s decrease was due to investors  supposed concern for various political uncertainties Factors to Influence Third Quarter EarningsProgress in Government Business Medicare Advantage  MA  and Medicaid  Although MA remains one of the most attractive markets  it is underpenetrated and provides enough scope for expansion  These insurance plans are in huge demand from the baby boomers  which are rising by the day  Most health insurance giants  namely United Health  Humana  Aetna  NYSE AET  Anthem and Well Care Health have witnessed a secular uptrend in their MA business and the trend is expected to continue in the to be reported quarter Per The Centers for Medicare   Medicaid Services  CMS   Medicaid expenditures will exceed  540 billion by 2025 of which nearly 60  is expected to be serviced by managed care as state Medicaid programs increasingly turn to health insurers to take responsibility for the care of their most complex and chronically ill beneficiaries This shift toward managed Medicaid presents a growth opportunity for the industry players  Medical enrollment historically  from 2013 to 2018  has augmented for UnitedHealth  Centene  NYSE CNC   Anthem  WellCare Health Plans and is likely to shoot up further Gains From Pharmacy Benefit Management Business The healthcare sector witnessed a transition in recent years with a string of mergers between entities from the two major industries  such as Pharmacy Benefit Managers  PBM  and Health insurers The integration of PBMs and Payors started with UnitedHealth building its own PBM business  Optum Rx  and other insurers following suit Last year  Cigna acquired the PBM major Express Scripts  NASDAQ ESRX   Also  Aetna was bought by another PBM major CVS while Anthem is developing its own PBM platform called IngenioRx  Further  Humana functions through its own in house PBM Humana Pharmacy Solutions In the second quarter  revenues from the respective PBM businesses under UnitedHealth  CVS Health  NYSE CVS  and Humana ascended 11 7   4 2  and 7   respectively  Players expect a spurt in adjusted scripts  which should aid revenues from this line of business   Share Buybacks  Given the surplus capital resource available at their disposal  major health insurers have been actively repurchasing their shares  Except Cigna and CVS  other players inclusive of UnitedHealth  Anthem and Humana bought back shares  only to bump up the bottom line in turn  Given the fact that the share repurchase authorizations of most companies are still pending  we expect more buybacks in the ensuing quarters   We are thus upbeat about an overall positive performance from the sector in absence of any significant headwind Stocks to Bet on for Q3 Earnings BeatBelow we pick up three stocks that are likely to deliver a third quarter positive earnings surprise These are the stocks with the perfect combination of a favorable Earnings ESP and a top Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  You can see the complete list of today s Zacks  1 Rank stocks here Our research shows that for stocks with this ideal mix  chances of a positive earnings surprise are as high as 70  Notably  Earnings ESP provides the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate  You can uncover the best stocks to buy or sell before they re reported with our Earnings ESP Filter Cigna Corp  has an Earnings ESP of  0 25  and a Zacks Rank  2  For the to be reported quarter  the company s earnings are expected to grow 13 8   The stock surpassed estimates in three of the last four quarters  the average positive surprise being 7 02   You can see the complete list of today s Zacks  1 Rank stocks here Anthem Inc  has an Earnings ESP of  4 31  and a Zacks Rank of 2  For the quarter to be reported  the company s earnings are estimated to jump 26 5   The stock outpaced estimates over the trailing four quarters  the average being 4 57  Humana Inc  has an Earnings ESP of  1 77  and is Zacks  2 Ranked  For the impending quarterly results  earnings for the company are anticipated to inch up 0 22    The stock trumped earnings estimates in all the preceding four quarters  the average being 7 79  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better See these 7 breakthrough stocks now   Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-09-30,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-unitedhealth-cigna-anthem-and-humana-200469251,200469251
141380,362895,HUM,U S  to consider expanding Medicare drug price negotiation,news,"By Yasmeen Abutaleb and Michael Erman WASHINGTON NEW YORK  Reuters    The Trump administration is considering expanding Medicare s ability to negotiate the cost of drugs by giving private payers a role in setting the price of medicines administered in hospitals and doctors  offices  Health and Human Services Secretary Alex Azar said on Monday  Azar s comments provided more details on the plan to lower prescription drug costs for Americans announced on Friday by President Donald Trump   While Trump assailed  middlemen   an apparent reference to health insurers and pharmacy benefit managers  PBMs   for pocketing negotiated rebates on drugs rather than passing savings to consumers  the proposal discussed on Monday appears to see them as part of the solution to high prices  Shares of leading PBMs and insurers rose on Monday  CVS Health Corp  N CVS  shares climbed 3 7 percent with Express Scripts Holding  up 1 2 percent  while  Humana Inc   N HUM  shares rose 1 7 percent and  Cigna Corp   N CI  closed up 2 2 percent   On the one hand we are talking about banning rebates  but on the other we are talking about how great the private market is at controlling costs   said Craig Garthwaite  director of the healthcare program at Northwestern University s Kellogg School of Management   Where exactly do we think those price reductions come from   Trump has vowed to tackle rising drug prices since running for office  but his plan spared the pharmaceutical industry from direct government negotiations to control costs  a proposal he endorsed during the 2016 presidential campaign  Shares of drugmakers rose for a second day on Monday as Wall Street analysts said the new policies were unlikely to hurt industry profits  Medicare is the national health insurance plan run by the federal government for Americans over the age of 65 and the disabled  Azar  a former pharmaceutical company executive  said Trump views tougher negotiation as key to the plan  Azar said his agency will consider an alternative system for buying Medicare Part B drugs  which are administered by a healthcare provider and covered directly by the government  such as many cancer treatments and infused biotech drugs  The administration would seek to allow private payers to negotiate the price of those medicines  as health insurers and PBMs already do in Medicare Part D  which covers drugs patients get at the pharmacy   We believe there are more private sector entities equipped to negotiate these better deals in Part B  and we want to let them do it   Azar said   More broadly  the President has called for me to merge Medicare Part B drug payments into Part D  where negotiation has been so successful   Health and Human Services senior officials said at a briefing with reporters on Monday that they could experiment with moving some drugs from Medicare Part B to Part D in a pilot program  but did not say when that might begin  HHS likely has authority to pilot or experiment with limited programs  health policy experts said  But Joe Antos  of the conservative American Enterprise Institute  said the bulk of expensive drugs will likely remain in Part B  limiting the proposal s ability to significantly lower drug prices   These are sophisticated drugs for complicated diseases   Antos said   It s a relatively small part of the Medicare population  but it s a big chunk of spending   Under the current system  drugmakers and physicians are incentivized to keep prices high in Medicare Part B  Leerink analyst Ana Gupte said  
She said companies best positioned to participate in the new proposal would be insurers that have their own PBMs  Part D plans and Medicare Advantage business  such as UnitedHealth Group  N UNH   Humana  Anthem Inc  N ANTM  and Cigna if the Trump administration approves its merger with Express Scripts ",2018-05-14,Reuters,https://www.investing.com/news/politics-news/us-considering-expanding-medicare-drug-price-negotiation-1445809,1445809
141381,362896,HUM,Colombia s leftist Petro  the candidate who wants to upset the status quo,news,"By Helen Murphy and Luis Jaime Acosta BOGOTA  Reuters    Gustavo Petro  a former insurgent turned rabble rousing mayor  is fighting to become Colombia s first leftist president  turning his humble beginnings and revolutionary past into a rallying cry for millions of the nation s youth and poor  The 58 year old economist ranks second behind right wing candidate Ivan Duque to replace President Juan Manuel Santos  If no candidate garners more than 50 percent in Sunday s election  a second round in June will decide the presidency  Petro s strong showing in polls   he has around 30 percent support  compared to Duque s 42 percent   has worried many in the traditionally conservative nation  where the right has kept a vice like grip on power  Proposals from Petro to change the nation s economic model by piling taxes on unproductive landowners and abandoning oil and coal for clean energy have spooked investors  Some fear his efforts to shift wealth from rich to poor could turn Colombia into another Venezuela  Known for his fiery speeches from the Senate against corruption and right wing paramilitary groups  Petro says his political awakening began in 1973 with the military coup that ended the rule of Chile s socialist President Salvador Allende  Colombia was descending into violence around the same time  as guerrilla groups began a wave of kidnappings and attacks on civilians  It was then that Petro  the son of a teacher  pledged to fight the  feudal  oligarchy enriching itself at the expense of Colombia s poor  he said   Twenty first century politics is between the politics of life and the politics of death   the father of six told Reuters in April   I represent the politics of life   Inspired as a child by political biographies  Petro reportedly raised the ire of his Catholic teachers by reading books by Karl Marx and Friedrich Engels   Although never a combatant  Petro s years in the now defunct M19 rebel group   which stormed the Supreme Court in 1985  leading to the deaths of more than 100 people   have created fodder for critics  He was arrested that year for weapons possession and served 18 months in prison  where he has said he was tortured  Petro s 2011 election as mayor of Bogota  Colombia s second most powerful post after the presidency  was seen as proof that politics was the way forward for insurgent movements like the Revolutionary Armed Forces of Colombia  FARC   which demobilized last year and formed a political party  In 2010 he came fourth in the presidential vote with 1 3 million votes  less than half of what he garnered in March s primaries   Petro represents a clearly populist project   said Andres Molano  director of the Hernan Echavarria Olozaga institute of political science   He presents himself as an outsider   an enemy of the elites   and has elaborated a messianic and anti liberal discourse that promises a kind of revolution both politically and economically    A win for Petro may help shore up Colombia s fragile peace process that ended five decades of war with the FARC  but angered many by giving their commanders a political voice instead of a jail cell  Petro promises Latin America s fourth largest economy will include all of society  creating a public banking system that guarantees cheap credit to small and medium sized businesses and expanding free education  That may be difficult  The economy remains weak  a new wave of drug trafficking crime gangs have moved into areas once controlled by the FARC and half a million Venezuelan migrants have crossed into Colombia looking for food and work   Critics say his ideas are strikingly similar to the early days of late socialist leader Hugo Chavez s government in Venezuela   There are many echoes of the so called 21st century socialism that flourished in Latin America during the last two decades   said Molano   Petro has said he does not plan to expropriate property  but he raised eyebrows with his recent offer to buy a huge piece of productive land from billionaire sugar baron and media mogul Carlos Ardila Lulle to give to the poor  While it may be tough for Petro to push radical change through Congress   his Colombia Humana  NYSE HUM  party won just six seats in March s legislative election   he said he would seek alliances with center  left and other minority parties or attempt a change to the constitution through a constituent assembly  Known for his stubborn management style and ruling by decree  the bespectacled Petro has taken flack for living in a gated community and wearing  500 shoes  but his expensive lifestyle has not swayed voters or his discourse  
 Because I m from the left  I have to wear espadrilles   he responded wryly in a recent radio interview ",2018-05-24,Reuters,https://www.investing.com/news/world-news/colombias-leftist-petro-the-candidate-who-wants-to-upset-the-status-quo-1461362,1461362
141382,362897,HUM,Humana down 10  premarket on light volume,news,Humana  NYSE HUM  is down 10  premarket  albeit on only 1 000 shares  The only relevant news appears to be a modest sale by institutional investor Bridger Management LLC  which sold 50 178 shares last quarter  trimming its stake by 16 5  Now read ,2018-05-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/humana-down-10-premarket-on-light-volume-1468141,1468141
141383,362898,HUM,Humana  HUM  Tops Q2 Earnings And Revenue Estimates,opinion,"Humana  HUM  came out with quarterly earnings of  6 05 per share  beating the Zacks Consensus Estimate of  5 24 per share  This compares to earnings of  3 96 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 15 46   A quarter ago  it was expected that this health insurer would post earnings of  4 30 per share when it actually produced earnings of  4 48  delivering a surprise of 4 19  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Humana  which belongs to the Zacks Medical   HMOs industry  posted revenues of  16 25 billion for the quarter ended June 2019  surpassing the Zacks Consensus Estimate by 2 26   This compares to year ago revenues of  14 26 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Humana shares have lost about 0 7  since the beginning of the year versus the S P 500 s gain of 20 2  
What s Next for Humana 
While Humana has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Humana was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  4 91 on  15 93 billion in revenues for the coming quarter and  17 48 on  63 74 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   HMOs is currently in the top 8  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-tops-q2-earnings-and-revenue-estimates-200447937,200447937
141384,362899,HUM,Outlook For Health Insurance Industry Looks Sanguine,opinion,"The Health Maintenance Organization  HMO  industry comprises entities  either private or public  that take care of the basic and supplemental health services of its subscribers  Companies in this space primarily assume the risks involved and assign premiums for health and medical insurance policies  Industry participants also provide administrative and managed care services for self funded insurance Services are generally provided by a network of approved care providers  called in network   which include primary care physicians  clinical facilities  hospitals and specialists  However  out of network exceptions are made in emergencies or when medically necessary  Health insurance plans can be availed by ways such as private purchase  social insurance or social welfare programs such as Medicare and Medicaid  funded by the government Let us take a look at the industry s three major themes      As life expectancy continues to increase in the United States and seniors account for a higher percentage of the total U S  population  overall demand for health insurance for seniors will increase  According to the 2018 U S  Census  between 2010 and 2030  the number of individuals aged 65  is projected to nearly double from 39 million to 73 million  a growth rate nearly 5 times faster than the 17  increase expected for the total population  The census estimates this group to grow from 13  to 21  by 2030   one of the fastest growing within U S  population  This senior population has fueled demand for Medicare Advantage  MA   the private version of the government Medicare program  MA plans have proven beneficial for all concerned groups  customers  government and health insurers  Customers gains from better coverage and services  and government on the other hand gains from reduction in cost of care  These plans have also led to considerable revenue growth for the likes of UnitedHealth Group Inc   UNH   Humana Inc   NYSE HUM  and Anthem Inc   NYSE ANTM  among other health insurers      The HMO industry is rapidly consolidating with mergers and acquisitions  The most common takeovers in recent years have been in the nature of horizontal expansion in the areas of Medicare and Medicaid as the players seek to garner a greater share of the attractive MA  market  Lately  however  the companies have shown interest in expanding vertically and add capabilities to its supply chain through mergers and acquisitions  The mega mergers of Aetna  NYSE AET  with CVS Health Corp  NYSE CVS    CVS  and Cigna Corp   CI  with Express Scripts  NASDAQ ESRX  are the best examples of inter industry deals that led to the union of a health insurer and a pharmacy benefit manager      The industry has also witnessed development in ancillary business to diversify revenue sources in the wake of tough regulations laid  via the ACA  on health insurance business   These businesses  mostly in the form of health care services  are growing rapidly  opening up new avenues of growth and forming an increased proportion of the industry s total revenues  Health services business is an important growth area for HMOs as these provide unregulated cash flows and enable players to become comprehensive healthcare providers  Ample opportunities of growth exist in the health service business and continued investments are being made in this area  A poster child for the same is UnitedHealth s Optum  which provides a  range of healthcare related services Zacks Industry Rank Indicates Bright ProspectsThe group s   which is basically the average of the Zacks Rank of all the member stocks  indicates upbeat prospects in the near term  The Zacks   which is an 11 stock group within the broader Zacks  sector  currently carries a Zacks Industry Rank  25  which places it at the top 10  of 255 Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperforms the bottom 50  by a factor of more than 2 to 1 The industry s positioning in the top 50  of the Zacks ranked industries is a result of positive earnings outlook for the constituent companies in aggregate  In a year s time  the industry s earnings estimate for the current year has gone up by 4 6  One Year Price PerformanceBefore we present a few HMO stocks that you may want to consider for your portfolio  let s take a look at the industry s recent stock market performance and valuation picture Industry Return Underperformed S P 500  and its SectorThe Zacks Medical HMO industry has underperformed both the Zacks S P 500 composite and its own sector over the past year We see that the stocks in this industry have collectively lost 5 7  over the past year  while the Zacks S P 500 composite and Zacks Medical Sector have rallied 1 8  and 11 4   respectively HMO Industry s Current ValuationOn the basis of forward 12 month price to earnings  P E  ratio  which is commonly used for valuing HMO stocks  the industry is currently trading at 14 53X compared with the S P 500 s 16 39X and the sector s 19 32X Over the past five years  the industry has traded as high as 20 53X  as low as 14 27X and at a median of 16 21X Price to Earnings  P E  Ratio  F12M Price to Earnings  P E  Ratio  F12M  Bottom LineDespite earnings outperformance by the companies  the industry has underperformed in a year s time due to various regulatory issues and the uncertainty in policy changes if new a president gets elected  These may have kept investors away from the industry   Shrugging aside the intermittent political disruptions  players in the industry will continue to ride on technological investment and upgrade  application of blockchain technology  growth of new business units  international expansion  better claims handling  medical cost management  mergers and acquisitions  and a healthy balance sheet HMO Stocks to Buy NowFour stocks in the Zacks Medical HMO space currently carry a Zacks Rank  2  Buy  You can see   The Joint Corp   JYNT    The stock has surpassed earnings estimates in two of the last four quarters with an average positive surprise of 190  Price and Consensus  JYNTAnthem Inc   ANTM   The stock has surpassed earnings estimates in each of the trailing four quarters with an average positive surprise of 4 57   The Zacks Consensus Estimate for this Minnetonka  MI based company s 2019 earnings has gone up 0 3  over the past 30 days Price and Consensus  ANTMCentene  NYSE CNC  Corp   CNC   The Zacks Consensus Estimate for 2019 bottom line of this Louisville  KY based company has been raised 0 7  over the past 30 days  The stock has surpassed earnings estimates in each of the last four quarters with an average positive surprise of 4 56  Price and Consensus  CNCUnitedHealth Group  Inc   UNH   The Zacks Consensus Estimate for this Minnetonka  MI based company s 2019 earnings has gone up 0 6  over the past 30 days  The stock has surpassed earnings estimates in each of the trailing four quarters with an average positive surprise of 3 37   Price and Consensus  UNH 
This Could Be the Fastest Way to Grow Wealth in 2019  Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market   Breaking news in this space frequently creates quick double  and triple digit profit opportunities  These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-08-07,Zacks Investment Research,https://www.investing.com/analysis/outlook-for-health-insurance-industry-looks-sanguine-200452328,200452328
141386,362901,HUM,U S  health insurers to sell cheaper pared down coverage in October,news,The Trump administration has cleared the way for insurers to begin selling short term health coverage that is less expensive and less comprehensive than Obamacare plans  The rollout will start in October when open enrollment for 2019 exchange coverage begins  The pared down plans may be renewable for up to 36 months Short term plans are exempt from coverage mandates under the Affordable Care Act  ACA   allowing insurers to reduce the cost of premiums  Critics  like Georgetown University Professor Sabrina Corlette  say buyers need to be aware that some policies are  truly junk insurance  The administration says insurers will be required to provide  clear notice  to consumers that short term plans do not provide Obamacare protections and clearly outline what the plans do cover Scott Flanders  CEO of eHealth  believes as many as 5M short term policies could be sold next year Selected tickers  XLV  HIIQ  WCG  UNH  GTS  MOH  HUM  CI  CNC  ANTM  AET  VHT  IYH  IXJ  FHLC  FXHNow read ,2018-08-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/us-health-insurers-to-sell-cheaper-pareddown-coverage-in-october-1555104,1555104
141387,362902,HUM,Centene Expands Existence In Health Insurance Marketplace,opinion,Centene Corporation   NYSE CNC   recently announced expansion of offerings in the 2020 Health Insurance Marketplace  The company is penetrating 10 markets  namely Arizona  Florida  Georgia  Kansas  North Carolina  Ohio  South Carolina  Tennessee  Texas and Washington to gain a strong foothold for establishment in the marketplace business Centene  the country s leading provider of health insurance marketplace plans  would now be able to dispense affordable and quality healthcare in the aforementioned states  As of Jun 30  2019  the company served around 1 9 million exchange members across 20 states  reflecting a rise of 27  year over year The key characteristics of these members  such as age  gender  etc  remain intact over the last years per the company s record with more than 90  of them eligible for subsidies The company s procedures for regulatory approvals of the target areas in 2020 are already on track In January 2019  the company also extended its offerings across Pennsylvania  North Carolina  South Carolina and Tennessee besides boosting its presence in the existing markets of Florida  Georgia  Indiana  Kansas  Missouri and Texas With better patient care  demand for marketplace business is growing  following which Centene made this announcement  This is also evident from the solid profit margins reported by insurers  The company s Marketplace business continues to be in the 5 10  range per the last reported results  This  in turn  boosted its revenues in the second quarter of 2019 The company has constantly been putting in efforts to increase its membership through market growth plus acquisitions and mergers Centene is on course to acquire WellCare Health Plans  Inc    NYSE WCG    which is expected to close by the first half of 2020   The combined entity will have a wider scale and diversification with more than 12 million Medicaid and around 5 million Medicare members in its fold  In total  it will have around 22 million members across the 50 US states  All these initiatives poise the company well for long term growth Active collaborations and buyouts have been a major growth trajectory in this industry  A few other players  such as Anthem  Inc    NYSE ANTM   and Humana Inc    NYSE HUM   have also been purchasing units and collaborating with companies to improve membership and enhance respective portfolios Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-14,Zacks Investment Research,https://www.investing.com/analysis/centene-expands-existence-in-health-insurance-marketplace-200455548,200455548
141388,362903,HUM,Why Is It Worth Holding Humana  HUM  In Your Portfolio ,opinion,Humana Inc    NYSE HUM   is well poised for growth on the back of its solid Medicare business and strategic initiatives The stock carries an impressive  of A  Here V stands for Value  G for Growth and M for Momentum with the score being a weighted combination of all three factors   It flaunts a commendable earnings surprise history  having exceeded the Zacks Consensus Estimate in the trailing four quarters  the average being 7 8   This stellar surprise record reflects  the company s operating excellence as well It recently delivered operating earnings per share of  6 05  beating the Zacks Consensus Estimate by 15 5  and also soaring 52 8  year over year owing to Medicare Advantage membership growth and higher revenues Humana now anticipates adjusted EPS at around  17 60  up from the earlier expectation of  17 25   17 5  indicating 21  growth from the year ago reported quarter  Individual Medicare Advantage membership is now predicted in the 480 000 500 000 range  above the previous projection of 415 000 440 000  The company now projects retail segment revenues between  64 2 billion and  64 8 billion  up from the earlier range of  55 1  55 7 billion Humana s Medicare business has been delivering encouraging results over the last several quarters on the back of sturdy operating measures  Strength in Medicare Advantage performance led to a better 2018 Retail segment benefit ratio  evident from higher Medicare membership  which shot up by 54  from 2013 to 2018  Given its constant efforts  we expect it to gain from its solid Medicare business Moreover  its strategic moves have carved a growth path for the company  Significant purchases  such Family Physicians Group  Your Home Advantage  Curo and a share in Kindred at Home helped the company deepen its reach in the home health and hospice market  We believe  these endeavors augur well for long term growth Humana has been efficiently deploying excess capital for the past several years  It has been hiking its dividend since 2011  In February 2019  the company raised dividend by 10  to 55 cents per share  In July  the company s board of directors approved a new  3 billion share repurchase plan  replacing its previous buyback authorization  We believe that its financial power will continue to instill investor confidence in the stock However  escalating expenses over the past many quarters remain a major concern for the company  Humana expects to witness an elevation in benefit expenses  which will induce overall higher operating expenses  which might further hurt its bottom line Shares of this Zacks Rank  3  Hold  company have lost 10 4  in a year s time  wider than its  s decline of 7 8  Stocks to ConsiderInvestors interested in the medical sector can take a look at some better ranked stocks like Centene Corporation   NYSE CNC    Anthem  Inc    NYSE ANTM   and Universal Health Services  Inc    NYSE UHS    each carrying a Zacks Rank  2  Buy   You can see  Centene works as a diversified and multi national healthcare enterprise in the United States  In the trailing four quarters  the company came up with average beat of 4 6  Anthem works as a health benefits company in the United States  In the last four quarters  the company delivered average beat of 4 57  Universal Health operates acute care hospitals  outpatient facilities and behavioral health care facilities  In the previous four quarters  the company s average beat was 4 46  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-15,Zacks Investment Research,https://www.investing.com/analysis/why-is-it-worth-holding-humana-hum-in-your-portfolio-200455939,200455939
141389,362904,HUM,Should Value Investors Consider Humana  HUM  Stock Now ,opinion,"Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Humana Inc    NYSE HUM   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Humana has a trailing twelve months PE ratio of 16 81  as you can see in the chart below  This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 17 78  If we focus on the long term PE trend  Humana s current PE level puts it below its midpoint over the past five years  Further  the stock s PE compares favorably with the Zacks Medical sector s trailing twelve months PE ratio  which stands at 20 51  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers   We should also point out that Humana has a forward PE ratio  price relative to this year s earnings  of just 16 86  which is tad higher than the current level  So it is fair to expect an increase in the company s share price in the near term P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings  Right now  Humana has a P S ratio of about 0 67  This is lower than the S P 500 average  which comes in at 3 14 right now   Also  as we can see in the chart below  this is below the highs for this stock in particular over the past few years   If anything  HUM is in the higher end of its range in the time period from a P S metric  suggesting some level of overvalued trading at least compared to historical norms  Broad Value Outlook In aggregate  Humana currently has a Zacks Value Score of A  putting it into the top 20  of all stocks we cover from this look  This makes Humana a solid choice for value investors What About the Stock Overall    Though Humana might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of A and a Momentum Score of C  This gives HUM a Zacks VGM score   or its overarching fundamental grade   of A   You can read more about the Zacks Style Scores    Meanwhile  the company s recent earnings estimates have been mixed at best  The current quarter has seen six estimates go lower in the past sixty days compared to no movement in the opposite direction while the current year estimate has seen eight upward revision compared to no downward in the same time period      This has had a notable impact on the consensus estimate though as the current quarter consensus estimate has declined by 8 1  in the past two months  while the current year estimate has inched up by 0 7   You can see the consensus estimate trend and recent price action for the stock in the chart below Humana Inc  Price and Consensus
 
   This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term Bottom Line  Humana is an inspired choice for value investors  as it is hard to beat its incredible line up of statistics on this front  A strong industry rank  among top 22  of more than 250 industries  further instils our confidence  In fact  over the past two years  the Zacks Medical   HMOs industry has clearly outperformed the market at large  as you can see below  However  a Zacks Rank  3 makes it hard to get too excited about this company overall So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick Legalizing THIS Could Be Even Bigger than MarijuanaAmericans spend an estimated  150 billion in this industry every year  more than twice as much as they spend on marijuana Now that 8 states have fully legalized it  with several more states following close behind   Zacks has identified 5 stocks that could soar in response to the powerful demand  One industry insider described the future as  mind blowing    and early investors can still get in ahead of the surge ",2019-08-19,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-consider-humana-hum-stock-now-200456784,200456784
141392,362907,HUM,Humana Ties Up To Enhance Facilities For Members In Michigan,opinion,Humana Inc    NYSE HUM   recently entered an agreement with McLaren Physician Partners   MPP   to enhance in network facilities for Humana Medicare Advantage members in Michigan  who are seeking treatment at the McLaren Health Care hospitals and outpatient facilities Moreover  the transaction allows in network access for Humana Medicare Advantage members to physicians and clinicians associated or affiliated with McLaren Health Care in Michigan MPP  which is a physician hospital organization  covers 14 Michigan hospitals and is committed toward a clinically integrated network to boost health care delivery The already effective agreement gives health plan members in network access to Humana Medicare Advantage Health Maintenance Organization  HMO   Preferred Provider Organization  PPO  and Private Fee for Service  PFFS  at all McLaren Health Care outpatient facilities  They can also get services at eight other McLaren Health Care hospitals in Central and Eastern Michigan The hospital options integrate six more Health Care system hospitals and ambulatory facilities in Michigan formerly contracted as in network for Humana Medicare Advantage members  This deal also includes a value based care model  aimed at boosting patient health outcomes and enriched patient experiences for local Humana HMO and PPO members The move is in line with Humana s commitment toward providing quality healthcare and better health outcomes to the members by working with locally owned health systems Humana has a vast and spreading value based care presence  As of Jun 30  2019  the company had around 2 3 million individual Medicare Advantage members and 115 000 commercial members across 43 states and Puerta Rico  Its Medicare Advantage membership totals to more than four million  including members affiliated with givers in value based care and Medicare Advantage settings Shares of the Zacks Rank  3  Hold  company have lost 18 7  in a year  wider than the  s decline of 17   Stocks to ConsiderInvestors interested in the medical sector can take a look at some better ranked stocks like UnitedHealth Group Incorporated   NYSE UNH    Universal Health Services  Inc    NYSE UHS   and Molina Healthcare  Inc    NYSE MOH   UnitedHealth Group works as a diversified health care company  In the trailing four quarters  it came up with average beat of 3 4   The company currently carries a Zacks Rank of 2  Buy   You can see  Universal Health owns and operates acute care hospitals  outpatient facilities  and behavioral health care facilities  In the last four quarters  the company delivered average beat of 4 5   It is a Zacks  2 Ranked player Molina Healthcare provides managed health care services under the Medicaid and Medicare programs  and through the state insurance marketplaces  The company currently sports a Zacks Rank  1  It managed to pull off average four quarter positive surprise of 66 9  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-08-27,Zacks Investment Research,https://www.investing.com/analysis/humana-ties-up-to-enhance-facilities-for-members-in-michigan-200459337,200459337
141395,362910,HUM,Humana  HUM  Ties Up To Boost Medicare Advantage Network,opinion,Humana Inc    NYSE HUM   has entered into a new partnership with Iora Health to add 11 more Iora Primary care practices to its Medicare Advantage network in areas like Texas  Georgia and Arizona  With this deal  Humana Medicare Advantage members can now experience an impactful  relationship based primary care Notably  people of Arizona  Colorado  Georgia and Washington are already benefiting from the relationship of these two companies  In 2019  another chain of Medicare focused primary care practices is being launched in Phoenix and Atlanta as well as for the very first time in Houston These practices in particular provide Humana Medicare Advantage HMO  Preferred Provider Organization  PPO  and Dual Eligible Special Needs  which can be accessed by people eligible for Medicare and Medicaid plans along with Original Medicare with or without the most supplement plans and the access to Iora s care model Iora is leading the market when it comes to changing the way primary care is being delivered  Patients experience value based care with longer appointments  assistance from an integrated team that takes care of the patient s health  convenience and access to healthcare professionals for emergencies via phone plus same or next day appointments for urgencies  etc Iora s knowhow combined with Humana s wide array of in network experts aims at delivering a coordinated healthcare plan to patients Meanwhile  Humana is expanding its network through these new practice locations so that its members get better health outcomes from the same  Both Humana and Iora Health have worked together over the years to help Medicare Advantage health plan members across the country Last month  Humana also signed an agreement with McLaren Physician Partners to boost in network facilities for Humana s Medicare Advantage members in Michigan  who are seeking treatment at the McLaren Health Care hospitals and outpatient facilities Humana has a comprehensive and expanding value based care existence  As of Jun 30  2019  it had around 2 3 million individual Medicare Advantage members and 115 000 commercial members across 43 states and Puerto Rico  It should be noted that it has a total of around 4 million Medicare Advantage members Shares of the Zacks Rank  3  Hold  company have lost 17 8  in a year  wider than the  s decline of 16 1  Stocks to ConsiderInvestors interested in the medical sector can take a look at some better ranked stocks like UnitedHealth Group Incorporated   NYSE UNH    Universal Health Services  Inc    NYSE UHS   and Molina Healthcare  Inc    NYSE MOH   UnitedHealth Group works as a diversified health care company  In the trailing four quarters  it came up with average beat of 3 4   The company currently carries a Zacks Rank  2  Buy   You can see  Universal Health owns and operates acute care hospitals  outpatient facilities and behavioral health care facilities  In the last four quarters  the company delivered average beat of 4 5   The stock is a Zacks  2 Ranked player Molina Healthcare provides managed health care services under the Medicaid and Medicare programs as well as via the state insurance marketplaces  The company currently sports a Zacks Rank  1 and managed to pull off average four quarter positive surprise of 66 9  It s Illegal in 42 States  But Investors Will Make Billions LegallyIn addition to the companies you read about above  today you get details on the newly legalized industry that s tapping into a  habit  that Americans spend an estimated  150 billion on every year That s twice as much as they spend on marijuana  legally or otherwise Zacks special report revealing how investors can profit from this new opportunity  As more states legalize this activity  the industry could expand by as much as 15X  Zacks  has just released a Special Report revealing 5 top stocks to watch in this space ,2019-09-04,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-ties-up-to-boost-medicare-advantage-network-200461986,200461986
141399,362914,HUM,Is Humana  HUM  A Great Value Stock Right Now ,opinion,"While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks  we also know that investors tend to develop their own individual strategies  With this in mind  we are always looking at value  growth  and momentum trends to discover great companies 
Looking at the history of these trends  perhaps none is more beloved than value investing  This strategy simply looks to identify companies that are being undervalued by the broader market  Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued  leaving room for profits 
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits  For example  value investors will be interested in stocks with great grades in the  Value  category  When paired with a high Zacks Rank   A  grades in the Value category are among the strongest value stocks on the market today 
One company value investors might notice is Humana  HUM   HUM is currently sporting a Zacks Rank of  2  Buy   as well as an A grade for Value 
Another notable valuation metric for HUM is its P B ratio of 3 05  The P B ratio is used to compare a stock s market value with its book value  which is defined as total assets minus total liabilities  This company s current P B looks solid when compared to its industry s average P B of 3 07  HUM s P B has been as high as 4 60 and as low as 2 90  with a median of 3 63  over the past year 
Finally  our model also underscores that HUM has a P CF ratio of 11 95  This data point considers a firm s operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook  This stock s P CF looks attractive against its industry s average P CF of 12 12  Over the past year  HUM s P CF has been as high as 25 05 and as low as 11 55  with a median of 17 06 
These are only a few of the key metrics included in Humana s strong Value grade  but they help show that the stock is likely undervalued right now  When factoring in the strength of its earnings outlook  HUM looks like an impressive value stock at the moment ",2019-09-15,Zacks Investment Research,https://www.investing.com/analysis/is-humana-hum-a-great-value-stock-right-now-200464946,200464946
141400,362915,HUM,Why Should You Retain Centene  CNC  Stock In Your Portfolio ,opinion,Centene Corporation   NYSE CNC   is well poised for development on the back of a growing top line plus mergers and acquisitions strategy The company has witnessed 2020 earnings estimates move 0 4  north over the past seven days Centene also boasts a stellar earnings surprise history  having outpaced the Zacks Consensus Estimate in the trailing four quarters  the average being 4 4   This trend of consecutive estimate beats vouches for the company s operating efficiency The company is well placed for growth  evident from its favorable  of A  Here V stands for Value  G for Growth and M for Momentum with the score being a weighted combination of all three factors Moreover  it revised its 2019 guidance after delivering solid second quarter results  It now expects revenues in the range of  73 6  74 2 billion  indicating the mid point to be 23 2  above the reported figure of 2018  Adjusted EPS is expected in the band of  4 29  4 49  the mid point suggested to be 24  higher than last year s reported figure Now let s see what makes this stock an investor favorite Centene has been witnessing consistent and significant revenue growth since 2002  The company saw a CAGR of 39 6  from 2012 to 2018  This momentum also continued in the first half of 2019 with the metric surging 34 4  year over year  This upside could primarily be backed by membership growth  expansion of contracts and other investments and we expect the top line to continue growing The company s mergers and acquisitions activity mainly targets expanding its markets and increasing its Medicaid membership  A few buyouts like that of Community Medical Holdings  MHM Services and Fidelis Care have helped it boost its portfolio and strengthen capabilities  Last July  the company struck a joint venture with Ascension to establish a Medicare Advantage plan  which will be operational in multiple geographies beginning 2020 Moreover  Centene s purchase of WellCare Health Plans  Inc    NYSE WCG   is on track and is expected to close by the first half of 2020  The combination of these two entities will lead to a wider scale and diversification with more than 12 million Medicaid and around 5 million Medicare members  It is presumed that this new company will have estimated pro forma 2019 revenues in excess of  100 billion and an EBITDA of  5 billion  The deal is projected to generate adjusted earnings per share accretion of approximately mid single digits during the year two following its completion with long term growth opportunities and cost reduction benefits across markets and products The company s long term growth rate is pegged at 14 2   higher than its industry s average of 14  Shares of this Zacks Rank  3  Hold  company have lost 35 9  in a year s time  wider than its  s decline of 13 4  Stocks to ConsiderInvestors interested in the medical sector can take a look at some better ranked stocks like Molina Healthcare  Inc   NYSE MOH   and Humana Inc    NYSE HUM    You can see  Molina offers Medicaid related solutions to meet the health care needs of low income families and individuals  In the trailing four quarters  the company came up with average beat of 66 9   The stock sports a Zacks Rank  1 Humana works as a health and well being company in the United States  The company has a Zacks Rank of  2  Buy  and pulled off average positive surprise of 7 79  in the last four quarters 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-09-15,Zacks Investment Research,https://www.investing.com/analysis/why-should-you-retain-centene-cnc-stock-in-your-portfolio-200465034,200465034
141403,362918,HUM,CNBC  Walmart looking to buy online pharmacy startup PillPack,news,Walmart  NYSE WMT  is in talks to acquire online pharmacy start up PillPack for less than  1B  CNBC reports PillPack s focus on making it easier for customers to order and fulfill  medications is an attractive proposition for WMT and other  e commerce companies that are looking to enhance their health care  offerings  according to the report  which also says Amazon  NASDAQ AMZN  at one point held discussions with the company Health experts say that a PillPack purchase makes sense for WMT   especially in light of its recent talks with Humana  NYSE HUM   as both companies are looking  for ways to serve vulnerable seniors with one or more medical  conditions Now read ,2018-04-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/cnbc-walmart-looking-to-buy-online-pharmacy-startup-pillpack-1374756,1374756
141404,362919,HUM,Kindred shareholders back Human merger,news,Kindred Healthcare  KND  0 6   shareholders have approved its planned merger with Humana  HUM  0 7   and affiliates of TPG Capital  Welsh Carson  Anderson   Stowe Activist investor Brigade Capital had urged investors to reject the transaction which it said undervalued the company The merger should close this summer Previously  Activist investor Brigade urges Kindred shareholders to reject Humana deal  March 29 Now read ,2018-04-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/kindred-shareholders-back-human-merger-1380157,1380157
141405,362920,HUM,Humana acquires Florida family physician group,news,Humana  NYSE HUM  has acquired Orlando based Family Physicians Group  an operator of 22 clinics in central Florida serving over 22K Medicare Advantage patients  including almost 4K Humana members Financial terms are not disclosed  Humana says the transaction will not have a material effect on 2018 guidance Now read ,2018-04-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/humana-acquires-florida-family-physician-group-1388213,1388213
141406,362921,HUM,Colombian candidate Petro seeks to close social gap,news,"By Helen Murphy and Luis Jaime Acosta BOGOTA  Reuters    A former Colombian guerrilla insurgent who is trying to become the country s first leftist president  Gustavo Petro said he would focus on narrowing its yawning gap between rich and poor if elected  The 57 year old leftist economist  who was mayor of Bogota from 2011 to 2013  ranks second in polls to replace President Juan Manuel Santos and is pledging to change the nation s economic model  by taxing owners of unproductive land and shifting away from oil and coal   I want to transform the country  It s what I have wanted since I was a boy   Petro said in an interview late on Tuesday   The core generator of problems in Colombia is inequality   The election may determine the fate of Colombia s fragile peace process  which ended five decades of war with Marxist FARC rebels but angered many by giving their commanders a political voice instead of a jail cell  and highlighted the wealth divide Petro is targeting  Petro s proposals  which include expanding education  clean energy and a tax overhaul  have spooked some investors who fear he will expropriate land and turn Colombia into another Venezuela  a charge he denied   We would not be an ally of Venezuela  because Venezuela entered the world of the fossil economy   he said  referring to Colombia s crisis hit socialist neighbor  Petro added that he would gradually eliminate oil  coal and gas and replace it with energy from clean sources like wind and water  Petro will hike taxes on unproductive fertile land  encouraging landowners to sell to the state to pass on to poor farmers  That may upset cattle ranchers  among others    A tax cannot be called expropriation  it s a tax on productive land   he said  Once a member of the now defunct M19 rebel group  Petro s election as Bogota mayor was seen as proof that politics was the way forward for insurgent movements like the FARC  which demobilized last year and formed a political party  But in late 2013 he was removed from his post   the most powerful after the presidency   by the inspector general for mismanagement of garbage collection and banned from holding office for 15 years  a ruling that brought thousands to the streets and was later overturned  Ivan Duque  a protege of right wing former President Alvaro Uribe  is leading Petro in polls by about 10 points in Colombia  a country of 50 million that has historically been governed by the right  SELL BONDS A father of six  Petro rails against the Colombian traditional political class  accusing it of corruption and enriching itself at the expense of the poor  Petro s Colombia Humana  NYSE HUM  party won just six seats out of 280 in the recent legislative election  making it tough for him to push radical reforms through congress  He said he would seek alliances with center  left and other minority parties or call for a change to the constitution through a constituent assembly  He plans to sell bonds to finance the land purchases and move poor farmers   like those who grow coca  the raw material for cocaine   to grow legal crops   To contain the fiscal deficit  he would promote another tax reform to raise duties on corporate dividends and foreign profits and eliminate tax exemptions for large investors   An investor is a gambler and the first thing he does is to examine the rules of the game  We want to put the rules of the game on the table  without hidden cards  we want to move from an extractive economy to a productive economy   he said  
A first round ballot will be held on May 27  but if none of the candidates get more than half the votes  a second round will be held in June ",2018-04-11,Reuters,https://www.investing.com/news/world-news/colombian-candidate-petro-seeks-to-close-social-gap-1390641,1390641
141407,362922,HUM,IQVIA Q1 revenues up 9   earnings down 31   cash flow up 225   revenue guidance raised,news,IQVIA Holdings  NYSE IQV  Q1 results   M   Revenues  2 563   8 6   Net income  69   31 0    non GAAP net income  285   8 0    EPS  0 32   25 6    non GAAP EPS  1 34   19 6    cash flow ops  182   225 0   2018 Guidance  Revenues   10 05B   10 25B from  10 00B   10 20B  non GAAP EPS   5 20   5 45  unch  Q2 Guidance  Revenues   2 47B   2 52B  non GAAP EPS   1 17   1 24 Now read ,2018-05-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/iqvia-q1-revenues-up-9-earnings-down-31-cash-flow-up-225-revenue-guidance-raised-1426152,1426152
141410,362925,HUM,Why Earnings Season Could Be Great For Humana  HUM  ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Humana Inc    NYSE HUM   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Humana is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for HUM in this report In fact  the Most Accurate Estimate for the current quarter is currently at  5 32 per share for HUM  compared to a broader Zacks Consensus Estimate of  5 24 per share  This suggests that analysts have very recently bumped up their estimates for HUM  giving the stock a Zacks Earnings ESP of  1 57  heading into earnings season Humana Inc  Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that HUM has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for Humana  and that a beat might be in the cards for the upcoming report Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-30,Zacks Investment Research,https://www.investing.com/analysis/why-earnings-season-could-be-great-for-humana-hum-200446940,200446940
141423,362938,HUM,HHS debuts new rule allowing increased access to short term insurance plans,news,The Trump administration has released a new rule that will allow Americans greater access to short term health insurance plans  specifically allowing people to buy health insurance coverage for up to one year Under the Affordable Care Act   or Obamacare  short term plans  intended to fill gaps in coverage due to events such as job loss  cannot be used for more than three months The new short term plans offer pared down benefits and do not have to abide by all Obamacare regulations  For example  the plans can charge higher premiums based on medical history  cap the amount of benefits and do not have to offer the 10 baseline types of care The plans will cost less upfront  but critics say they will siphon more healthy people from Obamacare thereby driving up costs for sicker patients who remain since the risk pool will be smaller  Middle class enrollees could be hit especially hard since they are don t receive the same level of subsidies as lower income beneficiaries Selected tickers   AET  0 2   CI  0 5   UNH  0 6   HUM  0 8   UHS  0 8   LPNT  0 5   CYH  0 5   XBI  0 2   VHT  0 2   XLV  0 5   BME  0 2   IXJ  0 6   THW  0 4   GRX  1 1  Now read ,2018-02-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/hhs-debuts-new-rule-allowing-increased-access-to-shortterm-insurance-plans-1281296,1281296
141424,362939,HUM,Colombians pick candidates in two primaries for May presidential election,news,"BOGOTA  Reuters    Right wing candidate Ivan Duque and leftist Gustavo Petro will lead their respective coalitions in Colombia s May presidential election after winning primaries on Sunday  Duque  a prot g  of former President Alvaro Uribe and the standard bearer for the Democratic Center party  beat fellow candidates Marta Lucia Ramirez and Alejandro Ordonez for his coalition s nomination  He got more than 3 9 million votes and 96 percent of the votes counted   Petro  a prominent leftist  former member of the disbanded M 19 guerrilla group and former mayor of Bogota  defeated Carlos Caicedo for their left wing coalition s nomination  with 2 7 million votes and 96 percent of votes counted  That represented about 30 percent fewer votes than Duque  though the two have been close in presidential vote polls  Voters were allowed to vote in one primary and also voted in legislative elections  in which no party won a majority  Many Colombians will have voted strategically in the primaries  hoping to influence candidate selection for the presidential vote on May 27  Duque and Petro are among several other candidates running for the presidency  including former mayor of Medellin Sergio Fajardo and ex vice president German Vargas Lleras  Duque  41  is a lawyer and senator who worked at the Inter American Development Bank and United Nations  He has enjoyed solid showing in polls  coming within the margin of error behind Petro in the most recent presidential survey  Supporters of 57 year old Petro s Colombia Humana  NYSE HUM  party highlight his work to improve conditions for the poor  He has pledged to create a  social economy  that will shift the economy from oil toward agriculture  Some voters gathered outside polling places to protest a shortage of ballots for the primaries  But the head of the national registry  which runs voting in the Andean country  rejected suggestions to close polls later  FARC MAKES DEBUT No party won a majority in either legislature  Duque s Democratic Center party was leading the number of votes in the Senate  with 88 percent reporting  with over 2 2 million of 15 6 million votes  The Radical Change party was second and the Liberal party third  In the lower house  with 86 percent reporting  the Liberal party was leading  with more than 2 1 million votes of 15 3 million total  The Democratic Center party was a close second  with more than 2 million votes  The elections mark the debut of the former FARC rebels as a political party  The group  which preserved its famous initials with its new name  the Revolutionary Alternative Common Force  demobilized under a 2016 peace deal  The FARC is guaranteed five seats in both the 108 member Senate and the 172 member lower house under the terms of the accord  It fielded 74 legislative candidates but got only 0 22 percent of votes for the lower house and just 0 35 percent in the Senate  The group s presidential candidate withdrew from the race last week due to ill health and the party is not naming a replacement  Peace talks dominated elections in 2014  Now candidates in the 50 million strong country are focusing on health  education  corruption and the economy   Now we ve signed peace  the principal problem is corruption   34 year old construction worker Alvaro Jaimes said before voting in Bogota  Jaimes said he planned to vote for Petro in the left wing primary  
High voter abstention is typical in the country  Just over 40 percent of eligible voters turned out for the legislative elections ",2018-03-11,Reuters,https://www.investing.com/news/world-news/colombians-pick-candidates-in-two-primaries-for-may-presidential-election-1335934,1335934
141425,362940,HUM,Kindred prevails in shareholder attempt to block Humana takeover,news,A Delaware court has ruled in favor of Kindred Healthcare  NYSE KND  in a lawsuit brought by investor Brigade Capital Management who claimed Humana  NYSE HUM  s  9 share bid was inadequate Kindred will hold its special meeting of stockholders today to vote on the merger Previously  Big Kindred holder against Humana deal  Dec  27  2017 Now read ,2018-03-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/kindred-prevails-in-shareholder-attempt-to-block-humana-takeover-1366681,1366681
141426,362941,HUM,Walmart talking with Humana on closer ties  acquisition possible  sources,news,"By Carl O Donnell and Greg Roumeliotis  Reuters     U S  retailer Walmart  NYSE WMT  Inc is in early stage talks with health insurer  Humana Inc   NYSE HUM  about developing closer ties  with the acquisition of Humana being discussed as one possibility  people familiar with the matter said on Thursday  Should the talks lead to a tieup  it would be the latest deal to bring together a retail chain and a health insurer in the last few months  following CVS Health  NYSE CVS  Corp s  69 billion deal to acquire  Aetna Inc   NYSE AET  and Cigna  NYSE CI  Corp s  54 billion deal to buy Express Scripts Holding Co  Walmart approached Humana earlier this month and the deliberations are preliminary  two of the sources said  While the conversations have focused on new partnerships  an acquisition of Humana by Walmart is also something being discussed  the sources added  The sources asked not to be identified because the deliberations are confidential  Humana and Walmart declined to comment  Walmart and Humana have market capitalizations of  264 billion and  37 billion  respectively  An acquisition of Humana would represent a significant strategic shift for Walmart  which is the world s largest retailer and has been focused on fending off Amazon com Inc  NASDAQ AMZN  in online shopping  Amazon has also been looking at entering the healthcare sector  Earlier this year  Amazon  Berkshire Hathaway  NYSE BRKa  Inc and JPMorgan Chase   Co  NYSE JPM   said they would form a company aimed at cutting healthcare costs for their U S  employees   The risks  for Walmart  of becoming entangled in the complex U S  healthcare industry are considerable  especially at a time when Walmart is grappling with the competitive challenges of a rapidly shifting retail market   Neil Saunders  managing director of retail consultancy GlobalData Retail  wrote in a note   The hammering out of any agreement  which would be Walmart s largest ever corporate deal  would  of itself  be an enormous distraction   Saunders added  Walmart currently has a co branded Medicare drug plan with Humana that steers patients to Walmart stores  The partnership offers a prescription drug plan that can save up to 20 percent in drug costs for customers   Closer ties between the two companies could allow Walmart to tap into Humana s patient population  expanding low level medical services in its pharmacies to avoid ER visits  They could allow it to better manage prescription drug use though access to medical records  
Humana s biggest business is managing Medicare Advantage health plans for older and disabled people  a heavily regulated business that Walmart would have to take on in an acquisition  Memberships in retail Medicare Advantage plans   where individuals sign up directly with Humana   rose about 1 percent to 2 86 million  as of Dec  31  Employer or other group based Medicare Advantage membership climbed 24 percent to 441 400  Last month  Walmart reported a sharp drop in profit and online sales growth during the critical holiday period and forecast annual profit at the lower end of expectations ",2018-03-30,Reuters,https://www.investing.com/news/stock-market-news/walmart-discussing-closer-ties-with-humana-including-possible-acquisition-sources-1371233,1371233
141427,362942,HUM,Come for your drugs  leave with more shopping  Walmart s new growth strategy ,news,"By Nandita Bose and Chris Prentice  Reuters    Walmart Inc s  N WMT  efforts to develop closer ties with health insurer  Humana Inc   N HUM   which came to light on Thursday  point to a brave new world of retail where superstores become healthcare centers offering basic medical care  They are also aimed at boosting Walmart s slowing growth in brick and mortar store sales as it faces increasing pressure online from Amazon com Inc  O AMZN   Deepening its existing partnership with Humana  or even acquiring the company outright  could be a step toward turning its 4 700 or so U S  stores into healthcare centers that aim to attract more shoppers over 65   The end goal here is to get more people in their stores  get them to buy drugs and make an additional purchase while they are in the store   said Charles Sizemore  founder of Sizemore Capital Management LLC  who owns shares of Walmart  If Walmart can offer  competitive rates  on primary care and other health services  he said  it  can grow traffic and push store visits   Walmart approached Humana this month  and the companies began to discuss closer ties focused on new partnerships  two people familiar with the matter told Reuters on Thursday  An acquisition of Humana by Walmart is also being discussed  the sources said   Walmart declined comment Friday  Humana could not immediately be reached for comment  Closer ties between the two could enable the retailer to tap into Humana s patient roster and possibly put some of its physician clinics in stores to offer medical care to customers  Walmart is the largest retailer to hit upon the combination of retail and health insurance  but it is not the first   CVS Health Corp  N CVS  has struck a  69 billion deal to acquire  Aetna Inc   N AET   Separately  insurer  Cigna Corp   N CI  has a  54 billion deal to buy pharmacy benefits company Express Scripts Holding Co  O ESRX   The two deals  if approved  will put pressure on the entire health care supply chain   AMAZON CHECKMATE  Humana could provide Walmart with  one more way to checkmate Amazon and equal and eclipse the CVS Target partnership and equal and eclipse the CVS Aetna partnership   said Burt Flickinger at marketing consulting firm Strategic Resource Group   It allows them to get ahead of everybody from warehouse club operators like Costco  NASDAQ COST   Target and other retailers who run chain drugstores as well as food and drug combo operators like Kroger  NYSE KR  and Wegmans   Bentonville  Arkansas based Walmart already has pharmacies at many store locations and has a co branded drug plan with Humana that caters to patients using Medicare  the federal health insurance program for people over 65  That plan steers patients to Walmart stores for their pharmacy needs  offering customers an opportunity to save up to 20 percent on drug costs  analysts said   Louisville  Kentucky based Humana is one of the country s largest providers of Medicare Advantage plans   a type of coverage offered by a private company that contracts with Medicare  Humana has 5 1 million seniors on prescription drug benefits and another 3 5 million on full medical benefits  according to Ana Gupte  senior health care analyst with Leerink Partners in New York   Walmart superstores  could be a one stop shop for seniors   said Gupte  adding that Humana already has about 50 pharmacies sharing locations with doctors  clinics  and could expand that model using Walmart s real estate and pharmacies   DATA ANALYSIS  There is also a potential for Walmart and Humana to benefit from their mass of customer data  said Neil Saunders  managing director of GlobalData Retail    One thing retailers have is a very good understanding of customers  They know their eating habits and other consumption patterns and that is quite useful in forming insurance decisions   he said   That is certainly something that Walmart would be able to leverage    Humana patients are most likely already heavy shoppers at Walmart  according to David Friend at the BDO Center for Healthcare Excellence and Innovation   
 If you know that somebody is on a certain medicine you can sell them other products and services and that will help keep customer loyalty   he said ",2018-03-31,Reuters,https://www.investing.com/news/stock-market-news/come-for-your-drugs-leave-with-more-shopping-walmarts-new-growth-strategy-1372121,1372121
141428,362943,HUM,Walmart opens next gen  small format grocery store in China,news,Walmart  NYSE WMT  turns the lights on for its first small sized supermarket outlet in China loaded with  smart retail  tech features  The store located in Shenzhen will stock 8K items  according to Reuters  Customers will be able to use the WeChat app to skip traditional checkout counters and receive online delivery of orders  Shares of Walmart are down 1 07  in premarket trading  with last week s report of a potential blockbuster deal with Humana  NYSE HUM  hanging in the wind  Now read ,2018-04-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/walmart-opens-nextgen-smallformat-grocery-store-in-china-1373014,1373014
141430,362945,HUM,Wolfe Research positive on potential Walmart Humana deal,news,Wolfe Research analyst Scott Mushkin weighs in on the possibility that Walmart  WMT  4 5   will explore an acquisition or deep collaboration with Humana  NYSE HUM   Wolfe on the Walmart upside   Our analysis suggests the best course of action for Walmart may be to pursue a buyout of Humana as the transaction looks to be both strategically sound and accretive  Our research indicates that Walmart is highly valued by its core customer  a customer that over indexes to chronic health conditions and has more limited access to quality healthcare  By extending the company s reach more broadly into healthcare services  we believe Walmart can do good by the communities it serves and simultaneously do good by shareholders  While the transaction appears accretive given Walmart s strong financial condition  we see the opportunity over time for significant revenue synergies  Previously  Humana up 13 5  on report Walmart eyes possible acquisition  March 29 Previously  Sell siders weigh in on potential Walmart   Humana tie up  April 2  Now read ,2018-04-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/wolfe-research-positive-on-potential-walmarthumana-deal-1374128,1374128
141435,362950,HUM,Why The Earnings Surprise Streak Could Continue For Humana  HUM ,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  Humana  HUM   which belongs to the Zacks Medical   HMOs industry  could be a great candidate to consider 
When looking at the last two reports  this health insurer has recorded a strong streak of surpassing earnings estimates  The company has topped estimates by 4 46   on average  in the last two quarters 
For the most recent quarter  Humana was expected to post earnings of  4 30 per share  but it reported  4 48 per share instead  representing a surprise of 4 19   For the previous quarter  the consensus estimate was  2 53 per share  while it actually produced  2 65 per share  a surprise of 4 74  
Price and EPS Surprise

With this earnings history in mind  recent estimates have been moving higher for Humana  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the company is positive  which is a great sign of an earnings beat  especially when you combine this metric with its nice Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Humana currently has an Earnings ESP of  1 62   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  3  Hold  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on July 31  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-07-11,Zacks Investment Research,https://www.investing.com/analysis/why-the-earnings-surprise-streak-could-continue-for-humana-hum-200439345,200439345
141436,362951,HUM,Cigna Stock Gains Near 9  On Drug Rebate Proposal Pullback,opinion,"On Jul 11  Cigna Corp    NYSE CI   shares witnessed a rise  following the announcement made by the Trump administration about dropping its proposal to curb drug rebates to pharmacy benefit managers  PBM  
Cigna s acquisition of Express Scripts  NASDAQ ESRX  for  67 billion helped it gain a huge exposure to the PBM business  However  its shares had been under pressure for some time since the administration had plans to ban the rebate on drugs in the hands of PBM  This proposal  if executed  would have dented the company s profitability 
While Cigna was up 9 24   other health insurers having PBM business such as UnitedHealth Group Inc    NYSE UNH    Anthem Inc    NYSE ANTM   and Humana Inc    NYSE HUM   soared on the heels of the news 
PBMs basic role was to help manage prescription claims for insurers for Medicare Part D plans  But over time  they have evolved to play an extended role in drug supply chain by helping with formulary management  drug utilization review  determining which pharmacies are in network and how much those pharmacies will receive in reimbursement  Thus  they became more important carriers for insurers 
In recent years  health insurers like Cigna and others have integrated PBM functionality into their businesses  While some of them acquired PBM companies  others have developed their in house PBMs 
Cigna s acquisition of Express Scripts has been successful and its first quarter results post the buyout witnessed revenue growth of 192  and earnings beat of 4 3   The company also saw an increase in membership in its Medicare Part D segment due to the acquisition 
Following the strong first quarter earnings  Cigna raised its earnings projection for the year 2019 on the back of strong performance in its health insurance and pharmacy benefits businesses  The company expects the deal to increase earnings per share from  18 to  20  21 in 2021  The combined company will generate free cash flow of at least  6 billion in 2021 
Barring yesterday s gain  the company has declined 15 5  year to date  compared with the  s gain of 15  

 
Now  with the lifting of the proposed rebate ban  the company s share price should bounce back  Cigna s solid business positioning  good cost control is expected to place it in a good position going forward  
Cigna carries a Zacks Rank  3  Hold  
You can see 
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-07-12,Zacks Investment Research,https://www.investing.com/analysis/cigna-stock-gains-near-9-on-drug-rebate-proposal-pullback-200439444,200439444
141437,362952,HUM,After Pullback  This Health Care Stock Has More Upside Coming,opinion,"All of the leading managed health care stocks have been very volatile in 2019  Political pressure from both sides of the aisle have been the catalyst for the excessive whipsaw in this industry group  Stocks such as Humana  NYSE HUM   Cigna  NYSE CI   UnitedHealth  NYSE UNH  and others have been susceptible to political news on a daily basis  Last week  the sector rallied sharply higher after the White House abandoned its plan to eliminate rebates from government drug plans  Unfortunately  these same stocks pulled back on Monday after presidential candidate Joe Biden proposed a public health insurance option for anyone who wants it  giving power to Medicare to negotiate drug prices 
Watch This Level
Last week  the managed health care stocks all broke out on a technical basis  Humana is one stock that should have more upside despite Monday s pullback when HUM fell by  4 48 to  286 77 a share  Traders and investors should now watch and see if this stock can consolidate on the charts as last week s break out pattern suggests a move back up to the  310 level  This major resistance level is where the stock sold off in late February 2019  I will be be keeping HUM s stock on my radar for a bullish pattern development ",2019-07-15,Nicholas Santiago,https://www.investing.com/analysis/after-pullback-this-healthcare-stock-has-more-upside-coming-200439905,200439905
141438,362953,HUM,What s In The Offing For Anthem s  ANTM  Earnings In Q2 ,opinion,Anthem Inc    NYSE ANTM   will release second quarter 2019 results on Jul 24 before market open  In the first quarter of 2019  the company delivered a positive earnings surprise of 2 9   driven by higher membership and the expansion of its clinical and specialty services Let s see  how things are shaping up for this announcement The company s performance in the to be reported quarter is likely to be supported by a robust operating performance and strength displayed at all its businesses  Membership of the company is also expected to improve in the same time frame  The Zacks Consensus Estimate for earnings is pegged at  4 61  up 8 5  from the year ago reported figure Its top line is also likely to continue its winning streak on the back of its Government business and Commercial   Specialty Business segments  The Zacks Consensus Estimate for second quarter revenues stands at  24 7 billion  up 8 7  from the prior year reported number The consensus mark for revenues in the Commercial Business segment and the Government business indicates a respective 15  and 9 2  rise from the year earlier reported figures Increase in membership is projected in Medicare business as the company is focusing on growing this line of business Total medical membership for the quarter to be reported is likely to burgeon owing to the company s constant efforts to boost its portfolio  The Zacks Consensus Estimate for medical enrollment implies an improvement of 3 6  from the year ago reported figure The second quarter has possibly witnessed a steady cash flow in the company  Moreover  Anthem is anticipated to have continued enhancing its shareholder value through a disciplined capital deployment However  we predict an elevated selling  general and administrative expense ratio as Anthem escalates investment in areas  such as technology modernization  population and consumer digital health plus data analytics and product development capabilities Also  its overdependence on debt might persist to weigh down the margins What the Quantitative Model StatesOur proven model conclusively shows that Anthem is likely to beat on earnings this time around  This is because the stock has the right combination of a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Earnings ESP  Anthem has an Earnings ESP of  0 73   This is because the Most Accurate Estimate is pegged at  4 64  higher than the Zacks Consensus Estimate of  4 61  You can uncover the best stocks to buy or sell before they are reported with our  Anthem  Inc  Price and EPS Surprise   Zacks Rank  Anthem carries a Zacks Rank  3  which increases the predictive power of ESP  Along with a positive ESP in the combination  chances of an earnings beat are significantly higher for the stock this reporting cycle Conversely  the Sell rated stocks   4 or 5  should never be considered going into the earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks to ConsiderSome other stocks worth considering from the Health Maintenance Organization industry with the perfect combination of elements to also surpass estimates in the next releases are as follows WellCare Health Plans  Inc    NYSE WCG   is set to report second quarter 2019 earnings on Jul 30  The stock has an Earnings ESP of  1 65  and a Zacks Rank  3  You can see  Molina Healthcare  Inc   NYSE MOH   is set to report second quarter earnings on Jul 29  The stock has a Zacks Rank of 1 and an Earnings ESP of  3 02  Humana Inc    NYSE HUM   has an Earnings ESP of  1 57  and a Zacks Rank of 3  The company is set to report second quarter earnings on Jul 31 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-07-21,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-offing-for-anthems-antm-earnings-in-q2-200442687,200442687
141439,362954,HUM,What To Expect For Universal Health s  UHS  Q2 Earnings,opinion,Universal Health Services  Inc    NYSE UHS   is set to report second quarter 2019 results on Jul 25 after market close  In the last reported quarter  the company reported adjusted earnings of  2 45 per share  missing the Zacks Consensus Estimate by 5 8  For the to be reported quarter  the Zacks Consensus Estimate for earnings is pegged at  2 49  up 0 8  from the year ago reported figure So  let s see how things are shaping up for this announcement In the second quarter of 2019  the company s performance is likely to have been fueled by both its Acute Care and Behavioral Health segments  The Zacks Consensus Estimates for net revenues at its Acute Care and Behavioral Health segments implies an upside of 4 8  and 4 5   respectively  from the prior year reported numbers The Zacks Consensus Estimate for total revenues in the second quarter stands at  2 8 billion  indicating growth of 4 8  from the year earlier reported figure Licensed beds in both Acute Care hospitals and the Behavioral Health centers  which have been increasing since 2012  are expected to maintain the momentum in second quarter results as well  The Zacks Consensus Estimate for average licensed beds at Behavioral Health Centers suggests a 2 3  rise from the year ago reported number  Also  the Zacks Consensus Estimate for average licensed beds at Acute Care Hospitals in the United States and Puerto Rico indicates an increase of 1 9  from the prior year reported figure Higher bed count is owing to the addition of facilities in the second quarter Further  this solid bed count is expected to have aided admissions across both Acute Care and Behavioral Health segments during the quarter Universal Health might have consistently enhanced its shareholder value in the period under review However  Universal Health is anticipated to have incurred escalating operating expenses due to higher salaries  wages and benefits plus other operating expenses  which could negatively impact second quarter earnings Moreover  its long term debt  which has been piling up since 2013  dipped to some extent in the first quarter of 2019   might have deteriorated further  Interest expenses of the company might also remain at elevated levels What the Quantitative Model StatesOur proven model does not conclusively show that Universal Health is likely to beat on earnings this reporting cycle  This is because the stock needs to have the right combination of a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  which is not the case here   You can see  Earnings ESP  Universal Health has an Earnings ESP of 0 00   This is because both the Most Accurate Estimate and the Zacks Consensus Estimate is pegged at  2 49  You can uncover the best stocks to buy or sell before they are reported with our  Universal Health Services  Inc  Price and EPS Surprise   Zacks Rank  Universal Health carries a Zacks Rank  4  Sell   We caution against the Sell rated stocks  4 or 5  going into an earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderSome stocks worth considering from the medical sector with the perfect mix of elements to surpass estimates in the next releases are as follows WellCare Health Plans  Inc    NYSE WCG   is set to report second quarter earnings on Jul 30  The stock has an Earnings ESP of  1 65  and a Zacks Rank  3 Molina Healthcare  Inc   NYSE MOH   is set to report second quarter earnings on Jul 29  The stock has a Zacks Rank of 1 and an Earnings ESP of  3 02  Humana Inc    NYSE HUM   has an Earnings ESP of  1 57  and a Zacks Rank of 3  The company is set to report second quarter earnings on Jul 31 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-07-21,Zacks Investment Research,https://www.investing.com/analysis/what-to-expect-for-universal-healths-uhs-q2-earnings-200442671,200442671
141440,362955,HUM,Centene s  CNC  Q2 Earnings Beat Estimates  Improve Y Y,opinion,Centene Inc    NYSE CNC   delivered second quarter 2019 adjusted earnings per share of  1 34  beating the Zacks Consensus Estimate by 8 1   Also  the bottom line improved 48 9  year over year on the back of operational excellence and higher revenues   For the second quarter  total revenues rose 29  to  18 4 billion from the year ago period  primarily aided by the Fidelis buyout  Health Insurance Marketplace business  expansions and new programs across many states in 2018 and 2019  Moreover  the top line surpassed the Zacks Consensus Estimate by nearly 2   However  this upside was offset by the health insurer fee moratorium to some extent Quarterly Operational UpdateAs of Jun 30  2019  managed care membership came in at 15 million  up 17  year over year Health Benefit Ratio  HBR  for the reported quarter was 86 7  compared with 85 7  in the prior year period  This increase can be attributable to the Health Insurance Marketplace business Adjusted Selling  General   Administrative  SG A  expense ratio was 9  for the second quarter of 2019 compared with 9 6  for the same period last year  This contraction of 60 basis points year over year is due to the impact of the Fidelis Care acquisition Centene Corporation Price  Consensus and EPS Surprise   Financial UpdateAs of Jun 30  2019  the company s cash and cash equivalents totaled  6 8 billion  up 28 7  from the figure at 2018 end As of Jun 30  2019  total assets were up by 11 2  year over year to  34 3 billion Centene s long term debt summed  7 billion  up 6  year over year For the first half of 2019  cash outflow from operations was  2 2 billion  up 69 2  year over year 2019 OutlookFollowing solid second quarter results  the company has revised its 2019 guidance It now expects revenues in the range of  73 6  74 2 billion  up from the earlier projection of  72 8 73 6 billion Adjusted EPS is expected in the band of  4 29  4 49  up from the  4 24  4 44 range HBR is expected within 86 6 87 1   up from 86 5 87  Adjusted SG   A expense ratio is estimated between 9 1  and 9 6   better from the previous estimate of 9 3 9 8  HighlightsIn June 2019  Centene and WellCare shareholders approved the pending buyout of WellCare Health Plans  Inc Zacks RankCentene carries a Zacks Rank  3  Hold   You can see  Upcoming Releases From Medical SectorSome better ranked stocks from the medical sector are as follows Molina Healthcare  Inc   NYSE MOH   is set to report second quarter earnings performance on Jul 29  The stock has a Zacks Rank  1 and an Earnings ESP of  3 88  WellCare Health Plans  Inc    NYSE WCG   is set to report second quarter earnings on Jul 30  The stock has an Earnings ESP of  1 65  and a Zacks Rank of 3 Humana Inc    NYSE HUM   has an Earnings ESP of  1 57  and is a Zacks  3 Ranked player  The company is set to report second quarter earnings on Jul 31 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-22,Zacks Investment Research,https://www.investing.com/analysis/centenes-cnc-q2-earnings-beat-estimates-improve-yy-200443368,200443368
141441,362956,HUM,Koninklijke Philips   PHG  Q2 Earnings   Sales Rise Y Y,opinion,Koninklijke Philips N V    NYSE PHG   reported second quarter 2019 adjusted earnings of 49 cents per share and revenues of  5 25 billion The company reported earnings of  0 43  up 23  from the year ago quarter  Sales increased 9  on a year over year basis to  4 67 billion Comparable sales  includes adjustments for consolidation charges   currency effects  grew 6   reflecting mid single digit growth in all businesses The company s comparable order intake increased 8  year over year  driven by double digit growth in Diagnosis   Treatment and mid single digit decline in the Connected Care business Sales increased 9  on a comparable basis in growth geographies  driven by double digit growth in China and high single digit rise in Central   Eastern Europe  Comparable order intake grew double digit  driven by double digit growth in China and Latin America Koninklijke Philips N V  Price  Consensus and EPS Surprise   Sales in mature geographies increased 5  on a comparable basis  due to high single digit growth in other mature geographies and mid single digit rise in both North America and Western Europe  Comparable order intake was flat year over year Segment DetailsDiagnosis   Treatment revenues increased 9 9  from the year ago quarter to  1 88 billion  Comparable sales grew 6   driven by double digit growth in Image Guided Therapy and high single digit growth in Ultrasound  Diagnostic Imaging revenues were flat year over year On a geographic basis  China witnessed double digit growth  Mature geographies grew at a mid single digit rate  reflecting high single digit growth in North America  mid single digit rate in other mature geographies and low single digit growth in Western Europe Image Guided Therapy devices business grew at a double digit rate  driven by robust performance from all major coronary and peripheral vascular product families During the quarter  Philips presented the three year results from two major Stellarex clinical studies  involving roughly 600 patients  The study showed that Stellarex drug coated balloon  DCB  is the only low dose DCB with a significant treatment effect and had a high safety profile through three years  Both studies showed no difference in mortality compared with the current standard of care Moreover  the company extended the advanced automation capabilities of its EPIQ CVx cardiology ultrasound platform  This makes examinations faster and easier to conduct  while improving clinician productivity Connected Care business revenues increased 11 1  to  1 05 billion  Comparable sales climbed 6   driven by mid single digit growth in Monitoring   Analytics and Sleep   Respiratory Care Mature geographies grew mid single digits  primarily due to double digit growth in Western Europe  high single digit growth in other mature geographies and low single digit growth in North America  Growth geographies increased at high single digit rates  reflecting double digit growth in Latin America and high single digit rise in China The company s solutions to treat obstructive sleep apnea  a condition that affects more than 100 million patients globally  continue to benefit from healthy demand  Adoption of DreamStation GO s portable therapy options remained strong in the reported quarter Personal Health sales increased 5  year over year to  1 28 billion  Comparable sales grew 5   driven by high single digit growth in Oral Healthcare and mid single digit rise in Personal Care and Domestic Appliances Growth geographies increased in high single digit  driven by double digit growth in China and Central   Eastern Europe  Mature geographies showed mid single digit growth  reflecting double digit growth in other mature geographies  mid single digit growth in Western Europe and low single digit growth in North America In the reported quarter  Philips launched Sonicare DailyClean  an entry level product that addresses lower price segments  The company also introduced Sonicare ExpertClean  featuring premium brush heads  connectivity and design  in the United States Moreover  Philips Shaver Series 9000 Prestige continued to gain significant market share in the premium shaver market  especially China  Germany and the United States Other segment sales increased 15 7  to  96 million in the reported quarter primarily due to higher IP royalty income Important PartnershipsDuring the quarter  Philips inked a 10 year agreement with Centre Hospitalier R gional Universitaire de Nancy in France to implement the IntelliSpace Enterprise Imaging Solution of the former The company also announced a 10 year agreement with Rutherford Diagnostics to deliver advanced imaging solutions to five new diagnostic centers of the former across the U K Further  Philips teamed up with Humana   NYSE HUM   to improve care for at risk  high cost populations  The pilot program will support independent living for high acuity patients with congestive heart failure by providing 24 7 access to care Operating DetailsGross margin contracted 130 basis points  bps  on a year over year basis to 45 5  in the reported quarter Selling  research   development  and general   administrative expenses declined 200 bps  40 bps and 10 bps  respectively In the reported quarter  cost savings totaled  146 million  reflecting procurement savings of  48 million  Savings from overhead and other productivity programs were  98 million Philips  adjusted earnings before interest  taxes and amortization  EBITA    the company s preferred measure of operational performance   were  549 million  up 13 9  from the year ago quarter  Adjusted EBITA margin expanded 50 bps on a year over year basis to 11 8   benefiting from sales growth and operational improvements While Diagnosis   Treatment EBITA margin expanded 190 bps  Connected Care and Personal Health EBITA margins contracted 220 and 70 bps  respectively Balance Sheet   Other DetailsAs of Jun 30  2019  Philips  cash and cash equivalents were  1 08 billion and total debt was  5 82 billion Meanwhile  net cash flow generated from operating activities came in at  390 million  Free cash flow was  174 million Philips completed its  1 5 billion share buyback program  announced on Jun 28  2017  in the reported quarter  The company has also completed 21 1  of its share buyback program that was announced on Jan 29  2019 Moreover  Philips completed the cancellation of 30 million shares that were acquired as part of the share buyback programs mentioned above  Additionally  the company successfully placed a  750 million 0 500  Green Innovation Bond  which is due 2026 GuidancePhilips continues to expect the U S  health care market to grow low  to mid single digits in 2019  Western Europe is expected to grow at a modest low single digit rate  China is expected to rise mid  to high single digit  primarily due to favourable government policies expansion of private sector investments in health care facilities Tariffs  as a result of the U S  China trade war  are expected to have a negative impact of  45 million in 2019  This does not include potential U S  batch 4 tariffs that will bring an additional  20 million headwind in the year  if made effective immediately Moreover  the company expects net costs of  40 million in the third quarter and  120 million for 2019  Included in these numbers are  15 million of restructuring cost and other incidental items in the third quarter and around  40 million for the full year  These are expected to hurt EBITA Nevertheless  Philips expects EBITA margin to improve in the second half of the year  Management expects EBITA margin to be closer to 14  The company still expects free cash flow between  1 billion and  1 5 billion for 2019 Philips reiterated its overall targets of 4 6  comparable sales growth and an adjusted EBITA margin improvement of 100 bps on average per year for the 2017 2020 period Management expects the company to become a  20 billion health technology company with an adjusted EBITA margin close to 15  by 2020 Zacks Rank and Other Stocks to ConsiderCurrently  Phillips sports a Zacks Rank  1  Strong Buy  Lattice Semiconductor   NASDAQ LSCC   and Alteryx   NYSE AYX   are similar ranked stocks in the broader Computer   Technology sector  You can see  While Lattice Semiconductor is set to report on Jul 30  Alteryx is expected to report on Jul 31 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3   This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-22,Zacks Investment Research,https://www.investing.com/analysis/koninklijke-philips-phg-q2-earnings--sales-rise-yy-200443241,200443241
141442,362957,HUM,Anthem s  ANTM  Q2 Earnings Beat Estimates  Increase Y Y,opinion,Anthem Inc    NYSE ANTM   delivered second quarter 2019 earnings of  4 64 per share  marginally beating the Zacks Consensus Estimate by 0 7   Additionally  the bottom line improved 9 2  year over year on the back of higher revenues Further  Anthem reported operating revenues of  25 2 billion  beating the Zacks Consensus Estimate by 2 1   Moreover  the top line was up 10 8  year over year  aided by membership growth across businesses and the premium rate increases to cover the overall cost trends  However  this upside was partially offset by the year long waiver of the health insurance tax in 2019 Quarterly Operational UpdateMedical enrollment inched up 3 3  year over year to 40 9 million members  backed by growth in Medicaid and Medicare  partly offset by the declines in Commercial   Specialty Business enrollment Anthem s benefit expense ratio of 86 7  expanded 330 basis points  bps  from the prior year quarter  The increase was attributable to one year waiver of the health insurance tax in 2019 and the medical cost in the Medicaid business SG A expense ratio of 13  contracted 210 bps from the year ago quarter towing to the year long waiver of the health insurance tax in 2019 plus growth in the operating revenues Anthem  Inc  Price  Consensus and EPS Surprise   Strong Segmental ResultsCommercial   Specialty BusinessOperating revenues were  8 9 billion in the second quarter  down 1 1  year over year Operating gain totaled  983 million  down 6 2  year over year  This decline is due to the effect of higher favorable risk adjustor adjustments recognized in 2018 Operating margin was 10 4   down 120 bps year over year Government BusinessOperating revenues were  15 5 billion  up 14 1  from the prior year quarter Operating gain was  478 million  down 10 2  year over year due to persistently elevated medical cost experience in Medicaid across select states and the one year waiver of the health insurance tax in 2019  However  the same was offset by out of period revenue adjustments and Medicare membership improvement Operating margin was 3 1   down 80 bps year over year OtherThe Other segment s operating loss of  28 million is wider than the year earlier quarterly loss of  21 million Financial UpdateAs of Jun 30  2019  Anthem s cash and cash equivalents summed  4 1 billion  up 3 7  from 2018 end As of Jun 30  2019  its long term debt less current portion inched up 1 3  to  17 4 billion from the level at 2018 end Operating cash outflow at the end of the first six months of 2019 was  3 1 billion  up 11 2  year over year Capital DeploymentDuring the second quarter  Anthem bought back shares worth  458 million  As of Jun 30  2019  the company had shares worth around  4 7 billion remaining under its share buyback authorization Moreover  the company paid out a quarterly dividend of 80 cents per share  adding up to a distribution of cash worth  206 million The company announced a third quarter dividend of 80 cents per share on Jul 23  2019  payable Sep 25 to shareholders of record on Sep 10  2019 Revised Guidance for 2019Based on solid second quarter results  Anthem has updated its outlook for 2019  The company s adjusted net income is now expected to be higher than  19 30 per share  up from the prior projection of  19 20 Medical membership is still estimated in the range of 41 41 3 million  tightened from the earlier expectation of 40 9 41 3 million Operating revenues are predicted to be around  102 billion including the premium revenues of  93  94 billion  Operating cash flow is envisioned to be higher than  5 2 billion SG A ratio is forecast in the band of 13 2 13 5  The company estimates the benefit expense ratio to be 86 2 86 5  Zacks RankAnthem carries a Zacks Rank  3  Hold   You can see  Upcoming Releases From Medical SectorMolina Healthcare  Inc   NYSE MOH   is set to report second quarter earnings performance on Jul 29  The consensus estimate for second quarter earnings is pinned on  2 56  The stock sports a Zacks Rank  1 WellCare Health Plans  Inc    NYSE WCG   is set to report second quarter earnings on Jul 30  The Zacks Consensus Estimate for the same is pegged at  4 10  The stock has a Zacks Rank  2  Buy  Humana Inc    NYSE HUM   is set to report second quarter earnings on Jul 31  The Zacks Consensus Estimate for the same stands at  5 24  The company has a Zacks Rank of 3 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-07-23,Zacks Investment Research,https://www.investing.com/analysis/anthems-antm-q2-earnings-beat-estimates-increase-yy-200444127,200444127
141457,362972,HUM,Humana in talks to buy Kindred Healthcare with equity firms  source,news,"NEW YORK  Reuters    U S  health insurer  Humana Inc   N HUM  is in advanced talks to acquire acute care provider  Kindred Healthcare Inc   N KND  in partnership with private equity firms Welsh  Carson  Anderson   Stowe and TPG  a source familiar with the matter said on Sunday   A deal would provide the latest example of the growing convergence between consumer health and insurance  following CVS Health Corp s  N CVS  agreement earlier this month to acquire  Aetna Inc   N AET  for  69 billion  Humana has been investing significantly in its home health capabilities  Humana At Home  which the insurer touts as a compliment to its Medicare Advantage franchise  If the negotiations are successful  a deal could come as early as this week  the source said  asking not to be identified because the matter is confidential   The Wall Street Journal  which first reported on the talks  said the deal could value Kindred at  9 per share  On Friday  the company s stock closed at  8 60  giving it a market value of  750 million   Welsh  Carson  Anderson   Stowe and TPG would take over Kindred s facility focused business  which includes long term acute care hospitals and rehabilitation centers  The private equity firms together with Humana would get Kindred s home and hospice care operations  the WSJ reported  citing sources it did not identify  Kindred and Humana did not immediately respond to requests for comment  TPG and Welsh  Carson  Anderson   Stowe also were not immediately available for comment   Based in Louisville  Kentucky  Kindred is the largest home healthcare provider and hospice operator in the United States   The company  which has long term debt of  3 2 billion  has suffered due to its reliance on the Medicare federal health insurance program for revenue  It is also at risk for changes to how post acute care services are reimbursed if U S  President Donald Trump restructures the healthcare system  Earlier this year  Kindred announced plans to coordinate skilled nursing operations with Genesis HealthCare Inc  N GEN   one of the largest operators of skilled nursing facilities in the United States  In 2015  Kindred acquired Gentiva Health Services Inc for  1 8 billion  turning it into the biggest U S  provider of home health and hospice care  but also saddling it with debt  
Health insurance companies are exploring new ways to diversify their revenues with acquisitions in acute care  after federal regulators blocked two major mergers in the sector  and insurance exchanges set up under the Affordable Care Act  popularly known as Obamacare  came under pressure from Republicans ",2017-12-17,Reuters,https://www.investing.com/news/stock-market-news/humana-in-talks-to-buy-kindred-healthcare-with-equity-firms-source-1001605,1001605
141458,362973,HUM,Kindred to be acquired by three group consortium for  9 per share,news,Kindred Healthcare  NYSE KND  has agreed to be acquired by Humana  NYSE HUM  and two private equity firms  TPG Capital and Welsh  Carson  Anderson   Stowe  for   4 1B in cash   9 share  Humana will take a 40  stake and will have the option to acquire the remaining 60  over time via a put call arrangement Kindred s LTAC hospitals  in patient rehab facilities and contract rehabilitation services businesses will be operated as a separate specialty hospital company owned by the PE firms Yesterday s close was  9 50  Shares are down 5  premarket on increased volume Now read ,2017-12-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/kindred-to-be-acquired-by-threegroup-consortium-for-9-per-share-1008649,1008649
141459,362974,HUM,Big Kindred holder against Humana deal,news,The  9 per share cash price from Humana  HUM  0 2   is materially inadequate  says Brigade Capital  reporting an upped stake in Kindred Healthcare  NYSE KND  Brigade s 5 8  stake would make it Kindred s fifth largest shareholder KND  0 25  to  9 45 Now read ,2017-12-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/big-kindred-holder-against-humana-deal-1033449,1033449
141460,362975,HUM,Premarket analyst action   healthcare,news,Miragen Therapeutics  NASDAQ MGEN  initiated with Outperform rating and  13  52  upside  price target by Oppenheimer Humana  NYSE HUM  upgraded to Buy by Jefferies Anthem  NYSE ANTM  upgraded to Buy by Jefferies Aradigm  NASDAQ ARDM  downgraded to Neutral by Ladenburg Thalmann after negative Ad Com vote on Linhaliq Axovant Sciences  NASDAQ AXON  downgraded to Market Perform by Cowen   Co ,2018-01-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-1096277,1096277
141461,362976,HUM,UnitedHealth s Q4 beat buoys peers,news,UnitedHealth Group s  UNH  2 2   Q4 results  reported yesterday  have stoked buying the managed care health insurance space Selected tickers   AET  0 3   ANTM  3 1   CNC  1 9   CI  2 7   CIVI  0 6   HUM  2   MOH  2 8   WCG  1 8   GTS  2 8  Previously  UnitedHealth Group beats by  0 07  beats on revenue  Jan  16 Previously  UnitedHealth Group Q4 revenues up 10   non GAAP EPS up 23   updates 2018 guidance  Jan  16 Now read ,2018-01-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/unitedhealths-q4-beat-buoys-peers-1116753,1116753
141462,362977,HUM,Healthcare stocks are getting smoked after Amazon finally said something about the industry,news,    and  are teaming up to try to make healthcare more affordable for their US based employees  Insurance stocks like      and others are deeply in the red early Tuesday after the news hit  Pharmacy stocks and benefits managers were down too    Shares of insurance providers  benefits managers  pharmacies  and other healthcare companies are getting smoked in pre market trading Tuesday after three of the country s largest companies   Amazon  JPMorgan  and Berkshire Hathaway    for their employees that will be  free from profit making incentives and constraints   The negative impact the announced collaboration is having on healthcare stocks is just the latest example of the outsized influence both Amazon and Berkshire can have on industries they explore  Armed with mountains of cash and an abundance of resources  their forays into new sectors can erase billions of dollars of market value in a short time   The healthcare system is complex  and we enter into this challenge open eyed about the degree of difficulty   Amazon CEO Jeff Bezos    Hard as it might be  reducing healthcare s burden on the economy while improving outcomes for employees and their families would be worth the effort  Success is going to require talented experts  a beginner s mind  and a long term orientation   Here s the scoreboard      11 19      7 19      6 73      3 66      1 92      1 06      1 03      0 22  Americans on average spent  714  or 1 6  of their take home pay on  in 2016  according to a report from JPMorgan Chase  NYSE JPM   That was up 3 6  from the year before and up 13 5  from 2013  The bank also found that the US spent 18  of gross domestic product on healthcare  up from 13  in 2000  Aetna s move also correlates with its  that beat analyst expectations  MetLife s selloff began Monday afternoon when the company  originally planned for Tuesday ,2018-01-30,Business Insider,https://www.investing.com/news/stock-market-news/healthcare-stocks-are-getting-smoked-after-amazon-finally-said-something-about-the-industry-1170690,1170690
141463,362978,HUM,Molina Q4 revenues up 9   net loss widens due to  356M in charges,news,Molina Healthcare  NYSE MOH  Q4 results   M   Total revenues  4 949   9 2    Premiums  4 689   11 9   Net loss   262    457 4    loss share   4 59    440 0    cash flow ops   153    482 5   Q4 results include  356M of impairment losses  restructuring and separation costs and loss of debt extinguishment 2018 guidance  Total revenues    18 8B  premiums    17 5B  medical care costs    15 6B  medical care ratio   89   net income   202M   236M  EPS   3 00   3 50  non GAAP EPS   3 23   3 73 Now read ,2018-02-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/molina-q4-revenues-up-9-net-loss-widens-due-to-356m-in-charges-1233628,1233628
141466,362981,HUM,4 Stocks To Buy Despite Year to Date Fall In Health Insurance,opinion,"In spite of strong fundamentals  the health insurance industry has underperformed so far this year due to regulatory noise The Zacks   industry  which comprises health insurance stocks  is down nearly 2  year to date compared with the Zacks S P 500 composite s gain of 11 2   The decline in the industry is mainly due to investors  apprehensions stemming from the proposal of  Medicare for All  by Democrats   an agenda for the 2020 presidential elections The proposal seeks to eliminate private health insurance and replace it with a universal Medicare plan on the premise that the same would reduce administrative inefficiencies and control costs in the health care system All the major industry participants are against the proposal  since it would replace the current private insurance plans and eat into the earnings of health insurers UnitedHealth  NYSE UNH  Group s CEO said on the company s first quarter earnings call that Medicare for All would  surely jeopardize the relationship people have with their doctors  destabilize the nation s health system and limit the ability of clinicians to practice medicine at their best  Recently  another major health insurer Humana  NYSE HUM  opposed the proposal as it will not support any legislation   making private health coverage illegal Though nothing of this proposal gets transpired now  at least till 2021   when the election is finalized  the uncertainty caused by the proposal is enough to push investors away from the industry  which is highly policy regulated Medicare and Medicaid to Drive GrowthKeeping this noise aside  a look at the fundamentals shows the industry s going strong with rise in revenues and enrollment  solid balance sheets and stable growth in margins The most prominent factor driving growth for the players would be the changing U S  demography  which features the growing baby boomer population  which is driving demand for Medicare Advantage   MA   plans  a substitute for Government sponsored Medicare plan for retirees  The segment remains underpenetrated with large untapped market potential  Based on the CMS March 2019 Medicare monthly enrollment report  MA grew by 7 4  year over year  Furthermore  most of the players in the industry have expanded their MA geographic presence to capture market share  having done so mainly via mergers and acquisitions  and buyouts  The same has also trigged massive consolidation in the health insurance industry  in recent years Another attractive growth opportunity for health insurers is Medicaid  Over the past decade  states have continued to move toward managed care in an effort to better manage rising costs and as a result of ACA expansion  As many as 36 states have opted for Medicaid Expansion  with the remaining 14 apparently having very low chances given their republican control  Of these 14 states  Texas and Florida look most promising  though no substantial Medicaid development has been seen here A strong balance sheet has allowed players to consolidate through acquisitions  Recent mergers in the health insurance space have brought health insurers and pharmacy benefit  managers  PBM  together  In house PBM would allow health insurers to gain more control on drugs and therefore management of medical costs Though PBMs are also under government radar as they are working on cutting the role of middlemen to reduce the final pricing  nothing much has been achieved on this front either The regulatory developments will continue with the final rule nowhere near  In the meantime  let s take a closer look at some of the stocks worth considering in the space  It is important to note here that geopolitical uncertainty and trade war between the United States and China are less likely to upset the health insurance as most of its business is domestic oriented This provides one more reason to invest in stocks of this industry Stocks to ConsiderWe have chosen some stocks in the industry that carries a Zacks Rank  1  Strong Buy  or 2  Buy   You can see  Magellan Health  Inc    NASDAQ MGLN   carries a Zacks Rank  1 and has witnessed an upward revision in 2019 earnings estimates by 0 3  over the past 30 days  The company s 2019 earnings are expected to grow by 60  compared with the industry s growth of 16 7   The stock has gained 19  year to date   Molina Healthcare  Inc    NYSE MOH   sports a Zacks Rank  1 and has witnessed an upward revision in 2019 earnings estimates by 9 8  over the past 30 days  The stock has gained 14  year to date The Joint Corp    NASDAQ JYNT   carries a Zacks Rank  1 and has witnessed an upward revision in 2019 earnings estimates by 9 5  over the past 30 days  The company s 2019 earnings are expected to grow by 135  compared with the industry s growth of 20   The stock has gained 98  year to date WellCare Health Plans  Inc    NYSE WCG   carries a Zacks Rank  2  It has witnessed an upward revision in 2019 earnings estimates by 2 7  over the past 30 days  The company s 2019 earnings are expected to grow by 27  compared with the industry s growth of 17   The stock has gained 17  year to date 
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-05-30,Zacks Investment Research,https://www.investing.com/analysis/4-stocks-to-buy-despite-yeartodate-fall-in-health-insurance-200426489,200426489
141467,362982,HUM,Why Is Humana  HUM  Up 0 2  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Humana  HUM   Shares have added about 0 2  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Humana due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Humana Q1 Earnings   Revenues Beat Estimates  Surge Y YHumana Inc  NYSE HUM   s first quarter 2019 operating earnings per share of  4 48 beat the Zacks Consensus Estimate of  4 30 by 4 2   The bottom line also improved 33 3  year over year  This upside can primarily be attributed to solid revenues and Medicare Advantage membership growth Operational UpdateRevenues of  16 1 billion were up nearly 2  in the first quarter  Moreover  the top line surpassed the Zacks Consensus Estimate by 12 8  Adjusted consolidated pre tax income of  803 million increased 17 4 on the back of lower than expected utilization in the individual Medicare Advantage business Benefit expense ratio expanded 130 basis points to 86 2  in the quarter Segmental ResultsRetailRevenues from the Retail segment were  14 01 billion  up 16  year over year  This can primarily be attributed to robust revenues drawn from the company s individual and group Medicare Advantage membership strength  solid per member premiums plus a rise in the state based contracts membership Benefit ratio of 88 3  expanded 90 bps year over year  primarily because of the suspension of HIF in 2019 as well as the negative impact of its higher than expected individual Medicare Advantage membership growth The segment s operating cost ratio of 8 2  contracted 190 bps year over year  This was mainly owing to the suspension of HIF and operating cost efficiencies Group and SpecialtyRevenues from the Group and Specialty segment were  1 89 billion  down 4  from the prior year quarter due to a reduction in its fully insured group commercial and specialty membership  impact of the contractual incentives and adjustments related to the previous TRICARE as well as lower premium revenues Benefit ratio expanded 320 bps year over year to 76 4   induced by an unfavorable prior period development in the first quarter  suspension of health insurance industry fee  HIF  and membership mix Operating cost ratio deteriorated 170 bps year over year to 21 9  Healthcare ServicesRevenues of  6 10 billion increased 8  year over year  primarily owing to Medicare Advantage membership growth Operating cost ratio increased 40 bps year over year to 96 6  due to investments in the company s provider services business as well as a change in mix of the pharmacy spend Individual CommercialHumana exited this business effective Jan 1  2018 and consequently  the result reflects its run out Financial UpdateAs of Mar 31  2019  the company had cash  cash equivalents and investment securities of  14 18 billion  up 11  from the level at 2018end Debt to total capitalization as of Mar 31  2019 was 36   down 140 bps from Dec 31  2018 Operating cash outflow totaled  896 million in the first quarter  up 155 3  year over year Capital DeploymentThe company paid cash dividends worth  68 million in the first quarter of 2019 Last November  it entered into an agreement to affect a  750 million accelerated share repurchase  ASR  program under its current share repurchase authorization  During the first quarter  the company bought back around 2 541 100 of its outstanding shares at average price of  295 15 2019 GuidanceFor 2019  Humana now expects adjusted EPS in the range of  17 25   17 5  up from the prior projection of  17  17 5  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  The consensus estimate has shifted 10 47  due to these changes 
VGM Scores
Currently  Humana has a great Growth Score of A  though it is lagging a bit on the Momentum Score front with a B  Charting a somewhat similar path  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of these revisions looks promising  Notably  Humana has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-30,Zacks Investment Research,https://www.investing.com/analysis/why-is-humana-hum-up-02-since-last-earnings-report-200427034,200427034
141468,362983,HUM,Health Insurers Rejoice On Pullback Of Drug Rebate Plan,opinion,Yesterday  the Trump administration announced that it has pulled back its proposed rebate ban on pharmacy benefit managers  PBMs   Notably  PBMs act middle man between drug makers and health insurers  negotiating with the former to make drugs available at lower prices for the latter and grabbing part of the benefit in between The Rebate Ban PlanThe rebate ban was intended at passing down the benefit of negotiated drug prices among drug makers and PBMs and drug distributors to patients so as to make prescription drugs affordable One of the mainstays of Trump s political agenda has been to redo the health care system in America  which is one of the costliest in the world and is weighing on federal budgets The administration has been cracking down on drug manufacturers to lower drug prices  Health insurers and pharmacy benefit managers came under intense criticism from employers  Congress and the Trump administration  Soon  PBM s share of rebates turned into a nationwide controversy  Thus  the rebate ban appeared one of the ways of achieving the goal of lowering drug cost Why the Reversal The highly promoted rebate ban proposal reached a dead end after the nonpartisan Congressional Budget Office estimated that the plan would weigh on the federal budget by over  177 billion over the 10 years and that there would be no certainty on the main goal to control manufacturer drug prices The administration  however  clarified that although this measure would be repealed  other ways and means will be applied to control drug prices   Health Insurers RejoiceWhile the news was taken negatively by drug manufacturers  it was a clear positive for health insurers as they will continue getting drugs at lower prices  PBMs initial role post the formation of the Affordable Care Act was to help manage prescription claims for insures for Medicare Part D plans  But over time  PBMs have evolved to play an extended role in drug supply chain by taking care of functions such as formulary management  drug utilization review  determining which pharmacies are in network and how much those pharmacies will receive in reimbursement  They thus became more important carriers for insurers In recent years  health insurers have gone further to integrate PBM functionality into their businesses  with an aim of forward integration across the supply chain network  While some of them resorted to acquiring PBM companies  some others have developed their in house PBMs Insurers like UnitedHealth Group Inc    NYSE UNH    Anthem Inc    NYSE ANTM   and Humana Inc    NYSE HUM   have their own in house PBMs named Optum Rx  IngenioRx  and Humana Pharmacy Solutions  respectively  Notably  UnitedHealth also acquired a PBM company  Catamaran  back in 2015  which further expanded its PBM capabilities Cigna Corp    NYSE CI   recently acquired the nation s leading PBM  Express Scripts  NASDAQ ESRX   which now contributes more than 60  of the company s combined revenues Since most the leading insurers are also playing the role of a PBM  their stocks surged on the news  Cigna  UnitedHealth  Humana  Anthem each saw their stock price gain 9 24   5 53   4 58  and 5 54   respectively Big players in fact came under the pressure of rebate plan and announced that they would pass some of the pharmacy discounts they get from drug manufacturers  This news thus removes a dark cloud hanging over the health insurance industry This news came as a relief against the backdrop of regulatory noise in the industry  which led to a decline in the Zacks  industry  comprising health insurers which lagged the broader S P 500 Index  year to date Recent NoisesRecently  Trump declared an executive order to disclose hospital pricing of products and services to patients as well as contracts between insurers and hospitals  Also  a debate was held in the United States Courts of Appeals in front of a three member panel on the constitutionality of the ACA  which was declared as unconstitutional in December 2018 It is most likely that the case would go to Supreme Court  but if ACA is rendered unconstitutional  health insurers would suffer a major blow as they have greatly gained from an increase in business volumes since the passage of the act in 2010  Moreover  presidential candidate Joe Biden s Medicare for All proposal has also been disturbing health insurers since the plan aims to replace private health insurance by a single government controlled health plan Winners Till NowThe health insurance space is heavily regulated  Yet  over time  the players have accustomed themselves to frequent jerks caused by political and regulatory issues  Health insurers have nevertheless come a long way  building a formidable business by diversifying into different revenue lines  managing costs and keeping together a solid balance sheet This is also revealed by the Zacks Medical HMO Industry   gain of 430  since the passage of the ACA to date  The Zacks S P composite has grown 161  in the said period    Among the companies mentioned above UnitedHealth carries a Zacks Rank  2  Buy    You can see The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-07-11,Zacks Investment Research,https://www.investing.com/analysis/health-insurers-rejoice-on-pullback-of-drug-rebate-plan-200439365,200439365
141482,362997,HUM,Exclusive  CVS eyes major expansion of health clinics with Aetna deal   sources,news,"By Carl O Donnell  Bill Berkrot and Caroline Humer NEW YORK  Reuters    CVS Health Corp  N CVS  is planning to significantly expand health services at its retail pharmacies if it completes a more than  66 billion deal for insurer  Aetna Inc   N AET   a move that could save more than  1 billion annually  people familiar with the matter said   A key rationale is to use many of the U S  pharmacy chain s 9 700 brick and mortar outlets to improve access to preventative care and cut back on some emergency room visits for Aetna s roughly 23 million members with medical coverage  these people said   The full benefits of the strategy will take several years to realize  requiring billions of dollars in investment to increase the number of CVS clinics and provide the staff and equipment for a wider variety of treatments  the people said   Those funds would be diverted from planned investments in CVS retail facilities  and not amount to additional expenses  they said   Deal talks between the companies are still underway  and an agreement could be announced as early as Sunday or Monday  sources familiar with the matter told Reuters  It is also possible that a deal is delayed or does not materialize  they said   Health insurers have redoubled their efforts to cut costs in a time of steep prescription drug price rises and requirements to care for even the sickest patients under the Affordable Care Act   Aetna last year tried to buy rival  Humana Inc   N HUM  to gain more leverage over costs  but that transaction  as well as a proposed merger between Anthem Inc  N ANTM  and  Cigna Corp   N CI   was shot down by antitrust regulators   Many insurers have already been encouraging patients to use urgent care centers  which can provide some of the same services as emergency rooms for as little as a tenth of the cost  said Laurel Stoimenoff  chief executive of the Urgent Care Association of America   MINUTECLINICS  The industry has grown to about 8 000 urgent care centers nationwide  as more hospitals  insurers and private operators open such walk in facilities  Stoimenoff said  with 400 to 500 centers added each year  They may be staffed by doctors and provide relatively advanced care including X rays   CVS operates more than 1 000 MinuteClinics  which offer more basic services ranging from flu shots to physicals and are mainly staffed by nurse practitioners   Combined with Aetna  the company would be able to seamlessly access medical records  offer certain preventive services to covered members for free and make drugs promptly available in adjacent CVS pharmacies  said Dan Mendelson  president of consultancy Avalere Health   The in store clinics could provide immunizations  check if a patient needs antibiotics  help manage chronic illnesses like diabetes or even administer medications by infusion  but are unlikely to offer acute treatment of serious injuries  healthcare experts said    It would probably be unsettling to people coming in to buy socks to have someone with a bleeding head come in for stitches   said Greg Burke of the United Hospital Fund  a non profit focused on improving healthcare in New York   Expanding the clinics could eventually save the combined company more than  1 billion annually by substituting low cost treatments in CVS stores for more expensive hospital visits  two people familiar with the matter said  The combined net income of Aetna and CVS is forecast to be about  9 25 billion in 2017  according to Thomson Reuters data   Aetna competitor UnitedHealth Group Inc  N UNH  operates 230 MedExpress urgent care centers in 17 states in one of its fastest growing divisions  with nearly 20 percent compounded revenue growth per year   For CVS  which has seen non pharmacy sales decline at its stores  the clinics could have the added benefit of bringing in new customers and providing alternatives for less productive retail space   
 It s a tough retail environment  I think they re going to devote less space to it and more to different healthcare services and clinics   said Jeff Jonas  a portfolio manager at Gabelli Funds which owns shares in Aetna and CVS ",2017-12-01,Reuters,https://www.investing.com/news/stock-market-news/exclusive-cvs-eyes-major-expansion-of-health-clinics-with-aetna-deal--sources-942813,942813
141483,362998,HUM,CVS Health to acquire Aetna for  69 billion in year s largest acquisition,news,"By Carl O Donnell and Caroline Humer  Reuters    U S  drugstore chain operator CVS Health Corp  N CVS  said on Sunday it had agreed to acquire U S  health insurer  Aetna Inc   N AET  for  69 billion  seeking to tackle soaring healthcare spending through lower cost medical services in pharmacies  This year s largest corporate acquisition will combine one of the nation s largest pharmacy benefits managers  PBMs  and pharmacy operators with one of its oldest health insurers  whose national business ranges from employer healthcare to government plans   The deal comes after Aetna s  37 billion plan to acquire smaller U S  health insurance peer  Humana Inc   N HUM  was blocked in January by a U S  federal judge over antitrust concerns  A proposed combination of peers Anthem Inc  N ANTM  and  Cigna Corp   N CI  was also shot down   Aetna shareholders stand to receive  207 per share in the deal with CVS  the companies said  The consideration comprises  145 per share in cash and 0 8378 CVS shares for each Aetna share  Reuters first reported the terms of the deal earlier on Sunday   Aetna shareholders will own about 22 percent of the combined company  while CVS shareholders will own the remainder  The companies said that cost synergies in the second full year after the transaction closes    2020 if the deal closes in the second half of 2018 as they expect    would amount to  750 million  They foresee it adding to adjusted earnings per share by the low  to mid single digit percentage points  Their vision expands beyond capitalizing on CVS  existing MinuteClinic structure  which largely offers preventative services like flu shots  the companies  chief executives said in an interview    When you walk into CVS there s the pharmacy  What if there s a vision and audiology center  and perhaps a nutritionist  and some sort of care manager   CVS CEO Larry Merlo said   Aetna will be operated as a separate unit and Aetna s existing leadership is expected to run the Aetna businesses  Merlo said  Aetna will have two of its directors  in addition to Aetna CEO Mark Bertolini join the board of CVS  The deal comes as healthcare payers and pharmacies are responding to a shifting landscape  including changes in the Affordable Care Act  rising drug prices and the threat of competition from online retailers such as Amazon com Inc  O AMZN    CVS plans to use its low cost clinics to provide medical services to Aetna s roughly 23 million medical members  In addition to health clinics and medical equipment  CVS could provide assistance with vision  hearing and nutrition   A combined insurer and PBM will also likely be better placed to negotiate lower drug prices  and the arrangement could boost sales for CVS s front of store retail business  The company expects to invest billions of dollars in the coming years to add clinics and services  largely financed by diverting funds away from other planned investments   That could eventually cut costs substantially  with the clinics serving as an alternative to more expensive hospital emergency room visits  Meanwhile  deeper collaboration between Aetna s insurance business and CVS s PBM division could drive down drug costs by adding clients and boosting the PBM s leverage with drugmakers  Independent PBMs have long been criticized for potential conflicts of interest with insurance company clients  because they could potentially keep cost savings from drug negotiations rather than passing them on to patients   Health insurers meanwhile have sought to cut costs amid steep prescription drug price rises and requirements to care for even the sickest patients under the Affordable Care Act  Large corporate customers of Aetna are taking a wait and see attitude regarding the impact on costs  benefits experts have said  Analysts have said the CVS Aetna deal could prompt other healthcare sector mega mergers  as rivals scramble to emulate the strategy   It could spur a merger between Walgreens Boots Alliance Inc  O WBA  and Humana Inc  N HUM   or between Humana and Wal Mart Stores Inc  N WMT   Ana Gupte  analyst at Leerink Partners  said recently   VERTICAL MERGER  Although CVS and Aetna s planned merger does not directly consolidate the health insurance or pharmaceutical industries  the U S  Department of Justice has been taking a closer look at so called vertical mergers  where the companies are not direct competitors   Last month  the Justice Department sued to block AT T Inc s  N T  planned  85 4 billion merger with  Time Warner  Inc  N TWX   saying the integration of a content producer with a distributor could reduce consumer choice  The CVS Aetna deal could attract similar scrutiny if regulators feared it could block Aetna customers from frequenting other pharmacies or contracting with other PBMs  several investors said  asking not to be named because they were not authorized to talk to the press   But four antitrust experts said there is little doubt the deal will be approved  although it might need to meet conditions to convince antitrust enforcers to sign off  It is unclear whether it would be evaluated by the U S  Federal Trade Commission or the Justice Department but that decision might be made based on which agency is less busy  said Matthew Cantor of law firm Constantine Cannon    The companies  want the FTC to get it  The reason that the FTC is better at this point is that the Justice Department has just broken with decades of precedent of how to deal with vertical mergers   said Cantor  referring to the decision to refuse conduct remedies and file a lawsuit to stop AT T Inc  N T  from buying Time Warner Inc  N TWX    Barclays   LON BARC  and Goldman Sachs  NYSE GS  served as financial advisers to CVS  and Centerview Partners also provided financial advice to CVS s board  Shearman   Sterling LLP  Dechert LLP  and McDermott Will   Emery LLP were legal advisers to CVS   
Lazard Ltd and Allen   Company LLC were financial advisers to Aetna and Evercore served as independent financial adviser to Aetna s board  Davis Polk   Wardwell LLP was Aetna s legal adviser ",2017-12-04,Reuters,https://www.investing.com/news/stock-market-news/aetnas-board-set-to-approve-68-billion-sale-to-cvs-health-sources-945874,945874
141484,362999,HUM,CVS  Aetna executives defend  69 billion deal to skeptical Wall Street,news,"By Caroline Humer NEW YORK  Reuters    CVS Health Corp  N CVS  and  Aetna Inc   N AET  said on Monday their  69 billion deal to combine the pharmacy and drug benefit manager and the No  3 U S  health insurer would transform healthcare and deliver cost savings  but investors took a pessimistic view of the combination in the short term  CVS and Aetna announced on Sunday that they had reached an agreement for a deal that will allow CVS to expand cheaper medical services in its pharmacy based MinuteClinics and rein in soaring U S  healthcare costs for consumers  large corporations  and the government  CVS CEO Larry Merlo said on an investor call on Monday that he expects the deal to close in 2018 after an antitrust review  and that he expects  750 million in savings from eliminating duplicate corporate functions at CVS and Aetna and combining some drug health plan and drug benefit management areas  But investors on Monday described the savings as modest and worried that they will not kick in until 2020 at the earliest  Investors are also concerned that CVS earnings would not grow as much as expected next year due to deal costs   CVS shares fell 4 6 percent to close at  71 69 on Monday and Aetna shares fell 1 4 percent to close at  178 70  LONG TERM GROWTH  SHORT TERM PAIN CVS and Aetna envision a new healthcare system in which patient health is improved as the companies integrate pharmacy and medical claims and increase preventative services in clinics from the current emphasis on flu shots to include other areas such as vision  hearing and nutrition  Strategically  Gabelli Funds portfolio manager Jeff Jonas said  he likes the idea  which could drive customer growth in CVS s MinuteClinics   Financially  though  it s really a stretch   he said  CVS s plan to cancel share buybacks likely means lower earnings per share next year and the deal   the biggest merger of 2017   will increase the company s debt costs  Two ratings agencies  Moody s and S P  said on Monday that the debt load from the deal could spur them to lower credit ratings on the companies  The companies are turning to several banks to provide  49 billion in financing to fund the cash portion of the deal  Leerink analyst Ana Gupte said investors were increasingly skeptical  and that attaining the  750 million in savings would be difficult given the stiff competition with rivals and pricing pressure on health insurance products and pharmaceuticals  But she said the deal would probably be approved after regulators ask for small asset sales of Medicare drug plans to maintain market competition   Antitrust regulators last year blocked two separate mergers proposed by the large insurers  Aetna s plan to buy  Humana Inc   N HUM  and Anthem Inc s  N ANTM  acquisition of  Cigna Corp   N CI   saying they would hurt consumers   Unlike those deals  the CVS Aetna combination is a  vertical  integration in which the companies do not directly overlap operations  Several antitrust experts said they expected the CVS Aetna deal to gain approval for that reason  but that it would be scrutinized closely   Large corporate customers were a major factor in the antitrust litigation on the insurer mergers  and benefits consultants said they are taking a wait and see attitude about the companies  promises for the CVS deal  Addressing investor skepticism during a conference call with analysts on Monday  Aetna Chief Executive Officer Mark Bertolini said the companies   which were already working together on pharmacy benefits and to expand MinuteClinics   needed to merge so that CVS could have more control on finding the savings and other opportunities    Owner economics matter here   Bertolini said when asked by a Wall Street analyst why the two companies did not simply partner  The payout from the deal for Bertolini  who plans to remain a director  could be worth as much as  85 million if he leaves the company  as he is due to receive  6 7 million in severance  more than  9 million in deferred compensation and his unvested stock awards vest  according to data from the company s filings  
That would be on top of the roughly  120 million from the 574 000 shares he already owns  as well as additional money from shares that will vest between now and the deal s closing ",2017-12-04,Reuters,https://www.investing.com/news/stock-market-news/cvs-aetna-executives-expect-to-save-by-reducing-redundancy-948412,948412
141485,363000,HUM,Humana  HUM  Beats Q1 Earnings And Revenue Estimates,opinion,"Humana  HUM  came out with quarterly earnings of  4 48 per share  beating the Zacks Consensus Estimate of  4 30 per share  This compares to earnings of  3 36 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 4 19   A quarter ago  it was expected that this health insurer would post earnings of  2 53 per share when it actually produced earnings of  2 65  delivering a surprise of 4 74  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Humana  which belongs to the Zacks Medical   HMOs industry  posted revenues of  16 11 billion for the quarter ended March 2019  surpassing the Zacks Consensus Estimate by 1 99   This compares to year ago revenues of  14 28 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Humana shares have lost about 10 8  since the beginning of the year versus the S P 500 s gain of 17 5  
What s Next for Humana 
While Humana has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Humana was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  4 75 on  15 87 billion in revenues for the coming quarter and  17 50 on  63 37 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   HMOs is currently in the top 6  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-05-01,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-beats-q1-earnings-and-revenue-estimates-200414751,200414751
141486,363001,HUM,Humana  HUM  Beats Q1 Earnings And Revenue Estimates,opinion,"Humana  HUM  came out with quarterly earnings of  4 48 per share  beating the Zacks Consensus Estimate of  4 30 per share  This compares to earnings of  3 36 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 4 19   A quarter ago  it was expected that this health insurer would post earnings of  2 53 per share when it actually produced earnings of  2 65  delivering a surprise of 4 74  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Humana  which belongs to the Zacks Medical   HMOs industry  posted revenues of  16 11 billion for the quarter ended March 2019  surpassing the Zacks Consensus Estimate by 1 99   This compares to year ago revenues of  14 28 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Humana shares have lost about 10 8  since the beginning of the year versus the S P 500 s gain of 17 5  
What s Next for Humana 
While Humana has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Humana was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  4 75 on  15 87 billion in revenues for the coming quarter and  17 50 on  63 37 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   HMOs is currently in the top 6  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-05-01,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-beats-q1-earnings-and-revenue-estimates-200414584,200414584
141488,363003,HUM,Obamacare insurance options dwindle for neediest U S  patients,news,"By Yasmeen Abutaleb WASHINGTON  Reuters    Josh Brookhart has four health insurers to choose from in Seattle s King County for 2018  more than many Americans like him who buy coverage on the Obamacare individual market   Yet none of the plans cover all the complex medical care needed for his seven year old son  Gabriel   Born with an extreme form of Chiari malformation  Gabriel required surgery to reinsert a part of his brain into his skull  He lives with hydrocephalus  or extra fluid in his brain  and spina bifida  which causes abnormal development of the spinal cord  The Brookharts  insurer  Regence BlueShield of Washington  said in June it would exit the Obamacare markets in 2018  citing unsettled marketplaces across the country  a move common to many insurers uncertain about the program s future under President Donald Trump   All of Gabriel s specialists  who span multiple medical centers and practices and have been coordinating his care for five years  were covered under Regence   Based on the limited options for 2018 enrollment  the Brookharts plan to pick an insurer that will cover some of Gabriel s care and expect to pay tens of thousands of dollars for the rest of his needs   I would pay a high price for a good policy  It s just mind boggling to me that it doesn t exist no matter how much I would want to pay   Brookhart said  Gabriel s case shows how difficult it can still be to find adequate healthcare for very complex conditions four years after Obamacare took full effect  In many cases  an insurer will cover medical care but not certain prescription drugs  In other cases  an insurer may cover one specialist doctor but not others  or cut expensive academic medical centers out of their networks to lower costs   Patients with complex medical cases often take high cost prescription drugs  rely on specialists who sometimes coordinate their care and may require sophisticated surgeries  among other needs  The challenge of finding adequate healthcare on the Obamacare market is expected to intensify as the Trump administration strips away aspects of the law  healthcare experts say   Instability is just a very stressful thing for people dependent on a stable connection to the healthcare system   said Daniel Polsky  professor at the University of Pennsylvania and executive director of the Leonard Davis Institute of Health Economics   Even just a change of doctors could result in some difficult health consequences   RESTRICTED CHOICE U S  consumers have often complained that subsidized health insurance under former President Barack Obama s Affordable Care Act restricted their choice of doctors  or forced them to change providers  In some cases  that may mean switching primary care providers  But for patients with serious medical needs it can prevent them from seeing their specialists   The Obama administration attempted a fix  directing more federal oversight of the plans  requiring transparency from insurers on what they did  and did not  cover and setting guidelines for insurers to cover enough healthcare providers  Trump has promised to repeal Obamacare and is using executive powers to undermine it  including a rule finalized in April that allows individual states to determine whether insurers provide enough access to doctors   The administration has also proposed giving states more authority over their insurance markets and allowing them to water down some Obamacare benefits in 2019  That could create wide discrepancies in access to doctors among states  said Sabrina Corlette  an expert on health insurance markets at Georgetown University  There is no national estimate of how many people with complex medical cases may struggle to find a plan that covers their particular doctors  About 2 2 million people on the individual market have some form of a pre existing chronic condition  according to Avalere Health  a research and consulting firm   Seventy three percent of the Obamacare 2018 individual market is comprised of restrictive plans  or those that cover fewer providers  according to Avalere  up from 68 percent in 2017 and 54 percent in 2015  Research has shown that insurers are more likely to offer limited access to doctor practices in markets where they compete against one or more rivals  This helps keep insurer costs down  and therefore allows them to offer lower prices  Matt Slaby of Denver  Colorado  can choose between six Obamacare insurers  but none cover all the care for his genetic blood clotting disorder  called Factor V Leiden  He relies on the bloodthinner Xarelto  which costs about  400 per month without insurance  to prevent life threatening clots   His insurer from last year   Cigna Corp   N CI   dropped his plan from the Denver market for 2018    There are no plans that cover everything I need   Slaby said   Finding two or three  the intersection of things that keep me alive  that s the challenge    In U S  counties with a single insurer  there is less incentive to whittle down the provider list because there is no competition  The departure of major insurers including  Aetna Inc   N AET  and  Humana Inc   N HUM  from Obamacare markets has left about half of U S  counties with only one insurer selling plans  up from one third in 2017   But that does not guarantee that a sole insurer in a market will cover medical care at any specific hospital or physician practice  In Virginia s Chesterfield County  a single insurer  Cigna  is offering Obamacare coverage  presenting a tough choice for Jodi Smith Lemacks  whose son was born with a heart defect  The plan does not cover her son s specialists at Children s Hospital of Philadelphia  CHOP  five hours away  where Joshua Lemacks  14  has been treated since he was in utero for hypoplastic left heart syndrome   There is no cure for his condition  In three major surgeries  doctors at CHOP have rerouted Joshua s anatomy so that his blood can pump through one heart chamber instead of two  They have also provided medication  some through a clinical trial  to help prolong his heart s ability to function in this way  Lemacks spends  6 000 to  7 000 a year out of pocket for Joshua s medical expenses  and once had medical debt close to  100 000 due to the surgeries  She decided to put him on her employer s plan for 2018  but says if anything were to happen to her job at a nonprofit or she chooses to change jobs  she would need to return to the Obamacare market  
 You do everything you can to protect your kids but at the end of the day if you can t get coverage  you can t get coverage   she said ",2017-12-07,Reuters,https://www.investing.com/news/economy-news/obamacare-insurance-options-dwindle-for-neediest-us-patients-963508,963508
141489,363004,HUM,Humana  HUM  Beats Q1 Earnings And Revenue Estimates,opinion,"Humana  HUM  came out with quarterly earnings of  4 48 per share  beating the Zacks Consensus Estimate of  4 30 per share  This compares to earnings of  3 36 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 4 19   A quarter ago  it was expected that this health insurer would post earnings of  2 53 per share when it actually produced earnings of  2 65  delivering a surprise of 4 74  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Humana  which belongs to the Zacks Medical   HMOs industry  posted revenues of  16 11 billion for the quarter ended March 2019  surpassing the Zacks Consensus Estimate by 1 99   This compares to year ago revenues of  14 28 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Humana shares have lost about 10 8  since the beginning of the year versus the S P 500 s gain of 17 5  
What s Next for Humana 
While Humana has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Humana was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  4 75 on  15 87 billion in revenues for the coming quarter and  17 50 on  63 37 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   HMOs is currently in the top 6  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-05-01,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-beats-q1-earnings-and-revenue-estimates-200414339,200414339
141490,363005,HUM,Why You Should Hold Humana  HUM  Stock In Your Portfolio,opinion,Humana Inc    NYSE HUM   is well poised for growth on the back of its robust Medicare business and strategic initiatives The company has an impressive  of A and this style score analyzes its growth prospects It flaunts a commendable earnings surprise history  having exceeded the Zacks Consensus Estimate in the trailing 12 quarters  the average being 5 05   The stellar surprise record underlines the company s operating excellence  It expects 2019 adjusted EPS in the range of  17 25   17 5  up from the earlier expectation of  17  17 5  Individual Medicare Advantage membership is now predicted in the band of 415 000  440 000  up from the preceding range of 375 000 400 000  This strong guidance instills investor confidence in the stock The company s return on tangible equity   a profitability measure   stands at 33 1  against its industry s negative 120 6  Humana s Medicare business has been delivering encouraging results over the last several quarters on the back of solid operating initiatives  Strength in Medicare Advantage performance led to a better 2018 Retail segment benefit ratio  evident from higher Medicare membership  which shot up by 54  from 2013 to 2018  In the first quarter of 2019  Individual Medicare membership rose 13 7  year over year  The company expects sturdy individual Medicare Advantage membership growth in 2019 and raised its guidance to a range of 415 000 440 000 members  up from the prior estimate of 375 000 400 000 The company has also been making concerted efforts in executing strategic buyouts to fuel its business growth  Certain buyouts  such as Family Physicians Group  Your Home Advantage  Curo and a share in Kindred at Home poise the company well for growth Humana has been prudently deploying excess capital for the past several years that consistently impresses investors  While it has been hiking its dividend since 2011  last November  the company inked a deal to affect a  750 million ASR program under its current share repurchase authorization  We believe that this financial strength will continue to boost investor optimism on the stock However  Humana has been persistently witnessing a rise in operating expenses since 2010  Although the same declined to some extent in 2017  the metric again rose in 2018 and during the first quarter of 2019 as well  The company expects to further witness an elevation in benefit expenses  which will induce overall higher operating expenses  Rising expenses are also likely to hurt the bottom line The company is well placed for growth  evident from its favorable  of A  Here V stands for Value  G for Growth and M for Momentum with the score being a weighted combination of all three factors The long term earnings growth rate is expected at 13 9   above the  s average of 13 6   which is an upside for the company The Zacks Consensus Estimate for the company s current year earnings is pegged at  17 57  indicating an increase of 20 8  from the year ago reported figure on revenues of  63 8 billion  which again implies a 12  rise from the prior year reported number For 2020  the Zacks Consensus Estimate for earnings stands at  18 96 on  69 2 billion revenues  suggesting a respective 7 9  and 8 6  improvement from the year earlier reported figures Shares of this Zacks Rank  3  Hold  company have lost 15 9  in a year s time  wider than its industry s decline of 2 4  Stocks to ConsiderInvestors interested in the medical sector can take a look at some better ranked stocks like The Joint Corp    NASDAQ JYNT    Molina Healthcare  Inc   NYSE MOH   and WellCare Health Plans  Inc    NYSE WCG    You can see  Joint Corp  develops  owns  operates  supports and manages chiropractic clinics  In the last four quarters  the company delivered average beat of 190   It sports a Zacks Rank  1  Strong Buy  Molina offers Medicaid related solutions to meet the health care needs of low income families and individuals  It carries a Zacks Rank  2  Buy   In the trailing four quarters  the company came up with average beat of 88 17  WellCare Health offers managed care services to government sponsored health care programs  The company pulled off average positive surprise of 13 52  in the preceding four quarters  It has a Zacks Rank of 2 This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-05-19,Zacks Investment Research,https://www.investing.com/analysis/why-you-should-hold-humana-hum-stock-in-your-portfolio-200423084,200423084
141491,363006,HUM,Humana Stock Bulls Haven t Lost The Battle Yet,opinion,"Humana  NYSE HUM  climbed to an all time high of  356 in early November 2018  following a rally from as low as  18 57 in March 2009  In less than ten years  the company rewarded the patience of its investors with a total return of over 1820   not counting dividends 
Unfortunately  the last six months were nothing like the past ten years  In mid April  Humana dived below  223  down over 37  from its peak  Now  if this is the start of a bigger selloff  then it is time to stay aside  But could it actually be a buy the dip opportunity 

The weekly chart above allows us to put Humana s entire progress since the year 2000 into Elliott Wave context  The Financial Crisis of 2008 2009 is labeled as wave II  The phenomenal uptrend to  356 is a textbook five wave impulse in wave III 
Humana Bulls Aiming at  400 a Share Before Giving Up
This brings us to the present and the recent pullback  which fits in the position of wave IV  It has already touched the 38 2  Fibonacci level  where fourth waves often terminate  The missing piece of the puzzle is wave V  Provided it s not a truncation  the fifth wave is supposed to exceed the top of wave III  In terms of price  wave V s initial targets lie near  360 a share  but  400 is quite reasonable as well 
On the other hand  the bulls should tread very carefully  According to the theory  a three wave correction in the opposite direction follows every impulse  Investors hoping that the 2019 dip is going to fuel a rally similar to the one that followed the dip in 2009 are up for a disappointment 
If this count is correct  Humana is still in an uptrend and aiming at a new all time high  However  a bearish reversal near the  400 mark can open the door for a  50  plunge towards the support near  200 a share 
DISCLAIMER  This report does not constitute personal investment advice  nor does it take into account the individual financial circumstances or objectives of the clients who receive it  All information and research produced by Hantec Markets is intended to be general in nature  it does not constitute a recommendation or offer for the purchase or sale of any financial instrument  nor should it be construed as such 
All of the views or suggestions within this report are those solely and exclusively of the author  and accurately reflect his personal views about any and all of the subject instruments and are presented to the best of the author s knowledge  Any person relying on this report to undertake trading does so entirely at his her own risk and Hantec Markets does not accept any liability  
Original post",2019-05-23,EWM Interactive,https://www.investing.com/analysis/humana-stock-bulls-havent-lost-the-battle-yet-200424201,200424201
141501,363016,HUM,Anthem s  ANTM  Q1 Earnings Beat Estimates  Improve Y Y,opinion,Anthem Inc    NYSE ANTM   delivered first quarter 2019 earnings of  6 03 per share  surpassing the Zacks Consensus Estimate by 2 9   Additionally  the bottom line improved 11 5  year over year on the back of higher membership and the expansion of its clinical and specialty services Anthem reported operating revenues of  24 4 billion  beating the Zacks Consensus Estimate by 1 7   Moreover  the top line was up 9 2  year over year  aided by membership growth across the businesses and premium rate increases to cover the overall cost trends  However  this upside was partially offset by the one year waiver of the health insurance tax in 2019 Quarterly Operational UpdateMedical enrollment inched up 1 2  year over year to 40 8 million members  backed by the Government Business enrollment and the Commercial   Specialty Business Anthem s benefit expense ratio of 84 4  expanded 290 basis points  bps  from the prior year quarter  boosted by the one year waiver of the health insurance tax in 2019 SG A expense ratio of 13  contracted 230 bps from the year ago quarter due to the year long waiver of the health insurance tax in 2019  growth in the operating revenues and the overall expense management Anthem  Inc  Price  Consensus and EPS Surprise   Strong Segmental ResultsCommercial   Specialty BusinessOperating revenues were  9 3 billion in the first quarter  up 4 9  year over year Operating gain totaled  1 6 billion  up 12 6  year over year  This upside is led by an improved medical cost performance in Local Group and higher administrative fee revenues in the company s self funded businesses Operating margin was 16 9   up 120 bps year over year Government BusinessOperating revenues were  14 9 billion  up 12  from the prior year quarter Operating gain was  383 million  down 20 4  year over year due to the non recurrence of retroactive revenue adjustments in 2018 and the continued elevated medical cost experience in Medicaid across select states  However  the same metric was offset by the reduced selling  general and administrative expensesOperating margin was 2 6   down 100 bps year over year OtherThe Other segment s operating loss of  16 million is narrower than the year earlier quarterly loss of  22 million Financial UpdateAs of Mar 31  2019  Anthem s cash and cash equivalents summed  4 5 billion  up 13 9  from year end 2018 As of Mar 31  2019  its long term debt less current portion inched up 1  to  17 4 billion from the level at 2018 end Operating cash outflow at the end of the first quarter was  1 6 billion  down 26 4  from the figure as of Dec 31  2018 Capital DeploymentDuring the first quarter  Anthem bought back shares worth  294 million  As of Mar 31  2019  the company had shares worth around  5 2 billion remaining under its share buyback authorization Moreover  the company paid a quarterly dividend of 80 cents per share  adding up to a distribution of cash worth  206 million The company announced a dividend of 80 cents per share on Apr 23  2019 for the second quarter  payable Jun 25 to shareholders of record on Jun 10  2019 Revised Guidance for 2019Based on solid first quarter results  Anthem has updated its outlook for 2019  The company s adjusted net income is now expected to be higher than  19 20 per share  up from the prior projection of more than  19 Medical membership is still estimated in the range of 40 9 41 3 million Operating revenues are predicted to be around  100 billion including the premium revenues of  90 5  92 5 billion  Operating cash flow is envisioned to be higher than  5 2 billion SG A ratio is forecast in the band of 13 5       30 bps  The company estimates the benefit expense ratio to be 86 2      30 bps  Zacks RankAnthem carries a Zacks Rank  2  Buy   You can see  Upcoming Releases From Medical SectorSome other stocks worth considering from the medical sector are as follows Aduro Biotech  Inc    NASDAQ ADRO   is slated to release first quarter earnings figures on May 1  This stock has an positive  of  82 00  and a Zacks Rank of 2  You can uncover the best stocks to buy or sell before they are reported with our  bluebird bio  Inc    NASDAQ BLUE   has an Earnings ESP of  12 12  and a Zacks Rank  3  The company is set to report first quarter earnings on May 1 Humana Inc    NYSE HUM   is set to report first quarter 2019 earnings performance on May 1  The stock has an Earnings ESP of  0 84  and a Zacks Rank of 3 Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-04-23,Zacks Investment Research,https://www.investing.com/analysis/anthems-antm-q1-earnings-beat-estimates-improve-yy-200410299,200410299
141512,363027,HUM,U S  judge questions states seeking to restore Obamacare payments,news,"By Dan Levine SAN FRANCISCO  Reuters    A U S  judge on Monday appeared skeptical toward a request from several states that want him to order the administration of Republican President Donald Trump to continue payments to health insurers under Obamacare   At a hearing in San Francisco federal court  U S  District Judge Vince Chhabria said he aimed to issue a ruling on Tuesday   The Trump administration earlier this month terminated the payments  which help cover out of pocket medical expenses for low income Americans  as part of several moves to dismantle the signature healthcare law of his Democratic predecessor  Barack Obama   Trump had threatened to cut off the subsidies for months  prompting health insurers such as Anthem Inc   Humana Inc   NYSE HUM   UnitedHealth Group Inc  NYSE UNH  and  Aetna Inc   NYSE AET  to raise premiums or exit insurance markets  Democratic attorneys general from 18 states and the District of Columbia sued the federal government and asked for an immediate order halting Trump s move while the case is being litigated and argued that terminating the payments harmed customers by raising insurance rates   But Chhabria on Monday suggested that California and other states had anticipated Trump s move and worked with insurers to make sure most consumers would not be harmed  That weakens the case for a court order forcing the payments  Chhabria said    Why should I be ordering the administration to make these payments in the next few months while we get the case adjudicated   Chhabria asked  Since cutting off the payments  Trump has alternately supported  and dismissed  an effort by Republican and Democratic senators that would reinstate the subsidies for two years until a broader replacement to the 2010 Affordable Care Act  commonly known as Obamacare  can be negotiated  While Democrats accused Trump of sabotaging Obamacare  the president argued that the subsidies made insurance companies  rich    In a court filing on Friday  the U S  Department of Justice pointed to a prior ruling from a Washington  D C  federal court that said Congress had never appropriated the money for the subsidies  An appeal of that ruling is currently on hold  Either side could appeal Chhabria s ruling to the 9th U S  Circuit Court of Appeals  which is weighted with Democratic appointed judges   
From there  any further appeal would go to the U S  Supreme Court ",2017-10-23,Reuters,https://www.investing.com/news/politics-news/us-judge-to-review-trump-healthcare-payments-cut-545678,545678
141513,363028,HUM,CVS makes more than  66 billion bid for Aetna  sources,news,"By Carl O Donnell and Greg Roumeliotis  Reuters    U S  pharmacy operator CVS Health Corp  NYSE CVS  has made an offer to acquire No  3 U S  health insurer  Aetna Inc   NYSE AET  for more than  200 per share  or over  66 billion  people familiar with the matter said on Thursday  A deal would merge one of the nation s largest pharmacy benefits managers and pharmacy operators with one of its oldest health insurers  whose far reaching business ranges from employer healthcare to government plans nationwide  Aetna shares rose more than 11 percent  or  18 48  to  178 60  while CVS shares fell 3 percent  or  2 22  to  73 31  after the Wall Street Journal first reported on the talks earlier on Thursday   Healthcare consolidation has been a popular route for insurers and pharmacies  under pressure from the government and large corporations to lower soaring medical costs   Pharmacy benefit managers  PBMs  such as CVS negotiate drug benefits for health insurance plans and employers  and have in recent years taken an increasingly aggressive stance in price negotiations with drugmakers  They often extract discounts and after market rebates from drugmakers in exchange for including their medicines in PBM formularies with low co payments  A tie up with Aetna could give CVS more leverage in its price negotiations with drug makers  But it would also subject it to more antitrust scrutiny   The deal could also help counter pressure on CVS s stock following speculation that Amazon com Inc  NASDAQ AMZN  is preparing to enter the drug prescription market  using its vast e commerce platform to take market share from traditional pharmacies   CVS made the offer earlier this month  although the two companies have been in discussions about a potential deal for several months  the sources said   These talks were carried out primarily between CVS Chief Executive Officer Larry Merlo and Aetna CEO Mark Bertolini  and were aimed at making executives comfortable with the idea of a merger  the sources said  CVS and Aetna started discussing terms only recently  and a deal is not expected for a few weeks  one of the sources added  cautioning that the pace of the talks could accelerate given the publication of the negotiations   The sources did not specify how much of CVS  bid is cash versus stock  but given CVS s and Aetna s market capitalizations of  77 billion and  54 billion  respectively  a substantial stock component is likely in any deal  Aetna and CVS declined to comment  Aetna earlier this year closed the door on a deal with rival insurer  Humana Inc   NYSE HUM  after antitrust regulators said that combination and a rival deal between Anthem Inc and  Cigna Corp   NYSE CI  were anti competitive  UNCERTAIN TIMES AHEAD The deal comes after years of major changes to the U S  health insurance industry under former President Barack Obama  whose 2010 Affordable Care Act created new ground rules for how insurers operate and expanded insurance to 20 million more Americans  Republican President Donald Trump has promised to turn back many of the Affordable Care Act s facets  but Congress has not been able to agree on a repeal or a replacement  The lack of progress   as well as Trump s executive order to bring down healthcare costs   has created uncertainty for insurers as they head into 2018  After the deal with Humana fell apart  Bertolini has said that he did not believe large deals were possible in the insurance industry  But analysts have speculated about a tighter partnership between Aetna and CVS since early in the year  CVS and Aetna have a long term contract in which CVS has provided pharmacy benefits for Aetna customers   Aetna really makes the best sense  said Jeff Jonas  a portfolio manager at Gabelli Funds   It s their largest client on the PBM side  They really have similar views as to where healthcare should go  which is to the retail setting   Jonas  who owns both Aetna and CVS shares  noted the two companies were already talking about working together on Minute Clinic  on home infusion and other services   To go from that to a full merger is a big step but it s not huge   he said  Last week No  2 insurer Anthem Inc  announced plans to manage its own pharmacy benefits with the help of CVS  a move that would give it a set up similar to UnitedHealth Group Inc  NYSE UNH   and its Optum unit  Insurers want more control over the pharmaceutical component of care as they implement pricing schemes with doctors and hospitals that are based on health outcomes  not just procedures  
They also want to work on driving down costs  and as a pharmacy benefit manager  would negotiate directly with drugmakers ",2017-10-26,Reuters,https://www.investing.com/news/stock-market-news/cvs-makes-bid-for-aetna-source-548782,548782
141515,363030,HUM,CVS deal for Aetna could help retailer face Amazon entry  analysts,news,"By Ankur Banerjee  Reuters    U S  pharmacy operator CVS Health Corp s  N CVS  move to buy health insurer  Aetna Inc   N AET  could shore up CVS  vulnerable pharmacy business and spur another round of dealmaking in an industry fearing Amazon s arrival  analysts said  Shares of Aetna  the third largest U S  health insurer  closed down 3 percent on Friday after closing 12 percent higher on Thursday on reports of the deal  CVS Health was down 5 9 percent  CVS Health has made an offer to acquire Aetna for more than  200 per share  or over  66 billion  making it the biggest deal of the year   nL2N1N12JO   A potential combination would diversify CVS profit streams ahead of an Amazon entry and set the stage for a new healthcare retail delivery model    Morgan Stanley   NYSE MS  analysts wrote in a note  Amazon com Inc  O AMZN  is planning to move into online prescription drug sales  multiple media reports have said  potentially posing an existential threat to brick and mortar pharmacies  That possibility has hit shares of most drugstore operators on fears that the online retailer would leverage its vast ecommerce platform in prescription drug sales   We believe CVS does need to respond to the potential threat and strike a different path   Cowen   Co analyst Charles Rhyee said in a note  A deal would make CVS Aetna a one stop shop for customers  health care needs   ranging from employer healthcare and government plans to managing benefits and running drug stores  The vertical integration of retail pharmacy  PBM  and insurers fits with broader healthcare themes of expanded access  consumerism and cost reduction  Jefferies analysts said  adding that the deal chatter was not a complete surprise   It would address each company s need for a fresh script   The deal between companies in two very concentrated industries will likely prompt concern about their rivals having an access to market  or foreclosure  two antitrust expert said  But the deal will likely win approval from antitrust enforcers because the two companies are in different businesses along the same supply chain  or a vertical merger  other experts said   I don t doubt that there will be a lot of people that will be concerned about such a huge deal   said Andre Barlow of the law firm Doyle  Barlow and Mazard   But articulating an antitrust theory  to stop it  is difficult   The two companies overlap in at least one area   providing Medicare Part D pharmacy prescription drug coverage  Analysts at Evercore ISI estimated that 23 percent of Aetna s Part D clients were in counties where there may be antitrust concerns but these could likely be remedied through asset sales  Some analysts said the deal could also trigger a wave of consolidation across the industry  It could be a possible catalyst for higher health insurance sector valuation  BMO Capital Markets analyst Matt Bosch said  adding that WellCare Health Plans  N WCG   Humana  N HUM  and  Centene   N CNC  could be possible acquisition targets  
Aetna earlier this year scrapped plans to merge with rival Humana after antitrust enforcers said that the combination and a rival deal between Anthem Inc  N ANTM  and  Cigna Corp   N CI  were anti competitive ",2017-10-27,Reuters,https://www.investing.com/news/stock-market-news/cvsaetna-deal-gets-wall-street-thumbs-up-amid-amazon-entry-fears-549327,549327
141516,363031,HUM,CVS bid for Aetna  A  66 billion bet on cutting drug costs,news,"By Caroline Humer and Carl O Donnell NEW YORK  Reuters    The proposed merger between U S  pharmacy operator CVS Health Corp  NYSE CVS  and No  3 health insurer  Aetna Inc   NYSE AET  represents a  66 billion bet that insurers can drive down high U S  drug prices by cutting out the middleman  The move is the most expensive effort to date that would enable a national health insurer to take back full control of prescription medicines for their customers by negotiating prices with pharmaceutical manufacturers and setting customer out of pocket costs for each drug  CVS  one of the largest U S  pharmacy benefits managers  has offered to buy No  3 health insurer Aetna for more than  200 per share  sources said on Thursday  It could take at least several weeks for any deal to materialize  If the deal happens  it would likely pressure rival insurers  drugmakers  pharmaceutical benefits managers  and retail pharmacies to also consider mergers or switching partners to try to keep up with the potential healthcare cost savings or increase in profit margins    It s an alternate model at this point  It s not clear that it s definitely a better one   BMO Capital Markets analyst Matt Borsch said   More consolidation could lead to pressure on some of the brand name drug prices and a better counterweight to the big pharma companies    For years  insurers paid drug benefits managers like CVS and Express Scripts Holdings Co to negotiate down drug prices  with both parties taking a share of any discount by the time a medicine was paid for by consumers   But outrage over the high costs of drugs has grown as consumers have picked up a larger portion of the tab for drug costs and it is threatening profit margins all along the drug supply chain  from manufacturers to distributors  insurers and pharmacies  UnitedHealth Group Inc  NYSE UNH  and  Humana Inc   NYSE HUM  currently have in house pharmacy benefits businesses  and say that it has helped them keep medical costs down   Anthem Inc recently decided to go down that same path  It cut ties with Express Scripts during a  3 billion legal fight  and said it would use CVS to build its own pharmacy benefits business in the next few years  That tie up could now be at risk if CVS reaches a deal to buy Aetna  Leerink analyst Ana Gupta said       CVS also provides management services for Aetna rival  Cigna Corp   NYSE CI   If CVS buys Aetna  that could revive Cigna s interest in buying Humana  analyst Christine Arnold of investment bank Cowen   Co said in a research note   Aetna earlier this year closed the door on a deal with rival insurer Humana Inc after antitrust regulators said that combination and a rival deal between Anthem Inc and Cigna Corp were anti competitive  The pharmacy chain Walgreens Boots Alliance  NASDAQ WBA  could need to match its business model closer to CVS to attempt to stay competitive  Arnold said in a note  and may look at buying Express Scripts   Jefferies analyst Brian Tanquilut said that Express Scripts could also be a target for Amazon  NASDAQ AMZN  Inc which is reported to be looking to get into the pharmacy business       SWINGING PENDULUM Over the past decade  health insurers have diverged on the value of the pharmacy benefits business   Anthem sold its pharmacy benefit manager to Express Scripts and outsourced almost all of the business in 2010   UnitedHealth took the opposite approach when it decided in 2011 to bring its pharmacy benefits management in house  then bought an even bigger standalone benefits manager  Catamaran  in 2015       Humana operates its own pharmacy benefit manager and Cigna and Aetna have hybrid approaches where they manage some parts in house and outsource others        Until recently  insurers sought to expand their profit margins by reducing their spending on hospital services  using their size to negotiate down what they pay to healthcare providers   But with those profits in hand  and with drug prices representing a bigger proportion of overall healthcare spending  they see new opportunity in targeting the pharmacy benefits  Leerink s Gupta said  
    Another potential lure of a deal for Aetna would be to capitalize on the growing number of simple health services offered in a CVS store  from flu shots to blood pressure checks  Reimbursing such patient care outside of a doctor s office or hospital could cut healthcare costs  Gupta said ",2017-10-29,Reuters,https://www.investing.com/news/stock-market-news/cvs-bid-for-aetna-a-66-billion-bet-on-cutting-drug-costs-550333,550333
141517,363032,HUM,Humana declares  0 40 dividend,news,Humana  NYSE HUM  declares  0 40 share quarterly dividend  in line with previous Forward yield 0 62 Payable Jan  26  for shareholders of record Dec  29  ex div Dec  28 Now read ,2017-11-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/humana-declares-040-dividend-763155,763155
141518,363033,HUM,Anthem top executive Swedish to become adviser  Boudreaux named CEO,news," Reuters    Anthem Inc s  N ANTM  Joseph Swedish will be replaced as chief executive by industry veteran Gail Boudreaux but will stay on as executive chairman until May 2018 and be a senior adviser through May 2020  the health insurer said on Monday  The Wall Street Journal first reported the news on Friday  Swedish will continue to receive his current salary as executive chairman and be eligible for a prorated bonus and as an adviser  he will be paid  4 5 million per year  Swedish s move comes at a time of change for Anthem  the No  2 U S  health insurer  The company cut Obamacare individual market participation by 70 percent for next year and recently announced plans to bring its pharmacy benefit management in house  It also may face a much larger  Aetna Inc   N AET   which is considering a deal with CVS Health Corp  N CVS   according to sources  Boudreaux was most recently CEO of United Healthcare  a unit of the biggest U S  health insurer  UnitedHealth Group Inc  N UNH   Before that  she was an executive at the next largest operator of Blue Cross Blue Shield licensed insurers  Health Care Services Corp  and at Aetna  BMO Markets analyst Matthew Borsch said in a research note that Boudreaux is held in high regard by investors but that Anthem s stock is still a  market perform  given the company s slower growth business mix   We expect there may be a period of uncertainty among investors until the reasons for the reported leadership change are understood and fully accepted by the market   he wrote  Boudreaux  who will take on the role of CEO on Nov  20  will receive an annual salary of  1 4 million with a potential bonus of up to 350 percent of her salary  along with an initial stock grant worth  2 million  Long term incentives are worth up to  10 25 million  Swedish orchestrated Anthem s  54 billion deal for smaller rival  Cigna Corp   N CI  in 2015  which was ultimately scrapped as regulators said that and Aetna s proposed acquisition of  Humana Inc   N HUM  would be anti competitive  Two weeks ago  news broke that Aetna and CVS were in talks over a deal that would create a combined health insurance  pharmacy benefit management  and pharmacy company  The deal is expected in December  Reuters reported  
The impact of that deal is unclear on Anthem s recently announced plan to use CVS to help manage its pharmacy benefits business as it exits its contract with Express Scripts Holding  O ESRX  ",2017-11-06,Reuters,https://www.investing.com/news/stock-market-news/anthem-ceo-joseph-swedish-to-step-down-764308,764308
141519,363034,HUM,UnitedHealth Stock Looks Strong Despite Uncertainty,opinion,"Whether Obamacare is unconstitutional or not is up to the policy makers  but the uncertainty surrounding the matter caused a broad selloff in the healthcare sector  Cigna  NYSE CI   Humana  NYSE HUM   CVS Health  NYSE CVS  and UnitedHealth  NYSE UNH  lost a significant chunk of their respective market caps after the DOJ sided with a December 2018 Texas district court ruling that the Affordable Care Act should be struck down 
Following the news  analysts at Goldman Sachs  NYSE GS  and JPMorgan  NYSE JPM  trimmed their price targets on UnitedHealth citing  fear of policy proposals  that could wreak havoc on the company s financial results 
On the other hand  where there is risk there is reward  We cannot know what the healthcare chatter is eventually going to produce  but at least we can look for recognizable Elliott Wave patterns on the related stocks  One such pattern can be found on the 2 hour chart of UnitedHealth below 

The chart reveals that UNH s pullback from  288 in  208 looks like a simple A B C zigzag correction with a triangle in wave B  This patterns gives us plenty of reasons to turn bullish on UnitedHealth stock 
A Base has been Formed in UnitedHealth Stock
Triangles are known to precede the last wave of the sequence  In that case  this is wave C down to  208 on April 17th  Once a correction is over  the larger trends resumes  Since UNH was clearly in an uptrend prior to December 4th  2018  it makes sense to expect the bulls to return 
Another reason for optimism is provided by the fact that the A B C retracement developed within the parallel lines of a corrective channel  The lower line of the channel caused a sharp bounce to  232 a share so far 
If this analysis is correct  all the uncertainty in the U S  healthcare sector has created a good buying opportunity in UnitedHealth stock  The anticipated rally should exceed the previous all time high  making  300 a share a very realistic target 
Original post",2019-04-24,EWM Interactive,https://www.investing.com/analysis/unitedhealth-stock-looks-strong-despite-uncertainty-200409963,200409963
141520,363035,HUM,Is A Beat In Store For WellCare Health s  WCG  Q1 Earnings ,opinion,WellCare HealthPlans  Inc  s   NYSE WCG   is scheduled to release first quarter 2019 results on Apr 30  In the last reported quarter  the company delivered a positive surprise of 5 2   primarily backed by the Meridian buyout and membership growth  Moreover  the bottom line skyrocketed 409 4  year over year The company flaunts an impressive surprise history  having delivered an earnings beat in all the trailing four quarters  the average being 15 43  What to Expect for Q1 EarningsWe expect revenues in the quarter under review to have gained from higher membership   The Zacks Consensus Estimate for first quarter revenues is pegged at  6 5 billion  indicating a40 8  surge from the year ago reported figure The consensus mark for the company s first quarter earnings is pegged at  3 10  suggesting25 5  growth from the prior year reported number  This uptrend is likely to be supported by solid revenues In the to be reported quarter  Medicaid Membership is likely to rise on the back of strategic initiatives like the expansion of the company s contracts  The consensus estimate for total Medicaid membership is pegged at 4 1 billion  implying49 8  growth from the year earlier period s level The company managed to grow its organic Medicare Advantage by around 16000 members in January 2019  which represents 3  growth from the 2018 end level  This upside in membership is expected to be consistent in the remainder of the first quarter as well  The Zacks Consensus Estimate for Medicare Advantage membership is pegged at 572 million  indicative of 13  rise from the tally in the comparable quarter last year  The upside is likely to be boosted by organic growth The Zacks Consensus Estimate for the company s total membership stands at 6 2 billion  hinting at 45 1  improvement from the prior year quarter s reported figure However  WellCare Health is likely to suffer the burden of high debt level due to its growth related investments  which increases its financial risk In the quarter to be reported  the company might face escalated expenses due to higher medical and pharmacy costs  selling  general and administrative  SG A  expenses as well as operating costs What the Quantitative Model StatesThe proven Zacks model conclusively shows that WellCare Health is likely to beat on earnings this to be reported quarter  This is because the stock needs to have the right combination of a positive and a top Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Earnings ESP  WellCare Health has an Earnings ESP of  1 91   This is because the Most Accurate Estimate is pegged at  3 16  higher than the Zacks Consensus Estimate of  3 10 You can uncover the best stocks to buy or sell before they are reported with our WellCare Health Plans  Inc  Price and EPS Surprise   Zacks Rank  WellCare Health carries a Zacks Rank  3  which increases the predictive power of ESP  Moreover  a favorable ESP in the combination raises the odds of a likely positive surprise Conversely  the Sell rated stocks   4 or 5  should never be considered going into the earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks to ConsiderSome other stocks worth considering from the medical sector with the perfect combination of elements to also surpass estimates in the upcoming quarterly releases are as follows Aduro Biotech  Inc    NASDAQ ADRO   is slated to release first quarter earnings figures on May 1  This stock has an Earnings ESP of  82 00  and a Zacks Rank  2  You can see  bluebird bio  Inc    NASDAQ BLUE   has an Earnings ESP of  12 12  and a Zacks Rank  3 The company is set to report first quarter earnings on May 1 Humana Inc    NYSE HUM   is set to report first quarter 2019earnings performance on May 1  The stock has an Earnings ESP of  0 84  and a Zacks Rank of 3 Zacks  Top 10 Stocks for 2019 In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-25,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-wellcare-healths-wcg-q1-earnings-200411727,200411727
141521,363036,HUM,What s In Store For HCA Healthcare s  HCA  Q1 Earnings  ,opinion,HCA Healthcare  Inc    NYSE HCA   is scheduled to release first quarter 2019 results on Apr 30  In the last reported quarter  the company delivered a positive surprise of nearly 15 4   backed by higher same facility admissions  Moreover  the bottom line shot up nearly 41  year over year Let s see  how things are shaping up prior to this announcement A likely increase in beds  admissions and patient days should aid revenue growth in the to be reported quarter  The Zacks Consensus Estimate for first quarter revenues stands at  12 3 billion  indicating 7 8  growth from the year ago reported figure  The Zacks Consensus Estimate for equivalent admissions is pegged at 879 million  implying3 5  increase from the year earlier quarter s reported figure  This uptick would likely be backed by the company s network expansion The Zacks Consensus Estimate for patient days has also been revised 2 7  upward from the year ago quarter s reported figure  Moreover  the consensus mark for weighted average licensed beds has moved2 4  north from the prior year s reported number The consensus estimate for the total number of hospitals is likely to be raised2 2  from the reported tally in the same period last year The company might have been consistent with capital deployment  which should further favor its bottom line HCA Healthcare has likely witnessed a steady cash flow in the first quarter  retaining the momentum over the last several quarters However  the Zacks Consensus Estimate for earnings in the to be reported quarter is pegged at  2 31  suggesting a 0 9  dip from the year ago reported figure  This downside is most likely due to higher expenses because of the company s growth related investments and operating costs  Higher expenses should also weigh on the company s margins Further  we expect the company s leverage ratio to persistently deteriorate as it incurs more debt to finance its acquisitions What the Quantitative Model StatesThe proven Zacks model does not conclusively show that HCA Healthcare is likely to beat on earnings this to be reported quarter  This is because the stock needs to have the right combination of a positive   and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you can see below Earnings ESP  HCA Healthcare has an Earnings ESP of  1 84   This is because the Most Accurate Estimate is pegged at  2 27  lower than the Zacks Consensus Estimate of  2 31  You can uncover the best stocks to buy or sell before they are reported with our HCA Healthcare  Inc  Price and EPS Surprise   Zacks Rank  HCA Healthcare has a Zacks Rank  3  which increases the predictive power of ESP  However  a negative ESP lowers the chances of an earnings beat as only a positive value in the combination can significantly increase the investor confidence about a likely positive surprise  Thus  surprise prediction is left inconclusive here for the stock  You can see  We caution against the Sell rated stocks   4 or 5  going into an earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderSome stocks worth considering from the medical sector with the perfect mix of elements to surpass estimates this earnings season are as follows Aduro Biotech  Inc    NASDAQ ADRO   is slated to release first quarter earnings figures on May 1  This stock has an Earnings ESP of  82 00  and a Zacks Rank  2 bluebird bio  Inc    NASDAQ BLUE   has an Earnings ESP of  12 12  and a Zacks Rank of 3  The company is set to report first quarter earnings on May 1 Humana Inc    NYSE HUM   has an Earnings ESP of  0 84  and a Zacks Rank of 3  The company is set to report first quarter earnings on May 1 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year  Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-25,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-hca-healthcares-hca-q1-earnings-200411726,200411726
141522,363037,HUM,Universal Health  UHS  Q1 Earnings  Revenues Miss Estimates,opinion,Universal Health Services Inc    NYSE UHS   reported first quarter 2019 adjusted earnings of  2 45 per share  missing the Zacks Consensus Estimate by 5 8   Meanwhile  the bottom line matched the prior year quarter s figure on the back of revenue growth Results were impacted by a pre tax unrealized loss of  4 3 million due to a decline in the market value of shares of certain marketable securities   Net revenues increased 4 3  year over year to  2 8 billion  banking on higher admissions and patient days  However  the metric lagged the Zacks Consensus Estimate by 0 4  Total operating expenses of  2 5 billion at the end of the first quarter rose4 7  year over year  mainly due to salaries  wages and benefits along with other operating expense plus supplies expenses Universal Health Services  Inc  Price  Consensus and EPS Surprise   Segment UpdateAcute Care Hospitals Adjusted admissions and adjusted patient days were up 4 9  and 4 4   respectively  from the prior year quarter  Net revenues  on a same facility basis  climbed 4 7  in the first quarter  majorly aided by a rise in admissions and patient days Behavioral Hospitals On same facility basis  adjusted admissions inched up 2 9  while adjusted patient days dipped 0 9   both on a year over year basis  Net revenues were up 3  during the quarter under review on same facility basis Financial UpdateAs of Mar 31  2019  the company had cash and cash equivalents of nearly  62 7 million  down 40 4  from the year end 2018 level Total assets were  11 7 billion as of Mar 31  2019  up 4 1  from the figure as of 2018 end The company s long term debt came in at   3 8 billion  down 2 9  from the number as of Dec 31  2018 For the first quarter  net cash provided by operating activities totaled  391 million  down 4 6  year over year due to an unfavorable change in accounts receivable as well as other combined adverse changes Buyback ProgramDuring the first quarter  the company bought back shares worth  106 3 million Moreover  last December  its board of directors authorized a  500 million jump from the existing share repurchase program Zacks RankUniversal Health currently carries a Zacks Rank  3  Hold   You can see  Upcoming Releases From Medical SectorSome stocks worth considering from the medical sector are as follows Aduro Biotech  Inc    NASDAQ ADRO   is slated to release first quarter earnings figures on May 1  This stock has an Earnings ESP of  82 00  and a Zacks Rank  2  Buy   You can uncover the best stocks to buy or sell before they are reported with our  bluebird bio  Inc    NASDAQ BLUE   has an Earnings ESP of  12 12  and a Zacks Rank of 3  The company is set to report first quarter earnings on May 1 Humana Inc    NYSE HUM   is set to report first quarter 2019 earnings performance on May 1  The stock has an Earnings ESP of  0 84  and a Zacks Rank of 3 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-25,Zacks Investment Research,https://www.investing.com/analysis/universal-health-uhs-q1-earnings-revenues-miss-estimates-200411724,200411724
141545,363060,HUM,Exclusive  T Mobile  Sprint plan merger without selling assets,news,"By Liana B  Baker and Anjali Athavaley  Reuters    T Mobile U S  Inc  O TMUS  and Sprint Corp  N S  plan to announce a merger agreement without any immediate asset sales  as they seek to preserve as much of their spectrum holdings and cost synergies as they can before regulators ask for concessions  according to people familiar with the matter  While it is common for companies not to unveil divestitures during merger announcements  T Mobile s and Sprint s approach shows that the companies plan to enter what could be challenging negotiations with U S  antitrust and telecommunications regulators without having made prior concessions   Reuters reported last week that some of the U S  Justice Department s antitrust staff were skeptical about the deal  which would combine the third and fourth largest U S  wireless carriers  However  regulators can only begin reviewing a corporate merger once it has been agreed to and announced   T Mobile and Sprint are preparing a negotiating strategy to tackle demands from regulators regarding asset sales  including the divestment of some of their spectrum licenses after their deal is announced  the sources said   The companies  announcement of a merger agreement  currently expected to come either in late October or early November  will focus on the potential benefits of the deal for U S  consumers  including the advancement of next generation 5G wireless technology  which requires considerable investment  the sources added   The sources asked not to be identified because the deliberations are confidential  T Mobile and Sprint declined to comment   It is better for Sprint and T Mobile to listen and learn the concerns of regulators first  and see whether there is anything that can be done to address those concerns   MoffettNathanson research analyst Craig Moffett said  A combination of T mobile and Sprint would create a business with more than 130 million U S  subscribers  just behind  Verizon Communications  Inc  N VZ  and AT T Inc  N T    Companies often chose not to make any pre emptive announcements on divestitures when they announce mergers  For example  when U S  health insurers Anthem Inc  N ANTM  and  Aetna Inc   N AET  separately announced deals two years ago to acquire peers  Cigna Corp   N CI  and  Humana Inc   N HUM   they did not reveal which assets they would be willing to divest  U S  federal judges shot down both mergers on antitrust grounds earlier this year  Some media and telecommunications deals in recent years have been announced with divestitures  such as U S  cable operator Comcast Corp s  O CMCSA  proposed takeover of Time Warner Cable in 2014  which was later called off after regulatory pushback  When U S  TV station owner Sinclair Broadcast Group  O SBGI  announced its acquisition of peer  Tribune Media Co   N TRCO  in May  it said it might sell certain stations to comply with regulators  Companies often also choose to place caps in their merger agreements on the size of divestitures they would be willing to accept in their negotiations with regulators  T Mobile and Sprint have not yet agreed to include such a cap in their merger agreement  though it is possible they will do so  one of the sources said  SPECTRUM HOLDINGS UBS research analyst John Hodulik said in a research note earlier this month that the U S  Federal Communications Commission will likely force T Mobile and Sprint to make some divestitures of spectrum  since the combined company would have the most airwaves in its sector with more than 300 MHz  putting it ahead of Verizon s and AT T s holdings   T Mobile spent  8 billion in a government auction of airwaves earlier this year  Sprint stayed out of the auction  touting its holdings of high band spectrum  which it says can move large volumes of information at high speeds   Having access to a lot of spectrum is particularly important for the 5G wireless offerings that AT T and Verizon hope to launch to better compete with high speed Internet services from cable companies  T Mobile and Sprint believe that the U S  antitrust enforcement environment has become more favorable since the companies abandoned their previous effort to combine in 2014 amid regulatory concerns  according to the sources   The two companies have not yet introduced a breakup fee in their merger negotiations that would compensate one side if regulators reject the deal  though it is possible one will be agreed to by the time the deal is signed  the sources said  Investors have been waiting for the deal to be announced since Reuters first reported last month that T Mobile and Sprint were close to agreeing tentative merger terms  Sprint shareholders are expected to receive little to no premium in the deal  meaning that Japan s SoftBank Group Corp  T 9984   which controls Sprint  and other Sprint shareholders will own around or more than 40 percent of the combined company  T Mobile majority owner Deutsche Telekom AG  DE DTEGn  and the rest of the T Mobile shareholders will own the remainder   
It is still possible that the negotiations between T Mobile and Sprint will conclude without a deal  the sources have cautioned ",2017-10-16,Reuters,https://www.investing.com/news/stock-market-news/exclusive-tmobile-sprint-aim-to-announce-merger-without-asset-divestitures--sources-541695,541695
141546,363061,HUM,Centene On Track With Inorganic Strategies To Aid Growth,opinion,Centene Corp    NYSE CNC   is well poised for long term growth on the back of its successful acquisition profile  which complements its organic growth The company has  to its credit  a number of acquisitions  The most notable ones are that of Fidelis Care  made last year  which expanded Centene s scale and size in New York State  and MHM Services  a behavioral healthcare company  Its acquisition of Health Net in 2016 also broadened the service offerings   Further  the company has also made small purchases that act as bolt on to its existing business The company s membership  revenue and earnings growth in 2018 was primarily driven by the Fidelis Care acquisition  Health Net also accrued to the company s 2017 earnings and revenues  This reinforces its success at integrating acquisitions Notably  it recently inked a deal to buyout WellCare Health Plans Inc    NYSE WCG   for about  17 3 billion The deal is expected to generate nearly  500 million of cost synergies by the second year of the takeover and add to adjusted EPS by mid single digit percent The deal will broaden Centene s government business that consists of Medicaid and Medicare and will place it at the 5th position in the health insurance industry with respect to pro forma revenues and EBIDTA It will also make Centene the number one player in the Medicaid market  accounting for 65  of the combined company s total revenues   This market is expected to grow as many states are adopting Medicaid expansion   Other niche players in this market are Molina Healthcare Inc    NYSE MOH   and Humana Inc    NYSE HUM  The company inorganic growth strategies have sided an impressive operating performance  having generated shareholders  return of nearly 935  since 2010   Its membership has grown since then from 1 5 million to 14 5 million till 2018  Furthermore  it expects the same to increase to more than 22 million members in 2019 The company s acquisition strategy is backed by its financial strength and scale  which generates significant cash flow from operations   Though the WellCare buyout will increase leverage ratio  significant cash flow from operations will be used to bring down debt levels Centene carries a Zacks Rank  1  Strong Buy   Year to date  the stock has lost 0 6  against its  s growth of 2 5   The fall in price gives an attractive entry point as it is relatively undervalued and currently trading at a 12 month forward price to earnings ratio of 13 2  which compares with the industry s P E ratio of 15 6 Also  the stock carries an impressive Value Score of B  Our research shows that stocks with a Value Score of A or B when combined with a Zacks Rank  1 or 2  Buy  offer the best opportunities in the value investing space  You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-04-11,Zacks Investment Research,https://www.investing.com/analysis/centene-on-track-with-inorganic-strategies-to-aid-growth-200405913,200405913
141547,363062,HUM,White House says Trump opposes Senate s bipartisan Obamacare deal,news,"By Yasmeen Abutaleb and Amanda Becker WASHINGTON  Reuters    A bipartisan deal from two senators to stabilize Obamacare by restoring subsidies to health insurers suffered major setbacks on Wednesday with the White House saying President Donald Trump now opposes it and senior Republicans speaking out against it  House of Representatives Speaker Paul Ryan  Senate Finance Committee Chairman Orrin Hatch  Senate Republican leadership member John Thune and others expressed hostility to the deal announced on Tuesday by Republican Lamar Alexander and Democrat Patty Murray  It was uncertain if it would ever come to a vote in a Congress controlled by Trump s fellow Republicans  The agreement would shore up Obamacare by reviving billions of dollars of federal subsidies to insurers for two years to help lower income Americans obtain medical coverage  Alexander said on Wednesday that Trump had  completely engineered  the bipartisan proposal  but the president backed away from support he had expressed a day earlier  On Tuesday  Trump said the White House was involved in the negotiations and that the agreement was  a very good solution  for a short term approach  but said on Wednesday he could  never support bailing out  insurance companies  Trump has cut off subsidies to the companies  saying Congress has not provided money for them and that they enrich insurers  White House spokeswoman Sarah Sanders said Trump did not support the deal in its current form  although she called it  a good step in the right direction    Look  we ve said all along that we want something that doesn t just bail out the insurance companies but actually provides relief for all Americans   she said at a briefing   And this bill doesn t address that fact   BILL S FATE AN  OPEN QUESTION  The confusion among lawmakers in both parties over Trump s position on the healthcare deal and the lack of trust some of them have in the president come as Congress is entering a crucial period when important bills on federal spending  the U S  debt limit and tax cuts are due for consideration  Thune said the agreement might have  stalled out  and that its future was an  open question   Republicans have a 52 48 Senate majority  but other than Alexander only a few have publicly embraced the plan  including Senators John McCain  Susan Collins  Lisa Murkowski  Mike Rounds and Bob Corker   No way to pay for it   Hatch said   Oh my gosh  give me a break  I appreciate the innovation and the attempt to do it right  But it doesn t help   Trump  who campaigned on a promise to get rid of Obamacare but has been frustrated by the failure of Republicans in Congress to pass legislation to do so  also made clear he wanted broader legislation to repeal and replace the law   Lamar Alexander s working on it very hard from our side  And if something can happen  that s fine   Trump told reporters at the White House   But I won t do anything to enrich the insurance companies      They ve been enriched by Obamacare like nothing anybody s ever seen before   Insurers say they do not profit from the subsidies under the Affordable Care Act  former Democratic President Barack Obama s signature legislative achievement dubbed Obamacare  but pass them on directly to consumers to reduce deductibles  co payments and other out of pocket medical expenses for low income people  Ending the subsidies  which are called cost sharing reduction payments  could create chaos in the 2018 health insurance markets set up under Obamacare  Some leading insurers  including UnitedHealth Group  NYSE UNH    Aetna Inc   NYSE AET  and  Humana Inc   NYSE HUM   have largely exited those markets  citing financial losses  Others including Anthem Inc have significantly reduced their presence in the state based markets  Ryan gave no indication of willingness to consider the Alexander Murray agreement   The speaker does not see anything that changes his view that the Senate should keep its focus on repeal and replace of Obamacare   Ryan spokesman Doug Andres said   HOW HIGH   The proposal drew broad Democratic support  Top Senate Democrat Chuck Schumer ripped Trump for his shifting stances on the Alexander Murray deal   This president cannot govern if  whenever the hard right frightens him and says   Jump   he says   How high    Schumer told reporters   The president is pointing fingers   Schumer said   He blames  Senate Majority Leader  Mitch McConnell for obstruction  He blames the Democrats for obstruction  He s the obstructionist in chief because he cannot stick to a position   The proposal would meet some Democratic objectives  such as reviving subsidies for Obamacare and restoring  106 million in funding for a federal program that helps people enroll in insurance plans  In exchange  Republicans would get more flexibility for states to offer a wider variety of health insurance plans while maintaining the requirement that sick and healthy people be charged the same rates for coverage  Democratic attorneys general from 18 states and the District of Columbia who have filed a legal challenge to the subsidy cutoff asked a judge in California to direct the administration by Thursday to continue the payments  Murray  speaking to Reuters on Wednesday  said her agreement with Alexander was still very much alive  
 Absolutely   Murray said   Lamar and I are working to have a good set of co sponsors   and hope to formally introduce it as a Senate bill on Thursday ",2017-10-18,Reuters,https://www.investing.com/news/politics-news/senate-backers-of-deal-to-stabilize-obamacare-seek-to-build-support-543315,543315
141548,363063,HUM,The Zacks Analyst Blog Highlights  McDonald s  Enterprise Products Partners  Charles Schwab  BB T And Humana,opinion,"For Immediate Release
Chicago  IL   April 12  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  McDonald s   NYSE MCD    Enterprise Products Partners   NYSE EPD    Charles Schwab   NYSE SCHW    BB T Corp   NYSE BBT   and Humana   NYSE HUM   
Here are highlights from Thursday s Analyst Blog  
Top Research Reports for McDonald s  Enterprise Products   Charles Schwab
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including McDonald s  Enterprise Products Partners and Charles Schwab  These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
McDonald s shares have gained  17 1  in the past year  underperforming the Zacks Restaurants industry which has gained  19 4  over the same period  The Zacks analyst thinks high labor costs and currency headwinds remain major concerns 
Moreover  revenues have been under pressure for quite some time due to strategic refranchising initiatives  Even its heightened focus on refranchising might cut the capital requirements and facilitate EPS growth  McDonald s margins have been under pressure from worldwide wage increases 
However  McDonald s impressive earnings surprise history  various sales and digital initiatives  as well as positive comparable sales  bode well  In fact  global comps at McDonald s have been positive over the trailing 14 quarters 
Furthermore  increased focus on delivery and accelerated deployment of Experience of the Future restaurants in the United States should boost its performance  These apart  efforts to drive growth in International Lead   High Growth Markets bode well 
Shares of Buy ranked Enterprise Products have gained  6 9  over the past three months  outperforming the Zacks Oil Production Pipeline MLP industry s increase of  5 4   The Zacks analyst likes Enterprise Products  extensive network of pipelines that is spread across nearly 50 000 miles 
Importantly  the pipeline network  which is connected to every major U S  shale play  provides services to producers and users of commodities by transporting gas  liquids  and refined products  At present  Enterprise s  5 1 billion pipeline of fee oriented midstream projects positions it to enjoy above average growth in distributable cash flow over the next two years  in turn expanding its distribution coverage ratio 
Most importantly  its ethane export facilities in the Gulf Coast  which link domestic producers to the overseas market  should drive further growth as the use of ethane is rapidly increasing to manufacture plastic instead of naphtha  As such  the partnership holds tremendous upside potential 
Schwabshares have outperformed the Zacks Investment Brokers industry over the past year  declining  14 5  vs   19 4   The Zacks analyst likes Schwab s impressive earnings surprise history  having surpassed expectations in each of the trailing four quarters  Estimates have been stable lately ahead of the company s first quarter 2019 earnings release 
The company remains well positioned to gain from the higher interest rates and its initiatives to strengthen trading income  Also  the company s efforts to improve operating efficiency will go a long way to support profitability  Its efficient capital deployment activities reflect a strong balance sheet position 
However  continuously rising operating expenses are likely to hurt bottom line growth to an extent  Moreover  the company s significant dependence on fee based revenues remains a major concern as it might hamper financials 
Other noteworthy reports we are featuring today include BB T Corp and Humana 
Breakout Biotech Stocks with Triple Digit Profit Potential
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better 

Media Contact
Zacks Investment Research
800 767 3771 ext  9339
 
 
Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ",2019-04-11,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-mcdonalds-enterprise-products-partners-charles-schwab-bbt-and-humana-200406342,200406342
141549,363064,HUM,Why Humana  HUM  Is Poised To Beat Earnings Estimates Again,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  Humana  HUM   which belongs to the Zacks Medical   HMOs industry  could be a great candidate to consider 
This health insurer has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 5 75  
For the most recent quarter  Humana was expected to post earnings of  2 53 per share  but it reported  2 65 per share instead  representing a surprise of 4 74   For the previous quarter  the consensus estimate was  4 29 per share  while it actually produced  4 58 per share  a surprise of 6 76  
Price and EPS Surprise

For Humana  estimates have been trending higher  thanks in part to this earnings surprise history  And when you look at the stock s positive Zacks Earnings ESP  Expected Surprise Prediction   it s a great indicator of a future earnings beat  especially when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Humana has an Earnings ESP of  0 84  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  3  Hold   it shows that another beat is possibly around the corner  The company s next earnings report is expected to be released on May 1  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-04-15,Zacks Investment Research,https://www.investing.com/analysis/why-humana-hum-is-poised-to-beat-earnings-estimates-again-200407343,200407343
141550,363065,HUM,Is A Beat In The Cards For Anthem s  ANTM  Q1 Earnings ,opinion,Anthem Inc    NYSE ANTM   will release first quarter 2019 results on Apr 24 before market open  In fourth quarter 2018  the company delivered a positive earnings surprise of 10 9   driven by a solid operating performance and increased contribution from its Government business and Commercial   Specialty Business segments Let s see  how things are shaping up for this announcement The Zacks Consensus Estimate for earnings is pegged at  5 86  up 8 3  year over year  This upside would likely be supported by a robust operating performance and strength displayed at all its businesses Anthem s revenues have been rising over the last few quarters  The Zacks Consensus Estimate for first quarter revenues is pegged at  24 3 billion  up 8 5  year over year  Both its Government business and Commercial   Specialty Business segments are likely to contribute to the bottom line  The consensus mark for the Commercial Business segment and the Government business is expected to witness a respective year over year rise of 14 3  and 3 1  in revenues Total medical membership for the first quarter is likely to grow owing to the company s constant efforts to boost its portfolio  Higher membership is expected in Medicare business as the company is thoroughly focusing on growing this line of business  The company expects Medicare Advantage membership to be more than 1 50 000 in the first quarter of 2019  The Zacks Consensus Estimate for total membership stands at 41 4 million  up 4 6  year over year However  we predict an increase in the selling  general and administrative expense ratio as the company escalates investment in areas  such as technology modernization  population and consumer digital health plus data analytics and product development capabilities What the Quantitative Model StatesOur proven model conclusively shows that Anthem is likely to beat on earnings this time around  This is because the stock has the right combination of a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Earnings ESP  Anthem has an Earnings ESP of  1 29   This is because the Most Accurate Estimate is pegged at  5 94  higher than the Zacks Consensus Estimate of  5 86  You can uncover the best stocks to buy or sell before they are reported with our  Anthem  Inc  Price and EPS Surprise   Zacks Rank  Anthem carries a Zacks Rank  2  which increases the predictive power of ESP  Along with a positive ESP in the combination  chances of an earnings beat are significantly higher for the stock this reporting cycle Conversely  the Sell rated stocks   4 or 5  should never be considered going into the earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks to ConsiderSome other stocks worth considering from the Health Maintenance Organization industry with the perfect combination of elements to also surpass estimates in the next releases are as follows WellCare Health Plans  Inc    NYSE WCG   is set to report first quarter 2019 earnings on Apr 30  The stock has an Earnings ESP of  1 91  and a Zacks Rank  3  You can see  Molina Healthcare  Inc    NYSE MOH   is set to report first quarter earnings on Apr 29  The stock has a Zacks Rank of 1 and an Earnings ESP of  3 49  Humana Inc    NYSE HUM   has an Earnings ESP of  0 84  and a Zacks Rank of 3  The company is set to report first quarter earnings on May 1 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-17,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-anthems-antm-q1-earnings-200408511,200408511
141576,363091,HUM,Healthcare sector erases losses as McCain just doomed Obamacare repeal,news,The Health Care SPDR  NYSEARCA XLV  had been in the red this session  but it s returned to flat after the Arizona Senator says he won t vote for Graham Cassidy  The GOP could theoretically still pass the bill  but that would require getting  yes  votes from two of three from the Collins  Murkowski  and Paul trio Hospital names are moving higher  and insurers as well  some remain in red  but are well off lows    Centene   CNC  2 4    Molina  MOH  5 2    UnitedHealth  UNH  1    WellCare  WCG  0 7    Aetna  AET  0 1    Cigna  CI  0 2    Humana  HUM  0 1  ETFs  XLV  VHT  IYH  HQH  CURE  THQ  FHLC  FXH  RXL  RYH  RXD  SICK  LNGR  BTEC  JHMH  HCRFNow read ,2017-09-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare-sector-erases-losses-as-mccain-just-doomed-obamacare-repeal-531984,531984
141577,363092,HUM,Senator McCain opposes Obamacare repeal bill  a possible fatal blow,news,"By Susan Heavey and Susan Cornwell WASHINGTON  Reuters    U S  Senator John McCain said on Friday he opposes the latest Republican bill to dismantle Obamacare  dealing the measure what could be a fatal blow given the party s slim Senate majority  With several other Republicans still undecided on the measure  Senate Majority Leader Mitch McConnell said earlier this week he intended to bring it to the Senate floor for a vote next week  though he did not promise to do so  A vote would set the stage for another dramatic Capitol Hill decision on the 2010 law that brought health insurance to millions of Americans and became former Democratic President Barack Obama s signature domestic achievement  For seven years  Republicans have hammered Obamacare as an unwarranted government intrusion into American healthcare  President Donald Trump made repealing Obamacare one of his top campaign promises in 2016  Democrats have fiercely defended it  The announcement by McCain  a Republican who has often been at odds with Trump and who cast a crucial  no  vote in July that helped defeat an earlier Republican repeal bill  had the potential to up end McConnell s plans  McConnell s office did not immediately respond to requests for comment  At a rally in Alabama  Trump said McCain s decision was  totally unexpected  terrible   Despite the setback  Trump said   We still have a chance  We re going to do it eventually   Republicans have only a narrow Senate majority and cannot afford to lose many votes on the bill  They are also on a tight timetable  McConnell has been trying to schedule a vote on the bill by Sept  30  the last day on which the bill could pass with only a simple majority of 51 votes in the Senate  A vote taken any later than that would have to garner at least 60 votes for passage  Weeks after the humiliating defeat in July  when the Obamacare repeal fight seemed to be over  the current bill was introduced by Republican Senators Bill Cassidy and Lindsey Graham  a close friend of McCain s  and seemed to gain momentum  MCCAIN SAYS DETAILS ON IMPACT NEEDED But McCain on Friday laid out his opposition in a statement   I cannot in good conscience vote for the Graham Cassidy proposal   He said he took no pleasure in announcing his opposition and noted that the bill s authors  are my dear friends   McCain complained about the rushed process Republicans used to push the bill forward  He said he would consider supporting a bill like it if it had emerged from extensive hearings  debate and amendment   But that has not been the case   he said   McCain  who cast his  no  vote in July just days after being diagnosed with an aggressive brain cancer  said he could not support the bill without knowing how much it would cost  how it would affect insurance premiums and  how many people will be helped or hurt by it   information that will not be available until the non partisan Congressional Budget Office provides a full assessment at the end of September  The Graham Cassidy bill would take federal money spent on the Medicaid program for the poor and disabled  as well as subsidies to help Americans buy private insurance  and divvy it up to the states in block grants  Advocates say that would give states more discretion to manage their own healthcare schemes  Although the CBO has not yet fully assessed the bill s effects  independent analyses indicate it would fundamentally redistribute federal healthcare money  generally with Republican leaning states benefiting and Democratic leaning states losing  largely because a majority of the states that opted to expand Medicaid under Obamacare were Democratic leaning  A Washington Post ABC News opinion poll said Americans prefer Obamacare to the Graham Cassidy alternative by 56 percent to 33 percent  Graham said in a statement he was not giving up   We press on   he said  Shares of health insurers turned up after McCain announced his oppositions  Centene ended 1 6 percent higher while Humana  NYSE HUM  closed up 0 2 percent  reversing earlier losses   WINNERS AND LOSERS AMONG STATES  State by state impacts from Graham Cassidy would vary  the Axios news website reported on Friday  citing a study by the Centers for Medicare and Medicaid Services  CMS   the unit of the Department of Health and Human Services that oversees Medicaid and the Obamacare program  The CMS study found that by 2026  Alaska would lose 38 percent of its federal funding for insurance subsidies and Medicaid  Arizona would lose 9 percent  Maine would gain 44 percent  Ohio would lose 18 percent  and West Virginia would lose 23 percent  Axios reported  These states are home to Republican senators who are under pressure on healthcare  Both of Alaska s Republican senators  Lisa Murkowski and Dan Sullivan  are still on the fence over Graham Cassidy  The CMS had no immediate comment on the Axios report  Besides McCain  Kentucky s Rand Paul is the only other Republican senator who has publicly said he opposes the bill  Maine s Susan Collins said she was leaning against the bill  the Portland Press Herald newspaper reported on Friday  Kansas  Jerry Moran is also undecided  No Democrats support the bill  To pass Graham Cassidy  the Republicans need at least 50 votes in the 100 seat Senate  which they control 52 48  with Vice President Mike Pence casting a potential tie breaking vote  The insurance industry  hospitals  medical advocacy groups such as the American Medical Association  American Heart Association and American Cancer Society  the AARP advocacy group for the elderly and consumer activists oppose the bill  
The Center on Budget and Policy Priorities  a liberal think tank in Washington  estimated the bill would cause more than 30 million people to lose insurance ",2017-09-22,Reuters,https://www.investing.com/news/world-news/senates-mccain-opposes-obamacare-repeal-bill-532004,532004
141578,363093,HUM,Trump pressures U S  senators to back Republican healthcare bill,news,"By Amanda Becker WASHINGTON  Reuters    U S  President Donald Trump on Saturday blasted Senator John McCain for dealing a possibly fatal blow to the latest Republican attempt to dismantle Obamacare  According to a new independent analysis  the bill awaiting a Senate vote could lead to 21 million fewer Americans having health insurance  McCain  an Arizona Republican who is being treated for brain cancer and cast a crucial  no  vote to defeat a similar bill in July  said on Friday that he could not  in good conscience  vote for the proposal authored by Republican Senators Bill Cassidy and Lindsey Graham   He campaigned on Repeal   Replace  Let Arizona down   Trump wrote about McCain on Twitter early Saturday morning  Senate Majority Leader Mitch McConnell has said he will schedule a vote on the Graham Cassidy bill by Sept  30  the last day when it could pass in the chamber with a simple majority of 51 votes instead of the 60 typically required  The bill would take federal money spent on the Medicaid program for the poor and disabled  as well as subsidies to help individuals buy private insurance  and deliver it to the states in block grants   The non partisan Congressional Budget Office  which analyzes legislation  has not had time to assess the Graham Cassidy bill before the expected vote  McCain  a close friend of Graham  said he could not support it without knowing how much it would cost  its effect on insurance premiums  and how many people would be affected  But the Brookings Institution said on Friday that the Graham Cassidy bill could leave at least 21 million fewer Americans with health insurance by 2020 to 2026  The Washington think tank has generally been supportive of Obamacare  which is formally known as the Affordable Care Act   The coverage estimate  likely understates  reductions in insured Americans because it is not clear how states would use the money or if they would face obstacles in setting up new programs  according to Brookings researchers   What is clear  however  is that the legislation would result in very large reductions in insurance coverage   they wrote  Late Saturday  six associations representing U S  doctors  hospitals and insurers said they opposed the bill because it would cause patients with pre existing conditions to lose coverage and result in more expensive health insurance   The Senate should reject it   the groups said in a statement   U S  Department of Health and Human Services Secretary Tom Price told Fox News Channel s  America s News HQ  on Saturday that he is  providing technical assistance and information  to senators working on the bill   Price said that the bill was  not dead  despite McCain s announcement and wavering support from several other Republican senators   The reason it s not dead is because it s not finished  The bill hasn t been completed  We continue to work with the authors on it through this weekend   Price said  The Senate Finance Committee on Monday will hold a hearing on the Graham Cassidy bill  Cassidy  a physician  is expected to testify  CBO estimates of previous Republican proposals showed they could lead to more than 20 million fewer insured Americans  This complicated passage in the 100 member Senate  where Republicans hold 52 seats and Democrats are unanimously opposed to repeal and replace measures   Republicans need at least 50 votes to pass the bill  relying on Vice President Mike Pence to break a tie  Republican Senator Susan Collins of Maine has said she was leaning against the Graham Cassidy bill  as has Senator Rand Paul of Kentucky  Kansas Senator Jerry Moran and Alaska s Lisa Murkowski are undecided  After blasting McCain  Trump on Saturday singled out Paul and Murkowski   I know Rand Paul and I think he may find a way to get there for the good of the Party   Trump wrote on Twitter  Regarding Murkowski  he tweeted that in Alaska   Deductibles high  people angry    The insurance industry  hospitals  consumer activists  the AARP advocacy group and organizations such as the American Medical Association  American Heart Association and American Cancer Society all oppose the bill   
Shares of some health insurers closed higher on Friday after McCain announced his opposition  Centene Corp ended up 1 6 percent  while  Humana Inc   NYSE HUM  gained 0 2 percent and  Aetna Inc   NYSE AET  rose 0 1 percent  reversing earlier losses ",2017-09-23,Reuters,https://www.investing.com/news/politics-news/trump-pressures-senators-to-back-republican-healthcare-bill-532145,532145
141579,363094,HUM,U S  Senate opposition to Obamacare repeal bill grows,news,"By Richard Cowan WASHINGTON  Reuters    A proposal by U S  Republicans to repeal and replace the Obamacare health insurance program suffered serious new setbacks within the party on Sunday  when Senator Ted Cruz expressed his opposition and Senator Susan Collins dug in with strong criticism of the legislation  Two other Republican senators  John McCain and Rand Paul  already said last week they would vote against the so called Graham Cassidy bill  One more  no  vote among Republicans would effectively kill the party s latest effort in their seven year mission to overturn Obamacare  while dealing a new blow to President Donald Trump  Senate Majority Leader Mitch McConnell  a Republican  has said he  intends  to put the bill up for a vote this week  but he has withheld public comment over the past few days as some of his rank and file Republicans abandoned Trump  Treasury Secretary Steven Mnuchin  interviewed on CNN s  State of the Union   reflected the uncertainty in the battle   It is going to be very close  I hope it passes   he said   Phil Novack  a spokesman for Cruz  confirmed that the Republican senator said at an event in Texas   Right now  they don t have my vote  and I don t think they have  Senator  Mike Lee s vote  either   Lee is a conservative Republican and close ally of Cruz  A spokesman for Lee said the senator wanted  some technical changes  to the legislation  but did not provide details   We haven t committed to anything yet   Conn Carroll said in an email  Politico reported that Cruz complained that the latest Obamacare repeal bill did not address his concerns about bringing down the costs of healthcare  On Friday  news of McCain s opposition sent shares of health insurance companies up  Centene ended 1 6 percent higher and Humana  NYSE HUM  closed up 0 2 percent  Trump has pressured his fellow Republicans for quick passage on what would be his first victory on major legislation  All Democrats are expected to vote against it   COLLINS SUPPORT IN DOUBT But Collins  perhaps the most moderate of Republican senators  appeared poised to oppose her party s latest replacement plan for the Affordable Care Act  former Democratic President Barack Obama s signature legislative achievement  She  along with McCain and Alaska Senator Lisa Murkowski  voted in July against an earlier version of Obamacare repeal   It is very difficult for me to envision a scenario where I would end up voting for this bill   Collins said on CNN s  State of the Union  on Sunday  two days after saying she was  leaning against  the legislation   Collins said her concerns centered on the impact the legislation would have on the federal Medicaid program  which helps disabled children and low income elderly people get healthcare  The Senate  which Republicans control by 52 48  faces a Saturday deadline for deciding on the bill under an expiring rule that lets the healthcare proposal pass with just a simple majority in the 100 member chamber  instead of the 60 vote threshold needed for most legislation  Paul  interviewed on NBC s  Meet the Press   attacked the centerpiece of the Republican bill that would have the federal government basically turn the health insurance system over to states in the form of  block grants     They could remove the block grants from it  and we can vote on what we actually agree on   Paul said   I can t in good conscience vote to keep all the spending   Some key Senate Republicans were still pushing to forge ahead  Senator Lindsey Graham  who is leading the charge on the latest version of Obamacare repeal  told ABC he believed he would have the votes to pass the legislation   The only way you know how people will vote is you have the vote   he said   
Graham did not detail the path he sees to victory ",2017-09-24,Reuters,https://www.investing.com/news/politics-news/senator-collins-leaning-against-voting-for-republican-healthcare-bill-532215,532215
141580,363095,HUM,As 2018 Obamacare deadline nears  U S  states believe every county covered,news,"By Caroline Humer NEW YORK  Reuters    U S  states have negotiated to the bitter end to keep health insurers selling Obamacare plans in every county next year  in some cases taking a hard line to prevent exits that leave residents without access to health coverage  But states cannot rule out a last minute pullout by an insurance company   Insurers must sign government contracts detailing where they will offer 2018 coverage by midnight on Wednesday  In recent months  dozens of U S  counties risked having no insurer offering subsidized individual insurance next year after national players including Anthem Inc   Aetna Inc   NYSE AET  and  Humana Inc   NYSE HUM  announced plans to pull out     Many insurers have lost money on their Obamacare business  Others fear exposure to a program targeted by President Donald Trump and the Republican controlled Congress for repeal  Trump has also threatened to cut billions in subsidy payments to insurers to undermine predecessor Barack Obama s healthcare law  Still  insurance commissioners in Republican leaning states such as Tennessee  Missouri  and Virginia spent months negotiating with insurers to see who might pull out of their markets and either convince them to stay  or find a replacement  By Tuesday  it appeared they had succeeded in keeping every county covered in all states  But individuals will still face challenges  Nearly half of U S  counties have no choice  with only one insurer offering individual plans  And many insurers filed price hikes of 20 percent or more to offset the political uncertainty  Some states still fear a last minute surprise   My colleagues and I are still very concerned that today insurers are making a decision about whether or not to participate   Tennessee insurance commissioner Julie McPeak said   That makes us nervous   After Humana said it would exit the Obamacare business entirely  leaving the Knoxville area with no insurer  Blue Cross Blue Shield of Tennessee said it would step into the region  Georgia regulators warned Anthem that it could not sell in the state for five years if it left any bare counties  Deputy Insurance Commissioner Jay Florence said  As a result  after first proposing to stay in just one county next year  Anthem only left markets in Georgia where it could be sure at least one other insurer is offering coverage  In Virginia  Anthem planned an exit that would have left more than 60 counties without any individual insurance options  but changed course two weeks ago after discussions with the state   Bare counties is a highly political issue and health plans have been concerned about the consequences of being called out publicly   said Caroline  Pearson   LON PSON   senior vice president at healthcare consultancy Avalere Health  SCANT COMPETITION  HIGH PRICES The push could not preserve competition in many states  In 2018  nearly half of U S  counties will have only one insurer offering individual plans  according to federal data  In 2017  a third of counties had only one insurer  In 2016  only 7 percent of counties had only a single choice  But it did convince some to alter plans  Molina Healthcare said in July it would exit two states and was considering further departures   In the end  it is remaining in seven states where it sells individual plans   include California  Florida  Michigan  New Mexico  Ohio  Texas and Washington   a spokeswoman said Tuesday   Cigna Corp   NYSE CI   which had planned to sell Obamacare coverage in six states for 2018  said it will make final details public after the deadline  Anthem and HealthCare Services Corp  which runs Blue Cross Blue Shield in Illinois  Texas and other states  did not comment further on their plans  Such insurers will wade into 2018 Obamacare markets with no certainty over the program s fate  Senate Republicans on Tuesday failed again to muster enough votes to repeal and replace the 2010 Affordable Care Act  but vowed to revive the effort in the coming months after tackling tax reform  State health commissioners allowed them to propose monthly premium increases of 20 percent  or even more  from 2017 to compensate for the uncertainty  
 We didn t really have much choice   McPeak of Tennessee said   We were fearful that insurers  if they filed lower rates  would decide not to come into the market  ",2017-09-27,Reuters,https://www.investing.com/news/politics-news/as-2018-obamacare-deadline-nears-us-states-believe-every-county-covered-533355,533355
141581,363096,HUM,Why Is Humana  HUM  Down 11 7  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Humana  HUM   Shares have lost about 11 7  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Humana due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Humana s Q4 Earnings Surpass Estimates  Improve Y YHumana s fourth quarter 2018 operating earnings per share of  2 65 beat the Zacks Consensus Estimate by 4 7   The bottom line also improved 28 6  year over year  This upside can primarily be attributed to Medicare Advantage membership growth and significant operating efficiency Operational UpdateRevenues of  14 2 billion were up nearly 9  in the fourth quarter  Moreover  the top line surpassed the Zacks Consensus Estimate of  13 9 billion by 2 2  year over year Adjusted consolidated pre tax income of  480 million declined 16 7   primarily due to rise in outpatient spending in the Retail segment  However  this downside was partially offset by the persistence of lower inpatient medical utilization Benefit ratio expanded 40 basis points to 83 4  Operating cost ratio deteriorated 110 basis points to 15  Segmental ResultsRetailRevenues from the Retail segment were  12 04 billion  up 10  year over year  This can primarily be attributed to higher revenues from the company s individual and group Medicare Advantage membership strength and improved per member premiums for a few segments  products Benefit ratio of 84  expanded 20 bps year over year  primarily owing to reinstatement of the non   deductible health insurance industry fee The segment s operating cost ratio of 12 9  deteriorated 110 bps year over year  This was mainly due to the reinstatement of the non   deductible health insurance industry fee in the year  rise in incentive compensation costs and strategic investments in the fourth quarter of 2018 as a result of the Tax Reform Law Group and SpecialtyRevenues from the Group and Specialty segment were  1 91 billion  up 1  from the prior year quarter  primarily backed by higher stop   loss premiums related to the company s level   funded ASO accounts and rise in per member premiums across the commercial fully   insured business   Benefit ratio expanded 150 bps year over year to 84 6   driven by retroactive contractual rate adjustments  membership mix  impact of the exit of the Workplace Voluntary Benefit  WVB  and Financial Protection Products  FPP  of business in the second quarter Operating cost ratio deteriorated 200 bps year over year to 23 9  Healthcare ServicesRevenues of  6 19 billion increased 3  year over year  primarily owing to Medicare Advantage membership growth  rise in intersegment revenues associated with certain buyouts and favorable external services revenues Operating cost ratio deteriorated 80 bps year over year to 96 8  Individual CommercialHumana exited this business effective Jan 1  2018 and consequently  the result reflects its run out  The segment incurred  2 million loss in the reported quarter compared with segment losses of  14 million in the year ago quarter Financial UpdateAs of Dec 31  2018  the company had cash  cash equivalents and investment securities of  12 4 billion  down 9  from 2017 end level Debt to total capitalization as of Dec 31  2018 was 37 4   up 410 bps from Dec 31  2017 Operating cash outflow totaled  333 million in the fourth quarter against cash inflow of  218 million in the year earlier quarter Capital DeploymentThe company paid cash dividends worth  69 million in the fourth quarter of 2018 Last November  it entered into an agreement to affect a  750 million ASR program under its current share repurchase authorization  During the fourth quarter  the company bought back shares worth  600 million 2019 GuidanceFor 2019  Humana expects adjusted EPS in the range of  17  17 50  Consolidated revenues is expected to be in between  63 1 billion to  63 7 billion  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates 
VGM Scores
At this time  Humana has a nice Growth Score of B  though it is lagging a bit on the Momentum Score front with a C  However  the stock was allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending upward for the stock  and the magnitude of these revisions looks promising  Notably  Humana has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-03-07,Zacks Investment Research,https://www.investing.com/analysis/why-is-humana-hum-down-117-since-last-earnings-report-200395819,200395819
141582,363097,HUM,Why Is It Worth Keeping Humana  HUM  In Your Portfolio Now ,opinion,"Humana Inc    NYSE HUM   is well poised for growth on the back of robust Medicare business and strategic initiatives  The company has an impressive  of B and this style score analyzes its growth prospects The company flaunts a commendable earnings surprise history  having exceeded the Zacks Consensus Estimate in the trailing 12 quarters  reflecting operating excellence  It expects 2019 adjusted EPS in the range of  17  17 50  translating into year over year growth of 18 6   Consolidated revenues are anticipated between  63 1 billion and  63 7 billion  up 11  year over year  This strong guidance instills investor confidence in the company Its return on tangible equity   a profitability measure   stands at 31 5  against its industry s negative 107 24  Over the past 30 days  the company s earnings estimate for 2020 have been revised 0 1  upward  This in turn  reflects analysts  optimism on the stock Humana s Medicare business has been performing strongly over the last several quarters on the back of solid operating initiatives  Strength in Medicare Advantage performance resulted in a better 2018 Retail segment benefit ratio  evident from higher Medicare membership by 54  from 2013 to 2018  The company expects 2019 individual Medicare Advantage to grow 12 13 The company has also been making concerted efforts in executing strategic buyouts to fuel its business growth Humana is prudently deploying excess capital for the past several years that remains impressive for investors  While It has been hiking its dividend since 2011  during last November  the company inked a deal to effect a  750 million ASR program under its current share repurchase authorization  We believe that its financial strength will continue to boost investor confidence in the stock  Cash flow from operations for 2019 is projected between  2 5 billion and  2 9 billion However  Humana has been persistently witnessing a rise in operating expenses since 2010  The company expects to further witness an elevation in benefit expenses  which will induce overall higher operating expenses  Rising expenses are also likely to hurt the bottom line  Shares of this Zacks Rank  3  Hold  company have gained 3 2  in a year s time  underperforming its industry s rise of 11 1  The company is well placed for growth  evident from its favorable   of A  Here V stands for Value  G for Growth and M for Momentum with the score being a weighted combination of all three factors The long term earnings growth rate is expected at 13 9   above the  s average of 12 8   which is an upside for the company Stocks to ConsiderInvestors interested in the medical sector can take a look at some better ranked stocks like UnitedHealth Group Incorporated   NYSE UNH    Centene Corporation   NYSE CNC   and WellCare Health Plans  Inc    NYSE WCG    each currently carrying a Zacks Rank  2  Buy   You can see  UnitedHealth operates as a diversified health care company in the United States  In the last four quarters  the company delivered average beat of 3 39  Centene operates as a diversified and multi national healthcare enterprise in the United States  It came up with average earnings surprise of 4 99  in the trailing four quarters WellCare Health offers managed care services to government sponsored health care programs  The company pulled off average positive surprise of 15 43  in the preceding four quarters 
 Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-03-14,Zacks Investment Research,https://www.investing.com/analysis/why-is-it-worth-keeping-humana-hum-in-your-portfolio-now-200398230,200398230
141583,363098,HUM,Humana  Accolade To Team Up For Providing Advanced Healthcare,opinion,Humana Inc    NYSE HUM   and Accolade announced to have combined their expertise for offering differentiated healthcare and benefits to patients  With this deal  employers and their health plan members would be able to enjoy advantages of Humana s provider networks  They could benefit from innovative medical  dental  pharmacy  Employee Assistance Program  EAP   Work life Services and Go365 wellness reward program capabilities  This apart  Accolade s solid member engagement services  and health and benefits programs should continue to support In order to improve consumer engagement  experience  outcomes and expenses in healthcare  Humana with Accolade created an advanced platform and a customized advocacy solution for Humana s self funded employer clients along with their employees and families With a unique approach  Humana will integrate a wide range of data on Accolade s platform  which leverages machine learning intelligence  This in turn has the potential to decrease complexity and waste This tie up is yet another addition to Humana s effort to reinvent healthcare to cater to clients  It will not only be able to meet specific healthcare needs with this partnership but would also enhance its business  It constantly put in efforts to collaborate and buy companies to boost portfolio Some of the acquisitions made by the company will help it achieve long term growth  These include acquisitions of Family Physicians Group  Your Home Advantage  Curo and a share in Kindred at Home  which helped Humana to deepen its reach in the home health and hospice market  In the first half of 2018  the company was busy with the launch of Conviva and the acquisition of Orlando based Family Physicians Group Shares of this Zacks Rank  3  Hold  company have gained 3 7  in a year s time  underperforming its  s growth of 12 1   Its solid fundamentals like Medicare business and acquisitions and dispositions should continue driving the stock going forward   Stocks to ConsiderInvestors interested in the medical sector can take a look at some better ranked stocks like UnitedHealth Group Incorporated   NYSE UNH    Centene Corporation   NYSE CNC   and WellCare Health Plans  Inc    NYSE WCG    each currently carrying a Zacks Rank  2  Buy   You can see  UnitedHealth operates as a diversified health care company in the United States  In the last four quarters  the company delivered average beat of 3 39  Centene operates as a diversified and multi national healthcare enterprise in the United States  It recorded average earnings surprise of 4 99  in the trailing four quarters WellCare Health offers managed care services to government sponsored health care programs  The company pulled off average positive surprise of 15 43  in the preceding four quarters Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-03-17,Zacks Investment Research,https://www.investing.com/analysis/humana-accolade-to-team-up-for-providing-advanced-healthcare-200398661,200398661
141584,363099,HUM,Humana s Arm To Open 10 Medical Centers To Serve Seniors,opinion,Humana Inc  s   NYSE HUM   unit Partners in Primary Care will launch its unique  senior focused primary care model across 10 more locations in 2019  The company will open a chain of five medical centers in South Carolina and another five in Texas  All these centers are expected to be unveiled between June and September 2019 This subsidiary is part of the family of primary care centers that focuses on aging population and delivers care to 35 000 Medicare Advantage patients  Every Partners in Primary Care center caters to members from multiple Medicare health plans Like its current centers where a team of board certified physicians and care teams have been trained to serve the aging population  similar working personnel would be joining the new centers  Doctors spend more time with their patients while care teams make diligent efforts to create some tailor made care plans for the benefit of patients  providing them with the best health outcomes  They will continue to focus on the seniors  well being and their unique health needs in the new centers as well Partners in Primary Care will add five more care centers to its existing four centers in South Carolina along with penetrating the market in Houston  TX With the introduction of these centers  Humana remains committed to its focus on providing advanced care to seniors in the underserved locations Humana s Medicare business has been performing strongly over the last many quarters  The Medicare Advantage business has been delivering impressively owing to the company s operating initiatives  The solid Medicare Advantage performance led to an improved 2018 Retail segment benefit ratio  evident from 54  growth in Medicare membership from 2013 to 2018  Given the company s initiatives in this field  Medicare Advantage business is well poised for growth Shares of this Zacks Rank  3  Hold  company have slid 1 6  in a year s time against its  s rally of 11 5  Stocks to ConsiderInvestors interested in the medical sector can take a look at some better ranked stocks like Anthem Inc   NYSE ANTM    Centene Corporation   NYSE CNC   and WellCare Health Plans  Inc    NYSE WCG    You can see  Anthem and its subsidiaries operate as a health benefits company in the United States   In the last four quarters  the company delivered average beat of 7 1   It flaunts a Zacks Rank  1 Centene operates as a diversified  multi national healthcare enterprise in the United States  The company carries a Zacks Rank  2  Buy  and came up with average earnings surprise of 4 99  in the trailing four quarters WellCare Health offers managed care services to government sponsored health care programs  The company pulled off average positive surprise of 15 43  in the preceding four quarters  The stock has a Zacks Rank of 2 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-03-26,Zacks Investment Research,https://www.investing.com/analysis/humanas-arm-to-open-10-medical-centers-to-serve-seniors-200401501,200401501
141585,363100,HUM,2020 Medicare Rate Exceeds Proposal  Health Insurers To Gain,opinion,The Centers for Medicare and Medicaid Services  CMS   a division of the U S  Department of Health and Human Services  has decided to raise 2020 Medicare Advantage reimbursement rate by 2 53   In February  CMS had proposed a hike of 1 59  but the rate hike is higher than expected Medicare Advantage  MA  plans were initiated by the government some years ago to control the rising cost of Medicare  a government program for retirees  and were administered by private insurance companies  The health insurers often add extra benefits to make these plans more appealing to consumers  thus justifying its name   Medicare Advantage  The government reimburses a certain amount per enrolee to health insurers in return of the care provided Why is Government Pitching for High Reimbursement Rates The higher than proposed increase in reimbursement rate for 2020 is meant to attract private health insurers with the aim of increasing managed care participation  This move will alleviate government healthcare  which is reeling under high Medicare costs According to CBO  total Medicare spending is expected to grow 7  per year after 2018 to about  1 2 trillion by 2028   Medicare spending is anticipated to rise more rapidly relative to GDP owing to a number of factors  including a large aging population and faster growth in health care costs compared with growth in the economy on a per capita basis  In an effort to decrease the burden of rising healthcare costs  the government intends to rope in health insurers that are effective in managing costs In fact  the government has actually witnessed cost reduction by delegating Medicare to private players and is encouraging customers to opt for Medicare Advantage  The recent higher than expected rate highlights the government s efforts to stabilize these plans and provide enough resources to insurance companies to support beneficiaries enrolled in private Medicare plans Cash Cow for Health InsurersMeanwhile  these plans have been highly profitable for health insurers  Since MA members have higher medical utilization rates  they bring in about three times more revenues than commercial members  This trend has aided top line growth of the companies engaged in MA  Further  health insurers have been able to maintain profitability in these plans by keeping claim cost down via measures such as preventive healthcare and accountable care organizations  This business has proven to be a boon for the health insurance industry In a year s time  the  has gained 13 8  compared with the Zacks S P 500 composite growth of 12 2  Bottom LineGiven that MA is one of the few areas that has bipartisan support  its future appears bright  Industry analysts believe that the recent increase in reimbursement rates will lead to strong enrollment growth in this business in the next five years Some companies such as UnitedHealth Group Inc    NYSE UNH    Humana Inc    NYSE HUM    WellCare Health Plans Inc    NYSE WCG   and Anthem Inc   NYSE ANTM   with large exposure to MA business are set to gain Currently  Anthemsportsa Zacks Rank  1  Strong Buy  and Wellcare holds a Zacks Rank  2  Buy   UnitedHealth and Humana carry a Zacks Rank  3  Hold  each  You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-04-01,Zacks Investment Research,https://www.investing.com/analysis/2020-medicare-rate-exceeds-proposal-health-insurers-to-gain-200403048,200403048
141613,363128,HUM,Anthem to sell Obamacare health plans in Virginia counties that don t offer them,news,NEW YORK  Reuters    U S  health insurer Anthem Inc  N ANTM  said on Friday it plans to sell Obamacare health plans in 68 cities and counties in Virginia next year  covering the only remaining U S  counties that are currently without insurers offering the plans  Anthem said last month it was exiting the Obamacare market in the state  but reconsidered the move after no other insurer stepped up to cover most of Virginia s counties  The Centers for Medicare and Medicaid Services said earlier this week that 63 counties nationwide could be  bare counties   with no insurers selling the Obamacare plans  It said that 1 472 counties could have only one insurer in 2018  Insurers such as UnitedHealth Group Inc  N UNH    Aetna Inc   N AET  and  Humana Inc   N HUM  have exited most of the states where they sold Obamacare plans  They cited uncertainty over the healthcare legislation and whether the administration of U S  President Donald Trump will maintain subsidies that keep costs down  But other insurers  like  Centene  Corp  N CNC   have filled those gaps  expanding into new counties that had lost their coverage options  Earlier this week  a spokesperson for Virginia s insurance regulator said the state was in serious negotiations to bring in an insurer to cover its bare counties   Anthem has said that it is still working with some state regulators on its market participation for next year ,2017-09-15,Reuters,https://www.investing.com/news/stock-market-news/anthem-to-sell-obamacare-health-plans-in-virginia-counties-that-dont-offer-them-529518,529518
141614,363129,HUM,Is Humana  HUM  Stock Undervalued Right Now ,opinion,"Here at Zacks  our focus is on the proven Zacks Rank system  which emphasizes earnings estimates and estimate revisions to find great stocks  Nevertheless  we are always paying attention to the latest value  growth  and momentum trends to underscore strong picks 
Of these  perhaps no stock market trend is more popular than value investing  which is a strategy that has proven to be successful in all sorts of market environments  Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large 
In addition to the Zacks Rank  investors looking for stocks with specific traits can utilize our Style Scores system  Of course  value investors will be most interested in the system s  Value  category  Stocks with  A  grades for Value and high Zacks Ranks are among the best value stocks available at any given moment 
Humana  HUM  is a stock many investors are watching right now  HUM is currently holding a Zacks Rank of  1  Strong Buy  and a Value grade of A  The stock holds a P E ratio of 16 98  while its industry has an average P E of 17 24  Over the past 52 weeks  HUM s Forward P E has been as high as 22 59 and as low as 15 66  with a median of 19 42 
We also note that HUM holds a PEG ratio of 1 16  This popular figure is similar to the widely used P E ratio  but the PEG ratio also considers a company s expected EPS growth rate  HUM s PEG compares to its industry s average PEG of 1 27  Over the past 52 weeks  HUM s PEG has been as high as 1 81 and as low as 1 07  with a median of 1 41 
These are just a handful of the figures considered in Humana s great Value grade  Still  they help show that the stock is likely being undervalued at the moment  Add this to the strength of its earnings outlook  and we can clearly see that HUM is an impressive value stock right now ",2019-01-27,Zacks Investment Research,https://www.investing.com/analysis/is-humana-hum-stock-undervalued-right-now-200380020,200380020
141615,363130,HUM,Humana  HUM  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"Wall Street expects a year over year increase in earnings on higher revenues when Humana  HUM  reports results for the quarter ended December 2018  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on February 6  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This health insurer is expected to post quarterly earnings of  2 53 per share in its upcoming report  which represents a year over year change of  22 8  
Revenues are expected to be  13 92 billion  up 5 6  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1 19  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Humana 
For Humana  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 07  
On the other hand  the stock currently carries a Zacks Rank of  2 
So  this combination makes it difficult to conclusively predict that Humana will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Humana would post earnings of  4 29 per share when it actually produced earnings of  4 58  delivering a surprise of  6 76  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Humana doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-01-29,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-reports-next-week-wall-street-expects-earnings-growth-200381231,200381231
141616,363131,HUM,BioTelemetry  BEAT  Hits 52 Week High  Can The Run Continue ,opinion,"Have you been paying attention to shares of BioTelemetry  BEAT   Shares have been on the move with the stock up 26 7  over the past month  The stock hit a new 52 week high of  77 58 in the previous session  BioTelemetry has gained 28 1  since the start of the year compared to the 5 9  move for the Zacks Medical sector and the 15 8  return for the Zacks Medical Services industry 
What s Driving the Outperformance 
The stock has a great record of positive earnings surprises  as it hasn t missed our earnings consensus estimate in any of the last four quarters  In its last earnings report on October 30  2018  BioTelemetry reported EPS of  0 53 versus consensus estimate of  0 32 
For the current fiscal year  BioTelemetry is expected to post earnings of  1 78 per share on  398 9 million in revenues  Meanwhile  for the next fiscal year  the company is expected to earn  1 98 per share on  439 18 million in revenues  This represents a year over year change of  1 38  and 10 1   respectively 
Valuation Metrics
BioTelemetry may be at a 52 week high right now  but what might the future hold for the stock  A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level 
On this front  we can look at the Zacks Style Scores  as these give investors a variety of ways to comb through stocks  beyond looking at the Zacks Rank of a security   These styles are represented by grades running from A to F in the categories of Value  Growth  and Momentum  while there is a combined VGM Score as well  The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style 
BioTelemetry has a Value Score of D  The stock s Growth and Momentum Scores are A and C  respectively  giving the company a VGM Score of B 
In terms of its value breakdown  the stock currently trades at 43X current fiscal year EPS estimates  On a trailing cash flow basis  the stock currently trades at 40 9X versus its peer group s average of 19 7X  Additionally  the stock has a PEG ratio of 4 3  This isn t enough to put the company in the top echelon of all stocks we cover from a value perspective 
Zacks Rank
We also need to look at the Zacks Rank for the stock  as this supersedes any trend on the style score front  Fortunately  BioTelemetry currently has a Zacks Rank of  2  Buy  thanks to rising earnings estimates 
Since we recommend that investors select stocks carrying Zacks Rank of 1  Strong Buy  or 2  Buy  and Style Scores of A or B  it looks as if BioTelemetry passes the test  Thus  it seems as though BioTelemetry shares could have a bit more room to run in the near term 
How Does BioTelemetry Stack Up to the Competition 
Shares of BioTelemetry have been rising  and the company still appears to be a decent choice  but what about the rest of the industry  Some of its industry peers are also looking good  including UnitedHealth Group  UNH   Anthem  NYSE ANTM   and Humana  HUM   all of which currently have a Zacks Rank of at least  2 and a VGM Score of at least B  making them well rounded choices 
The Zacks Industry Rank is in the top 35  of all the industries we have in our universe  so it looks like there are some nice tailwinds for BioTelemetry  even beyond its own solid fundamental situation ",2019-02-04,Zacks Investment Research,https://www.investing.com/analysis/biotelemetry-beat-hits-52week-high-can-the-run-continue-200383687,200383687
141617,363132,HUM,Humana  HUM  Tops Q4 Earnings And Revenue Estimates,opinion,"Humana  HUM  came out with quarterly earnings of  2 65 per share  beating the Zacks Consensus Estimate of  2 53 per share  This compares to earnings of  2 06 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 4 74   A quarter ago  it was expected that this health insurer would post earnings of  4 29 per share when it actually produced earnings of  4 58  delivering a surprise of 6 76  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Humana  which belongs to the Zacks Medical   HMOs industry  posted revenues of  14 17 billion for the quarter ended December 2018  surpassing the Zacks Consensus Estimate by 1 76   This compares to year ago revenues of  13 19 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Humana shares have added about 5 9  since the beginning of the year versus the S P 500 s gain of 9 2  
What s Next for Humana 
While Humana has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Humana was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  4 13 on  15 42 billion in revenues for the coming quarter and  17 56 on  61 61 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   HMOs is currently in the top 9  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-02-05,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-tops-q4-earnings-and-revenue-estimates-200384264,200384264
141618,363133,HUM,Universal Health s  UHS  Q4 Earnings Beat Estimates  Up Y Y,opinion,Universal Health Services Inc    NYSE UHS   delivered fourth quarter 2018 adjusted earnings of  2 37 per share  beating the Zacks Consensus Estimate by 0 9   Moreover  the bottom line improved 18 5  year over year and the upside is mainly attributable to rising revenues Net revenues increased 4 2  year over year to  2 8 billion and also surpassed the Zacks Consensus Estimate by 2 6   backed by higher admissions and patient days Total operating expenses of  2 5 billion at the end of the four quarter increased 8 2  year over year  mainly due to salaries  wages and benefits along with other operating expense Segment UpdateAcute Care Hospitals Adjusted admissions and adjusted patient days inched up 2 2  and 4 8   respectively  from the prior year quarter  Net revenues  on a same facility basis  climbed 4 7  in the fourth quarter  majorly aided by rise in admissions and patient days Behavioral Hospitals On same facility basis  adjusted admissions rose 4 5  while adjusted patient days dipped 1 2   both on a year over year basis  Net revenues were up 2  during the quarter under review on same facility basis owing to higher admissions Financial UpdateAs of Dec 31  2018  the company had cash and cash equivalents of nearly  105 2 million  up 41 4  from year end 2017 Total assets were  11 billion as of Dec 31  2018  up 4 7  from year end 2017 The company s long term debt came in at   3 9 billion  up 12 6  from year end 2017 For 2018  net cash provided by operating activities totaled  1 3 billion  up 13 6  year over year Buyback ProgramDuring the fourth quarter  the company bought back 1 22 million shares worth  149 3 million Moreover  last December  its board of directors authorized a  500 million jump from the existing share repurchase program In 2018  the company bought back shares worth  401 3 million Full Year HighlightsFor 2018  net revenues grew 3 5  to  10 8 billion  Adjusted net income of the year summed  9 53 per share  up 26 6  year over year 2019 OutlookNet revenues for the year are projected between  11 2 billion and  11 4 billion  Adjusted EPS for the year is estimated at  9 70   10 40  Capital expenditures are expected between  675 million and  725 million Zacks RankUniversal Health currently carries a Zacks Rank  4  Sell  You can see  Releases From the Medical SectorAmong other players from the medical sector having reported fourth quarter earnings so far  the bottom line results of Humana Inc    NYSE HUM    Centene Corporation   NYSE CNC   and Molina Healthcare  Inc   NYSE MOH   outpaced the respective Zacks Consensus Estimate Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-02-27,Zacks Investment Research,https://www.investing.com/analysis/universal-healths-uhs-q4-earnings-beat-estimates-up-yy-200393493,200393493
141619,363134,HUM,Is UnitedHealth A Good Buy Despite Recent Regulatory Noise ,opinion,"Shares of UnitedHealth Group Inc    NYSE UNH   have declined recently following the proposal from the White House to lower drug prices and the Medicare for All bill that was submitted in late February The stock has declined nearly 3 5  since Feb 27  when the Medicare for All bill was presented to the House of Representatives Regulatory Developments Concerning UnitedHealthMedicare for AllThe Medicare for All bill seeks to implement a single national plan that will be looked after and funded by the Federal government This bill is of concern to Medicare Advantage heavyweights like UnitedHeath Group  Humana Inc    NYSE HUM    WellCare Health Plans Inc    NYSE WCG   as the Medicare for All policy might replace the private health insurance plans offered by these players  thus draining their business   Drug Price RebatesAnother concern for UnitedHealth has stemmed from the decline in drug price rebates received from pharmaceutical companies  after these have come under intense pressure to lower prices UnitedHealth owns its Pharmacy Benefits Management  PBM  business  named OptumRx  which negotiates and manages drugs  with pharmaceutical companies  required by its members  The PBMs get discounts or rebates from drug companies  which is passed on to insurers and then to consumers Any cut in drug prices would imply lower revenues for OptumRx  and consequently lower earnings for UnitedHealth Near Term LikelihoodMarket participants are of the opinion that Medicare for All will not be easy to implement  The plans entails huge burden on already constrained Federal budget deficit Alongside  it is also being said that the bill has little chances of passing through the Senate committee  which is controlled by Republicans  who are opposed to this bill Also  Trump s proposed regulatory change would end the practice of PBM rebates in the Medicare and Medicaid programs as of Jan 1  2020  However  players having PBM business have been proactively moving their business away from the rebate model and therefore the rule if implemented would not do much damage to UnitedHealth Does the Stock Look Attractive These legislative noise has pulled down the stock of UnitedHealth  which lost nearly 10  of its value in the last six months  almost in line with the  s decline  Thus the stock offers a good buying opportunity The company  with its massive business size that offers economies of scale  solid balance sheet and expanding international business  is poised to grow over the long term The recent weakness in the stock has made it attractively valued  The stock is trading at the 12 month forward price to earnings ratio of 16 13X which is near its low level of 15 8X and lower than median level of 18 4X UnitedHealth carries a Zacks Rank  2  Buy  
Another stock worth considering is Anthem  NYSE ANTM  Inc    with a Zacks Rank  1  Strong Buy   The stock has surpassed earning estimate in each of the four quarters with an average positive surprise of 7 04    You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-05,Zacks Investment Research,https://www.investing.com/analysis/is-unitedhealth-a-good-buy-despite-recent-regulatory-noise-200395092,200395092
141643,363158,HUM,Humana Q2 top line down 3   earnings up 109   cash flow negative  guidance raised,news,Humana  NYSE HUM  Q2 results   M   Revenues  13 534   3 4    Premiums  13 203  3 3   Retail  Individual Medicare Advantage  8 282   2 9    Group Medicare Advantage  1 277   17 7    Medicare Stand Alone PDP  925   8 9    State based contracts  671   1 0    Medicare Supplement  118   11 3   Group and Specialty  1 821   2 4    Healthcare Services  5 974   4 9    Pharmacy Solutions  5 214   4 2   Net Income  650   109 0    Non GAAP Net Income  942   3 7    EPS  4 46   116 5    Non GAAP EPS  3 49   6 1    CF Ops   106    64 2   Benefit ratio  82 5    2 1   2017 Guidance  EPS   17 83 from  16 91  Non GAAP EPS   11 50 from  11 10  Includes net gain of  4 36 share   947M pre tax  from the termination of the merger agreement with Aetna  NYSE AET  Now read ,2017-08-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/humana-q2-top-line-down-3-earnings-up-109-cash-flow-negative-guidance-raised-513395,513395
141644,363159,HUM,Anthem to exit Obamacare market in Virginia next year,news," Reuters    U S  health insurer Anthem Inc  N ANTM  said on Friday it will exit Obamacare markets in Virginia and reduce its plan offerings in Washington and Scott counties and the city of Bristol next year  The move comes nearly two weeks after President Donald Trump took aim at insurers by threatening to cut the healthcare subsidy payments that make Obamacare plans affordable  after repeatedly failing in his efforts to dismantle former President Barack Obama s healthcare law  Insurers are facing an upheaval in their health insurance businesses due to uncertainty over the healthcare legislation as Republican lawmakers seek to follow through on their promise to repeal and replace the Affordable Care Act  Health insurers  such as UnitedHealth Group Inc  N UNH    Aetna Inc   N AET  and  Humana Inc   N HUM   have also exited most of the states where they used to sell plans  The insurers have asked the government to commit to making the  8 billion in subsidy payments for 2018  saying they may raise rates or leave the individual insurance marketplace if there is too much uncertainty  On Monday  Anthem said it would no longer offer Obamacare plans in Nevada s state exchange and half of Georgia s counties in 2018  The company said on Friday it will only offer off exchange plans in Washington and Scott counties and the city of Bristol  Hundreds of U S  counties are at risk of losing access to private health coverage in 2018 as health insurers consider pulling out of those markets in the coming months  
Last week   Molina Healthcare Inc   N MOH  said it would stop selling Obamacare plans in Utah and Wisconsin ",2017-08-11,Reuters,https://www.investing.com/news/stock-market-news/anthem-to-exit-obamacare-market-in-virginia-next-year-517855,517855
141645,363160,HUM,Why Does The Stock Of Cigna  CI  Look Attractive Now ,opinion,The stock of Cigna Corp    NYSE CI   has seen the Zacks Consensus Estimate for current year earnings being revised 7 2  upward over the last seven days  This shows analysts  optimism over Cigna  which recently closed the acquisition of Express Scripts  NASDAQ ESRX   the pharmacy benefit manager  which will transform it into a diversified health services company The addition of Express Scripts will provide a nice diversification to the company s existing businesses   administrative services  international operations  and disability and life insurance   which are already performing strongly The combination of Express Scripts  pharmacy benefit business with Cigna s health insurance business  will help control drug pricing cost to a large extent  one of the biggest components of soaring medical cost  Cigna anyway has a better control over its medical cost than other players in the industry  The decline in medical costs should further aid its margins Another distinguishing feature of the company is its international business  which provides additional diversification opportunities   Cigna s international business  which includes India  Hong Kong  Turkey and the Middle East  among others  has overall recorded double digit revenue and earnings growth for the past seven years  The biggest international market for Cigna is South Korea  where it has been operating for more than three decades Moreover  the company has a large chunk of revenues coming from the administrative services only  ASO  business  which though has lower profitability  is growing in size and provides opportunities for cross selling Another positive for Cigna is its strong capital position  Its cash flow from operations has been increasing consistently for the past four years and the trend continued in the first nine months of 2018  An increasing cash flow provides scope for investment in business  Though the company s leverage levels have increased due to the purchase of Express Scripts  the same should moderate by next year as the company repays debt Cigna expects adjusted EPS in 2019 to gain in the double digits range  this excludes any impact from transitioning of clients by Express Scripts specially Anthem  NYSE ANTM    By the year 2021  Cigna projects adjusted EPS of  20 to  21  of which  2 to  3 will come from Express Scripts In a year s time  the stock has lost 8 1  compared with the  s decline of 20 3  Some equally ranked stocks in the same space are UnitedHealth Group  Inc    NYSE UNH    Humana Inc    NYSE HUM   and WellCare Health Plans  Inc    NYSE WCG   You can see  Each of these stocks has surpassed their respective estimates in the last the four reported quarters  with an average positive surprise of 3 7   4 7  and 27 2   respectively Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-09,Zacks Investment Research,https://www.investing.com/analysis/why-does-the-stock-of-cigna-ci-look-attractive-now-200374434,200374434
141646,363161,HUM,3 Reasons Why Growth Investors Shouldn t Overlook Humana  HUM ,opinion,"Growth investors focus on stocks that are seeing above average financial growth  as this feature helps these securities garner the market s attention and deliver solid returns  However  it isn t easy to find a great growth stock 
That s because  these stocks usually carry above average risk and volatility  In fact  betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss 
However  it s pretty easy to find cutting edge growth stocks with the help of the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects 
Our proprietary system currently recommends Humana  NYSE HUM  as one such stock  This company not only has a favorable Growth Score  but also carries a top Zacks Rank 
Research shows that stocks carrying the best growth features consistently beat the market  And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy  
While there are numerous reasons why the stock of this health insurer is a great growth pick right now  we have highlighted three of the most important factors below 
Earnings Growth
Earnings growth is arguably the most important factor  as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors  And for growth investors  double digit earnings growth is definitely preferable  and often an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Humana is 14 1   investors should actually focus on the projected growth  The company s EPS is expected to grow 21 4  this year  crushing the industry average  which calls for EPS growth of 13 8  
Impressive Asset Utilization Ratio
Growth investors often overlook asset utilization ratio  also known as sales to total assets  S TA  ratio  but it is an important feature of a real growth stock  This metric exhibits how efficiently a firm is utilizing its assets to generate sales 
Right now  Humana has an S TA ratio of 1 83  which means that the company gets  1 83 in sales for each dollar in assets  Comparing this to the industry average of 1 61  it can be said that the company is more efficient 
In addition to efficiency in generating sales  sales growth plays an important role  And Humana looks attractive from a sales growth perspective as well  The company s sales are expected to grow 8 2  this year versus the industry average of 7 8  
Promising Earnings Estimate Revisions
Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions  A positive trend is of course favorable here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
There have been upward revisions in current year earnings estimates for Humana  The Zacks Consensus Estimate for the current year has surged 0 2  over the past month 
Bottom Line
Humana has not only earned a Growth Score of B based on a number of factors  including the ones discussed above  but it also carries a Zacks Rank  2 because of the positive earnings estimate revisions 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that Humana is a potential outperformer and a solid choice for growth investors ",2019-01-15,Zacks Investment Research,https://www.investing.com/analysis/3-reasons-why-growth-investors-shouldnt-overlook-humana-hum-200376089,200376089
141647,363162,HUM,Why You Should Hold Mednax  MD  Stock In Your Portfolio,opinion,Mednax  Inc   NYSE MD   remains well poised for growth  given its strong revenue momentum and strategic initiatives Its return on equity   a profitability measure   is 10 4   better than the industry average of  236 1   This reflects the company s efficiency in utilizing shareholders  funds The company has also retained investors  optimism by sustaining its beat streak in three of the last four reported quarters  the average positive surprise being 1 48   This  highlights the company s operational excellence Mednax has been witnessing constant revenue growth over the past few years  primarily driven by favorable operating performance  ramp up of inorganic growth profile and strong segmental performances  This upside is evident from a CAGR of 13 94  during the 2008 2017 period  The winning momentum continued into the first three quarters of 2018 as well with the metric rising 6 6  Moreover  Mednax has been extremely active when it comes to boosting its portfolio via strategic initiatives  One of the company s notable buyouts was that of vRad that helped the company expand its services in telemedicine  It seeks to purchase physician s practices group and complementary service businesses  In the first three quarters of 2018  Mednax has closed the transactions of five physician group practices including two radiology practices  one neonatology practice and two pediatric subspecialty practices  which aided the company to drive its national network of physician practices  In Oct 2018  it also bought South Dade Neonatology  a private neonatology practice based in Miami as well as Radiology Specialists  LTD  a private radiology physician group based in Las Vegas  All these acquisitions poise the company well for growth However  escalating expenses have been hurting Mednax from the past many years  It should be noted that increasing expenses surpassed revenue growth in the past couple of years and the same continued into the first nine months of 2018 as well  Despite cost curbing initiatives taken by the company   high labor costs should keep exerting pressure on salaries and benefit component of total expenses  This might in turn  continue to weigh on the margins The Zacks Consensus Estimate for the company s current year earnings is pegged at  3 81  representing a year over year growth of 14 1  on revenues of  3 6 billion For 2019  the Zacks Consensus Estimate for earnings stands at  4 12 on  3 7 billion revenues  translating into a respective 8 2  and 3 1  improvement Shares of this Zacks Rank  3  Hold  company have plunged 32  in a years  time against its  s growth of 24 8  Stocks to ConsiderInvestors interested in the medical sector can take a look at some better ranked stocks like UnitedHealth Group Incorporated   NYSE UNH    Humana Inc    NYSE HUM   and WellCare Health Plans  Inc    NYSE WCG    each carrying a Zacks Rank  2  Buy  UnitedHealth operates as a diversified health care company in the United States  In the last four reported quarters  the company delivered average preceding four quarter beat of 3 39   You can see  Humana operates as a health and well being company in the United States  It came up with average last four quarter earnings surprise of 4 73  WellCare Health offers managed care services for government sponsored health care programs  The company managed to pull off average trailing four quarter positive surprise of 27 24   Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-21,Zacks Investment Research,https://www.investing.com/analysis/why-you-should-hold-mednax-md-stock-in-your-portfolio-200377918,200377918
141663,363178,HUM,Anthem to leave Ohio s Obamacare insurance market in 2018,news,"By Caroline Humer  Reuters    Anthem Inc  which has urged Republican lawmakers to commit to paying government subsidies for the Obamacare individual health insurance system  on Tuesday announced it would exit most of the Ohio market next year  The high profile health insurer  which sells Blue Cross Blue Shield plans in 14 states including New York and California  for months has said that uncertainty over the payments used to make insurance more affordable could cause it to exit markets next year  Anthem CEO Joseph Swedish two weeks ago reiterated that the company was reviewing its participation in the individual markets that are a key piece of the Affordable Care Act  commonly called Obamacare  Republican lawmakers and President Donald Trump have promised to repeal and replace the law  but have disagreed over the details  creating uncertainty at a time when insurers must submit plans and premium rates for 2018  In addition  Republicans are trying to cut off these Obamacare subsidy payments in court proceedings and President Donald Trump has made conflicting statements about continuing paying them   Insurance departments across the country have reported that insurers have submitted premium rate increases of up to 50 percent and 60 percent or even higher for 2018  Anthem attributed the Ohio decision to volatility and uncertainty about whether the government would continue to provide cost sharing subsidies  It said it would continue to sell Obamacare compliant plans outside of the exchange in Pike County  Ohio as well as other individual plans that were grandfathered when the law went into effect  Anthem is the only insurer selling health insurance exchange products in all 88 Ohio counties in 2017 and the only insurer in 20 counties  according to Ohio Department of Insurance spokesman Chris Brock  In 2018  the move would leave about 10 500 people in at least 18 counties with no insurer   Congressional action is needed to restore stability   Brock said  The insurance department is looking for options for those affected  he said  Other large health insurers have also pulled out for 2018  including  Aetna Inc   NYSE AET  and  Humana Inc   NYSE HUM   leaving other areas facing the possibility of no insurer  Anthem s decision was made as rate filings were due to the state and after discussions with the insurance department   States can beg and plead  but much of this is out of their hands   said Larry Levitt  health economist at the Kaiser Family Foundation  
Anthem shares rose  1 19  or 0 64 percent  to  187 88 in early afternoon trading ",2017-06-06,Reuters,https://www.investing.com/news/stock-market-news/anthem-plans-to-leave-obamacare-market-in-ohio-in-2018-492432,492432
141664,363179,HUM,Major ObamaCare hikes in NY ,news,New York health insurers requested double digit increases as high as 47  for ObamaCare policies next year as the debate rages in Washington on how to overhaul the law The state s Department of Financial Services will decide on 2018 rates following a 30 day public comment period  but noted that the average proposed increase for individual policies for 2018 is 16 6  Related tickers  AET  ANTM  CI  HUM  UNH,2017-06-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/major-obamacare-hikes-in-ny -493663,493663
141665,363180,HUM,Cigna s 2017 growth may include Medicare Advantage acquisitions,news,"By Caroline Humer NEW YORK  Reuters     Cigna Corp   N CI  Chief Executive David Cordani told investors on Wednesday that the company has  7 billion to  14 billion in capital it could use in 2017 for mergers and acquisitions in several areas  including Medicare Advantage for older people   Cordani  speaking during the company s first meeting with investors since its deal to be bought by Anthem Inc  N ANTM  officially broke off last month  also said the company would do at least  2 billion in share buybacks this year and set a target of  16 in earnings per share for 2021   He said M A areas that the No  5 health insurer is considering also include growing internationally and building out its pharmacy and physician related businesses  its retail capabilities and its government risk based insurance programs  Cigna has a pharmacy management business that it is looking to expand both internally and through acquisitions  Cordani said   But the most attention regarding Cigna s M A prospects on Wednesday was around rival  Humana Inc   N HUM   where Medicare Advantage accounts for two thirds of revenue  Several Wall Street analysts have recently written research notes about the merits of Cigna buying Humana  a deal they said had been under consideration before the Anthem deal was made two years ago  When an investor asked if Cigna was as interested now in building its Medicare Advantage business as it was two years ago  Cordani confirmed that was the case  In an interview  Cordani declined to discuss the possibility that the company is interested in buying Humana or give a size or timing for any acquisitions    We tend not to get too fixated on the headlines   Cordani said  The company considers deals based on if they create value for shareholders and moves ahead if they do  he said  Shares of Cigna were up 0 2 percent and Humana gained 1 2 percent in afternoon trading  OBAMACARE INDIVIDUAL MARKETS Cordani said Cigna has filed premium rates to stay in the same seven states where it now offers Obamacare individual plans for 2018  but that the company is waiting to make a final decision about its participation   Republicans and U S  President Donald Trump have pledged to repeal the Affordable Care Act  also known as Obamacare  Insurers deciding about participation must submit rates to HealthCare gov by the end of Wednesday  but can withdraw as late as September  
Cigna s decision depends on new government rules or regulations for insurance or legislation  including whether the government will continue to fund the cost sharing subsidies that affect individuals  out of pocket payments  it said ",2017-06-21,Reuters,https://www.investing.com/news/stock-market-news/cigna's-2017-growth-may-include-medicare-advantage-acquisitions-497918,497918
141666,363181,HUM,Poll shows most Americans have negative view of GOP healthcare plan,news,Results from a Reuters Ipsos poll that canvassed 1 492 adult Americans  671 Dem and 501 GOP  showed most are skeptical of the Republicans approach to replace Obamacare  The poll  conducted June 9   13  revealed that 41  oppose the House version while 30  support it  and 29  who  don t know  Republicans  rebooted version  AHCA 2 0  if you will  will be released tomorrow  The majority opinion is that the plan will be harmful to low income Americans  people with pre existing conditions and Medicaid recipients Tomorrow s action should be entertaining Selected tickers  CI ANTM HUM AET CNC UNH WCG MOHNow read ,2017-06-21,Seeking Alpha,https://www.investing.com/news/stock-market-news/poll-shows-most-americans-have-negative-view-of-gop-healthcare-plan-497927,497927
141667,363182,HUM,GOP healthcare plan to provide  50B to stabilize insurance exchanges  insurers rally,news,The complete draft of Republicans  healthcare bill is not due to be released for another hour  but Bloomberg reports that it provides  50B over four years to stabilize insurance exchanges in addition to cost sharing subsidy payments through 2019 A person familiar with the plan said  15B will be earmarked for the next two years and  10B year in 2020 and 2021 It will also provide  62B over eight years to a state innovation fund that can be used to cover high risk patients  reinsurance and other items  Obamacare s expansion of Medicaid would be phased out over three years starting in 2021 ETFs  GRX THW IXJ BME IRYSelected tickers   AET  0 7   ANTM  0 4   CNC  0 1   CI  0 3   HUM  0 4   MOH  0 7   UNH  0 7   WCG  1 3  Now read ,2017-06-22,Seeking Alpha,"https://www.investing.com/news/stock-market-news/gop-healthcare-plan-to-provide-$50b-to-stabilize-insurance-exchanges,-insurers-rally-498266",498266
141668,363183,HUM,Humana out of individual market   CEO,news,Humana  HUM  0 6   chief Bruce Broussard says his company will stay out of the individual insurance market after it exits Obamacare exchanges this year  regardless of the outcome of Republicans  American Health Care Act In an interview  Mr  Broussard said   This is just not a business that we will be good at  No matter what they do in Washington  we are not going to go back in  The company announced its intentions in February Now read ,2017-06-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/humana-out-of-individual-market---ceo-498390,498390
141669,363184,HUM,Top Ranked Growth Stocks To Buy For December 31st,opinion,"Here are three stocks with buy ranks and strong growth characteristics for investors to consider today  December 31st 
Jones Lang LaSalle Incorporated  JLL   This investment management services provider  which carries a Zacks Rank  1  Strong Buy   has witnessed the Zacks Consensus Estimate for its next year earnings increasing 7 4  over the last 60 days Jones Lang LaSalle Incorporated Price and Consensus

   Jones Lang LaSalle has a PEG ratio 1 07  compared with 1 39 for the industry  The company possesses a  of A Jones Lang LaSalle Incorporated PEG Ratio  TTM 

   Humana Inc  NYSE HUM    HUM   This health and well being company  which carries a Zacks Rank  2  Buy   has witnessed the Zacks Consensus Estimate for its next year earnings increasing 1 8  over the last 60 days Humana Inc  Price and Consensus

   Humana has a PEG ratio 1 34  compared with 2 45 for the industry  The company possesses a Growth Score of B Humana Inc  PEG Ratio  TTM 

   IBERIABANK Corporation  IBKC   This commercial and retail banking services provider  which carries a Zacks Rank  2  has witnessed the Zacks Consensus Estimate for its next year earnings increasing 0 3  over the last 60 days IBERIABANK Corporation Price and Consensus

   IBERIABANK has a PEG ratio 1 22  compared with 1 29 for the industry  The company possesses a Growth Score of B IBERIABANK Corporation PEG Ratio  TTM 

   EPAM Systems  Inc   EPAM   This digital platform engineering and software products and services provider  which carries a Zacks Rank  2  has witnessed the Zacks Consensus Estimate for its next year earnings increasing 2 9  over the last 60 days EPAM Systems  Inc  Price and Consensus

   EPAM Systems has a PEG ratio 1 35  compared with 2 67 for the industry  The company possesses a Growth Score of A EPAM Systems  Inc  PEG Ratio  TTM 

   See the 
Learn more about the  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-12-30,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-growth-stocks-to-buy-for-december-31st-200372026,200372026
141670,363185,HUM,Anthem Or Humana  Which HMO Stock Is A Better Buy For 2019 ,opinion,"With many economists anticipating recession in the United States in 2019  investment in the Health Maintenance Organization  HMO  industry seems like a prudent move given its defensive nature  However  a federal judge in Texas threw a spanner in the works by ruling that the Affordable Care Act   ACA   is unconstitutional  Nevertheless  the ruling has been  appealed in the Supreme Court  and ACA will remain in force until the final verdict  Consequently  the industry is expected to remain unaffected by the ruling at least in 2019  So  let s delve a little deeper and analyze the factors that are likely to influence the industry The industry is anticipated to witness sustained growth across the markets  particularly in expanding government programs  Medicare business is expected to stay on growth trajectory as the population ages and becomes even more polychronic  in turn increasing the value of products delivered by the HMOs compared with Original Medicare Another government business  Medicaid is likely to grow as states continue to expand coverages and traditional fee for service offerings move to managed care  Medicaid players in the industry are likely to witness persistent intense competition in Request for Proposals  RFP  in 2019 and beyond  The dependence of states on innovation and fiscal discipline of managed care has resulted in increased RFP activity  as states are looking for options to provide health care coverage to as many people as possible in effective ways Business combinations will continue to be one of the primary ways by which players will seek to improve their capacities to serve more people in more geographies   These players will also continue to diversify business  and achieve scale and service efficiencies The Health Insurer Tax   HIT   deferral combined with CMS rates for 2019 resulted in meaningful benefit investments from most managed care organizations  This is likely to lead to expanding Medicare Advantage footprint in 2019 The stabilization of health insurance exchanges are another positive  Administrative actions  such as encouraging people to maintain continuous coverage and attracting younger and healthier people to join the market  taken last year by the CMS  have started to yield results as evident from the return of some players to markets they exited in 2016 and 2017  Some of the returning companies include Anthem  Wellmark  Molina Healthcare Inc    NYSE MOH    and Cigna Corp    NYSE CI   All in all the health insurance industry is poised well for growth in 2019 Amid this scenario  let s focus on two HMO stocks  namely Anthem Inc    NYSE ANTM   and Humana Inc    NYSE HUM    to ascertain which is a better investment option for 2019  Both these companies have exhibited steady performance  stable earnings and cash flow generation Both the above mentioned stocks carry a Zacks Rank  2  Buy   While Anthem has a market capitalization of  65 96 billion  the same for Humana is  38 63 billion  You can see Price PerformanceShares of Anthem and Humana have returned 9 2  and 4 7   respectively  compared with the  s growth of 9  over the same period Debt to Capital RatioThe debt to capital ratio is a good indicator of the financial position of a company  The indicator reveals how much debt is utilized to run the business  Anthem and Humana s debt to equity ratio stands at 62 4  and 48 8   respectively  compared with the industry s 61 4  Return on Equity  ROE ROE is a measure of a company s efficiency in utilizing its shareholders  funds  In the trailing 12 months  ROE of Anthem and Humana stands at 14  and 19   respectively  Both the companies underperformed the industry s ROE of 22  Long Term Earnings Growth and Surprise TrendEarnings of Anthem and Humana are expected to improve 13 1  and 14 6  in the long term  three to five years   The industry is expected to grow by 13 2  Anthem and Humana both have outpaced the Zacks Consensus Estimate in each of the four reported quarters and recorded average positive earnings surprise of 5 11  and 4 73   respectively Estimate MovementFor 2019  the Zacks Consensus Estimate for Anthem has moved up 0 4  to  17 59 in the past 60 days  while the same for Humana was revised up by 1  to  17 50 Outcome
Markedly  it is quite evident from the above comparisons that Humana is a better HMO stock to accumulate  
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-01-03,Zacks Investment Research,https://www.investing.com/analysis/anthem-or-humana-which-hmo-stock-is-a-better-buy-for-2019-200372858,200372858
141671,363186,HUM,Ensign Group s  ENSG  Buyout To Expand Business In Utah,opinion,"The Ensign Group  Inc    NASDAQ ENSG   recently announced that it has completed the acquisition of the real estate and operations of Bella Terra Cedar City  a skilled nursing facility with 120 nursing beds in Cedar City  UT  The buyout was effective Jan 1  2019 The acquirer  looking to establish further in Cedar City  is really hopeful about the outcome of this buyout  Ensign Group is expecting to meet the local community needs with the combination of its expertise in this field and the trained team of caregivers at Bella Terra This purchase is Ensign Group s another strategic initiative to boost its capabilities  It adds to its expanding portfolio  consisting of 189 skilled nursing operations  Of this  24 are assisted living operations  56 assisted and independent living operations  22 are hospice agencies  24 home health agencies and seven are home care businesses across 16 US states The company boasts a strong inorganic growth story with more than 234 transactions made over a span of 18 years  The company has expertise in acquiring real estate or leasing post acute care operations and transforming the same into market leaders  With each acquisition  the company has honed its expertise  both clinically and financially The company s growth strategies and acquisitions have driven it top line which has been growing since 2012  Revenues have witnessed a five year CAGR  2012 17  of 17 6   The same was up 10 4  year over year in the first nine months of 2018 Currently  the company is aggressively seeking opportunities to buy real estate and lease well performing and struggling skilled nursing  assisted living and other healthcare related businesses across the United States Shares of this Zacks Rank  3  Hold  company have soared 58 4  in a year s time against its  s decline of 0 4  Stocks to ConsiderInvestors interested in the medical sector can check out some better ranked stocks like Molina Healthcare  Inc    NYSE MOH    Humana Inc    NYSE HUM   and Anthem  Inc    NYSE ANTM    each carrying a Zacks Rank  2  Buy  Molina offers Medicaid related solutions to meet the health care needs of low income families and individuals  In the last four reported quarters  the company delivered average four quarter beat of 82 55   You can see  Humana operates as a health and well being company in the United States  It came up with average four quarter earnings surprise of 4 73  Anthem operates as a health benefits company in the United States  The company managed to pull off average trailing four quarter positive surprise of 5 11  
 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-01-03,Zacks Investment Research,https://www.investing.com/analysis/ensign-groups-ensg-buyout-to-expand-business-in-utah-200372897,200372897
141672,363187,HUM,Molina Renews Pact With CVS To Boost PBM Service Platform,opinion,Molina Healthcare  Inc    NYSE MOH   recently announced extending its agreement with CVS Caremark for Pharmacy Benefit Management  PBM  services through 2021  This renewal  effective Jan 1  2019  followed a comprehensive procurement process With this deal  CVS Caremark will continue to administer pharmacy benefits for around 4 million members whom Molina Healthcare serves via its Medicaid  Medicare and Marketplace health plans  The deal modifies Molina Healthcare s current contract with CVS Caremark to orient Molina Healthcare s pharmacy management strategy with better functional measures  which are under process since last year The pact is immediately accretive to earnings and will allow Molina Healthcare to stay responsive to its state partner requirements  Notably  the latter controls around  3 billion of the company s annual pharmacy costs in a growing government sponsored health care scenario It is needless to say that this is another effort by Molina Healthcare to control its expenses that include clinical strategies with formulary  utilization management and generic dispensing initiatives In the second quarter of 2017  the company started a comprehensive restructuring and profitability improvement plan to streamline its organizational structure with an aim to improve efficiency as well as the speed and quality of decision making  The company plans to reduce annualized run rate expenses by approximately  300  400 million by the end of 2018  In the first nine months of 2018  the company incurred  35 million to meet the goals of its 2017 restructuring scheme  As part of this endeavor  the company sold its units    Pathways Health and Community Support  LLC and Molina Medicaid Solutions   to be able to focus on core growth areas The renewed tie up and the streamlining attempts have helped the company provide better results to its members as well Shares of this Zacks Rank  2  Buy  company have surged 31 4  in a year s time  outperforming its s growth of 5 7  Other Stocks to ConsiderInvestors interested in the medical sector can also take a look at other top ranked stocks like Centene Corporation   NYSE CNC    Humana Inc   NYSE HUM   and Anthem  Inc    NYSE ANTM    each carrying a Zacks Rank of 2 Centene operates as a diversified and multi national healthcare enterprise in the United States  In the last four reported quarters  the company delivered average four quarter beat of 4 90   You can see  Humana operates as a health and well being company in the United States  It came up with average four quarter earnings surprise of 4 73  Anthem operates as a health benefits company in the United States  The company managed to pull off average trailing four quarter positive surprise of 5 11  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-01-03,Zacks Investment Research,https://www.investing.com/analysis/molina-renews-pact-with-cvs-to-boost-pbm-service-platform-200372894,200372894
141673,363188,HUM,GOP leadership aims for Friday deal on healthcare bill,news,Bloomberg reports that Senate Majority Leader Mitch McConnell is scrambling to bring all GOP senators into the fold to support its version of the American Health Care Act  He aims to reach a deal with holdouts by Friday so the Congressional Budget Office can analyze its ramifications over the July 4 recess A vote is tentatively scheduled for mid July McConnell has very little leeway with the number of Republican votes needed for passage  The GOP has 52 seats in the Senate and 50 votes are needed to OK the bill Moderate Republicans  like Susan Collins of Maine  want to see less cutbacks to Medicaid and less Americans forced out of coverage before committing their support  Conservatives  meanwhile  want to see fewer insurance regulations Senate Democrats have been uniformly critical of the bill so the GOP is not counting on any votes from their side of the aisle Selected tickers  AET ANTM CNC CI HUM UNH BIB GRX THW BIS CNCR IXJ BME IRY ARKGNow read ,2017-06-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/gop-leadership-aims-for-friday-deal-on-healthcare-bill-500206,500206
141674,363189,HUM,Can Humana  HUM  Keep The Earnings Surprise Streak Alive ,opinion,"If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report  you should consider Humana  HUM   This company  which is in the Zacks Medical   HMOs industry  shows potential for another earnings beat 
When looking at the last two reports  this health insurer has recorded a strong streak of surpassing earnings estimates  The company has topped estimates by 5 62   on average  in the last two quarters 
For the most recent quarter  Humana was expected to post earnings of  4 29 per share  but it reported  4 58 per share instead  representing a surprise of 6 76   For the previous quarter  the consensus estimate was  3 79 per share  while it actually produced  3 96 per share  a surprise of 4 49  
Price and EPS Surprise

Thanks in part to this history  there has been a favorable change in earnings estimates for Humana lately  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the stock is positive  which is a great indicator of an earnings beat  particularly when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Humana currently has an Earnings ESP of  0 22   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  2  Buy  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on February 6  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-01-06,Zacks Investment Research,https://www.investing.com/analysis/can-humana-hum-keep-the-earnings-surprise-streak-alive-200373355,200373355
141675,363190,HUM,Molina Healthcare  MOH  In Focus  Stock Moves 7 4  Higher,opinion,Molina Healthcare  Inc   NYSE MOH   was a big mover last session  as the company saw its shares rise more than 7  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This stock  which remained volatile and traded within the range of  105 90  142 79 in the past one month time frame  witnessed a sharp increase yesterday The company has seen no changes when it comes to estimate revision over the past few weeks  while the Zacks Consensus Estimate for the current quarter has also remained unchanged  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future Molina Healthcare currently has a Zacks Rank  1  Strong Buy  while its  is 0 00  Molina Healthcare  Inc Price   Investors interested in the Medical   HMOs industry may consider a better ranked stock like Humana Inc    NYSE HUM    which carries a Zacks Rank  2  Buy   You can see  Is MOH going up  Or down  Predict to see what others think Up or DownWall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-01-07,Zacks Investment Research,https://www.investing.com/analysis/molina-healthcare-moh-in-focus-stock-moves-74-higher-200373612,200373612
141676,363191,HUM,Are Investors Undervaluing Humana  HUM  Right Now ,opinion,"The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks  Nevertheless  we know that our readers all have their own perspectives  so we are always looking at the latest trends in value  growth  and momentum to find strong picks 
Considering these trends  value investing is clearly one of the most preferred ways to find strong stocks in any type of market  Value investors use tried and true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels 
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits  For example  value investors will be interested in stocks with great grades in the  Value  category  When paired with a high Zacks Rank   A  grades in the Value category are among the strongest value stocks on the market today 
One company value investors might notice is Humana  HUM   HUM is currently holding a Zacks Rank of  2  Buy  and a Value grade of A  The stock has a Forward P E ratio of 15 66  This compares to its industry s average Forward P E of 15 83  HUM s Forward P E has been as high as 22 59 and as low as 15 66  with a median of 19 52  all within the past year 
HUM is also sporting a PEG ratio of 1 07  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  HUM s industry has an average PEG of 1 16 right now  Over the past 52 weeks  HUM s PEG has been as high as 1 81 and as low as 1 07  with a median of 1 42 
These are only a few of the key metrics included in Humana s strong Value grade  but they help show that the stock is likely undervalued right now  When factoring in the strength of its earnings outlook  HUM looks like an impressive value stock at the moment ",2019-01-09,Zacks Investment Research,https://www.investing.com/analysis/are-investors-undervaluing-humana-hum-right-now-200374444,200374444
141697,363212,HUM,Aetna fully exits Obamacare exchanges with pull out in two states,news,"By Deena Beasley  Reuters    Health insurer  Aetna Inc   N AET  said on Wednesday it will exit the 2018 Obamacare individual insurance market in Delaware and Nebraska   the two remaining states where it offered the plans  Aetna had already said it would exit the individual commercial market in Virginia and Iowa  after pulling out of several other states last year  Aetna has now  completely exited the exchanges   the company said in an emailed statement  Insurers  Humana Inc   N HUM  and UnitedHealth Group Inc  N UNH  have also pulled out of most of the government subsidized individual health insurance market  Republicans in the U S  House of Representatives last week voted to undo the Affordable Care Act  often called Obamacare  the signature domestic achievement of former President Barack Obama  But even if the Republicans  bill   known as the American Health Care Act   is passed by the Senate it would not solve a critical outstanding issue for insurers looking at 2018  Will the government continue to fund the cost sharing subsidies that help individuals pay for care  Health insurers have said they cannot plan amid the uncertainty  In addition  the balance of sick and healthy customers has been worse than expected  and premium rates on the individual insurance market went up 25 percent this year   This decision is not a surprise given continued uncertainty about market stability and whether cost sharing subsidies will continue to flow   Evercore ISI analyst Michael Newshel said in an investor research note  He noted that only one health plan remains in both Delaware  where Highmark Blue Cross Blue Shield sells Obamacare coverage  and Nebraska  where Medica still offers coverage but has warned it may exit the program   Aetna projected around  225 million in losses from its exchange plan businesses this year following a loss of  700 million for 2014 through 2016  The insurer attributed the losses to  marketplace structural issues  that have led to co op failures and carrier exits  and subsequent risk pool deterioration   Aetna said it had 964 000 individual commercial plan members as of the end of 2016  but that number dropped to 255 000 at the end of March  
Evercore ISI said Delaware exchange sign ups fell 2 4 percent year over year in 2017  while sign ups in Nebraska fell 3 9 percent  which was close to the 3 7 percent nationwide drop ",2017-05-10,Reuters,https://www.investing.com/news/stock-market-news/aetna-to-exit-delaware-and-nebraska-individual-insurance-markets-482772,482772
141698,363213,HUM,Democratic attorneys general seek to intervene in Obamacare case,news,"By Dan Levine  Lawrence Hurley and Yasmeen Abutaleb SAN FRANCISCO WASHINGTON  Reuters    More than a dozen Democratic attorneys general on Thursday sought to intervene to defend a key part of the Obamacare healthcare law   subsidy payments to insurance companies   which is under threat in a court case  The 16 attorneys general  led by California Attorney General Xavier Becerra and New York Attorney General Eric Schneiderman  filed a motion to intervene in the case pending in the U S  Court of Appeals for the District of Columbia Circuit  The case  which dates back to the Obama administration  was filed by the Republican led House of Representatives against the federal government in an effort to cut off subsidy payments to insurers for the individual plans created by the Affordable Care Act  often called Obamacare  The subsidies payments help cover out of pocket medical expenses for low income Americans   The stakes are very high  In Maryland we have more than 400 000 people who depend on the Affordable Care Act to get normal healthcare  It sounds alarming  but it s true  lives are at stake   said Maryland Attorney General Brian Frosh  who signed on to the filing  Trump has repeatedly threatened to withhold the payments to insurers  which amount to about  7 billion this year  and referred to them as a  bailout    The attorneys general cited in the court filing Trump s own words vowing to let Obamacare  explode  as part of the reasoning for their intervention  Trump has made it clear he views decisions on health insurance for millions of Americans  as little more than political bargaining chips   the court filing said  The situation is extremely urgent  the Democratic officials argued  because state insurance regulators are making critical choices that will shape their insurance markets for the next year  Several insurers  including Aetna  N AET  and Humana  N HUM   have largely left the Obamacare exchanges  citing a pool of patients who are sicker than expected and therefore more expensive  Insurers have also repeatedly called on the Trump administration to fund the cost sharing subsidies   Attorneys general and proponents of Obamacare have said the threats to withhold the payments have already wreaked havoc in the marketplaces and are part of the reason some healthcare consumers have seen double digit rate increases   SIGNIFICANT OPPONENTS Democratic attorneys general have emerged as significant opponents to the Trump administration  They took a lead role to successfully block Trump s executive orders restricting travel from some Muslim majority countries  and they are also resisting efforts to roll back environmental regulations  The attorney general from Kentucky  a deeply conservative state  is among those Democrats joining the court filing even as the state s Republican governor has pledged to rollback a Medicaid expansion made possible by Obamacare   In May 2016  a U S  judge ruled in favor of the Republicans in the subsidies case  finding that the Obama administration needed explicit congressional approval  The Obama administration appealed before Trump took office  leaving the new administration to ponder how to proceed  The appeals court put the litigation on hold after the November presidential election at the request of the Republican House lawmakers   The motion to intervene may not be granted by the court  In February  the same court rejected a similar motion filed by Democratic attorneys general seeking to help defend the Consumer Financial Protection Bureau in a legal battle that could defang the agency  The litigation could become moot if Congress passes new healthcare legislation to replace Obamacare  The House passed a bill  called the American Health Care Act  earlier this month  The Senate recently began writing its own version of the bill but has warned it could take months to pass   
The Trump administration has taken action over the past several months to undercut Obamacare through regulatory authority  It backed off enforcing the individual mandate  which requires everyone to purchase health insurance or else pay a penalty  tightened enrollment in Obamacare markets and has enabled people to sign up for insurance plans outside of healthcare gov  the flagship site of Obamacare that the Obama administration heavily advertised ",2017-05-18,Reuters,https://www.investing.com/news/politics-news/democratic-attorneys-general-seek-to-intervene-in-obamacare-case-486142,486142
141699,363214,HUM,Trump administration wants Obamacare subsidy case put on hold  again,news,"By Lawrence Hurley and Yasmeen Abutaleb WASHINGTON  Reuters    The Trump administration asked on Monday that a major federal court case weighing the fate of the Obamacare cost sharing subsidies be put on hold again  leaving billions of dollars in payments to insurers up in the air for 2017 and 2018  In a joint filing with the U S  House of Representatives submitted to the U S  Court of Appeals for the District of Columbia Circuit  the administration and Republican lawmakers asked for a second 90 day extension  The subsidies are available to low income Americans who buy individual health insurance on the exchanges created under the 2010 Affordable Care Act  former President Barack Obama s signature healthcare law  popularly known as Obamacare  President Donald Trump and Republican lawmakers want to repeal and replace the law and are working on legislation to overhaul it that would also secure the subsidy funding during a transition period  But it is not clear if or when they will pass it  The two sides said they wanted more time because they were discussing measures that would no longer require a judicial decision  including the new healthcare legislation  Insurers that are trying to set premium rates for insurance plans to be sold in 2018 are running up against deadlines and have repeatedly asked Congress to fund the subsidies during the transition  One Republican senator said on Monday that he believed the money for the subsidies should be appropriated by Congress   I think we have to   Senator Bill Cassidy of Louisiana told reporters outside the Senate   We need to stabilize premiums  or we re not going to have a market   He said he was speaking for himself and not Republican leaders  The legal case was filed by the Republican led House against the Obama administration to cut off the subsidy payments  A lower court had ruled in favor of the lawmakers  saying that Congress must appropriate the money for the subsidies and that the government could not simply pay for them in the way it does now   Insurers and medical groups reiterated their view on Monday after the court filing about continuing the payments  which amount to about  7 billion this year and help low income consumers pay for out of pocket medical costs    Uncertainty is destabilizing the market and leading health plans to raise their rates for 2018 to account for the political risk brought on by Congress and the administration through a protracted debate over the fate of these reimbursements   Margaret Murray  chief executive officer of the Association for Community Affiliated Plans  said in a statement  While the proposed legislation from the House would keep the payments through 2019  Trump has said he could stop paying the subsidies at any time  That has insurers concerned that the monthly government payments could end and leave them exposed financially   
Several insurers  including  Aetna Inc   NYSE AET  and  Humana Inc   NYSE HUM   have already exited the Obamacare marketplace for 2018   Credit Suisse   SIX CSGN  analyst Scott Fidel said insurers such as Centene Corp and Molina Healthcare Inc that focus on the low income families that qualify for the subsidies have the most at risk  Centene shares closed down 1 4 percent at  74 02 and Molina fell 0 8 percent to  66 84 ",2017-05-22,Reuters,https://www.investing.com/news/politics-news/trump-administration-asks-for-time-to-weigh-obamacare-subsidies-487167,487167
141700,363215,HUM,Health Insurance Stocks Tumble  Watch This Trade Level,opinion,"Today  most of the leading health insurance stock are falling sharply lower  Leaders in the industry group such as Humana  NYSE HUM   WellCare Health Plans  NYSE WCG   UnitedHealth Group  NYSE UNH  and others are all trading in negative territory  A couple days ago  a Federal judge voiced concerns over the DOJ s approval of CVS Aetna merger  This news is the likely catalyst for the big decline in the sector 
Humana is a leading stock in the health insurance group that is trading lower by  14 76 to  309 71 a share  This stock is now testing its 200 day moving average  Should this stock close below this key moving average it would indicate lower prices ahead  The next major support area that looks attractive for HUM stock will be around the  290 00 level  This is where the stock broke out in May 2018 and should be very solid chart support when retested ",2018-12-06,Nicholas Santiago,https://www.investing.com/analysis/health-insurance-stocks-tumble-watch-this-trade-level-200365899,200365899
141701,363216,HUM,Can A Divided Congress Boost Healthcare Stocks  4 Picks,opinion,A split Congress coupled with new trends in biotechnology and implementation of emerging technologies in healthcare could have been the reasons behind the healthcare sector s continuous gains this year  Despite the U S  China trade war s off putting effect on the other sectors  U S  healthcare has gained remarkably Therefore  it would be prudent to invest in a few healthcare stocks to gain from the factors boosting the sector Divided Congress is a Tailwind for Healthcare Sector GrowthWhile there are many factors pushing healthcare stocks to gain prominence at present  the role of different parties in the House and Senate is unprecedented  A divided Congress could prove beneficial because it would prevent any fundamental changes in healthcare laws Ultimately  it would result in the continuation of Obama era healthcare policies  This means that the Affordable Healthcare Act is here to stay  With Democrats gaining control of the House of Representatives  more than half a million low income individuals would gain medical insurance coverage  This would largely be an outcome of expansion ballot initiatives and key gubernatorial victories U S  Healthcare Sector Faring Well The Health Care Select Sector SPDR  XLV  has gained 10 3  on a year to date basis  which can be deemed impressive given the downward trend in other major sectors such as energy and finance In addition  national spending on healthcare rose 3 9  to  3 5 trillion  increasing for a second year in 2017  per a U S  Centers for Medicare and Medicaid Services report earlier in December The number of new job creations also increased the most in healthcare in November than in any other sector  adding new roles in hospitals and ambulatory healthcare services  This is indicative of the fast growth that the sector is encountering  favored more by increased spending Stocks to BuyGiven the positive outlook for healthcare stocks  we have handpicked a couple of HMO stocks from the sector that carry a Zacks Rank  1  Strong Buy  or 2  Buy  Molina Healthcare  Inc   NYSE MOH   provides Medicaid related solutions to low income individuals and families The company s expected earnings growth rate for the current year is more than 100  compared with the Zacks industry s projected rise of 20 2   The Zacks Consensus Estimate for the current year has increased 2 7  over the last one month  The stock sports a Zacks Rank  1  You can see Anthem  Inc    NYSE ANTM   functions as a health benefits company in the United States  The company provides a wide range of network based managed care health benefit plans to individuals  large and small group  Medicaid  and Medicare market segments The company s expected earnings growth rate for the current year is 30  compared with the Zacks Medical   HMOs industry s projected rise  The Zacks Consensus Estimate for the current year hasn t changed over the last 30 days  The stock carries a Zacks Rank  2 Humana Inc    NYSE HUM   along with its subsidiaries  provides healthcare services The company s expected earnings growth rate for the current year is 23 3  compared with the Zacks Medical   HMOs industry s projected rise  The Zacks Consensus Estimate for the current year has advanced 0 4  over the last month  The stock carries a Zacks Rank  2 WellCare Health Plans  Inc    NYSE WCG   offers managed care services for healthcare programs sponsored by government The company s expected earnings growth rate for the current year is 29 2  compared with the Zacks Medical   HMOs industry s projected rise  The Zacks Consensus Estimate for the current year has advanced 1 4  over the last two months  The stock carries a Zacks Rank  2 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-11,Zacks Investment Research,https://www.investing.com/analysis/can-a-divided-congress-boost-healthcare-stocks-4-picks-200367351,200367351
141702,363217,HUM,Is Humana  HUM  Outperforming Other Medical Stocks This Year ,opinion,"Investors focused on the Medical space have likely heard of Humana  HUM   but is the stock performing well in comparison to the rest of its sector peers  One simple way to answer this question is to take a look at the year to date performance of HUM and the rest of the Medical group s stocks 
Humana is a member of our Medical group  which includes 841 different companies and currently sits at  2 in the Zacks Sector Rank  The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups 
The Zacks Rank is a successful stock picking model that emphasizes earnings estimates and estimate revisions  The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months  HUM is currently sporting a Zacks Rank of  2  Buy  
Over the past three months  the Zacks Consensus Estimate for HUM s full year earnings has moved 1 79  higher  This shows that analyst sentiment has improved and the company s earnings outlook is stronger 
Based on the latest available data  HUM has gained about 23 38  so far this year  Meanwhile  stocks in the Medical group have gained about 1 62  on average  This means that Humana is outperforming the sector as a whole this year 
Looking more specifically  HUM belongs to the Medical   HMOs industry  which includes 12 individual stocks and currently sits at  89 in the Zacks Industry Rank  Stocks in this group have gained about 22 27  so far this year  so HUM is performing better this group in terms of year to date returns 
HUM will likely be looking to continue its solid performance  so investors interested in Medical stocks should continue to pay close attention to the company ",2018-12-11,Zacks Investment Research,https://www.investing.com/analysis/is-humana-hum-outperforming-other-medical-stocks-this-year-200367394,200367394
141703,363218,HUM,4 HMOs Likely To Cruise Ahead Of Industry In 2019 ,opinion,"With an estimated 85 million people representing more than  1 trillion in annual health care spending still not served through managed care in the United States alone  players in the HMO industry are well positioned for continued growth  New markets continue to emerge around areas like social determinants  specialty and supplemental coverage  and global opportunities which should create business opportunities in 2019 and beyond Recently  a federal court judge in the state of Texas declared the Individual Mandate clause in the Affordable Care Act  ACA or Obamacare  unconstitutional  thus challenging the constitutionality of the ACA overall  This decision  which is being repealed by more than a dozen states  will cast uncertainty over the viability of the ACA   The ACA  which was enacted in 2010  led to a decline in the uninsured population thus aiding the earnings of the HMO players  Repealing or holding the Individual mandate unconstitutional will be like breaking the backbone of the ACA  This might lead to an increase in uninsured population and soaring of health insurance premiums Nevertheless  the recent ruling by the federal judge is not very disappointing since this is the initial step of a likely lengthy appeals process  One of the health insurers  Molina Healthcare said  regardless  the ACA will remain in effect for 2019  and we are optimistic that it will remain in effect thereafter Brokerage Evercore ISI said it expected no immediate impact from the ruling  calling it only a declaratory judgment and not an injunction Keeping this in mind  let s see the likely factors affecting the industry in 2019 In 2019 and beyond  players should see potential for sustained growth across the markets  particularly in expanding government programs   With more baby boomers reaching retirement age  the number of people eligible for Medicare is projected to reach 72 million by 2025  up from about 63 million at present  with gross spending for Medicare expected to surpass  1 2 trillion by 2025  up from more than  800 billion projected for 2019  Medicare Advantage continues to be a popular choice  now serving more than one third of those enrolled in Medicare  Players like UnitedHealth  NYSE UNH   Anthem and Humana are positioned for strong growth as the Medicare Advantage market continues to expand and evolve Another government business  Medicaid should continue to grow as states continue to expand coverage and as traditional fee for service offerings move to managed care  Medicaid players in the industry should witness continued intense competition in Request for Proposals  RFP  in 2019 and beyond  The dependence of states on innovation and fiscal discipline of managed care has resulted in increased RFP activity  as states are vying options to provide health care coverage to as many people as possible in effective ways Business combinations will continue to be one of the many ways that players should improve their capacities to serve more people in more geographies as well as continue to diversify business and achieve scale and service efficiencies The Health Insurer Tax  HIT  deferral combined with CMS rates for 2019 resulted in meaningful benefit investments from most managed care organizations  This should lead to Medicare Advantage expasion in 2019 Players in the HMO industry expect utilization of services to increase at a consistent rate in 2019  They should continue to mitigate medical cost increases with their medical management strategies  further adoption of value based reimbursement and advancements in consumer decision making due to their use of market leading engagement tools Other than these  investment in technological investment and upgrade  application of blockchain technology  growth of new business units  international expansion  better claims handling  medical cost management  mergers and acquisitions  and healthy balance sheets should fuel overall growth of the industry The stabilization of health insurance exchanges is another positive  Administrative actions  such as encouraging people to maintain continuous coverage and attracting younger and healthier people to join the market  taken last year by the CMS  have paid off as the some of the players that exited the health insurance exchanges in many markets in 2016 and 2017 have now returned to markets  Some of the returning companies are Anthem  Wellmark  Molina and Cigna The  industry has gained 19 41  year to date compared with the Zacks S P 500 Composite decline of 2 7   The HMO industry is slated for another good ride in 2019 and therefore picking some good stocks from this space should be a good investment move  Each of these stocks has witnessed an upward revision in earnings estimates for 2019 and carries a strong Zacks Rank Our PicksAnthem  Inc    NYSE ANTM   operates as a health benefits company in the United States  The company should see top line growth from an increase in enrollment in Medicare Advantage plans  A strong balance sheet with positive cash flows should help it to invest in growth The company currently has a Zacks Rank  2 and Value Style Score of A  The Zacks Consensus Estimate for 2019 earnings has moved up by 2 9  in the last 60 days  Humana Inc    NYSE HUM   should gain from its growing Medicare business  as the same is in high demand from the retiring baby boomer population  Also  its health services business provides diversification benefits  The company currently has a Zacks Rank  2 and Value Style Score of A  The Zacks Consensus Estimate for its 2019 earnings has moved up 1  in the last 60 days Cigna Corp    NYSE CI   is a health benefits company and its acquisition of Express Scripts  NASDAQ ESRX   a pharmacy benefits manger  due to be closed this month   bodes well for long term growth  which will help it to expand vertically  The company currently has a Zacks Rank  1 and Value Style Score of B  The Zacks Consensus Estimate for its 2019 earnings has moved up 3 1   in the last seven days Molina Healthcare  Inc    NYSE MOH   deals mainly in government related plans such as Medicaid and is expected to gain from Medicaid expansion  The company currently has a Zacks Rank  1 and Value Score of B  The Zacks Consensus Estimate for 2019 earnings has moved up by 31 3   respectively  in the last 60 days  
In addition to the stocks discussed above  would you like to know about our 10 top tickers to buy and hold for the entirety of 2019 These 10 are painstakingly handpicked from over 4 000 companies covered by the Zacks Rank  They are our primary picks poised to outperform in the year ahead ",2018-12-17,Zacks Investment Research,https://www.investing.com/analysis/4-hmos-likely-to-cruise-ahead-of-industry-in-2019-200369097,200369097
141704,363219,HUM,Centene Unit Collaborates With RxAdvance For New PBM Platform,opinion,Centene Corporation   NYSE CNC   recently announced the implementation of a transformative pharmacy benefit management model through RxAdvance s Collaborative PBM Cloud platform by its Mississippi arm  Magnolia Health  This service is available to 240 000 Mississippi Medicaid members  The collaboration is expected to reduce overall administrative costs and contribute to the betterment of health outcomes by decreasing medical costs Earlier this year  the company also informed about a tie up with RxAdvance  aiming to create an advanced pharmacy management solution  Magnolia Health is the company s first unit that has successfully implemented this model  With the amalgamation of this Pharmacy Solutions business  RxAdvance s unique platform and a new business model  this new solution is likely to be a game changer  The parent company is also anticipated to provide a value based care to its members at affordable costs with this transparent Pharmacy Benefit Management model The company has been constantly making endeavors to enhance the experience of its members at a low cost  Apart from collaborations  Centene is also actively taking up mergers and acquisitions for the past many quarters for expanding its markets and increasing its Medicaid membership  In March 2016  the company acquired Health Net  which has substantially been accretive to the company s top line This year  Centene bought Community Medical Holdings  MHM Services and Fidelis Care  In July 2018  the company entered into a joint venture with Ascension to establish a Medicare Advantage plan  which will be operational across multiple geographic markets beginning 2020  These acquisitions and partnership should bolster the company s operations and aid long term growth Shares of this Zacks Rank  3  Hold  have rallied 15 5  in a year s time  outperforming its  s growth of 11 6  Stocks to ConsiderInvestors interested in the Medical HMO industry can check out some better ranked stocks like Molina Healthcare  Inc   NYSE MOH    Humana Inc   NYSE HUM   and Anthem  Inc    NYSE ANTM   Molina offers Medicaid related solutions to meet the health care needs of low income families and individuals  It sports a Zacks Rank  1  Strong Buy   In the last four reported quarters  the company delivered average four quarter beat of 82 55   You can see  Humana operates as a health and well being company in the United States  It carries a Zacks Rank  2  Buy  and came up with average four quarter earnings surprise of 4 73  Anthem operates as a health benefits company in the United States  A Zacks  2 Ranked player  the company managed to pull off average trailing four quarter positive surprise of 5 11  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-12-19,Zacks Investment Research,https://www.investing.com/analysis/centene-unit-collaborates-with-rxadvance-for-new-pbm-platform-200369879,200369879
141732,363247,HUM,Trump may halt insurer payments to force Democrats to table on healthcare,news,"WASHINGTON  Reuters    U S  President Donald Trump told The Wall Street Journal on Wednesday that he might consider withholding billions of dollars of Obamacare payments to health insurers to force Democrats back to the negotiating table on healthcare  Insurers and major medical groups have warned that not funding the payments  called cost sharing reduction subsidies  which help cover out of pocket medical expenses for low income Americans  could wreak havoc in the individual insurance markets  Trump told The Wall Street Journal that by withholding the payments  Democrats will call him to negotiate   Major medical and insurance groups penned a letter to Trump on Wednesday urging him to maintain funding for the subsidies  which amount to about  7 billion a year and are paid directly to insurers  They help cover premiums  deductibles and other medical expenses for about 7 million people who purchase health insurance on the individual health insurance market  House of Representatives Republicans sued the Obama administration for funding the subsidies  which they argue have to be appropriated by Congress  A federal judge in May 2016 ruled in favor of the Republicans  prompting an appeal by the Obama administration  The case is pending in the U S  Court of Appeals for the District of Columbia Circuit  
Major insurers  including  Humana Inc   NYSE HUM  and Aetna  NYSE AET   have left or announced their intention to leave the Obamacare exchanges  citing multi million dollar losses and patient populations that are far costlier and sicker than they expected  They warned that withholding the subsidies would destabilize the market further and leave millions of consumers with little or no choice in picking a health insurance plan ",2017-04-12,Reuters,https://www.investing.com/news/politics-news/trump-may-halt-insurer-payments-to-force-democrats-to-negotiate-on-healthcare-473972,473972
141733,363248,HUM,Trump administration issues final rule on stricter Obamacare enrollment,news,"By Yasmeen Abutaleb WASHINGTON  Reuters    The Trump administration on Thursday issued a final rule that will shorten the Obamacare enrollment period and give insurers more of what they say they need in the individual insurance market  likely making it harder for some consumers to purchase insurance  healthcare experts said   It could also raise out of pocket medical expenses  the experts said  because it gives insurers more flexibility in determining the value of their coverage  The rule  which takes effect later this year  comes as President Donald Trump and Republicans in Congress have renewed efforts to repeal and replace the Affordable Care Act  commonly known as Obamacare  after an effort to pass a bill in the U S  House of Representatives failed last month   Issued by a division of the U S  Department of Health and Human Services and first proposed in February  the rule aims to aid insurers  who have lost hundreds of millions of dollars in the individual insurance markets set up by Obamacare  Several major insurers  including  Humana Inc   NYSE HUM  and  Aetna Inc   NYSE AET   have announced plans to exit some state exchanges in 2018   Insurers welcomed the rule but said there is still too much uncertainty in the market  On Wednesday  Trump told the Wall Street Journal that he may withhold Obamacare payments to insurers that amount to about  7 billion a year to force Democrats back to the negotiating table   Marilyn Tavenner  president and chief executive of America s Health Insurance Plans  said in a statement that funding for the payments must continue uninterrupted  Otherwise  she said premiums will rise 20 percent across the market and more insurers would drop out of the exchanges   The changes under Thursday s final rule include a shortened open enrollment period for Obamacare plans  They also make it harder for people to enroll outside that period  which is allowed under certain circumstances such as a pregnancy or a move   The rule could also allow insurers to collect unpaid premium payments and make it tougher for people to move in and out of insurance plans  according to healthcare industry experts   Insurers say  gaming the system  has created an unprofitable mix of healthy and sick customers  The rule also gives states broader authority by removing the federal government s role in overseeing doctor and hospital networks included in insurance plans  Republicans have said any healthcare reform or overhaul must give states more flexibility  
The Affordable Care Act enabled 20 million Americans to gain insurance  mostly through the individual insurance markets set up by the law or through an expansion of Medicaid  the government health insurance program for the poor and disabled ",2017-04-13,Reuters,https://www.investing.com/news/politics-news/trump-administration-issues-final-rule-on-stricter-obamacare-enrollment-474359,474359
141734,363249,HUM,Anthem denies report of talks with Justice Dept regarding merger,news,"WASHINGTON  Reuters    Health insurer Anthem Inc  N ANTM  denied a report on Thursday that it was in negotiations with the Justice Department in an effort to save its merger with smaller rival  Cigna Corp   N CI   Cigna shares jumped as much as 2 4 percent early in the session on a spike in trading volume to hit their highest level since July 2015  Anthem was last up 1 3 percent to  168 95  Cigna was up 2 3 percent at  155 50  The companies are awaiting a decision from a federal appeals court  which had been asked to rule on whether the Justice Department could stop the  54 billion merger on antitrust grounds  The lawsuit was originally brought by the Obama administration and a federal judge agreed that the deal should be stopped  Asked about a report from CTFN  a service specializing in merger news  that Anthem was in talks with the Justice Department  spokeswoman Bonnie Jacobs said in an email   Not accurate   The Justice Department declined to comment  An Anthem purchase of Cigna would create the largest U S  health insurer  Rivals  Aetna Inc   N AET  and  Humana Inc   N HUM  had also sought to merge  but that deal collapsed amid opposition from the federal government and states  
Adding to obstacles facing a deal  Anthem and Cigna  which have had difficult relations for months  are suing each other ",2017-04-20,Reuters,https://www.investing.com/news/stock-market-news/anthem-denies-report-of-talks-with-justice-dept-regarding-merger-475922,475922
141735,363250,HUM,Government costs could rise  2 3 billion without Obamacare payments  study,news,"WASHINGTON  Reuters    The U S  government s costs could increase by  2 3 billion in 2018 if Congress and President Donald Trump decide not to fund Obamacare related payments to health insurers  according to a study released Tuesday by the Kaiser Family Foundation  The payments amount to about  7 billion in fiscal year 2017 and help cover out of pocket medical costs for low income Americans who purchase insurance on the individual insurance exchanges created by the Affordable Care Act  often called Obamacare   Trump has threatened to withhold the payments to force Democrats to the negotiating table on a healthcare bill to replace Obamacare   He has also said he will fund the subsidies if Democrats agree to funding for his proposed border wall with Mexico as part of efforts to pass a government funding bill this week and avert a shutdown  Democrats have rejected the conditional offer   If no deal is made  parts of the federal government will shut down at 12 01 am on Saturday  The payments are the subject of a pending Republican lawsuit that was appealed by the Obama administration and put on hold when Trump took office   The government could save  10 billion by revoking the payments  Kaiser said  But insurers that remain in the market would have to hike premiums nearly 20 percent to cover their losses  Kaiser found  so the government would have to spend  12 3 billion on tax credits to help pay for Americans  premium costs   a net increase of 23 percent on federal spending on marketplace subsidies  The projection assumes that insurers remain in the marketplace next year  Health policy experts have said without the payments  many insurers could not afford to stay in the market and will likely exit  which would leave some U S  counties without an insurer   
Aetna  N AET   UnitedHealth Group Inc  N UNH  and Humana  N HUM  have already exited most state exchanges for 2017 and said they will do so next year as well ",2017-04-25,Reuters,https://www.investing.com/news/politics-news/government-costs-could-rise-$2.3-billion-without-obamacare-payments:-study-476969,476969
141736,363251,HUM,U S  appeals court blocks Anthem bid to merge with rival Cigna,news,"By Diane Bartz WASHINGTON  Reuters    A U S  appeals court on Friday blocked health insurer Anthem Inc s  N ANTM  bid to merge with Cigna  N CI   upholding a lower court s decision that the  54 billion deal should not be allowed because it would lead to higher prices for healthcare  The ruling will probably kill the proposed merger  which was opposed by the U S  Justice Department  11 states and a District Court judge after consumers  medical professionals and others objected to it  In the end  Cigna itself tried to back out  Still  Anthem and Cigna have the option of trying to save the deal by asking the appeals court to re consider the case or appealing straight to the U S  Supreme Court  Shares of Cigna closed Friday at  156 37  up 0 1 percent  while Anthem shares ended at  177 89  down 0 2 percent  Anthem s purchase of Cigna would create the largest U S  health insurer  Rivals  Aetna Inc   N AET  and  Humana Inc   N HUM  had also sought to merge but that deal collapsed this year amid opposition from the federal government and states  Insurers made the deals as they adjusted to new pressures from the insurance overhaul of Obamacare  officially known as the Affordable Care Act  They now face the potential for another remaking of the industry  though the exact changes are unclear because of Republican disagreements over how to repeal and replace Obamacare   Anthem  said in a statement late Friday that it was disappointed by the appeals court s decision   We are committed to completing the transaction and are currently reviewing the opinion and will carefully evaluate our options   the company said in a statement  In a split decision  the U S  Court of Appeals for the D C  Circuit disagreed with Anthem s contention that the Justice Department and lower court improperly rejected its assertions that the deal would lead to billions of dollars in medical savings   Anthem has not explained why these projected savings would even exist   Judge Judith Rogers wrote in the opinion   The record is clear that Anthem  unlike Cigna  has already achieved whatever economies of scale are available   In a dissent  Judge Brett Kavanaugh argued that the merger would benefit the biggest customers  mainly large companies with employees in many states  Kavanaugh argued that a combined Anthem Cigna would require higher payments to manage the accounts but that would be offset by better negotiated rates paid to providers  Kavanaugh  however  noted that the deal could be stopped based on monopsony arguments that the new company would have too much heft in negotiating with doctors and hospitals  Anthem  a member of the Blue Cross Blue Shield Association  is the second biggest seller of medical insurance to big U S  companies  Cigna is in third place  Bill Baer  the former head of the Justice Department s Antitrust Division who had made the decision to challenge both insurance mergers  said in an email that the ruling on the Anthem Cigna deal  is a ringing endorsement of the importance of competition in health insurance markets    The Justice Department  now under President Donald Trump  also said that it was pleased by the decision  Eric Schneiderman  attorney general of New York  which was among the states that had opposed the deal  also said he was pleased with the ruling   This is a red letter day for consumers   said David Balto  an antitrust lawyer who opposed the deal  
In another obstacle  Anthem and Cigna have been at loggerheads for months and are suing each other  Cigna has sought to abandon the merger and force Anthem to pay a  1 85 billion breakup fee while Anthem filed a lawsuit to force its smaller rival to go through with the combination ",2017-04-28,Reuters,https://www.investing.com/news/stock-market-news/u.s.-appeals-court-blocks-anthem-bid-to-merge-with-rival-cigna-478536,478536
141737,363252,HUM,Insurer Aetna posts loss  evaluates Obamacare exposure,news,"By Caroline Humer  Reuters     Aetna Inc   N AET  reported a quarterly net loss on Tuesday related to costs from its failed acquisition of  Humana Inc   N HUM  and said it will cut exposure to money losing Obamacare coverage in 2018  Like other U S  based health insurers including Anthem Inc  N ANTM  and Molina Healthcare Corp  N MOH   Aetna faces deadlines to file 2018 plans but is uncertain about components of premium rates such as the continuation of government subsidies and the mandate for Americans to have insurance  President Donald Trump has vowed to repeal and replace the Affordable Care Act  often called Obamacare  although Republican lawmakers have not agreed on how to do so  Insurers are weighing unresolved issues such as a costly health insurance tax in 2018 and the loss of significant government subsidies as soon as this year   We continue to evaluate our footprint with a view towards significantly reducing our exposure to individual commercial products in 2018   Aetna Chief Financial Officer Shawn Guertin said during a conference call  In an interview  Guertin explained that the company is making decisions about the three remaining states where it sells these plans based on the current situation  Aetna  which has 255 000 customers in individual plans that comply with Obamacare  said customer medical costs were high and recorded a  110 million premium deficiency reserve in the first quarter for future losses   The company said its first quarter net loss was  381 million  or  1 11 per share  compared with a profit of  737 million  or  2 08 per share  a year earlier   That reflected a more than  1 billion termination fee for walking away from Humana in January after a federal judge backed the U S  Justice Department s decision to block the deal on antitrust grounds  Aetna said that even without Humana  it will grow its Medicare government business for elderly people and that it is pursuing contracts in the Medicaid program for the poor  Excluding one time costs  the company reported a better than expected  2 71 per share  above analysts  average estimate of  2 37  according to Thomson Reuters I B E S  Aetna shares were up 1 6 percent  or  2 21  at  139 02   Leerink analyst Ana Gupte said the shares had already risen in recent weeks after UnitedHealth Group Inc  N UNH  and Anthem Inc  N ANTM  reported earnings  capping today s gains   Aetna raised its forecast for 2017 adjusted earnings to  8 80  9 00 per share from at least  8 55 per share  but Gupte said that while the forecast for this year was strong Aetna s medium term outlook was weak compared to rivals   
 They don t have any really exciting growth platform   she said ",2017-05-02,Reuters,https://www.investing.com/news/stock-market-news/health-insurer-aetna's-adjusted-profit-breezes-past-estimates-479241,479241
141738,363253,HUM,Company News For Nov 8  2018,opinion,DISH Network Corporation s   NASDAQ DISH   shares gained 2  after the company reported third quarter 2018 earnings of  0 82 per share  beating the Zacks Consensus Estimate of  0 67 per shareShares of Michael Kors Holdings Limited   NYSE KORS   plummeted 14 6  after the company reported second quarter fiscal 2019 revenues of  1 253 8 million  missing the Zacks Consensus Estimate of  1 259 3 millionHumana Inc  s   NYSE HUM   shares jumped 6 7  after the company reported third quarter 2018 operating earnings of  4 58 per share  surpassing the Zacks Consensus Estimate of  4 29 per shareDean Foods Company s   NYSE DF   shares declined 22 1  after the company reported third quarter 2018 loss of  0 28 per share  wider than the Zacks Consensus Estimate of a loss of  0 06 per share,2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-nov-8-2018-200356909,200356909
141739,363254,HUM,Here s What Makes Molina Healthcare  MOH  An Attractive Bet,opinion,"Molina Healthcare  Inc    NYSE MOH   should gain from the recent mid term elections  which saw the Democratic party gaining control of the House of Representatives  This  means that chances of the repeal of Obamacare  as sought by the Republican party over the past two years has dimmed  It also implies that changes to health insurance exchanges  HIX  and Medicaid expansion will be off the table Moreover  Medicaid expansion has been approved in the three states of Nebraska  Idaho  and Utah  covering around 300 000 low income people  Molina Healthcare should gain from Medicaid expansion in Utah along with the proposed expansion in Wiconsin Molina Healthcare primarily deals in Government health insurance plans such as Medicaid  Medicaid etc  As of Sep 30  2018  the company s Medicaid membership  3 515 million  was 88  of its total membership  The Medicaid business generated 77  of the company s total premium in the first nine months of 2018  Since 2014   when Medicaid expansion came into effect  through Sep 30  2018  the company s membership from Medicaid expansion has grown  to 664 000 from 385 000  Therefore expansion in Medicaid business bodes well for Molina Healthcare Moreover  Molina Healthcare s revenues have an exposure of nearly 9  to HIX  The company s Marketplace business is now stable after years of corrective pricing actions and instability  It is now producing after tax margins of 9  to 10   The Marketplace business is a significant part of the company s overall margin recovery story  Thus stabilization in the Marketplace business across the industry should aid Molina Healthcare s revenues Apart from industry specific and regulatory factors  the company is gaining from the margin turnaround initiatives taken at the start of the year  The company s results for the first nine months of 2018reflected continued improvement in its business performance and the significant progress made in executing margin recovery and sustainability plan  which saw total expenses come down by 12   The company also recently sold its business Molina Medicaid Solutions to focus on core growth areas and to use funds for deleveraging  thus strengthening its balance sheet The company has also raised its full year guidance to a range of  8 80 to  9 00 per diluted share  marking an increase of  1 65 on a GAAP basis and an increase of  2 60 on a non GAAP basis at the midpoint from its previous guidance issue on Aug 1 This increase has been driven by better medical cost control  better than expected performance in Marketplace business and steady performance of its Medicaid product All in all  Molina Healthcare is well poised for growth due to both company specific and industry related factors  The stock has gained a good 67  in a year s time  handily outperforming the  s growth of 28  We believe this Zacks Rank  1  Strong Buy  stock is further poised for growth given its strong fundamentals 
You can see  Other stocks worth mentioning are UnitedHealth Group Inc    NYSE UNH    Anthem Inc    NYSE ANTM   and Humana Inc    NYSE HUM    Each of these stocks carries a Zacks Rank  2  Buy  and has surpassed the Zacks Consensus Estimate in each of the four reported quarters  with an average positive surprise of 3 67   5 11  and 4 73   respectively Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-11-15,Zacks Investment Research,https://www.investing.com/analysis/heres-what-makes-molina-healthcare-moh-an-attractive-bet-200359480,200359480
141740,363255,HUM,Humana Sees Hammer Chart Pattern  Time To Buy ,opinion,Humana Inc    NYSE HUM   has been struggling lately  but the selling pressure may be coming to an end soon  That is because HUM recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom What is a Hammer Chart Pattern  A hammer chart pattern is a popular technical indicator that is used in candlestick charting  The hammer appears when a stock tumbles during the day  but then finds strength at some point in the session to close near or above its opening price  This forms a candlestick that resembles a hammer  and it can suggest that the market has found a low point in the stock  and that better days are ahead Other FactorsPlus  earnings estimates have been rising for this company  even despite the sluggish trading lately  In just the past 60 days alone 12 estimates have gone higher  compared to none lower  while the consensus estimate has also moved in the right direction Estimates have actually risen so much that the stock now has a Zacks Rank  2  Buy  suggesting this relatively unloved stock could be due for a breakout soon  This will be especially true if HUM stock can build momentum from here and find a way to continue higher of off this encouraging trading development  You can see Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-21,Zacks Investment Research,https://www.investing.com/analysis/humana-sees-hammer-chart-pattern-time-to-buy-200361363,200361363
141741,363256,HUM,Here s Why Humana  HUM  Stock Looks Attractive Right Now,opinion,"Humana Inc    NYSE HUM   stock looks promising at the moment considering the mid term election  which should enable averting  modifications to Obamacare and aid the Medicaid expansion and Medicare growth Though Humana has low percentage of revenues drawn from Medicaid business  it is growing further and should also gain from certain developments contributing to the stock s growth  The company s Medicare business commands a strong position in the market  which should ride on increased demand from the retiring American population We are optimistic about the company s prospects and believe that the time is right for investors to add the stock to their portfolio as it looks to possess great potential and is poised to carry the momentum ahead The stock has seen the Zacks Consensus Estimate for current year earnings being revised 1 9  upward over the past 30 days Humana boasts a stellar earnings surprise history  having missed estimates only once in the last 14 reported quarters  that too by just a cent or 0 01    The company s earnings surprise record has instilled enough confidence in investors  Though past performance doesn t guarantee future results  it certainly lends a broader perspective to the company s operational efficiency   Moreover  with no serious headwinds posing a threat to the company  we believe that its favorable earnings trend will continue into the coming quarters  The company s stock price should therefore consistently rally since an earnings beat is one of the main factors to push up the stock price Shares of Humana have outperformed the industry  in a year s time  having rallied 27  compared with the   s growth of 22  Factors That Make the Stock Attractive Gain From Medicaid Expansion  The company should benefit from the recent mid term election  which saw the Democratic party gaining control of the House of Representatives  This means that chances of the repeal of Obamacare as sought by the Republican party over the past couple of years have slimmed  It also implies that changes to health insurance exchanges  HIX  and Medicaid expansion will be off the table  Other companies that should gain from this change are Molina Healthcare Inc    NYSE MOH    Centene Corp    NYSE CNC    WellCare Health Plans  Inc    NYSE WCG    et al Demographic Change to Boost Medicare Business  Humana has a significant presence in the Medicare Advantage market  a profitable business for private insurers  The company witnessed average 5 5  growth of total Retail Medicare membership in the last four years  Also  the same increased 8 5  year over year for the first nine months of 2018  This business is definitely slated for strong growth taking into account hordes of baby boomers  who touch the retirement age on a daily basis and even prefer the Medicare Advantage plans  Also favorable  medicare reimbursement rates for 2019 makes this business attractive Acquisitions  More than a dozen buyouts made over the past decade provided the company with a robust inorganic growth story to operate in the competitive healthcare environment This year  the company completed the transactions of Kindred Healthcare and Family Physicians Group  which point to its concerted efforts in acquiring providers of care  While Kindred Healthcare provides Humana an entry in the home healthcare industry  which is poised for rapid growth  Family Physicians as one of the largest providers to Medicare and Medicaid beneficiaries in Central Florida will enable the company to woo patients insured by Medicare and private Advantage plans in the state Earnings Guidance Lifted  Better than expected third quarter 2018 results prompted Humana to raise its EPS outlook for 2018  It now expects the same to be around  14 40  up from the prior prediction of  14 15  GAAP EPS is projected at around  11 92  above the past forecast of  11 52  This bullish guidance buoys investor s optimism on the stock and also fuel the stock price surge Top Rank   VGM Score  Humana currently has a Zacks Rank  2  Buy  and an impressive  of A  Our research shows that stocks with a VGM Score of A or B when combined with a Zacks Rank  1  Strong Buy  or 2  offer the best investment opportunities for investors  Thus  the company appears to be a compelling investment proposition at the moment 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-11-22,Zacks Investment Research,https://www.investing.com/analysis/heres-why-humana-hum-stock-looks-attractive-right-now-200361998,200361998
141742,363257,HUM,Humana To Gain From Share Buyback  Raise Membership Outlook,opinion,"Shares of Humana Inc    NYSE HUM   have gained by more than 6  in yesterday s trading  after the company announced an accelerated share buyback program and revised 2019 Medicare Advantage  MA  membership outlook  The company also reaffirmed its 2018 adjusted earnings per share guidance of  14 40 
Humana plans to repurchase its common stock worth  750 million through an accelerated stock repurchase agreement  the  ASR Agreement   as part of the  3 0 billion share repurchase program  announced by the company on Dec 14  2017 The ASR Agreement is consistent with the company s previously anticipated capital deployment plans for the remainder of 2018 and 2019  This should aid the bottom line The company increased its membership growth outlook for Individual MA in 2019 from 350 000 to 400 000 members  This represents an increase of 100 000 members from its initial estimate  and 11  to 13  increase from the expected year ended Dec 31  2018 membership level of approximately 3 07 million members The upward revision was driven by better than expected retention of existing members during the Annual Enrollment Period  AEP  and higher than expected sales For Group MA  net membership gains for 2019 are expected to increase approximately 30 000 members year over year 
However  for Prescription Part D  PDP   the company now estimates a net membership decline of 750 000 to 800 000 members for the year ended Dec 31  2019  compared to its initial estimate of a decline of approximately 500 000 members  The net decline is primarily attributable to the competitive nature of the industry and the erosion of the pricing discipline enjoyed by the company so far 
Humana generates more than 50  of its premiums from MA and an increase in membership in these lines of business definitely bodes well for the company  Moreover  a favorable MA reimbursement is another tailwind 
Year to date  stock of the company has gained 33  compared with the  s growth of 26  

 
Earlier during the week  UnitedHealth Group Inc    NYSE UNH   also provided strong guidance for 2019  The health insurance industry has performed very well this year and is slated for further growth from expected Medicaid expansion  increase in Medicare Advantage and overall improvement of regulatory climate   
Zacks Rank   Other Stocks to Consider
Humana carries a Zacks Rank  2  Buy   Other stocks worth considering are Molina Healthcare Inc    NYSE MOH   and Anthem  Inc    NYSE ANTM    Both the companies carry a Zacks Rank  1  Strong Buy  
You can see  
Both Molina Healthcare and Anthem have surpassed their respective estimates in each of the trailing four quarters with average positive surprises of 82 6  and 5 11   respectively 
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-29,Zacks Investment Research,https://www.investing.com/analysis/humana-to-gain-from-share-buyback-raise-membership-outlook-200363728,200363728
141743,363258,HUM,HMO Industry Surges Almost 4 Times S P 500  4 Picks,opinion,"The Health Maintenance Organization  HMO  industry has been one of the solid gainers so far this year  despite the stiff regulations binding it  Interest rate hike and trade war disturbances  which caused far and wide fluctuation to returns of many industries like utilities  banks  automobiles  manufacturing  have little or almost no effect on this industry of the health care sector The S P 500 Managed Health Care Index has gained 23 7  in a year s time compared with the 6 12  rise in the S P 500 Index The ruling factors of the HMO industry are the many state and federal regulations that monitor their working and affect their business performance  The most stringent regulatory reform was the Affordable Care Act that was enacted in 2010  But insurers have synced their operations in line with the regulatory mandates  which are now paying off The year also saw many trials by the Trump administration to repeal the ACA  which however  failed to take place  The changes  if would have taken place  would have led insurers to again adapt to new regulations  thus subjecting them to again redo some parts of their business workings But mid term elections  which saw the change in Republican control in the house of representatives  have now further pushed backed or almost put off the table any changes that would be made to the ACA in the near term  This implies that the existing regulations would continue and health insurers will not have to commit resources to fine tune their operations at least for now An increase in employment has also induced demand for health insurance from employers for their employees  aiding revenue growth for the health insurance companies  Also  changes in demography with baby boomers retiring in hordes each day  have driven up demand for Medicare plans of the HMOs Moreover  business growing outside the health insurance realm has diversified earnings of the players in the industry  The poster child of the same is the development of the Optum unit of UnitedHealth  NYSE UNH   which has contributed to an increasing proportion of revenues to its consolidated revenues and falls outside the regulations that bind the business of health insurance  Other companies such as Humana and Anthem have also been consistently growing their health service business Zacks Industry Rank and ReturnsThe group s   which is basically the average of the Zacks Rank of all the member stocks  indicates bright prospects in the near term  The Zacks   which is an 11 stock group within the broader Zacks  sector  currently carries a Zacks Industry Rank  38  which places it at the top 15  of 257 Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperforms the bottom 50  by a factor of more than 2 to 1 The industry s positioning in the top 50  of the Zacks ranked industries is a result of positive earnings outlook for the constituent companies in aggregate  In a year s time  the industry s earnings estimate for the current year has gone up 17 2  The Zacks Medial HMO on industry  which is a stock group within the broader Zacks Medical Sector  has outperformed both the S P 500 and its own Medical sector over the past year We see that the stocks in this industry have collectively gained 29 3  over the past year  while the Zacks S P 500 composite and Zacks Medical Sector have rallied 4 7  and 4 5   respectively What s in Store for 2019 The industry is expected to continue with its stellar performance in 2019  with the easing out of regulatory uncertainty  investment in technological investment and upgrade  application of blockchain technology  growth of new business units  international expansion  better claims handling  medical cost management  mergers and acquisitions and healthy balance sheets Also  the midterm elections  which saw the passage of ballot initiatives to expand Medicaid under the ACA  are a positive for the industry  This bodes well for HMOs as increasing member enrollment in Medicaid should aid their top line The stabilization of health insurance exchanges is also favorable  Administrative actions  such as encouraging people to maintain continuous coverage and attracting younger and healthier people to join the market  taken last year by the CMS  have paid off as some of the players that exited the health insurance exchanges in many markets over 2016 and 2017 have returned  Some of the returning companies are Anthem  Molina and Cigna All in all the health insurance industry is slated for another good ride in 2019  So picking up some solid stocks from this space should be a good investment move  Each of these stocks have has witnessed an upward revision in earnings estimates for 2018 and 2019 and carries a strong Zacks Rank Top PicksAnthem  Inc    NYSE ANTM   operates as a health benefits company in the United States  The company should see top line growth from an increase in enrollment in Medicare Advantage plans  A strong balance sheet with positive cash flows should help it to invest in growth The company currently has a Zacks Rank  2 and VGM Score of B  The Zacks Consensus Estimate for its current year earnings and 2019 moved up 1 2  and 0 4   respectively  in the last 60 days 
You can see Humana Inc    NYSE HUM   should gain from its growing Medicare business  as the same is in high demand from the retiring baby boomer population  Also  its health services business provides diversification benefits The company currently has a Zacks Rank  2 and VGM Score of A  The Zacks Consensus Estimate for its current year earnings and 2019 moved up 1 8  and 1   respectively  in the last 30 days Cigna Corp    NYSE CI   is a health benefits company and its acquisition of Express Scripts  NASDAQ ESRX   a pharmacy benefits manger  due to be closed this month  bodes well for its long term growth  which will help it to expand vertically  It company currently has a Zacks Rank  1  The Zacks Consensus Estimate for its current year earnings and 2019 moved up 0 9  and 3 9   respectively  in the last 30 days Molina Healthcare Inc    NYSE MOH   deals mainly in government related plans such as Medicaid  and is expected to gain from the Medicaid expansion  The company currently has a Zacks Rank  1 and Value Score of B  The Zacks Consensus Estimate for its current year earnings and 2019 moved up 10 9  and 10 4   respectively  in the last 30 days 
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-03,Zacks Investment Research,https://www.investing.com/analysis/hmo-industry-surges-almost-4-times-sp-500-4-picks-200364757,200364757
141766,363281,HUM,Top 5 Things to Know in the Market on Monday,news,"Investing com   Here are the top five things you need to know in financial markets on Monday  February 27 
1  Global stocks in holding pattern before Trump speech
U S  stock market futures pointed to a muted open near all time highs on Monday morning  as investors looked ahead to President Donald Trump s speech to Congress on Tuesday  where he is expected to provide clues on his plans to cut taxes 
President Trump has been credited with being a major catalyst behind the stock market s impressive rally in recent weeks  although he has yet to outline his economic policies in detail 
In Europe  stocks were mixed in mid morning trade  but held near their best levels since late 2015 
Earlier  in Asia  markets ended mostly lower  with the Shanghai Composite in China closing down around 0 8   while Japan s Nikkei dropped about 0 9  
2  Dollar treads water ahead of busy week
The dollar was little changed against the other major currencies on Monday as traders avoided taking strong positions before President Trump s address to Congress  a speech by Federal Reserve Chair Janet Yellen and important economic data in the week ahead 
The U S  dollar index  which measures the greenback s strength against a trade weighted basket of six major currencies  was steady at 101 05 in New York morning trade 
Treasury yields inched higher after falling to a five week low of 2 31  on Friday  with the U S  10 Year bond at around 2 338  
Against the yen  the dollar added 0 1  to 112 24  after falling to a low of 111 92 earlier in the session  its lowest since February 9 
Meanwhile  the euro was up 0 2  on the day at 1 0582  as concerns about France s upcoming election eased following favorable opinion polls for independent presidential candidate Emmanuel Macron 
3  Trump to meet with health insurers
President Donald Trump will meet with top executives from the health insurance industry at the White House on Monday 
Cigna  NYSE CI  s chief executive officer  David Cordani  and Humana  NYSE HUM  CEO Bruce Broussard are among a group of industry leaders due to meet with the president  The Blue Cross Blue Shield Association  which represents insurers in every state  will also attend 
Trump has pledged to repeal and replace Obamacare  former President Barack Obama s national healthcare law that redesigned the U S  insurance market for individuals  It is not clear yet what Republicans will agree upon to replace the current insurance  Insurers say any new plans are not likely to hit the market before 2019 
4  Scottish referendum fears weigh on pound
The British pound dropped against all its major peers on Monday  following a report of a possible Scottish independence referendum in March 
GBP USD skidded 0 3  to 1 2428  after touching a daily low of 1 2385  a level not seen since February 15  while EUR GBP gained 0 3  to 0 8515 
Sterling was pressured after The Times reported that U K  Prime Minister Theresa May is preparing for the Scottish government to call a second independence referendum  which will reportedly coincide with the triggering of Article 50 expected in March 
On Friday  the pound began to slide after the Independent newspaper reported the Scottish government is seriously considering a second independence referendum next year 
5  LSE  Deutsche Boerse deal in jeopardy
 London Stock Exchange  Group  LON LSE  said its proposed merger with Deutsche Boerse  DE DB1Gn  was unlikely to be approved by the European Commission  leaving the stock market operators  third attempt at combining on the brink of failure 
The two exchanges announced plans to merge in a 29 billion euro deal just over a year ago  aiming to create a giant trading powerhouse that would better compete against U S  rivals that were starting to encroach on the pair s turf 
But the LSE said late Sunday it wouldn t sell its majority owned fixed income trading platform in Italy to appease antitrust concerns over the deal 
Shares of LSE lost more than 3  in London  while Deutsche Boerse shares dropped 3  in Frankfurt ",2017-02-27,Investing.com,https://www.investing.com/news/economy-news/top-5-things-to-know-in-the-market-on-monday-462317,462317
141767,363282,HUM,Anthem and Blue Crosses loom large in Obamacare talks,news,"By Caroline Humer NEW YORK  Reuters    Anthem Inc   N ANTM  and other U S  health insurers complained to the White House for more than a year that they were losing money on people who waited to sign up for Obamacare coverage until they were sick  They pleaded with the Obama administration to stem their losses by tightening up on the enrolment rules  When their pleas went unmet  UnitedHealth Group Inc  N UNH    Humana Inc   N HUM   and  Aetna Inc   N AET  pulled out of most of the government subsidized health insurance market  But now that the new Trump administration and Republican lawmakers control the future of healthcare  the industry is getting a new hearing  And Anthem   the last national insurer playing big in the Obamacare market   is the loudest industry voice in meetings with policymakers who all have pledged to overthrow former President Barack Obama s signature law  President Donald Trump  who has said Obamacare coverage is too costly for customers and taxpayers  is set to meet with insurance industry executives today  Since the election  lobbyists for Anthem and affiliated Blue Cross insurers have met  24 7   with Republicans leading the change effort  including House Speaker Paul Ryan and Senate Majority Leader Mitch McConnell  according to one healthcare industry lobbyist  They are there  every time Senators and staffers are on the Hill   the lobbyist said  Another industry source who attended some of the meetings said lawmakers and aides were keen on hearing what the insurers needed to stay in the market  That clout may explain Anthem Chief Executive Joseph Swedish s optimism in comments to investors earlier this month that policymakers would introduce new enrollment rules limiting when people can opt into coverage   We do have some positive indicators that stabilization could very likely occur   Swedish said   I am again hopeful that our recommendations will be looked at very carefully and adopted   A day later  the Trump administration took its first concrete stab at Obama s Affordable Care Act  proposing regulations that would shorten the enrollment period  establish a new eligibility verification process and force members to pay delinquent premiums if they want to return to the same insurer  The so called stabilization proposal addressed many of the industry s top demands for shoring up the individual market and came after Anthem said it was considering whether it would remain in 2018  Anthem is the largest insurer among the Blues  a collection of companies that share a governing board  a brand and networks  As a group  they cover the vast majority of people covered by Obamacare  That means they have the most at stake and a lot of influence in shaping the future of an insurance market that covers more than 10 million people  according to people close to the negotiations   Blue Cross Blue Shield does have a larger role in discussing changes   said an aide to a key Republican Senator  TRUMP S 3  R s  REPEAL  REPLACE  REPAIR Trump has said he wants to jettison the 2010 law that created Obamacare and replace it with legislation that would change access to individual insurance and the Medicaid program for the poor  A copy of the administration s Feb  10 working draft leaked out Friday  But it was not clear whether there was enough support for all of the measures or how it would evolve  Any major changes aren t likely to affect consumers before 2019  In the meantime  Republican lawmakers are hammering out tweaks to Obamacare they view necessary to preventing any more insurers from exiting  They are looking at ways to limit monthly premium increases  For 2017  the average premium went up 25 percent in these Obamacare plans  which incensed many consumers  Anthem and other Blue Cross plans dominated the individual market before Obamacare coverage took effect in 2014  Obamacare remade that market and sought to stimulate competition by financing the start up of about two dozen smaller insurance co ops  The Obama administration also courted big players  such as Aetna and UnitedHealth  by forecasting rapid enrolment growth to more than 20 million people  which failed to materialize  Anthem operates the BCBS license in 14 states and insures more than 800 000 people in the Obamacare exchanges   the single biggest portion  It said it was making a slight profit on that business  Its rivals exited after losing hundreds of millions of dollars last year  Wall Street analysts said Anthem was better at pricing and benefited from a well known brand  Its huge pool of members also helps Anthem drive good deals with doctors and hospitals  Still  Anthem s business is mostly in the employer based market  Obamacare customers comprised only about 4 percent of its members at the end of 2016  Ethan Lovell  co portfolio manager at the Janus Global Life Sciences fund that owns Anthem shares  said without changes to the exchange rules  the company would likely have to raise the average premium 20 percent in 2018  as it did for this year  to keep from losing money  In addition to the enrolment rules  Anthem is seeking changes in the way payments for the sickest patients are calculated  It also wants an extension to the planned discontinuation at year s end of plans that were issued before Obamacare and that don t meet the law s coverage requirements  Ed Haislmaier  senior health policy research fellow at The Heritage Foundation  helped draft the proposed stabilization rule Trump announced Feb  2  He said he expected the Trump administration to also address Anthem s older plans  Swedish also wants the elimination of one of Obamacare s most controversial revenue sources   an industry wide premium tax that insurers say has driven up premiums in all private U S  health insurance and that lawmakers agreed last year to set aside for a year  
On January 4  Representatives Kristi Noem  a Republican from South Dakota  and Kyrsten Sinema  a Democrat from Arizona  introduced the Jobs and Premium Protection Act that would repeal the premium tax  it has 145 co sponsors ",2017-02-27,Reuters,https://www.investing.com/news/stock-market-news/anthem-and-blue-crosses-loom-large-in-obamacare-talks-462314,462314
141768,363283,HUM, U S  futures lower as markets wait for Trump  durable goods on tap,news,"Investing com   Wall Street futures pointed to a slightly lower open on Monday as investors waited for a couple of data points with markets likely to be on hold ahead of President Donald Trump s speech to Congress a day later 
The blue chip Dow futures fell 27 points  or 0 13   by 6 57AM ET  11 57GMT   the S P 500 futures slipped 1 point  or 0 06   while the tech heavy Nasdaq 100 futures lost 7 points  or 0 12  
Markets showed little movement as investors looked ahead to Trump s speech to Congress on Tuesday  where he is expected to provide clues on his plans to on policy priorities and goals  especially on taxes  trade and public investment 
On Monday  the President will meet with top executives from the health insurance industry at 10 30AM ET  15 30GMT  at the White House in what would appear to be preparation for his plan to repeal and replace Obamacare 
Cigna  NYSE CI  s chief executive officer  David Cordani  and Humana  NYSE HUM  CEO Bruce Broussard are among a group of industry leaders due to meet with the president  The Blue Cross Blue Shield Association  which represents insurers in every state  will also attend 
On the data front  January durable goods orders will be out at 8 30AM ET  13 30GMT  followed by pending home sales for the same month at 10 00AM ET  15 00GMT  
Dallas Federal Reserve president Robert Kaplan will also be speaking at 11 00AM ET  16 00GMT  
Meanwhile  oil prices traded higher on Monday  rising back toward an eight week high on increasing confidence that OPEC s supply curbs will outweigh a gain in U S  stockpiles 
U S  crude futures gained 0 69  to  54 36 by 6 58AM ET  11 58GMT   while Brent oil traded up 0 87  to  56 80 
Elsewhere  sterling was under pressure Monday on reports of a possible push for a fresh Scottish referendum over its independence from Britain as the U K  moves forward with plans to leave the European Union 
The Times reported U K  PM Theresa May s government is bracing for a new move for a vote on Scottish independence which could coincide with the triggering of the Article 50 which begins negotiations for Britain to leave ",2017-02-27,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-futures-lower-as-markets-wait-for-trump;-durable-goods-on-tap-462332,462332
141769,363284,HUM,Wall St closes lower  Dow posts first 2 day losing streak since Jan 2 ,news,"Investing com   Wall Street closed lower on Tuesday  as investors considered the prospect of a March rate hike while healthcare stocks tumbled after a warning from President Donald Trump 
Healthcare stocks  started the session on the back foot  after President Donald Trump claimed on Tuesday that he will bring drug prices  way down  



Trump s tweet supported his earlier statement in January  when he claimed that pharmaceutical companies are  getting away with murder  in what they charge the government for medicine 
Merck   Company Inc  NYSE MRK    Pfizer  Inc  NYSE PFE  as well as a slew of European household pharmaceutical stocks sank lower 
Meanwhile  economic data had little impact on U S  equities  after data showed the U S  trade deficit grew in January to its widest monthly level in almost five years 
The commerce department said Tuesday  the trade gap widened by 9 6  to  48 5 billion in January  the highest level since March 2012  and in line with economists  forecasts 
The Dow Jones Industrial Average closed 0 15  lower at 20 922  The S P 500 shed 0 29  and the Nasdaq Composite lost 0 26  to close at 5 833  It was the first time since Jan 2  the Dow and S P closed lower for a second straight session 
In corporate earnings news  Dick s Sporting Goods Inc  NYSE DKS  slumped more than 9  despite decent posting decent earnings for the fourth quarter  as the retailer issued a downbeat forecast for 2017 
The top S P 500 gainers included  Humana Inc   NYSE HUM  up 2 4   and Viacom B Inc  NASDAQ VIAB  up 1 8   while  Albemarle  Corporation  NYSE ALB  added 1 6  
Frontier Communications Corporation  NASDAQ FTR  down 5 1   Southwestern Energy Company  NYSE SWN  down 4 2  and Express Scripts Holding Co  NASDAQ ESRX  slumped 3 8   were among the worst S P 500 performers of the session ",2017-03-07,Investing.com,https://www.investing.com/news/commodities-news/wall-st-closes-lower:-dow-posts-first-2-day-losing-streak-since-jan-2-464437,464437
141770,363285,HUM,U S  investigates four insurers over Medicare payments,news,"By Nate Raymond  Reuters    The U S  Justice Department has disclosed an investigation into four health insurers after a lawsuit accused them of defrauding Medicare by claiming patients were treated for conditions they did not have or received no treatment for  The probe of Health Net Inc  PK MAHN    Aetna Inc   N AET   Cigna Corp s  N CI  Bravo Health Inc and  Humana Inc   N HUM  was revealed in papers filed on Tuesday in federal court in Los Angeles  in a lawsuit the government recently joined against UnitedHealth Group Inc  N UNH   The department last month partially intervened in the U S  False Claims Act lawsuit brought by a former UnitedHealth executive  Benjamin Poehling  whose whistleblower case against the company and other insurers was filed under seal in 2011  Under the False Claims Act  whistleblowers can sue companies on the government s behalf to recover taxpayer money paid out based on fraudulent claims  If successful  whistleblowers receive a percentage of the recovery  A government decision to intervene is typically a major boost to such cases  When it initially intervened in the case in February  the Justice Department said it was declining to pursue claims against other insurers named in the lawsuit besides UnitedHealth  But on Tuesday  the Justice Department filed a  corrected notice  of intervention  saying that  due to ongoing investigations of Health Net  Aetna  Bravo and Humana  it could not make a decision as to whether to proceed against them  Humana spokesman Tom Noland said in an email the company had previously disclosed the investigation in filings with the U S  Securities and Exchange Commission  Humana has said it would cooperate with authorities  UnitedHealth has said it rejects the allegations  A spokesman had no immediate comment on Friday  Aetna and Health Net declined to comment  Representatives for Cigna did not respond to a request for comment on Friday  nor did the Justice Department  A lawyer for Poehling had no immediate comment  Poehling s lawsuit accused UnitedHealth  Health Net  Aetna  Bravo Health  Humana and other insurers of defrauding the United States of hundreds of millions   and likely billions   of dollars through claims for payments from the Medicare healthcare program for the elderly  The lawsuit centered on  risk adjustment  payments that Medicare makes to managed care plans to offset the increased costs associated with treating patients with multiple or serious health conditions  The lawsuit claimed that  in seeking those payments  the insurers falsely claimed that patients were treated for diagnoses they did not have or were not treated for  
The case is U S  ex rel  Benjamin Poehling v  UnitedHealth Group Inc et al  U S  District Court  Central District of California  No  16 cv 08697 ",2017-03-17,Reuters,https://www.investing.com/news/stock-market-news/u.s.-probing-insurers-beyond-unitedhealth-over-medicare-charges-467057,467057
141771,363286,HUM,Obamacare exploding  Maybe just a slow burn,news,"By Caroline Humer and Yasmeen Abutaleb NEW YORK WASHINGTON  Reuters    U S  President Donald Trump said on Friday that Obamacare was  exploding  after Republican lawmakers shelved legislation that would have dismantled the healthcare law   That s not going to happen this month  Probably not even this year  The more than 12 million people who bought 2017 health insurance plans on HealthCare gov and other websites the law created are not in danger of losing their healthcare or having their premiums go up right now  experts say  But 2018 is another story  Republicans could choose to pass a budget that defunds Obamacare s cost sharing subsidies  which help low income people cover out of pocket and other medical costs  But that would be highly unpopular among consumers who would likely blame the president and Congress for skyrocketing healthcare costs  experts said    That is one of the ways that is available to monkey wrench the Affordable Care Act   said Morgan Tilleman  an associate with the law firm Foley   Lardner  who represents insurers  Obamacare  former Democratic President Barack Obama s signature legislation created by the Affordable Care Act of 2010  has had a tough beginning  The mix of sick and healthy customers has been worse than expected  and premium rates on the individual insurance market went up 25 percent this year  Other parts of the law  like the expansion of Medicaid to enhance coverage for the poor  and changes to allow young people to stay on their parents  health plans  have been popular  And the defeat of the bill is a win for the hospitals that have benefited from those increased Medicaid dollars  But many counties across the country have only one insurer  after  Humana Inc   NYSE HUM    Aetna Inc   NYSE AET  and UnitedHealth Group Inc  NYSE UNH  pulled out after reporting hundreds of millions of dollars of losses   The insurers who are left  Anthem Inc and other BlueCross BlueShield insurers across the country  as well as smaller players like Centene Corp and Molina Healthcare Inc need to decide in the next few months where to sell insurance and how much to charge   And that is where the market s slow burn takes off  with insurers leaving and premiums rising  Jeff Jonas  a portfolio manager at Gabelli Funds who focuses on health care  said that for consumers  2018 looks uncertain  with a  death spiral  of decreasing competition and increasing premium rates ramping up   LOOKING TO 2018  After the failed Republican effort to push through the bill  insurers are looking at changes to help 2018  America s Health Insurance Plans spokeswoman Kristine Grow said  That includes the market s cost sharing subsidies as well as other government payments for sicker than usual customers and finalizing a rule the Trump administration proposed that addresses issues insurers say drives up costs   The Trump administration could do some of that itself if it wants to  such as using its regulatory authority to adjust the formula for how it compensates insurers for the sickest people  Elizabeth Carpenter at healthcare consultancy and research firm Avalere Health said   But it is unknown if the administration will try to work within the law s existing framework or take actions to undermine it and blame the Democrats for its failure   If they fail to act and they don t act in an appropriate way  that will further destabilize the marketplace   Dr  Mario Molina  CEO of Molina Healthcare  said  Molina s enrollment ballooned to 1 million exchange enrollees this year and the company is weighing if it will submit plans for next year  The administration could also decide to not enforce the individual mandate  which requires that everyone purchase health insurance or pay a fine  It already took steps to erode that provision last month  when it backed off implementing tougher oversight that was due to go into effect for 2016 taxes  Experts said the individual mandate still cost less than purchasing insurance  but as it increases each year more young and healthy people would have incentive to join the healthcare market  helping to offset the cost of sicker patients   The nonpartisan Congressional Budget Office estimated that 14 million more people would be uninsured under the Republican bill next year  with most of the increase coming from the repeal of the penalty associated with the individual mandate  It s unclear what the Republicans will do  Trump said this bill had been shelved but that Republicans would end up with a  great  healthcare bill in the future  but for now that they are moving onto tax reform   
Until they do that  they will have to work within the 2010 Affordable Care Act  It can also undercut the healthcare law through regulatory authority at the Department of Health and Human Services ",2017-03-24,Reuters,https://www.investing.com/news/politics-news/obamacare-exploding -maybe-just-a-slow-burn-468772,468772
141772,363287,HUM,Anthem likely to pull back from Obamacare markets in 2018  Jefferies,news," Reuters    Anthem Inc  N ANTM  is likely to exit from a large portion of its Obamacare individual insurance markets next year  Jefferies analysts said  nearly a week after Republican leaders pulled legislation to overhaul the U S  healthcare system  Anthem is one of the few health insurers that still sells plans under Obamacare   Humana Inc   N HUM    Aetna Inc   N AET  and UnitedHealth Group Inc  N UNH  pulled out after reporting hundreds of millions of dollars of losses  Anthem is leaning toward exiting a  high percentage  of the 144 rating regions in which it currently participates  Jefferies analysts said in a note on Thursday after talking to the health insurer  Obamacare  former Democratic President Barack Obama s signature legislation created by the Affordable Care Act of 2010  has had a tough beginning  The mix of sick and healthy customers has been worse than expected  and premium rates on the individual insurance market went up 25 percent this year   The Republicans  failure to repeal Obamacare  at least for now  means it remains federal law   We continue to actively pursue policy changes that will help with market stabilization and achieve the common goal of making quality health care more affordable and accessible for all   Anthem said in a statement  Shares of the company were up 1 4 percent at  167 29 in late afternoon trading  
The company s management notes that regulatory advocacy needs to progress significantly in a  month or so   said analysts David Windley and David Styblo  raising their price target on the stock to  177 from  172 ",2017-03-30,Reuters,https://www.investing.com/news/stock-market-news/anthem-likely-to-pull-back-from-obamacare-markets-in-2018:-jefferies-470055,470055
141773,363288,HUM,Is A Beat In Store For Humana  HUM  Stock In Q3 Earnings ,opinion,Humana Inc  s   NYSE HUM   third quarter 2018 results are scheduled to be reported on Nov 7  2018  In the last reported quarter  the company came up with a positive earnings surprise of 4 49  led by solid strategies  Medicare Advantage enrollment growth  lower inpatient medical utilization in Retail segment and impressive operating cost efficiencies The Zacks Consensus Estimate for third quarter earnings is pegged at  4 29  up 26 5  year over year Other FactorsThe company s top line is likely to increase on the back of Medicare Advantage as well as by strong segmental performances  The consensus mark for the metric stands at  13 9 billion  up 5  year over year The company s Retail segment would likely continue with its winning streak owing to higher revenues from its individual and group Medicare Advantage business as well as increased per member premiums for a few segmental products Humana s Group and Specialty segment would likely witness growth in revenues during the third quarter  boosted by premiums across most business lines in the segment   Humana expects its core health trend to be 6   plus or minus 50 basis points  along with the pre tax income guidance to remain the same for the entire year The overall Medical membership of the company stands at  16 5 billion  up by 18 3  from the prior year quarter Per the company  the reinsurance transactions would have a de minimis impact on its pretax for the second half of the year but would leave a significant effect on its benefit ratio  Humana also estimates the third quarter adjusted EPS to be around 31  of its full year tally What the Quantitative Model StatesOur proven model conclusively shows that Humana is likely to beat on earnings this to be reported quarter  This is because the stock needs to have the right combination of a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Earnings ESP  Humana has an Earnings ESP of  2 22   This is because the Most Accurate Estimate is pegged at  4 39  higher than the Zacks Consensus Estimate of  4 29  You can uncover the best stocks to buy or sell before they are reported with our  Humana Inc  Price and EPS Surprise    Zacks Rank  Humana carries a Zacks Rank  2  Buy   which increases the predictive power of ESP  Further  a positive ESP significantly raises the odds of a likely earnings surprise Conversely  the Sell rated stocks   4 or 5  should never be considered going into the earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks to ConsiderSome other stocks worth considering from the medical sector with the perfect combination of elements to also surpass estimates in the next releases are as follows BioDelivery Sciences International  Inc    NASDAQ BDSI   is slated to release third quarter earnings figures on Nov 8  This stock has an Earnings ESP of  1 89  and a Zacks Rank  3  You can see  National Vision Holdings  Inc    NASDAQ EYE   has an Earnings ESP of  6 12   This  1 Ranked company is set to report third quarter earnings on Nov 13 CRISPR THERAPTC   NASDAQ CRSP   is scheduled to announce third quarter 2018 earnings performance on Nov 14  The stock has an Earnings ESP of  3 53  and a Zacks Rank of 1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-04,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-humana-hum-stock-in-q3-earnings-200354764,200354764
141774,363289,HUM,Is A Surprise Coming For Humana  HUM  This Earnings Season ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Humana Inc    NYSE HUM   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because HUM is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for HUM in this report In fact  the Most Accurate Estimate for the current quarter is currently at  4 39 per share for HUM  compared to a broader Zacks Consensus Estimate of  4 29 per share  This suggests that analysts have very recently bumped up their estimates for HUM  giving the stock a Zacks Earnings ESP of  2 22  heading into earnings season Humana Inc  Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that HUM has a Zacks Rank  2  Buy  and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Clearly  recent earnings estimate revisions suggest that good things are ahead for HUM  and that a beat might be in the cards for the upcoming report Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/is-a-surprise-coming-for-humana-hum-this-earnings-season-200355422,200355422
141775,363290,HUM,Humana  HUM  Beats Q3 Earnings And Revenue Estimates,opinion,"Humana  HUM  came out with quarterly earnings of  4 58 per share  beating the Zacks Consensus Estimate of  4 29 per share  This compares to earnings of  3 39 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 6 76   A quarter ago  it was expected that this health insurer would post earnings of  3 79 per share when it actually produced earnings of  3 96  delivering a surprise of 4 49  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Humana  which belongs to the Zacks Medical   HMOs industry  posted revenues of  14 21 billion for the quarter ended September 2018  surpassing the Zacks Consensus Estimate by 1 73   This compares to year ago revenues of  13 28 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Humana shares have added about 33 8  since the beginning of the year versus the S P 500 s gain of 3 1  
What s Next for Humana 
While Humana has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Humana was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  2 58 on  13 88 billion in revenues for the coming quarter and  14 18 on  56 37 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   HMOs is currently in the top 12  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2018-11-06,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-beats-q3-earnings-and-revenue-estimates-200356059,200356059
141776,363291,HUM,Humana s  HUM  Q3 Earnings Beat Estimates  Improve Y Y,opinion,Humana Inc  s   NYSE HUM   third quarter 2018 operating earnings per share of  4 58 beat the Zacks Consensus Estimate of  4 29 by 6 8   The bottom line also improved 35 1  year over year  The upside can primarily be attributed to Medicare Advantage membership growth  lower impatient medical utilization  favorable prior period medical claims reserve development and significant operating efficiency of the company Humana Inc  Price  Consensus and EPS Surprise    Operational Update Revenues of  14 2 billion were up nearly 7  on the back of the company s Medicare Advantage business plus Group and Specialty segment  Moreover  the top line surpassed the Zacks Consensus Estimate of  13 9 billion  Adjusted consolidated pre tax income of  922 million improved 0 8   primarily due to higher membership   Benefit ratio was 82  in the quarter under review  Operating cost ratio deteriorated 170 basis points to 13 5   Segment Results Retail Revenues from the Retail segment were  12 7 billion  up 9  year over year  This can primarily be attributed to higher revenues from the company s individual and group Medicare Advantage business resulting from increased membership  and improved per member premiums for a few segment s products  Benefit ratio of 83 2  declined 110 bps year over year  primarily due to reinstatement of the non deductible health insurance industry fee   The segment s operating cost ratio of 11 2  deteriorated 140 bps year over year  Group and Specialty Revenues from the Group and Specialty segment were  1 89 billion  up 2  from the prior year quarter  primarily backed by transition to the East Region TRICARE contract on Jan 1  2018  increased stop loss premiums related to the company s level funded ASO accounts  and high per member premiums across the commercial fully insured business   Benefit ratio increased 110 bps year over year to 80 7  driven by retroactive contractual rate adjustments  membership mix  negative impact of seasonality on fully insured group commercial medical claims and lesser Prior Period Development  Operating cost ratio deteriorated 270 bps year over year to 23 6   Healthcare Services Revenues of  5 97 billion decreased 1  year over year  primarily owing to the company s exit from individual commercial business  decline in pharmacy solutions intersegment revenues and the company s provider services business of the lower Medicare rates in areas where the Humana s  provider assets are mainly located  Operating cost ratio deteriorated 50 bps year over year to 96 1   Individual Commercial Humana exited this business effective Jan 1  2018 and consequently  the result reflects run out of this business  Financial Update As of Sep 30  2018  the company had cash  cash equivalents and investment securities of  13 8 billion  up 1 7  from 2017 end level  Debt to total capitalization as of Sep 30  2018 was 32 8   up 50 bps from Dec 31  2017  Operating cash flow totaled  225 million in the third quarter  down 19  from year ago quarter  Capital Deployment The company paid cash dividends worth  69 million in the third quarter of 2018  2018 Guidance Raised Humana now expects adjusted earnings per share to be around  14 40  up from the prior guidance of  14 15  GAAP EPS is projected around  11 92  up from the prior projection of  11 52  Zacks Rank and Performance of Other Players Humana carries a Zacks Rank  2  Buy   You can see  Among other players in the HMO industry that have reported first quarter earnings  the bottom line of Centene Corp    NYSE CNC    Anthem Inc    NYSE ANTM   and UnitedHealth Group Inc    NYSE UNH   beat the respective Zacks Consensus Estimate Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-11-06,Zacks Investment Research,https://www.investing.com/analysis/humanas-hum-q3-earnings-beat-estimates-improve-yy-200356167,200356167
141807,363322,HUM,Health insurer Anthem could rise 30 percent on earnings potential  Barron s,news,"NEW YORK  Reuters    Anthem Inc  N ANTM  shares could rise by 30 percent as the U S  health insurer is undervalued and has the most room for improvement in profit margins and earnings among its peers  Barron s reported  The company also has the lowest price to earnings ratio among its peers including UnitedHealth Group Inc  N UNH  and Aetna  N AET   Barron s said  adding that the stock trades at just 13 times the projected 2017 earnings  a discount to its four big rivals  Last week  a U S  judge blocked Aetna s proposed  34 billion acquisition of smaller peer  Humana Inc   N HUM   raising the stakes for rival Anthem as it battles to close a  54 billion deal to buy  Cigna Corp   N CI   If Anthem does manage to complete the deal  investors are likely to view that as a positive development since the company projects a  3 a share in earnings benefits in 2018  Barron s said  U S  President Donald Trump and a Republican controlled legislature are seeking to undo much of the Affordable Care Act  better known as Obamacare  The law has reshaped the U S  healthcare industry by mandating health insurance and creating online exchanges where consumers can shop for individual policies and get subsidies  Companies including Anthem had cited Obamacare as one of the main reasons their industry needed to consolidate   Anthem could be a winner from a potential move by Trump to repeal Obamacare since it insures nearly 900 000 people on health exchanges and is losing money on that business  Barron s said  
Barron s listed several possible benefits to earnings   1 a share from public exchange reform  50 cents from a repeal of a special health insurer tax   2 to  3 from a lower corporate tax rate and  2 from renegotiation or ultimate lapsing of the Express Scripts  O ESRX  drug benefit contract ",2017-01-29,Reuters,https://www.investing.com/news/stock-market-news/health-insurer-anthem-could-rise-30-percent-on-earnings-potential:-barron's-456432,456432
141808,363323,HUM,Health insurer Aetna s quarterly profit beats,news," Reuters    Health insurer  Aetna Inc   N AET   whose  34 billion deal for  Humana Inc   N HUM  was blocked last week  reported quarterly profit ahead of estimates on Tuesday  helped by higher premiums for its plans and lower than expected medical costs  Aetna s results come nearly two weeks after Republican President Donald Trump signed his first executive order  directing the federal government to scale back regulations  taxes and penalties under the Affordable Care Act  popularly known as Obamacare  The insurance was set up as part of former President Barack Obama s health reform law  Insurers  including UnitedHealth Group Inc  N UNH  and Aetna  largely pulled out of these plans for 2017  saying they were losing too much money   Aetna s net profit fell to  139 million  or 39 cents per share  in the fourth quarter ended Dec  31  from  321 million  or 91 cents per share  a year earlier  Excluding items  Aetna earned  1 63 per share  handily beating analysts  average estimate of  1 44 per share  according to Thomson Reuters I B E S   Aetna said its total health care medical benefit ratio   the percent of premiums spent on claims   rose to 82 1 percent from 81 9 percent  a year earlier  mainly due to higher medical costs in its individual commercial products  The No  3 U S  health insurer s total revenue rose about 5 percent to  15 73 billion  but was below analysts  average estimate of  15 86 billion  Total medical membership came in at 23 1 million at the end of December  lower than 23 49 million  a year earlier   The company said it expects 2017 operating earnings of at least  8 55 per share  Analysts  on average estimated earnings of  8 79 per share   The decrease in quarterly net income was primarily due to an increase in restructuring costs  which included a  215 million expense recorded during the quarter related to a voluntary early retirement program  Restructuring costs and exchange medical loss ratio pressured the quarter  but was offset by performance in the government and group insurance businesses  Piper Jaffray analyst Sarah James said  Aetna and Humana have said they will consider all available options for their proposed merger after a court ruled against the deal  saying it would lower competition  The court ruling also casts doubt on Anthem Inc s  N ANTM  proposed  54 billion deal to buy fellow health insurer  Cigna Corp   N CI   
The U S  Justice Department filed a lawsuit last July to block the two deals  arguing they would lead to higher prices  A court ruling on the Anthem Cigna deal is pending ",2017-01-31,Reuters,https://www.investing.com/news/stock-market-news/health-insurer-aetna's-quarterly-revenue-rises-about-5-percent-456828,456828
141809,363324,HUM,Anthem CEO uncertain about 2018 Obamacare participation,news,"By Caroline Humer  Reuters    Anthem Inc said on Wednesday that it might stop selling individual plans on the Obamacare exchanges in 2018 unless the U S  government tightens enrollment and eligibility rules to better balance sick and healthy customers  Anthem Chief Executive Officer Joseph Swedish  speaking to analysts about the company s better than expected fourth quarter earnings  said he was optimistic that will occur soon enough for the insurer to decide in the next few months how it will proceed  U S  President Donald Trump has vowed to repeal and replace Obamacare  former president Barack Obama s health reform law  saying it is unaffordable  But he has also promised to fix it and not  pull the rug  out from under anyone  Insurers say they also want to keep customers in health plans   They have a shared interest in as little disruption as possible for the market   healthcare research group Avalere Health CEO Dan Mendelson said   Anthem and other insurers  such as  Aetna Inc   NYSE AET   say they need changes that would improve the balance of sick and healthy customers to be able to submit 2018 exchange plans in April or May    As we approach the end of the first half of this year  we will have to make decision on whether or not we surgically extract ourselves from certain rating regions or even on a larger scale  depending on the stability of the marketplace   Swedish said   Swedish said Anthem was talking to lawmakers and the new administration about its proposed changes  and other insurers have been lobbying as well  Republican lawmakers have spent years devising ways to replace Obamacare but have yet to agree on the specifics of how to proceed    The window for them to implement those changes in a prudent and judicious manner is small   said Morningstar analyst Vishnu Lekraj  referring to Republican lawmakers   and if they can t get it done soon  they are going to have to delay  or it might not even happen    Insurers say they will not be ready to sell any new products until 2019 at the earliest  and these Obamacare plans may be the only individual products available in 2018  Fewer insurers in the market mean less competition and possibly higher premiums  Changes can move forward in various ways  Republican Senator Lamar Alexander of Tennessee  for instance  has said such insurer requests should be part of an immediate  rescue package  for the exchanges  Or the Department of Health and Human Services could make the rule changes  with the White House signing off  Anthem and other large insurers say the enrollment rules  lax eligibility confirmation and premium payments by third parties skew the pool of patients to the unhealthy   Anthem  the No  2 U S  health insurer  is one of the biggest players in the more than 10 million customer Obamacare individual market  It is also one of the few large insurers that expect to break even or be profitable there this year   The company has more than 800 000 people in plans purchased through the online exchanges that offer income based subsidies   Aetna  which has 190 000 people in these exchange plans  says it expects to lose money on them  Shares of Anthem were up 2 7 percent at  158 26   The company said during the conference call that it was restarting stock buybacks after a period of inactivity  a change that Aetna is making as well and which buoyed its shares on Tuesday  AWAITING CIGNA JUDGMENT  Anthem is still waiting for a ruling on the U S  government s lawsuit to block its deal to buy  Cigna Corp   NYSE CI   Most Wall Street analysts expect the deal to be rejected on antitrust grounds   A different U S  judge blocked health insurer Aetna s proposed  34 billion acquisition of smaller rival  Humana Inc   NYSE HUM  last week  Anthem said it expected 2017 operating revenue of  86 5 billion to  87 5 billion  Analysts on average were forecasting  86 68 billion  according to Thomson Reuters I B E S  The company said it expected earnings of more than  11 50 per share this year before special items  compared with analysts  estimates of  11 53  
Fourth quarter net income rose to  368 4 million  or  1 37 per share  from  180 9 million  or 68 cents per share  a year earlier ",2017-02-01,Reuters,https://www.investing.com/news/stock-market-news/u.s.-health-insurer-anthem's-quarterly-revenue-rises-7.6-percent-457137,457137
141810,363325,HUM,U S  proposes 0 25 percent hike in Medicare Advantage payments,news,"NEW YORK  Reuters    The U S  government on Wednesday proposed an increase of 0 25 percent on average in payments to health insurers who offer Medicare Advantage insurance  which provides health benefits to more than 18 million elderly or disabled people  The figure was in line with estimates from analysts  J P Morgan s Gary Taylor  for instance  had been expecting a proposal for payments that were flat to slightly up from the rate that the government is now paying insurers who provide plans  The government will finalize the proposed rate on April 3 and could make changes between now and then after the industry reacts  Last year  the government proposed an increase of about 1 35 percent but later trimmed that back about 50 basis points  UnitedHealth Group Inc  NYSE UNH  and  Humana Inc   NYSE HUM  are two of the largest providers of these plans  which cover more than one third of Medicare beneficiaries  Their shares were unchanged in after hours trading  
The Centers for Medicare   Medicaid Services  the division of the U S  Department of Health   Human Services that regulates Medicare  also said that it expected insurers to benefit from an additional 2 5 percent increase in payments related to how they code medical services ",2017-02-01,Reuters,https://www.investing.com/news/politics-news/u.s.-proposes-0.25-percent-hike-in-medicare-advantage-payments-457300,457300
141811,363326,HUM,U S  court blocks Anthem Cigna merger  dealing blow to consolidation,news,"By Diane Bartz and Caroline Humer  Reuters    A federal judge on Wednesday ruled against U S  health insurer Anthem Inc s  N ANTM  proposed  54 billion merger with smaller rival  Cigna Corp   N CI   derailing an unprecedented effort to consolidate the country s health insurance industry  The U S  Justice Department sued in July to stop Anthem s purchase of Cigna  a deal that would have created the largest U S  health insurer by membership  and Aetna Inc s  N AET  planned  33 billion acquisition of Humana  N HUM   The merger would have worsened an already highly concentrated market and is likely to raise prices  Judge Amy Berman Jackson of the U S  District Court for the District of Columbia said while issuing the ruling against Anthem s deal  Last month  a different U S  judge ruled against Aetna s proposed deal for Humana  Government antitrust officials argued that both deals would lead to less competition and higher prices for Americans  The acquisitions would have reduced the number of large national U S  insurers from five to three   Jackson had separated the Justice Department s case into two trials  Her ruling focused only on the first one in which the Justice Department argued that the tie up would hurt the ability of large national employers to get competitive rates for the health coverage they provide workers   The second trial considered overlaps in the two insurers  business selling health benefits to individuals  and administering Medicare Advantage coverage to the elderly  Anthem argued that there was enough competition because large companies with more than 5 000 employees often used multiple smaller players in the national market  but the judge disagreed   Regional firms and new specialized  niche  companies that lack a national network are not viable options for the vast majority of national accounts  and they will not ameliorate the anticompetitive effects of this merger   Jackson wrote  Cigna intends to carefully review the opinion and evaluate its options in accordance with the merger agreement  it said in a statement  Anthem said on Thursday that it intends to promptly file a notice of appeal and request an expedited hearing of its appeal to reverse the court s decision  PROTECTING CONSUMERS  Acting Assistant Attorney General Brent Snyder of the Justice Department s Antitrust Division said the ruling had prevented American consumers from facing higher health insurance premiums and less innovation  Bill Baer  who was head of the Justice Department s antitrust division when it decided to sue to block both the insurance deals but has since left the agency  also hailed the decision   Together with the decision on Aetna and Humana  this preserves five large national providers of critically important health insurance products   he said   The fifth player  UnitedHealth Group Inc   N UNH  was not involved in the deals  Some Wall Street analysts expect all four of the companies to now move on  although Aetna and Humana have not committed to doing so  Their deal expires Feb  15    The likelihood of success in an appeal would be very low   said Matthew L  Cantor  a partner in the law firm of Constantine Cannon in New York  He noted points in the judge s order about the concentrated national market  the high barrier to entry for competitors  and the companies  roles as direct competitors  The deals were announced at a time when former President Barack Obama s national healthcare reform law was fully in place and the four insurers were growing in the individual insurance market it established  The insurers said new costs  from higher taxes to investments in new Obamacare products  were driving their need for scale  That landscape is less certain now  Aetna and Humana have cut back Obamacare enrollment for 2017 after losses  and President Donald Trump and fellow Republicans are weighing a  repeal and replace  path for Obamacare  More deals may be in the offing  JPMorgan  NYSE JPM  analyst Gary Taylor said in a research note   Given Anthem and Cigna s pursuit of Humana in 2015  we think new potential combinations could emerge   He does not expect shares in either Anthem or Cigna to move given that investors had expected this ruling  Cigna is entitled to receive from Anthem a  1 85 billion break up fee if the deal fails to win regulatory approval  according to the merger agreement  The agreement also requires Cigna to have put forth its best effort on that front  But Anthem and Cigna disagreed about the deal in court  Jackson wrote in her order  with Cigna refusing to sign off on Anthem s interpretation of how the companies could garner savings  Anthem is the largest member of the Blue Cross Blue Shield Association and operates BCBS plans in 14 states  It and said it could apply its discounts to Cigna members while Cigna said its collaborations with doctors would save money  
Pre merger integration was stalled and incomplete  the judge said ",2017-02-09,Reuters,https://www.investing.com/news/stock-market-news/u.s.-court-blocks-anthem-cigna-deal-458806,458806
141812,363327,HUM,Aetna  Humana drop merger  Cigna wants to end Anthem deal,news,"By Caroline Humer and Diane Bartz NEW YORK WASHINGTON  Reuters    Health insurers  Aetna Inc   NYSE AET  and  Humana Inc   NYSE HUM  walked away from their  34 billion merger on Tuesday and  Cigna Corp   NYSE CI  sought to end its deal with Anthem  shelving the industry consolidation they charted to address former President Barack Obama s Affordable Care Act  Humana also said it would exit the Obamacare individual insurance market after this year  saying that early medical costs were running a bit high  Humana was one of several insurers that lost money in 2016 and then cut back offerings for this year  saying the program needs to be changed  President Donald Trump and Republicans have vowed to repeal and replace Obamacare  the national healthcare reform law that created new individual insurance and expanded Medicaid  adding 20 million people to the ranks of the insured  Trump on Tuesday tweeted about Humana s decision to exit the market  promising he  Will repeal  replace   save healthcare for ALL Americans   The insurers  in seeking their mergers  had said the combinations would help them grow after the law changed everything from how doctors and hospitals are paid to the benefits insurers must provide   The Aetna Humana and Cigna Anthem deals were announced in July 2015 and the Justice Department filed antitrust lawsuits a year later seeking to block the deals  Two federal judges separately ruled against the deals in recent weeks   Government antitrust officials argued that both mergers would lead to less competition and higher prices for Americans  which Aetna and Anthem tried to disprove  The acquisitions would have reduced the number of national U S  insurers from five to three  After the defeat in court on Jan  23  Aetna and Humana said they were weighing an appeal  But they opted on Tuesday to scrap the merger  Aetna shares rose 3 percent to  125 81  while Humana fell 0 4 percent to  205 97  Aetna will pay Humana a  1 billion breakup fee  or  630 million after taxes  and terminated its plan to sell some Medicare Advantage assets to Molina Healthcare Inc  the companies said  Molina will receive a  75 million breakup fee  Humana said it will buy back at least  2 billion worth of shares in 2017 and earn a net profit of  16 65 to  16 85 per share  helped by the payment from Aetna  and raise its dividend  Humana is the first insurer to withdraw from the Obamacare exchanges for 2017  but Aetna and Anthem have both said they are considering doing so if changes are not made to the plan  Wall Street analysts and investors suggested that the Trump administration might be friendlier to deals  and that Humana could again be a target for Anthem or Cigna  Humana CEO Bruce Broussard said on a conference call that the company would consider any takeover offer  balancing  the probability and timing of completing a transaction   the current environment and the process it has just gone through  CIGNA GOES TO COURT Cigna said on Tuesday that it had notified Anthem that it had terminated its merger and that Anthem was required to pay a  1 85 billion breakup fee   It also filed a lawsuit in Delaware  asking a judge to declare legal its decision to terminate the deal and to approve  13 billion in damages for shareholders who did not receive the takeover premium  Anthem responded that the merger agreement was in place until April 30  2017  and that Cigna could not back out  Anthem s shares closed down less than 1 percent at  163 32 while Cigna rose less than 1 percent to  146 68  Several antitrust lawyers said the two companies   which have been at odds for the past year   likely will settle the lawsuit  
 We knew for weeks that all they were doing was positioning themselves for this fight   said Matthew Cantor  an antitrust litigator with the law firm Constantine Cannon   Over 90 percent of these high stakes commercial litigation settle  ",2017-02-14,Reuters,"https://www.investing.com/news/stock-market-news/aetna,-humana-terminate-$34-billion-deal;-humana-to-receive-$1-billion-459761",459761
141813,363328,HUM,Trump administration proposes stricter Obamacare rules,news,"By Caroline Humer and Yasmeen Abutaleb
NEW YORK WASHINGTON  Reuters    The Trump administration on Wednesday proposed changes to the Obamacare individual insurance market that insurers welcomed as a good start but that raised the possibility of higher out of pocket cost for consumers 
President Donald Trump and congressional Republicans have promised to scrap the 2010 healthcare law that is a key legacy of Democrat Barack Obama s presidency  But they are struggling to agree on a replacement for the law  which extended health insurance to 20 million Americans 
The proposed new rule  issued by a division of the U S  Department of Health and Human Services  sets out changes that are meant to shore up the system developed by Obama  and comes after  Humana Inc   N HUM  on Tuesday said it would pull out of this market in 2018  It is unclear which elements of Obamacare could survive in the Republicans  replacement 
The rule does not address changes that must be made by law  such as for Obamacare s income based subsidies 
The changes would tighten enrollment processes and allow insurers to collect unpaid premium payments  making it tougher for people to move in and out of insurance plans  Insurers say  gaming the system  has created an unprofitable mix of healthy and sick customers 
The Affordable Care Act aimed to chip away at soaring healthcare spending  but data shows costs are still rising  The U S  government reported separately on Wednesday that total U S  medical spending in 2017 is estimated to rise 5 4 percent to  3 36 trillion after a 4 8 percent spending uptick in 2016 
The administration on Wednesday also backed off implementing tougher oversight of the individual mandate  the requirement for all Americans to have health insurance or pay a fine  that was due to go into effect for 2016 taxes 
The U S  Internal Revenue Service said as a result of Trump s executive order to reduce regulatory burden  it will not reject tax filings for the year 2016 that fail to indicate whether they had health coverage or paid the penalty set under Obamacare  This is a return to the policy for 2015 taxes  the IRS said 
The mandate was supposed to bring in healthy customers but Republicans have vowed to overturn it and insurers say it has not worked 
Aetna  N AET  CEO Mark Bertolini on Wednesday said during a Wall Street Journal forum that the Obamacare exchanges had entered a  death spiral  in which rising premiums pushed out the healthiest customers  which in turn raises rates 
Aetna cut back offering new plans for 2017 and it and Anthem Inc   N ANTM  have said that without changes  they might not take part after this year 
Bertolini said in a statement that new Health Secretary Tom Price and the Trump administration have  taken some good initial steps with the proposed regulation   The top two industry groups  America s Health Insurance Plans and Blue Cross Blue Shield Association  echoed that view 
Shares of insurers were mixed in the early afternoon on Wednesday with Aetna gaining 1 percent to  127 01  Cigna  NYSE CI  off less than 1 percent at  146 07 and Humana off 0 3 percent to  205 34  Anthem fell less than 1 percent to  162 90 
TOUGHER TO ENROLL
The Centers for Medicare   Medicaid Services  which are part of the Department of Health and Human Services  on Wednesday proposed the new rule that includes verifying the status of enrollees outside of the usual enrollment period 
It also proposes insurers can collect unpaid premiums from members when they sign up with the same issuer again  an incentive for people to always have insurance 
In addition  it proposed lowering the amount of guaranteed coverage for some  silver  level plans in the program  which it said could raise out of pocket spending and cut premiums 
It would give the states oversight of doctor and hospital networks included in the plans  reflecting a Republican theme that healthcare oversight be reduced at the federal level 
The rule proposes shortening the open enrollment period for the individual market to Nov  1 through Dec  15  similar to employer sponsored insurance market and Medicare 
The weakening of the mandate and the new CMS rule making it tougher for people to sign up would have contradictory effects on premium pricing  according to Jonathan Gruber  professor of economics at MIT and one of the architects of the Affordable Care Act 
 You re basically saying on the one hand  we have to weaken the mandate for political reasons but we have to lower prices  so we have to kick people out of the exchanges   Gruber said 
Patient advocate Families USA said the new rules would discourage younger  healthier people from enrolling  reduce financial assistance for families and make it harder for them to find networks that include their doctors 
Republican lawmakers  who are working on an Obamacare replacement  said the rule was a start 
 If we don t take more steps like that  having an Obamacare subsidy will be like having a bus ticket in a town where no buses run  because there will be zero choices to buy   Senator Lamar Alexander  chairman of the Senate health committee  told reporters outside the Senate 
Wall Street said the proposed changes could help insurer profitability but it was not clear by how much 

 As one would expect tightening special enrollment periods  shortening the open enrollment period to six weeks and mandating payment of premiums before coverage should lead to an improvement in the risk pool   Leerink Partners analyst Ana Gupte said ",2017-02-15,Reuters,https://www.investing.com/news/politics-news/trump-administration-proposes-stricter-obamacare-rules-460136,460136
141814,363329,HUM,Anthem sues Cigna to block termination of merger,news,"By Michael Erman  Reuters    Anthem Inc on Wednesday won a temporary restraining order that blocks smaller rival  Cigna Corp   NYSE CI  from officially terminating their proposed  54 billion merger  a transaction already rejected by U S  antitrust regulators  Judge Travis Laster of Delaware s Court of Chancery granted the temporary order  saying it would keep the deal together so Anthem could appeal its loss against the Justice Department  The deal would have created the largest U S  health insurer  Rivals  Aetna Inc   NYSE AET  and  Humana Inc   NYSE HUM  had sought their own merger  representing an unprecedented consolidation among U S  health insurers  In separate rulings  federal judges struck down both deals as anticompetitive  at the request of the Justice Department  Aetna and Humana said on Tuesday they were ending their deal  but Anthem filed an appeal of its ruling  Cigna  however  said on Tuesday it notified Anthem it had ended the deal and that Anthem was required to pay a  1 85 billion break up fee under their agreement   Cigna also filed a lawsuit in Delaware  seeking legal sanction for its decision to end the deal and  13 billion in damages  Anthem responded with its own lawsuit on Wednesday to request a temporary restraining order that would prevent Cigna from ending the deal  arguing there is still enough time to complete the transaction first announced in July 2015  In the lawsuit  Anthem said  Cigna s lawsuit and purported termination is the next step in Cigna s campaign to sabotage the merger and to try to deflect attention from its repeated willful breaches of the Merger Agreement   Cigna said on Wednesday that Anthem s allegations were meritless  Anthem said it was pursuing an expedited appeal of the court decision and remained committed to complete the merger either through a successful appeal or through a settlement with the new leadership at the Justice Department under the Trump administration  Cigna maintained that the effort was doomed   There is no viable path to completing this transaction   Cigna said  Cigna had increased its share repurchase program to  3 7 billion  but said on Tuesday it would limit the share repurchase amount to  250 million per quarter  Some analysts questioned whether this signaled a new intent by the insurer to seek an acquisition  
 We believe this suggests Cigna was looking to deploy the capital in another way  potentially M A  but we are hesitant to suggest another public public merger offer   Piper Jaffray analyst Sarah James said in a client note ",2017-02-15,Reuters,https://www.investing.com/news/stock-market-news/anthem-sues-cigna-to-block-deal-termination-460045,460045
141815,363330,HUM,BCBS  Cigna among insurer groups to meet with Trump on Monday,news,"By Caroline Humer NEW YORK  Reuters    The Blue Cross Blue Shield Association  which represents insurers in every state   Cigna Corp   NYSE CI  and  Humana Inc   NYSE HUM  said on Friday they would attend a meeting between the health insurance industry and President Donald Trump on Monday   Cigna s chief executive officer  David Cordani  and Humana CEO Bruce Broussard will attend  spokesmen for both companies said  Bloomberg reported earlier on Friday that top executives from U S  health insurers would attend a meeting  based on unnamed sources  The White House has not confirmed the Bloomberg report  Trump has pledged to repeal and replace Obamacare  former President Barack Obama s national healthcare law that redesigned the U S  insurance market for individuals  It is not clear yet what Republicans will agree upon to replace the current insurance  Insurers say any new plans are not likely to hit the market before 2019  Insurers have also asked for changes to the individual insurance market that would go into effect for 2018 to make the market more attractive to the industry  where some plans have lost hundreds of millions of dollars because member costs were higher than they expected  The Trump administration proposed a rule last week to address some insurer concerns  but insurers would also like to see the elimination of an industry wide tax on health insurance premiums   though the tax is on hiatus this year   and a promise that the government will continue to provide cost sharing subsidies to certain individual insurance members   
Since taking office on Jan  20  Trump has held a series of White House meetings with executives from different sectors including those from manufacturing companies  pharmaceutical makers  technology businesses and car makers ",2017-02-24,Reuters,"https://www.investing.com/news/stock-market-news/bcbs,-cigna-among-insurer-groups-to-meet-with-trump-on-monday-462096",462096
141816,363331,HUM,Molina Healthcare Clinches Medicaid Contracts In Florida,opinion,Molina Healthcare  Inc    NYSE MOH   recently announced that its wholly owned subsidiary  Molina Healthcare of Florida  Inc   has been granted Medicaid Managed Care contracts by the Florida Agency for Health Care Administration  AHCA   in Regions 8 and 11 of the Florida Statewide Medicaid Managed Care Invitation to Negotiate  ITN   Services under this new contract are expected to commence on Jan 1  2019 The managed healthcare service provider caters to around 105 000 Medicaid members residing in the above mentioned areas including Miami Dade  Monroe  Sarasota  DeSoto  Charlotte  Glades  Hendry and Collier Counties  Revenues from these regions account for around  550 million The contract awards will enable the company to serve quality health care to the Medicaid members in Regions 8 and 11 as well as expand its Marketplace and Medicare businesses in Florida  Moreover  this geographic footprint would contribute to the enterprise business portfolio of the company  lending it an overall boost Molina Healthcare has filed protests of AHCA s Medicaid Managed Care awards across all the 11 regions of Florida in May 2018  The outcome of these negotiations between Molina Healthcare and AHCA is the grant of awards in Regions 8 and 11  The company has withdrawn its protests from all the regions at present  Apart from the two regions where Molina Healthcare will provide care for Medicaid beneficiaries in 2019  the company would also continue to offer Medicare as well as Marketplace products across Florida Medicare is a federal program that offers hospital  medical insurance and drug benefits to senior citizens aged 65 and above as well as to disabled people  Molina Healthcare  a primary operator in the government plans for Medicare and Medicaid  has grown its Medicaid membership from the expansion of Medicaid in 2014 under the HealthCare Reform Act  This business continues to remain lucrative as several US states are increasingly outsourcing this plan to private insurers for its effective cost management Shares of this Zacks Rank  3  Hold  company have surged 38 5  in the past year  outperforming the  s growth of 33 7  Stocks to ConsiderInvestors interested in the Medical HMO industry might take a look at the better ranked stocks like WellCare Health Plans  Inc    NYSE WCG    Triple S Management Corporation   NYSE GTS   and Humana Inc    NYSE HUM   WellCare offers managed care services for government sponsored health care programs  Sporting a Zacks Rank  1  Strong Buy   the company delivered an average four quarter positive surprise of 51 70   You can see  Triple S and its subsidiaries offer a portfolio of managed care and related products in the commercial  Medicare and Medicaid markets in Puerto Rico and the United States  It holds a Zacks Rank  2  Buy  and came up with an average whopping four quarter beat of 260 65  Humana operates as a health and well being company in the United States  It has a Zacks Rank of 2 and pulled off an average four quarter earnings surprise of 6 16  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-06-18,Zacks Investment Research,https://www.investing.com/analysis/molina-healthcare-clinches-medicaid-contracts-in-florida-200326173,200326173
141817,363332,HUM, Humana Or Anthem  Which Is A Better Health Insurance Stock ,opinion,"A strong U S  economy has enabled the health insurance industry to stand in good stead  A record low unemployment rate and a gradual wage increase bode well for this space  High employment and wage growth fuel demand for health insurance and various other health related services provided by insurers Rising enrollment and top line growth   increasing contribution from complementary businesses  product modifications  improved service  demographic changes  expansion of international operations  better claims handling  medical cost management  technological investment and upgrade  mergers and acquisitions plus healthy balance sheets have long sustained the mojo for health insurers  The overall bullish scenario reinforces our sentiment to believe that the growth cadence for the sector should continue in the long run Per a McKinsey   Co  report  the private payor market in North America is expected to grow from  583 billion in 2010 to  1 421 billion in 2025 Furthermore  health insurance is one industry  which remains unperturbed by the flaring trade wars and volatile oil prices  causing indexes to fluctuate wildly  Hence  it has performed quite well compared with the broader markets The  has rallied 13 3  year to date  more than thrice the 4  increase clocked by the S P 500 index  The buoyancy in the health insurance space is further confirmed by its   within the top 40   102 of the 256 plus groups   In such a situation  it is a wise idea to invest in health insurance companies Some stocks promising sturdy growth in this flourishing industry are Humana Inc    NYSE HUM    Anthem Inc    NYSE ANTM    Triple S Management Corp    NYSE GTS   and WellCare Health Plans  Inc    NYSE WCG   While Humana  Anthem and Triple S carry a respective Zacks Rank  2  Buy   WellCare sports a Zacks Rank  1  Strong Buy  
You can see  Let s indulge in a comparative analysis of two health insurers   Anthem and Humana   to decide which is a better stock While Humana has a market capitalization of  42 billion  the same for Anthem is  62 3 billion As both staffing firms hold the same robust Zacks Rank  we are using certain other parameters to find out which company is better positioned Earnings ExpectationsEarnings growth along with stock price gains is often an indication of a company s strong prospects Humana s current quarter earnings are projected to grow 8 9  compared with 23 4  rise for Anthem  Looking at the full year 2018 picture  Humana s earnings are estimated at 19 5  growth while the same for Anthem is expected to increase 27 9  Thus  Anthem has an edge over Humana in terms of quarterly and annual earnings growth projections Earnings Surprise HistoryA stock s earnings surprise history helps investors derive an idea about its performance in the previous quarters Both Humana and Anthem boast a decent earnings surprise history with the metric having surpassed the Zacks Consensus Estimate in all the last four reported quarters for each company However  Anthem visibly has a vantage point over Humana in terms of its average positive earnings surprise  which reads 7 2   While Humana s average beat stands below at 6 2  Net MarginNet profit margin aids investors to evaluate a company s business model in terms of pricing policy  cost structure and operating efficiency  It also shows how good it is at converting revenues into profits  Hence  a strong net profit margin is preferred by all classes of investors With a TTM net margin TTM net margin  Anthem compares favorably with the Humana s ROE of 3 3   Though both companies lag the industry s 4 9  TTM net margin  Anthem still commands a better margin profile ValuationThe Price to Earnings Ratio  P E  metric is used for measuring a company s value in relation to its earnings  In general  a lower number or multiple is preferred to a higher one The trailing 12 month price to earnings multiple for Anthem and Humana is 15 2 and 19 8  respectively  while that of the industry is 17 9 Going a step further and baking in both the companies  growth rates shows a 12 month PEG ratio of 1 44 for Humana and 1 30 for Anthem compared with the industry s PEG ratio of 1 37 This clearly shows that Anthem is more valued than Humana   Bottom LineOur comparative assessment shows that Anthem is much better placed than Humana on all fronts From a fundamental perspective too  Anthem dwells on a firmer ground with guidance raised for 2018  increased membership strength  a sound balance sheet  numerous accretive acquisitions as well as growth in service business  which seem to drive the stock in the coming months 
Today s Stocks from Zacks  Hottest Strategies 
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-06-19,Zacks Investment Research,https://www.investing.com/analysis/humana-or-anthem-which-is-a-better-health-insurance-stock-200326472,200326472
141818,363333,HUM,Humana  Walgreens Team Up To Provide Better Senior Care,opinion,Humana Inc    NYSE HUM   has decided to collaborate with Walgreens for providing better primary and other services to senior citizens via primary care clinics  Notably  Walgreens is a provider of trusted care  included in the Retail Pharmacy USA Division of Walgreens Boots Alliance   NASDAQ WBA    This alliance is part of the ongoing and shared commitment of both companies to the health and well being of the Kansas City community The partnership forged between Humana  a leading health and well being company and Walgreens  the provider of trusted pharmacy services and care would essentially create a senior focused neighborhood approach to health  which would include primary care  pharmacy  in person health plan support and additional services for Medicare beneficiaries  The companies are also interested in expanding this collaboration into other markets in the near future Partners in Primary Care  a wholly owned subsidiary of Humana  would operate senior focused primary care clinics  on a pilot basis  in two Walgreens stores in the Kansas City  Missouri area  Located most conveniently  the clinics are expected to open doors this fall with a spacious area of around 2 500 square feet and would complement Walgreens pharmacy services along with the four Partners in Primary Care centers  inaugurated last year in Kansas City The clinics cater to aged people participating in a few Medicare plans  Partners in Primary Care focus on offering care services beyond addressing just the acute and immediate health issues  Additionally  the unit caters to developing long term relationships with patients suffering chronic conditions Humana currently provides health related programming and resources to its more than 65 000 Medicare Advantage and Medicare stand alone Part D Prescription Drug plan members in the region  While Walgreens supports more than 75 000 Medicare beneficiaries in the Kansas City community through above 50 neighborhood pharmacies and other points of care Humana expects its initiative with Walgreens to deliver a way simpler and better experience for people  which would in turn encourage them to take care of their health more seriously while being closely in touch with the doctors  This senior focused care by the company is a continuation of its strategy to revolve around integrating care via clinical programs intersecting health with lifestyle  The humanitarian service also supports Humana s multi faceted approach to healthcare in general The win win program has aided Walgreens to expand its pharmacy services and expertise plus drive the digital tools and other programs  aimed at helping the grey populace in the community  It is one of Walgreens  efforts to make cost effective healthcare accessible to patients  providing them with a value for money experience Shares of this Zacks Rank  2  Buy  company have rallied 20 86  year to date  outperforming the  s growth of 12 87   You can see  This deal charts out the obvious course of action for Walgreens as it braces itself well for handling the pressing competition from the likely entry of Amazon  NASDAQ AMZN  in the pharmacy business  Also  CVS Health Corp    NYSE CVS   is on track to acquire Aetna Inc    NYSE AET    which should expand the combined entity s scale and size in the industry These health oriented pacts point to the blurring of the boundaries between two subsectors of the healthcare industry such as  the pharmacies and drug stores and health insurers  These alliances are a way forward for the companies  striving to emerge as comprehensive healthcare players and cost controllers  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-06-19,Zacks Investment Research,https://www.investing.com/analysis/humana-walgreens-team-up-to-provide-better-senior-care-200326502,200326502
141819,363334,HUM,Community Health s Ratings Downgraded By Moody s,opinion,Credit rating giant Moody s Investors Service recently downgraded the ratings of Community Health Systems   NYSE CYH    The ratings include Corporate Family Rating  CFR   which were lowered to Caa2 from Caa1 and the Probability of Default Rating  PDR   which deteriorated to Caa2 PD LD from Caa1 PD  The ratings outlook remains stable The above was based on the company s announcement of the final results of its debt exchange wherein holders exchanged part of unsecured notes due 2019  2020 and 2022 for new junior lien notes due 2023 and 2024  The credit rating agency considered this transaction a distressed exchange  in other words  a default according to them  Moreover  Moody s appended the PDR with an   LD   indicating a limited default  However  it will be removed after three business days The transaction largely addresses the company s 2019 and 2020 notes maturities  The agency expects that Community Health will seek to amend or extend the maturity of its Term Loan G in the upcoming weeks  If the Term Loan G is successful  then the next significant debt maturity will be due Jan  2021 Although the progress in extending maturities exists  the downgrade of the CFR and PDR ratings indicates the agency s prediction of weakening interest coverage  cash flow and liquidity  It forecasts that the negative free cash flow over the next 12 to 18 months and interest coverage  EBITDA capex interest  to stay below 1 0x  A Caa3 rating was also assigned to the new secured junior lien notes due 2023 and 2024 by Moody s  Additionally  the ratings on the remaining unsecured notes due 2019  2020 and 2022 from Caa2  reflects the subordination to the new junior lien debt The credit rating body has also downgraded the rating on the first lien secured debt from B2 to B3  The Speculative Grade Liquidity Rating was affirmed as SGL 3 Ratings RationaleCaa2 Corporate Family Rating indicates the agency s expectation that the company will continue its operation with high financial leverage over 8 0x  The rating agency also anticipates negative free cash flow over the next 12 to 18 months because of the company s significant capital requirements and high interest costs Another concerning factor is the industry wide operating headwinds which would limit operational improvement despite Community Health s turnaround initiatives  The ratings have been supported by the company s large scale  demographic diversity and divestiture plans The proceeds would be used for repaying the debt of the company Future Rating ActionMoody s can downgrade the ratings provided there is deterioration in the company s earnings  declines in liquidity or a rising risk of payment failure or wearing off credit recovery potential The agency could upgrade the ratings if operational initiatives result in better volume growth as well as margin expansion  Also  declining leverage or improving free cash flow by dint of which  Community Health s ability to refinance future debt maturities along with sustaining the current capital structure might lead to rating upgrade Shares of this Zacks Rank  3  Hold  company have rallied 13 38  quarter to date  outperforming its  s growth of 7 73   Stocks to ConsiderInvestors interested in the medical industry might take a look at a few better ranked stocks  namely WellCare Health Plans  Inc    NYSE WCG    Anthem  Inc    NYSE ANTM   and Humana Inc    NYSE HUM   WellCare offers managed care services for government sponsored health care programs  The stock sports a Zacks Rank  1  Strong Buy  and delivered an average four quarter positive surprise of 51 70   You can see  Anthem and its subsidiaries operate as a health benefits company in the United States  With a Zacks Rank  2  Buy   the stock came up with an average four quarter beat of 7 22  Humana operates as a health and well being company in the United States  The company carries a Zacks Rank of 2 and pulled off an average four quarter positive earnings surprise of 6 16  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-06-20,Zacks Investment Research,https://www.investing.com/analysis/community-healths-ratings-downgraded-by-moodys-200326831,200326831
141820,363335,HUM,Triple S Management  GTS  Soared To A 52 Week High  Time To Cash Out ,opinion,"Have you been paying attention to shares of Triple S Management   NYSE GTS    Shares have been on the move  with the stock up 14 7  over the past month  GTS hit a new 52 week high of  41 92 in the previous session  Triple S Management has gained 67 9  since the start of the year compared to the 2 3  move for the Medical sector and the 13 7  year to date return for its peer group 
What s Driving the Outperformance 
The stock has a great record of positive earnings surprises  having beaten the Zacks Consensus EPS estimate in each of the last four quarters  In its last earnings report on May 8  2018  Triple S Management reported EPS of  0 60 vs  the Zacks Consensus of  0 24  while it beat the consensus revenue estimate by 4 93  
For the current fiscal year  Triple S Management is expected to post earnings of  1 90 per share on  3 04 billion in revenues  This represents a 0 53  change in EPS on a 4 89  change in revenues  For the next fiscal year  the company is expected to earn  2 20 per share on  3 17 billion in revenues  This represents a year over year change of 15 79  and 4 27   respectively 
Valuation Metrics
Triple S Management may be at a 52 week high right now  but what might the future hold for GTS  A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level 
On this front  we can look at the Zacks Style Scores  as these give investors a variety of ways to comb through stocks  beyond looking at the Zacks Rank of a security   These styles are represented by grades running from A to F in the categories of Value  Growth  and Momentum  while there is a combined VGM score as well  The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style 
Triple S Management has a Value Score of A  The stock s Growth and Momentum Scores are A and D  respectively  giving the company a VGM score of A 
In terms of its value breakdown  the stock currently trades at 21 9X current fiscal year EPS estimates  On a trailing cash flow basis  the stock currently trades at 14 5X versus its peer group s average of 15 3X  Additionally  the stock has a PEG ratio of 2 2  This isn t enough to put the company in the top echelon of all stocks we cover from a value perspective 
Zacks Rank
We also need to look at the Zacks Rank for the stock  as this supersedes any trend on the style score front  Fortunately  Triple S Management currently has a Zacks Rank of  2  Buy  thanks to rising earnings estimates 
Since we recommend that investors select stocks carrying Zacks Rank of 1  Strong Buy  or 2  Buy  and Style Scores of A or B  it looks as if Triple S Management fits the bill  Thus  it seems as though GTS shares could still be poised for more gains ahead 
How Does Triple S Management Stack Up to the Competition 
Shares of Triple S Management have been moving higher  and the company still appears to be a decent choice  but what about the rest of the industry  Some of its industry peers are also looking good  including WellCare Health Plans   NYSE WCG    Anthem   NYSE ANTM    and Humana   NYSE HUM    all of which currently have a Zacks Rank of at least  2 and a VGM Score of at least B  making them well rounded choices 
The Zacks Medical HMOs industry is in the top 24  of all the industries we have in our universe  so it looks like there are some nice tailwinds for GTS  even beyond its own solid fundamental situation ",2018-06-21,Zacks Investment Research,https://www.investing.com/analysis/triples-management-gts-soared-to-a-52weekhigh-time-to-cash-out-200326880,200326880
141821,363336,HUM,UnitedHealth s Ratings Upgraded By A M  Best  Outlook Stable,opinion,Credit rating giant A M  Best recently upgraded UnitedHealth Group Incorporated s   NYSE UNH   Long term Issuer Credit Ratings from  a  to  a   and has also affirmed the Financial Strength Rating  FSR  of A  Excellent  for most UnitedHealthcare insurance subsidiaries  The outlook remains stable Additionally  the credit rating body has upgraded the Long Term ICR of the company to  a   from  bbb   along with the Long Term Issue Credit Ratings  Long Term IR  to  a   from  bbb   for the existing senior unsecured notes and its Short Term Issue Credit Rating  Short Term IR  to AMB 1 from AMB 2  The outlook for the Credit Ratings is stable The credit rating giant has also assigned a Long Term IRs of  a   for the company s recently marketed senior unsecured notes A M  Best has also upgraded the FSR for Dental Benefit Providers of California  Inc   San Francisco  CA   Nevada Pacific Dental  Las Vegas  NV  and National Pacific Dental  Inc   Richardson  TX  from A   Excellent  to A  Excellent  and the Long term ICR from  a  to  a   The outlook of these ratings remains stable Ratings RepresentationThe rating agency acknowledges UnitedHealth s balance sheet strength  its solid operating performance  extremely favorable business profile and strong enterprise risk management The rating upgrades represent the strengthening of risk adjusted capitalization  steady strong premium growth  favorable earnings along with low volatility  The company s significant nationwide presence  large and growing enrollment base  diversified premium revenues  business strategy and developed risk management program play an instrumental role behind its sturdy balance sheet and operating trends The solid risk adjusted capitalization is supported by consistent profitability  conservative high credit quality asset collection  etc  However  it was partially offset by dividends to the parent entity  A significant level of liquidity at the company s insurance operations is led by growing operating cash flows that are again supplemented by credit facilities with the parent company The operating performance of the company has been commendable along with top line growth  rate hikes and organic growth  The credit rating agency expects the company s operating margins to stay stable with the bottom line boosted by increased premium revenues A M  Best also expects the company s membership o continue growing but at a moderate pace  driven mostly by Medicare and Medicaid  UnitedHealth s long term partnership with AARP is the main driver of its strong growth in the senior market Business diversification that the company derives from its service segment named Optum is positively seen by the rating agencies  This segment  which provides services to the insurance operations of its main segment UnitedHealthcare  generates significant earnings and cash flow to the parent company  which are non regulated and do not require approval for dividend payments Shares of this Zacks Rank  3  Hold  stock have surged 37 58  in the past year  outperforming the  s growth of 31 39   Stocks to ConsiderInvestors interested in the medical industry might consider a few better ranked stocks such as WellCare Health Plans  Inc    NYSE WCG    Anthem  Inc    NYSE ANTM   and Humana Inc    NYSE HUM   WellCare offers managed care services for government sponsored health care programs  The stock sports a Zacks Rank  1  Strong Buy  and managed to come up with an average four quarter positive surprise of 51 70  You can see  Anthem operates as a health benefits company in the United States  With a Zacks Rank  2  Buy   the stock delivered an average four quarter beat of 7 22  Humana operates as a health and well being company in the United States  It carries a Zacks Rank of 2 and pulled off an average four quarter earnings surprise of 6 16   Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-06-21,Zacks Investment Research,https://www.investing.com/analysis/unitedhealths-ratings-upgraded-by-am-best-outlook-stable-200327386,200327386
141822,363337,HUM,Molina Healthcare Hits 52 Week High  Is Further Upside Left ,opinion,On Jun 22  2018  Molina Healthcare  Inc    NYSE MOH   hit a 52 week high of  103 27 but ended the trading session at  101 48  The stock seemed to have gained investors  attention after the recent receipt of Florida Medicaid contract In a year s time  shares of the company have surged 43  compared with the  s growth of 33   What Led the Shares to RallyMolina Healthcare was awarded contracts to continue serving Florida Medicaid members in Region 8  includes Collier  Lee and Sarasota counties  and Region 11  includes Miami Dade   Although the awards might currently diminish the size of its Florida Medicaid footprint across seven regions of the state  it still looks an upside for the company  which received no award during the first procurement  which would have otherwise caused a revenue loss from the entire Florida contract The company was however  successful in getting contracts for two regions after it challenged the state s decision  The company will also be able to expand and sustain the Marketplace as well as Medicare businesses in Florida   These contracts are likely to fetch  550 million in annual revenues for the company starting Jan 1  2019 The news brought in much relief to the company having recently lost Medicaid contract in Mexico   Moreover  the Florida market presents a very good Medicaid growth opportunity for Molina Healthcare  given a large population of the state being enrolled in Medicaid plans   Also  the receipt of Florida contract provides investors with a positive view on the company  reflecting its fare chances of performing well in the upcoming Pureto Rico and Texas Medicaid contracts This further throws light on the efforts made by the company s CEO Joseph Zubretsky to focus more on growing the most important area of the company s business  which is  request for proposals to  provide greatest returns on investment Further Upside Left Moving ahead  the stock should get a further boost as it is showing marked changes from transformation initiatives  undertaken recently  New leadership  cost cutting efforts  profit improvement initiatives and a focus on improving efficiency of core operating processes should aid the company s results The company s first quarter results  beating estimates by 111 11  and its increased 2018 guidance bear an evidence of early success  achieved from its transformational plans  Moreover  the company recently disclosed its progress on turnaround initiatives in detail  which showed that it is well on track for overall  well balanced growth Zacks RankMolina Healthcare carries a Zacks Rank  3  Hold   Investors interested in the Medical HMO industry might take a look at some better ranked stocks  namely WellCare Health Plans  Inc    NYSE WCG    Triple S Management Corporation   NYSE GTS   and Humana Inc    NYSE HUM   WellCare offers managed care services for government sponsored health care programs  Sporting a Zacks Rank  1  Strong Buy   the company delivered an average four quarter positive surprise of 51 70   You can see  Triple S and its subsidiaries offer a portfolio of managed care and related products in the commercial  Medicare and Medicaid markets in Puerto Rico  the United States  It holds a Zacks Rank  2  Buy  and came up with an average four quarter beat of a whopping 260 65  Humana operates as a health and well being company in the United States  It has a Zacks Rank of 2 and pulled off an average four quarter earnings surprise of 6 16  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-06-24,Zacks Investment Research,https://www.investing.com/analysis/molina-healthcare-hits-52-week-high-is-further-upside-left-200327589,200327589
141823,363338,HUM,Will New Products Drive TransEnterix s  TRXC  Q3 Earnings ,opinion,TransEnterix  Inc    NYSE TRXC   is scheduled to report third quarter 2018 results on Nov 8  after the market closes In the last reported quarter  the company s loss per share of 6 cents was in line with the Zacks Consensus Estimate  It witnessed negative surprises in two of the trailing four quarters  the average miss being 138 1  Let s see  how things are shaping up prior to this announcement Factors at PlayTransEnterix is expected to make a strong top line contribution in the third quarter from its several new product developments within the company score Senhance Surgical System line  Among the resent developments  in the third quarter  the company gained an FDA approval for its additional 5 millimeter Senhance System instruments  This apart  it has received CE Mark approval for its Senhance Ultrasonic Instrument System  In this regard  the company has also filed a FDA 510 k  submission for its Senhance Ultrasonic Instrument System TransEnterix  Inc  Price and Consensus    Earlier  the company secured an FDA 10 K clearance for expanded indications with regard to Senhance for including both laparoscopic inguinal hernia repair and laparoscopic gall bladder surgery  Per TransEntrix  both are high volume procedures and hence have the potential to double the company s addressable procedure market to more than three million procedures per year  These launches and expanded indications for use  are expected to significantly contribute to the company s revenues per procedure in the third quarter Of late  TransEnterix made a notable progress  internationally  In the last reported quarter  it sold three systems in EMEA  each of which was done by one of its distribution partners to an end user hospital  Based on the success of the company s distribution partners in EMEA  TransEnterix is currently targeting internal spending on distribution support network  which includes training  regulatory  language continuity  service and sales support  This should further aid the company s third quarter performance Within Asia Pacific  the company has so far achieved meaningful growth in Japan  The island country is the second largest robotics market in the world after the United States and TransEnterix consistently sees a significant inbound interest in the region Here s What Our Quantitative Model PredictsOur proven Zacks model clearly indicates that a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has good chances of beating estimates if it also has a positive   You can uncover the best stocks to buy or sell before they re reported with our  TransEnterix has a Zacks Rank  4  Sell   which lowers the predictive power of ESP  Further  its Earnings ESP of 0 00  in the combination makes surprise prediction difficult   Thus  this combination fails to forecast a positive surprise Stocks Worth a LookFollowing are a few medical stocks worth considering with the right combination of elements to beat on earnings in the upcoming quarterly results Haemonetics Corporation   NYSE HAE   has an Earnings ESP of  5 56  and a Zacks Rank of 1  You can see  Humana Inc    NYSE HUM   has an Earnings ESP of  2 22  and a Zacks Rank  2 Natera  Inc    NASDAQ NTRA   has an Earnings ESP of  6 01  and a Zacks Rank of 2 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/will-new-products-drive-transenterixs-trxc-q3-earnings-200353263,200353263
141848,363363,HUM,Trump adds antitrust expert to Justice transition team,news,WASHINGTON  Reuters    A Republican antitrust veteran has been named on Monday to U S  President elect Donald Trump s transition team for the Justice Department  a choice that lawyers say signals a more hands off approach to antitrust enforcement compared to Democratic President Barack Obama  David Higbee  a partner at the law firm Hunton   Williams LLP  worked for President George W  Bush s administration from 2001 to 2005  spending the last year in the Antitrust Division  Since then he has advised clients on merger reviews  antitrust litigation and government investigations   Higbee joins Joshua Wright  an economist and former commissioner at the Federal Trade Commission  as the only two people on Trump s transition team with a background in antitrust  The Obama administration has challenged an unusually large number of mergers in the last few years  leading to the collapse of Halliburton  NYSE HAL  Co s plan to buy Baker Hughes Inc  among others  Currently  the Justice Department is suing Anthem Inc to prevent it from buying  Cigna Corp   NYSE CI  and  Aetna Inc   NYSE AET  to stop its purchase of  Humana Inc   NYSE HUM   While Trump  who campaigned as a populist  has talked tough on media mergers such as AT T Inc  NYSE T  buying  Time Warner  Inc  NYSE TWX   and singled out Amazon com Inc  NASDAQ AMZN  for antitrust scrutiny  Higbee s naming heralds a return to a traditional Republican view of merger enforcement  lawyers said   Higbee will have that sensible caution   said Bruce McDonald  another veteran of the Bush administration now at the law firm Jones Day   He will be more confident in business and markets and less confident that government can identify and fix problems   An antitrust division designed by Higbee would be tough on price fixing and mergers of competitors but would be cautious in challenging deals where companies buy suppliers or incidents where companies are accused of breaking antitrust law to run competitors out of business  McDonald said ,2016-11-28,Reuters,https://www.investing.com/news/politics-news/trump-adds-antitrust-expert-to-justice-transition-team-444133,444133
141849,363364,HUM,Techs buoy S P  Nasdaq  Goldman pushes Dow to record high,news,"By Yashaswini Swamynathan  Reuters    Financial and technology stocks powered the Dow to an all time high on Monday  and set the S P and the Nasdaq for their best day in two weeks  The Dow has been enjoying a record setting rally  largely driven by bank and industrial stocks  which are expected to benefit the most from higher spending on infrastructure and simpler regulations under a Donald Trump administration   The index has risen 5 percent since the Nov  8 vote  while the S P financial index  SPSY  has surged 14 3 percent   Goldman Sachs  N GS  rose 2 2 percent to  228 33  its highest in nine years  after HSBC initiated coverage with a  buy  rating and a  250 price target   At 12 35 p m  ET  1735 GMT   the Dow Jones Industrial Average  DJI  was up 59 69 points  or 0 31 percent  at 19 230 11  easing after hitting a record high of 19 274 85  The S P 500  SPX  was up 12 01 points  or 0 55 percent  at 2 203 96 and the Nasdaq Composite  IXIC  was up 45 41 points  or 0 86 percent  at 5 301 07  Nine of the 11 S P 500 sectors were higher  with financials  1 31 percent giving the broader index its biggest boost  followed by a 0 87 percent gain in technology  SPLRCT   Health insurers Aetna  N AET  and Humana  N HUM  were down more than 3 percent  dragging down the healthcare index  SPXHC   after Justice Department attorneys argued to a judge that Aetna s acquisition of Humana violated antitrust law for its Medicare and Obamacare exchange businesses   The defensive utilities  SPLRCU  sector was the other laggard   Over the last few months  we had this increasingly pessimistic outlook on the stock market and the economy   said Brent Schutte  chief investment strategist at Northwestern Mutual Wealth Management   Trump has been sort of a wake up call for some complacent investors to take a look and see that inflation was moving higher and the economy is improving    New York Federal Reserve President William Dudley told CNBC that downside risks to the U S  economy had reduced  while his Chicago counterpart Charles Evans said the economy was entering a period of rising interest rates  Traders have priced in a 92 percent chance of the Fed raising interest rates when it meets on Dec  13 14  Shares of Chesapeake Energy  N CHK  were up 5 percent at  7 56 after the U S  natural gas producer said it would sell a part of its acreage in the Haynesville Shale area for  450 million to a private company  FairPoint  O FRP  shares jumped 12 percent after Consolidated Communications  O CNSL  said it would buy the broadband service provider in an all stock deal valued at  1 5 billion  including debt  Shares of Consolidated were off 4 4 percent  Advancing issues outnumbered decliners on the NYSE by 2 112 to 777  On the Nasdaq  2 098 issues rose and 664 fell  
The S P 500 index showed 49 new 52 week highs and two new lows  while the Nasdaq recorded 176 new highs and 14 new lows ",2016-12-05,Reuters,https://www.investing.com/news/stock-market-news/futures-up-as-oil-prices-top-$55-445625,445625
141850,363365,HUM,U S  attorney argues Aetna Humana deal violates antitrust law  trial,news,"By Diane Bartz WASHINGTON  Reuters    A U S  Justice Department attorney told a federal judge on Monday that health insurer Aetna  NYSE AET  Inc s planned acquisition of  Humana Inc   NYSE HUM  broke antitrust law by reducing competition in Medicare Advantage and Obamacare exchange businesses  kicking off a trial expected to last weeks  The Justice Department filed a lawsuit in July asking the court to stop Aetna s  34 billion deal for Humana  arguing it would lead to higher prices for participants in Medicare and the individual insurance program created under the Affordable Care Act  popularly known as Obamacare   Aetna argued on Monday that Medicare Advantage competes with the government s traditional Medicare program for elderly or disabled patients and said that it plans to stay out of the Obamacare exchanges in the near future  Both those programs  as well as antitrust enforcement  could face changes under Republican President elect Donald Trump  Justice Department lawyer Craig Conrath told Judge John Bates of the U S  District Court for the District of Columbia that traditional government managed Medicare does not compete with Medicare Advantage  which is managed by insurance companies  The Justice Department called as a witness Richard Frank  a former Department of Health and Human Services official now at Harvard Medical School  He told the court that seniors were generally reluctant to switch insurers  in a recent year some 78 percent stayed with their Medicare Advantage plan  11 percent changed from one Medicare Advantage plan to another  5 percent were involuntarily switched  3 percent died and just 2 percent changed from Medicare Advantage to Medicare  he said  The Justice Department s Conrath also told the judge that Aetna s plan to largely exit the Obamacare exchanges in 2017 should be disregarded because the company could re enter the market as soon as 2018 if it chooses  Conrath said written communications showed that Aetna left Obamacare because of the antitrust lawsuit  Aetna has denied that and said it would not return to the exchanges until 2019 at the earliest  Shares in Humana fell 3 6 percent to  206 03 by midafternoon  while Aetna dropped 3 8 percent to  128 41  both on the New York Stock Exchange  Aetna attorney John Majoras argued that traditional Medicare and Medicare Advantage did compete  citing a U S  government website which describes the two programs  There could soon be more competition  he said  noting  entry has been common and it has been widespread   Majoras also argued that the Obamacare exchanges were unprofitable and that that was the real reason the company planned to drop out of 11 of the 15 states where they are on the exchanges   The result to Aetna has been mounting losses   said Majoras   Humana s losses were actually even a bit worse   The Justice Department filed another lawsuit in July to stop Anthem Inc s planned  45 billion purchase of  Cigna Corp   NYSE CI   That trial is underway in the same courthouse  The trials will be over before Trump s inauguration on Jan  20  He has pledged to repeal and replace Obamacare and has said Medicare should be modernized   
Humana is the second largest Medicare Advantage insurer while Aetna is the fourth  and the two compete in more than 600 counties  the government said in its complaint ",2016-12-05,Reuters,https://www.investing.com/news/stock-market-news/u.s.-attorneys-argue-aetna-humana-deal-violates-antitrust-law:-trial-445685,445685
141851,363366,HUM,Trump order paves way for agencies to weaken health law,news,"By David Morgan and Susan Cornwell WASHINGTON  Reuters    President Donald Trump is ordering federal agencies to undermine Obamacare through regulatory action  a move that could weaken enforcement of the requirement for Americans to buy health coverage and give insurers leeway to drop some benefits   Trump s first executive order  signed hours after taking office on Friday  directs the federal government to scale back regulations  taxes and penalties under President Barack Obama s healthcare law  the Affordable Care Act  ACA    Republican lawmakers  who are working on new legislation to repeal and replace Obamacare  praised the order as showing Trump s commitment to gutting the program and lowering steep healthcare costs they blame on the law  Trump did not specify which parts of the program would be affected by his order  and any changes are unlikely to affect the government funded or subsidized insurance plans covering more than 20 million people in 2017   Trump s nominee to head the U S  Department of Health and Human Services  Georgia Representative Tom Price  has said there was no plan for  pulling the rug out  on millions of Americans  healthcare as a replacement is designed  But the scope of Trump s order drives home the uncertainties of that process  healthcare experts said   The order could affect virtually anything in the law  provided it is couched as a delay in implementing the law   said Stuart Butler  a senior fellow at the Brookings Institution  Trump s administration could decide to delay or not enforce the individual mandate  a requirement that Americans buy health coverage if they do not already have benefits from their employer or the government  as well as a similar requirement for employers of a certain size to insure their workers  experts said  Others say those changes  if not handled carefully  could force insurance premiums higher and make healthcare less affordable for Americans   outcomes that Trump and Republicans say they are trying to avoid   The administration has to run a really fine line here   said Dan Mendelson  chief executive of the Washington based consulting firm Avalere Health   They re not going on record as saying what they re going to do at this point   The administration could also alter  or fail to enforce  requirements that insurers cover a basic set of health benefits in all of their plans  from maternity and newborn care to mental health services   This could be a signal to the insurance industry that they could offer new products that  for example  didn t include maternity benefits  in order to attract more sales from people who would prefer a slimmer package   said Joe Antos of the American Enterprise Institute think tank   FLEXIBILITY  URGED  Republican Lamar Alexander  chairman of the Senate Health Committee  said last week that Price  once confirmed  could relax requirements for U S  states to get exemptions from the law  as well as make it easier for states to get waivers on the Medicaid health plan for low income households   Allow states more flexibility to determine the essential health benefits     that s probably the single most important step that could be taken to create a market where more insurers are likely to sell policies   Alexander said   His committee is one of several in the House and Senate working on repealing and replacing Obamacare   Three of the largest health insurers    Aetna Inc   NYSE AET   UnitedHealth Group  NYSE UNH  Incand  Humana Inc   NYSE HUM    have essentially pulled out of the market offering health insurance to individuals under Obamacare  citing financial losses for covering a population that was sicker than they had expected  The remaining players include Anthem Inc  as well as insurers that specialize in administering lower cost Medicaid plans  such as Molina Healthcare Inc  Ana Gupte  a senior healthcare analyst at the investment bank Leerink Partners  said Trump s executive order could reassure people in the market that Obamacare will be dismantled one way or another   That could be positive for insurers who would no longer face the law s health insurance tax  she said  But it could negatively impact acute care hospitals that have seen more customers and insurers that sell policies to state Medicaid programs  which could shrink in size  
 It s clear that Congress is looking to repeal the law and that it s poised to happen with a replacement  This is one more avenue to make sure their agenda is executed   Gupte said ",2017-01-21,Reuters,https://www.investing.com/news/stock-market-news/trump-order-paves-way-for-agencies-to-weaken-health-law-454797,454797
141852,363367,HUM,U S  blocks health insurer Aetna s  34 billion Humana acquisition,news,"By Diane Bartz  Reuters    A U S  judge blocked on Monday health insurer Aetna  NYSE AET  Inc s proposed  34 billion acquisition of smaller peer  Humana Inc   NYSE HUM   raising the stakes for rival Anthem Inc as it battles to close a  54 billion deal to buy  Cigna Corp   NYSE CI   The ruling is another victory for the U S  Justice Department  whose antitrust enforcement became much more aggressive during former U S  President Barack Obama s eight years in office  which ended last week   Obama s successor  Donald Trump  and a Republican controlled legislature are seeking to undo much of the Affordable Care Act  better known as Obamacare  The law reshaped the U S  healthcare industry by mandating health insurance and creating online exchanges where consumers can shop for individual policies and get subsidies  Aetna  Humana  Anthem and Cigna had cited Obamacare as one of the main reasons their industry needed to consolidate to cope with the costs of expanding coverage  Their shares ended trading on Monday at levels that suggested that investors continued to see little chance that the two mergers would happen   The U S  Justice Department filed a lawsuit last July to block Aetna s acquisition of Humana and Anthem s acquisition of Cigna  arguing that the two deals would lead to higher prices   Anthem and Cigna are still waiting for a judge to rule on whether their merger can proceed  Investors have long been skeptical that this deal can be approved  and Leerink Research analyst Ana Gupte reiterated on Monday that she expected to also see this deal blocked  In his ruling  Judge John Bates of the U S  District Court for the District of Columbia said the proposed deal would  substantially lessen competition  in the sale of Medicare Advantage plans in 364 counties in 21 states that the Justice Department had identified in its complaint  and on the Obamacare exchange in three Florida counties    We re reviewing the opinion now and giving serious consideration to an appeal after putting forward a compelling case   Aetna spokesman T J  Crawford said  Humana did not respond to a request for comment  Humana stands to receive a  1 billion breakup fee from Aetna should the deal be abandoned  Jeffrey Jacobovitz  a litigator at law firm Arnall Golden Gregory LLP  said that appeals at the D C  Circuit succeed about one third of the time and can take a year to resolve  He added that it would be difficult  though not impossible  for Aetna to wait for Trump s new antitrust enforcers to be named and then strike a settlement to save the merger  perhaps by offering to divest more assets  Bates dismissed Aetna s argument that there was plenty of choice for consumers because Medicare Advantage  which is managed by insurance companies  competes with traditional Medicare for the elderly and disabled  which is managed by the government   In that  Medicare Advantage  market  which is the primary focus of this case  the merger is presumptively unlawful   a conclusion that is strongly supported by direct evidence of head to head competition as well  The companies  rebuttal arguments are not persuasive   Bates wrote in a 158 page decision  Humana shares ended trading up 2 2 percent at  205 02  as investors brushed off the widely expected ruling  Shares of Cigna  the other health insurer to be acquired  were almost flat at  145 31 SEVERAL DEALS TORPEDOED Several big deals were torpedoed by antitrust regulators last year  including the  35 billion merger between oil field service groups Halliburton  NYSE HAL  Co and Baker Hughes Inc and the  6 billion combination of  Staples Inc   NASDAQ SPLS  and Office Depot Inc    Bill Baer  the former head of the Justice Department s antitrust division who initiated the lawsuit to block the Aetna Humana deal  called the decision  a strong affirmation of the role that competition plays in health insurance markets   Doctors and hospitals had urged the Justice Department to block the deal  fearing it would erode their pricing power  Some large employers also opposed the combination    Today s ruling is a decisive victory for jobs  consumers  and healthcare  Mega mergers like the proposed consolidation of Aetna and Humana raise prices  lower health care quality   and kill jobs   said Senator Richard Blumenthal  a Connecticut Democrat   Aetna had offered to sell a portfolio of about 290 000 Medicare Advantage members in 21 states to smaller peer Molina Healthcare Inc for  117 million  but that deal failed to appease Judge Bates   We are disappointed by the court s ruling today  However  whatever the ultimate outcome of that litigation  we remain committed to growing our Medicare Advantage product line   Molina spokeswoman Sunny Yu said  Humana is the second largest Medicare Advantage insurer while Aetna is the fourth  and the two compete in more than 600 counties  the government said in its complaint  Despite the adverse regulatory environment  some analysts suggested that an acquisition of Humana by someone other than Aetna was possible  
 We still suggest other potential M A optionality exists for Humana  since nothing in the verdict seems to preclude it from possible buyers that expressed historic interest and that have less market overlap  namely Cigna and Anthem  JPMorgan Chase   Co  NYSE JPM  analysts wrote in a note ",2017-01-23,Reuters,https://www.investing.com/news/economy-news/u.s.-blocks-health-insurer-aetna's-$34-billion-humana-acquisition-455079,455079
141853,363368,HUM,Aetna  Humana to consider all options after court blocks merger,news," Reuters    Aetna  N AET  and Humana  N HUM  would consider all available options for their proposed  34 billion merger  the two U S  health insurers said on Tuesday  a day after a court ruled against the deal due to fears it would lower competition  The deal would  substantially lessen competition  in the sale of Medicare Advantage plans in 364 counties in 21 U S  states and on the Obamacare exchange in three Florida counties  the U S  District Court for the District of Columbia ruled on Monday   We continue to believe a combined company will create access to higher quality and more affordable care  and deliver a better overall experience for those we serve   Aetna Chief Executive Officer Mark Bertolini and Humana Chief Executive Offer Bruce Broussard said in a joint statement on Tuesday  Aetna spokesman T J  Crawford said on Monday that the company was considering whether to appeal the court s ruling  Analysts  however  do not expect an appeal to be successful  Leerink Partners analyst Ana Gupte said an appeal was unlikely to pass muster under the Trump Administration   We see the new Trump Administration as focused on deregulation and driving down prices through competitive intensity in Medicare Advantage   Gupte said in a client note  The court ruling also casts doubt on Anthem Inc s  N ANTM  proposed  54 billion deal to buy fellow health insurer  Cigna Corp   N CI   The U S  Justice Department filed a lawsuit last July to block the two deals  arguing they would lead to higher prices  A court ruling on the Anthem Cigna deal is pending  Analysts believe it is unlikely that Humana would extend the deadline to close the merger beyond the agreed date of Feb  15  Humana is among the top players in the profitable Medicare Advantage business  which  Gupte said  could attract takeover interest in the company from insurers including Cigna and Anthem  
Aetna s shares were down nearly 2 percent on Tuesday  while Humana dropped 1 5 percent  Anthem and Cigna were up 0 7 percent ",2017-01-24,Reuters,"https://www.investing.com/news/stock-market-news/aetna,-humana-to-consider-all-options-after-court-blocks-merger-455344",455344
141854,363369,HUM,Humana  HUM  Up 3  Since Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Humana Inc    NYSE HUM    Shares have added about 3  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is HUM due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers Humana  HUM  Tops Q1 Earnings and Revenues  Lifts GuidanceHumana s first quarter 2018 operating earnings per share of  3 36 beat the Zacks Consensus Estimate of  3 21  The bottom line also improved 22 2  year over year The company benefited from Medicare Advantage enrollment growth  solid segmental performances  lower taxes as well as a favorable impact of share buybacks Operational UpdateRevenues of  14 3 billion were up nearly 6  on higher Retail revenues from the company s Medicare Advantage business plus Group and Specialty segment  Moreover  the top line surpassed the Zacks Consensus Estimate of  14 2 billion Adjusted consolidated pre tax income of  384 million declined 8 9   primarily due to lower earnings in the company s Retail and Healthcare segments  This was partially offset by higher earnings in the Group and Specialty segment  The prior year quarter also benefited from net gain associated with terminated merger agreement Benefit ratio deteriorated 40 basis points to 84 9  in the reported quarter Operating cost ratio deteriorated 70 basis points to 12 4  Segment ResultsRetailRevenues from the Retail segment were  12 1 billion  up 6  year over year  primarily owing to higher revenues from the company s Medicare Advantage business resulting from increased membership Benefit ratio of 87 4  improved 70 bps year over year  primarily owing to reinstatement of the non deductible health fee The segment s operating cost ratio of 10 1  deteriorated 170 bps year over year Adjusted pre tax income was  273 million  down 27  year over year Group and SpecialtyRevenues from the Group and Specialty segment were  1 97 billion  up 5  from the prior year quarter  primarily backed by higher stop loss premiums related to small group level funded accounts  stronger service revenues and higher per member premiums Benefit ratio improved 240 bps year over year to 73 2  owing to the impact of the reinstatement of the health insurance industry fee Operating cost ratio deteriorated 200 bps year over year to 23 6  Adjusted pre tax income of  212 million increased 23  year over year  driven by the company s higher earnings related to fully insured business Healthcare ServicesRevenues of  5 7 billion decreased 5  year over year  primarily due to exit from individual commercial business  lower Pharmacy Solutions intersegment revenues and lower revenues from  provider service business Operating cost ratio deteriorated 70 bps year over year to 96 2  Adjusted pre tax income for the segment was  196 million  down 23  due to optimization process associated with the company s chronic care management program and higher operating cost ratio Individual CommercialHumana exited this business effective Jan 1  2018 and thus  the result reflects run out of this business The company witnessed a pre tax gain of  53 million  down 15 9  year over year Financial UpdateAs of Mar 31  2018  the company had cash  cash equivalents and investment securities of  20 96 billion  up 28  from 2017 end level As of Mar 31  2018  cash and short term investments held by the parent company were  567 million  down 18  from 2017 end level Debt to total capitalization as of Mar 31  2018 was 33 9   up 60 bps from Dec 31  2017 Operating cash flow totaled  351 million  down from  1 1 billion in the year ago quarter Dividend and Share Repurchase UpdateThe company did not buy back any shares in the quarter under review and has worth  2 billion remaining under its repurchase authorization The company paid cash dividends worth  57 million 2018 Guidance RaisedHumana expects adjusted earnings per share in the range of  13 70   14 10  up from  13 50  14  guided earlier  GAAP EPS is projected between  13 54 and  13 94  up from the previous forecast of  13 16 and  13 66 Total revenues are anticipated in the band of  55 8  56 4 billion Cash flow from operations is estimated between  2 2 billion and  2 6 billion while capital expenditure is likely to be between  500 and  600 million 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There have been seven revisions lower for the current quarter Humana Inc  Price and Consensus    VGM Scores
At this time  HUM has a great Growth Score of A  though it is lagging a bit on the momentum front with a B  The stock was also allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is equally suitable for value and growth investors while momentum investors may want to look elsewhere 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Notably  HUM has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-06-01,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-up-3-since-earnings-report-can-it-continue-200321360,200321360
141855,363370,HUM,Wellcare  WCG  Downgraded By Moody s On Meridian Buyout News,opinion,Credit rating giant Moody s Investors Service has placed a downgrade rating review of Ba2 senior debt rating for WellCare Health Plans  Inc    NYSE WCG   and Baa2 insurance financial strength   IFS   rating for its subsidiary WellCare of Florida  Inc The agency decided to review the ratings after the company announced its intention to acquire Meridian   consisting of Meridian Health Plan of Michigan  Inc   Meridian Health Plan of Illinois  Inc  and pharmacy benefits manager  MeridianRx   for a transaction value of  2 5 billion This strategic move will enable WellCare expand its Medicaid portfolio to as many as 13 states with a leading market share across six of the lot Factors Driving Rating ActionThe rating agency is concerned about the increase in leverage ratio due to usage of debt to fund the Meridian buyout  It estimates the company s debt to equity ratio to deteriorate from 35  as of Mar 31  2018 to 44  or above  depending on the amount of debt issues  The company is expected to issue debt worth  0 6 billion and  1 billion and draw on the revolver credit of up to  400 million WellCare s debt to EBITDA is supposed to increase from 1 9x to 2 8x  A significant amount of goodwill is also expected to increase along with the decline of EBITDA coverage of interest income Additionally  standard integrations risks associated with this kind of large scale acquisition is another concern However  Meridian s consolidation will likely prove accretive and improve WellCare s scale and geographic diversification Moody s might review its current ratings downgrade when the deal draws to a close or prior to that if additional information allows the rating giant to reach a particular conclusion  Moreover  the agency wants to analyze Meridian s financial performance in order to understand its financial plans WellCare gave an indication to bring adjusted debt to capital ratio below 40  within a year of the transaction s completion date  This will be achieved by paying a revolving credit line used for financing the deal along with increasing retained earnings The ratings of the company have been a reflection of its decent demographic presence  consistent growth  solid capital levels and a low leverage  relative to peers  However  factors like lack of non risk business  relatively small size and government business concentration are partial offsets Shares of this Zacks Rank  1  Strong Buy  company have rallied 13 39  year to date  outperforming the  s rise of 7 8   Other Stocks to ConsiderInvestors interested in the Medical HMO industry can also check out other stocks worth considering like Anthem  Inc    NYSE ANTM    Humana Inc    NYSE HUM   and UnitedHealth Group Incorporated   NYSE UNH    You can see  Anthem and its subsidiaries operate as a health benefits company in the United States  With a Zacks Rank   2  Buy   the company managed to pull off an average trailing four quarter positive surprise of 7 22  Humana works as a health and well being company in the United States  The stock carries a Zacks Rank of 2  In the past four quarters  the company came up with an average positive earnings surprise of 6 16  UnitedHealth operates as a diversified health care company in the United States  The stock is a Zacks  2 Ranked player and delivered an average four quarter beat of 3 64  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-06-04,Zacks Investment Research,https://www.investing.com/analysis/wellcare-wcg-downgraded-by-moodys-on-meridian-buyout-news-200322341,200322341
141856,363371,HUM,Ensign Group Expands In Arizona With Sun West Choice Buyout,opinion,The Ensign Group  Inc    NASDAQ ENSG   has closed the acquisition of Sun West Choice Healthcare and Rehabilitation  The acquired entity is a 140 bed skilled nursing facility located in Sun City West  AZ  The transaction was effective Jun 1  2018 The buyout is the result of relationships built with the company s local operators over the years  With this consolidation  the acquirer would be able to add capabilities to its footprint in Arizona  Additionally  this accretive move will strengthen Ensign s growing portfolio to 184 skilled nursing operations  of which  22 include living operations  51 assisted and independent living operations  22 hospice agencies  20 home health agencies and four home care businesses across 15 states The provider of skilled nursing  rehabilitative care services  home health care  hospice care and assisted living companies is the owner of 67 establishments of total 235 healthcare operations  It is also actively seeking opportunities to acquire real estate and lease out well performing and struggling skilled nursing  assisted living and other healthcare related businesses in the United States  Sun West Choice enjoyed an 87  occupancy rate at the time of its acquisition  It also includes an adjacent 50 bed long term acute care hospital  currently run by a third party under a lease agreement Ensign Group is very active when it comes to acquisitions  The company has been whetting its clinical and financial expertise through inorganic route  It boasts 234 acquisitions from a period of 18 years  Over the past few months  the company has been successfully acquiring Cedar Hills Senior Living  a 37 unit assisted living facility and Deer Creek Senior Living  a 37 unit assisted living facility  both at Texas along with Comfort Hospice Care  a hospice provider serving the communities in Las Vegas  Pahrump and the surrounding clusters in Southern Nevada Ensign Group continues to see a steady flow of acquisition opportunities across all its business segments and therefore we expect to hear more on this front in the coming quarters Shares of this Zacks Rank  2  Buy  company have gained a whopping 101 91  against the  s decline of 3 82   Other Stocks to ConsiderInvestors interested in the Medical sector may also check out other top ranked stocks such as  WellCare Health Plans  Inc    NYSE WCG    Anthem  Inc    NYSE ANTM   and Humana Inc    NYSE HUM    You can see  WellCare offers managed care services for government sponsored health care programs  The stock sports a Zacks Rank  1 and pulled off an average trailing four quarter positive surprise of 51 70  Anthem operates as a health benefits company in the United States  A Zacks  2 Ranked player  the company came up with an average positive earnings surprise of 7 22  Humana operates as a health and well being company in the United States  The company has a Zacks Rank of 2 and managed to deliver an average four quarter beat of 6 16  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-06-05,Zacks Investment Research,https://www.investing.com/analysis/ensign-group-expands-in-arizona-with-sun-west-choice-buyout-200322585,200322585
141857,363372,HUM,Humana  HUM  And Monida Ink Deal  Enhances In Network Access,opinion,Humana Inc    NYSE HUM   has signed an agreement with Monida Healthcare Network for increasing the in network access between Monida member hospitals and clinics in Montana for Humana Medicare members  However  terms of the agreement were not disclosed With this agreement  Humana Medicare Advantage members would be able to get medical care at the five member hospitals of the Montana based association of healthcare providers  The hospitals include Broadwater Health Center  Townsend   Clark Fork Valley Hospital  Plains   Granite County Medical Center  Philipsburg   Mineral Community Hospital  Superior   St  Luke Community Hospital  Ronan  along with 11 Monida member clinic locations across five western Montana counties Additionally  the option complements other hospitals such as Barett Hospital   Healthcare in Dillon  previously contracted for in network access to Humana Medicare Advantage members  who would be facilitated with more medical care location options  As of Mar 31  2018  Humana had around 19 000 Medicare Advantage members at Montana Both companies are well aligned to meet the needs of patients they serve and this agreement is likely to further improve their quality of service and skills in the near future In the past six months  shares of this leading healthcare provider have rallied 17 14   outperforming the  s growth of 8 58   The stock holds a Zacks Rank  2  Buy   Other Stocks to ConsiderInvestors interested in the Medical HMO sector may also take a look at other top ranked stocks  namely WellCare Health Plans  Inc    NYSE WCG    Anthem  Inc    NYSE ANTM   and UnitedHealth Group Incorporated   NYSE UNH    You can see  WellCare offers managed care services for government sponsored health care programs  It sports a Zacks Rank  1  Strong Buy   In the past four quarters  the company managed to come up with an average positive surprise of 51 70  Anthem works as a health benefits company in the United States  With a Zacks Rank of 2  it pulled off an average positive earnings surprise of 7 22  UnitedHealth works as a diversified health care company in the United States  The stock is a Zacks  2 Ranked player and managed to deliver an average four quarter beat of 3 64  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-06-07,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-and-monida-ink-deal-enhances-innetwork-access-200323428,200323428
141858,363373,HUM,3 Solid Reasons To Add WellCare Health To Your Portfolio,opinion,Estimates for WellCare Health Plans  Inc    NYSE WCG   have been revised upward over the past 30 days  reflecting analysts  confidence in the stock  The stock has seen the Zacks Consensus Estimate for 2018 and 2019 earnings being raised 0 88   and 0 9   respectively WellCare Health offers managed care services for government sponsored health care programs  The company flaunts an impressive  of A  Here V stands for Value  G for Growth and M for Momentum with the score being a weighted combination of all three factors  The stock also sports a Zacks Rank  1  Strong Buy  In the past year  shares of the company have surged 38 4   outperforming the  s growth of 34 46   Now  let us focus on some important factors that make WellCare Health stock an investor favorite Increasing Top Line  The company has seen steady revenue growth since 2006  riding high on solid organic and inorganic growth strategies as well as a strong balance sheet  Revenues have witnessed a five year CAGR  2012 2017  of 18   The company is expected to retain its revenue momentum in the future as well  In first quarter 2018  the top line improved 17 5   Moreover  the company has been actively expanding its geographical footprint and its presence across different industries Inorganic Growth  Active acquisitions and partnerships over the past six years have helped the company grow substantially  The company s Medicaid business and portfolio were aided by the buyouts of Care1st Arizona and Advicare  In 2017  it completed the consolidation of Universal American Corp  which aided in driving 42  growth year over year in Medicaid Health premiums during the first quarter of 2018  Arizona based Medicaid assets of Phoenix Health Plan was also acquired by WellCare Health  Recently  the company announced to acquire Meridian Health Plans of Michigan and Illinois and MeridianRx  a pharmacy benefit manager  PBM   to become the top most Medicaid provider in both states Strong Cash Flow  WellCare Health enjoys a robust cash position in the current scenario  With increasing cash flows from operating activities  the company witnessed a four year CAGR of 55 6  during the 2013 2017 period  High level of financial liquidity is likely to boost inorganic growth initiatives like before  Also  the company s 47  leverage ratio is lower than the industry s 58 5  ratio  mirroring its inherent strength Other Stocks to ConsiderInvestors interested in the Medical HMO industry may also take a look at a few other top ranked stocks like Anthem  Inc    NYSE ANTM   and Humana Inc    NYSE HUM   and UnitedHealth Group Incorporated   NYSE UNH    You can see  Anthem operates as a health benefits company in the in the United States  providing network based managed care health benefit plans to individuals   small as well as large groups  Medicaid and Medicare markets  With a Zacks Rank  2  Buy   the company managed to deliver an average four quarter beat of 7 22  Humana operates as a health and well being company in the United States  It carries a Zacks Rank of 2 and pulled off an average four quarter positive surprise of 6 16  UnitedHealth Group Incorporated operates as a diversified health care company in the United States  The stock is a Zacks  2 Ranked player and came up with an average four quarter earnings surprise of 3 64  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-06-13,Zacks Investment Research,https://www.investing.com/analysis/3-solid-reasons-to-add-wellcare-health-to-your-portfolio-200324986,200324986
141859,363374,HUM,UnitedHealth Senior Notes Receive Rating Action From Moody s,opinion,Credit rating giant Moody s Investor Service recently assigned an A3 senior unsecured debt rating to the planned issuance of around  4 billion senior unsecured debt of UnitedHealth Group Incorporated   NYSE UNH    The total amount is due in June 2021  2023  2028 and 2048  The rating outlook stays stable Net proceeds from the same would be used for repaying commercial paper borrowings as well as general corporate expenditure of the company  that might consist of redeeming or repurchasing outstanding securities or refinancing debt  Ratings RepresentationThe credit rating agency expects the proceeds to be primarily used for paying back  4 4 billion of commercial paper outstanding as of Mar 31  2018  As such there should not be any considerable change in the company s indebtedness Moody s debt to capital was 42 5  as of Mar 31  2018  above the high end of its rating expectation  Moreover  the agency notes that the  4 9 billion worth acquisition of DaVita Medical Group  which is expected to be closed in 2018  would be paid through a combination of commercial paper  cash and debt  This acquisition will effectively increase the leverage ratio of the company to more than 44   lying above the rating agency s benchmark As on Mar 31  the parent company had  587 million in cash and cash equivalents The A3 senior unsecured debt rating and A1 insurance financial strength rating of UnitedHealthare based on its  strong business profile  primarily driven by its national presence  brand value  membership base  diverse benefits and services product offerings as well as an impressive level of unregulated revenues The ratings also find support in a solid financial profile characterized by a steady  consistent earnings performance  a conservative and well diversified investment portfolio plus a strong interest coverage from both regulated and unregulated operations  However  all these are partially offset by the aforementioned high leverage and a significant amount of goodwill and intangibles from past acquisitions Factors That May Lead to  Rating ChangePer Moody s  the ratings of the company may be upgraded if its financial leverage is maintained below 35   EBITDA interest coverage is above 15x and a consolidated risk based capital ratio is more than 275  of company action level Additionally  the ratings can get downgraded if the financial leverage of the company is maintained above 40   the RBC  risk based capital  ratio is sustained below 250  of CAL as well as with a significant write down or increased likelihood of goodwill or intangibles In the past year  this Zacks Rank  2  Buy  stock has surged nearly 40 6   outperforming the  s growth of 34 6   Other Stocks to ConsiderInvestors interested in the Medical HMO industry can also check out some other top ranked stocks like WellCare Health Plans  Inc    NYSE WCG    Anthem  Inc    NYSE ANTM    and Humana Inc    NYSE HUM   WellCare provides managed care services for government sponsored health care programs  It sports a Zacks Rank  1  Strong Buy  and delivered a whopping four quarter positive surprise of 51 7   You can see  Anthem operates as a health benefits company in the United States  With a Zacks Rank of 2  the company managed to pull off an average trailing four quarter earnings surprise of 7 22  Humana works as a health and well being company in the United States  It holds a Zacks Rank  2  Buy   In the past four quarters  the company came up with an average beat of 6 16  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-06-14,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-senior-notes-receive-rating-action-from-moodys-200325306,200325306
141886,363401,HUM,S P set to snap losing streak after strong jobs report,news,"By Lewis Krauskopf  Reuters    Wall Street gained modestly on Friday after a strong U S  employment report as investors sought bargains after a spate of selling sparked by uncertainty over the impending U S  elections  The S P 500 was on track to snap a streak of eight straight days of declines  which had been the benchmark s longest run of down days since the 2008 financial crisis  The tech heavy Nasdaq was also on pace to snap an eight session losing streak  Over its losing streak  the S P 500 had fallen nearly 3 percent  Investors have been unnerved by signs of a tightening presidential race between Democrat Hillary Clinton and Republican Donald Trump  after Clinton had until recently been thought to have a clear lead   Investors are buying anything that looks like a dip and that is because the fundamentals continue to be pretty good even though I think there is a lot of anxiety about next week s election   said Kate Warne  investment strategist with Edward Jones in St  Louis   With the pullback  I think investors are seeing some bargains out there   The Dow Jones industrial average  DJI  rose 5 24 points  or 0 03 percent  to 17 935 91  the S P 500  SPX  gained 3 78 points  or 0 18 percent  to 2 092 44 and the Nasdaq Composite  IXIC  added 5 47 points  or 0 11 percent  to 5 063 88  U S  employers maintained a strong pace of hiring in October and boosted wages for workers  the Labor Department report on Friday showed  Nonfarm payrolls increased by 161 000 jobs last month amid gains in construction  healthcare and professional and business services  While that was below economists  forecast for growth of 175 000 jobs  solid labor market fundamentals were underscored by revisions to August and September data  which showed 44 000 more jobs created than previously reported    The upward revisions over the last two months suggest that the overall picture is continued job growth   Warne said   That means that consumers have more money and that should continue to support economic growth   For the year  the S P 500 is up 2 5 percent  In an encouraging sign for stocks  S P 500 companies are on pace to increase earnings by 3 9 percent in the third quarter  ending a four quarter streak of profit declines  according to Thomson Reuters I B E S  Higher than expected quarterly profits from biotech company Regeneron  O REGN  and health insurer Humana  N HUM  lifted those companies  shares along with the S P healthcare sector  SPXHC   which was the best performing group on Friday  Advancing issues outnumbered declining ones on the NYSE by a 1 55 to 1 ratio  on Nasdaq  a 1 75 to 1 ratio favored advancers  
The S P 500 posted 4 new 52 week highs and 13 new lows  the Nasdaq Composite recorded 28 new highs and 126 new lows ",2016-11-04,Reuters,https://www.investing.com/news/stock-market-news/wall-st.-set-to-open-flat-as-investors-await-election-437660,437660
141887,363402,HUM,Exclusive  U S  states join Dow DuPont merger probe   sources,news,"By Diane Bartz WASHINGTON  Reuters    U S  state attorneys general have joined a federal antitrust probe of the planned merger between DuPont  N DD  and  Dow Chemical  Co  N DOW   according to three people familiar with the matter  heightening risks to a deal that could help reshape the global farm industry  A separate group of state attorneys general are expected to join a probe of Bayer AG s  DE BAYGn   66 billion plan to buy  Monsanto  Co  N MON   one of the sources said  The involvement of the state attorneys general increases scrutiny of the mega deals and will complicate what are already expected to be tough and lengthy reviews by U S  antitrust enforcers  About seven states  including California  have joined the probe of Dow s planned merger with DuPont  according to two people familiar with the matter  It was not yet clear how many states would join the Bayer Monsanto merger investigation  one source said  The states are concerned that the companies may raise pesticide and herbicide prices for farmers following a merger  and have less incentive to compete to introduce better and cheaper products  two of the sources said  The sources asked not to be named because they were not authorized to speak with the media DuPont and Dow said in separate statements they expected to win approval for their deal   In the U S   we are working constructively with federal and state regulatory authorities  elected officials and all agriculture stakeholders to show the pro competitive benefits of the merger   the companies said   Bayer said in a statement it looked forward to  working diligently with regulators to ensure a successful close   Monsanto did not respond to a request for comment  While it is up to the Justice Department to decide whether to file a lawsuit to stop a merger  states provide information on how the mergers would affect their jurisdictions and conduct joint calls to gather data from the companies  as well as critics and supporters of the deals  The Justice Department  with help from states  sued in July to stop two of the year s most controversial deals   Aetna Inc s  N AET  plan to buy  Humana Inc   N HUM  and Anthem Inc s  N ANTM  bid for  Cigna Corp   N CI   Eleven states and the District of Columbia joined the federal government in the Anthem lawsuit while eight states and Washington  DC  joined the Aetna lawsuit  Chemical companies DuPont and Dow agreed in December to create a company worth  130 billion  with a plan to split into three companies with one specializing in agriculture  another in materials and a third in specialty products  The Dow deal with DuPont and Bayer s plan to buy Monsanto are two of four mergers in the business of selling farmers seeds  fertilizer  pesticides and herbicides  The others are ChemChina s plan to buy  Syngenta  AG  S SYNN  and Potash Corp s  TO POT  plan to buy  Agrium  Inc  TO AGU   A FOCUS ON ALTACOR  INTREPID  The state probe of Dow s planned merger with DuPont is focused on the companies  overlap in pesticides used on high value crops like almonds  pistachios  grapes and apples  two of the sources said  The insecticides in question are DuPont s Altacor and Dow s Intrepid  which are chemically different but which both fight insects that can kill or mar almonds  apples and other nuts and fruit  If allowed to combine  Dow and DuPont would also have 41 percent of the market for U S  corn seeds and traits and 38 percent of the U S  soybean seeds and traits market  according to a  Morgan Stanley   NYSE MS  research report in February  The Bayer Monsanto review will likely focus on the companies  overlap in cotton seed  a source said   
The state attorneys general will also look at traits since Bayer licenses genetic traits that make seeds resistant to Liberty  a popular herbicide  while Monsanto licenses traits that make seeds resistant to Roundup  another popular herbicide ",2016-11-07,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-u.s.-states-join-dow-dupont-merger-probe---sources-438502,438502
141888,363403,HUM,Healthcare on the move ,news,Healthcare stocks  the weakest sector this year  may become winners  as Obamacare reforms are set to be  repealed and replaced  and major legislation is likely to be introduced to clamp down on drug prices While Trump has not set out a comprehensive alternative to the Affordable Care Act  which may see 22M Americans lose current insurance coverage   he says he ll encourage competition between markets in different states Related tickers  UNH  AET  ANTM  CI  HUM  WCG  CNC  MOH  GTS  HQY Election2016,2016-11-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare-on-the-move -439035,439035
141889,363404,HUM,Trump victory clouds outlook for Time Warner AT T  other mergers,news,"By Diane Bartz and Olivia Oran WASHINGTON NEW YORK  Reuters    U S  corporate dealmakers were likely to put major merger plans on hold as they assess whether U S  President elect Donald Trump will follow through on his populist promises and a threat to block AT T Inc s  N T  purchase of  Time Warner  Inc  N TWX   or act more like traditional business friendly Republican administrations  Trump s rhetoric and the personal nature of the campaign  which included little discussion of policy  left many uncertain about the new U S  leader s plans  including how his administration will handle mega mergers  Wall Street braced for a drop in deals  with Goldman Sachs  NYSE GS  on Wednesday projecting a 20 to 30 percent downside for earnings of banks that focus on merger and acquisition advice  and Jefferies saying that uncertainty about Trump s policy on trade  healthcare  taxes and energy could hamper underwriting activity and M A globally   I think a lot of deals will hit the pause button for a bit until we get some clarity on whether President Trump will moderate or be as disruptive as some expect   said a senior Wall Street banker who asked not to be named because he was not authorized to speak with the media   It s going to be a tough environment for everything until we see how  Trump  behaves as a leader   the banker added  Trump said in October that AT T s proposed  85 billion acquisition of the owner of HBO  CNN and the Warner Bros film studio was an example of a  power structure  rigged against him and voters  and that he would block a deal  The gap between Time Warner shares and the implied value of AT T s cash and stock bid was over 23 percent in afternoon trading on Wednesday  compared to around 22 percent at Tuesday s close  indicating greater investor skepticism that the companies will be able to complete the transaction   Still  some investors believed the man who considers himself business friendly would take a more moderate tone than in the campaign once he assumes office  as he did on Tuesday night in his acceptance speech   We think Trump will be pretty good for merger and acquisition activity  As a general proposition  he is pro business and pro free market   said Roy Behren  portfolio manager at Westchester Capital Management  Other big pending U S  deals also did not see sharp changes in their spreads on Wednesday morning  and the spreads of three pharmaceutical or health care related deals that have encountered antitrust troubles  Aetna  N AET  Humana  N HUM   Anthem  N ANTM  Cigna  N CI  and Walgreens  O WBA  Rite Aid  N RAD   actually narrowed  signaling investors may think they are more likely to close under a Trump administration  The president does not directly decide if a merger is illegal under antitrust law and the job is done by the U S  Justice Department or Federal Trade Commission  which divide up the work of assessing mergers  If one of the agencies decides to stop a deal  it must convince a judge to agree  AT T Chief Financial Officer John Stephens on Wednesday said his company was looking forward to working with Trump and  optimistic  regulators would approve the deal   Trump s policies and discussions  about infrastructure investment  economic development  and American innovation all fit right in with AT T s goals   Stephens said at the  Wells Fargo   NYSE WFC  technology  media and telecoms conference in New York  Time Warner s shares were last down 1 percent to  86 71  after trading as low as  85 60  while AT T shares were up just under 1 percent at  37 24  The Dow and S P 500 were both over 1 percent higher in late afternoon trading  The election results mean  increased risks  for the AT T Time Warner deal  Angelo Zino  analyst at CFRA Research  said   At the very least  there are going to be individuals put in place  by a Trump administration  that are going to make the deal a lot more challenging to complete   he added   Trump s protectionist stance also raises the risk that some foreign corporations  including from China  may face higher hurdles in trying to take over American companies  dealmakers said  
 If you were thinking about doing a cross border deal six months ago you weren t considering things like potential trade barriers  protectionism and tariffs  These are things you have to at least develop a view on and factor into the risk assessment of doing an overseas deal now   said Johs Worsoe  MUFG s head of investment banking   markets in the Americas ",2016-11-09,Reuters,"https://www.investing.com/news/stock-market-news/at-amp;t,-time-warner-shares-fall-amid-concern-trump-will-block-deal-439119",439119
141890,363405,HUM,Aetna  Humana upgraded at Credit Suisse on brighter prospects under Trump,news,Aetna  AET  0 4   and Humana  HUM  0 4   are upgraded to Outperform from Neutral at  Credit Suisse   SIX CSGN   which says a Trump administration may improve prospects for health care stocks in general and also increase the chances that AET s pending deal to buy HUM would pass muster with  antitrust officials  The firm also says prospects for Medicare Advantage appear  particularly bright   while there is uncertainty around the stocks of companies that are highly leveraged to the Affordable Care Act as a driver of their growth stories  particularly hospitals and Medicaid MCOs  Credit Suisse raises its stock price target for AET to  135 from  120 and for HUM to  210 from  170 ,2016-11-11,Seeking Alpha,"https://www.investing.com/news/stock-market-news/aetna,-humana-upgraded-at-credit-suisse-on-brighter-prospects-under-trump-440041",440041
141891,363406,HUM,U S  congressional panel  SEC reach deal in insider trading probe,news,"By Nate Raymond NEW YORK  Reuters    A U S  House of Representatives panel and an ex staff member have agreed to end a fight over subpoenas the U S  Securities and Exchange Commission issued during a probe into possible insider trading on leaked information about Medicare reimbursement rates  In a letter filed on Monday in federal court in Manhattan  lawyers for the SEC  the House Ways and Means Committee and ex staffer Brian Sutter said they had reached an agreement on a protocol for the agency to review documents it had sought  The SEC said the congressional panel and Sutter had as a result agreed to dismiss an appeal of a November 2015 ruling by U S  District Paul Gardephe that had required them to comply with subpoenas issued in the probe   The parties are hopeful that their agreement  although presently only a partial resolution of the referenced proceeding  may culminate in a full resolution of it   the letter said  Representatives for the committee  the SEC and Sutter did not immediately respond to a request for comment  The decision to drop the appeal came after a three judge panel of the 2nd U S  Circuit Court of Appeals in June appeared during oral arguments to lean in favor of forcing Congress to comply at least somewhat with two SEC subpoenas  The case was seen as a test of how far securities enforcers may go to police the murky world of  political intelligence   in which firms seek to gather and sell information for traders  According to court filings  the SEC has been looking into an email a lobbyist at the law firm Greenberg Traurig LLP sent to an analyst at broker dealer Height Securities regarding a deal struck in Congress about Medicare reimbursement rates in 2013  The SEC said the email was sent before the Centers for Medicare and Medicaid Services announced the rates after U S  markets closed and about 30 minutes before Height issued a report suggesting the change could help companies such as  Humana Inc   N HUM   The SEC s probe came to focus in part on Sutter  who the regulator said on the day of the announcement had spoken with the Greenberg Traurig lobbyist and had discussed the rate announcement on that call  Federal prosecutors in Manhattan had also launched an investigation related to the alleged leak  according to congressional records  The status of that probe was unclear on Monday  
The case is SEC v  Committee on Ways and Means of the U S  House of Representatives et al  U S  District Court  Southern District of New York  No  14 mc 00193 ",2016-11-14,Reuters,"https://www.investing.com/news/stock-market-news/u.s.-congressional-panel,-sec-reach-deal-in-insider-trading-probe-440701",440701
141892,363407,HUM,Here s Why Teladoc Reaches A 52 Week High  Stock Up 22 ,opinion,Teladoc  Inc    NYSE TDOC   gains traction from a strong first quarter 2018 earnings release as well as a solid guidance  The stock hit a 52 week high of  47 15 on Thursday What Drives the Stock This telehealth service provider rides high on an inorganic growth profile  strong demand for its telehealth services  an increasing clientele base and a gradual march toward a breakeven profitability  All these factors have held stock in a good shape Since the release of the company s results on May 1  2018  shares have rallied 22   outperforming the industry s growth of 2   In a year s time  the sock has returned 60   significantly higher than the  s rise of 9 3   Let s look at the catalysts for this bull run Investors note that the company is in growing stage and the consistent bottom line losses over the past several quarters are a result of heavy expenditures incurred on marketing and substantial investments made to acquire new clients  build a proprietary network of healthcare providers and develop technology platform All the more encouraging is that these investments are reaping fruits  reflected by a strong increase in membership  visits and client base  These upsides have contributed to an upsurge in revenues at the company  which has witnessed a CAGR of 74  during the 2014 2017 period  The top line skyrocketed 109  year over year in the first quarter of 2018   The company s inorganic strategies have provided enough fuel to its overall growth  A number of acquisitions  namely Best Doctors  HealthiestYou  StatDoc and BetterHelp completed in the past three years have enhanced growth in membership and visits  Both metrics registered a CAGR of 42  and 70   respectively  during the 2014 2017 phase  The two were also up 41  and 57   each in the first quarter Investors are also confident about a decline in the expenditures with the company gradually starting to realize leverage from the scale of operations  In the fourth quarter of 2017  the company reported a positive EBIDTA  first ever since its IPO   which shows that it is on track to achieve a bottom line profitability  Though the company posted a negative EBIDTA in first quarter 2018  management has issued a positive guidance for adjusted EBIDTA in the second quarter and also for the full year Stock s Unique Position in a Thriving IndustryTeladoc is fast gaining ground in the rapidly growing telehealth services industry in the United States with ample scope for flourish owing to concerning health care cost following inefficient care  duplication of services  significant waste and extreme variation in access  cost and quality of care Teladoc can address this inefficiency in care by providing superior quality of care through a platform that caters to consumer demand and physician availability in real time and in various modalities such as video  web  mobile and telephone  Moreover  the emergence of technology via big data and analytics  cloud based solutions  online video and mobile applications offers the company with huge opportunity for growth Will the Stock Rally Further The company s upbeat guidance for 2018 further lends a positive insight into its performance going forward  which in turn should support the stock price rise Zacks Rank and Stocks to Consider Teladoc carries a Zacks Rank  3  Hold   Some better ranked stocks in the medical space are Charles River Laboratories International  Inc    NYSE CRL    Anthem Inc    NYSE ANTM   and Humana Inc    NYSE HUM    each holding a Zacks Rank  2  Buy  Anthem beat estimates in each of the trailing four quarters with an average positive surprise of 7 22  Humana delivered positive surprises in each of the last four quarters with an average beat of 6 2 Charles River Laboratories surpassed estimates in each of the preceding four quarters with an average positive surprise of 9 14   You can see Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana       Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-05-11,Zacks Investment Research,https://www.investing.com/analysis/heres-why-teladoc-reaches-a-52-week-high-stock-up-22-200315609,200315609
141893,363408,HUM,5 Reasons To Add WellCare Health Plans To Your Portfolio,opinion,Estimates for WellCare Health Plans  Inc    NYSE WCG   have been revised upward over the past seven days  reflecting analysts  confidence in the stock post solid first quarter earnings results  The stock has seen the Zacks Consensus Estimate for 2018 and 2019 earnings being raised 0 5  and 0 8  to  10 16 and  12 02  respectively WellCare offers government sponsored managed care services  Shares of this Zacks Rank  1  Strong Buy  securities exchange have gained 8 9  year to date  outperforming the  s growth of 6 2   Let s focus on the factors that make WellCare an attractive stock to hold on to for greater returns Raised Guidance  Backed by strong first quarter 2018 results  the company has lifted its 2018 earnings outlook  It expects adjusted earnings per share in the band of  10  10 30  up from the previously guided range of  9 55  9 85 to account for improvement in medical benefit ratios across all its segments Improving Top Line  The last few years saw WellCare s top line rise  witnessing a five year CAGR of 18  on the back of its organic and inorganic growth strategies   Apart from premium growth  accretive acquisitions have helped WellCare Health grow its market share by expanding its presence across geographies and different industries  For 2018  total adjusted premium revenues are expected in the bracket of  17 925  18 425 billion  up 7  from 2017 Financial Strength  WellCare enjoys commendable liquidity  banking on its robust cash position  Its cash flow from operating activities has been consistently registering a remarkable four year CAGR of 55 6   This high level of financial liquidity is likely to support the company s inorganic growth initiatives  which have been the main revenue driver to date Growth Projections  The Zacks Consensus Estimate for current year earnings per share is pegged at  10 16  representing a year over year increase of 19 3  on 9 2  higher revenues of  18 6 billion For 2019  the consensus mark for earnings per share is pegged at  12 02 on  20 16 billion revenues  thus depicting a respective 18 3  and 8 6  year over year rise WellCare has an expected long term earnings per share growth rate of 14 1   outperforming the industry s average of 13 2  VGM Score  WellCare carries a favorable  of A  Here V stands for Value  G for Growth and M for Momentum with the score being a weighted combination of all three factors   Backtested results prove that stocks with an impressive VGM Score of A or B coupled with a bullish Zacks Rank offer the best investment bets Positive Earnings Surprise History  The company boasts an encouraging earnings surprise history  having exceeded the Zacks Consensus Estimate in each of the trailing 13 quarters with an average beat of 14   This trend of consecutive estimate beats denotes the company s operational excellence Other Stocks to ConsiderSome other top ranked stocks from the HMO industry are Anthem  Inc    NYSE ANTM    Humana Inc    NYSE HUM   and Triple S Management Corporation   NYSE GTS    each carrying a Zacks Rank  2  Buy   You can see  Anthem operates as a health benefits company in the United States  It pulled off an average four quarter positive surprise of 7 22  Humana operates as a health and well being company in the United States  It delivered an average four quarter beat of 6 16  Triple S Management provides a portfolio of managed care and related products in the commercial  Medicare and Medicaid markets in Puerto Rico  the United States  It came up with an average four quarter beat of 260 65  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-05-13,Zacks Investment Research,https://www.investing.com/analysis/5-reasons-to-add-wellcare-health-plans-to-your-portfolio-200316044,200316044
141894,363409,HUM,Centene Banks On Investments And Acquisitions For Growth,opinion,"Centene Corp    NYSE CNC    a health insurer  primarily dealing with government insurance products such as Medicare and Medicaid  is rapidly evolving into a diversified healthcare enterprise 
Centene has resorted to a number of acquisitions and investments  which will add substantially to the company s business portfolio  In April  Centene agreed to certain undertakings with the New York Department of Health  This includes a  340 million contribution to the State of New York to be paid over a five year period  This contribution will be used for initiatives consistent with Centene s mission of providing high quality healthcare to vulnerable populations within the state 
In the same month  Centene completed the acquisition of MHM Services  a national provider of healthcare and staffing services to conventional systems and other governmental agencies  This acquisition adds one new state to Centene s portfolio to 13 states 
In March  the company completed the acquisition of Community Medical Group  CMG   which represents the company s targeted approach toward vertical integration in healthcare  In addition to CMG s primary care services  its specialty care  transportation and a suite of social and other support services should enhance Centene s service portfolio 
In the same month  Centene made an equity investment in RX Advance  a full service pharmacy benefits manager  The company expects to use the company s cloud based technology platform to significantly reduce administrative cost and affordable drug impacted medical cost 
Also in March  the company made an additional 61  investment in Interpreta  This is an innovative health IT company focused on clinical and genomic data  as well as real time analytics 
These transactions testify to Centene s continued execution on its diversification strategy  This would enhance its position as a healthcare enterprise and a leader in government sponsored healthcare  Adding capabilities in the provider  pharmacy and technology categories should provide growth and margin opportunities for Centene well into the future 
Centene has given a strong operational performance for the past many years  a trend which continued in the first quarter  marked by solid top and bottom line growth and robust operating cash flows  Membership at the end of the first quarter increased 6   revenues were up 13  and earnings per share surged 94  
Its robust results led to a 6 5  surge in share price  outperforming the  s growth of 1 9  

Centene carries a Zacks Rank  3  Hold   Some better ranked stocks in the same space are WellCare Health Plans Inc    NYSE WCG    Anthem  Inc    NYSE ANTM   and Humana Inc    NYSE HUM     
While WellCare carries a Zacks Rank  1  Strong Buy   each of the other two companies carries a Zacks Rank  2  Buy   You can see  
WellCare surpassed estimates in each of the last four reported quarters  with an average positive surprise of 51 7  
Humana beat estimates in all four reported quarters  with an average positive surprise of 6 2  
Anthem came up with a positive surprise in each of the last four reported quarters at an average of 7 2  
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-05-24,Zacks Investment Research,https://www.investing.com/analysis/centene-banks-on-investments-and-acquisitions-for-growth-200319149,200319149
141924,363439,HUM,U S  judge in Anthem merger trial sets trial for November 21  plans ruling by late January 2017,news,"By Diane Bartz WASHINGTON  Reuters    The judge overseeing the U S  Justice Department s bid to stop health insurer Anthem  N ANTM  from merging with competitor Cigna  N CI  said on Friday her goal was to have a ruling by the end of January  later than the Dec  30 date sought by Anthem  Anthem had sought a ruling by the end of the year on whether the government could stop the deal because the insurer said it needed time to wrap up merger reviews by state insurance commissioners by April 30  a deadline the companies set to complete the deal  Anthem has said failure to meet the deadline could prompt Cigna to pull out  In a brief order issued late on Friday  Judge Amy Berman Jackson of the U S  District Court for the District of Columbia set a trial date for Nov  21  with a conclusion by Dec  30  She gave the government 10 days to present its case and gave Anthem six days  The judge said in a pre trial hearing on Friday morning that she expected a decision in January   My current thinking is that I m going to aim for a decision by the end of January   she said  Cigna is unlikely to agree to extend the April 30 deadline because of the two companies  contentious relationship  a lawyer for Anthem said last week   The Justice Department filed lawsuits on July 21 asking a federal court to stop two huge healthcare mergers  Anthem s planned  45 billion purchase of Cigna  as well as Aetna  N AET  Inc s  33 billion planned acquisition of Humana  N HUM   The trial on the Aetna deal is set for Dec  5  Anthem s lawyer  Christopher Curran  indicated during the hearing that the company was most concerned about reviews on the merger in Colorado  Connecticut  Georgia and New Hampshire  During the hearing  lawyers for the Justice Department and Anthem both said they were willing to discuss a settlement but neither indicated that talks were ongoing   There is absolutely a willingness  to hold settlement discussions  said the Justice Department s Jon Jacobs  who added  however  that any proposed remedy would take time to evaluate  Anthem s Curran said the company  stands ready  to discuss a settlement  The Justice Department argues that the deals would reduce competition  raise prices for consumers and stifle innovation if the number of large  national insurers fell from five to three  
If both mergers go through  No  1 U S  insurer UnitedHealth Group Inc  N UNH  would rank second after Anthem  Aetna would be No  3 ",2016-08-12,Reuters,https://www.investing.com/news/stock-market-news/u.s.-judge-in-anthem-merger-trial-plans-ruling-by-late-january-420060,420060
141925,363440,HUM,Aetna warned it would cut Obamacare if Humana deal was blocked,news,"By Caroline Humer
NEW YORK  Reuters     Aetna Inc  s  N AET  top executive said in a letter to the U S  Department of Justice during the review of its deal to buy rival  Humana Inc   N HUM  that the insurer would exit much of the individual Obamacare insurance market if the agency challenged the merger 
News of the letter came after Aetna said on Monday that it would pull out of selling individual insurance on the government run websites in 11 states  citing financial losses on the business 
In the July 5 letter  Chief Executive Officer Mark Bertolini said it would be some time before the company recouped the investment it had made over the past 2 1 2 years in the government subsidized insurance plans created under President Barack Obama s national healthcare reform law 
 Our ability to withstand these losses is dependent on our achieving anticipated synergies in the Humana acquisition   Bertolini wrote  according to a copy of the letter posted on the Huffington Post website  which obtained the document though the Freedom of Information Act 
 Unfortunately  a challenge by the DOJ to that acquisition and or the DOJ successfully blocking the transaction would have a negative financial impact on Aetna and would impair Aetna s ability to continue its support   he wrote 
UnitedHealth Group Inc  N UNH  and Humana Inc  N HUM  have cited similar concerns about financial losses on the Obamacare exchanges and have also cut back most of their plans for 2017 
The Justice Department moved on July 21 to block Aetna s acquisition of Humana and Anthem Inc s  N ANTM  purchase of  Cigna Corp   N CI   saying the two deals would lead to higher prices 
Bertolini s letter followed Assistant Attorney General William Baer s request to Aetna on June 30 for information on the consequences of not completing the deal 
A copy of that document shows the Justice Department asked for data on costs such as the breakup fee  the impact on Aetna s business strategy  including participation on the Obamacare exchanges  and documents related to a June board meeting and the Humana deal or the exchanges 
Aetna spokesman TJ Crawford said in an emailed statement that since the company submitted the letter to the Justice Department  it had a better view of the business line s second quarter performance 
 That deterioration  and not the DOJ challenge to our Humana transaction  is ultimately what drove us to announce the narrowing of our public exchange presence for the 2017 plan year   Crawford said 
Aetna shares rose 0 5 percent to  119 58  Humana fell 0 3 percent to  179 08 ",2016-08-17,Reuters,https://www.investing.com/news/stock-market-news/aetna-warned-it-would-cut-obamacare-if-humana-deal-was-blocked-420866,420866
141926,363441,HUM,Obama asks U S  insurers for help enrolling the young and healthy,news," Reuters    President Barack Obama on Monday urged U S  insurers offering coverage next year under his national healthcare law to step up their efforts to enroll those who remain uninsured  especially younger and healthier Americans  Several big insurers  including UnitedHealth Group Inc  NYSE UNH    Aetna Inc   NYSE AET  and  Humana Inc   NYSE HUM   have announced they will pull back from the Obamacare individual insurance market in 2017  citing financial losses due to the costs of covering members who are sicker than expected  Their planned exit has prompted new questions over whether Obamacare can survive over the long term if insurers cannot create a viable business from the market  Insurance premiums for consumers have jumped each year since Obamacare plans took effect in 2014  and those price increases are expected to grow steeper as fewer insurers participate   Obama  in a letter to all insurers selling health plans next year on the exchanges  noted that the program has helped reduce the percentage of Americans without health insurance to a record low  and acknowledged that it could still be improved to benefit insurers and consumers  His administration will help find and enroll those who still lack coverage  with a particular focus on enrolling young adults    Since the remaining uninsured are disproportionately younger and healthier  signing them up improves the risk pool and consequently the affordability of coverage for all enrollees   Obama said in the letter   Obama  Secretary of Health and Human Services Sylvia Burwell and other top health advisers on Monday met with executives from several leading insurance companies  including  Cigna Corp   NYSE CI  Chief Executive David Cordani and Humana CEO Bruce Broussard  to discuss ways to strengthen the marketplace ahead of its fourth open enrollment period  which begins Nov  1  according to a White House official   A spokeswoman for industry group America s Health Insurance Plans said the meeting s focus included increasing enrollment   
 As health plans are preparing for open enrollment  today s meeting was focused on how to build on the continued progress in reducing the uninsured rate and moving forward with policy solutions that will support a stable  affordable market for 2017 and beyond   AHIP spokeswoman Clare Krusing said ",2016-09-12,Reuters,https://www.investing.com/news/politics-news/obama-asks-u.s.-insurers-for-help-enrolling-the-young-and-healthy-425697,425697
141927,363442,HUM,Anthem judge considering splitting merger trial into two sections,news,"By Diane Bartz WASHINGTON  Reuters    The judge who will rule on whether the government may stop health insurer Anthem  N ANTM  from buying competitor Cigna  N CI  said Friday that she was considering splitting the trial into phases  Judge Amy Berman Jackson of the U S  District Court for the District of Columbia said that she was mulling hearing separately about the effect of the merger on the national market in one phase and on local markets in a second phase with a potential decision after the first set of arguments  The Justice Department argues that the deal would reduce competition and raise prices for consumers   My initial reaction is that it s better   said Christopher Curran  who is arguing the case for Anthem   If we re going to lose and we lose quickly  that s better for everyone   The trial in the case is to begin on Nov  21  with a conclusion by Dec  30  The government also alleged that the merger would give the new  combined company too much power to set the rates of health care providers  essentially a monopsony case  That could be argued with either phase  said Jon Jacobs  who argued for the Justice Department   I m going to think about this  I think it s more complicated than I had thought   the judge said  adding that she still believed it would be beneficial to hear arguments in phases  Cigna s lawyer  Charles Rule  asked if he would be allowed to object to questions from Anthem  referring to the contentious relationship between the two companies   I m not sure exactly what will come up   said Rule    But  there may need to be an objection   The judge responded with surprise   I m not going to tell you that it s prohibited but I find it highly extraordinary   she said  Anthem had sought a ruling by the end of the year on whether the government could stop the deal because the insurer said it needed time to wrap up merger reviews by state insurance commissioners by April 30  a deadline the companies set to complete the deal  Anthem has said failure to meet the deadline could prompt Cigna to pull out  The Justice Department filed lawsuits on July 21 asking a federal court to stop two huge healthcare mergers  Anthem s planned  45 billion purchase of Cigna  as well as Aetna Inc s  N AET   33 billion planned acquisition of Humana  N HUM   The trial on the Aetna deal is set for Dec  5  
If both mergers go through  No  1 U S  insurer UnitedHealth Group Inc  N UNH  would rank second after Anthem  Aetna would be No  3 ",2016-09-30,Reuters,https://www.investing.com/news/stock-market-news/anthem-judge-considering-splitting-merger-trial-into-two-sections-429710,429710
141928,363443,HUM,Wall Street stocks close slightly higher after Fed minutes,news,"By Sinead Carew  Reuters    The S P 500 and the Dow Jones industrial average indexes ended Wednesday s session with small gains as expectations for timing on a rate hike were largely unchanged after U S  Federal Reserve minutes and investors waited on earnings reports   Several voting policymakers judged a rate hike would be warranted  relatively soon  if the U S  economy continued to strengthen  according to minutes from the September policy meeting released Wednesday afternoon  While keeping rates low has risks  the Fed decided it was more risky to raise rates when they are concerned we might be seeing a slowdown in economic growth  said Kate Warne  investment strategist at Edward Jones in St  Louis   Unfortunately  they also didn t provide a lot of clarity   Warne said   Traders have priced in small odds of a rate increase next month as the meeting falls days ahead of the Nov  8 U S  presidential election  The odds were still in favor of a December move  but down to 66 percent from 71 percent the day before  according to CME Group s FedWatch tool  With little news from the Fed  investors will see what earnings look like before they buy more stocks  said Steve Massocca  Chief Investment Officer  Wedbush Equity Management LLC in San Francisco   Overall  S P 500 third quarter earnings are currently expected to fall 0 7 percent  marking the fifth quarter of negative earnings in a row  according to Thomson Reuters data  The Dow Jones industrial average  DJI  rose 15 54 points  or 0 09 percent  to 18 144 2  the S P 500  SPX  gained 2 45 points  or 0 11 percent  to 2 139 18 and the Nasdaq Composite  IXIC  dipped 7 77 points  or 0 15 percent  to 5 239 02  The biggest weight on Nasdaq was Cisco Systems  O CSCO   which fell after rival Ericsson  O ERIC   ST ERICb  reported a huge profit decline Eight of the 11 major S P 500 indexes closed higher  led by real estate s  1 3 percent rise and a 1 percent increase in utilities  SPLRCU    Investors in both yield sensitive sectors may have feared a more hawkish Fed  according to Peter Jankovskis  co chief investment officer at OakBrook Investments LLC in Lisle  Illinois  Healthcare and energy were the weakest sectors with an 0 55 percent decline in the S P 500 healthcare index  SPXHC  and an 0 41 percent decline for energy  SPNY  percent  Oil prices fell after OPEC reported its September output at eight year highs   Humana Inc   N HUM  was the biggest loser on the S P  The insurer said a U S  government health department cut its quality rating on Humana Medicare plans  a move that could affect how much the government pays it in 2018  Advancing issues outnumbered declining ones on the NYSE by a 1 10 to 1 ratio   
About 5 6 billion shares changed hands on U S  exchanges  below the 6 77 billion daily average over the last 20 sessions    additional reporting by Yashaswini Swamynathan in Bengaluru  Editing by Anil D Silva and Nick Zieminski ",2016-10-12,Reuters,https://www.investing.com/news/stock-market-news/futures-slightly-lower-ahead-of-fed-minutes-431898,431898
141929,363444,HUM,UnitedHealth reports better than expected quarterly profit,news," Reuters    UnitedHealth Group Inc  N UNH   the largest U S  health insurer  reported better than expected quarterly profit and revenue  helped by strength in its Optum business and an improvement in its medical care ratio 
The company also raised its forecast for 2016 adjusted net earnings to about  8 00 per share  from  7 80  7 95 
Revenue from the company s Optum business  which manages drug benefits and offers healthcare data analytics services  rose 9 percent to  21 1 billion 
The company said its consolidated medical care ratio  or the amount it spends on medical claims compared with the insurance premiums that it brings in  decreased 60 basis points to 80 3 percent in the third quarter 
UnitedHealth which also sells employer based insurance as well as Medicare  Medicaid and Obamacare health plans  added that medical cost trends remained within expectations 
UnitedHealth s net earnings attributable to shareholders rose to  1 97 billion  or  2 03 per share  in the third quarter ended Sept  30  from  1 60 billion  or  1 65 per share  a year earlier 
On an adjusted basis  the health insurer earned  2 17 per share  beating average estimate of  2 08  according to Thomson Reuters I B E S 
Total revenue rose to  46 29 billion from  41 49 billion  slightly above analysts  estimate of  46 09 billion 
UnitedHealth along with  Aetna Inc   N AET  and  Humana Inc   N HUM  have said they will pull back from the Obamacare individual insurance market in 2017  citing financial losses due to the costs of covering members who are sicker than expected 
The third quarter results likely suggest that UnitedHealth has now largely ring fenced the risk within the premium deficiency reserve  that it boosted in the second quarter   Credit Suisse   SIX CSGN  analysts said in a note on Tuesday 
UnitedHealth s report often sets the tone for other health insurers 
Shares of UnitedHealth  which is the only large insurer not involved in any of the major consolidation deals under review by antitrust regulators  were up 1 4 percent at  136 in light trading 
Up to Monday s close  the company s shares had gained about 14 percent this year  compared with a 3 7 percent decline in the S P 500 healthcare index  SPXHC  ",2016-10-18,Reuters,https://www.investing.com/news/stock-market-news/unitedhealth-reports-better-than-expected-quarterly-profit-433081,433081
141930,363445,HUM,Obama says his departure may fix what ails Obamacare,news,"By Roberta Rampton MIAMI  Reuters    President Barack Obama said on Thursday that his departure from office in January might be what it takes to begin to heal the political scars over Obamacare and allow for needed fixes to his signature healthcare law  The 2010 Affordable Care Act tipped off a long and bitter political and legal battle between the White House and Republicans in the U S  Congress who said the 2010 law creates unwarranted government intervention in personal healthcare and private industry  Republicans have been quick to highlight a recent barrage of negative headlines about rising health insurance premiums and shrinking doctor networks for people participating in subsidized insurance plans offered under the law  Obama acknowledged the law is not working perfectly  but said the problems could be fixed by legislation  encouraging lawmakers to create a government run health insurance option to help U S  states where there is little or no competition among private insurers   Maybe now that I m leaving office  maybe Republicans can stop with the 60 something repeal votes they ve taken and stop pretending that they have a serious alternative     and just work with the next president to smooth out the kinks   he said in a speech at Miami Dade College   They can even change the name of the law to Reagancare  or Paul Ryan care   Obama said  evoking the name of the Republican speaker of the House of Representatives   I don t care  I just want it to work   But Ryan  in a written response  said he would continue to seek to repeal and replace the law   At this point  one thing is clear  this law can t be fixed   Ryan said  Obama was later slated to headline a rally in Florida  a battleground election state  for Hillary Clinton  the Democratic candidate in the Nov  8 presidential election  Clinton has said she would add a public option and expand tax incentives for healthcare costs  Republican nominee Donald Trump has pledged to repeal and replace the law  The government forecasts 13 8 million people will sign up for Obamacare plans in 2017  up 1 1 million from 2016  There are 10 7 million uninsured people who are eligible for the exchanges but have not enrolled  and about 40 percent of those are young  Health and Human Services Secretary Sylvia Burwell said on Wednesday  Obama said that nationwide  not enough young and healthy people have signed up to provide a revenue stream that offsets the costs of covering members with serious illnesses  As a result  several big insurers  including UnitedHealth Group Inc  N UNH    Aetna Inc   N AET  and  Humana Inc   N HUM   are pulling out of the online marketplaces selling the subsidized plans  citing bigger than expected financial losses  Monthly premium prices have climbed  which further discourages some people from signing up   Next year will tell whether those are growing pains  or they are more serious issues   Drew Altman  chief executive of the Kaiser Family Foundation  said in an interview  Analysis conducted by the nonpartisan foundation suggests at least 16 million people need to enroll before the online Obamacare insurance marketplaces stabilize  Obama said expanding insurance coverage for millions of people and reforming the healthcare system was a key reason he ran for office  He said he gets letters from Americans every day thanking him for the difference it has made in their lives  The law cut the number of uninsured Americans from 49 million in 2010 to 29 million in 2015  Much of the decline is due to the law s provision allowing states to expand Medicaid health coverage for the poor  The law also prohibited insurance companies from denying coverage to Americans for existing medical problems  and allowed parents to keep children insured on their health plans until age 26  Some health policy experts on both the political left and right say Congress may be more receptive to bipartisan efforts to fix the Affordable Care Act after Obama leaves office  Some Republican governors who refused to expand Medicaid may also be more willing to do so after the election   a change that would expand coverage for about 4 million people  
 I think the piece of Obamacare that people don t like is Obama   Kathleen Sebelius  Obama s former Health and Human Services secretary  who oversaw the program s launch  said in an interview   This has become a very personal battle about this president  which is I think really unfortunate  ",2016-10-20,Reuters,https://www.investing.com/news/politics-news/obama-to-give-his-diagnosis-for-what-ails-obamacare-433512,433512
141931,363446,HUM,Obama rallies Obamacare troops at  critical time  for program,news,"By Roberta Rampton WASHINGTON  Reuters    President Barack Obama on Thursday urged more than 25 000 volunteers and advocates who dialed in to a White House conference call to pull out the stops to boost the number of people signing up for Obamacare health insurance plans  Obama warned it will be challenging to overcome the skepticism about the plans given an onslaught of headlines about surging premium prices  but he said the stakes are high   I think we re at a critical time where we have to show that this program works for people  if they just see what their options are   he told the volunteers  who work in their communities to encourage and assist enrollment  Americans who do not receive health insurance through their employer or through Medicare or Medicaid programs shop online for subsidized insurance plans starting Nov  1 until the end of January  The average premium for benchmark 2017 plans sold on healthcare gov rose 25 percent compared with 2016  Obama said tax credits will help more than seven in 10 shoppers get a plan for less than  75 per month  but said many may not bother looking because they have heard about spiking costs   We re going to have to clear the bugs off the windshield so people can see the road ahead  and that s where you guys come in   Obama said  The law has been fought by Republicans in Congress  who said it creates unwarranted government intervention in personal healthcare and private industry  Several big insurers  including UnitedHealth Group Inc  N UNH    Aetna Inc   N AET  and  Humana Inc   N HUM   are pulling out of the online marketplaces selling the subsidized plans  citing bigger than expected financial losses  Aetna Chief Executive Mark Bertolini said on Thursday that the earliest his company may return to the marketplaces would be 2019  Obama said more young and healthy people need to sign up for plans  That would offset insurers  costs of covering members with serious illnesses  Obama has said there are a series of improvements that could be made to his signature domestic policy achievement   the 2010 Affordable Care Act   if Congress and the next president  who will take office on Jan  20  can work together  
 Part of what we can do this time is to overcome the skeptics  to prove people wrong  and to provide momentum so that when the next administration comes in  they are starting from a position of strength   Obama told the conference call ",2016-10-27,Reuters,https://www.investing.com/news/stock-market-news/obama-rallies-obamacare-troops-at-'critical-time'-for-program-435422,435422
141932,363447,HUM,Will UnitedHealth  UNH  Q1 Earnings Buoy On Revenue Growth ,opinion,"We expect higher revenues at UnitedHealthcare and Optum segments to drive UnitedHealth Group Inc  s   NYSE UNH   first quarter results scheduled to release on Apr 17  2018  Results should benefit from a reduction in corporate tax  partly offset by decline in premium revenues due to minimum loss ratio and lower net health insurance fee recapture effects Alongside  the company is expected to incur additional investment and operating costs in order to accelerate existing initiatives and artificial intelligence  data analytics  individual health record custodianship  digital health  net promoter score improvements and health related initiatives in local communities  These accelerated investments will lead to  200 million to  300 million in incremental operating expense for 2018  A part of these spend will be borne by the company in the first quarter  which might increase operating expense Factors to Influence Q1 ResultsRevenue Growth at UnitedHealthcare  This segment is expected to witness an increased revenue led by growth in the number of individuals served across its business lines and price increases for underlying medical cost trends  which might be partially offset by a reduction in the number of people served in ACA compliant individual products  The Zacks Consensus Estimate for the segment s revenues is  44 7 billion  up 11 5  year over year Higher Membership  We expect membership enrollment growth at the company  This should be led by broad based growth across group sizes and regions in the commercial group market on the back of gains in services to small groups  which should drive membership in risk based benefit plans  Fee based commercial group business might be under pressure due to the non renewal of one public sector customer  We expect to see higher Medicare advantage membership from growth in individual and employer sponsored group Medicare Advantage plans  Strong customer retention and new sales should cause higher membership in Medicaid Higher Contribution from Optum  Results should also show an increase in revenues from its health services  segment Optum  driven by higher contribution from sub segments OptumHealth  OptumInsight and OptumRx  Revenues and earnings from operations increased at OptumHealth primarily due to organic and acquisition related growth in care delivery  OptumInsight should see growth in revenue management services and business process services  whereas OptumRx should see an upside from client and consumer growth  The Zacks Consensus Estimate for revenues from the segment is  23 6 billion  up 11 3  year over year The bottom line should further get a cushion from the shares bought back in the first quarter UnitedHealth Group Incorporated Price and EPS Surprise
   Here is what our quantitative model predictsOur proven model does not conclusively show that UnitedHealth is likely to beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank of  1  2 or 3 for this to happen  That is not the case here as you will see below Zacks ESP  UnitedHealth has an Earning ESP of  1 05   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Though UnitedHealth carries a Zacks Rank  2  Buy   its negative ESP makes our surprise prediction difficult We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are some companies that you may consider as our model shows that these have the right combination of elements to post an earnings beat this quarter   Humana Inc    NYSE HUM   is expected to report first quarter 2018 earnings results on May 2  The company has an Earnings ESP of  0 41  and a Zacks Rank  3  You can see  Molina Healthcare  Inc    NYSE MOH   has an Earnings ESP of  14 57  and a Zacks Rank  3  Hold   The company is expected to report first quarter earnings results on Apr 30 Magellan Health  Inc    NASDAQ MGLN   has an Earnings ESP of  2 54  and a Zacks Rank  2  The company is expected to report first quarter earnings results on Apr 26 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-04-12,Zacks Investment Research,https://www.investing.com/analysis/will-unitedhealth-unh-q1-earnings-buoy-on-revenue-growth-200305353,200305353
141933,363448,HUM,UnitedHealth  UNH  Q1 Earnings To Gain From Optum Revenues,opinion,We believe UnitedHealth Group Inc  s   NYSE UNH   health services business Optum will be an important ingredient of its first quarter earnings growth  Optum serves the global healthcare marketplace  including payers  care providers  employers  governments  life sciences companies and consumers The company is investing in this segment with an aim to diversify earnings and seek protection from the highly regulated health services business  Other companies in the industry  Humana Inc    NYSE HUM    Anthem Inc    NYSE ANTM   and Aetna Inc    NYSE AET   are also diversifying into the health services business to become a comprehensive healthcare entity   Optum has been a jewel for UnitedHealth  Its revenue CAGR of 24  from 2014 to 2017 is highly impressive  The Zacks Consensus Estimate for revenues from the segment is  23 6 billion  up 11 3  year over year Revenue growth from this segment should be driven by increased contribution from each of its sub segments  OptumHealth  OptumInsight  Optum Rx Revenues from OptumHealth should be aided by organic growth acquisition related growth in care delivery  The segment has been indulging in market expansion in care delivery  as well as growth in consumer health engagement products and services  behavioral health services and health financial services  Increase in the number of consumers served and a rise in average revenue per consumer will contribute to the segment s top line  The Zacks Consensus Estimate of  5 69 billion for revenues from this segment represents 20 2  growth year over year OptumInsight s revenues will see accretion from growth in revenue management services  business process services and data analytics  The segment has been witnessing an increase in revenue backlog  which reflects strong demand for its solutions and the trend is expected to continue in the first quarter  The Zacks Consensus Estimate pegs revenues at  2 17 billion  up 17 5  year over year OptumRx  the company s pharmacy management arm has achieved sufficient scale in the PBM business from the acquisition of pharmacy benefit manager  Catamaran  in 2015  Recently  OptumRx was selected by 10 companies for healthcare transformation  driven by their interest in quality  cost transparency and total cost management  For the first quarter  we expect revenue growth from a surge in adjusted scripts  The Zacks Consensus Estimate for revenues from OptumRx is  15 85 billion  up 6  year over year UnitedHealth s solid market share  strong performance at UnitedHealthcare segment  membership enrollment growth and disciplined capital management are also anticipated to aid overall earnings UnitedHealth Group Incorporated Price and EPS Surprise    At present  UnitedHealth carries a Zacks Rank  4  Sell  You can see Investor Alert  Breakthroughs Pending A medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ,2018-04-15,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-unh-q1-earnings-to-gain-from-optum-revenues-200305990,200305990
141934,363449,HUM,UnitedHealth  UNH  Q1 Earnings   Revenues Top  View Lifted,opinion,"UnitedHealth Group Inc    NYSE UNH   reported earnings of  3 04 per share  beating the Zacks Consensus Estimate of  2 92  The bottom line also rose 28 3  year over year UnitedHealth Group Incorporated Price  Consensus and EPS Surprise
    Higher revenues  strength in both segments   UnitedHealthcare and Optum   plus membership growth led to this outperformance UnitedHealth has a tradition of guiding conservatively and then surpassing its own estimates to surprise investors The stock gained 1 79  in pre market trading session and we expect earnings beat to drive the stock higher Behind the HeadlinesUnitedHealth recorded revenues of  55 2 billion  which outpaced the Zacks Consensus Estimate of  54 9 billion  Moreover  the top line compared favorably with the year ago figure of  48 7 billion Total operating cost of  51 1 billion increased 12 9  year over year Net margin expanded 60 basis points to 5 1  Strong Performance Across SegmentsIn the reported quarter  the company s health benefits segment  UnitedHealthcare  logged revenues of  45 5 billion  up 13 3  year over year  Earnings from operations grew 12 3  year over year to  2 4billion Revenues from Optum improved 11 1  year over year to  23 6 billion  reflecting strong contributions from subsegments  namely OptumHealth and OptumInsight as well as OptumRx  Earnings from operations surged 29 2  year over year to  1 7 billion  A steady focus on accelerating growth as well as improving margins and productivity through enhanced integration and business alignment led to the segment s overall improvement Membership Enrollment IncreasesThe company s medical enrollment ascended 4 7  year over year to 48 9 million  led by growth in members served in the Public and Senior segment  partially offset by a lower Commercial and International membership Capital Position ImprovesCash and short term investments at the quarter end were  22 billion  up 42 3  from the 2017 end level Debt to total capital ratio was 41 6  on Mar 31  2018  having contracted 190 basis points year over year Return on equity increased 210 basis points year over year to 23 8  Adjusted cash flows from operations of  3 2 billion rose 5  year over year UnitedHealth Group spent  2 65 billion to buy back 11 6 million shares and paid  722 million in dividends  which increased 21  year over year Guidance UpdateUnitedHealth revised its 2018 financial outlook on the back of solid first quarter results  It now expects current year net earnings of  11 70  11 95 from  11 65  11 95 per share  estimated earlier  Adjusted net earnings have been raised to  12 40  12 65 from the previously projected  12 30  12 60 band  Cash flows from operations are anticipated in the range of  15  15 5 billion Stocks That Warrant a LookUnitedHealth with a Zacks Rank  4  Sell  has got this reporting cycle off to a flying start  While the other players in this space are lined up to report financial results  below are three stocks  poised to beat on earnings per the proven Zacks model Molina Healthcare  Inc   NYSE MOH   is expected to report first quarter earnings on Apr 30  The company has an Earnings ESP of  7 43  and a Zacks Rank  1  Strong Buy   You can see  Humana Inc    NYSE HUM   has an Earnings ESP of  0 30  and a Zacks Rank  2  Buy   The company is expected to release first quarter earnings numbers on May 2 WellCare Health Plans  Inc    NYSE WCG   has an Earnings ESP of  0 73  and a Zacks Rank of 2  The company is expected to announce first quarter financial figures on May 1 Breaking News  Cryptocurrencies Now Bigger Than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-04-16,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-unh-q1-earnings--revenues-top-view-lifted-200306234,200306234
141935,363450,HUM,Can Government Business Drive Centene s  CNC  Q1 Earnings ,opinion,Centene Corporation   NYSE CNC   will release first quarter 2018 results on Apr 24  before the market opens The company s membership has been rising over the past few quarters  significantly boosting the revenue base   This trend is likely to continue in the to be reported quarter as well led by membership growth in The Zacks Consensus Estimate for total membership is pegged at 13 billion  reflecting 7 5  year over year growth Centene s top line has largely benefitted from Medicaid expansion  The company s firm decision to continue with its public exchange business despite other health insurers exiting it  has aided its Medicaid membership growth  This momentum is expected to continue in the first quarter as well  The Zacks Consensus Estimate for Medicaid membership stands at 5 8 billion  representing a year over year rise of 2  Apart from Medicaid  the company s Medicare business is poised for long term growth  Increase in the company s Medicare membership is also anticipated in the impending quarterly results  The Zacks Consensus Estimate is pegged at 874 million  up 6  year over year Additionally  Centene s cost saving initiatives are projected to aid its margins in the first quarter  The consensus mark for total general and administrative expense ratio is pegged at 0 09 compared with 9 80 a year ago The company s exchange business has been performing well over the past many quarters  This upside is likely to recur in the period to be reported on the back of the company s increased participation in public exchanges Centene s share repurchase programs intended to enhance shareholders  value might impact its margins positively by reducing the outstanding share count Earnings WhispersOur proven model does not conclusively show that Centene is likely to beat on earnings this quarter  This is because a stock needs to have both a positive and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below Zacks ESP  Centene has an Earnings ESP of  1 77   You can uncover the best stocks to buy or sell before they re reported with our  Centene Corporation Price and EPS Surprise    Zacks Rank  Centene carries a Zacks Rank  3  which increases the predictive power of ESP  However  a company needs to have a positive ESP to be confident about an earnings surprise  Hence  this combination leaves surprise prediction inconclusive We caution against Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies from the same space that you may want to consider as these have the right combination of elements to beat estimates this time around Humana Inc    NYSE HUM   is set to report first quarter earnings on May 2  The company has an Earnings ESP of  0 30  and a Zacks Rank  2  You can see  Molina Healthcare  Inc   NYSE MOH   has an Earnings ESP of  7 43  and a Zacks Rank of 1  The company is set to report first quarter earnings on Apr 30 Wellcare Health Plans  Inc    NYSE WCG   has an Earnings ESP of  1 88  and a Zacks Rank of 2  The company is expected to report first quarter earnings on May 1 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-04-19,Zacks Investment Research,https://www.investing.com/analysis/can-government-business-drive-centenes-cnc-q1-earnings-200307462,200307462
141936,363451,HUM,Anthem  ANTM  Q1 Earnings  What s In Store For The Stock ,opinion,Anthem Inc    NYSE ANTM   will release first quarter 2018 results on Apr 25  before the market opens  Last quarter  the company delivered a positive earnings surprise of 3 20  Let s see  how things are shaping up for this announcement Anthem s revenues have been consistently growing over the past several quarters  driven membership growth  The company s fully insured and self funded memberships have boosted the total enrollment  The Zacks Consensus Estimate for first quarter revenues is pegged at  22 5 billion  reflecting a year over year rise of nearly 1  The company s Government business has been performing well over  a considerable period of time  supported by increasing Medicaid and Medicare enrollment  The consensus mark for total operating revenues of Government business is pegged at  12 8 billion  up 7  year over year However  higher medical costs for individual ACA compliant products and more claims leading to an escalated benefit expense ratio from its Medicaid business are expected to drain the bottom line Additionally  continuing with the earlier trend  Anthem is anticipated to have witnessed higher administrative costs in the first quarter Anthem s results are also likely to be affected by a persistent softness in its Individual business Earnings WhispersOur proven model does not conclusively show that Anthem is likely to beat on earnings this quarter  This is because a stock needs to have both a positive and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below Zacks ESP  Anthem has an Earnings ESP of  1 83   You can uncover the best stocks to buy or sell before they re reported with our  Anthem  Inc  Price and EPS Surprise   Zacks Rank  Anthem carries a Zacks Rank  2  which increases the predictive power of ESP  However  a company needs to have a positive ESP to be confident about an earnings surprise  Thus  this combination leaves surprise prediction inconclusive We caution against Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies you may wish to consider from the same space as these have the right combination of elements to beat estimates this time around Humana Inc    NYSE HUM   is scheduled to report first quarter earnings on May 2  The company has an Earnings ESP of  0 20  and a Zacks Rank of 2  You can see  Aetna  Inc   NYSE AET   has an Earnings ESP of  0 43  and a Zacks Rank  3  The company is set to report first quarter earnings on May 1 Wellcare Health Plans  Inc    NYSE WCG   has an Earnings ESP of  3 89  and is a Zacks  2 Ranked player  The company is expected to report first quarter earnings on May 1 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-04-22,Zacks Investment Research,https://www.investing.com/analysis/anthem-antm-q1-earnings-whats-in-store-for-the-stock-200308025,200308025
141937,363452,HUM,Why Humana Inc   HUM  Might Surprise This Earnings Season,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Humana Inc    NYSE HUM   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Humana is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings with the most up to date information possible is a pretty good indicator of some favorable trends underneath the surface for HUM in this report In fact  the Most Accurate Estimate for the current quarter is currently at  3 22 per share for HUM  compared to a broader Zacks Consensus Estimate of  3 21 per share  This suggests that analysts have very recently bumped up their estimates for HUM  giving the stock a Zacks Earnings ESP of 0 31  heading into earnings season  Humana Inc  Price and EPS Surprise    Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that HUM has a Zacks Rank  2  Buy  and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for Humana  and that a beat might be in the cards for the upcoming report Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-05-01,Zacks Investment Research,https://www.investing.com/analysis/why-humana-inc-hum-might-surprise-this-earnings-season-200311285,200311285
141938,363453,HUM,Humana  HUM  Tops Q1 Earnings And Revenues  Lifts Guidance,opinion,"Humana Inc  s   NYSE HUM   first quarter 2018 operating earnings per share of  3 36 beat the Zacks Consensus Estimate of  3 21  The bottom line also improved 22 2  year over year Humana Inc  Price  Consensus and EPS Surprise
    The company benefited from Medicare Advantage enrollment growth  solid segmental performances  lower taxes as well as a favorable impact of share buybacks Operational UpdateRevenues of  14 3 billion were up nearly 6  on higher Retail revenues from the company s Medicare Advantage business plus Group and Specialty segment  Moreover  the top line surpassed the Zacks Consensus Estimate of  14 2 billion Adjusted consolidated pre tax income of  384 million declined 8 9   primarily due to lower earnings in the company s Retail and Healthcare segments  This was partially offset by higher earnings in the Group and Specialty segment  The prior year quarter also benefited from net gain associated with terminated merger agreement Benefit ratio deteriorated 40 basis points to 84 9  in the reported quarter Operating cost ratio deteriorated 70 basis points to 12 4  Segment ResultsRetailRevenues from the Retail segment were  12 1 billion  up 6  year over year  primarily owing to higher revenues from the company s Medicare Advantage business resulting from increased membership Benefit ratio of 87 4  improved 70 bps year over year  primarily owing to reinstatement of the non deductible health fee The segment s operating cost ratio of 10 1  deteriorated 170 bps year over year Adjusted pre tax income was  273 million  down 27  year over year Group and SpecialtyRevenues from the Group and Specialty segment were  1 97 billion  up 5  from the prior year quarter  primarily backed by higher stop loss premiums related to small group level funded accounts  stronger service revenues and higher per member premiums Benefit ratio improved 240 bps year over year to 73 2  owing to the impact of the reinstatement of the health insurance industry fee Operating cost ratio deteriorated 200 bps year over year to 23 6  Adjusted pre tax income of  212 million increased 23  year over year  driven by the company s higher earnings related to fully insured business Healthcare ServicesRevenues of  5 7 billion decreased 5  year over year  primarily due to exit from individual commercial business  lower Pharmacy Solutions intersegment revenues and lower revenues from  provider service business Operating cost ratio deteriorated 70 bps year over year to 96 2  Adjusted pre tax income for the segment was  196 million  down 23  due to optimization process associated with the company s chronic care management program and higher operating cost ratio Individual CommercialHumana exited this business effective Jan 1  2018 and thus  the result reflects run out of this business The company witnessed a pre tax gain of  53 million  down 15 9  year over year Financial UpdateAs of Mar 31  2018  the company had cash  cash equivalents and investment securities of  20 96 billion  up 28  from 2017 end level As of Mar 31  2018  cash and short term investments held by the parent company were  567 million  down 18  from 2017 end level Debt to total capitalization as of Mar 31  2018 was 33 9   up 60 bps from Dec 31  2017 Operating cash flow totaled  351 million  down from  1 1 billion in the year ago quarter Dividend and Share Repurchase UpdateThe company did not buy back any shares in the quarter under review and has worth  2 billion remaining under its repurchase authorization The company paid cash dividends worth  57 million 2018 Guidance RaisedHumana expects adjusted earnings per share in the range of  13 70   14 10  up from  13 50  14  guided earlier  GAAP EPS is projected between  13 54 and  13 94  up from the previous forecast of  13 16 and  13 66 Total revenues are anticipated in the band of  55 8  56 4 billion Cash flow from operations is estimated between  2 2 billion and  2 6 billion while capital expenditure is likely to be between  500 and  600 million Zacks Rank and Performance of Other PlayersHumana carries a Zacks Rank  2  Buy   You can see  Among other players in the HMO industry that have reported first quarter earnings  the bottom line of Centene Corp    NYSE CNC    Anthem Inc    NYSE ANTM   and UnitedHealth Group Inc    NYSE UNH   beat the respective Zacks Consensus Estimate Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-01,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-tops-q1-earnings-and-revenues-lifts-guidance-200312038,200312038
141965,363480,HUM,Medicare Advantage grows  but provider choice is limited,news,By Mark Miller CHICAGO  Reuters    Medicare enrollees are moving in greater numbers than ever to the program s managed care option as a way to save money  But the tradeoff is much less ability to use their preferred doctors and hospitals  Seniors can choose between traditional fee for service Medicare   which is accepted by most healthcare providers   or a Medicare Advantage plan  The latter encompasses health maintenance organizations  HMOs  or preferred provider organizations  PPOs   which control costs by creating healthcare provider networks that enrollees must use  In theory  prospective Advantage enrollees can review lists of in network providers before opting into a plan  But a new study by the Kaiser Family Foundation  KFF  finds that provider data often is very difficult to review  can be out of date and frequently contain inaccurate information  KFF s review also found shortcomings in the quality of providers in some Medicare Advantage provider networks  One out of every five plans did not include a regional academic medical center   institutions which usually offer the highest quality care and top specialists  And only 40 percent of Advantage provider networks included top quality cancer centers  as indicated by membership in the National Cancer Institute s network  NCI designated cancer centers offer cutting edge treatments and tend to have greater access to clinical trials  They are especially important for patients with rare and advanced cancers  or other complicating conditions  said Gretchen Jacobson  KFF s associate director of the program on Medicare policy and co author of the study   The upshot  Medicare Advantage may be just fine if you are healthy  but problems may crop up if your healthcare needs become more complex and you have very specific healthcare provider preferences   This year  31 percent of Medicare enrollees are in Advantage plans  up from 11 percent in 2010  That number is expected to hit 41 percent by 2026  according to a forecast by the Congressional Budget Office  When Medicare enrollees join Medicare Advantage plans  their Part B premiums continue to be paid to Medicare  which then makes a monthly capitated payment to the Advantage plan  The payment is based on the plan s estimated cost per enrollee  the plan s quality rating and the health status of the enrollee  The largest providers are UnitedHealthcare   Humana Inc   NYSE HUM  and Blue Cross Blue Shield  One often hears critics claim that healthcare providers are bailing out of traditional Medicare in large numbers   but that is not actually the case  Last year  14 percent of Medicare enrollees who were seeking a new primary care doctor reported major problems in finding a physician who would treat them  according to survey data from the Medicare Payment Advisory Commission  an independent congressional agency  Among those seeking a new specialist  6 percent reported major problems  In both cases  that represents 1 percent of the total Medicare population   ADVANTAGES  PITFALLS  Advantage plans often offer extra benefits  such as health club memberships  vision care and some limited dental care  Cost sharing is often lower  and many plans provide prescription drug coverage with no extra premium   It can be very attractive to many seniors who are living on a fixed budget   Jacobson said  The trade off is limited provider networks   and the challenges prospective enrollees face in determining who they are allowed to see for healthcare  and who is off limits  KFF reviewed 409 Advantage plans  including 307 HMOs and 102 PPOs  Researchers found provider directories often were riddled with errors  omissions and outdated information   There s no reason in this era of technology why this needs to be as difficult as it is   Jacobson said   People should be able to simply tell the system who their doctors are  the illnesses they have  and get a recommendation for a plan that will work for them   KFF also found that Advantage provider network quality differs significantly  For example  Los Angeles has three NCI designated cancer centers  Most of the Advantage plans there do not include any of them  but one plan includes all three  A report last year by the U S  Government Accountability Office found that the Centers for Medicare   Medicaid Services  CMS   which runs Medicare  needs to improve its oversight of Advantage plans to assure that provider networks are robust  The report also criticized CMS for doing too little to assess the accuracy of Advantage plan provider lists  Even when Advantage enrollees are able to confirm participation by their healthcare providers  there is no guarantee that will continue  Advantage plans are free to add or drop health providers during the course of an enrollment season   That became an especially hot issue in 2014 when UnitedHealthcare dropped providers who covered thousands of the insurer s patients  including the prominent Yale New Haven Hospital system  Democrats in Congress have proposed legislation that would prohibit Advantage plans from dropping providers without cause during the middle of an enrollment year  Under current rules  plans must provide 30 days  notice to enrollees when providers are dropped  Enrollees who lose access to a provider can make a midyear plan change only under very limited circumstances   You can do it only if you are receiving ongoing care from a provider that is terminated   Jacobson said   Otherwise you need to wait until the next open enrollment period   The annual enrollment period for Advantage and Part D prescription drug plans are held from Oct  15 to Dec  7 each year  At that point  a beneficiary could switch to a different Advantage plan  or shift back to traditional Medicare  But a serious diagnosis in January would leave you hamstrung until the following year  Said Jacobson   It can be a roll of the dice    This version of the July 7 story corrects paragraph 8  An earlier version of this column said that the enrollee s Part B premium  goes to the insurance company providing the plan   ,2016-07-11,Reuters,"https://www.investing.com/news/economy-news/medicare-advantage-grows,-but-provider-choice-is-limited-412942",412942
141966,363481,HUM,Aetna  Humana map legal strategy to salvage merger,news,"By Caroline Humer and Carl O Donnell NEW YORK  Reuters    Health insurer  Aetna Inc   N AET   whose  33 billion purchase of  Humana Inc   N HUM  has been spurned by the U S  government  faces a tough but not impossible legal battle to try to reinstate the deal  Aetna vowed to fight  to the very end  after the Department of Justice filed suit earlier on Thursday to block the merger  which had been in the works for more than a year  Antitrust reviewers say the combination will hurt consumers and the companies  proposed fix   selling some health plans to a competitor   is insufficient   The Justice Department simultaneously sued to block Anthem Inc s  N ANTM  proposed  45 billion deal for Cigna Inc  N CI   moving against an unprecedented effort to consolidate the U S  health insurance market  Of the two deals  analysts and investors see Aetna and Humana as having a slight chance to reverse the decision through a court battle  They face a Justice Department empowered by a series of high profile successes against mega mergers  scuttling deals in industries from oil services to retail stores and telecommunications   My initial impression from the complaint     is that the Justice Department and the states are on much safer ground  in their argument against an Aetna Humana tie up  said Beau Buffier  co head of the antitrust group at Shearman   Sterling in New York  The Justice Department lawsuit focused on a county by county analysis of where Aetna and Humana have what is deemed too much market share in providing Medicare Advantage for elderly people and in the individual health plans created under President Barack Obama s healthcare reform law  Aetna will argue in court that the Justice Department defined the market for Medicare Advantage too narrowly  which has caused it to see competition issues where they do not exist  Chief Executive Officer Mark Bertolini said in an interview  The government has failed to take into account that seniors can not only choose between Medicare Advantage plans sold by private players  but also have the government run Medicare program as an option   Let a judge decide  Is Medicare Advantage competitive with Medicare fee for service  If that is indeed the case  then there isn t any market we need to divest   Bertolini said   If we have to divest  can we provide an appropriate remedy  And we have   The Justice Department has already rejected that argument  However  Aetna will use evidence that the Obama administration envisioned Medicare and Medicare Advantage as direct competitors as it sought support for the Affordable Care Act passed in 2010  Aetna and Humana also have an answer to the concerns over the Obamacare market  since Humana has already announced plans to cut back dramatically on its presence in that business   We think over time  that becomes less of an issue   Humana CEO Bruce Broussard said in an interview  Humana will in 2017 offer Obamacare plans in only about 160 U S  counties  compared with 1 351 counties this year  The Justice Department has signaled antitrust concerns in 19 counties  Aetna may also gain some leverage if the Anthem Cigna deal breaks up first  according to some antitrust experts  In that scenario  Anthem could become a buyer of some Medicare Advantage business they need to divest   If Cigna Anthem craters  I wouldn t be surprised to see the Justice Department agreeing to some kind of divestiture package   said Matthew Cantor  an antitrust lawyer at Constantine Cannon  Bertolini said Aetna has presented a package of assets to sell that nearly matches up with the 364 counties in 21 states where the Justice Department cites a lack of competition  Aetna has two buyers for those health plans that have experience in Medicare Advantage  he said  A source familiar with the situation said the two companies that have offered to buy all the assets are WellCare Health Plans Inc  N WCG  and Molina HealthCare Inc  N MOH   The Justice Department has argued that the proposed buyers are not strong enough players on their own   
 Overall  this will be all about litigating the fix   said Andrea Murino  co chair of Goodwin s antitrust group based in Washington D C   What DOJ wants when they come up with a remedy is an immediate and expansive competitive response   to substitute one company in for another without missing a beat  ",2016-07-22,Reuters,"https://www.investing.com/news/stock-market-news/aetna,-humana-map-legal-strategy-to-salvage-merger-415938",415938
141967,363482,HUM,U S  government s bid to block insurance mergers could spawn new ones,news,By Carl O Donnell and Caroline Humer  Reuters    The potential bust up of two mega deals among America s largest health insurance companies may have an unintended result   more mergers   The U S  Department of Justice on Thursday sued to block Aetna Inc s  N AET   37 billion purchase of  Humana Inc   N HUM  and Anthem Inc s  N ANTM  proposed  54 billion buyout of  Cigna Corp   N CI   arguing that they would cut competition and boost rates for patients   If no settlement is reached for one or both deals  the fallback strategy for the four insurers to ensure future growth would likely be a familiar one  Another buying spree  this time of smaller insurers less likely to raise the ire of regulators   Unless the market changes drastically  I don t see another major deal going through   said Norman Armstrong  a partner at King and Spalding LLP who focuses on antitrust   But with smaller deals there s more potential to get something done    The most obvious targets are midsized  national players in government healthcare plans such as  Centene  Corp  N CNC    Molina Healthcare Inc   N MOH   or WellCare Health Plans Inc  N WCG   according to analysts and investors  Although acquiring these companies would not produce the big boost to earnings sought by the planned mega mergers  they would offer a foothold in markets likely to grow rapidly in coming years  such as Medicaid health plans for the poor and Medicare Advantage coverage for the elderly   Both Molina and Centene have large exposure to private Medicaid plans  a more than  100 billion market that is benefiting as states outsource more responsibility for the government insurance program to private companies  Molina and WellCare were also said to be interested in Medicare Advantage plans that Aetna sought to divest to win approval for its Humana deal  according to a source familiar with the matter   Anthem has already expressed interest in acquiring Medicare and Medicaid members  In 2014  it purchased Simply Healthcare Holdings  a managed care company for government health insurance in Florida  In the case of Centene  the biggest impediment to a deal is that the company is not likely ready to sell  Centene sees itself as an acquirer  not a target  according to spokeswoman Marcela Manjarrez Hawn  Earlier this year  Centene acquired peer HealthNet for  6 3 billion    We believe it will be difficult for anyone to pay what we will be worth in the next 12 months   she said in a statement  Another option would be Magellan Health Inc  O MGLN   an insurer that focuses on niche types of patients  according to Ana Gupte  an equities analyst at Leerink Partners   Buying Magellan could help insurers build out their capabilities in dealing with specialty products  at a time when high prices for specialty drugs are attracting increasing attention  Gupte said  Aetna  Cigna and Magellan declined to comment  Anthem  Molina  Humana  and WellCare did not immediately respond to requests for comment   Even these smaller deals may not clear antitrust approval   For example  WellCare  with a market capitalization of under  5 billion  may be too much for Humana to swallow  largely because both companies have significant presences in the Medicare Advantage space    The  Justice Department  is on  high alert  right now  so maybe even a smaller deal is harder than in the past   said Gupte   To avoid the most intense regulatory scrutiny  any follow up deals are likely to be delayed until after the U S  presidential and congressional elections in November  when the prospect of big health insurance combinations will be less politically charged  according to a shareholder in Humana who asked not to be named because he was not authorized to talk to the media  In the interim  Aetna  Humana  Anthem and Cigna may seek to placate investors with share buybacks   Between them  the health insurance companies could buy back more than  14 billion worth of shares  providing an immediate boost to earnings per share to help offset the impact of the lost mergers  Christine Arnold  an analyst at Cowen and Company  wrote in a research note ,2016-07-22,Reuters,https://www.investing.com/news/stock-market-news/u.s.-government's-bid-to-block-insurance-mergers-could-spawn-new-ones-416148,416148
141968,363483,HUM,Walmart Seeks To Buy Humana  Good Idea  Walmart The Godsend  ,opinion,"Walmart Inc  NYSE WMT  is in negotiation with Humana  There is a range of options  including a direct buyout 
The Wall Street Journal reports  

Walmart Inc  is in preliminary talks to buy insurer Humana Inc  NYSE HUM    according to people familiar with the matter  a deal that would mark a dramatic shift for the retail behemoth and the latest in a recent flurry of big deals in health care services 
It isn t clear what terms the companies may be discussing  and there is no guarantee they will strike a deal  If they do  the deal would be big  Humana currently has a market value of about  37 billion 
Should there be a deal and should regulators and shareholders bless it it would transform Walmart overnight into one of the nation s largest health insurers  It would immerse the company in a complicated industry  one that continues to evolve eight years after the Affordable Care Act was enacted and as Washington remains deeply divided over health care policy 
The talks come as  particularly pharmacy chains are looking to diversify and bulk up in the face of the competitive threat from e commerce giant Amazon com  NASDAQ AMZN  Inc 
In December  VS Health  NYSE CVS  Corp  agreed to buy Humana rival Aetna  NYSE AET  Inc in a  69 billion deal aimed at allowing the drugstore chain to capture more of what consumers spend on health care  In March  health insurer Cigna Corp  NYSE CI     Co    the biggest administrator of prescription drug benefits in the U S   for  54 billion 
Walmart has a vast pharmacy business  with locations in most of its roughly 4 700 U S  stores and in many of its Sam s Club warehouse locations  Humana is a Medicare focused insurer that could deepen Walmart s relationship with a key demographic seniors at a time when the retailer is being threatened by Amazon on several fronts 
Humana  which had  53 8 billion in revenue last year  is the second biggest provider of the private Medicare plans known as Medicare Advantage  Humana has about 17  of the Medicare Advantage market  according to a tally by analysts at Wells Fargo  NYSE WFC   with about 3 5 million participants  Medicare is viewed as a growth engine in the insurance industry  as the baby boomers age into the program 
Many of the biggest health insurers are pairing up with others outside their industry to create behemoths with a far larger role in the health care sector after two attempted health insurance mergers were blocked in early 2017 by courts on antitrust grounds  Aetna Humana and Anthem Inc   Cigna 

Good Idea 
My simple question has many possible answers  It does not explain what I am after 
Good idea for whom  Shareholders  bondholders  Consumers 
I am concerned about the consumer  If a merger would lower costs for the consumer  I wholeheartedly endorse the merger 
I believe it will  but I am not positive it will 
Going one step further  I would like to see Walmart start competing directly with doctors and hospitals for all kinds of non emergency medical services 
It would not bother me one iota if Walmart operated as a bank  again assuming it would lower fees  ATM costs could drop quickly if we were to see such a move 
Walmart the Godsend 
Unlike many  I cheer Walmart and Amazon for bringing lower prices 
For example Barry Ritholtz moans  
American fast food workers receive more than  7 billion dollars in public assistance  says Ritholtz 
He resents those workers being partially subsidized  If Ritholtz would bother to think  he would understand that Walmart and McDonalds provide hundreds of thousands of jobs that would not otherwise exist at all 
Ritholtz s  simple solution  is to hike the minimum wage  Of course the price of food at fast food restaurants  already ridiculously overpriced would have to rise even more  Fewer stores would be build and fewer people would be employed 
Not once I have seen or heard Ritholtz address the fact that the Fed is hell bent on forcing up prices in a technologically deflationary world 
One Way Titanium
Ritholtz perpetually provides superficial non solutions with total disdain for the real economic problem 
The problem is not the lack of a minimum wage  but how far the dollar goes  I have pointed this out many times before  but Ritholtz has a mind encased in one way titanium  Bad ideas transmit freely  but sound economic ideas cannot enter or leave ",2018-04-01,Mike (Mish) Shedlock,https://www.investing.com/analysis/walmart-seeks-to-buy-humana-good-idea-walmart-the-godsend-200302177,200302177
141969,363484,HUM,What s Walmart s Gameplan With Humana ,opinion,"Rumors are circling that Walmart  NYSE WMT  might be acquiring Humana  NYSE HUM  or  at the very least  deepening its partnership with the health insurer 
I have my own thoughts on the matter  As I shared with Reuters  Nandita Bose 

 The end goal here is to get more people in their stores  get them to buy drugs and make an additional purchase while they are in the store   said Charles Sizemore  founder of Sizemore Capital Management LLC  who owns shares of Walmart 
If Walmart can offer  competitive rates  on primary care and other health services  he said  it  can grow traffic and push store visits  
To view full article see 

Walmart has been the master of cutting out the middle man for its entire multi decade history  and the company is well known for squeezing its suppliers  By acquiring or partnering with a major health insurer  Walmart can guarantee rock bottom pricing for prescription drugs  And if their ultimate goal is to simply attract more foot traffic to their stores  they can sell the drugs at breakeven  and it still makes economic sense 
Looking at the bigger picture  the government has failed miserably to contain health costs  And this is not a partisan complaint  the failure is shared by both parties  Yes  ObamaCare has been a disaster and accelerated healthcare inflation  but there would have never been political demand for the flawed program if either party had been successful in containing costs over the past several decades 
The private sector is stepping in where the government has failed  Walmart is potentially partnering with Humana  while Amazon  NASDAQ AMZN   Berkshire Hathaway B  NYSE BRKb  and JP Morgan  NYSE JPM  are working on a collaboration of their own to lower costs 
All of this is fantastic for consumers  Some of these attempts will almost certainly fail  success is created by trial and error  after all   but the important thing is that we re seeing the beginnings of innovation  That s good  because we sorely need it 
Disclaimer  This material is provided for informational purposes only  as of the date hereof  and is subject to change without notice  This material may not be suitable for all investors and is not intended to be an offer  or the solicitation of any offer  to buy or sell any securities nor is it intended to be investment advice  You should speak to a financial advisor before attempting to implement any of the strategies discussed in this material  There is risk in any investment in traded securities  and all investment strategies discussed in this material have the possibility of loss  Past performance is no guarantee of future results  The author of the material or a related party will often have an interest in the securities discussed  Please see  for a full disclaimer ",2018-04-01,Charles Sizemore,https://www.investing.com/analysis/whats-walmarts-gameplan-with-humana-200302231,200302231
141970,363485,HUM,Walmart Takes On Amazon Again  Look What It s Done This Time,opinion,Walmart Inc    NYSE WMT   does it again  It looks like this omni channel retailer is leaving no chance to strengthen operations and remain in focus   as evident from its latest plans to launch  Walmart2World  money transfer service  In a move to ease payments  the company plans to introduce this  game changing model  in collaboration with MoneyGram International   NASDAQ MGI    which is a money transfer service provider across the United States and globally Apart from this  there was a lot of buzz about Walmart being in talks to take over pharmacy start up  PillPack   a news that broke out just few days after sources revealed chances of the big box retailer to strengthen ties with Humana   NYSE HUM    Though some analysts are skeptical about the Walmart   Humana deal  which could also be the reason behind the supermarket giant s fall of 3 8  during yesterday s trading session  many remain hopeful about the prospects In fact  Walmart s robust headways in healthcare space seem to have rattled investors of Rite Aid and Walgreens  as these stocks declined nearly 3  and 3 6   respectively yesterday  Moreover  all these moves highlight Walmart s assiduous efforts to take on Amazon   NASDAQ AMZN    which dropped 5 2  on Apr 2  The e commerce giant  which has taken retail competition to the next level  has also been making efforts to grab a hold in the healthcare space Walmart2Walmart to Walmart2World  Lets Delve DeepWell  Walmart s plans to launch Walmart2World  also marks another initiative to enhance consumers  experience  which may help the company combat competition from Amazon  In fact  this is not the first time when Walmart has undertaken such a move  The retail giant introduced a low cost Walmart2Walmart money transfer service about four years back  which generated customer fees savings worth about  700 million since then While Walmart2Walmart serves customers on a domestic level  Walmart2World will help them send money to any MoneyGram agent location across about 200 countries in a jiffy  and at a low cost  Sources revealed that this global wire service  slated to hit all Walmart stores this month itself  is aimed at serving those U S  customers who are classified unbanked per the World Bank s Global Findex Further  with an exclusively transparent pricing structure  favorable exchange rate and speedy deliveries  this service stands apart from other international transfer services  Clearly  such features are likely to steer more traffic to Walmart s stores  thus being a boost for its top line  Talking of boosting traffic  Walmart also opened its first high tech supermarket in China  per a Reuters report issued on Apr 2  In this small supermarket  customers can use smartphones to make payments for products that are usually sold on Walmart s stores on JD com PillPack to Enhance Walmart s Healthcare Business Moving to the rounds about Walmart buying online medication delivery provider PillPack for less than  1 billion  we note that both Walmart and PillPack remained silent for any comments  However  media sources  PillPack  which raised nearly  118 million as venture funds  is likely to ease Walmart s customer orders and prescription management processes Apart from filling prescriptions  PillPack also sorts pills according to individual doses  provides timely deliveries of refills and offers non stop customer service  These services  particularly the pre sorting as per time and date  is a benefit for customers taking miscellaneous medicines including aged customers  In fact  the company also introduced a prescription management software last year  called PharmacyOS   which is a boon for customers with complicated medications  Thus  we believe that PillPack s acquisition will help Walmart drawing customers and enhance its healthcare services  The company operates pharmacies in most of its stores and Sam Club locations  while it also has in store clinics in Georgia  South Carolina and Texas   per media sourcesWill These Efforts Keep Walmart Firm Against Amazon Markedly  these constant initiatives should keep Walmart well placed against Amazon  which is planning to adopt a different way to ease experiences of potential customers with no bank accounts  Sources revealed that the online giant was in talks with J P  Morgan Chase and other such financial institutions to serve young and unbanked shoppers  In fact  there were rounds that Amazon also approached PillPack at some point  which along with other strategies underscores its quest to dominate the healthcare space too  Nevertheless  Walmart has been neck to neck with Amazon  so much so that the company emerged as an omni channel retailer officially earlier this year  In fact  with strength across its stores and online  this world s largest retailer has rallied 21 7  in a year  in comparison with the  s growth of 20 9   We expect such dedicated endeavors to help this Zacks Rank  3  Hold  company continue taking on Amazon  You can see The Hottest Tech Mega Trend of All             Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2018-04-02,Zacks Investment Research,https://www.investing.com/analysis/walmart-takes-on-amazon-again-look-what-its-done-this-time-200302684,200302684
141971,363486,HUM,Medicare Rate Up More Than Expected  Health Insurers To Gain,opinion,"The Centers for Medicare and Medicaid Services   CMS    a division of the U S  Department of Health and Human Services  has decided to raise 2019 Medicare Advantage reimbursement rate by 3 4   Notably  CMS previously proposed a hike of 1 84  in February but this rate increase is higher than expected Following the announcement  shares of companies with exposure to the MA business like UnitedHealth Group Inc    NYSE UNH    Humana Inc    NYSE HUM   and Anthem Inc    NYSE ANTM   rallied 
Medicare Advantage   MA   plans were initiated by the government some years ago to control the rising cost of Medicare  a government program for the retirees  Notably  this MA plans were administered by private insurance companies  The health insurers often add extra benefits to make these plans more appealing to consumers  thus justifying its name   Medicare Advantage  The government reimburses a certain amount per enrolee to the health insurers in return of the care provided 
Why Is Government Pitching for High Reimbursement Rates 
MA reimbursement rates for private plan increased by 0 45   0 85  for 2018  and  2017  respectively  The higher than expected increase in reimbursement rate for 2019 is meant  to attract the private health insurance players with the aim of increasing managed care participation  This move will alleviate government healthcare which is reeling under high Medicare costs 
According to CBO  total Medicare spending is expected to increase from  708 billion to  1 4 trillion from 2017 to 2027   Medicare spending is anticipated to rise more rapidly relative to GDP owing to a number of factors  including the aging population and faster growth in health care costs compared with growth in the economy on a per capita basis  In an effort to decrease the government s burden of rising healthcare costs  it intends to rope in health insurers who are effective in managing costs 
In fact  the government has actually witnessed cost reduction by delegating Medicare to the private players and is encouraging customers to opt for Medicare Advantage  The recent higher than expected rate highlights the government s efforts to stabilize these plans and provide enough resources to the insurance companies to support beneficiaries enrolled in private Medicare plans 
A Cash Cow for Health Insurers
Meanwhile  these plans have been highly profitable for the health insurers  Since MA members have higher medical utilization rates  they bring in about three times more revenues than commercial members  This trend has aided top line growth of the companies engaged in MA  Further  the health insurers have been able to maintain profitability in these plans by keeping claim cost down via measures such as preventive healthcare and accountable care organizations  This business has proven to be boon for the health insurance industry 
In a year s time the  has gained 33 7  compared with the S P 500 growth of 11 9  

MA   the Catalyst Behind Mergers and Acquisitions in the Industry
The lucrative nature of this business along with the players  intention to stake a claim in this rapidly growing market has fueled a number of mergers and acquisitions in the industry 
According to KPMG  MA has only been around since 2003 but it is rapidly gaining popularity as a health plan and also among seniors dissatisfied with traditional Medicare  MA plans are in great demand amid the baby boomers  a rapidly growing generation  presenting an immense business opportunity   KPMG projects the baby boomers population to be nearly 72 million by 2030 and almost 87 million by 2050  Per Anthem CEO Gail Boudreaux  11 000 baby boomers age into Medicare eligible population ever single day 
Analysis from Strategy   PwC s strategy consulting business  projects annual revenues for MA plans to rise from US 215 billion in fiscal year 2017 to more than  500 billion by 2025 
The most recent merger speculation doing rounds is that of Walmart s intention to buy Humana  which has nearly two thirds of its revenues coming from MA   Notably  this buyout also hinges around the coveted MA business  Its crystal clear that Walmart  NYSE WMT  is planning to cash in on the MA business via Humana  an established player in this field 
Recently Anthem stated that it is working to capture its fair share of the MA market 
Other big acquisitions in this arena in  were UnitedHealth Group s buyout of XLHealth Corporation  Preferred Care Partners and Medica HealthCare Plans  Further  Cigna  NYSE CI  s acquisition of HealthSpring  Humana s takeover  of MD Care and Aetna Inc  s   NYSE AET   buyout of Genworth s Medigap business are also noteworthy   In the same vein  WellCare Health Plans  Inc  acquired Universal American Corp  last year and is still on hunt for MA opportunities 
Bottom Line
Given that MA is one of the few areas which has a bipartisan support  its future remains bright  Industry analysts believe that the recent increase in reimbursement rates will lead to strong enrollment growth in this business in next five years 
Also the players thirst for MA business still remains unquenched  consequently we expect more mergers and acquisitions on this front 
Among the companies discussed above UnitedHealth carries a Zacks Rank  2  Buy   while Anthem  Humana and Aetna all carry a Zacks Rank of 3  Hold   You can see  
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-04-03,Zacks Investment Research,https://www.investing.com/analysis/medicare-rate-up-more-than-expected-health-insurers-to-gain-200302877,200302877
141972,363487,HUM,Check These 3 Health Insurers To Reap High Returns In Q2,opinion,The health insurers continue to gain traction from increasing enrollment  product development  business diversification  cost control efforts  increased operating efficiencies and a strong capital position  All these led to both top and bottom line growth for most players in the field  Many in the industry have also kept raising their full year guidance at the end of each quarter  thus indicating their rising operational excellence Banking on the above positives  the industry has gained nearly 35 9  in a year s time  outperforming the S P 500 average of 11 3   The is placed among the top 21  of the Zacks Ranked industries  Nevertheless  higher medical costs  public exchange woes  stiff competition  stringent regulations and compliance costs were a drag Government Plans Look LucrativeDespite the prevalent uncertainty surrounding the efforts to repeal and replace Obamacare  the industry continues to put up a good show in 2018   We see sustainable growth potential in expanding government programs  The recent announcement by the Centers for Medicare and Medicaid Services regarding raising 2019 Medicare Advantage reimbursement rate by 3 4  also proves that  This action will definitely attract the private health insurance players with the aim of increasing their managed care participation  Since the government plans have already been highly profitable for health insurers  their increased participation is likely to result in significant top and bottom line growth Apart from this upside  an increasing focus on preventive and value based care  growing accountable care organizations  international business expansion  mergers and acquisitions also keep the industry s growth trend alive Thriving Economy  Rising Interest Rates  Changing Demography Fuel GrowthGrowing demand for health insurance products and services on the back of changing demographics  increasing income  low unemployment and jobless claims continue to aid the insurance stocks  A strong economy enables people to spend more on their healthcare needs that again opens up scope for the health insurers  An ageing U S  population also boosts demand for Medicare Advantage plans  especially designed for the retirees to control the rising Medicare costs  This in turn encourages more participation from health insurers ensuring profitability on this ground Additionally  the recent interest rate hike by the Federal Reserve also bodes well for health insurers  The managed care companies benefit from the rising rates owing to a generally sizeable investment securities portfolio coupled with manageable debt levels Consolidation in the IndustryOf late  increasing consolidation has been a major phenomenon in the health insurance industry  This in turn leads to market concentration  which should help players enhance their operational scale as well as gain a substantial market share Health insurers are trying to integrate with pharmacy benefits managers to streamline and cut costs in the drug supply chain  The recently announced acquisitions of Express Scripts Holding Company   NASDAQ ESRX   by Cigna Corporation   NYSE CI   and Aetna Inc    NYSE AET   by CVS Health Corporation   NYSE CVS   underline the growing trend of two healthcare sector industries coming together to amicably provide a comprehensive care Retailers have also expressed their interest in the health insurance industry  Humana has been in talks to get acquired by Walmart  NYSE WMT  Inc  Eyeing the rewarding Medicare business provided to the surging baby boomers population  the retail major intends to invest big time in the health insurance industry  Recently  Amazon  NASDAQ AMZN  has also entered into a joint venture with JP Morgan and Berkshire Hathaway  NYSE BRKa  to manage insurance for their employees and is further looking for a CEO to helm its healthcare joint venture Stocks to Bet on Before Q2We zeroed in on three stocks  poised for an earnings beat in the second quarter of 2018  Our proven model shows that stocks with a favorable Zacks Rank  1  Strong Buy   2  Buy  and 3  Hold  when combined with a positive   have the potential to beat on earnings  Our screening also pin points stocks having witnessed a positive estimate revision in the past 60 days Humana Inc    NYSE HUM   is one of the largest health care plan providers in the United States  The company s Zacks Rank  3 and an Earnings ESP of  0 41  strengthen its potential for a second quarter earnings beat  The stock has also seen the Zacks Consensus Estimate for current year earnings being revised 8 2  upward in the last 60 days The company s expected long term earnings growth rate is pegged at 13 4   above the industry average of 13 3  Shares of Humana have surged 36 6   outperforming the industry s rally of 35 9  in a year s time  Magellan Health Inc    NASDAQ MGLN   is an American for profit managed health care company  The company s Zacks Rank  2 and an Earnings ESP of  2 54  heighten its potential for a second quarter beat  The stock has also seen the Zacks Consensus Estimate for 2018 earnings being revised 11 6  upward in the last 60 days The expected long term earnings growth rate for the company is 15   better than the industry average   Shares of Magellan Health have surged 61 6   outperforming the industry s rise in a year s time  Molina Healthcare  Inc    NYSE MOH   is a multi state managed care organization  participating exclusively in government sponsored healthcare programs  The company s Zacks Rank of 3 and an Earnings ESP of  8 38  bolster its possibility for a second quarter success  The stock has also seen the Zacks Consensus Estimate for 2018 bottom line being moved 4 2  north in the last 60 days The company s estimated long term earnings growth rate stands at 15 3   more than the industry average  Shares of Molina Healthcare have soared 75 1   outperforming the industry s increase in the last 12 months  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-04-04,Zacks Investment Research,https://www.investing.com/analysis/check-these-3-health-insurers-to-reap-high-returns-in-q2-200303378,200303378
141973,363488,HUM,Humana  HUM  Shores Up Government Business With FPG Buyout,opinion,Humana Inc    NYSE HUM   has recently announced that it has completed the acquisition of Orlando  FL based Family Physicians Group   FPG    Financial terms of the deal remain undisclosed Humana s Medicare ExpansionAmid speculations that Humana might be acquired by retail major Walmart  Inc    NYSE WMT    the deal is an indication that Humana is not giving up on its strategy of expanding its provider networks Humana s Medicare Advantage business has been strongly delivering owing to operating initiatives that have led to favorable prior period medical claims development and lower current year utilization  evident from average 5 5  growth of total Retail Medicare membership in the last four years  Earlier  the company acquired MD Care  which increased Humana s Medicare Advantage membership strength by approximately 15 000 members Shareholders have also gained confidence in the stock  given its strong Medicare membership base and growth potential  In a year s time  the stock has surged 34 8   outperforming the  s rise of 33 8   Why FPG FPG is known to be one of the largest at risk providers serving Medicare Advantage and Managed Medicaid HMO patients in Greater Orlando  The company serves more than 22 000 Medicare Advantage patients including nearly 4 000 Humana members  The company s expertise in treating people of Central Florida  especially seniors with chronic conditions  is expected to further fortify Humana s commitment to helping its Medicare  Medicaid plus government and commercial members achieve their best health Humana s value based care model revolves around physicians  utmost efforts to achieve improved health outcomes for patients  lowering medical expenses and transforming health care nationally  The company is aggressively widening its primary care model with intention to establish a national footprint of senior  high performing  focused primary care physicians Moreover  FPG s comprehensive care management model and proactive medical management initiatives successfully improve patient outcomes at a lower cost  The buyout of FPG significantly supports Humana s strategy to help physicians and clinicians manage members  health via a holistic approach Peers  Moves in the Medicare SpaceThe lucrative nature of Medicare business along with its leading players  objective to stake a claim in this rapidly growing health insurance market has fueled a series of mergers and acquisitions in the industry Cigna Corporation s   NYSE CI   acquisition of HealthSpring and Aetna Inc  s   NYSE AET   buyout of Genworth s Medigap business are noteworthy in this respect The recent announcement by the Centers for Medicare and Medicaid Services on account of raising 2019 Medicare Advantage reimbursement rate by 3 4  is likely to further boost the potential of Medicare space driving more consolidations Zacks RankHumana carries a Zacks rank  3  Hold   You can see  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-04-10,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-shores-up-government-business-with-fpg-buyout-200304757,200304757
141974,363489,HUM,Featured Stocks In April s Most Attractive Most Dangerous Model Portfolios ,opinion,"Recap from March s Picks
Our Most Attractive Stocks   4 5   outperformed the S P 500   5 3   as a long portfolio last month  Most Attractive Large Cap stock Humana Inc   NYSE HUM  gained 3   Most Attractive Small Cap stock Fonar Corporation  NASDAQ FONR  was up 14   Overall  22 out of the 40 Most Attractive stocks outperformed the S P 500 in March 
Our Most Dangerous Stocks   5 9   outperformed the S P 500   5 3   as a short portfolio last month  Most Dangerous Large Cap stock Summit Materials  SUM  fell by 12  and Most Dangerous Small Cap Stock Consolidated Communications  CNSL  fell by 16   Overall  21 out of the 40 Most Dangerous stocks outperformed the S P 500 in March  and 36 had negative returns 
The successes of these model portfolios highlight the value of our machine learning and AI   which helps clients fulfill the  and make smarter investments 
16 new stocks make our Most Attractive list this month and 17 new stocks fall onto the Most Dangerous list this month  April s Most Attractive and Most Dangerous stocks were made available to members on April 4  2018 
Our Most Attractive stocks have high and rising returns on invested capital    and low   Most Dangerous stocks have  and long  implied by their market valuations 
Most Attractive Stocks Feature for April  Winmark Corporation  NASDAQ WINA    130 share
Winmark  a specialty consignment retailer  is the featured stock from April s   WINA was also a featured Long Idea in  and is currently in our  
Over the past decade  WINA has grown revenue 8  compounded annually while after tax profit    has grown 21  compounded annually  Increased profit growth can be attributed to WINA s NOPAT margin rising from 11  in 2007 to 35  in 2017  The company has also improved its ROIC from 8  in 2007 to 42  in 2017 
Figure 1  WINA s Revenue   NOPAT Since 2006

Sources  New Constructs  LLC and company filings
WINA Valuation Provides Upside
Despite outperforming over the past two years  up 31  vs  29  for the S P 500   WINA remains undervalued  At its current price of  130 share  WINA has a price to economic book value    ratio of 1 0  This ratio means the market expects WINA s NOPAT to never meaningfully grow from its current levels  This expectation seems rather pessimistic given that WINA has grown NOPAT by 13  compounded annually since 1996 
If WINA can maintain 2017 NOPAT margins  35   and grow NOPAT by just 4  compounded annually over the next decade  the stock is worth  185 share today   a 42  upside  
Critical Details Found in Financial Filings By Our 
As investors  on fundamental research  research automation technology is needed to analyze all the critical financial   Below are specifics on the adjustments we make based on Robo Analyst findings in Winmark Corp s 2017 10 K 
Income Statement  we made  5 million of adjustments  with a net effect of removing  1 million in non operating income  1  of revenue   We removed  3 million in  and  2 million in   You can see all the adjustments made to WINA s income statement  
Balance Sheet  we made  19 million of adjustments to calculate invested capital with a net increase of  19 million  One of the largest adjustments was  13 million due to   This adjustment represented 33  of reported net assets  You can see all the adjustments made to WINA s balance sheet  
Valuation  we made  94 million of adjustments with a net effect of decreasing shareholder value by  94 million  There were no adjustments that increased shareholder value  The largest adjustment to shareholder value was  22 million in   This adjustment represents 4  of WINA s market cap  Despite the decrease in shareholder value  WINA remains undervalued 
Most Dangerous Stocks Feature  Darling Ingredients Inc  NYSE DAR    17 share
Darling Ingredients  DAR   a producer of natural ingredients from edible and inedible bio nutrients  is the featured stock from April s 
Since 2011  DAR s revenue grew 13  compounded annually while its economic earnings  the true cash flows of the business  fell from  112 million to   160 million  DAR s NOPAT margin fell from 11  in 2011 to 3  in 2017 while its ROIC fell from 15  to a bottom quintile 3  over the same time 
Figure 2  DAR s Revenue   Economic Earnings Since 2011

Sources  New Constructs  LLC and company filings
DAR Provides Poor Risk Reward Tradeoff
Over the past five years  DAR has significantly unperformed the S P 500   3  vs  S P  70    Even now  shares still hold significant downside risk given the deteriorating fundamentals 
To justify its current price of  17 share  DAR must maintain 2017 NOPAT margins  3   and grow NOPAT by 8  compounded annually for the next 17 years  This scenario seems overly optimistic after years of margin decline and the fact that DAR s NOPAT has fallen by 8  compounded annually since 2011   
Even if we assume DAR can achieve 5  NOPAT margins  average of last five years  and grow NOPAT by 8  compounded annually for the next decade  the stock is worth just   11 share today   a 35  downside   
Critical Details Found in Financial Filings By Our 
As investors  on fundamental research  research automation technology is needed to analyze all the critical financial   Below are specifics on the adjustments we make based on Robo Analyst findings in Darling Ingredient s 2017 10 K 
Income Statement  we made  256 million of adjustments  with a net effect of removing  8 million in non operating income   1  of revenue   We removed  132 million in  and  124 million in   You can see all the adjustments made to DAR s income statement  
Balance Sheet  we made  437 million of adjustments to calculate invested capital with a net increase of  387 million  One of the largest adjustments was  212 million due to   This adjustment represented 5  of reported net assets  You can see all the adjustments made to DAR s balance sheet  
Valuation  we made  2 3 billion of adjustments with a net effect of decreasing shareholder value by  2 3 billion  There were no adjustments that increased shareholder value  Apart from   which includes  128 million in   the largest adjustment to shareholder value was  253 million in   This adjustment represents 9  of DAR s market cap 
Disclosure  David Trainer and Kyle Guske II receive no compensation to write about any specific stock  style  or theme ",2018-04-11,David Trainer,https://www.investing.com/analysis/featured-stocks-in-aprils-most-attractivemost-dangerous-model-portfolios-200304675,200304675
142000,363515,HUM,Antitrust regulators worry about proposed Cigna Anthem merger  WSJ,news," Reuters    U S  antitrust regulators are concerned about health insurer Anthem Inc s  N ANTM  proposed acquisition of  Cigna Corp   N CI  and not sure the companies can offer enough concessions to maintain competition in the industry  the Wall Street Journal reported on Sunday 
Both companies have scheduled meetings this week with top U S  Department of Justice officials  the Journal reported  citing people familiar with the matter 
Some of the sources said the DOJ had not yet made a decision on whether to sue to block the deal 
Wall Street does not seem convinced the deal will go through  as evidenced in the wide spread between Anthem s offer and Cigna s share price  As of the market close on Friday  Cigna shares traded at a 32 5 percent discount to the offer  which has an equity value of about  44 billion 
Anthem announced plans to buy Cigna last summer  Also pending is  Aetna Inc   s  N AET  acquisition of  Humana Inc   N HUM  which faces significant antitrust concern as well  That deal is valued at about  34 billion ",2016-06-19,Reuters,https://www.investing.com/news/stock-market-news/antitrust-regulators-worry-about-proposed-cigna-anthem-merger:-wsj-409285,409285
142001,363516,HUM,Democratic senators ask Justice Department to block insurance megamergers,news,By Diane Bartz WASHINGTON  Reuters    Seven Democratic senators urged the U S  Justice Department on Wednesday to block two mergers of major health insurance companies  saying that the proposed deals would mean higher premiums and lower quality healthcare for consumers  The department is reviewing Aetna  NYSE AET  Inc s  33 billion plan to buy  Humana Inc   NYSE HUM  and Anthem Inc s  48 billion proposal to buy  Cigna Corp   NYSE CI   If approved  the deals  both of which were announced last July  would reduce the number of national health insurance carriers from five to three   We urge the DOJ  Justice Department  to challenge these mergers from proceeding and to prevent the damage they would cause to competition and consumers   wrote Senators Richard Blumenthal of Connecticut  Al Franken of Minnesota  Elizabeth Warren and Edward Markey of Massachusetts  Sherrod Brown of Ohio  Dianne Feinstein of California and Mazie Hirono of Hawaii  The letter was dated Wednesday and addressed to Renata Hesse  who heads the Justice Department s Antitrust Division  In the letter  the lawmakers said they were skeptical of the idea that the proposed deals would be good for consumers because the companies could use their larger size to hammer out better deals for patients    The evidence overwhelmingly suggests that few if any cost savings secured by the merging firms through the exercise of market power will be passed on to consumers   they wrote  The lawmakers also disagreed with the notion that the sale of carefully chosen assets to a competitor could resolve antitrust issues  and pointed to past instances where mergers with divestitures led to higher premiums or where competitors bought divested assets  but then did not use them   We are not convinced that any divestitures required of the merging parties will succeed today  given that they have so clearly failed in the recent past   the lawmakers wrote  Capitol Hill does not have a say in whether the Justice Department sues to stop deals  Aetna spokesman T J  Crawford said that the company planned to close the merger with Humana in the second half of this year   We believe a combined company is in the best interest of consumers  We continue to cooperate with the Department of Justice on its thorough review of the transaction   Crawford said  Representatives of Anthem could not immediately be reached for comment ,2016-06-22,Reuters,https://www.investing.com/news/politics-news/democratic-senators-ask-justice-department-to-block-insurance-megamergers-409966,409966
142002,363517,HUM,Illinois insurance regulator approves Aetna purchase of Humana,news,NEW YORK  Reuters    The Illinois Department of Insurance has approved Aetna Inc s  N AET  proposed  34 billion acquisition of  Humana Inc   N HUM  with no conditions  according to an order dated June 23 posted on the department s website   Aetna announced the deal last summer and it is under review by the U S  Department of Justice  which is looking at competition concerns around its combined Medicare Advantage business for older people and the disabled  In Illinois  Medicare Advantage plans  in which private insurers manage a customer s health benefits for the government  have enough competition because members can always turn to the traditional Medicare program if they are not happy  the state Department of Insurance said in its June 23 order   We now have change of control approvals in 17 of the 20 states required and continue to cooperate with the Department of Justice on its review   Aetna spokesman T J  Crawford said   The company continues to expect the transaction to close in the second half of 2016  he said ,2016-06-27,Reuters,https://www.investing.com/news/stock-market-news/illinois-insurance-regulator-approves-aetna-purchase-of-humana-410887,410887
142003,363518,HUM,Energy weighs on Wall St  but Costco shines,news,"By Marcus E  Howard  Reuters    The S P 500 and Dow industrials slipped on Thursday  weighed by energy shares  but gains in Costco and tech shares lifted the Nasdaq Composite  The energy sector of the S P  SPNY  was dragged lower by Exxon  NYSE XOM  and  Chevron   NYSE CVX  as oil futures prices  CLc1   LCOc1  fell nearly 5 percent after crude stockpiles fell slightly less than forecast  High yielding sectors also pulled the S P lower even as yields on long term U S  government debt  US30YT RR  remained near record lows   The utilities and the telecoms are also weak sectors  That s really selling into the strengths of higher dividend stocks   said Tim Ghriskey  chief investment officer of Solaris Group in Bedford Hills  New York   There s clearly some profit taking occurring there for no particular reason   The Dow Jones industrial average  DJI  fell 22 74 points  or 0 13 percent  to 17 895 88  the S P 500  SPX  lost 1 83 points  or 0 09 percent  to 2 097 9 and the Nasdaq Composite  IXIC  added 17 65 points  or 0 36 percent  to 4 876 81  The utilities sector of the S P  SPLRCU  was down the most at 1 8 percent after having risen sharply since Britain s vote to leave the European Union triggered a run to safer sectors of the market  The telecom services sector  SPLRCL  was down 1 6 percent  Costco  O COST  was the largest gainer on the Nasdaq and the S P a day after it reported June comparable sales rose more than expected  Shares ended up 4 9 percent at  163 70  a seven month high  U S  labor market data also gave the market support ahead of the monthly payrolls report due on Friday  The ADP national employment report showed that 172 000 jobs were added in the private sector in June  beating economists  expectation of 159 000  The weak jobs report for May raised concerns about the recovery in the economy and was seen as throwing the Federal Reserve off track from its plans to raise U S  interest rates in the near term   Right now  I think you have to look at the numbers and say it probably was just a one off  which should reassure the Fed   said Brad McMillan  chief investment officer for Commonwealth Financial in Waltham  Massachusetts  Shares of  Humana Inc   N HUM  closed down 9 6 percent at  162 74 after a source familiar with the situation said the U S  Department of Justice has significant concerns about Aetna Inc s  N AET  proposed acquisition of Humana  Aetna shares were down 4 percent at  115 47   There could be some more announcements out of that which require more asset sales or even bring the merger itself into question   said Solaris Group s Ghriskey of a scheduled DOJ meeting with both insurers on Friday  Advancing issues outnumbered declining ones on the NYSE by a 1 21 to 1 ratio  on Nasdaq  a 1 34 to 1 ratio favored advancers  The S P 500 posted 34 new 52 week highs and one new low  the Nasdaq Composite recorded 59 new highs and 25 new lows  
About 6 70 billion shares changed hands in U S  exchanges  compared with the 7 78 billion daily average over the past 20 sessions ",2016-07-07,Reuters,https://www.investing.com/news/stock-market-news/stock-futures-flat-as-investors-brace-for-economic-data-412948,412948
142004,363519,HUM,U S  Justice Dept has concerns over Aetna Humana deal  source,news,"By Caroline Humer and Diane Bartz  Reuters    The U S  Department of Justice has significant concerns about Aetna  NYSE AET  Inc s proposed acquisition of health insurer  Humana Inc   NYSE HUM   a source familiar with the situation said on Thursday  and shares of Humana fell more than 11 percent  Aetna s purchase of Humana would combine two of the largest providers of Medicare Advantage plans for elderly people  and investors have long been concerned the deal might pose a competition issue for antitrust regulators  The Justice Department is also reviewing Anthem Inc s proposed purchase of  Cigna Corp   NYSE CI   and investors are worried it will fail because of its impact on competition in the employer insurance market  Together  the two deals will decrease the number of national health insurers to three from five  News of the Justice Department s significant concerns come as the department is due to meet with officials from Aetna and Humana on Friday  as first reported by antitrust trade publication MLex   The source  who was not authorized to speak publicly about the matter  confirmed the department s concerns but did not expound on the exact nature of its worries  However  the issue raised investor worries on both deals  Jeff Jonas  portfolio manager for Gabelli Funds  which owns Humana and Cigna shares  said that he believes that the Aetna Humana deal still has a chance to go through with divestitures because there are plenty of buyers for the assets   Even after today s drop  I don t think people are totally ruling out Aetna and Humana   Jonas said  Reuters reported last week that Aetna had begun a process to divest about  1 billion of Medicare Advantage assets to address antitrust concerns   Antitrust regulators are mainly focused on whether the deal would limit consumer choices for Medicare Advantage health plans for the elderly  Aetna has argued that Medicare Advantage competes not just with other Medicare Advantage plans but with traditional Medicare  according to a different source familiar with the matter  
Aetna announced its plans to buy Humana Inc last summer in a deal now worth about  34 billion  Anthem s deal for Cigna was announced a few weeks later  Humana was not immediately available for comment  Aetna spokesman T J  Crawford said on a phone call that the company continues to cooperate with the Justice Department ",2016-07-07,Reuters,https://www.investing.com/news/stock-market-news/u.s.-justice-dept.-has-concerns-over-aetna-humana-deal:-source-413066,413066
142005,363520,HUM,Ensign Group  ENSG  Beats On Q4 Earnings  Raises  18 View ,opinion,"The Ensign Group  Inc   NASDAQ ENSG   reported record adjusted operating earnings of 40 cents per share in fourth quarter 2017  The bottom line surpassed the Zacks Consensus Estimate of 36 cents  Earnings increased 33 3  year over year owing to higher revenues The Ensign Group  Inc  Price  Consensus and EPS Surprise
    Net income was 21 cents per share  down 40  year over year Operational UpdateTotal revenues of  487 7 million increased nearly 12 6  year over year in the reported quarter and also beat the Zacks Consensus Estimate of  459 million Same store skilled nursing average daily revenue rates grew 4 9  year over year to  309 89 million  Same store managed care skilled nursing average daily revenue rates climbed 4 5  to  450 58 million  year over year Total Transitional and Skilled Services segment income was  39 9 million for the quarter under review  up 40 2  from the prior year period Total Assisted and Independent Living Services segment revenues and income were up 13 7  to  35 8 million and 66 3  to  4 3 million  respectively  year over year Total Home Health and Hospice Services segment revenues and income were up 27 5  to  39 7 million and 27 7  to  5 8 million  respectively  year over year Total expenses rose 16 2  year over year to  461 6 million  primarily due to higher cost of services and general and administrative expense Full Year HighlightsAdjusted operating earnings of  1 40 per share were in line with the Zacks Consensus Estimate Total revenues of  1 85 billion increased nearly 11 8  over the level in 2016 and also outpaced the Zacks Consensus Estimate of  1 80 billion Quarterly Segment UpdateTransitional  Skilled   Assisted Living ServicesThe segment reported revenues of  403 5 million  up 11 5  year over year  Solid growth in skilled nursing and facilities drove this upside  Notably  the segment accounted for 82 7  of the total revenues in the fourth quarter Home Health   Hospice ServicesFor this segment  total operating revenues were  39 7 billion  up 27 4  year over year  This segment contributed 8 1  to the total revenues Other ServicesThis segment reported revenues of  8 7 million  up 1 3  from the prior year quarter  This segment accounted for 1 8  of the total revenues Financial UpdateTotal cash and cash equivalents decreased 26 6  to  42 3 million as of Dec 31  2017 from  57 7 million as of Dec 31  2016 As of Dec 31  2017  long term debt was  302 9 million  up from  275 5 million at the end of 2016 Cash from operations in 2017 was  72 9 million  down 1 3  year over year Dividend UpdateEnsign Group paid 4 50 cents per share  up 5 9  over the past year 2018 GuidanceManagement expects earnings in the range of  1 80  1 87 per share  up from  1 58 to  1 66 Revenues are anticipated to remain within the band of  2  2 06 billion Zacks Rank   Performance of Other InsurersEnsign Group carries a Zacks Rank  3  Hold   You can see  Among other firms in the medical sector having reported fourth quarter earnings so far  the bottom line of Anthem Inc    NYSE ANTM    Humana Inc    NYSE HUM   and UnitedHealth Group Inc    NYSE UNH   beat the respective Zacks Consensus Estimate The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-02-08,Zacks Investment Research,https://www.investing.com/analysis/ensign-group-ensg-beats-on-q4-earnings-raises-18-view-200289107,200289107
142006,363521,HUM,Humana  HUM  Up 3 2  Since Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Humana Inc    NYSE HUM    Shares have added about 3 2  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is HUM due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers Humana Tops Q4 Earnings   Revenues  Issues  18 ViewHumana s  fourth quarter 2017 operating earnings per share of  2 06 beat the Zacks Consensus Estimate by approximately 3   The bottom line  however  declined 12  year over year Adjusted consolidated pretax income of  576 million declined 17  in the fourth quarter primarily due to lower earnings in the company s Retail and Healthcare segments  This was partially offset by higher earnings in the Group and Specialty segment In the fourth quarter  the company reported revenues of  13 2 billion  up 2 4  on higher Retail segment revenues from the company s Medicare Advantage business and Group and Specialty segment  Revenues also surpassed the Zacks Consensus Estimate by 1 2  Full Year UpdateThe company reported adjusted earnings of  11 71 per share  up 7 2  year over year  Full year earnings also surpassed Zacks Consensus Estimate of  11 63 Revenues came in at  53 8 billion  down 1  year over year due to lower revenues from Individual Commercial segment  partially offset by Retail segment revenues Quarterly Operational UpdateHumana s adjusted consolidated benefit ratio of 83  deteriorated 200 basis points  bps  from the prior year quarter Adjusted consolidated operating cost ratio of 13 9  improved 100 bps from the year ago quarter Q4 Segment ResultsRetailRevenues from the Retail segment were  10 95 billion  up 3  year over year  primarily owing to higher revenues from the company s Medicare Advantage business resulting from increased membership Benefit ratio of 84 2  deteriorated 130 bps year over year  primarily due to the impact of the temporary suspension of the health insurance industry fee in 2017 The segment s operating cost ratio of 11 8  improved 100 bps year over year because of the same reason Adjusted pretax income was  397 million  down 8  year over year Group and SpecialtyRevenues from the Group and Specialty segment were  1 89 billion  up 3  from the prior year quarter  primarily due to higher performance incentives earned under the previous TRICARE contract and increased group fully insured commercial medical premiums Benefit ratio deteriorated 250 bps year over year to 83 1   due to the impact of the temporary suspension of the health insurance industry fee in 2017 Operating cost ratio improved 260 bps year over year to 21 9  due to the temporary suspension of the health insurance industry fee in 2017 and operating cost efficiencies Adjusted pretax income of  48 million substantially increased 300  year over year driven by the company s higher earnings related to fully insured business  Also higher earnings from the company s military service business resulting from the TRICARE contract drove the upside Healthcare ServicesRevenues of  6 02 billion decreased 6  year over year  primarily due to the company s Pharmacy Solutions business as well as the impact of the optimization process associated with its chronic condition management programs Operating cost ratio deteriorated 60 bps year over year to 96  Adjusted pretax income for the segment was  227 million  down 19  due to optimization process associated with the company s chronic care management program and higher operating cost ratio Individual CommercialIndividual Commercial membership was 128 800 as of Dec 31  2017  down 80  year over year  primarily due to a decline in number of countries where the company offers on exchange coverage as well as the discontinuance of off exchange products Benefit ratio came in at 80 3  compared with 285 3  in the fourth quarter of 2016  The year over year improvement primarily resulted from the planned exit from certain markets with higher benefit ratio and premium increases The segment s operating cost ratio came in at 25 9   down from 51 3  in the year ago quarter  The improvement was primarily driven by the loss of scale efficiency from market exits in 2017 The company witnessed a pretax loss of  14 million in the quarter  narrower than the pretax loss of  634 million in the prior year quarter Financial UpdateAs of Dec 31  2017  the company had cash  cash equivalents and investment securities of  16 34 billion  down 23  sequentially As of Dec 31  2017  cash and short term investments held by the parent company was  688 million  down 70  sequentially Debt to total capitalization as of Dec 31  2017 was 33 3   up 280 bps from Sep 30  2017 Cash flows provided by operations totalled  4 05 billion for 2017 compared with  1 94 billion in the prior year  The improvement was positively impacted by the receipt of merger termination fee  higher earnings and the timing of working capital items Share Repurchase UpdateIn December 2017  Humana s board of directors approved a  3 billion share repurchase authorization  which will expire on Dec 31  2020 The company subsequently entered into an agreement with a third party financial institution on Dec 21  2017 to bring into effect a  1 billion ASR program under the authorization In 2017  the company bought back shares worth  3 1 billion As of Feb 6  2018  the company had nearly  2 billion of current share repurchase authorization remaining Dividend UpdateThe company paid cash dividends worth  58 million to its stockholders in the fourth quarter  During 2017  total amount of dividends paid was  220 million In Nov 17  the company declared a cash dividend of 40 cents per share that was paid on Jan 26  2018 to the shareholders of record on Dec 29  2017 2018 GuidanceHumana expects 2018 adjusted EPS to lie between  13 50 and  14 00Total revenues are expected be  55 8  56 4 billion Cash flow from operations is expected to range within  2 2 billion to  2 6 billion 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  There have been four revisions higher for the current quarter compared to three lower 
Humana Inc  Price and Consensus
    VGM Scores
At this time  HUM has a poor Growth Score of F  however its Momentum is doing a lot better with a C  Following the exact same course  the stock was also allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Zacks  style scores indicate that the company s stock is suitable for value and momentum investors 
Outlook
Estimates have been broadly trending upward for the stock and the magnitude of these revisions looks promising  It comes with little surprise HUM has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2018-03-08,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-up-32-since-earnings-report-can-it-continue-200296938,200296938
142007,363522,HUM,5 Reasons Why Anthem  ANTM  Is A Lucrative Investment Option,opinion,Anthem  Inc    NYSE ANTM   is one of the largest publicly traded managed care organizations in terms of membership  Also the company emerges as the largest Blue Cross Blue Shield plan provider in the United States  Estimates of Anthem have moved north over the past 60 days  reflecting analysts  confidence in the same  The stock has seen the Zacks Consensus Estimate for 2018 and 2019 being revised 14 9  and 13 8  upward to  15 09 and  16 617  respectively  during the period Shares of this Zacks Rank  2  Buy  company have outperformed its industry in a year s time  The stock has surged 39 2  compared with the  s growth of 33 2   Let s focus on the factors that make Anthem an attractive pick for investors Solid 2018 Guidance  Anthem has issued its earnings guidance for 2018  It expects adjusted net income per share to be more than  15 00  up 24 6  year over year  The medical insurer also projects operating revenues in the range of  90 5  91 5 billion  up 2  from 2017  This upbeat view further instills shareholders  optimism on the stock Consistent Top line Growth  Anthem has witnessed steady revenue growth over the past several years  CAGR of 8  from 2012 to 2017   Revenues have followed this uptrend on the back of a continuous increase in membership as well as rising net investment income  An impressive inorganic improvement has also contributed to this revenue appreciation Strong Capital Position  Anthem s solid cash position has enabled the company to approve regular dividend payouts and stock repurchases  The company has been rewarding shareholders with dividends since 2011 and has hiked the same by about 160  in the last five years  It has also been aggressively engaged in share buy backs  utilizing its excess capital to boost shareholder value Positive Earnings Surprise History  Anthem boasts an encouraging earnings surprise history  having outpaced the Zacks Consensus Estimate in each of the trailing four quarters with an average beat of 9 6  Attractive Valuation  Going by the price to earnings  P E  ratio  Anthem is trading at a trailing 12 month P E multiple of 19 4x  lower than the industry average of 21 1x  This also compares favorably with the S P 500 index s average of 21 6x  The company s valuation indicates that the stock is relatively undervalued compared with its peers  The stock carries an impressive  of B   Back tested results have shown that stocks with a Value Score of A or B combined with a favorable Zacks Rank  1  Strong Buy  or 2 offer best investment bets Other Stocks to ConsiderA few other top ranked stocks in the same space with a Zacks Rank of 2 are WellCare Health Plans  Inc    NYSE WCG    UnitedHealth Group Incorporated   NYSE UNH   and Humana Inc    NYSE HUM    You can see  WellCare Health provides managed care health plans  primarily through Medicaid  Medicare Advantage and Medicare Prescription Drug plans across the country  Its earnings surpassed estimates in each of the last four quarters with an average positive surprise of 53 8  UnitedHealth Group operates as a diversified health care company in the United States  Its earnings exceeded estimates in each of the trailing four quarters with an average beat of 4 8  Humana is a for profit American health insurance company that has delivered positive surprises in each of the last four quarters with an average positive surprise of 7  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-11,Zacks Investment Research,https://www.investing.com/analysis/5-reasons-why-anthem-antm-is-a-lucrative-investment-option-200297407,200297407
142008,363523,HUM,Here s Why Small Cap HealthCare ETFs   Stocks Are Good Picks,opinion,"Healthcare stocks are seen as relatively defensive and can provide safety to one s portfolio during market downturns  which has been the case this year now  Ebbing fears related to price gouging  flurry of positive clinical trials  increasing health care spending  decent valuation have also been benefiting the sector 
Two particular factors are likely to act as wind beneath the wings of the healthcare sector  pushing up small cap healthcare stocks and the related funds 
Tax Reform
Per  on Reuters  domestically geared healthcare companies that focus on services are likely to benefit from the lower tax rate  These companies have limited international exposure and considerable capital expenditures  as per the source 
Mizuho Securities indicated that  tax reform should be a   especially for healthcare services companies that tend to have limited international exposure and significant capital expenditures  
Merger and Acquisition 
The U S  healthcare supply chain is consolidating fast  with  ranging from insurers  pharmacies to drug distributors  According to  on Bloomberg  smaller insurers like WellCare Health Plans Inc    NYSE WCG    Centene Corp    NYSE CNC    Molina Healthcare Inc    NYSE MOH   and Obamacare focused startup Oscar Insurance Corp  appear to be lucrative acquisition targets  These companies may merge among themselves or can be lapped up by larger insurers eyeing scale advantage in a specific business area  read  
The range of M A activity is spreading beyond the healthcare sector  Leerink Partners analyst Ana Gupte noted retail giant  Walmart Inc    NYSE WMT    has a co branded Medicare drug plan with Humana  NYSE HUM  that steers patients to Walmart stores    which could make the retailer a prospective buyer of Humana  
Like many analysts  we also believe that  if  as an investor  one wants to make a lot from   targeting small cap stocks would be the best choice 
Against this backdrop  we highlight a few small cap oriented stocks and ETFs for investors 
ETF Picks
PowerShares S P SmallCap Health Care Portfolio 
The fund targets the S P SmallCap 600 Capped Health Care Index  The 77 stock fund has a keen focus on Healthcare Equipment  Pharmaceuticals Suppliers and Providers   Services  which account for about 75  of the portfolio  The fund charges 29 bps in fees  read    
SPDR S P Health Care Services  NYSE XHS  ETF 
The underlying S P Health Care Services Select Industry Index holds 49 stocks in its portfolio  Health Care Services comprises 37  of the fund  followed by Health Care Facilities  26 6   and Managed Health Care  22 7    The fund has 28  exposure to large cap stocks while small cap stocks hold 50  share  Mid cap stocks comprise the balance  It charges 35 bps in fees   
SPDR S P Health Care Equipment  NYSE XHE  ETF 
The fund puts 78  focus on Healthcare Equipments while Health Care Supplies takes the rest of it  Small cap stocks occupy the majority share  while around 21  is held by large cap stocks 
Stock Picks
Almost Family Inc    NASDAQ AFAM  
This Zacks Rank  2  Buy  company is a regionally focused provider of home health services 
Market Cap   817 9 million
Accuray Incorporated   NASDAQ ARAY  
This Zacks Rank  2 stock is a global leader in the field of radiosurgery and a non surgical treatment option for those diagnosed with cancer 
Market Cap   494 7 million
Surmodics  Inc    NASDAQ SRDX  
It is a provider of surface modification technologies in the areas of biocompatibility  site specific drug delivery  biological cell encapsulation  and medical diagnostics and holds a Zacks Rank  2 
Market Cap    448 04 million
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2018-03-13,Zacks Investment Research,https://www.investing.com/analysis/heres-why-smallcap-healthcare-etfs--stocks-are-good-picks-200297807,200297807
142009,363524,HUM,BioDelivery  BDSI  Q4 Loss Wider Than Expected  Sales Up Y Y,opinion,BioDelivery Sciences International  Inc    NASDAQ BDSI   reported a loss of 29 cents per share in the fourth quarter of 2017  wider than the Zacks Consensus Estimate of a loss of 22 cents  However  the reported loss was in line with the year ago figure BioDelivery s shares have outperformed the  in a year s time  The stock has gained 7 9  versus the industry s decline of 3   Revenues were  12 5 million in the reported quarter  significantly up 220 5  from the year ago period and 10 6   sequentially  The top line also surpassed the Zacks Consensus Estimate of  10 million  The year over year increase in revenues was mainly driven by the recognition of product revenues for Belbuca in comparison to royalties recorded a year ago We remind investors that BioDelivery reacquired the worldwide rights to Belbuca in January 2017 from Endo Pharmaceuticals  a subsidiary of Endo International Plc   NASDAQ ENDP    As a result of this reacquisition  the company started registering product revenues for Belbuca compared with the previously grossed royalties Quarter in DetailBioDelivery s opioid dependence drug  Bunavail  recorded  1 7 million sales in the quarter under review  up 15  year over year  However  revenues from the drug remained unchanged sequentially  The company is trying to enhance Bunavail sales through new and improved managed care contract Good news is that in October 2017  BioDelivery entered into a settlement agreement with Teva Pharmaceuticals   NYSE TEVA    resolving its Bunavail patent litigation  Pursuant to this non exclusive license agreement  Teva is anticipated to get permission to begin selling its generic version of Bunavail in the United States not before July 2028 In the fourth quarter  the company logged revenues of  9 4 million from Belbuca  up 47  from the third  However  the prescription volume for Belbuca expanded 10  compared with the previous quarter  Further  this growth momentum continued into the first quarter of 2018 with the company having recorded monthly total prescriptions in excess of 8 600 earlier this January  thereby reflecting an all time high Research and development expenses surged 33 3  to  6 8 million from the year ago period  Selling  general and administrative expenses also increased 26 5  year over year to  14 8 million 2017 ResultsFull year sales stood at  62 million  beating the Zacks Consensus Estimate of  54 9 million  Moreover  the top line significantly skyrocketed 300  compared with the year ago figure of  15 5 million The full year earnings of 9 cents per share missed the Zacks Consensus Estimate of 15 cents  However  the company reported a loss of  1 25 a year ago Other Updates From the QuarterNotably  in January 2018  BioDelivery along with partner Purdue Pharma announced that Belbuca was made commercially available in Canada following an approval in the country during second quarter 2017  BioDelivery signed a deal with Purdue Pharma last July for the commercialization of Belbuca in Canada  Per the terms of the agreement  BioDelivery is entitled to receive royalties on net sales of the drug and will be eligible for potential future sales related milestones Moreover  BioDelivery has recently signed a commercial agreement with Humana  NYSE HUM   the second largest medicare insurer in the United States  for adding Belbuca as a preferred agent for both companies  commercial and medicare patients  This in turn validates BioDelivery s managed care progress for the drug The company s portfolio consists of another product called Onsolis  fentanyl buccalsoluble film  a breakthrough in cancer pain in opioid tolerant adults   In May 2016  the company re acquired the North American rights to Onsolis from Meda  a subsidiary of Mylan   NASDAQ MYL    and signed a licensing agreement with Collegium for marketing Onsolis in the United States  BioDelivery plans to file a regulatory submission next month to qualify a new manufacturer for Onsolis BioDelivery Sciences International  Inc  Price  Consensus and EPS Surprise    Zacks RankBioDelivery carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-15,Zacks Investment Research,https://www.investing.com/analysis/biodelivery-bdsi-q4-loss-widerthanexpected-sales-up-yy-200298823,200298823
142034,363549,HUM,Cigna says Anthem deal could close in 2017  Anthem sticks to 2016,news,By Caroline Humer NEW YORK  Reuters    Health insurer  Cigna Corp   N CI   which announced plans to be bought by larger Anthem Inc  N ANTM  10 months ago  on Friday said the deal may close in 2017 rather than 2016 due to the complexity of the regulatory process  according to a filing with the Securities and Exchange Commission  The U S  Department of Justice is currently reviewing the Cigna Anthem deal  which would create the nation s largest health insurer  offering Medicare  Medicaid and commercial health insurance   The Justice Department is reviewing that deal in conjunction with Aetna Inc s  N AET  proposed purchase of  Humana Inc   N HUM   which was also announced last summer  Ever since the deals were announced  investors have worried that one or both may not close because of antitrust issues  Anthem has not changed its expectations  Anthem spokeswoman Jill Becher said in a statement    Although our merger agreement with Cigna gives us until April 30  2017 to obtain regulatory approvals  we continue to believe that we will obtain such approvals and close in the second half of 2016   she said  Cigna said in the filing that it continues to target closing in the second half of 2016 but that the closing hinges on regulators  timing and approval   In light of the complexity of the regulatory process and the dynamic environment  it is possible that such approvals may not be obtained in 2016   Cigna said in its first quarter financial filing on Friday  In a February regulatory filing it said that the merger was expected to close in the second half of 2016   A Cigna spokesman declined to comment beyond the filing  Shares in Cigna  which also reported first quarter earnings on Friday  fell 2 percent to  2 64 in midday trading  Anthem shares fell 0 4 percent to  136 55 ,2016-05-06,Reuters,https://www.investing.com/news/stock-market-news/cigna-says-anthem-deal-could-close-in-2017;-anthem-sticks-to-2016-400465,400465
142035,363550,HUM,Republicans win Obamacare legal challenge  add to insurer concerns,news,"By Lawrence Hurley WASHINGTON  Reuters    A U S  judge on Thursday handed a victory to congressional Republicans who challenged President Barack Obama s signature healthcare law  ruling that his administration overstepped its constitutional powers relating to government spending  U S  District Judge Rosemary Collyer  based in Washington  ruled that the administration cannot spend billions of dollars in federal funds to provide subsidies under the law known as Obamacare to private insurers without the approval of Congress  At issue in the case  brought by the Republican led House of Representatives  are reimbursements to insurance companies to compensate them for reductions that the law requires them to make to customers  out of pocket medical payments  The ruling will not have an immediate effect on the law because the judge put the decision on hold pending an expected appeal by the administration  But it adds to uncertainty over the future of Obama s signature domestic policy achievement ahead of the Nov  8 presidential and congressional elections  including whether enough health insurers will continue to participate in the program  Insurers have sustained losses from their Obamacare business  saying they have not attracted enough healthy customers to offset the costs of sicker members  Two of the largest players  UnitedHealth Group  NYSE UNH  and  Humana Inc   NYSE HUM   had already said they would not offer plans in many markets next year   If you re going to lose more money  why participate   asked Steve Halper  an analyst with FBR Capital Markets  Shares in hospital operators such as Community Health Systems Inc fell sharply  while insurer stocks including  Aetna Inc   NYSE AET   which plans to remain in at least 15 Obamacare markets next year  also declined  In court papers  the administration had warned that a court victory for the House Republicans would lead to a spike in insurance premiums for Americans and force the government to pay more in tax credits to insurance policy holders  As part of an appeal  the administration is likely to press its argument that the House lacks legal standing to sue    This suit represents the first time in our nation s history that Congress has been permitted to sue the executive branch over a disagreement about how to interpret a statute   White House spokesman Josh Earnest told reporters   It s unfortunate that Republicans have resorted to a taxpayer funded lawsuit to re fight a political fight that they keep losing   Earnest added   They ve been losing this fight for six years  and they ll lose it again   REPEATED CHALLENGES Conservatives have mounted a series of legal challenges to the Affordable Care Act since it was passed by Congress in 2010 over unified Republican opposition  Collyer was appointed to the bench by Republican former President George W  Bush  The law has helped bring insurance coverage to millions of Americans who previously had none  subsidizing the cost of insurance through tax credits  In addition  the federal government helped defray consumers  out of pocket costs  The House Republicans argued that the administration s action violated the U S  Constitution because it is the legislative branch  not the executive branch  that authorizes government spending   BIG win for the Constitution   House Speaker Paul Ryan wrote on Twitter  Jonathan Turley  the lawyer who spearheaded the lawsuit  in a blog post called the ruling  a resounding victory not just for Congress but for our constitutional system as a whole   The appeals court in Washington may be more receptive to the administration s arguments  in part because seven of its 11 active judges are Democratic appointees  including four picked by Obama  The case focuses on a cost sharing provision of Obamacare that requires insurers to reduce deductibles and co pays  Insurers are supposed to be reimbursed for these costs by the federal government  Cost sharing is determined by the income of the policyholder and is a mechanism for reducing healthcare costs for lower income households   The Obama administration has interpreted the provision as a type of federal spending that does not need to be explicitly authorized by Congress  The House Republicans who filed the challenge disagreed  Collyer ruled that the cost sharing provisions cannot be funded through the same permanent appropriation that covers tax credits made available under the law  The judge rejected the administration s contention that the appropriation should be viewed as permanent because the alternative interpretation would lead to  absurd economic  fiscal and healthcare policy results   
The U S  Supreme Court in June 2015  in a ruling authored by Bush appointed Chief Justice John Roberts  rejected a conservative challenge that could have gutted Obamacare  upholding nationwide tax subsidies crucial to the law  Roberts also wrote a major 2012 ruling preserving Obamacare ",2016-05-12,Reuters,https://www.investing.com/news/politics-news/u.s.-judge-hands-win-to-republicans-in-obamacare-challenge-401671,401671
142036,363551,HUM,Doubts mount over merger of health insurers Anthem  Cigna,news,"By Bill Berkrot  Reuters    Wall Street expressed growing doubts about a pending  54 billion merger of U S  health insurers Anthem Inc  N ANTM  and  Cigna Corp   N CI  on Monday as news of management squabbles added to concerns over its review by antitrust regulators  Cigna shares closed down 4 percent at  126 15  well below Anthem s original  188 per share offer of cash and stock announced last July  Anthem shares fell 1 8 percent to  133 18   The market is telling you that it feels the probability of the deal is significantly less than 100 percent   Morningstar analyst Vishnu Lekraj said in a telephone interview  He declined to provide his own probability forecast  Leerink Partners analyst Ana Gupte on Monday estimated the deal had a less than 50 percent chance of closing  down from her previous view of 70 percent  She also lowered her stock price targets on both companies  Anthem s bid for Cigna followed close on the heels of Aetna Inc s  N AET  proposed  34 billion purchase of  Humana Inc   N HUM   The two transactions would mark an unprecedented consolidation of the U S  health insurance market to three major players from five  Anthem and Aetna argue that they need the greater scale to help curb mounting U S  healthcare costs  both for hospital services and pharmaceutical prices  Both deals have faced close scrutiny from state and federal regulators over concerns that they may raise insurance costs for customers  In recent weeks  healthcare analysts have said they were more confident that Aetna could win approval for its Humana deal  They question whether Anthem and Cigna  which both compete for business from large U S  employers who provide health coverage for their workers  would be able to satisfy antitrust concerns  On Sunday  the Wall Street Journal reported that Anthem and Cigna were arguing behind the scenes over several issues  including a lawsuit by Anthem against pharmacy benefits manager Express Scripts Holding Co  O ESRX   and submissions of information to antitrust regulators reviewing the deals   nL2N18J09P    If the two companies are in a state of conflict  it makes an already challenging transaction very difficult   Gupte said in a telephone interview  But the bigger issue  she said  was that the companies  Fortune 500 clients might not be on board with the deal  based on feedback from antitrust and policy experts advising the government   
Lekraj said he believed Anthem and Cigna still felt the need to get the deal done to maintain profits as the government worked to trim healthcare costs and lower reimbursement rates   The Justice Department will ultimately approve the deal as long as management teams can get along and keep the deal intact  and egos don t work their way into the situation   he predicted  Both Cigna and Anthem declined to comment ",2016-05-24,Reuters,"https://www.investing.com/news/economy-news/doubts-mount-over-merger-of-health-insurers-anthem,-cigna-403916",403916
142037,363552,HUM,Anthem CEO expects U S  regulatory decision in July,news,"By Caroline Humer NEW YORK  Reuters    Anthem Inc  N ANTM  Chief Executive Officer Joseph Swedish said on Tuesday the health insurer was pushing for approval from antitrust regulators reviewing its  51 billion acquisition of  Cigna Corp   N CI  and expects to hear a decision in July  Anthem s bid for Cigna followed closely after Aetna Inc s  N AET  proposed  34 billion purchase of  Humana Inc   N HUM  last July  The two transactions would reduce the U S  health insurance market to three major players from five  raising questions about whether regulators scrutinizing the deals would approve both  Swedish said antitrust regulators have asked many questions about how it and Cigna manage healthcare benefits for large employers  but that the overall review was moving forward as expected  Speaking at the UBS Global Healthcare Conference  Swedish said Anthem has argued to regulators that the deal will save consumers money as the combined company would be able to negotiate better prices for medical services   Swedish expects the U S  Department of Justice to make a determination on the deal in July  He spoke openly about the process after the Wall Street Journal reported there was heated correspondence between Anthem and Cigna lawyers working on the review  The company had previously declined to comment   Anthem General Counsel Thomas Zielinski provided further detail  saying the company is due to meet with the Justice Department in July  when they expect to learn if the deal will be rejected  approved  or approved with remediations such as asset sales   The company announced plans to buy Cigna nearly a year ago in a cash and stock deal worth about  54 billion at the time  Anthem shares fell 1 9 percent  or  2 43  to  130 75 and Cigna shares were off 54 cents  or 0 4 percent  at  125 61 in Tuesday trading  Based on those share prices  the deal is worth  51 billion and values Cigna shares at  170 67   In particular  investors have focused on doubts that large national customers support the deal  an issue that has turned federal antitrust regulators against other acquisitions it has reviewed this year and last year  Zielinski said that both Anthem and Cigna had provided antitrust regulators with 30 to 50 national customers to contact  National hospitals and doctors groups have spoken out against the deal  saying it would hurt Americans  
Zielinski also told investors on Tuesday that he was considering several different ways that he could meet any conditions regulators might set  He did not provide details on those alternatives  but said that there were interested buyers for assets if sales were required ",2016-05-24,Reuters,https://www.investing.com/news/stock-market-news/anthem-ceo-expects-u.s.-regulatory-decision-in-july-404098,404098
142038,363553,HUM,Aetna Humana tie up is anti competitive in Missouri  state regulator,news,NEW YORK  Reuters    A tie up of  Aetna Inc   NYSE AET  and  Humana Inc   NYSE HUM  would be anti competitive in Missouri for several types of insurance  including individual Medicare Advantage plans where the combined company would have more than a 50 percent market share  the Missouri Department of Insurance said  The department said in an order  dated May 24 and posted on its website  that if the proposed acquisition of Humana by Aetna were to go forward  the companies would need to stop selling individual insurance  small group and certain Medicare Advantage plans in its state   The combination would exacerbate a consolidation trend that has contributed to higher insurance prices  the department said  Aetna announced plans last year to buy smaller rival Humana  The deal is being reviewed by the U S  Department of Justice as well as state insurance regulators and antitrust authorities  Investors have been uncertain that the purchase will close  in part because anti trust regulators are also reviewing competitor Anthem Inc s plan to buy  Cigna Corp   NYSE CI     This order does not impede the DOJ approval process  We are disappointed with the Missouri order but expect to have a constructive dialogue with the state to address their concerns   Aetna spokesman T J  Crawford said in a statement  According to the order  Aetna can submit a plan to the insurance regulator to address the impact of the acquisition ,2016-05-25,Reuters,https://www.investing.com/news/stock-market-news/aetna-humana-tie-up-is-anti-competitive-in-missouri:-state-regulator-404480,404480
142039,363554,HUM,U S  stocks rally late  ahead of critical June jobs report,news,"Investing com    U S  stocks staged a late rally on Thursday to close moderately higher  ahead of a key monthly jobs report  as a rebound in oil prices provided a lift to the major indices 
Oil erased sharp losses from early in the session after the U S  Energy Information Administration reported a draw of 1 4 million barrels in domestic crude inventories last week helping ease near record stockpiles at storage facilities nationwide  Earlier  OPEC broke off talks at its semi annual meeting in Vienna without reaching an agreement to cap its production ceiling  While Saudi Arabia pledged to resist the temptation of flooding global energy markets with a glut of supply  Iran offered few hints that it will slow production in the coming months  OPEC will meet next on November 30 
The Dow Jones Industrial Average gained 48 89 or 0 27  to 17 838 56  while the NASDAQ Composite index added 19 11 or 0 39  to 4 971 36  each extending recent hot streaks  The NASDAQ closed higher for the seventh consecutive session  The S P 500 Composite index  meanwhile  rose 5 93 or 0 28  to 2 105 26  as seven of 10 sectors closed in the green  With the slight gains  the S P 500 closed above a key technical level at 2 100  Stocks in the Health Care  Technology and Consumer Services industries led  while stocks in the Technology and Utilities sectors lagged 
The top performer on the Dow was EI du Pont de Nemours and Company  NYSE DD   which added 1 03 or 4 07  to 24 28  DuPont  NYSE DD  finished as the top performer on the Dow for the second consecutive session  On Wednesday  DuPont named Rudy van Engen as its new regional director for its Europe  Middle East and Africa region  Van Engen  owns more than 20 years of experience in the plastics and rubber industry  The worst performer was  Exxon Mobil  Corporation  NYSE XOM   which fell 0 71 or 0 80  to 88 53  following OPEC s decision  Shares in ExxonMobil have slumped 15   as the price of oil has tumbled over the last two years  In June  2014  oil prices peaked at  115 a barrel 
The biggest gainer on the NASDAQ was Endo International PLC  NASDAQ ENDP   which surged 0 86 or 5 17  to 17 48  Shares in Endo are up approximately 30  since the specialty drugmaker cut its forward guidance and completed a major shakeup of its executive leadership team in early May  The worst performer was NetEase Inc  NASDAQ NTES   which fell 2 16 or 1 23  to 174 00  Despite the slight losses  shares in the Chinese online video game manufacturer are still up by more than 24  over the last year 
Endo was also the top performer on the S P 500  just ahead of  Humana Inc   NYSE HUM   which jumped 8 72 or 4 92  to 186 12  Humana  NYSE HUM  shares have been in a holding pattern of late as investors await whether the Louisville based managed health care company will receive regulatory approval in its comprehensive merger with  Aetna Inc   NYSE AET   Over the last three months  Humana shares are down 1 83   The worst performer was  Diamond Offshore  Drilling Inc  NYSE DO   which fell 1 03 or 4 07  to 24 28 
On the New York Stock Exchange  advancing issues outnumbered declining ones by a 1 951 1 060 margin ",2016-06-02,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-stocks-rally-late,-ahead-of-critical-june-jobs-report-406202",406202
142040,363555,HUM,U S  court skeptical of lawmaker immunity in trading probe,news,By David Ingram NEW YORK  Reuters    A federal appeals court fired skeptical questions on Monday at a lawyer for a U S  congressional committee and a former staffer who argued that Congress is immune from having to cooperate with an insider trading investigation  During a hearing  a three judge panel of the 2nd U S  Circuit Court of Appeals appeared to lean in favor of forcing Congress to comply at least somewhat with two subpoenas from the U S  Securities and Exchange Commission  The case is a test of how far securities enforcers may go to police the murky world of  political intelligence   in which firms seek to gather and sell information for traders   The SEC is investigating trading in  Humana Inc   NYSE HUM  stock in 2013 ahead of a government announcement about physician reimbursement rates  which affect Humana and other health insurers  In court papers  the SEC said it believes a congressional staff member at the time  Brian Sutter   may have been a source  of an early leak to a lobbyist at the Greenberg Traurig law firm  who then passed the information to a Height Securities analyst  who in turn alerted clients  Lawmakers and their staff are not immune from prosecution under insider trading laws   But Sutter and his former employer  the U S  House of Representatives  Ways and Means Committee  refused to comply with subpoenas for documents and testimony  Their lawyers argued that they should be shielded from such investigative tactics because  under the legal principles of sovereign immunity and legislative independence  they cannot be questioned without their consent   Circuit Judge Richard Wesley asked if Sutter went beyond protected activity in talking to the lobbyist   I don t care what his job was at the Ways and Means Committee  he wasn t in charge of insider trading   he said  William Pittard  a lawyer for Sutter and the committee  said it was not the court s role to question the motives of congressional staff  SEC lawyer Jeffrey Berger told the court that a ban on insider trading by Congress would be an  empty shell  if the regulator lacked the power to investigate  The appeals court is expected to rule in the next several months  A Humana spokesman could not be reached for comment  A Greenberg Traurig spokeswoman declined to comment  Height Securities said in a statement it has not received a subpoena from or been formally investigated by the SEC ,2016-06-13,Reuters,https://www.investing.com/news/politics-news/u.s.-court-skeptical-of-lawmaker-immunity-in-trading-probe-408116,408116
142041,363556,HUM,California insurance commissioner urges U S  to block Anthem Cigna deal,news," Reuters    California s insurance commissioner on Thursday urged the U S  Department of Justice to block health insurer Anthem Inc s  N ANTM  acquisition of  Cigna Corp   N CI   saying he is concerned it will raise premiums in the state  Dave Jones  who as insurance commissioner in California does not have authority to approve the deal  said he believes his recommendation will hold weight with U S  antitrust regulators examining the acquisition  Anthem announced plans to buy Cigna last summer  Recently Anthem said it believed the Justice Department was examining the employer based health insurance market in which the insurer acts as the health plan administrator  In California  Anthem and Cigna would control 61 percent of the administrative services market alone  Jones said during a call with reporters   California has a highly consolidated insurance market today  This merger with Anthem and Cigna will only make that situation worse   Jones said  He said there were no divestitures that could improve the situation  In a letter to the Justice Department  Jones described California s  122 9 billion health insurance market as  highly concentrated   and accused Anthem of  a history of implementing substantial and unreasonable premium increases in California   Anthem disagreed with Jones   We do not believe that the California Department of Insurance s opinion is based on the true merits of this transaction   the company said in a statement   We are confident that the highly complementary nature and limited overlap of our organizations that will benefit the complex and competitive health insurance markets will be reviewed on the facts by the DOJ  Justice Department  and appropriate state authorities   Shares of Cigna rose 1 2 percent on Thursday to  128 12 while Anthem added 1 2 percent to  132 24  The deal is one of two major mergers being contemplated in the health insurance market  The other is Aetna s planned  33 billion tie up with Humana  NYSE HUM   
 This version of the story corrects the sixthth paragraph to say that California s health insurance market collects  122 9 billion  not  259 billion  in premiums each year  ",2016-06-16,Reuters,https://www.investing.com/news/stock-market-news/california's-insurance-commissioner-urges-u.s.-to-block-anthem-cigna-deal-408909,408909
142042,363557,HUM,Health Insurance Stock Outlook   January 2018,opinion,"The year gone by was a tumultuous one for health insurers as the industry reeled under constant uncertainty stemming from President Trump and the Republican Congress  efforts to repeal and replace Obamacare  Toward the end of the year  the individual mandate  which required most Americans to obtain health insurance or pay a fine  of Obamacare was stripped from the GOP tax bill Apart from political tumult  tough regulatory oversight led to the blockage of two mega mergers  Aetna Inc  NYSE AET    AET  with Humana Inc  NYSE HUM    HUM  and Cigna Corp   CI  with Anthem Inc   ANTM  On an operational level  rising medical costs  public exchanges woes  increased investments in technology  higher operating costs and stiff competition were some of the headwinds that prevailed  Nevertheless  the players emerged as winners with most of them reporting a rise in revenues  membership and margins  Factors such as low medical utilization  greater emphasis on value based care  diversification of operations  product and service development  cost control efforts and strong capital levels worked in their favor  Rapid evolution is being witnessed in the health insurance industry as the players are taking concerted efforts to transform themselves into comprehensive health care providers from their earlier role of traditional payers  This metamorphosis is being driven by growing consumerism  changes brought about by healthcare reform  more focus on value based care  the need to control rising medical costs and being more competitive  Another wind blowing across the industry is cross sector collaboration  wherein health insurers are foraying into another realm of the health care industry such as pharmacy benefit management  ambulatory care and physician services These combinations that qualify as lateral integrations are catching the eye of insurers since such deals enable them to broaden their service and product portfolio  and become a comprehensive healthcare company  Some of the mega deals in this vein are UnitedHealth Group s  UNH  acquisition of Catamaran and the pending merger of Aetna with CVS Health Corp  NYSE CVS    CVS   Despite all the ambiguity  the  remained an outperformer by growing 54  in a year s time compared with the S P 500 index s 24  gain What s in the Cards in 2018 The year 2018 will be fraught with risk and uncertainty as the repeal and replace conundrum continues  Though the individual mandate has been stripped off  legislators will have to come up with some replacement policy for the individual mandate Nevertheless  since insurers have been paying high tax  the tax reform pursuant to The Tax Cuts and Jobs Act of 2017 should come as a breather  Recently  UnitedHealth reported that it has gained  1 22 per share non cash benefit for 2017 from the revaluation of its net deferred tax liability due to the tax reform The savings from a lower tax rate will most likely be utilized in accelerating investments in data analytics  technology and innovations to better serve consumers and care systems and to advance new and existing business platforms The year 2018 should see more of vertical integration via mergers and acquisitions as players will look for suitable targets to a  strengthen an existing business or platform  b  provide a new platform for future growth  c  bring tools  technologies or skills that cannot be otherwise obtained or developed more efficiently  We also see the potential for sustained growth particularly in expanding government programs  Medicare and Medicaid  Increasing demand for Medicare plans from baby boomers and migration by more states to manage Medicaid have created huge growth opportunities in this line of business Is Further Upside Potential Left While the industry has outperformed the broader market  valuations remain a bit stretched and leave limited or no room for further upside The Zacks HMO industry is currently trading at a forward 12 month price to earnings ratio of 19 4 which compares unfavorably with 19 3 for the S P 500 index as a whole  Over the last 5 years  the industry has traded in a range of 9 3 to 21 8  with a median of 15 9What this shows is that while HMO stocks are somewhat pricey Zacks Industry RankWithin the Zacks Industry classification  health insurers are broadly grouped in the Medical sector  one of the 16 Zacks sectors  We rank 265 industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry  We put our industries into two groups  the top half  industries with the best average Zacks Rank  and the bottom half  the industries with the worst average Zacks Rank   Over the last 10 years  using a one week rebalance  the top half beat the bottom half by more than twice as much  The Zacks Industry Rank is  23  top 108    The ranking is available on the  Please note that the Zacks Rank for stocks  which is the core of our Industry Outlook  has an impressive track record    verified by outside auditors    of foretelling stock prices  particularly over the short term  1 to 3 months   The rank  along with   helps in predicting the probability of earnings surprises Stocks Worth ConsideringInvestors can consider the following HMO stocks that have solid fundamentals along with a favorable Zacks Rank UnitedHealth Group Inc  is a diversified health and well being company in the United States  The company offers consumer oriented health benefit plans and services  health care coverage  and health and well being services to individuals aged 50 and older  The stock currently has a Zacks Rank  2  Buy  and surpassed earnings estimates in each of  the trailing four quarters  with an average beat of 4 78   Also  the stock has seen the Zacks Consensus Estimate for 2018 being revised upward over the past seven days  Nobilis Health Corp   HLTH  own and manage ambulatory and acute care facilities for healthcare services  In addition  it owns and manages ambulatory surgery centers  acute care hospitals  imaging centers and urgent care clinics  The stock currently has a Zacks Rank  2 and has a Value Score of A  It surpassed earnings estimates two of the last four reported quarters  with an average beat of 9 6   Also  the stock has seen the Zacks Consensus Estimate for 2018 being revised upward over the past 60 days Anthem Inc   ANTM  provides medical products through its subsidiaries  It operates through Commercial  Consumer and Other segments  The company offers managed care plans to the large and small employer  individual  Medicaid and senior markets The stock currently has a Zacks Rank  2 and has a Value Score of A  It surpassed earnings estimates in each of the last four reported quarters  with an average beat of 11 5    Also  the stock has seen the Zacks Consensus Estimate for 2018 being revised upward over the past 30 days 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-01-22,Zacks Investment Research,https://www.investing.com/analysis/health-insurance-stock-outlook--january-2018-200282450,200282450
142043,363558,HUM,Health Insurers Bask Under Rising Insured  Medicare Business,opinion,"Despite industry disruptions  health insurers have managed to keep on their feet over the past year of disruptions  Rising enrollment and top line growth  development of ancillary business  product modifications  improved service  demographic changes  expansion of international operations  better claims handling  growth of new business units  mergers and acquisitions and a strong capital position have better armed insurers to fight industry woes and emerge as winners 
The same is evident from a strong stock market performance by the   as seen by the 54  gain in a year s time compared with the S P 500 s gain of 24  
Let s take a look at how insurers fared recently 
Decline in Uninsured Rates 
Over the past six years  the nation s uninsured rate has gone down  thanks to the Affordable Care Act  ACA  mandates  According to a recent report from Gallup  the percentage of U S  adults without health insurance was 12 2  in the fourth quarter of 2017  
It remains well below its peak of 18 0  measured in the third quarter of 2013  prior to the implementation of the ACA s healthcare exchanges and the requirement that most adults have health insurance or be subject to a fine  commonly known as the individual mandate 
Health insurers have capitalized on this surge in insured rates by raking in members  who added to their top line growth  Most of the insurers have reported a secular rise in enrollment and revenues since 2010  confirming the fact Medicare Advantage  a Cash Cow
Medicare Advantage  MA  plans  which were introduced by the government some years ago to rein in rising costs of Medicare  the main government program for retirees  are administered by private insurance companies  The plan is rightly called Medicare Advantage  because of the extra frills provided in it by health insurers to make it more appealing  compared to the traditional Medicare  to customers 
Health insurers are reimbursed a certain amount per enrollee from the government in return for the care provided by the insurer  This reimbursement has been quite attractive  and insurers    via their measures such as preventive healthcare and accountable care organizations    have been able to maintain profitability in these plans  This business has proven to be a cash cow for the insurance industry 
Players  attractiveness for MA business is increasing  fueled by demographic changes  With more baby boomers reaching retirement age  the number of people eligible for Medicare is projected to surpass 70 million individuals by 2024  up from 60 million at present  with gross spending for Medicare expected to reach  1 2 trillion by 2024  up from  770 billion projected for 2018 
Medicare Advantage continues to be a popular choice for approximately one third of those enrolled in Medicare  Players have ample scope of growth as the Medicare Advantage market continues to expand and evolve  
While two public providers  UnitedHealth Group Inc   UNH  and Humana Inc  NYSE HUM    HUM   are the biggest players in this space  others are in the race to win Medicare Advantage market share  The fastest way of achieving this is by acquiring a company in the same business 
Players have been resorting to mergers and acquisitions  joint ventures and partnerships in an effort to deepen their reach in the Medicare market  Some of the biggest deals in this space were the acquisitions of HealthSpring by Cigna Corp   CI   XLHealth Corp  by UnitedHealth Group  and Health Net by Centene Corp   CNC   Recently  Anthem Inc   ANTM  announced to buy Florida based Medicare Advantage insurer HealthSun and America s 1st Choice  a privately held Medicare Advantage plan International Markets Hold AttractionExcessive competition and pressure on profit margins in the U S  market have compelled U S  health insurers to look to foreign markets for business diversification  sustained growth and profitability  International markets appear attractive  as these are less penetrated and more competitive  Notably  Asia and Europe represent the best near term opportunities for U S  health insurers Cigna and UnitedHealth Group lead the private health insurance industry in terms of international deal activity  They re followed by Aetna Inc  NYSE AET    AET  and Humana  The deals have either been mergers and acquisitions or joint ventures with local insurance companies Some of the deals made by players in this field echo the emerging trend of globalization   Recently  Aetna acquired UK based Bupa Group s Thai business  Bupa Thailand  which will significantly increase Aetna s presence in Asia  Earlier  it bought U K  based InterGlobal  which offers private medical insurance to groups and individuals in the Middle East  Asia  Africa and Europe 
Another insurer  Cigna  penetrated the market in India through a joint venture with TTK Group 
UnitedHealth s purchase of a stake in AmilParticipacoes of Brazil and its recent announcement of buying Chilean company BanMedica points at the increasing trend of insurers going international 
Shift to Value Based Care
The industry is witnessing a change from volume based care to value based care in recent years which has led to the emergence of Accountable Care Organizations  ACOs   These are formed when a group of health care providers  physicians  hospitals  non physician providers  and the like  collectively take responsibility for the financial and quality outcome for a defined population The ACOs are appealing to insurers as these reduce medical cost and improve outcome  Insurers form an essential part of ACOs because these track and collect patient data  enabling an evaluation of patient care  
Since clinical information and care processes are shared and supported by all providers  it becomes easier to manage care and effectively lower the cost  With Obamacare  health insurers have to be more than just claims payers Under health care reform  insurers have lost flexibility in ways that they can cope with rising medical expenses  They can no longer rely on many of their traditional medical underwriting strategies  such as the exclusion of pre existing conditions 
The most effective approach for insurers now is to rely exclusively on the current cost control mechanisms to manage members  medical expenses  Private commercial payers  such as Cigna  Anthem and Aetna are thus supporting ACO formation  CIGNA and UnitedHealth have one of the most established track records in the group for ACOs 
This ACO wave is expected to continue as players scramble to protect their margins in a very competitive market place  which offers limited scope for top line growth  
Developing Ancillary BusinessesInsurers are eyeing growth and expansion opportunities that accompany the critical challenges of modernizing the health care system  They are branching out to the non traditional areas 
Over the last few years  several large insurers have acquired companies that fall outside the realm of traditional health insurance yet complement it 
Humana  Aetna and UnitedHealth have all been enthusiastically developing their health services businesses  These players have made several acquisitions both big and small to achieve fast paced growth in this space  UnitedHealth s Optum  for example  is a poster child of the growth of health services business that provides tremendous business diversification 
Players have well understood that sustainability over the long run would be possible only by branching out to a new business to relieve pressure on traditional health insurance  which is already saddled with huge competition  Areas such as data and analytics  pharmacy care services  ambulatory services and nursing services are on the radar of health insurers to expand 
Healthy Balance Sheet
Despite incurring heavy expenditures  most of the players in the industry boast solid capital levels  This reflects their profitable operations which have outpaced expense rise  leading to balance sheet growth 
Armed with enough capital  most of the players have resorted to share buyback to aid earnings in an environment when top line growth is a challenge  Strong cash reserves have also enabled players to make acquisitions and mergers to achieve growth  along with positioning them well to face industry issues 
Zacks Industry Rank Indicates Solid Upside Potential
This 13 company group currently carries a  of  23  which places it in the top 10  of the 250 plus Zacks classified industries  Our back testing shows that the top 50  of Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 
Stocks Worth Adding
Investors can consider the following HMO stocks that have solid fundamentals along with a favorable Zacks Rank 
Centene provides multi line managed care programs and related services to individuals receiving benefits under Medicaid  including Supplemental Security Income  SSI  and the State Children s Health Insurance Program  SCHIP  
It beat estimates in each of the last four quarters with an average positive surprise of 10 6   Also  the stock has seen the Zacks Consensus Estimate for 2018 being revised upward over the past 60 days 
Centene carries a Zacks Rank  1 and sports a Value Score of A  You can see  
Magellan Health  Inc   MGLN  is a for profit managed health care company  focused on behavioral healthcare 
It has a Zacks Rank  1 and a Value Score of A  The stock beat estimates in three of the last four quarters with an average positive surprise of 0 9   
Also  the stock has seen the Zacks Consensus Estimate for 2018 being revised upward over the past 60 days 
Molina Healthcare Inc   MOH   a multi state health care organization  arranges for the delivery of health care services and solutions to individuals and families through Medicaid  Medicare and other government funded programs 
It has a Zacks Rank  1 and a Value Score of A  The stock beat estimates in two of the last four quarters with an average positive surprise of 108   
Also  the stock has seen the Zacks Consensus Estimate for 2018 being revised upward over the past 60 days 
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-01-23,Zacks Investment Research,https://www.investing.com/analysis/health-insurers-bask-under-rising-insured-medicare-business-200282843,200282843
142044,363559,HUM,Disruptive Forces To Keep Health Insurers On Their Toes,opinion,"The year 2017 was beset by debate over U S  health care reform and the future of the Affordable Care Act  Finally  toward the end of the year  the individual mandate was repealed  The year 2018 should also be lined with continued policy changes and ongoing uncertainty  Against this backdrop  players in the health insurance industry will continue to work toward making their enterprise more resilient to the dynamic industry 
On an operating front  U S  health plans are expected to carry on their business in a lowered margin environment  given pricing pressure  rising medical costs  and regulatory compliance costs  Increased competition and general marketplace uncertainty are some of the headwinds faced by the players in the industry 
What Does the Individual Mandate Repeal Mean for Insurers 
In December  Obamacare s Individual Mandate  which required most Americans to be covered under health insurance or to pay a fine  was stripped away  This provision will no longer be in effect from 2019  This policy change might lead to healthy individuals opting to remain uninsured only to buy an insurance cover when sick  This should lead to an adverse change in customer mix with insurers getting sick customers mostly  which might increase their risk pool and cause high claim incidence 
Insurers have been lobbying against this repeal  fearing its unfavorable outcome  This might also destabilize the public exchanges where more sick customers would flock to buy insurance  causing an increase in insurance premiums  or lead the insurance companies to exit from exchanges if the businesses don t look sustainable  The Congressional Budget Office  CBO  has stated that repealing Obamacare s individual mandate would cause 13 million fewer Americans to be insured in 2027  This implies an increase in the uninsured rate  which is inversely proportional to insurers  earnings growth 
Mounting Pressure to Deliver in Medicare Advantage Business
Medicare Advantage has been a cash cow  but players are facing increased pressure to deliver on government quality ratings and gain operational efficiencies  which if not achieved may drive some insurers out of the market  In an effort to attract more customers  the players have to make smart strategic investments in customer experience designed to appeal to the growing baby boomer population which is technologically literate 
Customers have become conscious of choosing the plan from a company that can successfully address and take care of their individual needs  Also  in order to be more attractive to customers  companies are supposed to have strong ranking from the CMS   which depends on their provision of quality of care and customer service  among other factors  
The success of players in the Medicare Advantage market to a great extent depends on their Medicare Star ratings  which can only be achieved by investment in infrastructure  Some of the players that have invested are reaping the benefits  but for others it is imperative to make necessary investments to risk losing out to competitors   
Tough Regulatory Oversight to Prevail
Tough oversight of the Department of Justice  DoJ  led to the death of two mega mergers  Aetna Inc  NYSE AET    AET  with Humana inc   HUM  and Cigna Corp   CI  with Anthem Inc   ANTM   These mergers  which were in the form of horizontal combination  would have made the surviving entities to become mammoth players in the insurance market  but would have also nixed competition  While these combinations would have been highly beneficial for these entities from the business point of view  providing them with enough heft and size to bargain with their suppliers and customers  these were perceived to provide little good to the consumer 
Mergers and consolidation are rife in the sector  triggered by the changing industry environment  which calls for the businesses to grow in size in order to better command the market and remain leaders  and the best way for insurers to achieve this status is to engage in mergers and acquisitions  But these will not be easy to come by  given regulators  opportunities to strip down deals  which would go against the interest of consumers and throttle competition  Thus  the ride may not be easy for insurers on this front 
Margins to Stay Under Pressure
Minimum MLR rebate requirements limit the level of margin insurers  can earn in their Commercial Insured  Medicare Insured and Medicaid Insured businesses while leaving them  exposed to higher than expected medical costs  This has kept health insurers  margins under pressure lately  a trend that will likely continue in the coming quarters  A host of factors  including compliance costs related to health care reform regulation  increased fees and taxes  pricing pressure  stiff competition and rising medical costs   are also at play in compressing margins 
The industry is also witnessing a general shift in patient mix from commercial insurance to government  Medicare  Medicaid and state subsidized marketplace or exchange  which is another major dampener of insurers  profitability  Premiums for Medicare  Medicaid and state subsidized policies tend to be higher due to serious health issues for many enrollees  However  they carry smaller profitability margins compared to commercial insurance 
High Cost
Regulatory reforms sweeping through the sector have hit insurers with high compliance costs  Expenditures involved in redoing the internal systems have led to a spike in expenses  There has been huge spending on health information technology   HIT   as the system is going through a challenging transition to electronic medical records  which is expensive and requires expertise 
Increased Capital Expenditures  
Health insurers operate in a highly competitive environment in an industry that is subject to significant ongoing changes from marketplace pressures brought about by public policy forces  the ACA  changes to or repeal or replacement of the ACA  Insurance Exchanges  customer demands  demographic shifts  new and expanding health care capabilities  business consolidations  strategic alliances  new market entrants and marketing practices  As a result of these and other factors  their ability to grow profitably through the sale of traditional insured health care and related benefits products in the United States may be limited 
In order to grow profitably in the future  insurers need to diversify their sources of revenue and earnings and transform their business models  This includes developing and expanding Consumer Health and Services  making investments in consumer engagement capabilities and technology and other services for health systems and provider organizations  including joint ventures  ACOs and collaborative provider networks   optimizing business platforms and expanding internationally 
Achieving these goals will require significant senior management and capital resources to make acquisitions or other transactions  This required huge capital before any significant revenues or earnings are generated from such initiatives  
Stiff Competition 
The environment is particularly challenging for small insurers  Large employers having operations across states prefer to contract with insurers that can serve all of their employees throughout the country  Scale economies have therefore become imperative for acquiring business  The implication of these trends is an expectation of increasing consolidation 
Challenges from International OperationsInternational expansion has exposed insurers to political  legal and compliance  operational  regulatory  economic and other risks in foreign countries  A fragile economy in many parts of the world presents another headwind for insurers  One of the largest insurers  UnitedHealth Group  NYSE UNH   made an acquisition to reap benefits from the Brazil market but is now facing slowing growth rates in that country 
Also  fluctuations in foreign currency exchange rates are likely to have an impact on revenues  operating results and cash flows from international operations 
To Sum Up
Continued uncertainty will command the industry in 2018  Insurers will have to stay on their toes to constantly take stock of their business workings and build a resilient enterprise  This will require an increase amount of investment and talent  Players can only emerge as winners when they act proactively 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-01-24,Zacks Investment Research,https://www.investing.com/analysis/disruptive-forces-to-keep-health-insurers-on-their-toes-200283267,200283267
142045,363560,HUM,Zacks Industry Outlook Highlights  Aetna  Humana  Cigna And Anthem,opinion,For Immediate ReleaseChicago  IL   January 25  2018   Today  Zacks Equity Research discusses the Health Insurance  including Aetna Inc    NYSE AET    Humana Inc    NYSE HUM    Cigna Corp    NYSE CI  and Anthem Inc    NYSE ANTM   Industry  Health Insurance  Part 3Link   The year 2017 was beset by debate over U S  health care reform and the future of the Affordable Care Act  Finally  toward the end of the year  the individual mandate was repealed  The year 2018 should also be lined with continued policy changes and ongoing uncertainty  Against this backdrop  players in the health insurance industry will continue to work toward making their enterprise more resilient to the dynamic industry On an operating front  U S  health plans are expected to carry on their business in a lowered margin environment  given pricing pressure  rising medical costs  and regulatory compliance costs  Increased competition and general marketplace uncertainty are some of the headwinds faced by the players in the industry What Does the Individual Mandate Repeal Mean for Insurers In December  Obamacare s Individual Mandate  which required most Americans to be covered under health insurance or to pay a fine  was stripped away  This provision will no longer be in effect from 2019  This policy change might lead to healthy individuals opting to remain uninsured only to buy an insurance cover when sick  This should lead to an adverse change in customer mix with insurers getting sick customers mostly  which might increase their risk pool and cause high claim incidence Insurers have been lobbying against this repeal  fearing its unfavorable outcome  This might also destabilize the public exchanges where more sick customers would flock to buy insurance  causing an increase in insurance premiums  or lead the insurance companies to exit from exchanges if the businesses don t look sustainable  The Congressional Budget Office  CBO  has stated that repealing Obamacare s individual mandate would cause 13 million fewer Americans to be insured in 2027  This implies an increase in the uninsured rate  which is inversely proportional to insurers  earnings growth Mounting Pressure to Deliver in Medicare Advantage BusinessMedicare Advantage has been a cash cow  but players are facing increased pressure to deliver on government quality ratings and gain operational efficiencies  which if not achieved may drive some insurers out of the market  In an effort to attract more customers  the players have to make smart strategic investments in customer experience designed to appeal to the growing baby boomer population which is technologically literate Customers have become conscious of choosing the plan from a company that can successfully address and take care of their individual needs  Also  in order to be more attractive to customers  companies are supposed to have strong ranking from the CMS   which depends on their provision of quality of care and customer service  among other factors  The success of players in the Medicare Advantage market to a great extent depends on their Medicare Star ratings  which can only be achieved by investment in infrastructure  Some of the players that have invested are reaping the benefits  but for others it is imperative to make necessary investments to risk losing out to competitors   Tough Regulatory Oversight to PrevailTough oversight of the Department of Justice  DoJ  led to the death of two mega mergers  Aetna Inc  with Humana inc  and Cigna Corp  with Anthem Inc  These mergers  which were in the form of horizontal combination  would have made the surviving entities to become mammoth players in the insurance market  but would have also nixed competition  While these combinations would have been highly beneficial for these entities from the business point of view  providing them with enough heft and size to bargain with their suppliers and customers  these were perceived to provide little good to the consumer Mergers and consolidation are rife in the sector  triggered by the changing industry environment  which calls for the businesses to grow in size in order to better command the market and remain leaders  and the best way for insurers to achieve this status is to engage in mergers and acquisitions  But these will not be easy to come by  given regulators  opportunities to strip down deals  which would go against the interest of consumers and throttle competition  Thus  the ride may not be easy for insurers on this front Margins to Stay Under PressureMinimum MLR rebate requirements limit the level of margin insurers  can earn in their Commercial Insured  Medicare Insured and Medicaid Insured businesses while leaving them  exposed to higher than expected medical costs  This has kept health insurers  margins under pressure lately  a trend that will likely continue in the coming quarters  A host of factors  including compliance costs related to health care reform regulation  increased fees and taxes  pricing pressure  stiff competition and rising medical costs   are also at play in compressing margins The industry is also witnessing a general shift in patient mix from commercial insurance to government  Medicare  Medicaid and state subsidized marketplace or exchange  which is another major dampener of insurers  profitability  Premiums for Medicare  Medicaid and state subsidized policies tend to be higher due to serious health issues for many enrollees  However  they carry smaller profitability margins compared to commercial insurance High CostRegulatory reforms sweeping through the sector have hit insurers with high compliance costs  Expenditures involved in redoing the internal systems have led to a spike in expenses  There has been huge spending on health information technology   HIT   as the system is going through a challenging transition to electronic medical records  which is expensive and requires expertise Increased Capital Expenditures Health insurers operate in a highly competitive environment in an industry that is subject to significant ongoing changes from marketplace pressures brought about by public policy forces  the ACA  changes to or repeal or replacement of the ACA  Insurance Exchanges  customer demands  demographic shifts  new and expanding health care capabilities  business consolidations  strategic alliances  new market entrants and marketing practices  As a result of these and other factors  their ability to grow profitably through the sale of traditional insured health care and related benefits products in the United States may be limited In order to grow profitably in the future  insurers need to diversify their sources of revenue and earnings and transform their business models  This includes developing and expanding Consumer Health and Services  making investments in consumer engagement capabilities and technology and other services for health systems and provider organizations  including joint ventures  ACOs and collaborative provider networks   optimizing business platforms and expanding internationally Achieving these goals will require significant senior management and capital resources to make acquisitions or other transactions  This required huge capital before any significant revenues or earnings are generated from such initiatives  Stiff CompetitionThe environment is particularly challenging for small insurers  Large employers having operations across states prefer to contract with insurers that can serve all of their employees throughout the country  Scale economies have therefore become imperative for acquiring business  The implication of these trends is an expectation of increasing consolidation Challenges from International OperationsInternational expansion has exposed insurers to political  legal and compliance  operational  regulatory  economic and other risks in foreign countries  A fragile economy in many parts of the world presents another headwind for insurers  One of the largest insurers  UnitedHealth Group  NYSE UNH   made an acquisition to reap benefits from the Brazil market but is now facing slowing growth rates in that country Also  fluctuations in foreign currency exchange rates are likely to have an impact on revenues  operating results and cash flows from international operations To Sum UpContinued uncertainty will command the industry in 2018  Insurers will have to stay on their toes to constantly take stock of their business workings and build a resilient enterprise  This will require an increase amount of investment and talent  Players can only emerge as winners when they act proactively The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2018-01-24,Zacks Investment Research,https://www.investing.com/analysis/zacks-industry-outlook-highlights-aetna-humana-cigna-and-anthem-200283554,200283554
142046,363561,HUM,Amazon Is Building Its Own Healthcare Company  With The Help Of Berkshire   JPMorgan,opinion,"In some market shaking news  e commerce giant Amazon com   NASDAQ AMZN    that they are partnering with Warren Buffett s Berkshire Hathaway  NYSE BRKa   and JPMorgan Chase   NYSE JPM   to build a healthcare company in order to cut costs for their U S  employees and improve worker satisfaction 
As a result  shares of health sector companies are sliding in intraday trading  Insurance players like Anthem   NYSE ANTM    Cigna   NYSE CI    Aetna   NYSE AET    and Humana   NYSE HUM   are all down between 2 5  5 5   while pharmacy giants CVS Health   NYSE CVS    Walgreens Boots Alliance  NASDAQ WBA   and Rite Aid   NYSE RAD   each dipped around 5   Pharmacy benefits manager Express Scripts   NASDAQ ESRX   is down nearly 6  as well 
The goal of the partnership is to create a company with the sole intention of providing healthcare for its workforce  and the future entity will not aim to make a profit  but instead focus on the technology that will provide  simplified  high quality and transparent healthcare  
Amazon  Berkshire  and JPMorgan said that the kind of healthcare to be provided to employees will be long term  and that they hope to bypass the frustration associated with securing healthcare from a third party provider who is ultimately concerned with their own bottom line 
 The ballooning costs of healthcare act as a hungry tapeworm on the American economy   said Berkshire Chairman and CEO Buffett   Our group does not come to this problem with answers  But we also do not accept it as inevitable  
Amazon founder Jeff Bezos said that  Hard as  forming a new healthcare company  might be  reducing healthcare s burden on the economy while improving outcomes for employees and their families would be worth the effort   while JPMorgan s chief executive Jamie Dimon said the ultimate goal is to  create solutions that benefit our U S  employees  their families and  potentially  all Americans  
There have been rumors of an Amazon entry into the pharmacy business for a while now that so called Amazon Effect so this announcement is not entirely a surprise  The healthcare company is still in the  early planning  stages  though there is a temporary management team in place with leaders from each organization 
Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ",2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/amazon-is-building-its-own-healthcare-company-with-the-help-of-berkshire--jpmorgan-200285086,200285086
142047,363562,HUM,Health Care Stocks Tumble On Amazon  Berkshire  JPMorgan Announcement,opinion,"This morning  almost every leading health care stock is coming under major selling pressure  The weakness in the health care stocks comes after an announcement was made by Amazon com  NASDAQ AMZN  boss Jeff Bezos  Berkshire Hathaway  NYSE BRKa  boss Warren Buffett and JPMorgan Chase  NYSE JPM  Chairman Jamie Dimon announced Tuesday morning that they are  partnering on ways to address healthcare for their U S  employees  with the aim of improving employee satisfaction and reducing costs   Leading health care stocks such as UnitedHealth Group Incorporated  NYSE UNH   Aetna  NYSE AET   Cigna Corp  NYSE CI   Humana Inc  NYSE HUM   Express Scripts Holding Co  NASDAQ ESRX   CVS Health  NYSE CVS   and others are tumbling on the announcement 
As traders we must look at this decline in the health care stocks as a trading opportunity  Cigna Corporation  NYSE CI  is an equity that is now on my radar  The daily chart is showing very good support around the  205 00 level  This is where the stock formed a solid chart base in late December before breaking out to new highs  Often  a retest of this area will lead to a solid bounce for the stock  I will be finding more levels for other health care stocks in the coming days  but Cigna Corp  CI  is one stock that has caught my eye right now ",2018-01-30,Nicholas Santiago,https://www.investing.com/analysis/the-bezos-buffett--dimon-announcement-crushes-health-care-stocks-200285191,200285191
142048,363563,HUM,Can Solid Retail Segment Drive Humana s  HUM  Q4 Earnings ,opinion,Humana Inc   NYSE HUM   will report fourth quarter 2017 results on Feb 7  before the market opens The company has an impressive surprise history  It has delivered positive surprises in each of the last four quarters with an average beat of 6 6   Last quarter  the company pulled off a positive earnings surprise of 3 7  backed by solid performance of its Retail segment  Let s see how things are shaping up for this announcement  Humana s retail segment has been performing well over past many quarters driven by the company s Medicare and Medicaid expansion initiatives  The same trend is expected to continue in the fourth quarter as well  This is supported by the Zacks Consensus Estimate of  11 1 billion for the segment s revenues  reflecting 1 6  year over year growth The company s consistent growth in premium revenues has been largely driven by Medical membership growth  Humana has seen solid medical membership increase in its Individual Medicare Advantage and Group Medicare Advantage businesses  The fourth quarter 2017 Zacks Consensus Estimate for total premiums is currently pegged at  12 8 billion  up 1 6  year over year Other FactorsThe company is likely to witness growth in standalone Prescription Drug Plans membership in the fourth quarter  adding significantly to the Medicare business However  Humana has been witnessing a rise benefit expenses over past many years  The same trend is expected to continue in the fourth quarter as well  putting pressure on margins Humana s Individual commercial membership has remained a drag due to the rise in premiums along with benefit redesigns in place since the beginning of 2016  Along with other companies like Aetna Inc   NYSE AET    Anthem Inc   NYSE ANTM    UnitedHealth Group  Inc   NYSE UNH   and many more  Humana has also started scaling down this business and plans to exit it in 2018  This segment is expected to have continued to affect the company s results in the fourth quarter as well  putting pressure on membership and the overall revenue growth Earnings WhispersOur proven model shows that Humana has the right combination of two key ingredients to beat estimates this quarter Zacks ESP  Humana s   which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  0 01   The positive ESP is a leading indicator of a likely earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Humana Inc  Price and EPS Surprise   Zacks Rank  Humana carries a Zacks Rank  3  Hold   Note that stocks with a Zacks Rank  1  Strong Buy   2  Buy  or 3 have a significantly higher chance of beating on earnings  The combination of Humana s favorable Zacks Rank and positive Earnings ESP makes us reasonably confident of an earnings beat  You can see  Conversely  the Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-02-04,Zacks Investment Research,https://www.investing.com/analysis/can-solid-retail-segment-drive-humanas-hum-q4-earnings-200287021,200287021
142067,363582,HUM,Exclusive  State attorneys general joining probe of health insurer mergers,news,"By Diane Bartz WASHINGTON  Reuters    About 15 state attorneys general have joined the Justice Department s probe of two big insurance mergers  according to people familiar with the matter  increasing the scrutiny on proposed deals that would reduce the number of nationwide health insurers to three from five  The formation of a large group to scrutinize Aetna  N AET  Inc s plan to buy  Humana Inc   N HUM  and Anthem Inc s bid for  Cigna Corp   N CI  complicate what is already expected to be a tough and lengthy review by federal antitrust enforcers  Connecticut  Florida  Iowa  Massachusetts and Tennessee are among the states that have joined forces to investigate the proposed deals  according to sources close to the states  who spoke to Reuters over recent days  Antitrust probes are designed to determine if a merger would lead to higher prices or otherwise hurt consumers  The other states participating in the roughly 15 member group could not be learned  The sources asked not to be named because the investigation is not public  The presence of a large number of attorneys general joining a Justice Department probe underscores the hurdles that both proposed combinations face in winning U S  regulatory clearance  Democratic presidential candidate Hillary Clinton  several lawmakers and the American Medical Association  a leading physicians group  have said they feared the pending acquisitions would hurt consumers by leading to higher insurance premiums or limited access to healthcare providers  While it is up to the Justice Department to ultimately decide whether to file a lawsuit to stop a merger  states provide data to the department on how the mergers would affect their jurisdictions and conduct joint calls to gather data from the companies  as well as critics and supporters of the deals  One of the most controversial deals last year  the proposed acquisition of Time Warner Cable  N TWC  by Comcast  O CMCSA   attracted about two dozen state attorneys general who joined the federal antitrust review  Comcast abandoned the plan in the face of regulatory opposition  The chief executive of Anthem  Joseph Swedish  said in an interview that the decision of the state attorneys general to join with the Justice Department was  a good thing    The states created this path with the DOJ  Justice Department  to promote education  engagement  They develop a lot of insights so that when the DOJ does rule  our work with all of these states is probably enhanced quite a bit because we are not starting from scratch   he said  Aetna  separately  voiced confidence in the process   We are confident that our transaction will receive a fair  thorough and fact based review from the Department of Justice and the states   it said in a statement   Humana declined to comment  while Cigna did not immediately respond to a request for comment  Anthem announced in July it would buy Cigna for about  54 2 billion to create the largest U S  health insurer by membership  The announcement came weeks after Aetna struck a  37 billion agreement to buy Humana  Healthcare insurers say that becoming bigger will allow them to squeeze out administrative costs  negotiate with doctors and hospitals and push down the soaring costs of some drugs   But the American Medical Association estimates that 41 percent of U S  metropolitan areas already have a single health insurer with a commercial market share of 50 percent or more  It believes the decrease of nationwide health insurers to three from five would make more regions anticompetitive  The American Antitrust Institute  in a letter to the Justice Department on Monday  said the deals would  substantially lessen competition in numerous health insurance markets    The AAI recommends that the DOJ  just say no  to the two deals that would fundamentally restructure the nation s health insurance markets and create further incentives for  reactive  consolidation in the healthcare supply chain   the group said in the letter  
 This version of the story has been refiled to correct to  said in an interview   not a phone interview  in ninth paragraph ",2016-01-11,Reuters,https://www.investing.com/news/politics-news/exclusive:-u.s.-state-attorneys-general-joining-probe-of-health-insurer-mergers-379612,379612
142068,363583,HUM,Aetna CEO sees Humana deal on track to close this year,news,"By Caroline Humer SAN FRANCISCO  Reuters     Aetna Inc   N AET  Chief Executive Mark Bertolini said on Tuesday that he still expects the company s  37 billion acquisition of rival  Humana Inc   N HUM  to close this year  The deal is being reviewed by the U S  Department of Justice  which has been seeking documents about Aetna s and Humana s business as it assesses how the deal  and a pending  47 billion combination of Anthem Inc  N ANTM  and  Cigna Corp   N CI   could affect consumers    So far  we have nothing to believe it will be any slower than that  or any faster   Bertolini said in an interview at the JP Morgan Healthcare conference  The two proposed mergers would be an unprecedented consolidation of the U S  health insurance industry  and critics have warned it could lead to higher prices for consumers  Insurers say the combinations will give them greater leverage to control rising healthcare costs  Aetna said it expects the regulators to wrap up their document requests in the next month  and then the company will move onto discussions with them and consider any divestitures that might be needed  Aetna and Humana sell health plans for individuals as well as Medicare Advantage plans for seniors  Humana s operations does not overlap with Aetna s large corporate business  U S  antitrust regulators have recently blocked large mergers in a variety of industries  raising questions among investors about whether Aetna s and Anthem s acquisitions will close  Reuters reported on Monday that about 15 state attorneys general have joined the Justice Department s probe into the insurance mergers  potentially complicating what is already expected to be a tough and lengthy review  The government s joint review of both deals has probably increased the breadth and volume of information that Aetna has supplied  Bertolini said  
 If we were to look at 2016 we have two things to do  Deliver our results  and close our deal   he said ",2016-01-12,Reuters,https://www.investing.com/news/stock-market-news/aetna-ceo-sees-humana-deal-on-track-to-close-this-year-379776,379776
142069,363584,HUM,Health insurer Anthem reports lower than expected quarterly profit,news," Reuters    Health insurer Anthem Inc  N ANTM   which is in the process of buying smaller rival  Cigna Corp   N CI   reported a net profit that fell short of analysts  estimates  hampered by weakness in its Obamacare business  While the company s overall enrollment grew by 1 1 million during the year  it lost 118 000 members in its individual business  which sells plans under the Affordable Care Act  Anthem  which operates Blue Cross Blue Shield plans in more than a dozen states  said net profit fell to  180 9 million  or 68 cents per share  in the fourth quarter ended Dec  31  from  506 7 million  or  1 80 per share  a year earlier  The results included net negative adjustment items of 46 cents per share  the company said  Total operating revenue rose to  20 02 billion from  18 78 billion  Analysts were expecting revenue of 19 89 billion according to Thomson Reuters I B E S  On an adjusted basis the company earned  1 14 per share  below the average analyst estimate of  1 20 per share  
Anthem s deal with Cigna and Aetna Inc s  N AET  offer to buy smaller rival  Humana Inc   N HUM  are under heavy scrutiny as they would reduce the number of nationwide health insurers in the United States to three from five ",2016-01-27,Reuters,https://www.investing.com/news/stock-market-news/health-insurer-anthem-reports-higher-quarterly-revenue-381893,381893
142070,363585,HUM,Senate panel to hear from U S  antitrust bosses,news,WASHINGTON  Reuters    The Senate Judiciary Committee s antitrust subcommittee will hear from the top U S  antitrust bosses next month to discuss a wave of big mergers over the past year  according to a staffer briefed on the hearing  The Justice Department s Bill Baer  the assistant attorney general for the antitrust division  and Edith Ramirez  chairwoman of the Federal Trade Commission  will testify  the staffer said  The two divide the work of antitrust enforcement  The hearing will be March 9 at the Senate Judiciary Committee s antitrust panel  which is headed by Senator Mike Lee  a Republican from Utah  One matter that will be taken up is the FTC s use of Section Five  a portion of its authority that it uses to investigate companies which urge rivals to collude with them on price  The agencies are looking at a startling number of major  controversial mergers  The Justice Department is investigating two large insurance mergers    Aetna Inc   N AET  buying  Humana Inc   N HUM  and Anthem Inc buying  Cigna Corp   N CI    to insure they comply with antitrust law  It is also looking at Halliburton  N HAL  Co s purchase of Baker Hughes Inc  among a long list of other deals  The FTC is suing  Staples Inc   O SPLS  in hopes of stopping it from buying Office Depot Inc  It also said in late 2015 that it aimed to stop three mergers of medical centers  one in West Virginia  another in Chicago and a third in Pennsylvania ,2016-02-11,Reuters,https://www.investing.com/news/politics-news/senate-panel-to-hear-from-u.s.-antitrust-bosses-384369,384369
142071,363586,HUM,3 Outperformers From Health Insurance In 2017,opinion,"The year 2017 witnessed a lot of regulatory noise surrounding the Affordable Care Act  ACA   Also  health insurers scaled back their participation due to continued loss on public exchanges  Rising consolidation was another major issue 
The ACA had brought more Americans under health insurance plans  It largely benefitted the industry through a reduction in uninsured population  consequently adding to medical enrollment 
However  everyone was focused on President Trump s decision to abolish the act  Although the ACA is still not repealed  Trump signed the  Tax Cuts and Jobs Act  into law on Dec 22  which would make significant changes to the law 
The tax act ends the  individual mandate    a major component of ACA   that requires individuals to have health insurance or face a penalty fee  In the absence of the individual mandate  healthy people are likely to opt out of medical insurance  The Congressional Budget Office estimates that this would increase the count of uninsured Americans by 13 million and push premiums up by an average of around 10  from 2018 to 2027 
Despite facing stringent regulations  health insurers have shown impressive operating performance in 2017  with most of the top players clocking solid top line  bottom line and membership growth  Companies like WellCare Health Plans Inc    NYSE WCG    Anthem   NYSE ANTM    Humana   NYSE HUM    Centene Corp    NYSE CNC   have kept raising their full year guidance at the end of each quarter  indicating their rising operational excellence 
Increasing consolidation in the health insurance industry has led to a reduction in the number of players  Although the effect of market concentration might not have been good for consumers due to higher medical cost  it has helped the players enhance the scale of their operations and gain market share 
In 2017  although two big merger deals   Anthem with Cigna  NYSE CI  and Humana with Aetna  NYSE AET    have been blocked by the U S  Department of Justice  mergers and acquisitions activities continued to be rife 
The recent merger deal between two of the industry stalwarts   Aetna and CVS Health  NYSE CVS    is worth a mention here  The deal  if finalized  would join two branches of the industry  in this case health insurance and pharmacy benefit management 
However  public exchanges  formed to serve the underprivileged and patients  have not been much profitable for the insurers  They failed to attract sufficient enrollments from healthy and young individuals  which was required to balance the risk return trade off  Health insurers like Humana  Aetna  UnitedHealth and Anthem have already started scaling back their participation from these exchanges after incurring mounting losses 
Increasing operating costs related to regulations  investments in information technology  levy of fees and taxes also weigh on health insurers  margins  The insurers  however  are trying to manage this cost issue with the help of Accountable Care Organizations  ACOs  
Despite the challenges  the  has gained nearly 40 6  for 2017  outperforming the S P 500 average of 20   The HMO industry is among the top 4  of the Zacks Ranked industries 

Stocks in Focus
We zeroed in on three stocks that have outperformed in 2017 and have also seen upward estimate revision in the last 60 days 
Molina Healthcare  Inc    NYSE MOH    a leading health maintenance organization  has rallied 41 3  in 2017  The company has also seen its Zacks Consensus Estimate for 2018 earnings being revised upward by 5 2  in the past 60 days  It has a Growth Score of A  The stock sports a Zacks Rank  1  Strong Buy   You can see  

Centene  a multi national healthcare company of the United States  has gained 78 5  in 2017  The company has also seen its Zacks Consensus Estimate for 2018 earnings being revised upward by 4  in the past 60 days  It has a Growth Score of B  The stock also sports a Zacks Rank  1 

The Joint Corporation   NASDAQ JYNT    another leading managed care company  has gained 87 2  in 2017  The company has also seen its Zacks Consensus Estimate for 2018 earnings being revised upward to 6 cents from break even expected 60 days back  Joint It has a Growth Score of A  The stock carries a Zacks Rank  2  Buy  

Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ",2018-01-03,Zacks Investment Research,https://www.investing.com/analysis/3-outperformers-from-health-insurance-in-2017-200277380,200277380
142072,363587,HUM,The Zacks Analyst Blog Highlights  Anthem  Humana  Centene  Molina Healthcare And Joint,opinion,For Immediate ReleaseChicago  IL   Jan 04  2018   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Anthem   NYSE ANTM    Humana   NYSE HUM    Centene Corp    NYSE CNC    Molina Healthcare  Inc    NYSE MOH   and Joint Corporation   NASDAQ JYNT   Today  Zacks is promoting its   Buy   stock recommendations    Here are highlights from Wednesday s Analyst Blog  3 Outperformers from Health Insurance in 2017The year 2017 witnessed a lot of regulatory noise surrounding the Affordable Care Act  ACA   Also  health insurers scaled back their participation due to continued loss on public exchanges  Rising consolidation was another major issue The ACA had brought more Americans under health insurance plans  It largely benefitted the industry through a reduction in uninsured population  consequently adding to medical enrollment However  everyone was focused on President Trump s decision to abolish the act  Although the ACA is still not repealed  Trump signed the  Tax Cuts and Jobs Act  into law on Dec 22  which would make significant changes to the law The tax act ends the  individual mandate    a major component of ACA   that requires individuals to have health insurance or face a penalty fee  In the absence of the individual mandate  healthy people are likely to opt out of medical insurance  The Congressional Budget Office estimates that this would increase the count of uninsured Americans by 13 million and push premiums up by an average of around 10  from 2018 to 2027 Despite facing stringent regulations  health insurers have shown impressive operating performance in 2017  with most of the top players clocking solid top line  bottom line and membership growth  Companies like Anthem  Humana and Centene Corp  have kept raising their full year guidance at the end of each quarter  indicating their rising operational excellence Increasing consolidation in the health insurance industry has led to a reduction in the number of players  Although the effect of market concentration might not have been good for consumers due to higher medical cost  it has helped the players enhance the scale of their operations and gain market share In 2017  although two big merger deals   Anthem with Cigna  NYSE CI  and Humana with Aetna  NYSE AET    have been blocked by the U S  Department of Justice  mergers and acquisitions activities continued to be rife The recent merger deal between two of the industry stalwarts   Aetna and CVS Health  NYSE CVS    is worth a mention here  The deal  if finalized  would join two branches of the industry  in this case health insurance and pharmacy benefit management However  public exchanges  formed to serve the underprivileged and patients  have not been much profitable for the insurers  They failed to attract sufficient enrollments from healthy and young individuals  which was required to balance the risk return trade off  Health insurers like Humana  Aetna  UnitedHealth and Anthem have already started scaling back their participation from these exchanges after incurring mounting losses Increasing operating costs related to regulations  investments in information technology  levy of fees and taxes also weigh on health insurers  margins  The insurers  however  are trying to manage this cost issue with the help of Accountable Care Organizations  ACOs  Despite the challenges  the  has gained nearly 40 6  for 2017  outperforming the S P 500 average of 20   The HMO industry is among the top 4  of the Zacks Ranked industries Stocks in FocusWe zeroed in on three stocks that have outperformed in 2017 and have also seen upward estimate revision in the last 60 days Molina Healthcare  Inc   a leading health maintenance organization  has rallied 41 3  in 2017  The company has also seen its Zacks Consensus Estimate for 2018 earnings being revised upward by 5 2  in the past 60 days  It has a Growth Score of A  The stock sports a Zacks Rank  1  Strong Buy   You can see  Centene  a multi national healthcare company of the United States  has gained 78 5  in 2017  The company has also seen its Zacks Consensus Estimate for 2018 earnings being revised upward by 4  in the past 60 days  It has a Growth Score of B  The stock also sports a Zacks Rank  1 The Joint Corporation  another leading managed care company  has gained 87 2  in 2017  The company has also seen its Zacks Consensus Estimate for 2018 earnings being revised upward to 6 cents from break even expected 60 days back  Joint It has a Growth Score of A  The stock carries a Zacks Rank  2  Buy  Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now Today  Zacks is promoting its   Buy   stock recommendations   About Zacks Equity ResearchZacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year Follow us on Twitter  Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2018-01-03,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-anthem-humana-centene-molina-healthcare-and-joint-200277610,200277610
142073,363588,HUM,Humana Extends Contract With Tivity Health  Spurs Healthcare,opinion,Humana Inc    NYSE HUM   recently announced that it has extended the existing partnership with Tivity Health  Inc    NASDAQ TVTY   through Dec 31  2022  Per the terms of the alliance  Humana would offer Tivity Health s SilverSneakers fitness program to its Individual Medicare Advantage and Group Medicare Advantage members What is SilverSneakers Tivity Health s SilverSneakers  founded in 1992  is an overall wellness program offered to Medicare eligible and group retiree members of participating health plans  It offers a variety of options for all fitness levels and abilities with access to exercise equipments  classes and fun social activities at thousands of locations across the nation Apart from Humana  another leading health insurer   UnitedHealth Group Inc    NYSE UNH      has also been providing Tivity Health s SilverSneakers programs to its members What Aids Humana Humana is associated with SilverSneakers since 2004  The company has been successful in significantly motivating its Medicare Advantage members to actively improve their physical health  The extension of the alliance enables Humana to remain committed toward its Medicare Advantage members in order to help them achieve their best health Humana s constant approach toward connecting health and lifestyle has led it to include SilverSneakers as a key element in many of its Medicare Advantage plans to take care of one s complete health with both physical benefits and social enrichment The pact with SilverSneakers reflects the company s focus on preventive healthcare  which benefits both the consumers and the company   Preventive healthcare saves the consumers from serious sickness by educating them about various health precautionary measures  The company  on the other hand  gains from lower medical cost due to healthier consumers  which reduces its claim cost Recent Alliances or PactsHumana has always been engaged in building strategic partnerships to improve the health of its Medicare Advantage members  In August 2017  the company joined forces with biotechnology company Amgen Inc   NASDAQ AMGN   to improve health outcomes and efficiency  Prior to that  in July 2017  the company partnered with Oscar Health to offer commercial health insurance to small businesses in a nine county Nashville area Share Price PerformanceAlthough  last year  shares of Humana have gained 29 3   underperforming the  s rally of 43 2   its strategic initiatives are likely to favor the stock going forward Zacks Rank                      Humana carries a Zacks Rank  3  Hold   You can see    Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-01-09,Zacks Investment Research,https://www.investing.com/analysis/humana-extends-contract-with-tivity-health-spurs-healthcare-200279159,200279159
142074,363589,HUM,Higher Optum Revenues To Drive UnitedHealth  UNH  Q4 Earnings,opinion,"We believe UnitedHealth Group Inc  s   NYSE UNH   health services business named  Optum  will be a key driver for fourth quarter earnings  Notably  Optum serves the global health care marketplace including payers  care providers  employers  governments  life sciences companies and consumers The company is investing in this segment with an aim to diversify earnings and seek protection from the highly regulated health services business  which has been significant for the company   Its revenue CAGR of 21  from 2011 to 2017  on the basis of expected revenues  is impressive  Per the Zacks Consensus Estimate  revenues from this segment would be  23 98 billion  which translates into year over year growth of 8 2  Revenue growth from this segment is expected to be driven by increased contribution from each of its sub segments namely OptumHealth  OptumInsight and Optum Rx At OptumHealth  the top line should be aided by growth and market expansion in care delivery as well as increase in consumer health engagement products and services  behavioral health services and health financial services  Also  rise in number of consumers served and an improvement in average revenue per consumer will contribute to the segment s revenues  Per the Zacks Consensus Estimate  revenues of  5 4 billion represents 18 8  growth year over year Meanwhile OptumInsight s revenues will see accretion from growth in business process management services and data analytics  In fact  this segment has been witnessing an increase in revenue backlog  which reflects strong demand for its solutions  The trend is expected to continue in the fourth quarter as well  The Zacks Consensus Estimate for revenues is pegged at  2 24 billion  up 7 9  year over year OptumRx  the company s pharmacy management arm  has achieved sufficient scale in the PBM business from the acquisition of pharmacy benefit manager   Catamaran   in 2015  Revenues in this segment have been increasing over the past many quarters owing to acquisitions and organic growth  In the fourth quarter  we expect revenue growth from a surge in adjusted script grown  The Zacks Consensus Estimate for the fourth quarter revenues is pegged at  16 5 billion  up 4 1  year over year UnitedHealth s solid market share  growing Optum business  diversified premium revenue and disciplined capital management are also anticipated to aid overall earnings   Read more   Zacks Rank and Stocks That Warrant a LookUnitedHealth carries a Zacks Rank  3  Hold   Here are a few companies worth considering with the right combination of elements to deliver an earnings beat this quarter   
Centene Corp    NYSE CNC   is expected to report fourth quarter earnings performance on Feb 6  The company has an Earnings ESP of  0 25  and a Zacks Rank of 1  Strong Buy   You can see Anthem Inc    NYSE ANTM   has an Earnings ESP of  1 36  and a Zacks Rank  2  Buy   The company is expected to release fourth quarter earnings results on Jan 31 Humana Inc    NYSE HUM   has an Earnings ESP of  2 5  and a Zacks Rank  2  The company is expected to announce fourth quarter earnings results on Feb 7 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-01-14,Zacks Investment Research,https://www.investing.com/analysis/higher-optum-revenues-to-drive-unitedhealth-unh-q4-earnings-200280393,200280393
142075,363590,HUM,UnitedHealth  UNH  Beats On Q4 Earnings  Revises 2018 View,opinion,"UnitedHealth Group Inc    NYSE UNH   came up with earnings of  2 59 per share  beating the Zacks Consensus Estimate of  2 50  Earnings also rose 22 7  year over year 
Higher revenues  strength in both its segments  UnitedHealthcare and Optum  and membership growth led to the outperformance 
UnitedHealth has a tradition of guiding conservatively and then beating its own estimates to surprise investors 
The stock gained 3 54  in the pre market trading session and we expect earnings outperformance to drive the stock higher 
Beneficiary of Tax Reform
The company enjoyed a non cash benefit of  1 22 per share from the revaluation of its net deferred tax liability  as a result of the recent tax reform UnitedHealth Group Incorporated Price  Consensus and EPS Surprise   Behind the Headlines
UnitedHealth recorded revenues of  52 1 billion  which surpassed the Zacks Consensus Estimate of  51 5 billion  Also  it compared favorably with the year ago number of  47 5 billion 
Total operating cost of  48 1 billion increased 8 4  year over year  due to a surge in medical cost 
Net margin of 6 9  increased from 3 5  in the year ago quarter 
Strong Performance Across Segments
In the reported quarter  the company s health benefits segment  UnitedHealthcare  reported revenues of  41 6 billion  up 9 6  year over year  Earnings from operations increased 26  year over year to  1 8 billion 
Revenues from Optum improved 10  year over year to  24 4 billion  reflecting strong contribution from subsegments OptumHealth and OptumInsight as well as OptumRx  Earnings from operations surged 23 8  year over year to  2 2 billion  Continued focus on accelerating growth as well as improving margins and productivity through enhanced integration and business alignment led to the overall improvement of this segment 
Membership Enrollment Surges
The company s medical enrollment grew 1 9  year over year to 49 5 million  led by growth in members served in the Public and Senior segment  partially offset by lower Commercial and International membership 
Capital Position Improves
Cash and short term investments at quarter end were  15 5 billion  up 16 7  from the 2016 end level 
Debt to total capital ratio was 38 9  at Dec 31  2017  down 740 basis points year over year 
Cash flows from operations were  13 6 billion  up 39  year over year 
Guidance Update
UnitedHealth revised its 2018 financial outlook to reflect the effects of the U S  corporate tax law changes  It now expects 2018 net earnings of  11 65 to  11 95 per share and adjusted net earnings of  12 30 to  12 60 per share  Cash flows from operations are expected to range from  15 billion to  15 5 billion 
Other Stocks That Warrant a Look
UnitedHealth  with a Zacks Rank  3  Hold   has got this reporting cycle off to a flying start  While the other players in the space are lined up to report their financial results  below are three that are poised to beat on earnings as per our model 
Centene Corp    NYSE CNC   is expected to report fourth quarter earnings results on Feb 6  The company has an Earnings ESP of  0 25  and a Zacks Rank of 1  Strong Buy   You can see the complete list of today s Zacks  1 Rank stocks here 
Anthem Inc    NYSE ANTM   has an Earnings ESP of  1 36  and a Zacks Rank  2  Buy   The company is expected to release fourth quarter earnings results on Jan 31 
Humana Inc    NYSE HUM   has an Earnings ESP of  0 44  and a Zacks Rank  1  The company is expected to announce fourth quarter earnings results on Feb 7 
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-01-15,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-unh-beats-on-q4-earnings-revises-2018-view-200280732,200280732
142101,363616,HUM,Cigna CEO defends Anthem deal  says consumer will still have choice,news,By Caroline Humer NEW YORK  Reuters    Health insurer Anthem s planned  47 billion takeover of rival Cigna  NYSE CI  will not hurt consumers but increase choice and affordability  Cigna CEO David Cordani said  defending the merger against widespread criticism that it will harm competition  The Anthem Cigna deal and a plan by  Aetna Inc   NYSE AET  to buy Humana  NYSE HUM  have come in the wake of the implementation of the Affordable Care Act and amid pressure on insurers to keep healthcare spending down for their biggest customers   employers and the U S  government    It s going to increase choice  not decrease choice  It s going to increase affordability  not decrease affordability   Cordani told Reuters in an interview  saying results oriented contracts with doctors and hospitals would help consumers be healthier and trim medical spending  Cordani said the biggest overlap in a combination of their  115 billion businesses is their large employer based divisions and asset sales may be necessary to win regulatory approval  though he expects that would only be on a limited basis   Divestitures through the DOJ process should be modest and manageable  And we ve leaned on the conservative side of the business case that supports this   he said  but added it was too early to say what might be offered up  About 150 million Americans get their health insurance through their employers  many of which are large companies  In the past few weeks  both the American Medical Association and the American Hospital Association have issued written criticisms of the deal  Congress held a hearing on insurer competition last week and another hearing is scheduled in the Senate next week in which Anthem CEO Joseph Swedish and Aetna CEO Mark Bertolini are scheduled to appear  The company expects the Department of Justice review to take 12 to 18 months during which it will look at the extent of their overlap in market share for Medicaid for the poor  Medicare Advantage for seniors  individual insurance  small employers and large employers  Cordani said the detailed nature of the review would show few competitive issues  There was little geographical overlap in their Medicaid and Medicare businesses and he is also not anticipating issues with the individual business  where Cigna is a new player  nor with small employer based plans  He added that insurers would not see outsized benefits from cutting costs through their combinations because customers typically demand that spending savings be passed onto them  So far  Cordani said  employers have been optimistic that the combination will enable them to combine the results oriented care management programs for diseases like diabetes that Cigna has used to cut healthcare spending in Medicare and commercial plans  and combine them with the Anthem s strong Blue Cross Blue Shield networks   Within that  there may be deemed by the DOJ some overlap that is not acceptable and we ll deal with that   he said  On branding  he said that in a state like Georgia  where Cigna and Anthem both operate  the companies can continue with their Cigna and Anthem branded plans and designs ,2015-09-17,Reuters,"https://www.investing.com/news/stock-market-news/cigna-ceo-defends-anthem-deal,-says-consumer-will-still-have-choice-362027",362027
142102,363617,HUM,Antitrust lawmakers express concern about insurance mergers,news,"By Diane Bartz WASHINGTON  Reuters    Republican and Democratic lawmakers expressed concern about two multi billion dollar insurance mergers on Tuesday  using a Senate hearing to take issue with the companies  arguments that they face expanding competition from new rivals  Senator Mike Lee  a Republican from Utah who chairs the Senate Judiciary Committee s antitrust subcommittee  said he was worried that consumers would be  locked into the offerings of a few dominant companies    The hearing was called to discuss Anthem Inc s planned  47 billion takeover of rival  Cigna Corp   NYSE CI  and Aetna  NYSE AET  Inc s plan to buy rival  Humana Inc   NYSE HUM  for about  37 billion  The deals  announced in July  would reduce the number of nationwide insurers from five to three  The companies argue that their deals should be uncontroversial because they have little overlap  Overall  Aetna serves 46 million people on the commercial market while Humana has 14 million customers who are mainly served through Medicare Advantage  Anthem  the largest Blue Cross Blue Shield health plan  has 38 million customers in a diversified network while Cigna insures 14 million people  mostly through large corporate employers  The CEOs of Aetna  Mark Bertolini  and Anthem  Joseph Swedish  argued that they were facing growing competition from a variety of avenues  Senator Richard Blumenthal  a Democrat from Connecticut  disagreed and noted that earlier mergers had pushed prices up  saying   These mergers may be the triumph of hope over experience   I m deeply troubled by evidence that shows that neither providers nor consumers benefit  from consolidation    he said  Swedish argues that  competition is becoming more robust and not less   pointing to a two year old insurance company Oscar  which has 40 000 members    What I can share with you is that there are many new players who have entered the market   he said   Nationally  premiums paid for employer sponsored health insurance rose 4 percent in 2015 and workers are paying sharply higher deductibles  the Kaiser Family Foundation Health Research   Educational Trust said on Tuesday  Both Lee and Senator Amy Klobuchar  the top Democrat on the panel  pressed the companies on why they decided not to expand their existing operations but instead opted to buy a rival  
Both said it was cheaper and faster to merge  and that speed mattered   In that regard  this economic combination makes a lot of sense for us because we can get to market faster   said Anthem s Swedish ",2015-09-22,Reuters,https://www.investing.com/news/politics-news/antitrust-lawmakers-express-concern-about-insurance-mergers-362843,362843
142103,363618,HUM,Clinton has  serious concerns  about Aetna Humana  Anthem Cigna mergers,news,"By Amanda Becker WASHINGTON  Reuters    Democratic presidential candidate Hillary Clinton has  serious concerns  about health insurer Aetna s plan to acquire Humana and Anthem s proposal to buy Cigna  saying the multi billion dollar deals should be closely reviewed by U S  regulators  Stocks of the health insurers fell at least over 5 percent after Clinton said she was  very skeptical  the mergers would be good for consumers  A  37 billion plan for  Aetna Inc   N AET  to acquire smaller rival  Humana Inc   N HUM  approved by the shareholders of both companies this week would make Aetna the largest provider of Medicare Advantage plans for the elderly  Anthem Inc  N ANTM  agreed over the summer to acquire  Cigna Corp   N CI  in a  47 billion deal that would make it the largest U S  health insurer by membership  Clinton said she was  very skeptical  the mergers would be good for consumers  Both deals  which would reduce the number of nationwide for profit health insurers from five to three  are being closely reviewed by the U S  Department of Justice and state insurance regulators  and have been the subject of hearings in the U S  Congress   As we see more consolidation in health care  among both providers and insurers  I m worried that the balance of power is moving too far away from consumers   Clinton said in a statement    These mergers should be scrutinized very closely with an eye to preventing the undue concentration that they appear to create   Clinton added  Clinton  the frontrunner for the Democratic nomination  has over the past month detailed how she would reduce healthcare costs for consumers if she wins the White House in November 2016  Cigna stock fell more than 8 percent  and Humana shares tumbled over 7 percent  Aetna s stock dropped over 6 percent and Anthem shares fell by over 5 percent  Clinton has taken aim at the pharmaceutical industry for what she calls  price gouging  and said she would cap out of pocket prescription costs at  250 per month  Insurers say mergers will help them compete in the market as the government tries to rein in healthcare spending following the implementation of President Barack Obama s signature healthcare law  the Affordable Care Act  Anthem is  engaged in a constructive and transparent dialog  with regulators about how the Cigna transaction would lead affordable care and robust competition  spokeswoman Jill Becher said  
 Aetna is focused on evolving the health care industry to a new model   Aetna spokeswoman Cynthia Michener wrote in a statement  saying the Humana deal would create  positive change  in the marketplace ",2015-10-21,Reuters,"https://www.investing.com/news/politics-news/clinton-has-'serious-concerns'-about-aetna-humana,-anthem-cigna-mergers-367258",367258
142104,363619,HUM,U S  judge rules for SEC in fight with House panel over insider trading probe,news,"By Nate Raymond NEW YORK  Reuters    A U S  House of Representatives panel and a former staffer must comply with subpoenas issued by the U S  Securities and Exchange Commission as part of an insider trading probe  a federal judge has ruled  U S  District Paul Gardephe in Manhattan  in a decision made public on Monday  said the House Ways and Means Committee must produce some documents to the SEC  and Brian Sutter  a former staff director for its healthcare subcommittee  must be deposed  The decision came 16 months after the SEC first went to court over the committee s refusal to provide information as part of a probe of whether Sutter leaked material non public information about Medicare reimbursement rates to a lobbyist  The ruling came in one of the first publicly disclosed probes by federal authorities invoking provisions of a 2012 law called the STOCK ACT  which seeks to prevent people from using  political intelligence  to trade non public information  Both the SEC and federal prosecutors in Manhattan have launched investigations related to the alleged leak  according to court and congressional records  The House committee had resisted complying with the SEC s demands for information  arguing in part that the U S  Constitution shielded the panel and Sutter from being compelled to testify or produce documents  Gardephe ruled that while the House was protected from producing some legislative documents  some documents could be produced  including administrative or personal communications between Sutter and the lobbyist s firm  Greenberg Traurig LLP  Gardephe said the House must also produce Sutter s telephone records  with some redactions  and that the former staffer himself can be deposed  An SEC spokeswoman declined to comment  Representatives for the House and Sutter did not immediately respond to requests for comment  According to court filings  the SEC has been looking into an email a lobbyist at Greenberg Traurig sent to broker dealer Height Securities regarding a deal struck in Congress about Medicare rates in 2013  The SEC said the email was sent before the Centers for Medicare and Medicaid Services announced the rates after U S  markets closed  and about 30 minutes before Height issued a report suggesting the change could help companies such as  Humana Inc   N HUM  and Health Net Inc  Sutter  on the day of the announcement  had been emailing the Greenberg Traurig lobbyist about the termination of a client from the Medicare program  and they had spoken on the phone  the SEC said  
The case is SEC v  Committee on Ways and Means of the U S  House of Representatives et al  U S  District Court  Southern District of New York  No  14 mc 00193 ",2015-11-16,Reuters,https://www.investing.com/news/politics-news/u.s.-judge-rules-for-sec-in-fight-with-house-over-insider-trading-probe-371472,371472
142105,363620,HUM,UnitedHealth may exit Obamacare individual exchanges,news,By Caroline Humer  Reuters    UnitedHealth Group Inc  N UNH  raised new questions about the viability of Obamacare on Thursday  saying that in 2017 it might stop selling individual plans on the insurance exchanges created under U S  President Barack Obama s healthcare law  The largest U S  health insurer cited weak enrollment and high medical costs for people who did sign up  Rivals  Aetna Inc   N AET  and Anthem Inc said last month that they were seeing too few people enroll but have not signaled they would exit the business   We cannot sustain these losses   UnitedHealth Chief Executive Stephen Hemsley said during a conference call with investors   We can t really subsidize a marketplace that doesn t appear at the moment to be sustaining itself   A deterioration in the exchanges in the midst of the 2016 election campaign could provide additional fuel to Republican efforts to overturn the healthcare law  Several of Obama s fellow Democrats are also considering changes to the Affordable Care Act  including whether to alter the  Cadillac tax   a levy on high cost health plans sponsored by employers   The U S  government said that the exchanges were continuing to grow and giving millions of Americans access to affordable insurance    Every day  tens of thousands more Americans turn to the Health Insurance Marketplace for health coverage and even more return to the Marketplace for another year   U S  Department of Health and Human Services spokesman Ben Wakana said in a statement  Enrollment opened earlier this month   UnitedHealth shares fell 5 5 percent on Thursday  while Aetna lost 7 2 percent  and Anthem dropped 6 4 percent  Shares of hospital operators  which had benefited in recent years from an increase in insured patients  also fell  with HCA Holdings Inc down 5 9 percent and Community Health Systems down 8 5 percent   UnitedHealth has about 500 000 members with Obamacare plans  making it the fourth largest insurer on the exchanges  On Thursday  the company said it expected these plans to hurt current quarter profit by  425 million  or 26 cents per share  As a result  the company said it cut its full year earnings forecast to  6 per share from a previous range of  6 25 to  6 35   UnitedHealth also said it was pulling back on 2016 advertising  For next year  it forecast earnings of  7 10 to  7 30 per share  Analysts on average are expecting  7 28  according to Thomson Reuters I B E S  The company plans to evaluate during the first half of next year whether it would continue to offer Obamacare plans in 2017  More than 9 million people are enrolled through the exchanges  which operate in each of the 50 states and the District of Columbia  The majority of the policyholders receive some level of government subsidy to help pay for the plans  based on household income  The government recently estimated that 10 million people would enroll in 2016   NEW COST CONCERNS Just a month ago  UnitedHealth said that it was expecting substantial improvement for the Obamacare business in 2016  Hemsley said that since then  the enrollment picture has become worse  and it has become clearer that the medical costs of new customers were unsustainable   UnitedHealth had entered a small number of markets in 2014  the first year that the exchanges opened  but began selling plans in about two dozen states in 2015  It is still a smaller player on these markets than Anthem  Aetna and  Humana Inc   N HUM    Insurers had criticized the exchanges before they opened  due to technology problems tied to the federal government run HealthCare gov website and concerns about the cost of covering customers who might be sicker than the general population   The Obama administration mitigated some of that risk in the first year with payments to insurers  but that funding has since declined  About a dozen nonprofit cooperative health plans that sold plans on the exchanges have collapsed   Consumers have also criticized plans for requiring them to meet high deductibles out of pocket before their coverage kicks in  as well as steep increases in monthly premiums from year to year   UnitedHealth said the rest of its business continued to perform in line with its expectations   If exchange pricing risk does not stabilize near term   Susquehanna analyst Chris Rigg wrote in a note   we d expect a quick rebound in profits as  UnitedHealth  exits this business line  ,2015-11-19,Reuters,https://www.investing.com/news/politics-news/unitedhealth-may-exit-obamacare-individual-exchanges-372130,372130
142106,363621,HUM,4 Attractive Stocks To Buy In An Evolving Healthcare Space,opinion,"The healthcare sector has been under the spotlight for quite some time for a host of reasons  regulatory uncertainty  increasing consumerism and consolidation being the most prominent 
The recent deal of merger between two of the industry stalwarts Aetna Inc    NYSE AET   and CVS Health  NYSE CVS   once again points to increased activity in healthcare  The deal also testifies to the trend of joining two branches of the industry  in this case health insurance and pharmacy benefit management  to achieving diversification and economies of scale for affordable and convenient care 
Increasing Consolidation in Healthcare
Changing demographics  increasing regulatory restrictions  growing consumerism  need to control cost and attain speedier growth have necessitated unprecedented mergers and acquisitions in all subsectors of healthcare like hospitals  insurance and pharmaceutical 
The changing nature of the healthcare industry has encouraged companies to spread their operations so as to provide a bouquet of products and services and save cost at each touchpoint  The recent deal between Aetna and CVS Health is an excellent example of this  It qualifies as vertical integration  which would enable the surviving company to sell a range of services and products from drug to insurance cover 
A similar deal was made in 2015  when another insurance major UnitedHealth Group  NYSE UNH  acquired Catamaran  a pharmacy benefit management company  The acquisition has proved highly accretive to UnitedHealth Group and contributed meaningfully to its results 
Changing demographics  which has resulted in an increase in the baby boomer population  which has fueled demand for Government programs such as Medicare and Medicaid  has also led to a number of mega mergers in the industry in recent years  The failed mergers of Anthem Inc  with Cigna Corp  NYSE CI   and Humana Inc  NYSE HUM   with Aetna Inc  also belonged to this bracket 
Who Is the Real Gainer 
Increasing consolidation has led to a reduction in the number of players  greater market concentration and reduced competition  and increasing barriers of entry in the industry 
Though there s a bit of ambiguity as to whether increasing consolidation has brought about welfare  in real terms  for consumers  However  the companies certainly stand to benefit from their increased size  putting them in a powerful position to negotiate with suppliers and consumers 
U S  healthcare is a highly sensitive issue that has been gaining huge attention  Healthcare expenditure has been on the rise and though ways are being devised to control costs  a reversal in trend seems difficult to achieve  Companies in this space are thus set to thrive given continued demand for better healthcare needs 
Attractive Stocks to Pick
We therefore point out some stocks in the space that carry a strong Zacks Rank  2  Buy  and have outperformed the  s decline of 0 6  so far this year  Adding these stocks to an investment portfolio will fetch smart returns 
CareDx Inc    NASDAQ CDNA   develops  markets and delivers a diagnostic surveillance solutions for heart transplant recipients  So far this year  the stock has returned a staggering 140 4   The long term expected earnings growth rate for the company is 20   It carries a Growth Style Score of B and a Zacks Rank  2  You can see   

PRA Health Sciences  Inc    NASDAQ PRAH   operates as a global contract research organization  providing outsourced clinical development services to the biotechnology and pharmaceutical industries  It carries a Growth Style Score of B and a Zacks Rank  2  This year  the stock has rallied 47   The long term expected earnings growth rate for the company is 18  

Diplomat Pharmacy  Inc    NYSE DPLO   operates as an independent specialty pharmacy in the United States  It aids in the dispensing  delivery  dosing and reimbursement of clinically intensive and specialty drugs  It carries a Growth Style Score of A and a Zacks Rank  2  This year  the stock has returned 45   The long term expected earnings growth rate for the company is 6 7  ",2017-12-06,Zacks Investment Research,https://www.investing.com/analysis/4-attractive-stocks-to-buy-in-an-evolving-healthcare-space-200271092,200271092
142107,363622,HUM,The Zacks Analyst Blog Highlights  Aetna  CareDx  PRA Health Sciences And Diplomat Pharmacy,opinion,For Immediate ReleaseChicago  IL   Dec 7  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Aetna Inc    NYSE AET    CareDx Inc    NASDAQ CDNA    PRA Health Sciences  Inc    NASDAQ PRAH   and Diplomat Pharmacy  Inc    NYSE DPLO   Today  Zacks is promoting its   Buy   stock recommendations   Here are highlights from Wednesday s Analyst Blog  4 Attractive Stocks in an Evolving Healthcare Space The healthcare sector has been under the spotlight for quite some time for a host of reasons  regulatory uncertainty  increasing consumerism and consolidation being the most prominent The recent deal of merger between two of the industry stalwarts Aetna Inc  and CVS Health  NYSE CVS   once again points to increased activity in healthcare  The deal also testifies to the trend of joining two branches of the industry  in this case health insurance and pharmacy benefit management  to achieving diversification and economies of scale for affordable and convenient care Increasing Consolidation in HealthcareChanging demographics  increasing regulatory restrictions  growing consumerism  need to control cost and attain speedier growth have necessitated unprecedented mergers and acquisitions in all subsectors of healthcare like hospitals  insurance and pharmaceutical The changing nature of the healthcare industry has encouraged companies to spread their operations so as to provide a bouquet of products and services and save cost at each touchpoint  The recent deal between Aetna and CVS Health is an excellent example of this  It qualifies as vertical integration  which would enable the surviving company to sell a range of services and products from drug to insurance cover A similar deal was made in 2015  when another insurance major UnitedHealth Group  NYSE UNH  acquired Catamaran  a pharmacy benefit management company  The acquisition has proved highly accretive to UnitedHealth Group and contributed meaningfully to its results Changing demographics  which has resulted in an increase in the baby boomer population  which has fueled demand for Government programs such as Medicare and Medicaid  has also led to a number of mega mergers in the industry in recent years  The failed mergers of Anthem Inc  with Cigna Corp  NYSE CI   and Humana Inc  NYSE HUM   with Aetna Inc  also belonged to this bracket Who Is the Real Gainer Increasing consolidation has led to a reduction in the number of players  greater market concentration and reduced competition  and increasing barriers of entry in the industry Though there s a bit of ambiguity as to whether increasing consolidation has brought about welfare  in real terms  for consumers  However  the companies certainly stand to benefit from their increased size  putting them in a powerful position to negotiate with suppliers and consumers U S  healthcare is a highly sensitive issue that has been gaining huge attention  Healthcare expenditure has been on the rise and though ways are being devised to control costs  a reversal in trend seems difficult to achieve  Companies in this space are thus set to thrive given continued demand for better healthcare needs Attractive Stocks to PickWe therefore point out some stocks in the space that carry a strong Zacks Rank  2  Buy  and have outperformed the  s decline of 0 6  so far this year  Adding these stocks to an investment portfolio will fetch smart returns CareDx Inc  develops  markets and delivers a diagnostic surveillance solutions for heart transplant recipients  So far this year  the stock has returned a staggering 140 4   The long term expected earnings growth rate for the company is 20   It carries a Growth Style Score of B and a Zacks Rank  2  You can see  PRA Health Sciences  Inc  operates as a global contract research organization  providing outsourced clinical development services to the biotechnology and pharmaceutical industries  It carries a Growth Style Score of B and a Zacks Rank  2  This year  the stock has rallied 47   The long term expected earnings growth rate for the company is 18  Diplomat Pharmacy  Inc  operates as an independent specialty pharmacy in the United States  It aids in the dispensing  delivery  dosing and reimbursement of clinically intensive and specialty drugs  It carries a Growth Style Score of A and a Zacks Rank  2  This year  the stock has returned 45   The long term expected earnings growth rate for the company is 6 7  Today  Zacks is promoting its   Buy   stock recommendations   About Zacks Equity ResearchZacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year Follow us on Twitter  Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2017-12-06,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-aetna-caredx-pra-health-sciences-and-diplomat-pharmacy-200271339,200271339
142108,363623,HUM,Anthem Buys HealthSun To Expand Medicare Business In Florida,opinion,"Anthem  Inc    NYSE ANTM   has completed the acquisition of HealthSun  one of the fastest growing integrated Medicare Advantage health plans and health care delivery networks in Florida Financial terms of the transaction were kept under wraps and the consolidation is expected to be slightly accretive to the company s earnings in 2018 Benefits for AnthemHealthSun is a perfect fit for Anthem given its rapidly expanding Medicare Advantage  MA  business with vast presence in Florida  the state which houses a large retiree population Anthem should benefit from HealthSun s superior health care services through an effective network of primary care clinics  pharmacy support and transportation services plus a narrow network of physician specialists and integrated medical cost management The acquisition aligns with Anthem s long term strategy to grow in the thriving Government business  The integration will allow the company to serve more than 650 000 members in Florida Share Price PerformanceYear to date  the stock has surged 59  outperforming the  s growth of 43   Given its progress on fundamentals  the recently inked buyout deal should keep alive the momentum in the stock going forward Industry TrendMedicare Advantage  a private version of the Government sponsored health insurance for retirees  which provides extra benefits and services to senior citizens  has been in huge demand of late from the rising population of baby boomers A number of small and big acquisitions have been witnessed by the industry with the involved parties scrambling to grow this line of business  Some notable takeovers are Cigna Corp  s   NYSE CI   acquisition of HealthSpring and UnitedHealth Inc  s   NYSE UNH   buyout of XL Health Inc The unsuccessful mergers of recent times namely Anthem Inc  s with Cigna Corp  and Aetna s with Humana Inc    NYSE HUM   were also aimed at expanding the Medicare Advantage business Our TakeThe above mentioned deal comes as no surprise to us  given the company s desire to flourish in the lucrative MA business  This deal will boost the company to progress in the business line  especially after its blocked merger with Cigna  which could have elevated it as a leading player in the MA market   The company is also on track to acquire America s 1st Choice  a privately held Medicare Advantage organization for profit offering HMO products including Chronic Special Needs Plans  C SNP  and Dual Eligible Special Needs Plans in Florida The company is aggressively seeking to put its capital to fruitful use and is readily open for attractive acquisitions and we expect to hear more from its end on these lines Anthem carries a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-12-21,Zacks Investment Research,https://www.investing.com/analysis/anthem-buys-healthsun-to-expand-medicare-business-in-florida-200275395,200275395
142134,363649,HUM,Anthem set to announce deal for Cigna this week  source,news,"By Greg Roumeliotis  Reuters    Health insurer Anthem Inc is close to finalizing negotiations to acquire peer Cigna  NYSE CI  Inc and could announce a roughly  48 billion deal as early as this week  according to a person familiar with the matter  Most issues that were preventing a deal  such as price and the role of Cigna Chief Executive David Cordani  have been resolved  the person said  without offering details  Anthem has slightly improved on its previous cash and stock offer of  184 per share  the person added  The Wall Street Journal earlier reported that Anthem was nearing an agreement to pay about  187 per share for Cigna  Anthem and Cigna did not immediately respond to requests for comment   Cigna shares jumped 6 5 percent in after hours trading to  161 while Anthem s shares were marginally lower after closing at  155 10 on Wednesday  A merger between the two health insurers would follow Aetna  NYSE AET  Inc s deal to buy  Humana Inc   NYSE HUM  for  37 billion  part of an industry consolidation following the Supreme Court s decision to uphold the Obamacare reforms  
Anthem said in June that it had made several offers for Cigna but a deal had been delayed due in part to differences over who would lead the company and corporate governance  Cigna also said it was concerned that other members of the Blue Cross Blue Shield Association would be an obstacle ",2015-07-22,Reuters,https://www.investing.com/news/stock-market-news/health-insurer-anthem-nears-$48-billion-deal-to-buy-cigna:-wsj-352497,352497
142135,363650,HUM,Anthem to buy Cigna to create biggest U S  health insurer,news,"By Ankur Banerjee and Ransdell Pierson  Reuters    Anthem Inc said on Friday it would buy  Cigna Corp   NYSE CI  for about  54 2 billion  a deal that would create the largest U S  health insurer by membership and accelerate the consolidation of an industry from five national players to three  The proposed acquisition   the biggest ever in the health insurance industry   comes three weeks after  Aetna Inc   NYSE AET  agreed to buy  Humana Inc   NYSE HUM  for  37 billion   Health insurers are finding it tougher to raise prices following the roll out of President Barack Obama s healthcare law  while grappling with soaring costs for a growing list of innovative new medications such as some new cancer drugs that cost  100 000 annually for patients   State insurance regulators and federal antitrust authorities are expected to aggressively scrutinize how both of the proposed health insurer acquisitions will affect competition for Medicare and individual and commercial insurance  Under the deal  which the companies expect to close in the second half of 2016  Anthem Chief Executive Joseph Swedish would serve as CEO and Chairman of the combined company  Cigna CEO David Cordani would be president and Chief Operating Officer  In a joint conference call with industry analysts  Swedish said that Anthem has had no discussions  at all  with regulators ahead of the deal announcement  but was confident it will receive their approval  Shares of Cigna on Friday were trading at  147 64  far below their  188 per share value under the announced deal  suggesting significant Wall Street skepticism over whether it will survive antitrust scrutiny    Strategically and financially it s very attractive  but they will face regulatory scrutiny   said Ana Gupte  analyst with Leerink Partners   They also both possibly face divestitures and may have to make concessions to consumers to make the merger go through   The same apparent wariness of approval has been seen with Aetna s planned purchase of Humana  Humana shares are trading in the  183 range  well below the value of Aetna s cash and stock offer of  230 per share when it was first announced   Both Anthem and Cigna would be liable to pay the other a fee equivalent to 3 8 percent of the deal s value if either of them walk away from the planned merger  BIGGER THAN UNITEDHEALTH Anthem and Cigna are two of just four major insurers that administer self insured plans for major companies  The other two are UnitedHealth Group Inc  NYSE UNH  and Aetna  The combined company would have about 53 million members  UnitedHealth had 45 86 million members as of June 30  Growing concerns about market concentration came into sharp focus earlier this year when regulatory concerns scuttled Comcast  NASDAQ CMCSA  Corp s  45 billion bid for Time Warner Cable Inc  NYSE TWC    Anthem said it will pay  103 40 in cash and 0 5152 of its shares for every Cigna share  The deal is valued at  183 36 per share based on Anthem s Thursday close of  155 21  Anthem said the offer is valued at  188 per share  based on its unaffected share price as of May 28 before media reports surfaced that the two companies were in talks  The equity portion of the offer is valued at  49 11 billion  according to Reuters calculations based on 261 2 million Cigna shares outstanding as of March 31  Swedish said Anthem s mainstay Blue Cross Blue Shield insurance coverage requires the company to maintain a concentrated focus on that business  according to Blue Cross rules   We will remain Blue   Swedish said on the conference call  adding that Anthem feels confident that even after acquiring Cigna and its core Medicare Advantage plans  the combined company will satisfy  the Blue rules   The company has said the deal will help it reduce costs and allow it to negotiate lower prices with doctors and hospitals   The  spirit of our collaboration going forward is total collaboration   Swedish said  saying his and Cordani s different roles and responsibilities  are perfectly aligned   Swedish said he intended to remain CEO of the combined company for two years  and afterward become chairman  Anthem s lead financial adviser is UBS Investment Bank   Credit Suisse   SIX CSGN  also served as financial adviser  and White   Case LLP as legal adviser   
Morgan Stanley is Cigna s financial adviser and Cravath  Swaine   Moore LLP its legal adviser ",2015-07-24,Reuters,https://www.investing.com/news/stock-market-news/health-insurer-anthem-to-buy-cigna-in-$54.2-billion-deal-352767,352767
142136,363651,HUM,5 Things to Watch This Morning,news,"1  Investors await Federal Reserve announcement
All eyes on Wall Street will be on the Federal Reserve s policy statement today  due at 2 00PM ET 
Fed officials are expected to provide further signals that the central bank could raise rates as soon as September if the economy continues to improve as expected 
Fed Chair Janet Yellen will not hold a press conference after the release and there will be no updated economic projections 
2  Twitter  NYSE TWTR  plunges 12  in pre market trade
Shares of the microblogging company plunged sharply after reporting late Tuesday that its monthly average users grew at the slowest pace since it went public in 2013 
3  Wall Street earnings keep rolling in
Humana  NYSE HUM   Mastercard Incorporated  NYSE MA  and Wynn Resorts Limited  NASDAQ WYNN  are due to report quarterly earnings ahead of Wednesday s opening bell 
After Wednesday s close of trading  Facebook  NASDAQ FB  and Whole Foods Market  NASDAQ WFM  are scheduled to report 
4  U S  data in focus
The U S  will release data on pending home sales for June at 10 00AM  The data is expected to show a gain of 1 0   following a 0 9  increase in May 
5  Chinese stocks continue roller coaster ride
The Shanghai Composite took investors on another roller coaster ride on Wednesday  rising more than 1  after the open  only to turn negative after the midday break  and then rise again to end up 3 5  
Some analysts attribute the strong finish to a rush of buying by government backed funds in the final hour of trade 
Equity markets in China plunged sharply earlier this week  forcing policymakers to intervene and provide measures to boost liquidity and calm investors 
Chinese regulators pledged to buy more shares to stabilize markets  while the country s central bank hinted at more policy easing if needed 
On Monday  the Shanghai Composite tumbled 8 5   the biggest one day drop since February 2007  amid reports that government buying of stocks and securities has slowed ",2015-07-29,Investing.com,https://www.investing.com/news/economy-news/5-things-to-watch-this-morning-353434,353434
142137,363652,HUM,U S  pre market top movers of the day   Twitter  Yelp  Panera Bread,news,"Investing com   U S  stock futures pointed to a higher open on Wednesday  as investors looked ahead to the Federal Reserve s monetary policy statement due later in the session for fresh signals on the timing of a U S  interest rate hike 
During early morning hours in New York  the blue chip Dow futures rose 38 points  or 0 21   the S P 500 futures tacked on 4 points  or 0 21   while the tech heavy Nasdaq 100 futures advanced 11 points  or 0 24  
All eyes on Wall Street will be on the Federal Reserve s policy statement today  due at 2 00PM ET  Fed officials are expected to provide further signals that the central bank could raise rates as soon as September if the economy continues to improve as expected 
Fed Chair Janet Yellen will not hold a press conference after the release and there will be no updated economic projections 
U S  data will also be in focus  The U S  will release data on pending home sales for June at 10 00AM  The data is expected to show a gain of 1 0   following a 0 9  increase in May 
Elsewhere  the Shanghai Composite took investors on another roller coaster ride on Wednesday  rising more than 1  after the open  only to turn negative after the midday break  and then rise again to end up 3 5  
Some analysts attribute the strong finish to a rush of buying by government backed funds in the final hour of trade 
In earnings news  Twitter  NYSE TWTR  plunged 10 8  after reporting late Tuesday that its monthly average users grew at the slowest pace since it went public in 2013 
 Yelp   NYSE YELP  plummeted 20  after the consumer review website reported a surprise second quarter loss and forecast revenue for the current quarter that fell far below market expectations 
United States Steel Corporation  NYSE X  dropped 4 1  after reporting weaker than expected quarterly results 
On the upside  Panera Bread  NASDAQ PNRA  jumped 8   while Buffalo Wild Wings  NASDAQ BWLD  rallied 9 7  as investors cheered earnings from both companies 
Meanwhile  Gilead Sciences  NASDAQ GILD  advanced 4 5  after the biotech firm late Tuesday posted quarterly profit and revenue that beat forecasts 
 Altria Group   NYSE MO   Humana  NYSE HUM   Mastercard  NYSE MA  and Wynn Resorts Limited  NASDAQ WYNN  are due to report quarterly earnings ahead of Wednesday s opening bell  while Facebook  NASDAQ FB  and Whole Foods  NASDAQ WFM  are scheduled to report after Wednesday s close of trading 
Stay up to date on the latest pre market news and movers by visiting   ",2015-07-29,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-pre-market-top-movers-of-the-day---twitter,-yelp,-panera-bread-353440",353440
142138,363653,HUM,Anthem profit beats as medical costs stay at low end of estimates,news,"By Caroline Humer  Reuters    Health insurer Anthem Inc  N ANTM   which plans to buy rival  Cigna Corp   N CI  for  47 billion  on Wednesday said medical costs  particularly in its Medicaid and Medicare businesses  were at the low end of expectations and helped boost second quarter profit  Anthem raised its profit outlook for 2015 and said it expects health spending to increase at the lower end of a range of 6 5 percent to 7 5 percent this year  It also said that a key financial measure of medical costs fell during the quarter  Health insurers closely manage costs to contend with a constant rise in medical spending  Cost increases had been held back for many years by the weak economy  but began picking up in 2014 with the improved economy and as the national healthcare reform law extended insurance to millions more people  A few months ago  the largest U S  insurers began scrambling to line up merger partners that would give them leverage to contend with the trend and negotiate lower prices with medical providers   Consolidation has heated up across the healthcare industry  including among hospitals  doctor groups  pharmacy benefit managers  pharmacies and drugmakers   On July 3  No  3 health insurer  Aetna Inc   N AET  said it would buy rival  Humana Inc   N HUM  and Anthem on Friday said it would acquire Cigna for  47 billion in cash and stock to create the No  1 U S  health insurer with 53 million members   Anthem  which operates Blue Cross Blue Shield plans in more than a dozen states  said on Wednesday that spending on medical claims as a percentage of premiums fell to 82 1 percent from 82 7 percent a year ago  That is about 30 basis points better than Wall Street estimates  according to Leerink Partners analyst Ana Gupte  Anthem is the first insurer to report earnings since UnitedHealth Group Inc  N UNH  two weeks ago missed analyst expectations for that key ratio  a harbinger of cost increases    Anthem s  loss ratios came in very favorably  That s a big plus considering there were some concerns about the UnitedHealth report   Gupte said   Anthem shares were up 0 24 percent at  154 77   REVENUE TOPS EXPECTATIONS Anthem s net income rose to  859 1 million  or  3 13 per share  from  731 1 million  or  2 56 per share  a year earlier  Revenue increased 8 3 percent to  20 02 billion  topping analysts  expectations of  19 63 billion  The company cited strong growth in its government Medicaid and Medicare businesses  where revenue rose 25 7 percent  Medicaid membership increased 11 percent  Medicaid enrollments began to increase in earnest starting in July of last year as the expansion of Medicaid coverage for the poor kicked in  Anthem Chief Financial Officer Wayne DeVeydt said during a conference call  Anthem expects 2015 adjusted net income to be more than  10 per share  up from its previous forecast of more than  9 90   Analysts expected full year earnings of  10 11 per share  according to Thomson Reuters I B E S  
Excluding items  Anthem earned  3 10 per share in the second quarter  well above the average analyst estimate of  2 77 ",2015-07-29,Reuters,https://www.investing.com/news/economy-news/health-insurer-anthem's-profit-beats-as-medicaid-memberships-rise-353507,353507
142139,363654,HUM,Health insurer Cigna says second quarter medical costs stay low  profit beats,news,"By Caroline Humer  Reuters    Health insurer  Cigna Corp   NYSE CI   which agreed last week to be bought by Anthem Inc for  47 billion  said on Thursday that medical services use was low in the second quarter  helping to keep costs in check and beat Wall Street profit estimates  Cigna s report of a continued low utilization trend backs up a growing industry view of this closely watched component of insurer profitability  Anthem made similar comments on Wednesday  when it reported better than expected quarterly earnings  Health insurers have benefited from low medical services use during the past five years as the weak economy has kept down doctor visits and hospitalizations and membership growth has helped increase revenues  But the rate of overall health spending has begun to increase and medical use is expected to rise more as the economy improves  The national healthcare reform law  also known as Obamacare  has contributed to the increase as millions of people gained health insurance coverage in the past two years  That is driving insurers to consolidate to build scale to help keep costs down and negotiate better deals with doctors and hospitals    The reason why there is so much consolidation is because utilization and the cost trend overall will go up  which will pressure the profitability for these companies long term   Morningstar Research analyst Vishnue Lekraj said   Aetna Inc   NYSE AET  agreed to buy smaller rival  Humana Inc   NYSE HUM  in early July  just weeks before Anthem and Cigna reached a deal  The mergers are expected to face antitrust scrutiny as regulators consider their effect on insurance premium rates  The concerns have kept Cigna shares far from Anthem s offer price of more than  183  Cigna shares dipped 0 4 percent at  144 81 on Thursday  Cigna Chief Executive Officer David Cordani said on CNBC on Thursday that the companies were already talking to state and federal regulators   We will fully engage with state leaders and federal leaders and those conversations have already started   Cordani said  Cigna said its ratio of medical claims paid as a percentage of premiums taken in  or MCR  was 77 5 percent for its commercial business and 84 4 percent for its government business  It expects medical costs to rise 5 percent to 6 percent in 2015  Net profit rose to  588 million  or  2 26 per share  for the second quarter  from  573 million  or  2 12 per share  a year earlier  Excluding items  Cigna earned  2 55 per share  beating the average analyst estimate of  2 31  according to Thomson Reuters I B E S  On Friday when it announced the Anthem deal  Cigna said second quarter earnings would be at least  2 50 per share  Cigna manages insurance plans for large companies and sells health plans to individuals on government exchanges created under the U S  Affordable Care Act  It also manages government Medicare and Medicaid plans  Premiums and fees in Cigna s commercial and government businesses rose 10 percent in the second quarter  boosted by the addition of 524 000 customers  
Revenue rose about 9 percent to  9 49 billion  just below the average analyst estimate of  9 53 billion ",2015-07-30,Reuters,https://www.investing.com/news/stock-market-news/health-insurer-cigna's-profit-rises-as-it-adds-more-members-353632,353632
142140,363655,HUM,Aetna profit beats as government plans expand,news," Reuters     Aetna Inc   N AET  reported a better than expected adjusted net profit for the second quarter as it added more members to its government plans and medical costs remained stable  The third largest U S  health insurer  which is in the process of buying rival  Humana Inc   N HUM   also raised its full year forecast for adjusted net profit to at least  7 40 per share from  7 20  7 40   Memberships in government sponsored plans have increased as Obamacare has expanded health insurance coverage to thousands of uninsured and under insured U S  citizens  Aetna said on Tuesday it continued to experience moderate medical cost trends during the quarter  which helped improve its medical benefit ratio to 81 1 percent from 83 1 percent  The ratio  the percentage of premium income that an insurer spends on medical claims  is tracked by investors for signs of any increase in medical spending  Medical costs are expected to rise as the economy improves and the rate of overall health spending increases  driving insurers to consolidate  Aetna agreed to buy Humana in early July for  37 billion  just weeks before Anthem Inc  N ANTM  and  Cigna Corp   N CI  reached a deal for  47 billion  Aetna s net profit rose to  731 8 million  or  2 08 per share  in the second quarter ended June 30  from  548 8 million  or  1 52 per share  a year earlier  Excluding items  the company earned  2 05 per share  beating average analyst estimate of  1 82 per share  according to Thomson Reuters I B E S  
Revenue rose 5 percent to  15 24 billion  still short of analyst expectations of  15 43 billion ",2015-08-04,Reuters,https://www.investing.com/news/stock-market-news/aetna-profit-beats-as-government-plans-expand-354351,354351
142141,363656,HUM,Humana  HUM  Beats Q3 Earnings Estimates  Revenues Miss ,opinion,Humana Inc  s   NYSE HUM   third quarter 2017 operating earnings per share of  3 39 beat the Zacks Consensus Estimate by approximately 3 7   The bottom line improved 6 6  year over year driven by lower share count However  adjusted consolidated pretax income of  915 million declined 2  due to charges associated with voluntary and involuntary workforce reduction program and lower pretax earnings in the company s Healthcare services segment  However  this was partially offset by improvement in the company s Group   Specialty and Retail segments Operational UpdateAdjusted consolidated revenues of  13 1 billion grew 2  on higher Retail segment revenues from the company s Medicare business  Revenues  however  missed the Zacks Consensus Estimate by 2  Humana s adjusted consolidated benefit ratio of 82 4  deteriorated 90 basis points  bps  from the prior year quarter  primarily due to the impact of the temporary suspension of the health insurance industry fee in 2017 Adjusted consolidated operating cost ratio of 11 8  improved 70 bps from the year ago quarter  also due to the temporary suspension of the health insurance industry fee for 2017 Quarterly Segment ResultsRetail SegmentRevenues from the Retail segment were  11 05 billion  up 2  year over year  primarily owing to higher revenues from the company s Medicare Advantage business resulting from increased membership Benefit ratio of 84 3  deteriorated 70 bps year over year  primarily due to the impact of the temporary suspension of the health insurance industry fee in 2017  The segment s operating cost ratio of 9 8  improved 80 bps year over year because of the same reason Adjusted pretax income of  616 million remained flat year over year Group and Specialty SegmentRevenues from the Group and Specialty segment were  1 85 billion  up 1  from the prior year quarter  primarily due to increased group fully insured per member premiums Benefit ratio improved 140 bps year over year to 79 6   due to favorable utilization of the segment s fully insured commercial medical business and higher prior period development compared to the year ago quarter  Operating cost ratio improved 220 bps year over year to 21 6   due to the temporary suspension of the health insurance industry fee in 2017 as well as operating cost efficiencies Adjusted pretax income of  93 million  increased 158  year over year driven by the company s higher pretax earnings related to fully insured commercial medical products Healthcare ServicesRevenues of  6 billion decreased 6  year over year  primarily due to the company s Pharmacy Solutions business as well as the impact of the optimization process associated with its chronic condition management programs Operating cost ratio deteriorated 70 bps year over year to 95 6  Adjusted pretax income for the segment was  251 million  down 19  year over year due to optimization process associated with the company s chronic care management program and higher operating cost ratio Individual Commercial SegmentIndividual Commercial membership was 142 800 as of Sep 30  2017  down 80  year over year  primarily due to a decline in number of countries where the company offers on exchange coverage as well as the discontinuance of off exchange products Benefit ratio of 65 6  deteriorated 1680 bps from third quarter 2016  The year over year improvement primarily resulted from the planned exit from certain markets with higher benefit ratio The segment s operating cost ratio deteriorated 560 bps from the year ago quarter to 21 9   primarily due the loss of scale efficiency from market exits in 2017 The company witnessed a pretax income of  26 million  which compared favorably with a pretax income of only  2 million in the prior year quarter  This was owing to the exit from certain markets in 2017 and per member premium increases Humana Inc  Price  Consensus and EPS Surprise   Financial UpdateAs of Sep 30  2017  the company had cash  cash equivalents  and investment securities of  21 20 billion  up 12  sequentially As of Sep 30  2017  cash and short term investments held by the parent company was  2 32 billion  up 18  from Jun 30  2017 Debt to total capitalization as of Sep 30  2017 was 30 5   down 80 bps from Jun 30  2017 Cash flows used in operations totaled  3 83 billion for the first nine months of 2017  compared with  1 68 billion in the prior year period  The improvement was positively impacted by the receipt of merger termination fee  higher earnings and the timing of working capital items Share Repurchase UpdateIn February 2017  Humana s board of directors approved a  2 25 billion share repurchase authorization  which will expire on Dec 31  2017 The company subsequently entered into an agreement with a third party financial institution on Feb 16  2017 to bring into effect a  1 50 billion ASR program under the authorization  Under the terms of the agreement that was completed in the third quarter  the company bought back nearly 6 7 million shares at an average per share price of  224 81 Moreover  the company bought back shares worth  240 million under its existing share repurchases authorization in the third quarter of 2017 Over the first nine months of 2017  the company repurchased shares worth  1 74 billion As of Nov 3  2017  Humana has  239 million of share repurchase authorization remaining Dividend UpdateThe company paid cash dividends to its stockholders of  58 million in the third quarter  During the first nine months of 2017  total amount of dividends paid to the shareholders was  162 million In Nov 17  the company declared a cash dividend of 40 cents per share  to be paid on Jan 26  2018 to the shareholders of record on Dec 29  2017 Guidance Raised Humana increased its 2017 adjusted EPS guidance to  11 60 from the previous guidance of at least  11 50 Total revenues are expected to lie between  53 60 billion and  54 00 billion  as against the previous guidance of  53 5 billion and  54 5 billionCash flow from operations is expected to range within  3 3 billion to  3 6 billion as against the previously projected range of  3  3 4 billion Zacks Rank and Performance of Other InsurersHumana presently carries a Zacks Rank  3  Hold   You can see  Among the other firms in the medical sector that have reported third quarter earnings so far  the bottom lines of Centene Corp    NYSE CNC    Anthem Inc   NYSE ANTM   and UnitedHealth Group Inc    NYSE UNH   beat their respective Zacks Consensus Estimate Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-11-07,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-beats-q3-earnings-estimates-revenues-miss-200263576,200263576
142142,363657,HUM,Humana s  HUM  Q3 Earnings Beat  Revenues Miss,opinion,Humana Inc    NYSE HUM   is one of the largest health care plan providers in the United States At present Humana s core operations include the provision of health insurance benefits under Health Maintenance Organization  HMO   Private Fee For Service  PFFS   and Preferred Provider Organization  PPO  plans The company also provides other benefits with specialty products including dental  vision  and other supplementary benefits  Humana capitalizes on its established Accountable Care arrangement to provide its Medicare Advantage  MA  members with quality care at an affordable price   Humana has a solid history when it comes to earnings as the stock has beaten estimates in all of the last four quarters  making for an average surprise of 6 6  Currently  Humana has a Zacks Rank  3  Hold   but that could definitely change following its earnings report which was just released  You can see  We have highlighted some of the key stats from this just revealed announcement below Earnings  Humana surpassed our earnings estimate  Our consensus called for EPS of  3 27  and the company reported EPS of  3 39 Humana Inc  Price and EPS Surprise   Revenue  Revenues miss our estimates  Our consensus called for revenues of  13 394 million  and the company reported revenues of  13 057 million Key Stats to Note Benefit ratio deteriorated 90 basis points to 82 4  in the quarter  Operating cost ratio improved 130 basis points to 10 7  Operating cash flow totaled  2 8 billion  up 89  over the prior year quarter Check back later for our full write up on this HUM earnings report later Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-11-08,Zacks Investment Research,https://www.investing.com/analysis/humanas-hum-q3-earnings-beat-revenues-miss-200263558,200263558
142143,363658,HUM,Can Health Insurers Continue To Look Past ACA Threats In Q4 ,opinion,President Donald Trump s plans to repeal and replace the Affordable Care Act  ACA  or Obamacare have created quite an uproar among health insurers  ACA has been contributing significantly to health insurers  top line Despite the volatile regulatory scenario  health insurers recorded a solid third quarter and continue to remain profitable picks for investors Health insurance bigwigs like Humana Inc   NYSE HUM    Aetna Inc   NYSE AET    Anthem Inc   NYSE ANTM    UnitedHealth Group  Inc   NYSE UNH   have seen solid growth in the top and bottom line as well as membership in the third quarter  Their strong capital position also reflects profitable operations Business diversifying strategies with primary focus on ancillary services and products have also boosted the revenue base Q4 TrendsContinuously rising demand for government plans  especially Medicare and Medicaid  continues to favor health insurers  Hence  revenues of the companies offering these plans are likely to witness a consistent improvement in their government businesses Moreover  an aging U S  population that has boosted the overall demand for medical coverage is likely to prove favorable ObamaCare has significantly benefitted the industry through a reduction in uninsured population  boosting medical enrollment and aiding bad debt management  This trend is likely to drive the fourth quarter results as well A diversified product portfolio along with proposed mergers and consolidations are also likely to accelerate growth for health insurers in terms of global expansion as well as strengthening of foothold in existing markets However  the companies have been facing higher losses on public exchanges that have compelled them to scale back operations or plan an exit from the business Moreover  health insurers have been seeing escalating operating costs related to regulations  investments in information technology along with fees and taxes that continue to hurt profits  The companies  however  are trying to tackle the rise in costs with the help of Accountable Care Organizations  ACOs  Stocks to ConsiderDespite the challenges  the has gained nearly 8  quarter to date  outperforming the S P 500 average of 3 5   The is among the top 10  of the Zacks ranked industries   We have boiled down on three stocks that have outperformed in the third quarter and have also seen upward estimate revision in the last 30 days  Moreover  these stocks have maintained a solid quarter to date performance Triple S Management Corporation   NYSE GTS   is one of the leading managed care companies in the United States that delivered a positive earnings surprise of 327 8  in the recently reported quarter  The Zacks Consensus Estimate for its 2017 earnings has being revised 43  upward  while the same for 2018 increased 10 6  over the last 30 days   The company s shares have rallied 17 4   outperforming the industry  The stock sports a Zacks Rank  1  Strong Buy   You can see    WellCare Health Plans  Inc    NYSE WCG   is a managed care company in the United States that delivered a positive earnings surprise of 114 7  in the last reported quarter  The Zacks Consensus Estimate for its 2017 earnings rose 17   while the same for 2018 increased 8  over the last 30 days   The stock has rallied 17 2   beating the industry mark  The stock also sports a Zacks Rank  1   The Joint Corp    NASDAQ JYNT   offersnationwide network of chiropractors  The company delivered a positive earnings surprise of 50  in the recently reported quarter  The stock has seen the Zacks Consensus Estimate for 2017 earnings rise 17  over the last 30 days  The same for 2018 has increased to 6 cents from a breakeven expected 30 days back   The company s shares have rallied 13   outperforming the industry  The stock carries a Zacks Rank  2  Buy    Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-11-22,Zacks Investment Research,https://www.investing.com/analysis/can-health-insurers-continue-to-look-past-aca-threats-in-q4-200267830,200267830
142144,363659,HUM,Humana Partners Einstein Healthcare For Value Based Care,opinion,Humana Inc    NYSE HUM   recently entered in to a value based agreement with Einstein Healthcare Network  Per the agreement  both the companies would join forces to offer improved services to Humana s Medicare Advantage  MA  members Value based care has gained prominence in recent years in the healthcare industry  Health insurers have been forming strategic alliances for adopting this model that aims at providing coordinated  accessible  affordable and personalized health care to patients The deal  which extends the existing network contract between both the companies  would continue to provide access to Einstein Healthcare s wide range of health care services to Humana s MA members  The agreement also combines Humana with Einstein Healthcare s Accountable Care Organization  Einstein Care Partners  in order to improve patients  healthcare experience and outcomes in the Philadelphia area Humana s wide presence of value based care with more than 900 value based relationships across 43 states and Puerto Rico impresses  The company had 1 9 million individual MA members as of Sep 30  2017 along with 149 000 commercial members covered by 51 500 primary care providers Moreover  this new partnership will allow Humana s MA members to spend more personal time with health professionals and enjoy personalized care customized for each person s unique health situation  It would also provide Humana s MA members access to proactive health screenings and programs focused on preventing illness  This value based model would also offer better health solutions for people living with chronic conditions so that they can avoid health complications in an easier way The partnership would also build on updated technologies such as data analytics that would better connect physicians so that the coordinated effort can ensure better health outcomes for the patients  Moreover  the fee for service payment method for the physicians that considers the quality of the services being provided instead of the quantity  will also ensure better results This value based care program aligns well with Einstein Healthcare s mission to improve population health outcomes and reduce health disparities  It has a vision of providing high quality and low cost health care to the communities they serve Humana s shares have gained 26 7  year to date  underperforming the  s rally of 44 1   However  the company s strategic alliances and strong fundamentals are likely to favor the stock going forward  Zacks Rank   Other Stocks to ConsiderHumana sports a Zacks Rank  1  Strong Buy   You can see    Investors interested in the same space can also consider some other stocks like Triple S Management Corporation   NYSE GTS    Centene Corporation   NYSE CNC   and The Joint Corp    NASDAQ JYNT    While Triple S Management sports a Zacks Rank  1  the other two stocks carry a Zacks Rank  2  Buy  Triple S Management delivered positive surprises in two of the last four quarters  with an average beat of 74   The stock has gained 34 8   slightly outpacing the industry Centene delivered positive surprises in all of the last four quarters with an average beat of 10 6   Its shares have returned 66 2  year to date  beating the industry mark Joint Corp delivered positive surprises in three of the last four quarters  with an average beat of 5 5   Its shares have rallied 102 6  year to date  outperforming the industry Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-12-03,Zacks Investment Research,https://www.investing.com/analysis/humana-partners-einstein-healthcare-for-valuebased-care-200270213,200270213
142145,363660,HUM,Will Tax Cut Passage Be Easy ,opinion,"Monday  December 4  2017Dow futures have rocketed up more than 200 points in this morning s pre market on news that the Senate has passed its version of a tax reform bill in the wee hours of Saturday morning  The corporate tax rate shedding 15 percentage points   35  to 20    is one of the main items the Senate version shares with the House bill  which now faces reconciliation to make its way to President Trump s desk  which he would surely sign Same with the pass through rate and the elimination of the estate tax  In fact  many of the main tenets of each bill fit together  which should help reconciliation  made necessary because the tax cuts were decided on purely party grounds  no Democrats voted for either bill  with only a few defectors from the GOP voting against   There are still some wrinkles that both sides will need to iron out  but because this is far from a bipartisan effort  common ground should be fairly easy to reach More difficult will be those who were against the tax bills before they even saw the contents of them  Now that we can all see what s inside  be prepared to see economists  former Treasury Secretaries  etc  to voice their opposition  Republican representatives of  blue  states   those which tend to follow Democratic policies which generally include higher taxes at state and local levels   should be preparing themselves to hear from their voting constituencies  once these citizens recognize that their taxes are likely to go up  not down In order to help pay for the big tax cuts  elimination of tax write offs such as state and local  medical costs and waived college tuition look to add tax burdens on millions of households  At the same time  wiping out the estate tax  dubbed the  death tax  by supporters of the current bills  and the Alternative Minimum Tax appear to be clear handouts to singularly high wealth individuals  And the drastic corporate tax rate cut will already be a boon to shareholders of publicly traded corporations  another main piece of evidence that these tax reform packages are not aimed at working  and middle class families  as regularly claimed by supporters  but those much farther up the economic food chain All this is to say that the hard work may be yet to come  House Representatives and some Senators also face re election in the coming year  if their voting constituencies see the current tax proposals as being sell outs to the Wall Street upper class   which Candidate Trump explicitly campaigned against  it is worth noting   they may feel the expressed need to make their displeasure known Return of the Vertical MergerPharmacy retailer CVS Health   NYSE CVS   has come to terms to buy managed health care giant Aetna   NYSE T   for a cool  69 billion  This move looks to transform the way health care is managed  with agents of the deal calling the timing  perfect   The idea is that costs for employer supported healthcare will be more effectively managed by joining the retailer with the coverage  Recall a year ago  when a similarly sized merger between Aetna and competitor Humana   NYSE HUM     a horizontal merger  not a vertical one   did not pass antitrust regulation  This morning s vertical arrangement may be seen more palatable by these same regulators That s not to say all vertical merger agreements get a free pass  AT T s   NYSE T   proposal to buy Time Warner   NYSE TWX   faces litigation from none other that the U S  Department of Justice  Government antitrust regulators for this  85  billion deal claim the merger woulds harm competition and raise consumer prices  Yet thus far  we do not hear similar rhetoric from the Justice Department on the CVS Aetna merger  We will keep our ears and eyes open  going forward Mark VickerySenior Editor
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions 
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2017-12-03,Zacks Investment Research,https://www.investing.com/analysis/will-tax-cut-passage-be-easy-200270384,200270384
142146,363661,HUM,Dow Futures Up Above 200 Points In Pre Market,opinion,Dow futures have rocketed up more than 200 points in this morning s pre market on news that the Senate has passed its version of a tax reform bill in the wee hours of Saturday morning  The corporate tax rate shedding 15 percentage points   35  to 20    is one of the main items the Senate version shares with the House bill  which now faces reconciliation to make its way to President Trump s desk  which he would surely sign Same with the pass through rate and the elimination of the estate tax  In fact  many of the main tenets of each bill fit together  which should help reconciliation  made necessary because the tax cuts were decided on purely party grounds  no Democrats voted for either bill  with only a few defectors from the GOP voting against   There are still some wrinkles that both sides will need to iron out  but because this is far from a bipartisan effort  common ground should be fairly easy to reach More difficult will be those who were against the tax bills before they even saw the contents of them  Now that we can all see what s inside  be prepared to see economists  former Treasury Secretaries  etc  to voice their opposition  Republican representatives of  blue  states   those which tend to follow Democratic policies which generally include higher taxes at state and local levels   should be preparing themselves to hear from their voting constituencies  once these citizens recognize that their taxes are likely to go up  not down In order to help pay for the big tax cuts  elimination of tax write offs such as state and local  medical costs and waived college tuition look to add tax burdens on millions of households  At the same time  wiping out the estate tax  dubbed the  death tax  by supporters of the current bills  and the Alternative Minimum Tax appear to be clear handouts to singularly high wealth individuals  And the drastic corporate tax rate cut will already be a boon to shareholders of publicly traded corporations  another main piece of evidence that these tax reform packages are not aimed at working  and middle class families  as regularly claimed by supporters  but those much farther up the economic food chain All this is to say that the hard work may be yet to come  House Representatives and some Senators also face re election in the coming year  if their voting constituencies see the current tax proposals as being sell outs to the Wall Street upper class   which Candidate Trump explicitly campaigned against  it is worth noting   they may feel the expressed need to make their displeasure known Return of the Vertical MergerPharmacy retailer CVS Health   NYSE CVS   has come to terms to buy managed health care giant Aetna   NYSE T   for a cool  69 billion  This move looks to transform the way health care is managed  with agents of the deal calling the timing  perfect   The idea is that costs for employer supported healthcare will be more effectively managed by joining the retailer with the coverage  Recall a year ago  when a similarly sized merger between Aetna and competitor Humana   NYSE HUM     a horizontal merger  not a vertical one   did not pass antitrust regulation  This morning s vertical arrangement may be seen more palatable by these same regulators That s not to say all vertical merger agreements get a free pass  AT T s   NYSE T   proposal to buy Time Warner   NYSE TWX   faces litigation from none other that the U S  Department of Justice  Government antitrust regulators for this  85  billion deal claim the merger woulds harm competition and raise consumer prices  Yet thus far  we do not hear similar rhetoric from the Justice Department on the CVS Aetna merger  We will keep our ears and eyes open  going forward ,2017-12-03,Zacks Investment Research,https://www.investing.com/analysis/dow-futures-up-above-200-points-in-premarket-200270383,200270383
142166,363681,HUM,Aetna close to buying Humana  Bloomberg,news," Reuters    U S  health insurer  Aetna Inc   N AET  is close to buying rival  Humana Inc   N HUM  and a deal could be signed as early as this weekend  Bloomberg reported  citing people familiar with the matter  Humana has also received an offer from  Cigna Corp   N CI   but Humana s board prefers the offer from Aetna  Bloomberg reported   Aetna and Humana were in talks  a source familiar with the matter told Reuters on Thursday  adding that there was no certainty Aetna would prevail  Cigna is also in the running  a second source confirmed to Reuters  Aetna made a formal cash and stock bid this week to buy Humana  Bloomberg said  Humana  which had a market value of  27 59 billion as of Thursday s close  was not immediately available for comment   Aetna and Cigna declined to comment  Reuters has previously reported that Humana is in takeover talks with Aetna and Cigna  Bloomberg said discussions between Humana and Aetna intensified in the past few days after it emerged over the weekend that rivals Anthem Inc  N ANTM  and Cigna had held merger talks of their own  Anthem said on Saturday it had offered  47 billion in cash and stock for smaller rival Cigna  who rebuffed the offer the next day  The intensifying talks come as insurers seek scale to trim administrative costs and negotiate lower prices with doctors  moves they say will make plans more affordable  Aetna s shares jumped 4 3 percent to a record  133 05 after the report  while Humana s shares were up 6 5 percent at  196 21 in afternoon trading  
Cigna shares rose 2 7 percent to a record high of  170 20  before giving up some gains to trade up 1 pct at  167 51 ",2015-06-26,Reuters,https://www.investing.com/news/stock-market-news/aetna-close-to-buying-humana:-bloomberg-348264,348264
142167,363682,HUM,Anthem  Cigna in new round of talks  source,news," Reuters    U S  health insurer  Cigna Corp   N CI  has had its first meetings with competitor Anthem Inc  N ANTM  after it rebuffed Anthem s  47 billion merger proposal last month  a person familiar with the matter said on Thursday  It was not immediately clear if the new talks  which were held in the last few days  would lead to the companies reaching a deal  The talks come as both Cigna and rival  Aetna Inc   N AET  consider the possible acquisition of smaller player  Humana Inc   N HUM   people familiar with the matter have said previously  The source on the Cigna Anthem talks asked not to be identified because the discussions are confidential  Cigna and Anthem declined to comment  CNBC first reported on the latest talks between the two companies  A combined Cigna and Anthem would have 53 million customers in commercial  government  consumer and other kinds of health insurance plans   Big U S  health insurers are seeking acquisitions to boost membership in government paid healthcare plans and employer based insurance  The bigger the insurer  the more power it has negotiating prices and improving its doctor networks  Earlier on Thursday  U S  health insurer  Centene  Corp  N CNC  said it would buy smaller rival  Health Net Inc   N HNT  for  6 3 billion  underscoring the healthcare industry s rush to bulk up to negotiate more advantageous prices with suppliers and hospitals  and attract new customers  In rejecting Anthem s offer  Cigna previously cited Anthem s  lack of growth strategies   complications related to its membership of Blue Cross Blue Shield Association and a  massive  data breach it suffered in February  Cigna s board is also concerned by Anthem s  insistence  that one person   Joseph Swedish  Anthem s president and chief executive officer   assume four roles of the combined company  chairman  CEO  president and head of integration  
Anthem has said it believes investors support its refusal to guarantee that the CEO role of the combined company would go to Cigna CEO David Cordani ",2015-07-02,Reuters,"https://www.investing.com/news/economy-news/anthem,-cigna-in-new-round-of-talks:-source-349400",349400
142168,363683,HUM,Aetna CEO addresses antitrust concerns over Humana deal,news,"By Caroline Humer  Reuters    Aetna Inc s  N AET  chief executive said Monday he was confident an antitrust review of the health insurer s proposed purchase of smaller rival  Humana Inc   N HUM  would allow the deal to close in the second half of 2016  seeking to allay investor concerns  Mark Bertolini said Aetna had already prepared for possible divestitures to address overlaps with Humana s business in the largest ever U S  health insurance deal  The two sides announced the  37 billion transaction on Friday   We took a conservative view of what we would need to divest   Bertolini said during an investor conference call  Aetna has not discussed the deal directly with the U S  Department of Justice  but has consulted with regulatory experts  Bertolini told cable channel CNBC   We believe that given the legal advice we have   that this is a very manageable transaction   he said  Health insurers have been in a race to consolidate  saying that being larger would help them negotiate better prices with doctors and hospitals as well as cut administrative costs  No  2 health insurer Anthem Inc  N ANTM  has said that it seeking to buy No  5  Cigna Corp   N CI   though Cigna has so far turned down its offers  Aetna and Humana overlap in nine states in Medicare Advantage  a government paid insurance program for older people and the disabled  Combined  they would have market share of 88 percent in Kansas  80 percent in West Virginia  58 percent in Iowa and 51 percent in Missouri  U S  antitrust regulators are expected to review how insurance transactions could affect competition in each regional market where the insurers overlap  and their potential impact on each different health insurance product   
If an Anthem Cigna deal is announced within the next two to three months  then regulators could look at the impact of both mergers at the same time  Bertolini said   It really depends on whether or not any other deals are announced  I think currently we anticipate that our transaction will be viewed alone at this point in time  but they could be bundled together at some point   he said during the conference call  Aetna shares fell  5 04  or 4 percent  to  120 44 early on Monday  Humana rose  5 95  or 3 percent  to  193 50  but traded well below Aetna s proposed acquisition price of about  230 a share ",2015-07-06,Reuters,https://www.investing.com/news/stock-market-news/aetna-ceo-addresses-antitrust-concerns-over-humana-deal-349843,349843
142169,363684,HUM,Energy leads Wall St  lower with eyes on Greece  China,news,By Rodrigo Campos  Reuters    U S  stocks fell in a volatile Monday session as Greeks resoundingly backed their government in rejecting the austerity terms of a bailout and China implemented emergency measures to stop a selloff in Shanghai s market  Greek Prime Minister Alexis Tsipras promised German Chancellor Angela Merkel that Greece would bring a proposal for a cash for reforms deal to an emergency summit of euro zone leaders on Tuesday  a Greek official said  It was unclear how much it would differ from other proposals rejected in the past  Equity futures tumbled at the open late on Sunday after Greeks voted  No  to the terms imposed by its creditors  However the S P 500 didn t fall more than 1 percent throughout the Monday session and even turned positive in morning trading  Though Greece is causing a lot of uncertainty  a deal should get done to keep them in the Euro Zone  according to Karyn Cavanaugh  market strategist at Voya Investment Management in New York   Greece can t pay their bills  there s no middle ground there and other countries are going to have to foot the bill and they are angry   she said  But more than billions in debt are in play as  Greece is the southern gateway to Europe  The strategic value is not being quantified   The Dow Jones industrial average  DJI  fell 46 53 points  or 0 26 percent  to 17 683 58  the S P 500  SPX  lost 8 02 points  or 0 39 percent  to 2 068 76 and the Nasdaq Composite  IXIC  dropped 17 27 points  or 0 34 percent  to 4 991 94  Weighing further on investor sentiment  Chinese brokerages and fund managers vowed to buy massive amounts of stocks as Beijing unleashed an unprecedented series of support measures to stem a decline of nearly 30 percent in the main Shanghai index over the past three weeks   People see  emergency measures  and they think  that can t be good    said Voya s Cavanaugh  The Shanghai index  SSEC  rose 2 4 percent overnight but a measure of Chinese stocks traded in the United States  fell the most in 19 months  pointing to caution from investors outside of China about the effectiveness of the government s measures  Energy stocks led the decline on Wall Street after U S  crude futures prices  settled almost 8 percent lower on concern over growth in China and the Greek uncertainty  The S P 500 energy index  fell 1 3 percent  marking its fourth decline of more than 1 percent in the past seven sessions  Health insurer Aetna  N AET  fell 6 4 percent to  117 43 after it said it would buy smaller rival Humana  N HUM  for about  37 billion  Humana closed up 0 8 percent to  188 96  The deal is seen facing antitrust scrutiny  which could make other large scale mergers in the sector more difficult  Anthem  N ANTM   Cigna  N CI    Centene   N CNC  and Health Net  N HNT   which are all in takeover talks  ended lower  Declining issues outnumbered advancing ones on the NYSE by 1 946 to 1 132  for a 1 72 to 1 ratio on the downside  on the Nasdaq  1 600 issues fell and 1 181 advanced for a 1 35 to 1 ratio favoring decliners  The benchmark S P 500 index posted 5 new 52 week highs and 32 new lows  the Nasdaq Composite recorded 44 new highs and 130 new lows  About 6 6 billion shares traded on all U S  platforms  according to BATS exchange data  below the average of 7 6 billion in the past five sessions ,2015-07-06,Reuters,https://www.investing.com/news/stock-market-news/u.s.-futures-fall-as-greece-uncertainty-continues-349796,349796
142170,363685,HUM,Anthem  Cigna progressing toward deal  CNBC,news," Reuters    Health insurers Anthem Inc  N ANTM  and  Cigna Corp   N CI  were moving ahead to sign a merger deal as Cigna backed down on its differences over governance issues  CNBC tweeted  citing sources  The tweets also quoted sources as saying that UnitedHealth Group Inc  N UNH  was looking to bid for Cigna  Cigna shares were up 3 percent at  155 08 in early trading on the Nasdaq  Anthem shares were up marginally at  160 27  UnitedHealth shares were little changed at  119 88  Cigna declined to comment on the report  Anthem and UnitedHealth were not immediately available for comment  Anthem had made several offers for Cigna  but a deal had been hung up in part due to differences over leadership  Anthem made its bid public on June 20  offering Cigna  47 billion in cash and stock  The biggest U S  health insurers are seeking acquisitions to boost membership in government paid healthcare plans and the employer based insurance that is Cigna s specialty  Being bigger can help them negotiate better prices and improve their network of doctors  The U S  Supreme Court s decision to uphold subsidies for individuals under President Barack Obama s signature healthcare law removed a large overhang for the insurers who would benefit from increasing enrollments into the Medicare and Medicaid programs  The report comes less than a week after  Aetna Inc   N AET  said it would buy smaller rival  Humana Inc   N HUM  for about  37 billion in cash and stock  
Experts expect a potential acquisition of Cigna by Anthem to come under antitrust scrutiny ",2015-07-09,Reuters,"https://www.investing.com/news/stock-market-news/anthem,-cigna-progressing-towards-deal:-cnbc-350416",350416
142171,363686,HUM,Can Medicaid Business Drive Centene s  CNC  Q3 Earnings  ,opinion,Centene Corporation   NYSE CNC   will release third quarter 2017 results on Oct 24  before the market opens For the past few quarters  Centene has been witnessing consistent growth in its membership that has been driving the overall top line   The company expects this uptrend  to continue in the third quarter as well and impact revenues positively  The Zacks Consensus Estimate for total membership is currently pegged at 12 1 billion  reflecting 6 1  year over year growth The major contributor to this rising membership is Centene s continuously growing Medicaid base  Medicaid expansion  another provision of Affordable Care Act  has benefitted Centene  This was driven by Centene s intention to continue on exchanges while other health insurers are exiting it  The third quarter is also likely to witness further expansion of its Medicaid business  In the third quarter  the company successfully reprocured a new statewide Medicaid contract in Georgia and Nevada  The Zacks Consensus Estimate for Medicaid membership presently stands at 5 8 billion  reflecting a year over year growth of  3 6  Moreover  Centene has been taking several cost saving initiatives that are reducing the level of expenses  The margin is likely to be aided by lower  expenses in the third quarter  The Zacks Consensus Estimate for total general and administrative expenses ratio is currently pegged at 0 09 compared with 9 23 in the second quarter of 2017 Other FactorsApart from the Medicaid expansion  growing Medicare beneficiaries are also likely to drive the top line in the third quarter The company s Government sponsored Health Insurance business is anticipated to perform well  adding to the top line Centene also expects its exchange business to perform well in 2017 and the to be reported quarter is expected to reflect the same trend The international business is also likely to perform well in the third quarter as well as in 2017 The company s share repurchase programs intended to enhance shareholders  value might impact margins positively by reducing the outstanding share count Increasing costs related to interest payment  reserves for settlements  legal judgments and lawsuits  impairments of long lived assets might affect earnings Earnings PredictionsOur proven model shows that Centene has the right combination of two key ingredients to beat estimates this quarter Zacks ESP   which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  2 45   This is because the Most Accurate estimate of  1 28 is higher than the Zacks Consensus Estimate of  1 25  The positive ESP is a leading indicator of a likely earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Centene Corporation Price and EPS Surprise   Zacks Rank  Centene sports a Zacks Rank  1  Strong Buy   Note that stocks with a Zacks Rank  1  2  Buy  or 3  Hold  have a significantly higher chance of beating on earnings  The combination of Centene s favorable Zacks Rank and positive Earnings ESP makes us reasonably confident of an earnings beat Conversely  the Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement Other Stocks to ConsiderHere are some other companies from the medical sector that you may want to consider as these have the right combination of elements to post an earnings beat this quarter Aetna  Inc    NYSE AET    which is set to report third quarter earnings on Oct 31  has an Earnings ESP of  1 20  and a Zacks Rank  1  You can see  Teladoc Inc   NYSE TDOC   has an Earnings ESP of  0 76  and a Zacks Rank  3  The company is set to report third quarter earnings on Nov 1 Humana  Inc    NYSE HUM   has an Earnings ESP of  1 10  and a Zacks Rank  3  The company is set to report third quarter earnings on Nov 8 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-10-19,Zacks Investment Research,https://www.investing.com/analysis/can-medicaid-business-drive-centenes-cnc-q3-earnings-200220035,200220035
142172,363687,HUM,Can Enrollment Growth Drive Anthem  ANTM  In Q3 Earnings ,opinion,Anthem Inc    NYSE ANTM   will release third quarter 2017 results on Oct 25  before the market opens  Last quarter  the company delivered a positive earnings surprise of 3 7   Let s see how things are shaping up for this announcement Anthem has been witnessing revenue appreciation over the past many quarters  backed by membership growth  Both its fully insured and self funded memberships have grown consistently  The third quarter is also expected to witness the same uptrend The Zacks Consensus Estimate for third quarter revenue is currently pegged at  22 1 billion  reflecting year over year growth of nearly 5   Our consensus estimates for fully insured and self funded memberships stand at 15 3 million and 25 million  up 0 7  and 1 2   respectively Total medical enrollment has also been steadily rising on the back of Obamacare s Medicaid expansion  For the soon to be reported quarter  the Zacks Consensus Estimate for Medical enrollment is pegged at 40 3 million  up 1  year over year  The Government business of Anthem has been a major contributor behind this increase in Medical enrollment  Our consensus estimate for total operating revenue of Government business is  11 8 billion  up 3  year over year Operating revenues of its Commercial business have also been impressive over the years  The Zacks Consensus Estimate for total operating revenue from Commercial business is  10 1 billion  up 5  year over year Other Factors at PlayMedicare Advantage product offerings might have supported Medicare enrollment growth  again boosting the company s top line However  Anthem expects to witness higher medical costs for individual ACA compliant products as was the case last quarter In addition  the company is likely to have experienced higher benefit expense ratio from its Medicaid business due to higher claims Administrative costs are likely to have risen during the third quarter continuing the previous trend The Individual business is also expected to remain a drag in the third quarter Earnings PredictionsOur proven model shows that Anthem has the right combination of two key ingredients to beat estimates this quarter Zacks ESP Anthem has an  of  1 55   representing the difference between the Most Accurate estimate and the Zacks Consensus Estimate  This is because the Most Accurate estimate of  2 45 is pegged higher than the Zacks Consensus Estimate of  2 41  The positive ESP indicates a likely earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Anthem  Inc  Price and EPS Surprise   Zacks Rank  Anthem carries a Zacks Rank  3  Hold   Notably  stocks with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3 have a significantly higher chance of an earnings beat Conversely  the Sell rated stocks   4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks to ConsiderHere are some other companies from the medical sector that you may want to consider as these too have the right combination of elements to beat on earnings this quarter Aetna  Inc    NYSE AET   is set to report third quarter earnings on Oct 31 with an Earnings ESP of  1 20  and a Zacks Rank  1  You can see  Teladoc Inc   NYSE TDOC   has an Earnings ESP of  0 76  and a Zacks Rank  3  The company is set to report third quarter earnings on Nov 1 Humana  Inc    NYSE HUM   has an Earnings ESP of  1 10  and a Zacks Rank of 3 as well  The company is set to report third quarter earnings on Nov 8 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-10-22,Zacks Investment Research,https://www.investing.com/analysis/can-enrollment-growth-drive-anthem-antm-in-q3-earnings-200220429,200220429
142173,363688,HUM,Can Admissions Rise Fuel Universal Health  UHS  Q3 Earnings ,opinion,"Universal Health Services  Inc    NYSE UHS   is set to report third quarter 2017 results on Oct 25 after  market close 
Last quarter  the company delivered a negative earnings surprise of 6 3   Let s see how things are shaping up for this announcement 
The company s two segments  Acute Care and Behavioral Health  have been performing strongly over the past many quarters  The segments have been continuously witnessing a rise in admissions  licensed beds as well as patient days that have significantly resulted in higher revenues   This yet to be reported quarter is also likely to see the same bullish trend 
The Zacks Consensus Estimate for total revenue is pegged at  2 6 billion  reflecting year over year growth of 8    Our consensus estimates for revenues from Acute Care and Behavioral Health segments are currently pegged at  1 4 billion and  1 2 billion  up 10  and 6 4  respectively  year over year 
Since 2012  the average number of licensed beds in the Acute Care hospitals and Behavioral Health centers kept increasing and the trend is expected to continue in the third quarter   Our consensus estimates for Average Licensed Beds in Acute Care and Behavioral Health are pegged at 6 1 billion and 23 1 billion  up 3  and 6  year over year  respectively 
The Zacks Consensus Estimate for Admissions in Acute Care and Behavioral Health is pegged at 73 1 billion and 120 7 billion respectively  up 5  and 7  year over year  respectively  This in turn is expected to aid the company s top line in the third quarter significantly 
Other Factors
Universal Health s efforts to enhance shareholders  value through share repurchases might have boosted its bottom line by limiting share count 
Nevertheless  rising costs related to interest payment  reserves for settlements  legal judgments and lawsuits  plus impairments of long lived assets might have put pressure on margins 
Earnings Whispers
Our proven model does not conclusively show that Universal Healthis likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below 
Zacks ESP  Universal Health has an Earnings ESP of  1 01   You can uncover the best stocks to buy or sell before they re reported with our  
Universal Health Services  Inc  Price and EPS Surprise
   Zacks Rank  Universal Health carries a Zacks Rank  3  which though increases the predictive power of ESP  the company needs to have a positive ESP to be confident about an earnings surprise 
Conversely  we caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies from the medical sector that you may want to consider as these stocks have the right combination of elements to come up with an earnings beat this quarter Aetna  Inc    NYSE AET    which is set to report third quarter earnings on Oct 31  has an Earnings ESP of  1 20  and a Zacks Rank  1  You can see  
Teladoc Inc    NYSE TDOC   has an Earnings ESP of  0 76  and a Zacks Rank  3  The company is set to report third quarter earnings on Nov 1 
Humana  Inc    NYSE HUM   has an Earnings ESP of  1 10  and a Zacks Rank of 3 as well  The company is set to report third quarter earnings on Nov 8 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-10-23,Zacks Investment Research,https://www.investing.com/analysis/can-admissions-rise-fuel-universal-health-uhs-q3-earnings-200220499,200220499
142174,363689,HUM,Will CNC Q3 Earnings Come In Better Than ESRX On Oct 24 ,opinion,Third quarter earnings have already crossed the halfway mark  As of Oct 18  52 S P 500 companies reported results with strong earnings numbers Per the latest   third quarter 2017 results of the 52 S P 500 members that have reported results  account for 16 7  of the index s total market capitalization  Total earnings for these companies are up 13 3  year over year on 6 9  rise in revenues  with 73 1  beating earnings per share estimates As of Oct 18  5 4  of the total Medical sector  one of the seven sectors in the S P 500 group  reported third quarter results  The beat ratio is strong with 66 7  companies surpassing bottom line expectations Sector TrendsThe sector has been in the limelight ever since Donald Trump became the President  Trump s intention to repeal and replace the Health Care Reform Act  popularly known as Obamacare  has resulted in an uncertain future for the whole sector  As a result  the medical stocks continue to be in focus The U S healthcare industry substantially benefits from the strong membership base supported by medicare expansion under Obamacare  Aggressive inorganic strategies have helped the players achieve fast paced growth  In addition  new product launches  improving service  expansion into ancillary businesses and expense management strategies are expected to add to the top line However  medical stocks face threats like the rising level of bad debt  demand for increasing investments in technological innovation  integration cost related to acquisitions and high interest expenses on debt funded acquisitions  These are likely to put pressure on the bottom line Stocks to CompareLet s take a sneak peek into two Medical sector stocks that are set to report their quarterly earnings on Oct 24 We expect the third quarter earnings for Express Scripts Holding Company   NASDAQ ESRX   to show a decline in revenues at the pharmacy benefit manager  PBM  segment  which is one of the major revenue components  The Zacks Consensus Estimate for PBM revenues stands at  23 226 billion  reflecting a decline of 4 8  from the year ago quarter Moreover  the Zacks Consensus Estimate for PBM product network is pegged at  11 069 million  down 8 9  year over year  The Zacks Consensus Estimate for PBM service revenues is  365 million  down 3 2  year over year  Lackluster performance in these segments is likely to mar Express Scripts  revenues in the third quarter Per the company s guidance for the third quarter  its total adjusted claims are expected in the range of  340  350 million  Notably  the Zacks Consensus Estimate for total claims stands at  243 million  down 2 1  sequentially Adjusted earnings per diluted share for the third quarter are estimated in the range of  1 88  1 92  representing growth of 8  to 10  on a year over year basis  This excludes any contribution from Anthem and other transitioning clients Express Scripts announced that its biggest customer  leading health insurer Anthem Inc    NYSE ANTM    is not likely to extend its pharmacy benefits management agreement  which is slated for expiration by the end of 2019  Per management  Express Scripts might lose almost 50  of its revenues related to the Anthem contract in the third quarter itself Express Scripts has the right combination of two main ingredients   a positive  and Zacks Rank  2  Buy   Notably  the Earnings ESP for Express Scripts is  0 13  You can uncover the best stocks to buy or sell before they re reported with our  Express Scripts Holding Company Price and EPS Surprise   We expect Centene Corporation s   NYSE CNC   third quarter earnings to be aided by solid Medicaid expansion For the past few quarters  Centene has been witnessing consistent growth in its membership that has been driving the overall top line   The company expects this uptrend to continue in the third quarter as well and impact revenues positively  The Zacks Consensus Estimate for total membership is currently pegged at 12 1 billion  reflecting 6 1  year over year growth The major contributor to this rising membership is Centene s continuously growing Medicaid base  Medicaid expansion one of the provision of Affordable Care Act  has benefitted Centene  This was driven by Centene s intention to continue on exchanges while other health insurers like Humana Inc   NYSE HUM   and many more are exiting it The third quarter is also likely to witness further expansion of its Medicaid business  In the third quarter  the company successfully reprocured a new statewide Medicaid contract in Georgia and Nevada  The Zacks Consensus Estimate for Medicaid membership presently stands at 5 8 billion  reflecting year over year growth of 3 6  Moreover  Centene has been taking several cost saving initiatives that are reducing the level of expenses  The margin is likely to be aided by lower expenses in the third quarter  The Zacks Consensus Estimate for total general and administrative expenses ratio is currently pegged at 0 09 compared with 9 23 in the second quarter of 2017 Centene also has the right combination of two main ingredients   a positive Earnings ESP and Zacks Rank  1  Strong Buy  to strengthen the possibility for a beat  Notably  the Earnings ESP for Centene is  2 45  Centene Corporation Price and EPS Surprise   Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-10-23,Zacks Investment Research,https://www.investing.com/analysis/will-cnc-q3-earnings-come-in-better-than-esrx-on-oct-24-200220404,200220404
142175,363690,HUM,Is A CVS Health  CVS    Aetna  AET  Deal In The Cards  ,opinion,Pharmacy giant  CVS Health   NYSE CVS    has reportedly made an offer to acquire the nation s third largest health insurer Aetna  Inc    NYSE AET   for more than  66 billion  According to the Wall Street Journal  the companies are in talks and CVS has proposed to pay more than  200 per share for the acquisition Why Aetna   the Rationale behind the DealCVS is one of the key players in the pharmacy benefit management   PBM   business in the United States  Pharmacy benefit managers  PBMs  provide formulary management  Medicare Part D services  mail order  specialty pharmacy and infusion services  retail pharmacy network management services  prescription management systems  clinical services  disease management services and medical spend management They negotiate prices with drugmakers looking for additional rebates and discounts so as to lower out of pocket costs for consumers  Formulary coverage and exclusion lists are issued by PBMs to keep consumers aware of drugs that are covered without extra out of pocket costs being incurred   Clients include insurance companies with the focus being on providing drugs that are beneficial as well as cost effective  By merging with Aetna  CVS would be able to expand coverage to the full ambit of healthcare including the medical benefits space  The merged company would also be in a better position to negotiate discounts with drug manufacturers  Moreover  Aetna s insurance plans could help boost coverage and diversify CVS s business The potential Amazon com   NASDAQ AMZN   threat could be another reason for CVS s interest in acquiring Aetna  Amazon  which is rumored to be preparing to enter the pharmacy supply channel  would be a formidable competitor for PBMs  While there is not much visibility on how Amazon plans to enter the prescription drugs business  its potential entry poses a major threat for retail pharmacy chains like CVS  By merging with Aetna  CVS would be able to strengthen its position in the PBM business with a wider coverage Changing the Healthcare IndustryThe merger  if it goes through  would change the healthcare industry the way we know it today  Of late  insurers and PBMs have been coming together especially if one keeps in mind the UnitedHealth OptumRx combination  Given the changing healthcare scenario  the efforts to repeal and replace Obamacare  the uncertainty faced by insurers as the  repeal and replace Obamacare  scenario plays out and the demand for more transparency where drug pricing is concerned  there could be more such mergers round the corner Of course  it eventually remains to be seen whether the deal actually goes through  The insurance industry has seen quite a few failed deals recently including Aetna s attempts to acquire Humana  NYSE HUM  and Anthem s plans to acquire Cigna  NYSE CI  with both deals running into regulatory roadblocks   While CVS is a Zacks Rank  3  Hold  stock  Aetna is a Zacks Rank  1  Strong Buy  stock  You can see  Wall Street s Next AmazonZacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-10-26,Zacks Investment Research,https://www.investing.com/analysis/is-a-cvs-health-cvs--aetna-aet-deal-in-the-cards-200221518,200221518
142176,363691,HUM,Will Higher Admissions Aid HCA Healthcare  HCA  Q3 Earnings ,opinion,"HCA Healthcare  Inc    NYSE HCA   is scheduled to report third quarter 2017 results on Oct 31  before the opening bell The company has an impressive surprise history  It surpassed estimates in two of the last four quarters  with an average positive surprise of 3 6  Q3 ExpectationsWe expect earnings to reflect the prevailing industry wide softness in volumes  Factors such as payor initiatives to move volumes away from hospitals  rising deductibles and prevalence of high deductible health plans  and increased proportion of hospital care to be paid by consumers are driving away volumes  The same is likely to be seen in the quarter Patient admissions will  however  be sustained on the back of organic and inorganic growth measures  The Zacks Consensus Estimate for total admissions  one of the key revenue drivers   represents the total number of patients admitted to the company s hospitals and is a general measure of inpatient volume  is 483 000  which reflects year over year growth of 2 8  Shares bought back by the company in the third quarter will cushion the bottom line  The company has not paid regular dividend since its IPO in 2011  It prefers share buyback over dividend payment for allocating capital and will maintain this policy Preliminary ResultsRecently  the company announced preliminary financial and operating results for the to be reported quarter  It reported revenues of approximately  10 7 billion  up 4 1  year over year and adjusted EBITDA of approximately  1 8 billion  down 9 2  year over year  Earnings per share of  1 21 per share reflected a decline 25  year over year   The results bore the impact of recent hurricanes  which caused loss of  140 million in some of the company s major markets Same facility admissions in the third quarter increased 0 6   while same facility equivalent admissions increased 0 3  year over year  Same facility emergency room visits increased 0 3  year over year  The Zacks Consensus Estimate for same facility equivalent admissions points to an increase of 0 5  Here s what our quantitative model predicts Our proven model does not conclusively show that HCA Healthcare is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank of  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  This is not the case here as you will see below Zacks ESP  HCA Healthcare has an Earnings ESP of  14 89   This is because the Most Accurate estimate of  1 22 per share is lower than the Zacks Consensus Estimate of  1 43   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  HCA Healthcare carries a Zacks Rank  5  Strong Sell   We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies from the health care sector that you may want to consider as these have the right combination of elements to beat on earnings in the third quarter Aetna  Inc    NYSE AET   is set to report earnings results on Oct 31 with an Earnings ESP of  2 01  and a Zacks Rank  1  You can see  Teladoc Inc    NYSE TDOC   has an Earnings ESP of  15 65  and a Zacks Rank  3  The company is set to report financial results on Nov 1 Humana  Inc    NYSE HUM   has an Earnings ESP of  0 43  and a Zacks Rank of 3  The company is set to report earnings on Nov 8 
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-27,Zacks Investment Research,https://www.investing.com/analysis/will-higher-admissions-aid-hca-healthcare-hca-q3-earnings-200221545,200221545
142177,363692,HUM,Will Lower Health Care Revenues Mar Aetna  AET  Q3 Earnings ,opinion,"Aetna Inc    NYSE AET    scheduled to report third quarter results on Oct 31  is expected to witness a decline in revenues in its Health Care segment due to lower contribution from Commercial health insurance partly offset by premium increase in Government business  The Zacks Consensus Estimate for the same is  14 4 billion  down 4  year over year Medical Benefit Ratio  a metric used to measure medical costs as a percentage of premium revenues  is expected to increase in the third quarter  led by an unfavorable performance in individual Commercial products The company projects an increase in the ratio driven primarily by the suspension of the health insurer fee and experience rating pressure in the company s Group Commercial and Group Medicare Advantage products  partially offset by projected improvement in its Individual Commercial Insured products  The Zacks Consensus Estimate for the same is 84   up from 82  in the year ago quarter The Zacks Consensus Estimate for total medical membership  one of the key drivers of revenues is 22 14 million  down 4 2  year over year  The decline is likely to be driven by lower membership in the company s public exchange compliant Individual and Small Group products The company s focus on managing costs will keep a check on its operating expenses In the first quarter  Aetna resumed its share buyback which was terminated due to its planned merger with Humana  Share repurchases made by the company in the third quarter will help to lift its earnings Here is what our quantitative model predicts Our proven model shows that Aetna has the right combination of the two key ingredients to beat earnings estimates Zacks ESP    which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  1 68   This is because the Most Accurate estimate of  2 12 is pegged higher than the Zacks Consensus Estimate of  2 09 The positive ESP is a meaningful indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Aetna carries a Zacks Rank  1  Strong Buy   Note that stocks with a Zacks Rank of  1  2 or 3 have a significantly higher chance of beating on earnings Other Stocks to ConsiderHere are some companies from the health care sector that you may want to consider as these have the right combination of elements to beat on earnings in the third quarter Cigna Corp    NYSE CI    is set to report results on Nov 2  It has an Earnings ESP of  0 43  and a Zacks Rank  2  Buy   You can see   Teladoc Inc    NYSE TDOC   has an Earnings ESP of  0 76  and a Zacks Rank  3  Hold   The company s earnings release is slated for Nov 1 Humana  Inc    NYSE HUM   has an Earnings ESP of  1 10  and a Zacks Rank of 3  The company is set to report results on Nov 8 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-27,Zacks Investment Research,https://www.investing.com/analysis/will-lower-health-care-revenues-mar-aetna-aet-q3-earnings-200221544,200221544
142178,363693,HUM,Will High Costs Dent Envision Healthcare  EVHC  Q3 Earnings ,opinion,"Envision Healthcare Corp    NYSE EVHC   is scheduled to report third quarter 2017 results on Oct 31  after market close 
Last quarter  this health services company outperformed the Zacks Consensus Estimate by 3 7   However  earnings declined year over year due to an increase in expense  which outdid revenue growth 
The company does not have an impressive surprise history  Though it missed estimates in only one the last four quarters  the average is a negative earnings surprise of 0 7   This is depicted in the graph below 
Q3 Flashback
The company is likely to see lower revenues from its Ambulatory Services segment  which experienced soft business volumes in the past few quarters 
Moreover  the company is reeling under escalating operating expenses for several quarters  due to higher salaries and benefits expenses  Most alarming is the rate of increase in operating expense  which has overshadowed the revenue growth rate  thereby thwarting bottom line growth  The same is expected to be seen in the to be reported quarter 
A huge debt load is also niggling Envision Healthcare  Its total debt has been swelling since 2013  leading to a spike in interest expense  This  in turn  will dent its operating margins 
The quarter is likely to see increased interest expense as a result of increased borrowings related to the merger and incremental term loan borrowings to fund recent acquisitions 
We  nevertheless  expect to see an increase in revenues from the company s Physician Services segment  which contributes nearly 84  of the company s revenues   driven by synergy from recent acquisitions as well as organic growth  Revenue growth is expected to come from higher patient volumes as well as improved pricing  We also expect to see improved EBIDTA which must have benefited from merger related synergies 
The company s Ambulatory service segment will likely report a decline in revenues due to disposal of centers 
Earnings Whispers
Our proven model does not conclusively show that Envision Healthcare is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank of  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  This is not the case here as you will see below 
Zacks ESP  Envision Healthcare has an Earnings ESP of  10 98   This is because the Most Accurate estimate of 78 cents per share is below the Zacks Consensus Estimate of 88 cents  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Envision Healthcare carries a Zacks Rank  5  Strong Sell   We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks to ConsiderHere are some companies from the health care sector that you may want to consider as these have the right combination of elements to beat on earnings in the third quarter Aetna  Inc    NYSE AET   is set to report results on Oct 31  It has an Earnings ESP of  1 68  and a Zacks Rank  1  You can see  
Teladoc Inc    NYSE TDOC   has an Earnings ESP of  15 65  and a Zacks Rank  3  The company s earnings release is slated for Nov 1 
Humana  Inc    NYSE HUM   has an Earnings ESP of  0 43  and a Zacks Rank  3  The company is set to report results on Nov 8 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-27,Zacks Investment Research,https://www.investing.com/analysis/will-high-costs-dent-envision-healthcare-evhc-q3-earnings-200221527,200221527
142179,363694,HUM,Will Increased Visits Drive Teladoc s  TDOC  Q3 Earnings 	,opinion,Teldoc Inc    NYSE TDOC   third quarter results  scheduled for Nov 1  are expected to witness an increase in patient visits  one of the major driver of the company s revenues Telehealth services provided by the company are fast gaining acceptance due to their flexibility  cost effectiveness and superior quality  which are driving demand  This must have consequently propelled patient visits in the to be reported quarter  Also  the acquisition of HealthiestYou closed in 2016 is expected to result in higher visits and call volumes  The Zacks Consensus Estimate for the same is set at 293 721  up 45  year over year  The company s guidance for the same is between 275 000 and 300 000   A major component of the company s revenues  subscription access fees which account for 80  to 85  of the company s revenues  is driven primarily by the number of clients  the number of members in a client s population  the number oof services contracted for by a client and the contractually negotiated prices of the company s service Since the company has been continuously adding a number of clients by virtue of its superior service  a wide network of doctors and round the clock medical assistance  this revenue component is expected to see a surge in the third quarter  The Zacks Consensus Estimate for the same is  51 million  which translates into year over year growth of 83  The company is in its growth phase and incurring heavy expenditure in the form of substantial investments made to acquire new clients  build its proprietary network of healthcare providers and develop its technology platform Thus  the bottom line will see a drain from huge expenses on higher advertising  sales  technology and development  general and administrative functions  and depreciation and amortization  We  however  expect expenditures to decline as the company has started to realize leverage from the scale of its operations Teladoc  Inc  Price and EPS Surprise   Guidance for Q3The company expects net loss per share  based on 56 5 million weighted average shares outstanding  between a loss of 56 cents and 58 cents Revenues are expected in the range of  67  68 million   Adjusted EBITDA is expected in the range of a loss of  2  3 million   Membership is expected between 22 0 million and 22 5 million Here is what our quantitative model predicts Our proven model shows that Teladoc has the right combination of the two key ingredients to beat earnings estimates Zacks ESP    which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  15 65  The positive ESP is a meaningful indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Teladoc carries a Zacks Rank  3  Hold   Note that stocks with a Zacks Rank of  1  2 or 3 have a significantly higher chance of beating on earnings Conversely  we caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks to ConsiderAetna Inc    NYSE AET   is set to report results on Oct 31  It has an Earnings ESP of  1 68  and a Zacks Rank  1  Strong Buy    You can see  Cigna Corp    NYSE CI     is set to report results on Nov 2  It has an Earnings ESP of  0 43  and a Zacks Rank  2  Buy  Humana  Inc    NYSE HUM   has an Earnings ESP of  1 10  and a Zacks Rank of 3  The company is set to report results on Nov 8 Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-10-29,Zacks Investment Research,https://www.investing.com/analysis/will-increased-visits-drive-teladocs-tdoc-q3-earnings-200257092,200257092
142180,363695,HUM,Cigna  CI  Q3 Earnings Beat On Higher Enrollment  Guides Up ,opinion,"Cigna Corp    NYSE CI   reported third quarter 2017 earnings per share of  2 83  beating the Zacks Consensus Estimate of  2 36  Earnings also grew 46  year over year Better than expected earnings were primarily driven by broad based growth across its business segments Other DetailsCigna posted revenues of  10 27 billion  which surpassed the Zacks Consensus Estimate of  10 13 billion  Revenues grew 4 7  year over year Total benefits and expenses of  9 6 billion increased 5  year over year Operating expense ratio of 21 1  improved 100 basis points year over year Premium were up 5 6  year over year to  8 billion  while fees increased 4 7  to  1 14 billion The company medical enrollment grew to 15 82 million from 15 18 million in the year ago quarter  driven by growth in its Commercial market segments Cigna Corporation Price  Consensus and EPS Surprise   Strong Segment PerformanceGlobal Health Care  Premiums and fees from the segment increased 6  year over year to  7 2 billion  The improvement was driven by customer growth and specialty contributions in the Commercial employer group  However  the upside was partially offset by reductions in Government customers Adjusted operating earnings were  575 million  up 38 2  year over year on strong medical and specialty results  and continued effective medical cost Global Supplemental Benefits  Premiums and fees from this segment climbed 12 5  year over year to  937 million on the back of continued business growth Adjusted operating income increased 34 6  year over year to  109 million  reflecting business growth  favorable claims experience  particularly in South Korea  and effective operating expense management Global Disability and Life  Premiums and fees decreased 0 9  year over year to  1 02 billion The segment reported adjusted operating income of  73 million  up 37 8  year over year  reflecting a favorable claims experience in life business Financial PositionCash and cash equivalents were  3 66 billion at Sep 30  2017  up from  3 19 billion at year end 2016 Cigna s long term debt of  5 21 billion as of Sep 30  2017 increased from  4 76 billion as of Dec 31  2016 Year to date  the company has repurchased 13 2 million shares of common stock for approximately  2 3 billion 2017 Guidance IncreaseCigna pulled up its 2017 earnings guidance after strong results  It expects adjusted income from operations of  2 60 billion to  2 65 billion  previous estimate was  2 50 billion to  2 58 billion   or  10 20 to  10 40 per share   9 75  10 05 previously  The company expects a revenue growth rate of approximately 4  and global medical customer growth of nearly 0 65 million Our TakeCigna s results reflect broad based growth across its business segments  The company is poised for long term growth on the back of its robust Global Supplemental business  growing government business and increasing membership  A strong capital position and resumption of share buyback are the other positives  The company has also been successful in maintaining its medical cost ratio at low levels Zacks Rank and Performance of Other InsurersCurrently  Cigna carries a Zacks Rank  2  Buy   You can see the complete list of today s Zacks  1 Rank stocks here Among the other firms in the health care sector that have reported their second quarter earnings so far  the bottom line at Aetna Inc    NYSE AET    Humana Inc    NYSE HUM   and UnitedHealth Group Inc    NYSE UNH   beat their respective Zacks Consensus Estimate 
Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-11-01,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-q3-earnings-beat-on-higher-enrollment-guides-up-200257825,200257825
142203,363718,HUM,Cigna rebuffs Anthem s  deeply disappointing  proposal,news," Reuters    Health insurer  Cigna Corp   N CI  rebuffed Anthem Inc s  N ANTM   47 billion merger proposal on Sunday  saying it was  deeply disappointed  with Anthem s recent actions and the offer was not in the best interest of shareholders  Anthem s offer for smaller rival Cigna is part of a daisy chain of potential deals in the health insurance sector  The biggest players are seeking acquisitions to boost membership in government paid healthcare plans and employer based insurance  The bigger the insurer  the more negotiating power it has with prices and improving its doctor networks  Cigna Chairman Isaiah Harris  Jr  and Chief Executive David Cordani wrote a letter to Anthem s board outlining reasons why the company was rejecting Anthem s stock and cash offer  The list included Anthem s  lack of growth strategies   complications related to its membership of Blue Cross Blue Shield Association and its  massive  data breach in February   We have attempted to engage in dialogue so that we can understand and consider these issues   the letter said   Unfortunately  you have continued to avoid addressing these key concerns and have failed to demonstrate what has changed over the past few months   Anthem  the second largest U S  health insurer  said in a statement on Saturday that had made four offers for Cigna in June  Cigna s board is also concerned over Anthem s  insistence  that one person   Joseph Swedish  Anthem s president and CEO   assume four roles of the combined company  chairman  CEO  president and head of integration    Your proposal raises very serious questions regarding your views on proper governance  board oversight and risk management and underestimates the complexity of combining our organizations   A representative for Anthem was not immediately available to comment  In another strand of the consolidation efforts  Cigna and  Aetna Inc   N AET  are vying to acquire  Humana Inc   N HUM  according to sources  
Anthem s Swedish published a letter on Saturday that said it doubted that investors supported Cigna s rejection over Anthem s refusal to guarantee that the CEO role would go to Cordani  Cigna  according to Swedish s letter  had also refused to sign a two week standstill agreement with Anthem that would prevent both sides from having other deal talks ",2015-06-22,Reuters,https://www.investing.com/news/stock-market-news/cigna-calls-anthem's-offer-'inadequate'-347531,347531
142204,363719,HUM,U S  stocks surge amid Greek developments  flurry of M A activity,news,"Investing com    U S  stocks moved broadly higher on Monday as all three major indices rallied amid positive developments in longstanding Greek Debt talks  
The two sides in tense  five month long negotiations now appear optimistic that a temporary deal could reached later this week  unlocking critical aid to the cash strapped Mediterranean nation  On Sunday night  Greece made concessions in a new proposal on early retirement and Value Added Taxes to help bridge a wide gap with its international creditors 
Following one of its productive weeks in the last two months  the Dow Jones Industrial Average and the S P 500 Composite index gained more than 0 5  on Monday  The NASDAQ Composite index  meanwhile  closed at an all time record high  bolstered by gains in health care and consumer discretionary stocks  The Dow rose 103 83 or 0 58  to 18 119 78 on Monday  while the NASDAQ rose 36 97 or 0 72  to 5 153 97  eclipsing a previous record set last week 
The S P 500 jumped 12 86 or 0 61  to 2 122 85  as nine of 10 sectors closed in the green  Of the 10 industries on the S P  only Utilities closed lower on Monday  as yields on U S  10 Year Treasuries soared more than 10 basis points 
The top performer on the Dow on Monday was  Goldman Sachs Group  Inc  NYSE GS   which gained 3 15 or 1 48  to 216 34  The worst performer was Cisco Systems Inc  NASDAQ CSCO   which fell 0 09 or 0 31  to 28 94 
The biggest gainer on the NASDAQ was  American Airlines Group   NASDAQ AAL   which gained 1 42 or 3 42  to 42 98  Earlier on Monday  Barron s reported that airlines stocks could soar anywhere from 15 to 50  in a period of a year  amid lower fuel costs and less competition  The worst performer was Wynn Resorts Limited  NASDAQ WYNN   which dipped 2 27 or 2 20  to 100 84  For the year  shares in Wynn Resorts are down more than 45  
On the S P 500  shares in Williams Companies Inc  NYSE WMB  surged more than 23  after the pipeline giant rejected a takeover bid from rival  Energy Transfer  Equity LP  NYSE ETE   estimated at  48 billion  Williams Companies Inc  NYSE WMB  jumped 12 69 or 26 25  to 61 03  The worst performer was  Humana Inc   NYSE HUM   which plunged 12 70 or 6 28  to 189 61  amid reports of a flurry of merger activity among the major health care insurers throughout the U S  While Cigna Corporation  NYSE CI  reportedly rejected a  47 billion acquisition attempt from Anthem on Monday  rumors also surfaced that the Connecticut based insurer is vying with  Aetna Inc   NYSE AET  to purchase Louisville based Humana  
Shares in  Martha Stewart Living Omnimedia  Inc  NYSE MSO  plummeted 0 86 or 12 32  to 6 12  after Sequential Brands purchased the easy recipe and home d cor company for  353 million  Under the deal  Stewart will remain as the company s Chief Creative Officer 
Elsewhere  shares in  Ambarella Inc   NASDAQ AMBA  crashed more than 20  to 94 73  after a short seller set a 12 month price target for the video processing chip maker at  60 
On the New York Stock Exchange  advancers outnumbered decliners by a 1 883 to 1 277 margin ",2015-06-22,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-stocks-surge-amid-greek-developments,-flurry-of-m-a-activity-347692",347692
142205,363720,HUM,Anthem confident  but experts see antitrust hurdles to Cigna deal,news,"By Caroline Humer and Diane Bartz NEW YORK WASHINGTON  Reuters    U S  health insurer Anthem Inc  N ANTM  on Monday dismissed concerns that buying smaller competitor  Cigna Corp   N CI  would be considered anti competitive  even as antitrust experts said the combination would earn regulatory scrutiny  Any merger could require asset sales and would be complicated by potential deals among other insurers  which after years of change due to President Barack Obama s healthcare reform are now scrambling to tie up  Insurers are seeking to use scale to trim administrative costs and negotiate lower prices with doctors  moves they say will make plans more affordable but which regulators will closely scrutinize for the opposite effect on consumers  Besides the possible Anthem deal   Humana Inc   N HUM  is considering a sale  possibly to Cigna or  Aetna Inc   N AET   a source familiar with the situation previously told Reuters  The Wall Street Journal also reported that UnitedHealth Group Inc  N UNH  was interested in Aetna  The U S  Department of Justice will look at how the proposed combinations   with deal values estimated in the tens of billions of dollars   would increase market share in each county or region for each type of health insurance plan that the companies offer  antitrust experts say   If two deals were announced in the insurance industry  that would likely trigger more scrutiny from antitrust enforcers  said Barak Richman  who teaches at Duke University School of Law    The economics of the health insurance market makes it a complicated analysis  These are not doomed transactions   Richman said  The Justice Department has been aggressive  one expert said  pointing to Comcast  NASDAQ CMCSA  s failed bid for Time Warner Cable  NYSE TWC   It would likely be concerned if the number of competitors in the product market of any county dropped to three or fewer  said Andre Barlow  a Justice Department veteran now at Doyle  Barlow and Mazard PLLC       Any time you re down to two players or less you have a problem that needs to be resolved   said Barlow   Three  you may still have to divest   The mergers of the No  2 insurer with the No  5 insurer  and the No  3 with the No  4 insurer  could spark a change in the way they review deals  he said    There s no guarantee that they would review transactions within an industry similar to how they ve treated them in the past   Barlow said  Anthem  which runs Blue Cross Blue Shield plans in 14 states  disclosed on Saturday that it had offered to buy Cigna for  47 billion but said the deal was held up over issues like the role of Cigna s CEO at the merged company  Cigna on Sunday confirmed rejecting the offer  citing its own concerns about Anthem s management and saying the combination would run afoul of the rules governing members of the Blue Cross Blue Shield Association  The Blue Cross Blue Shield Association is made up of 37 different health plans  of which Anthem is the largest  who work together to create a national network of health insurance coverage    We believe there is a consensus of where there is overlap between our companies and that no substantive antitrust or insurance regulatory issues are present that would prevent completion of the transaction   Anthem CEO Joseph Swedish said Monday  By most measures  U S  insurance markets are extremely concentrated  Using a measure called the Herfindahl Hirschman Index  which defines a  highly concentrated  market as over 2 500 points  the U S  market for small group insurance is 3 841 and 4 038 for large groups  according to the Kaiser Family Foundation  Kaiser Family Foundation data of insurers in the large group and small group market show that in no instance is Aetna and Humana in the top three in any state  Anthem and Cigna overlap in just one state   New Hampshire  where their combined share for large groups is 67 percent   Both Aetna and Humana are in nine states in Medicare Advantage  Combined  they would have market share of 88 percent in Kansas  80 percent in West Virginia  58 percent in Iowa and 51 percent in Missouri  Anthem and Cigna are not the top three providers in any state for Medicare Advantage but do overlap in counties in a handful of states   The insurers don t compete the way they should and premiums are higher than they should be   said Leemore Dafny  an expert on the insurance industry at the Kellogg School of Management at Northwestern University   If past is prologue  insurance consolidation is unlikely to lead to lower premiums  In fact the contrary is true   
Cigna shares rose 4 7 percent to  162 60 while Anthem added 3 6 percent at  171 04 ",2015-06-22,Reuters,"https://www.investing.com/news/economy-news/anthem-confident,-but-experts-see-antitrust-hurdles-to-cigna-deal-347693",347693
142206,363721,HUM,Zacks com Featured Highlights  Humana  Alibaba Group Holding  Honeywell International  AGNC Investment And Wintrust Financial,opinion,For Immediate ReleaseChicago  IL   October 10  2017   Stocks in this week s article include Humana Inc   NYSE   NYSE HUM        Alibaba Group Holding Limited  NYSE   NYSE BABA        Honeywell International Inc   NYSE   NYSE HON        AGNC Investment Corporation  NASDAQ   NASDAQ AGNC       and Wintrust Financial Corporation  NASDAQ   NASDAQ WTFC       Screen of the Week of Zacks Investment Research 5 Low Leverage Stocks That Can Be Part of Your PortfolioIn the complex world of investment  debt financing is a well known strategy adopted by the majority of corporations for expanding their business operations from time to time  Dearth of ample funds is the primary driving force behind this strategy  Yet  resorting to debt is still considered a taboo as it carries the burden of interest payments In particular  companies with large debt loads are more vulnerable during economic downturns and can even go bankrupt in the worst case scenario  Of course  companies may resort to equity financing as an alternative option to boost their financial resources  However  it is the easy and cheap availability of debt that makes it more popular among corporations In fact  statistics indicate that America  the richest economy in the world  is the biggest borrower too  Notably  huge spending on wars  big tax cuts and stimulating economic programs have all added to the nation s burden over the years  The Congressional Budget Office estimates that the debt held by the public will rise to 150  of the economy s GDP in 2047 from 77  currently Nevertheless  this should not discourage investors from spending on U S  stocks  since debt has been part of the economy since its foundation and yet the country stands atop others  What investors need to do is choose stocks with caution  thus avoiding those that carry high debt loads Here comes the significance of leverage  better to say financial leverage  which indicates the degree to which a company utilizes debt to boost its operations and earn escalated profit margins  Usually investors tend to avoid companies bearing higher degree of financial leverage The next question that comes to our mind is that how can we measure a company s degree of financial leverage  To this end  several leverage ratios have been constructed as efficient tools to evaluate a company s credit level to support prudent equity investments The most popular among them is the debt to equity ratio Analyzing Debt to EquityDebt to Equity Ratio   Total Liabilities Shareholders  EquityThis metric is a liquidity ratio that indicates the amount of financial risk a company bears  A company with a lower debt to equity ratio implies that it has a more or less financially stable business  thereby making it a more worthy investment opportunity With the Q3 reporting cycle set to gain steam in the coming weeks  an investor must be looking for solid growth stocks  Blindly investing in stocks displaying solid earnings growth without considering their debt level might not be a wise move  As  uncertainty can hit the global equity market any time  it is reasonable to expect that investors will be more attracted to companies with low leverage than high earnings growth The Winning StrategyIn theory  the optimal capital structure for a company is one with the ideal debt to equity ratio that maximizes its value and minimizes its cost of capital  Since  in practice  screening stocks based on these criteria is a bit difficult  herein  we choose low leverage stocks as these are considered safe bets However  an investment strategy based solely on the debt to equity ratio might not fetch the desired outcome  To choose stocks that have the potential to give you steady returns  we have expanded our screening criteria to include some other factors Here are the other parameters Debt Equity less than X Industry Median  Stocks that are less leveraged than their industry peers Current Price greater than or equal to 10  The stocks must be trading at a minimum of  10 or above Average 20 day Volume greater than or equal to 50000  A substantial trading volume ensures that the stock is easily tradable Percentage Change in EPS F 0  F  1  greater than X Industry Median  Earnings growth adds to optimism  leading to a stock s price appreciation Estimated One Year EPS Growth F 1  F 0  greater than 5  This shows earnings growth expectation Zacks Rank  1  Strong Buy  or  2  Buy   No matter whether market conditions are good or bad  stocks with a Zacks Rank  1 or 2 have a proven history of success Excluding stocks that have a negative or a zero debt to equity ratio  here are five of the 46 stocks that made it through the screen Humana Inc   NYSE       It is a health services company that facilitates the delivery of health care services through networks of providers to its medical members  The company carries a Zacks Rank  2 and came up with an average positive earnings surprise of 7 24  in the trailing four quarters Alibaba Group Holding Limited  NYSE       The companyoperates online and mobile marketplaces in retail and wholesale trade  as well as cloud computing and other services It carries a Zacks Rank  2 and delivered an average positive earnings surprise of 12 16  in the trailing four quarters Honeywell International Inc   NYSE       It is a global diversified technology and manufacturing company with a wide range of aerospace products and services  It pulled off an average positive earnings surprise of 1 08  in the trailing four quarters and carries a Zacks Rank  2  You can see AGNC Investment Corporation  NASDAQ       It is a real estate investment trust  REIT  that focuses on leveraged investments in agency MBS  This includes residential mortgage pass through securities and collateralized mortgage obligations  CMOs   The Company carries a Zacks Rank  2 and delivered an average positive earnings surprise of 11 73  in the trailing four quarters Wintrust Financial Corporation  NASDAQ       It a bank holding company  which provides banking services  trust and investment services  commercial insurance premium financing  short term accounts receivable financing  and certain administrative services  The company carries a Zacks Rank  2 and delivered an average positive earnings surprise of 7 17  in the trailing four quarters Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and back testing software The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at   Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector  Sign up now for your free trial today and start picking better stocks immediately  And with the backtesting feature  you can test your ideas to see how you can improve your trading in both up markets and down markets  Don t wait for the market to get better before you decide to do better  Start learning how to be a better trader today  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material About Screen of the WeekZacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use  Each week  Zacks Profit from the Pros free email newsletter shares a new screening strategy  Learn more about it here About Zacks Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros   In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Contact  Jim GiaquintoCompany  Zacks comPhone  312 265 9268Email  Visit  Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2017-10-09,Zacks Investment Research,https://www.investing.com/analysis/zackscom-featured-highlights-humana-alibaba-group-holding-honeywell-international-agnc-investment-and-wintrust-financial-200217988,200217988
142207,363722,HUM,Molina Healthcare Appoints CEO  Will New Leadership Help ,opinion,"Molina Healthcare  Inc    NYSE MOH   has appointed Joseph M  Zubretsky as its new president and chief executive officer  CEO   effective Nov 6  2017 Zubretsky has to his credit a career spanning 35 years in the insurance and financial services industry  Most recently  he served as president and CEO of The Hanover Insurance Group and was a member of its board Until recently  Molina Healthcare was run by the two sons of its founders   J  Mario Molina and John Molina  Both were  however  ousted following the company s poor performance The appointment of the new CEO is one of the steps taken in the massive restructuring exercise undertaken by management to take the company back to profitability In the second quarter  the company s 2017 earnings guidance was withdrawn due to uncertainty regarding cost sharing reductions  cost trend in Florida  Illinois  New Mexico  and Puerto Rico  health plans and variability around timing of benefits and costs related to the restructuring plan Molina Healthcare s share price has returned 9 1  since the removal of the Molina brothers compared with the growth of 11 5  by the  it belongs to Other restructuring and profitability improvement steps include reduction in corporate and health plans workforce by 10   termination of public exchange participation in Utah and Wisconsin with additional states in review  and restructuring of Direct delivery operations These measures are aimed at generating  300  400 million in savings upon completion of restructuring in late 2018  The company expects nearly  200 million in savings related to staff reductions to fully contribute to 2018 earnings  The company expects an additional  130  150 million restructuring cost in the second half of 2017   Zubretsky  with his valuable experience is deemed as the perfect fit to lead the company successfully during this transformative period  He boasts a track of strong leadership across multiple businesses  both inside and outside managed care  He also successfully restructured other organizations earlier The transformation of the entire enterprise into a leaner  more streamlined organization  will enhance decision making  improve the company s operating performance  and aid its margins  Though the seeds of reformation have been planted  these will take time to bear fruit Molina Healthcare carries a Zacks Rank  5  Strong Sell    Some better ranked stocks in the same space are Anthem Inc    NYSE ANTM    Humana Inc    NYSE HUM   and Centene Corp    NYSE CNC    While Humana and Centene sport a Zacks Rank  1  Strong Buy  each  Anthem carries a Zacks Rank  2  Buy   You can see  Centene beat estimates in three of the last four quarters  with an average positive surprise of 7 7   Also  the Zacks Consensus Estimate for 2017 and 2018 have been raised 3 4  and 1 3   respectively  over the last 90 days Humana beat estimates in each of the last four quarters with an average positive surprise of 7 2   Also  the Zacks Consensus Estimate for 2017 and 2018 have gone up 4 1  and 1 4   respectively  in the last 90 days Anthem beat estimates in three of the last four quarters  with an average positive surprise of 8 6   Also  the stock has seen the Zacks Consensus Estimate for 2017 and 2018 being revised 0 7  and 0 3  upward  respectively  over the last 90 days 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-10,Zacks Investment Research,https://www.investing.com/analysis/molina-healthcare-appoints-ceo-will-new-leadership-help-200218205,200218205
142208,363723,HUM,Zacks com Featured Highlights Include Article Article Michael Kors Holdings  Humana  KEMET  Greenbrier Companies And Thor Industries,opinion,For Immediate ReleaseChicago  IL   October 12  2017   Stocks in this week s article Michael Kors Holdings Limited  NYSE    NYSE KORS        Humana Inc   NYSE    NYSE HUM        KEMET Corporation  NYSE    NYSE KEM        Greenbrier Companies  Inc   NYSE    NYSE GBX       and Thor Industries  Inc   NYSE    NYSE THO       Screen of the Week of Zacks Investment Research by Believe in Driehaus Strategy and Buy These 5 Momentum StocksInvestors  who generally have a high risk appetite  focus on momentum stocks to eke out strong gains  In this context  Richard Driehaus  investing strategy  which is based on the  buy high and sell higher  principle  Driehaus earned a place in Barron s All Century Team following the success of the investing strategy The American Association of Individual Investors  AAII  proved that the strategy has the potential to offer high returns  AAII s portfolio  which was developed following the strategy  returned 13 5  and 18 1  in the five  and 10 year time frames  respectively  compared with  1 1  and 4 2  gains registered by the S P 500  Thus investors with a high risk appetite may opt for this strategy to boost their portfolio returns A Detailed Look into the Driehaus StrategyRegarding the strategy  Driehaus once said   I would much rather invest in a stock that s increasing in price and take the risk that it may begin to decline than invest in a stock that s already in a decline and try to guess when it will turn around   In line with this insight  AAII took into account the percentage 50 day moving average as one of the key criteria before creating a portfolio following Driehaus  philosophy It is calculated by dividing the numerator  month end price minus 50 day moving average of month end price  by the 50 day moving average of the month end price  Another momentum indicator   positive relative strength   has also been included in this strategy  A positive percentage 50 day moving average indicates that the stock is trading at a price higher than its 50 day moving average level  indicating an uptrend Moreover  AAII found that Driehaus primarily focuses on strong earnings growth rates and impressive earnings projections to pick potential outperformers  Companies with a strong history of beating estimates are also given importance in this strategy  which was made to provide better returns over the long term Screening ParametersIn order to make the strategy more profitable  we have considered only those stocks that have a Zacks Rank  1  Strong Buy  or 2  Buy  and a Momentum Score of A or B  Our research shows that stocks with a  of A or B when combined with a Zacks Rank  1 or 2 offer the best upside potential   Zacks Rank equal to  1 Only Strong Buy rated stocks can get through  You can see     Last 5 year average EPS growth rates above 2  Strong EPS growth history ensures improving business   Trailing 12 month EPS growth higher than 0 and industry median Higher EPS growth compared to the industry average indicates superior stocks   Last four quarter average EPS surprise greater than 5  Positive EPS surprise indicates potential   Positive   50 day moving average and relative strength over 4 weeks High   50 day moving average and relative strength signal uptrend   Momentum Score equal to or less than B Favorable momentum score indicates that it is ideal to take advantage of the momentum with the highest probability of success These few parameters have narrowed down the universe of over 7 863 stocks to only 11 Here are five of the 11 stocks Michael Kors Holdings Limited  NYSE       is a retailer of branded women s apparel and accessories  and men s apparel  The company has a Momentum Score of A and an average four quarter positive earnings surprise of 11 5  Humana Inc   NYSE       is a health and well being company  The company has a Momentum Score of A and an average four quarter positive earnings surprise of 7 2  KEMET Corporation  NYSE       is a manufacturer and seller of passive electronic components  The company has a Momentum Score of B and an average four quarter positive earnings surprise of 64 8  Greenbrier Companies  Inc   NYSE       is a designer  manufacturer and marketer of railroad freight car equipment  The company has a Momentum Score of B and an average four quarter positive earnings surprise of 11 4  Thor Industries  Inc   NYSE       is a designer  manufacturer and seller of recreational vehicles  The company has a Momentum Score of B and an average four quarter positive earnings surprise of 11 9  You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at   Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector  Sign up now for your free trial today and start picking better stocks immediately  And with the backtesting feature  you can test your ideas to see how you can improve your trading in both up markets and down markets  Don t wait for the market to get better before you decide to do better  Start learning how to be a better trader today  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material About Screen of the WeekZacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use  Each week  Zacks Profit from the Pros free email newsletter shares a new screening strategy  Learn more about it here About ZacksZacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros   In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Contact  Jim GiaquintoCompany  Zacks comPhone  312 265 9268Email  Visit  Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2017-10-11,Zacks Investment Research,https://www.investing.com/analysis/zackscom-featured-highlights-include-article-article-michael-kors-holdings-humana-kemet-greenbrier-companies-and-thor-industries-200218407,200218407
142209,363724,HUM,WellCare  WCG  Unit Receives Favorable Star Ratings From CMS,opinion,WellCare  an affiliate of WellCare Health Plans  Inc    NYSE WCG    recently received favorable ratings from Centers for Medicare   Medicaid Services   CMS   for its Plan Year 2018 Medicare plans  CMS has given a rating of four out of five stars for the quality and service of its Medicare plans Florida based WellCare covered nearly 768 000 Medicaid members as of Jun 30  2017  The company is now enrolling more Medicare eligible Floridians for the 2018 Medicare annual election period ending on Dec 7  2017 Management believes that these favorable ratings are a result of the collaborative efforts of its associates and providers who aimed at providing WellCare s members continued access to quality care Medicare Advantage has significantly grown on the back of demographic changes in the U S health insurance market  Revenues from the managed care plans of Medicare Advantage are likely to grow as baby boomers retire  Players in the industry have been engaging in mergers and acquisitions  joint ventures and partnerships in order to strengthen their presence in the Medicare market WellCare has remained focused on revenue and margin growth of its Medicare business since 2015  To achieve these long term targets  the company developed its 2017 bid strategy  It has also improved its marketing and sales strategies which not only boosted the overall retention rate of existing Medicare members but also drove new enrollment rate for the company s Medicare plans WellCare s continuous focus on better serving its customers has helped the stock retain shareholders  confidence  In the last year  its shares have gained 48   outperforming the  s rally of 44  Star Ratings are calculated every year on a scale of one to five stars  five being the highest limit   and are subject to change  CMS rates MA and Medicare prescription drug plans  PDP  on the basis of how well they provide medication coverage  A number of other factors like the quality of customer service  count and frequency of member complaints  members  experience with drug plans and the level of safety associated with the drugs are also considered While assigning the ratings  CMS considers two parameters of the MA and PDPs namely  quality and performance  The MA plans are rated on the basis of their ability to take care of the members  overall health  help them manage chronic conditions  ensure positive experiences with health plan  attain member satisfaction and offer effective customer service Zacks Rank   Stocks to ConsiderWellCare presently carries a Zacks Rank  3  Hold  You can see   Investors interested in this space can consider stocks like Humana Inc   NYSE HUM    MEI Pharma  Inc   NASDAQ MEIP   and Centene Corp   NYSE CNC    While Humana and MEI Pharma sport a Zacks Rank  1  Centene carries a Zacks Rank  2  Buy  Humana s earnings surpassed expectations in three of the last four quarters with an average beat of nearly 8 6  MEI Pharma s earnings also surpassed expectations in three of the last four quarters with an average beat of nearly 67 8  Centene delivered positive surprises in three of the last four quarters with an average beat of 7 7  5 Trades Could Profit   Big League   from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-10-15,Zacks Investment Research,https://www.investing.com/analysis/wellcare-wcg-unit-receives-favorable-star-ratings-from-cms-200219063,200219063
142210,363725,HUM,UnitedHealth  UNH  Beats Q3 Earnings On Higher Membership,opinion,"UnitedHealth Group Inc    NYSE UNH   reported third quarter net operating earnings per share of  2 66  comfortably beating the Zacks Consensus Estimate of  2 57 and increasing 22 6  year over year Higher revenues  strength in both its segments  UnitedHealthcare and Optum  and membership growth led to the outperformance UnitedHealth has a tradition of guiding conservatively and then beating its own estimates to surprise investors  The company surpassed expectations in 25 out of 28 reported quarters and the quarter under review was no exception The stock gained 0 35  in the pre market trading session and we expect continued outperformance to drive the stock higher Behind the HeadlinesUnitedHealth posted net revenues of  50 3 billion  in line with the Zacks Consensus Estimate  Revenues were up 8 7  year over year  The company reported medical care ratio of 81 4   up 110 basis points year over year Operating cost ratio of 14 7  was down 50 basis points year over year Strong Segment PerformanceIn the reported quarter  the company s health benefits segmentUnitedHealthcare reported revenues of  40 7 billion  up 9 6  year over year  Earnings from operations increased 14 3  year over year to  2 4 billion Revenues from Optum improved 8 4  year over year to  22 9 billion  reflecting strong contribution from subsegments OptumHealth and OptumInsight as well as OptumRx  Earnings from operations surged 15 7  year over year to  1 7 billion  Continued focus on accelerating growth as well as improving margins and productivity through enhanced integration and business alignment led to the overall improvement of this segment Membership Enrollment SurgesThe company s medical enrollment grew to 49 million from 48 1 million in the year ago quarter Capital Position ImprovesCash and short term investments at quarter end were  19 8 billion  up 49  from the 2016 end level Debt to total capital ratio decreased to 38 2  at Sep 30  2017 from 41 3  at Jun 30  2017 Cash flows from operations were  7 4 billion  up 117  year over year Guidance UpdateEncouraged by its strong earnings performance  the company raised its outlook for 2017 earnings  The company now expects 2017 GAAP net earnings to approach  9 45 per share  versus  9 20 to  9 35 per share earlier  and adjusted net earnings to near  10 00 per share  versus previous guidance of  9 75  9 90  UnitedHealth Group Incorporated Price  Consensus and EPS Surprise   Political BackdropThe industry is lingering in uncertainty with the recent executive order by President Trump that proposes doing away with cost sharing reduction  CSR  payments that help low income Americans to pay for health insurance  This will further disrupt the public exchange markets  But UnitedHealth is better off than others in the industry given its well diversified business which shields it from strict regulations Other Stocks That Warrant a LookUnitedHealth with a Zacks Rank  3  Hold  has got this reporting cycle off to a flying start  While the other players in the space are lined up to report their financial results  below are three that are poised to beat on earnings as per our model Anthem Inc    NYSE ANTM   has an Earnings ESP of  1 57  and a Zacks Rank  3  It is expected to report third quarter earnings results on Oct 25 Aetna Inc    NYSE AET   has an Earnings ESP of  1 2  and a Zacks Rank  1  Strong Buy   The company is expected to report third quarter earnings results on Oct 31  You can see  Humana Inc    NYSE HUM   is expected to report third quarter earnings results on Nov 8  The company has an Earnings ESP of  1 4  and a Zacks Rank  3 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-16,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-unh-beats-q3-earnings-on-higher-membership-200219396,200219396
142213,363728,HUM,Ride On UnitedHealth Q3 Strength With These ETFs,opinion,"The U S  health insurer UnitedHealth Group   NYSE UNH   reported upbeat third quarter results  It topped our estimates on the bottom line and raised its full year outlook 
Net operating earnings per share of  2 66  comfortably beat the Zacks Consensus Estimate of  2 57 and were 22 6  higher year over year  Higher revenues  strength in both its segments  UnitedHealthcare and Optum  and membership growth led to the outperformance 
The company posted net revenues of  50 3 billion  in line with the Zacks Consensus Estimate  Revenues were up 8 7  year over year  The company reported medical care ratio of 81 4   up 110 basis points year over year 
Buoyed by its strong earnings performance  the company raised its outlook for 2017 earnings  The company now expects 2017 GAAP net earnings to touch  9 45 per share    and adjusted net earnings to near  10 00 per share  versus previous guidance of  9 75  9 90  
Market Impact
The market has welcomed UNH s earnings beat and its strong outlook  Shares of UNH jumped as much as 5 5  following its earnings announcement on about 3 28 times elevated volumes  After all  the stock has a VGM  Value  Growth  Momentum  Score of B and its Zacks Industry Rank is in the top 28  
Since UnitedHealth is the first insurer to report earnings and a bellwether  the result has acted as a cornerstone for the broad health insurance sector with stocks of other players in the space in green at the close on the day  Some of these players include Aetna   NYSE AET     up 2 9   Anthem   NYSE ANTM     up 1 9   Cigna   NYSE CI     up 1 2  and Humana   NYSE HUM     up 1 4  
Given UnitedHealth s strength to lift the health insurer corner of the broad health care space and the solid run up in its share price  some ETFs heavily invested in UnitedHealth could be worth watching for investors seeking to ride out the recent surge  Below we highlight a few ETFs 
iShares U S  Healthcare Providers ETF 
This ETF has exposure to companies that provide health insurance  diagnostics and specialized treatment  In total  the fund holds 45 securities in its basket with United Health at the top spot that accounts for the largest 14 19  share  The other in focus firms  AET  CI  ANTH  and HUM   are also among the top 10 holdings making up for a combined 25  of assets  read    
The fund has amassed  539 6 million in its asset base while volume is moderate at about 64 000 shares per day on average  It charges 44 bps in annual fees and expenses and added about 2  following the UNH earnings release  The product has a Zacks ETF Rank  2  Buy  
Health Care Select Sector SPDR Fund 
The 62 stock fund gives exposure to the broader healthcare sector  UnitedHealth takes the third spot with about 5 97  exposure  The  17 4 billion fund charges 14 bps in fees and gained more than 1 3  on Oct 17  XLV has a Zacks Rank  2  see all  here  
SPDR Dow Jones Industrial Average ETF   V DIA  
This fund follows the Dow Jones Industrial Average  providing exposure to 30 blue chip U S  stocks  The in focus UnitedHealth occupies the fourth position in the basket with 5 79  share  The  19 1 billion ETF is well spread out across a number of sectors with industrials  information technology  financials  consumer discretionary and health care taking the top five spots with a double digit exposure each  It charges 17 bps in annual fees from investors and has a Zacks ETF Rank  3  read    
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2017-10-17,Zacks Investment Research,https://www.investing.com/analysis/ride-on-unitedhealth-q3-strength-with-these-etfs-200219614,200219614
142216,363731,HUM,Humana Expands MA Offerings  Increases Benefits For Members,opinion,Humana Inc    NYSE HUM   recently announced that it has expanded the health plan choices for Medicare beneficiaries in six New Hampshire counties  The expansion involves multiple new Humana Medicare Advantage  MA  plan offerings during the 2018 MA and Prescription Drug Plan Annual Enrollment Period  AEP  The new Humana MA PPO plans would offer the members affordable alternatives to original Medicare or original Medicare paired with a Medicare Supplement plan  These plans would enable members to reap all the benefits of original Medicare and prescription drug plans Humana Medicare plans would be available at no or low monthly plan premiums along with low co payments for doctor visits and annual routine physical check ups  These also provide coverage for most of the annual screenings free of cost along with a broad network of physicians  specialists and hospitals  and worldwide emergency coverage This apart  the Humana MA health plans would provide members access to its nurse support service and to Silver Sneakers which is a specially designed exercise program  Silver Sneakers offers free fitness center memberships to nearly all of its Medicare Advantage members MA has significantly grown on the back of demographic changes in the U S   health  Revenues from the managed care plans of MA are likely to grow as baby boomers retire  Players in the industry like UnitedHealth Group  Inc    NYSE UNH    Anthem Inc    NYSE ANTM    WellCare Health Plans  Inc    NYSE WCG   and others have been engaged in mergers and acquisitions  joint ventures and partnerships to strengthen their presence in the Medicare market Humana has always remained focused on revenue and margin growth of its Medicare business  To achieve these long term targets  the company improved its marketing and sales strategies which not only boosted the overall retention rate of existing Medicare members but also drove new enrollment rate for the company s Medicare plans Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-10-18,Zacks Investment Research,https://www.investing.com/analysis/humana-expands-ma-offerings-increases-benefits-for-members-200219832,200219832
142236,363751,HUM,Government payments for Medicare Advantage plans to rise in 2016,news,"By Caroline Humer NEW YORK  Reuters    Payments to health insurers operating Medicare Advantage plans for the elderly and disabled will increase by 1 25 percent in 2016  the U S  government said on Monday  in response to expected growth in health spending      The announcement  by a division of the U S  Department of Health and Human Services  comes after the U S  government proposed a 0 95 percent cut in payments to insurers in February  More than 16 million people are enrolled in these plans  in which healthcare benefits are managed by private insurers  including UnitedHealth Group  NYSE UNH  Inc   Humana Inc   NYSE HUM  and  Aetna Inc   NYSE AET   Each April the government announces reimbursement rates for insurers  The information helps insurers determine how profitable it will be to sell these plans  which optional benefits to provide and in which regions and markets to compete  Shares of Humana  which receives about two thirds of its revenue from Medicare Advantage plans  rose about 1 percent to  180 in after hours trading  UnitedHealth  Aetna and Anthem Inc were mostly unchanged  The increase comes after many years of cuts to Medicare Advantage payments  because of an overall decline in healthcare spending and changes under the Affordable Care Act that seek to align payments more closely with the government run Medicare fee for service program   The increase is larger than expected  Leerink Partners analyst Ana Gupte said  and bodes well for insurers that sell these plans next year   2016 enrollment growth should be accelerated compared to previous years   Gupte said  Some insurers as well as the nation s largest insurer lobbyist group  America s Health Insurance Plans  had warned the government that any cuts would hurt the elderly    The final rate notice took a notable step to provide stable funding for the Medicare Advantage program   AHIP President Karen Ignagni said  adding  however  that the policy did not do enough to protect chronically ill and vulnerable populations  The increase for 2016 versus the decline announced in February results from expectations of Medicare Advantage spending growth of 4 2 percent  compared with the 1 7 percent the government forecast in February  The 4 2 percent growth reflects additional spending in 2014 and 2015  as well as higher expected outlays in 2016  The Centers for Medicare   Medicaid Services said higher spending was due to hospitalizations  rural health clinics and federally qualified health centers  It also includes a 0 1 percent increase based on the assumption that Congress will enact legislation raising Medicare payments to doctors  The government also said that it would move forward with changes to how it pays insurers for patients who are sicker than average  It will additionally leave the star ratings systems  which rewards high performing plans  as planned  and it will tighten oversight of each plan s pharmacy network and provider networks and directories  The government policies affect each insurer differently  said Ipsita Smolinski  an analyst with Washington  D C  based research firm Capitol Street  
 All of these numbers are averages and the bottom line 2016 impact is going to vary by plan  by location  by star rating and by coding practices   Smolinski said ",2015-04-06,Reuters,https://www.investing.com/news/politics-news/u.s.-regulator-says-2016-payments-for-medicare-advantage-to-rise-335799,335799
142237,363752,HUM,Wall St  ends down after Fed statement  GDP data,news,"By Caroline Valetkevitch  Reuters    U S  stocks ended lower on Wednesday as the Federal Reserve cited weakness in the U S  economy and data showed U S  growth slowed more sharply than expected in the first quarter  But the Fed s acknowledgement of weakness in some sectors of the economy makes it more likely it will not be ready to raise until at least September  which kept stocks from falling further   We all know the Fed would love to start normalizing rates  but the simple fact is  the data does not warrant that action right now   said Wayne Kaufman  chief market analyst at Phoenix Financial Services in New York  While concerned about lingering economic weakness  U S  investors also are worried about the possibility of the Fed raising interest rates too soon  Seven of the 10 S P 500 sectors ended lower  with just energy  financials and materials in positive territory   Insurer Humana s  N HUM  shares fell 7 2 percent to  168 05  the second biggest loser on the S P 500  after results missed forecasts  Shares of rivals also fell  including UnitedHealth  N UNH   which was down 3 4 percent at  113 61  The S P healthcare index  was down 0 8 percent  the biggest drag on the S P 500  The Dow Jones industrial average  DJI  fell 74 61 points  or 0 41 percent  to 18 035 53  the S P 500  SPX  lost 7 91 points  or 0 37 percent  to 2 106 85 and the Nasdaq Composite  IXIC  dropped 31 78 points  or 0 63 percent  to 5 023 64  The central bank s policy statement put in place a meeting by meeting approach toward the timing of its first rate hike since June 2006  making such a decision solely dependent on incoming economic data  Earlier in the day  data showed gross domestic product expanded at an only 0 2 percent annual rate as harsh weather put off shoppers and energy companies cut spending  Twitter  N TWTR  fell 8 9 percent to  38 49  a day after the company cut its full year forecast due to weak demand for its new direct response advertising  Other decliners included Wynn Resorts  O WYNN   which fell 16 6 percent to  108 77 after the casino operator reported weaker than expected first quarter profit  Salesforce com Inc  N CRM  jumped 11 6 percent to  74 65 after a Bloomberg report that it is working with financial advisers to help field takeover offers after being approached by a potential acquirer  Declining issues outnumbered advancing ones on the NYSE by 2 023 to 1 008  for a 2 01 to 1 ratio on the downside  on the Nasdaq  1 853 issues fell and 867 advanced for a 2 14 to 1 ratio favoring decliners  The benchmark S P 500 posted 11 new 52 week highs and 1 new low  the Nasdaq Composite recorded 54 new highs and 51 new lows  
About 7 2 billion shares changed hands on U S  exchanges  above the 6 3 billion daily average for the month to date  according to BATS Global Markets ",2015-04-29,Reuters,"https://www.investing.com/news/stock-market-news/stock-futures-down-ahead-of-fed-statement,-gdp-data-339452",339452
142238,363753,HUM,Anthem CFO says insurer could make  meaningful  acquisition ,news," Reuters    The financial chief of Anthem Inc  N ANTM   the second largest U S  health insurer  said on Tuesday that low interest rates and other conditions make it a good time for an acquisition  adding to speculation about merger activity in the sector  Cheap debt is creating opportunities for companies to grow through acquisitions  Anthem Chief Financial Officer Wayne DeVeydt told investors during the UBS Global Healthcare Conference in New York   I like the pricing environment a lot and we have a lot of capacity to work with to do a cash transaction of meaningful size   and it would be transformative   DeVeydt said  DeVeydt s comments came against a backdrop of renewed speculation about the potential for a major insurance deal that would shrink the field of large U S  players from five to four   Analysts have said for years that Anthem and No  3 insurer  Aetna Inc   N AET  are possible acquirers of smaller national competitors including  Humana Inc   N HUM  and  Cigna Corp   N CI   Last week  Leerink Research reignited that talk when it said in a research note after meeting with Aetna management that a deal between Aetna and one of the smaller players was likely  which pushed shares in the sector higher  The last major acquisition by Anthem was its purchase of government healthcare provider Amerigroup in 2012 for  4 5 billion  Aetna purchased Coventry  which also sells healthcare plans paid for by the U S  government  in 2013 for about  5 6 billion  Humana has a market capitalization of  26 5 billion and Cigna is worth  34 3 billion  There is also a field of smaller Medicaid providers that are acquisition targets  according to analysts  These include  Molina Healthcare Inc   N MOH   WellCare Health Plans Inc  N WCG    Health Net Inc   N HNT  and  Centene  Corp  N CNC   Their market capitalizations range from  3 5 billion to  8 3 billion  Anthem recently closed on the purchase of Simply Healthcare  a Medicaid provider in Florida   DeVeydt said the company was looking at expanding its Medicare business in Florida  Texas and California   three of the biggest healthcare markets  
 We would clearly love to have more scale in Medicare but our focus is first targeting the strategic markets that matter most   he said  referring to those three states  He said the company could increase its business in New York  Ohio and California without acquisitions ",2015-05-19,Reuters,https://www.investing.com/news/stock-market-news/anthem-cfo-says-insurer-could-make-'meaningful'-acquisition-342533,342533
142239,363754,HUM,U S  stocks end month on a sour note  as disappointing GDP data weighs,news,"Investing com    U S  stocks fell broadly on the final trading session of the month  as U S  GDP for the first quarter was revised downward on Friday as expected  providing a harbinger for tepid economic growth over the current period 

Stocks dropped considerably on Friday after GDP in the first quarter was lowered to minus 0 7  from an initial reading of 0 2   The reading was in line with analysts  expectations of a downward revision of minus 0 8   A surge in imports to 5 6  from an initial gain of 1 8   linked to an abrupt unloading of imports at West Coast ports was thought to be responsible for the revision  A port work stoppage throughout the winter weighed on the U S  economy in the first quarter 

The Dow Jones Industrial Average and the S P 500 Composite fell more than 0 6  on the session  while the NASDAQ dropped more than 25 points to fall out of near record territory  The Dow lost 115 44 or 0 64  to close the session at 18 010 68  The NASDAQ lost 27 95 or 0 55  to 5 070 03  while the S P 500 fell 13 40 or 0 63  to 2 107 39  as all10 sectors closed in the red  Stocks in the Technology  Financials and Industrials sectors lagged  each dropping by more than 0 7   
For the month  though  all three major indices closed higher after each reached an all time closing high at one point in May 

The top performer on the Dow was Merck   Company Inc  NYSE MRK   which gained 1 33 or 2 22  to 61 03  The worst performer was  Visa Inc   NYSE V   which fell 0 79 or 1 14  to 68 77  

The biggest gainer on the NASDAQ was Altera Corporation  NASDAQ ALTR   which gained 2 03 or 4 32  to 49 00  The worst performer was Paccar Inc   which lost 1 54 or 2 36  to 63 63 after Forbes reported that the Bellevue  Washington based manufacturer of heavy duty trucks has become one of the five highest shorted stocks on the NASDAQ 100  

On the S P 500   Humana Inc   NYSE HUM  surged more than 20  after Dow Jones reported that the Louisville  Kentucky based health insurer could be actively seeking a merger  Humana  the top performer on the S P 500  gained 35 74 or 20 03  to 214 15  
Bristol Myers Squibb Company  NYSE BMY   meanwhile  finished as the worst performer  plunging 4 35 or 6 29  to 64 80  The sell off transpired ahead of this weekend s American Society of Clinical Oncology Conference  ASCO  in Chicago  where the pharmaceutical giant is expected to present data which it says demonstrates promising findings related to its broad Immuno Oncology portfolio  The drugs are expected to help treat solid tumors and blood cancers  including Multiple Myeloma ",2015-05-29,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-stocks-end-month-on-a-sour-note,-as-disappointing-gdp-data-weighs-344190",344190
142244,363759,HUM,Public Exchange Woes Hit Health Insurers  Stocks In Focus,opinion,"Public exchanges  formed to serve the underprivileged and patients  have not been too successful in serving the insurers  This is evident from losses incurred by most of the health insurers participating in these exchanges 
Affordability Risk Pool Trade Off
The exchanges saw a deluge of very sick patients buying insurance cover online  thanks to the subsidies provided to the enrollees  They  however  failed to attract sufficient enrollments from healthy and young individual  which was required to balance the risk return trade off  This led to increase in claims on business conducted on these exchanges 
Let us discuss how the big four insurers have been affected by this public exchange business 
Aetna Inc   NYSE AET    one of the nation s largest health insurance companies  recently announced that it would pull back its participation from public exchanges  expecting a loss of  200 million in 2017  Aetna incurred pre tax operating losses of  450 in 2016 
Lackluster results from this line of business prompted the company to substantially reduce its risk exposure to these products for 2017  Aetna carries a Zacks Rank  2  Buy   You can see  
Anthem Inc   NYSE ANTM    a Zacks Rank  3  Hold  company  is another big insurer offering plans on Affordable Care Act  ACA   Anthem suffered a decline in enrollment in 2016 and the same continued in the first half 2017 
This prompted the company to scale back its participation in this loss making business for 2018  It pulled out of exchange plans in 11 states for 2017 Although management has been taking steps to ensure both a stable and sustainable individual market as well as a smooth transition for consumers  uncertainty remains 
UnitedHealth Group Inc    NYSE UNH   lost more than  1 billion on the exchanges in 2015 and 2016  After two years of losing money from plans sold on the ACA insurance exchanges  it exited nearly all of the exchanges for 2017  UnitedHealth presently carries a Zacks Rank  3 
Humana Inc    NYSE HUM   has already declared that it will exit its Individual Commercial business in 2018  After incurring mounting losses in this business in 2015 and 2016  Humana pulled back its participation from 11 states in 2016  The insurer anticipates incurring a modest  45 million loss on ACA exchange plans in 2017  excluding the effect of which  it estimates the earnings per share for 2017 to be at least  11 50  The company also carries Zacks Rank  3 
Continued Uncertainty
The health insurers that have been making significant losses on ACA exchange plans are uncertain about thefinal verdict from the Trump administration  This is because the administration has been vocal about removing cost reduction subsides that help insurance companies pay claims of patients buying coverage on public exchanges 
These players have been lobbying to keep these subsidies intact  which would otherwise lead to the health plan enrollees facing cost increases of 20 25  for 2018 coverage 
The U S  Senate is working on a bipartisan approach for shoring up the ACA s public exchanges by funding cost sharing subsidies for low income patients 
The uncertainty on the CSR funding puts a question mark on the sustainability of these  exchanges  In the event of an unfavorable outcome  it will not be surprising to see an exodus of insurance companies from these exchanges   This exit will lead to more Americans finding themselves with fewer healthcare options  causing an increase in uninsured rates  defeating the central tenet of the Health Care Reform Act 
4 Promising Stock Picks to Keep an Eye OnWith news stories about computer hacking and identity theft becoming increasingly commonplace  the cybersecurity industry looks like a promising investment opportunity  But which stocks should you buy  Zacks just released Cybersecurity  An Investor s Guide to Locking Down Profits to help answer this question This new Special Report gives you the information you need to make well informed investment choices in this space  More importantly  it also highlights 4 cybersecurity picks with strong profit potential ",2017-09-19,Zacks Investment Research,https://www.investing.com/analysis/public-exchange-woes-hit-health-insurers-stocks-in-focus-200214225,200214225
142245,363760,HUM,Mednax Stock Down 35  Year To Date  Will It Fall Further ,opinion,"Mednax  Inc    NYSE MD   has been plagued by a number of headwinds  of late  leading investors to lose optimism on the stock  Also  this tepid scenario doesn t seem to reverse anytime soon Meanwhile  a subdued pace of birth in neonatology and a change in payor mix in anesthesiology have kept the top line under pressure in both of the company s businesses  Additionally  growth in compensation expense for nurse anesthetists and spike in interest expenses have pressurized margins   These factors led to an earnings miss in the last quarter  Also  earnings missed in each of the last four quarters with an average negative surprise of 5 9  
The Zacks Consensus Estimate for 2017 and 2018 earnings were also revised 7 6  and 11 5  downward  respectively  over the last 60 days Furthermore  Mednax s headwinds have taken a toll on its share price that declined 35  year to date  underperforming 2 7  growth registered by the  it belongs to 

Let s take a look at other factors that have affected the price of the stock carrying a Zacks Rank  5  Strong Sell  Disappointing Earnings   The stock has been hurt by its disappointing performance in the first half of 2017  Mednax witnessed a 10 5   15 8  and 0 8  year over year declines in EBIDTA  adjusted EPS and cash flow from operations  respectively   
Fundamental headwinds   The company is suffering from a subdued pace of birth across the country  which has slowed growth of one of its core businesses   neonatology   which has in turn stressed revenue growth   Moreover  a change in payor mix in its anesthesiology business has pressurized its commercial volumes  This segment also suffers from growth in compensation expense for nurse anesthetists 
Additionally  Mednax s results have suffered due to huge investments made in diversification  These investments might create volatility in its quarter over quarter performance  before reaping long term growth 
Markedly  increase in expenses as a proportion of revenues owing to growth in compensation expense for supporting acquisition related growth further pressurized the margins  Also  growth at existing units including compensation for non physician clinicians increased at a faster pace than in the previous periods In fact  the company has been witnessing a dent in its bottom line led by a spike in its interest expenses for more than three years   It is also suffering from an increase in overall expenses  which has outpaced revenue growth compared with the last many years 
Lackluster Earnings Guidance   Mednax expects earnings per share for the three months  ending Sep 30  2017  to be in the range of 66 cents to 71 cents  down from  1 04 per share in the year ago quarter  Adjusted EPS will likely be in the range of 83 cents to 88 cents  down from  1 09 per share in third quarter of 2016 
The range for its third quarter guidance assumes anticipated same unit revenue of negative 2  to flat year over year  For the third quarter of 2017  the company expects EBITDA to decline by 17  to 21  year over year  as against growth of 7 7  in last year period 
Going Forward
Per management  the challenges in its business are expected to continue in the near term  We thus expect shares of the company to remain under pressure in the coming quarters 
Stocks to ConsiderSome better ranked stocks from the medical sector include Aetna Inc    NYSE AET    Centene Corp    NYSE CNC   and WellCare Health Plans  Inc    NYSE WCG    each holding a Zacks Rank  2  Buy   You can see  
Aetna surpassed earnings estimates in each of the trailing four quarters  with an average positive surprise of 19  Centene delivered positive earnings surprises in three of the last four quarters  with an average beat of 7 7  WellCare Health Humana  NYSE HUM  topped earnings estimates in each of the last four quarters  with an average positive surprise of 47 4  
4 Promising Stock Picks to Keep an Eye OnWith news stories about computer hacking and identity theft becoming increasingly commonplace  the cybersecurity industry looks like a promising investment opportunity  But which stocks should you buy  Zacks just released Cybersecurity  An Investor s Guide to Locking Down Profits to help answer this question This new Special Report gives you the information you need to make well informed investment choices in this space  More importantly  it also highlights 4 cybersecurity picks with strong profit potential ",2017-09-19,Zacks Investment Research,https://www.investing.com/analysis/mednax-stock-down-35-year-to-date-will-it-fall-further-200214222,200214222
142246,363761,HUM,Demographic Changes  Diversification Aid Health Insurers,opinion,"Health insurer stocks have performed strongly so far this year despite persistent policy uncertainty  The near term driver helping these stocks appears to have been the markets  skepticism about the GOP s  repeal   replace  effort  which has been borne out by the slow progression of the second  repeal   replace  effort  Graham   Cassidy  which looks as if it will not even be brought up for a vote in the U S  Senate 
The health insurance group also appears to be well placed as a result of a number of secular favorable factors  including rising enrollment and top line growth  development of ancillary businesses  product modifications  favorable demographic changes  expansion of international operations  better claims handling  M A and a strong capital position 
Some recent weakness notwithstanding  the industry s stock market performance this year has been very impressive  outperforming the S P 500 index in the year to date period   23  for the industry vs   11 6  for the large cap index 
Large diversified insurers like UnitedHealth Group Inc   UNH   Aetna Inc  NYSE AET    AET   Cigna Corp   CI   Humana Inc  NYSE HUM    HUM  and Anthem Inc   ANTM  are well placed  given that their earnings are buffered to a large extent from industry disruption 
Let s take a look at how insurers fared recently 
Decline in Uninsured Rates 
Over the past six years  the nation s uninsured rate has gone down to single digits  thanks to the Affordable Care Act mandates  According to the Centers for Disease Control and Prevention  in 2016 the uninsured rate was around 9  compared with 16  in 2010  The decline since 2010 corresponds with the passage of the Affordable Care Act  also known as Obamacare 
Health insurers have capitalized on this surge in insured rates by raking in members  who added to their top line growth  Most of the insurers have reported a secular rise in enrollment and revenues since 2010  confirming the fact Booming Medicare Business 
Demographic changes in the United States have fueled growth of Medicare Revenues from the managed care plans of Medicare Advantage are expected to grow significantly as baby boomers retire  Medicare Advantage is a privately run version of the government s Medicare insurance program for the aged and disabled 
The Kaiser Family Foundation states that since the ACA was passed in 2010  Medicare Advantage enrollment grew 71  as of Mar 31  2017  Medicare Advantage enrollment is projected to continue to grow over the next decade  rising to 41  of all Medicare beneficiaries by 2027 
While two public providers  UnitedHealth and Humana  are the biggest players in this space  others are in a race to win Medicare Advantage market share  The fastest way of achieving this is by acquiring a company in the same business 
Players have been resorting to mergers and acquisitions  joint ventures and partnerships in an effort to deepen their reach in the Medicare market  Some of the biggest deals in this space were the acquisition of HealthSpring by Cigna  XLHealth Corporation by UnitedHealth Group  and Health Net by Centene  Recently  Anthem announced that it will buy Florida based Medicare Advantage insurer HealthSun 
International Markets Hold AttractionPressure on profit margins in the U S  market has compelled American health insurers to look to foreign markets for sustained growth and profitability  International markets seem attractive as these are less penetrated and more competitive  Notably  Asia and Europe represent the best near term opportunities for U S  health insurers Cigna and UnitedHealth Group lead the private health insurance industry in terms of international deal activity  They re followed by Aetna and Humana  The deals have either been mergers and acquisitions or joint ventures with local insurance companies Some of the deals made by players in this field echo the emerging trend of globalization   Recently  Aetna acquired UK based Bupa Group s Thai business  Bupa Thailand  which will significantly increase Aetna s presence in Asia  Earlier  it bought U K  based InterGlobal  which offers private medical insurance to groups and individuals in the Middle East  Asia  Africa and Europe 
Another insurer  Cigna  penetrated the Indian market through a joint venture with TTK Group 
UnitedHealth s purchase of a stake in AmilParticipacoes of Brazil  and its recent announcement to buy Chilean company BanMedica  point toward the trend of insurers going international 
Managing Costs via ACOsThe industry is witnessing a change from volume based care to value based care in recent years  which has led to the emergence of Accountable Care Organizations  ACOs   These are formed when a group of health care providers  physicians  hospitals  non physician providers  and the like  collectively take responsibility for the financial and quality outcome for a defined population The ACOs are appealing to insurers as these reduce medical cost and improve outcome  Insurers form an essential part of ACOs because these track and collect patient data  enabling an evaluation of patient care  Since clinical information and care processes are shared and supported by all providers  it becomes easier to manage care and effectively lower the cost  With Obamacare  health insurers have to be more than just claims payers Under health reform  insurers have lost flexibility in ways that they can cope with rising medical expenses  They can no longer rely on many of their traditional medical underwriting strategies  such as the exclusion of pre existing conditions  The most effective approach for insurers now is to rely exclusively on the current cost control mechanisms to manage members  medical expenses  Private commercial payers    such as Cigna  Anthem and Aetna    are thus supporting ACO formation  CIGNA has one of the most established track records in the group for ACOs 
Developing Ancillary BusinessesInsurers are eyeing growth and expansion opportunities that accompany the critical challenges of modernizing the health care system  They are branching out to non traditional areas 
Over the last few years  several large insurers have acquired companies that fall outside the realm of traditional health insurance  yet complement it 
Players  Humana  Aetna  UnitedHealth have all been enthusiastically developing their health services business  These players have made several acquisitions  both small and large  to achieve fast paced growth in this space   
Recently  UnitedHealth Group announced the acquisition of Surgical Care Affiliates  It also announced that it will take over the health care business of The Advisory Board Company  ABCO   It also recently acquired Catamaran  These acquisitions and several others have been made in its health services business  Optum 
Healthy Balance Sheet
Despite incurring heavy expenditures  most of the players in the industry boast a solid capital level  This reflects their profitable operations which have outpaced expense rise  leading to balance sheet growth 
Armed with enough capital  most of the players have resorted to share buyback to aid earnings in an environment when top line growth is a challenge  Strong cash reserves have also enabled players to make acquisitions and mergers to achieve growth  along with positioning them well to face industry issues 
Zacks Industry Rank Indicates Solid Upside Potential
This 13 company group currently carries a  of  11  which places it in the top 4  of the 250 plus Zacks classified industries  Our back testing shows that the top 50  of Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 
Stocks Worth Adding
Investors can consider the following HMO stocks that have solid fundamentals along with a favorable Zacks Rank 
Centene Corp   CNC  beat estimates in three of the last four quarters with an average positive surprise of 7 7   Also  the Zacks Consensus Estimate for 2017 and 2018 moved up 2 5  and 2 1   respectively  in the last 60 days  Centene carries a Zacks Rank  2 and sports a Value Score of A 
You can see  
Magellan Health  Inc   MGLN  has a Zacks Rank  2 and a Value Score of A  The stock beat estimates in three of the last four quarters with an average positive surprise of 23 9   Also  the Zacks Consensus Estimate for 2018 has moved up 3 7  in the last 60 days 
WellCare HealthPlans Inc   WCG  carries a Zacks Rank  2 and has a Value Score of B  The stock beat estimates in each of the last four quarters with an average positive surprise of 47 4   Also  the Zacks Consensus Estimate for both 2017 and 2018 moved up 1 7  in the last 60 days 
Aetna carries a Zacks Rank  2 and has a Value Score of B  The stock beat estimates in each of the last four quarters with an average positive surprise of 19   Also  the Zacks Consensus Estimate for 2017 and 2018 moved up 6 1  and 2  in the last 60 days ",2017-09-26,Zacks Investment Research,https://www.investing.com/analysis/demographic-changes-diversification-aid-health-insurers-200215574,200215574
142247,363762,HUM,Zacks Industry Outlook Highlights  UnitedHealth Group  Anthem  Centene  Magellan Health And WellCare HealthPlans,opinion,For Immediate ReleaseChicago  IL   September 28  2017   Today  Zacks Equity Research discusses the Industry  Health Insurance  Part 2  including UnitedHealth Group Inc   NYSE    NYSE UNH        Anthem Inc   NYSE    NYSE ANTM        Centene Corp   NYSE    NYSE CNC        Magellan Health  Inc   Nasdaq    NASDAQ MGLN       and WellCare HealthPlans Inc   NYSE  WCG     Industry  Health Insurance  Part 2Link   Health insurer stocks have performed strongly so far this year despite persistent policy uncertainty  The near term driver helping these stocks appears to have been the markets  skepticism about the GOP s  repeal   replace  effort  which has been borne out by the slow progression of the second  repeal   replace  effort  Graham   Cassidy  which looks as if it will not even be brought up for a vote in the U S  Senate The health insurance group also appears to be well placed as a result of a number of secular favorable factors  including rising enrollment and top line growth  development of ancillary businesses  product modifications  favorable demographic changes  expansion of international operations  better claims handling  M A and a strong capital position Some recent weakness notwithstanding  the industry s stock market performance this year has been very impressive  outperforming the S P 500 index in the year to date period   23  for the industry vs   11 6  for the large cap index Large diversified insurers like UnitedHealth Group Inc   NYSE       and Anthem Inc   NYSE       are well placed  given that their earnings are buffered to a large extent from industry disruption Let s take a look at how insurers fared recently Decline in Uninsured RatesOver the past six years  the nation s uninsured rate has gone down to single digits  thanks to the Affordable Care Act mandates  According to the Centers for Disease Control and Prevention  in 2016 the uninsured rate was around 9  compared with 16  in 2010  The decline since 2010 corresponds with the passage of the Affordable Care Act  also known as Obamacare Health insurers have capitalized on this surge in insured rates by raking in members  who added to their top line growth  Most of the insurers have reported a secular rise in enrollment and revenues since 2010  confirming the fact Booming Medicare BusinessDemographic changes in the United States have fueled growth of Medicare  Revenues from the managed care plans of Medicare Advantage are expected to grow significantly as baby boomers retire  Medicare Advantage is a privately run version of the government s Medicare insurance program for the aged and disabled The Kaiser Family Foundation states that since the ACA was passed in 2010  Medicare Advantage enrollment grew 71  as of Mar 31  2017  Medicare Advantage enrollment is projected to continue to grow over the next decade  rising to 41  of all Medicare beneficiaries by 2027 While two public providers  UnitedHealth and Humana  NYSE HUM   are the biggest players in this space  others are in a race to win Medicare Advantage market share  The fastest way of achieving this is by acquiring a company in the same business Players have been resorting to mergers and acquisitions  joint ventures and partnerships in an effort to deepen their reach in the Medicare market  Some of the biggest deals in this space were the acquisition of HealthSpring by Cigna  NYSE CI   XLHealth Corporation by UnitedHealth Group  and Health Net by Centene  Recently  Anthem announced that it will buy Florida based Medicare Advantage insurer HealthSun International Markets Hold AttractionPressure on profit margins in the U S  market has compelled American health insurers to look to foreign markets for sustained growth and profitability  International markets seem attractive as these are less penetrated and more competitive  Notably  Asia and Europe represent the best near term opportunities for U S  health insurers Cigna and UnitedHealth Group lead the private health insurance industry in terms of international deal activity  They re followed by Aetna  NYSE AET  and Humana  The deals have either been mergers and acquisitions or joint ventures with local insurance companies Some of the deals made by players in this field echo the emerging trend of globalization   Recently  Aetna acquired UK based Bupa Group s Thai business  Bupa Thailand  which will significantly increase Aetna s presence in Asia  Earlier  it bought U K  based InterGlobal  which offers private medical insurance to groups and individuals in the Middle East  Asia  Africa and Europe Another insurer  Cigna  penetrated the Indian market through a joint venture with TTK Group UnitedHealth s purchase of a stake in AmilParticipacoes of Brazil  and its recent announcement to buy Chilean company BanMedica  point toward the trend of insurers going international Managing Costs via ACOsThe industry is witnessing a change from volume based care to value based care in recent years  which has led to the emergence of Accountable Care Organizations  ACOs   These are formed when a group of health care providers  physicians  hospitals  non physician providers  and the like  collectively take responsibility for the financial and quality outcome for a defined population The ACOs are appealing to insurers as these reduce medical cost and improve outcome  Insurers form an essential part of ACOs because these track and collect patient data  enabling an evaluation of patient care  Since clinical information and care processes are shared and supported by all providers  it becomes easier to manage care and effectively lower the cost  With Obamacare  health insurers have to be more than just claims payers Under health reform  insurers have lost flexibility in ways that they can cope with rising medical expenses  They can no longer rely on many of their traditional medical underwriting strategies  such as the exclusion of pre existing conditions  The most effective approach for insurers now is to rely exclusively on the current cost control mechanisms to manage members  medical expenses  Private commercial payers    such as Cigna  Anthem and Aetna    are thus supporting ACO formation  CIGNA has one of the most established track records in the group for ACOs Developing Ancillary BusinessesInsurers are eyeing growth and expansion opportunities that accompany the critical challenges of modernizing the health care system  They are branching out to non traditional areas Over the last few years  several large insurers have acquired companies that fall outside the realm of traditional health insurance  yet complement it Players  Humana  Aetna  UnitedHealth have all been enthusiastically developing their health services business  These players have made several acquisitions  both small and large  to achieve fast paced growth in this space   Recently  UnitedHealth Group announced the acquisition of Surgical Care Affiliates  It also announced that it will take over the health care business of The Advisory Board Company  It also recently acquired Catamaran  These acquisitions and several others have been made in its health services business  Optum Healthy Balance SheetDespite incurring heavy expenditures  most of the players in the industry boast a solid capital level  This reflects their profitable operations which have outpaced expense rise  leading to balance sheet growth Armed with enough capital  most of the players have resorted to share buyback to aid earnings in an environment when top line growth is a challenge  Strong cash reserves have also enabled players to make acquisitions and mergers to achieve growth  along with positioning them well to face industry issues Zacks Industry Rank Indicates Solid Upside PotentialThis 13 company group currently carries a  of  11  which places it in the top 4  of the 250 plus Zacks classified industries  Our back testing shows that the top 50  of Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 Stocks Worth AddingInvestors can consider the following HMO stocks that have solid fundamentals along with a favorable Zacks Rank Centene Corp   NYSE       beat estimates in three of the last four quarters with an average positive surprise of 7 7   Also  the Zacks Consensus Estimate for 2017 and 2018 moved up 2 5  and 2 1   respectively  in the last 60 days  Centene carries a Zacks Rank  2 and sports a Value Score of A You can see  Magellan Health  Inc   Nasdaq       has a Zacks Rank  2 and a Value Score of A  The stock beat estimates in three of the last four quarters with an average positive surprise of 23 9   Also  the Zacks Consensus Estimate for 2018 has moved up 3 7  in the last 60 days WellCare HealthPlans Inc   NYSE       carries a Zacks Rank  2 and has a Value Score of B  The stock beat estimates in each of the last four quarters with an average positive surprise of 47 4   Also  the Zacks Consensus Estimate for both 2017 and 2018 moved up 1 7  in the last 60 days Aetna carries a Zacks Rank  2 and has a Value Score of B  The stock beat estimates in each of the last four quarters with an average positive surprise of 19   Also  the Zacks Consensus Estimate for 2017 and 2018 moved up 6 1  and 2  in the last 60 days Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2017-09-27,Zacks Investment Research,https://www.investing.com/analysis/zacks-industry-outlook-highlights-unitedhealth-group-anthem-centene-magellan-health-and-wellcare-healthplans-200215922,200215922
142248,363763,HUM,3 Anti Trumpcare Stocks To Buy Now,opinion,"Yesterday  I broke news of the FAANGs  coming takeover rampage  and how you could mint a fortune  
But the FAANGs aren t the only ones flush with cash 
America s largest health insurance companies   Aetna  NYSE AET   Cigna  NYSE CI   UnitedHealth Group  NYSE UNH   Humana  NYSE HUM  and Anthem Inc  NYSE ANTM    are also printing money 
With collective profits of  10 3 billion through two quarters  a record shattering year is afoot 
More favorable still 
Now that Obamacare has survived the GOP s onslaught  the printing presses will run even hotter 
I suppose we should bless these despised health care providers with their own acronym 
Let s go with something cringe worthy  like  ACUHA    Sounds like a punch to the gut  
But can you bury your hate for five minutes 
Let me explain 
ACUHA is about to go on a historic acquisition spree 
To fuel growth  its eyes are fixed upon certain microcaps 
Of course  when buyouts are made public  the announcement stands to  break  the charts of the smaller companies 
Keep these  chartbreaking  opportunities in mind as you read our most appetizing takeover targets 
Ignore the Sob Story
Few industries get more hate from Americans than health insurance 
But the fact is  without them  many of us would go bankrupt paying off medical bills 
And while many insurers complain that Obamacare has made them unprofitable  their financial statements tell a different story 
Last quarter  America s top six health insurers earned a combined  6 billion in profit  according to CNBC 
And according to Thomson Reuters I B E S data  that represents a 29  jump from the same period last year 
So don t be fooled by their sob story 
Instead  do as they do  That is  keep an eye out for explosive companies with disruptive technology to buy up 
Here s one such company leading the pack 
iRhythm Technologies Inc  NASDAQ IRTC  is a health care company that s changing the game for medical biosensors 
The company s flagship product  Zio  is a continuous monitor patch that records weeks of a patient s heartbeat data 
IRhythm s patented machine learning algorithms analyze the recorded data and compile the conclusions into a readable 15 page report for a patient s doctor 
The goal  Diagnose heart arrhythmias faster and more accurately than traditional methods 
The less time it takes to diagnose the ailment  the faster a patient can be treated effectively 
And a swifter diagnosis can also result in lower medical costs for everyone involved 
Better still  because Zio s software is powered by machine learning  the larger iRhythm s database gets  the smarter the algorithms get 
This innovative company just went public last December  and its stock has nearly doubled on surging sales since then 
It s flush with cash with  110 million on the books and just  32 million in debt 
Best of all  with a market value of  1 1 billion  iRhythm is a cheap takeover target for virtually all of the health care giants 
Management Shakeup Greenlights Potential Takeover
With health care reform off the table for now  ACUHA companies can focus on expanding their network 
Now  the failure of the Republicans to cut back Obamacare makes it likely that future health care changes will focus on expanding service to currently uninsured or underinsured communities 
State subsidies to insurers covering these communities are likely to expand rapidly as the health care system attempts to serve them more cost effectively 
That makes Molina Healthcare Inc  NYSE MOH  a prime takeover target for larger health care companies 
Molina was founded in 1980 and is headquartered in Long Beach  California  The company offers clinic services with locations in 15 states  And it serves nearly 5 million patients 
The company also provides health care plans to individuals with state coverage  Molina focuses on the minority  immigrant and underserved communities that receive health care funding from Medicaid  Medicare and other government funded sources 
Molina recently ran into profit problems  with losses of  230 million in the second quarter of 2017  after which it announced 1 500 layoffs  This resulted in the departure of founding family members Mario Molina as CEO and John Molina as CFO  who were regarded as the biggest barriers to a sale of the company 
With a market capitalization of  3 8 billion  a business focused on an attractive market   and not to mention management turmoil   Molina represents an excellent takeover opportunity for ACUHA companies seeking to expand into the state subsidized health care market 
With revenue of  17 8 billion  four times its market value  Molina s potential for a big  is high 
Riches in Niches
Large  bureaucratic health insurers share a debilitating weakness 
That is  they re not nimble enough to expand into underserved  yet highly profitable niche markets 
That doesn t mean they re locked out altogether  It just means they have to expand into these markets via acquisitions instead of organically 
Such a reality puts the  382 million market cap Independence Holding Company  NYSE IHC  firmly in the cross hairs 
Founded in 1980  the company makes a mint focusing on specialized health insurance products  Sales and profits for the first six months of the year hit  154 1 million and  19 3 million  respectively 
This is no accident  either 

As the company plainly reveals in SEC filings   Our business strategy consists of maximizing underwriting profits through a variety of niche specialty health insurance  pet and group disability and life products and through distribution channels that enable us to access specialized or underserved markets in which we believe we have a competitive advantage  

The company s foothold in these highly profitable niches is so strong that large health insurers recently started reselling some of IHC s products to share in the riches 
It s only a matter of time before one of these insurers buys the company outright so it can reap all the rewards  To that end  IHC has been making all the right moves to up its takeover appeal 
In March 2016  it divested a valuable  but unrelated business segment  It then used the proceeds to pay off all its outstanding debt and aggressively invest in its fastest growing product lines 
To top it off  the never ending turmoil surrounding Obamacare plans supercharged demand for IHC s products  Indeed  the company is expected to  report significantly higher earned premiums and income in this segment in 2018  
Add it all up and the time is ripe for an acquirer to pounce while shares are still trading on the cheap 
At current prices  the stock sports a price earnings  P E  ratio of 13 6  That s a staggering discount of 35 60  compared with large cap health insurers like Cigna Corporation  NYSE CI  and Aetna Inc  NYSE AET   It certainly won t last forever 
Even management knows it  as they recently repurchased over  42 million worth of stock 
Bottom line  I don t expect Independence Holding Co  to maintain its independence much longer  Bet on it  And if I m wrong  you ll still be positioned to profit  as the company ranks as one of the cheapest and fastest growing providers of specialty insurance products 
Ahead of the tape ",2017-10-03,Louis Basenese,https://www.investing.com/analysis/3-antitrumpcare-stocks-to-buy-now-200216627,200216627
142249,363764,HUM,5 Low Leverage Stocks That Can Be Part Of Your Portfolio,opinion,In the complex world of investment  debt financing is a well known strategy adopted by the majority of corporations for expanding their business operations from time to time  Dearth of ample funds is the primary driving force behind this strategy  Yet  resorting to debt is still considered a taboo as it carries the burden of interest payments In particular  companies with large debt loads are more vulnerable during economic downturns and can even go bankrupt in the worst case scenario  Of course  companies may resort to equity financing as an alternative option to boost their financial resources  However  it is the easy and cheap availability of debt that makes it more popular among corporations In fact  statistics indicate that America  the richest economy in the world  is the biggest borrower too  Notably  huge spending on wars  big tax cuts and stimulating economic programs have all added to the nation s burden over the years  The Congressional Budget Office estimates that the debt held by the public will rise to 150  of the economy s GDP in 2047 from 77  currently Nevertheless  this should not discourage investors from spending on U S  stocks  since debt has been part of the economy since its foundation and yet the country stands atop others  What investors need to do is choose stocks with caution  thus avoiding those that carry high debt loads Here comes the significance of leverage  better to say financial leverage  which indicates the degree to which a company utilizes debt to boost its operations and earn escalated profit margins  Usually investors tend to avoid companies bearing higher degree of financial leverage The next question that comes to our mind is that how can we measure a company s degree of financial leverage  To this end  several leverage ratios have been constructed as efficient tools to evaluate a company s credit level to support prudent equity investments The most popular among them is the debt to equity ratio Analyzing Debt to EquityDebt to Equity Ratio   Total Liabilities Shareholders  EquityThis metric is a liquidity ratio that indicates the amount of financial risk a company bears  A company with a lower debt to equity ratio implies that it has a more or less financially stable business  thereby making it a more worthy investment opportunity With the Q3 reporting cycle set to gain steam in the coming weeks  an investor must be looking for solid growth stocks  Blindly investing in stocks displaying solid earnings growth without considering their debt level might not be a wise move  As  uncertainty can hit the global equity market any time  it is reasonable to expect that investors will be more attracted to companies with low leverage than high earnings growth The Winning StrategyIn theory  the optimal capital structure for a company is one  with the ideal debt to equity ratio that maximizes its value and minimizes its cost of capital  Since  in practice  screening stocks based on these criteria is a bit difficult  herein  we choose low leverage stocks as these are considered safe bets However  an investment strategy based solely on the debt to equity ratio might not fetch the desired outcome  To choose stocks that have the potential to give you steady returns  we have expanded our screening criteria to include some other factors Here are the other parameters Debt Equity less than X Industry Median  Stocks that are less leveraged than their industry peers Current Price greater than or equal to 10  The stocks must be trading at a minimum of  10 or above Average 20 day Volume greater than or equal to 50000  A substantial trading volume ensures that the stock is easily tradable Percentage Change in EPS F 0  F  1  greater than X Industry Median  Earnings growth adds to optimism  leading to a stock s price appreciation Estimated One Year EPS Growth F 1  F 0  greater than 5  This shows earnings growth expectation Zacks Rank  1  Strong Buy  or  2  Buy   No matter whether market conditions are good or bad  stocks with a Zacks Rank  1 or 2 have a proven history of success Excluding stocks that have a negative or a zero debt to equity ratio  here are five of the 46 stocks that made it through the screen Humana Inc    NYSE HUM    It is a health services company that facilitates the delivery of health care services through networks of providers to its medical members  The company carries a Zacks Rank  2 and came up with an average positive earnings surprise of 7 24  in the trailing four quarters Alibaba Group Holding Limited   NYSE BABA    The companyoperates online and mobile marketplaces in retail and wholesale trade  as well as cloud computing and other services It carries a Zacks Rank  2 and delivered an average positive earnings surprise of 12 16  in the trailing four quarters Honeywell International Inc    NYSE HON    It is a global diversified technology and manufacturing company with a wide range of aerospace products and services  It pulled off an average positive earnings surprise of 1 08  in the trailing four quarters and carries a Zacks Rank  2  You can see AGNC Investment Corporation   NASDAQ AGNC    It is a real estate investment trust  REIT  that focuses on leveraged investments in agency MBS  This includes residential mortgage pass through securities and collateralized mortgage obligations  CMOs  The company carries a Zacks Rank  2 and delivered an average positive earnings surprise of 11 73  in the trailing four quarters Wintrust Financial Corporation   NASDAQ WTFC    It a bank holding company  which provides banking services  trust and investment services  commercial insurance premium financing  short term accounts receivable financing  and certain administrative services  The company carries a Zacks Rank  2 and delivered an average positive earnings surprise of 7 17  in the trailing four quarters Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and back testing software The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at   Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ,2017-10-08,Zacks Investment Research,https://www.investing.com/analysis/5-low-leverage-stocks-that-can-be-part-of-your-portfolio-200217710,200217710
142250,363765,HUM,WellCare Health Grows On Revenues  Debt Level Hurts,opinion,WellCare Health Plans  Inc   NYSE WCG   continues to maintain a leading position in the industry on the back of its growth strategies  The company s revenues have been consistently rising over the last 10 years The ObamaCare Act  ACA  implemented by the former U S  President Barrack Obama contributed significantly to the company s top line growth  However  there remains uncertainty around  Repealing and Replacing  the ACA under the Trump administration  The Medicaid funding change is on gun point of the lawmakers which if materialises might hurt the company Despite the regulatory uncertainty prevailing in the industry  WellCare Health remains an attractive pick for investors Apart from the contribution of the ACA  the company s revenues have also been supported by strategic acquisitions  partnerships and alliances since 2011  These initiatives not only strengthened the company s presence in existing markets but also helped in geographic expansion Moreover  consistent cash inflow has helped it increase shareholders  value through several capital deployment initiatives like share repurchases  dividend payment etc   Year to date  its shares have gained 45  while the  has rallied 43   The company delivered positive earnings surprises in each of the last four quarters with an average beat of 47 37   In the second quarter  its earnings surpassed the Zacks Consensus Estimate and grew year over year on higher revenues Pursuant to the earnings beat  the company also raised its earnings and revenue guidance for 2017 that boosted shareholder optimism in the stock  The company has seen its Zacks Consensus Estimate for 2017 and 2018 earnings being revised upward by 0 6  and 0 2   respectively  in the past 60 days However  it suffers from rising level of debt that increases the borrowing cost  eventually draining the bottom line Also  the company has been witnessing a steep increase in the total expenses that are weighing on the margins Zacks Rank   Stocks to ConsiderThe stock currently carries a Zacks Rank  3  Hold  Investors interested in the same space can consider stocks like Humana Inc    NYSE HUM    Centene Corp    NYSE CNC   and Anthem Inc    NYSE ANTM    All of these stocks carry a Zacks rank  2  Buy   You can see  Humana  a leading managed care company  topped estimates in all of the last four quarters with an average beat of 7 2  Centene surpassed expectations in three of the last four quarters with an average positive surprise of 7 7 Anthem delivered positive surprises in three of the last four quarters with an average beat of 8 6 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-10-09,Zacks Investment Research,https://www.investing.com/analysis/wellcare-health-grows-on-revenues-debt-level-hurts-200217751,200217751
142265,363780,HUM,US STOCKS Futures jump 1 pct on relief over debt deal,news,"  Gold prices tumble while crude oil gains
   Humana raises full year profit view  stock edges higher
   Loews profit misses estimates  Allstate posts steep loss
   Futures up  Dow 153 pts  S P 15 4 pts  Nasdaq 27 5 pts
   For up to the minute market news see  STXNEWS US 
   Adds analyst comment  earnings details 
 By Ryan Vlastelica
 NEW YORK  Aug 1  Reuters    U S  stock index futures surged
more than 1 percent on Monday on relief over a deal in
Washington to raise the debt ceiling  avoiding an unprecedented
default 
 Lawmakers were expected to vote on Monday on the White
House backed agreement  which includes budget cuts of  2 4
trillion  The deal was seen passing the Democratic led Senate 
but it faces tougher opposition in the U S  House of
Representatives  where both conservative Tea Party supporters
and liberal lawmakers have criticized it  For details  see
 ID nN1E76U0F5 
 Even though a default was considered unlikely by many
investors  equities grew increasingly volatile as Washington
was stalemated  Wall Street ended its worst week in a year last
week 
  While no one could imagine there being no compromise
passed  no one could also imagine it taking this long to get
one  So there s justification for the rally because it takes
that anxiety away   said Oliver Pursche  president at Gary
Goldberg Financial Services in Suffern  New York 
 Gold   seen as a safe haven in times of economic
uncertainty  fell 0 7 percent following the deal  while U S 
crude oil  climbed 1 1 percent 
 Even with a deal  many investors remained concerned about a
possible downgrade of the United States  AAA sovereign debt
rating  as well as continued issues over European debt  Some
analysts said Monday s rally in futures could be short lived 
The FTSEurofirst 300  index of top shares was up 0 6
percent   ID nL6E7J10BR 
  Based on the comments Standard   Poor s has made so far 
they ve backed themselves into a corner  making it very likely
that we could see a downgrade   Pursche said   However  since
that is partially priced in and rating agencies don t have as
much credibility as they used to  I don t know how big of a
material impact it will have  
 S P 500 futures  rose 15 4 points and were above fair
value  a formula that evaluates pricing by taking into account
interest rates  dividends and time to expiration on the
contract  Dow Jones industrial average futures  soared
153 points  and Nasdaq 100 futures  jumped 27 5 points 
 In earnings news  Allstate Corp  recorded a
second quarter loss as its catastrophe losses soared 268
percent  while Loews Corp  posted quarterly profits below
estimates it was hit by higher catastrophe losses and lower
income from its biggest holding  CNA Financial  
 ID nL3E7J11S7  and  ID nL3E7J11OX 
 Separately  Humana Inc  raised its full year profit
view  sending the stock up 5 5 percent to  78 68 before the
bell   ID nL3E7J11R2 
 Economic indicators on tap include June construction
spending  which is seen as unchanged  and July ISM
manufacturing data  ISM is seen coming in at 54 9  down from a
read of 55 3 in June  July s non farm payroll number  due
Friday  will also be a focus for investors 
 HSBC Holding Plc  reported a surprise
first half profit and said it would cut 30 000 jobs as it
retreats from countries where it is struggling to compete 
U S  listed shares of the bank rose 3 8 percent to  50 73 in
premarket trading   ID nL3E7J11ER 
 Stocks fell for five straight days last week  with the S P
down 3 9 percent over the period on the political logjam in
Washington over the debt ceiling 
   Reporting by Ryan Vlastelica  editing by Jeffrey Benkoe ",2011-08-01,Reuters,https://www.investing.com/news/stock-market-news/us-stocks-futures-jump-1-pct-on-relief-over-debt-deal-220761,220761
142266,363781,HUM,US STOCKS Wall St rises on debt deal  gains may be short lived,news,"  Gold falls  crude oil gains on debt compromise
   Humana  Allstate rise on results
   Indexes up  Dow  S P 0 6 pct  Nasdaq 0 7 pct
   For up to the minute market news see  STXNEWS US 
   Updates to open 
 By Ryan Vlastelica
 NEW YORK  Aug 1  Reuters    U S  stocks rallied on Monday
on relief over a last ditch deal in Washington to raise the
U S  borrowing limit and avert an unprecedented default  though
analysts said the gains could be short lived 
 Lawmakers were due to vote later Monday on the White
House backed agreement  which includes spending cuts of  2 4
trillion over 10 years  The deal was seen passing the
Democratic led Senate  but faced tougher opposition in the U S 
House of Representatives  where both conservative Tea Party
supporters and liberal lawmakers have criticized it  For
details  see  ID nN1E76U0F5 
 Even though a default was considered unlikely by many
investors  equities grew increasingly volatile as Washington
was stalemated  Wall Street suffered its worst week in a year
last week 
  We re not seeing a bigger rally now because a deal was
expected  The only surprise is how close negotiations came to
the wire before potential Armageddon   said Neal Neilinger 
chief investment officer at Aladdin Capital in Stamford 
Connecticut  which manages  10 5 billion in assets   As the day
goes on  it s likely you ll see some profit taking  
 The Dow Jones industrial average  jumped 72 13
points  or 0 59 percent  at 12 215 37  The Standard   Poor s
500 Index  put on 7 84 points  or 0 61 percent  at
1 300 12  The Nasdaq Composite Index  was up 18 35
points  or 0 67 percent  at 2 774 73 
 Gold   seen as a safe haven in times of economic
uncertainty  fell more than 1 percent before recovering to
stand just half a percent down  September crude futures 
climbed 2 2 percent  The Select Sector Energy SPDR Fund 
rose 0 7 percent 
 Even with an agreement  many investors were concerned about
a possible downgrade of the United States  AAA sovereign debt
rating  as well as European sovereign debt problems  The
FTSEurofirst 300  index of top European shares dipped
0 3 percent   MKTS GLOB 
  The deal lowers the odds of a downgrade  but it doesn t
make it go away   said Wayne Kaufman  chief market analyst at
John Thomas Financial in New York   People still have question
marks in their minds about what comes next  
 In earnings news  Allstate Corp  recorded a
second quarter loss that was narrower than expected  while
insurer Humana Inc  raised its full year profit view 
 ID nL3E7J11S7  and  ID nL3E7J11R2 
 Allstate gained 2 6 percent to  28 45  and Humana advanced
0 4 percent to  74 79 
 HSBC Holding Plc  reported a surprise
first half profit and said it would cut 30 000 jobs as it
retreats from countries where it is struggling to compete 
U S  listed shares of the bank rose 2 3 percent to  49 98 
 ID nL3E7J11ER ",2011-08-01,Reuters,"https://www.investing.com/news/stock-market-news/us-stocks-wall-st-rises-on-debt-deal,-gains-may-be-short-lived-220767",220767
142267,363782,HUM,US STOCKS Wall St falls as data outweighs debt deal,news,"  Health insurer stocks hit amid debt deal worries
   ISM manufacturing data comes in under forecast
   Uncertainty about U S  debt deal high
   Indexes down  Dow 0 9 pct  S P 1 1 pct  Nasdaq 1 3 pct
   For up to the minute market news see  STXNEWS US 
  Updates to early afternoon 
 By Caroline Valetkevitch
 NEW YORK  Aug 1  Reuters    U S  stocks fell a sixth day on
Monday as weaker than expected U S  manufacturing data and
uncertainty over the debt deal in Washington kept the mood
skittish on Wall Street 
 Healthcare stocks  including United Health   were
among the worst performers as investors feared the debt ceiling
deal could lead to cuts in Medicare and other federal health
programs  analysts said  For details  see  ID L3E7J11R2 
 Early gains over the deal aimed at avoiding a U S  default
quickly faded after the Institute for Supply Management  ISM 
reported the U S  manufacturing sector grew at the slowest pace
in two years in July  The ISM report also showed new orders
contracted   ID nN1E7700HA 
  One has to carefully consider this economic data point as
an indication of a continuing slowdown which will perhaps bleed
into earnings   said Chad Morganlander  portfolio manager at
Stifel  Nicolaus   Co in Florham Park  New Jersey   It
indicates a lack of vitality that would improve employment  
 If lawmakers approve the debt deal before the Tuesday
deadline  it may end months of debate over whether the United
States can avoid a debt default 
 Lawmakers were due to vote later Monday on the White
House backed agreement  which includes spending cuts of  2 4
trillion over 10 years   ID nN1E76U0F5 
 Even though a default was considered unlikely by many
investors  the threat of a credit rating downgrade continued to
weigh on sentiment after Wall Street s worst week in a year
last week 
 The Dow Jones industrial average  was down 106 68
points  or 0 88 percent  at 12 036 56  The Standard   Poor s
500 Index  was down 14 49 points  or 1 12 percent  at
1 277 79  down for a sixth day  The Nasdaq Composite Index
 was down 35 16 points  or 1 28 percent  at 2 721 22 
 The S P 500 was well below its 200 day moving average at
1 285 37  which had been pegged as support 
  We re moving toward the lower end of  a trading  range  so
investors are getting more nervous   said Michael Sheldon 
chief market strategist  RDM FINANCIAL in Westport 
Connecticut 
 The S P health care index  fell 2 5 percent  leading
losses among S P 500 sectors 
  Medicare is the one that s on the chopping block    the
one that s getting all the threat of a cut if they can t
agree   said Marc Pado  U S  market strategist at Cantor
Fitzgerald   Co in San Francisco 
 Shares of United Health were down 4 3 percent at  47 48
while shares of Humana Inc  dropped 3 1 percent to
 72 26  despite Humana reporting a higher than expected
second quarter profit 
 Among other health care stocks  shares of Pfizer 
were down 1 7 percent at  18 91 
 Defense related shares also declined  with the iShares Dow
Jones US Aerospace and Defense Index Fund  down 2
percent 
 U S  congressional leaders on Monday tried to get the votes
needed to pass the White House backed deal  which emerged after
heavy negotiations over the weekend 
  It was a patched compromise deal  with still a lot of
uncertainty  so people don t want to get their hands on this
issue  If the deal passes  we ve averted the threat of a
default  but I always thought that was unlikely   said Carl
Kaufman  who helps manage just under  2 billion at the
Osterweis Strategic Income fund in San Francisco 
   Additional reporting by Ashley Lay and Ryan Vlastelica 
Editing by Kenneth Barry ",2011-08-01,Reuters,https://www.investing.com/news/stock-market-news/us-stocks-wall-st-falls-as-data-outweighs-debt-deal-220788,220788
142268,363783,HUM,US STOCKS Wall St cuts losses  ends down as debt vote looms,news,"  Health  defense stocks hit by debt deal worries
   ISM manufacturing data comes in below forecast
   Uncertainty about U S  debt limit deal high
   Dow off 0 1 pct  S P off 0 4 pct  Nasdaq off 0 4 pct
   For up to the minute market news see  STXNEWS US 
  Updates to close 
 By Edward Krudy
 NEW YORK  Aug 1  Reuters    The S P 500 fell for a sixth
day on Monday as time runs out for the government to pass a
deal to avoid default and the economy showed further signs of
stalling 
 The market pared losses late in the day before Congress was
expected to vote on Monday on a debt deal backed by the White
House  which includes spending cuts of  2 4 trillion over 10
years  For details  see  ID nN1E76U0F5 
 The deadline for a deal  which includes raising the U S 
borrowing limit  is Tuesday at midnight 
  It s an on again  off again market  and it reflects the
on again  off again nature of these debt ceiling
deliberations   said Hugh Johnson  chief investment officer of
Hugh Johnson Advisors LLC in Albany  New York 
  Investors now believe that the debt limit will be raised 
that the vote will be positive in the Senate and positive in
the House  but there s still a bit of skepticism or caution  
 Stocks fell after the Institute for Supply Management said
the U S  manufacturing sector grew at the slowest pace in two
years in July  The ISM report followed similarly weak reports
from much of Asia and Europe   ID nN1E7700HA 
 The defense and health care sectors  which would be
subject to U S  budget cuts if a deal is not reached  were
among the hardest hit  The iShares Dow Jones US aerospace and
defense exchange traded fund  fell 1 1 percent while
S P s healthcare index  lost 1 7 percent 
 Healthcare stocks also fell after the Centers for Medicare
  Medicaid Services said Friday that it will cut payments to
skilled nursing facilities by 11 percent  Kindred Healthcare
 fell 30 percent and Skilled Healthcare  lost
more than 43 percent   ID nN1E7700Z3 
 The Dow Jones industrial average  dropped 10 75
points  or 0 09 percent  to 12 132 49  The Standard   Poor s
500 Index  fell 5 34 points  or 0 41 percent  to
1 286 94  The Nasdaq Composite Index  lost 11 77 points 
or 0 43 percent  to 2 744 61 
  Today s trading has exposed the market  It apparently was
hiding behind the  debt ceiling  curtain  but now that that has
been pulled back  we find that there are other problems   
namely  the economy   said Larry McMillan  president of
McMillan Analysis Corp 
 The S P 500 rallied back above its 200 day after dipping
sharply below that  The level has acted as strong support over
the last two months and the fact that S P 500 was able to rally
back above it was a comfort to investors 
  The S P which sliced through the 200 day moving average at
1 285  has taken that back in the last half hour  of trading   
said  Elliot Spar  market strategist at Stifel  Nicolaus   Co
in Shrewsbury  New Jersey  noting that as a sign of underlying
resilience 
 Stocks traded in a wide range  A rally in equity markets
that began in Asia last night on optimism over a debt agreement
eroded as the outcome seemed to struggle throughout Monday to
bring the deal to a close 
 If lawmakers approve the debt deal before the Tuesday
deadline  it may end months of debate over whether the United
States can avoid a debt default 
 Even though a default was considered unlikely by many
investors  the threat of a credit rating downgrade continued to
weigh on sentiment after Wall Street marked its worst week in a
year last week 
 Shares of United Health  slid 3 2 percent to  48 02
while Humana Inc  dropped 3 percent to  72 36  despite
Humana reporting a higher than expected second quarter profit 
 Among other health care stocks  shares of Pfizer 
shed 1 2 percent at  19 01 
 Some 8 3 billion shares changed hands on the New York Stock
Exchange  NYSE Amex and Nasdaq  above the daily average of
around 7 48 billion 
 Advancers outweighed decliners on the NYSE by about 9 to 8 
while on Nasdaq losers outpaced winners by about 5 to 4 
  Reporting by Edward Krudy  Additional reporting by Caroline
Valetkevitch  Editing by Kenneth Barry ",2011-08-01,Reuters,"https://www.investing.com/news/stock-market-news/us-stocks-wall-st-cuts-losses,-ends-down-as-debt-vote-looms-220804",220804
142269,363784,HUM,House panel opposes giving SEC documents for insider trading probe,news,"NEW YORK  Reuters    A U S  House of Representatives panel said on Friday it should not have to comply with a federal regulator s demand for documents sought for an insider trading probe involving the staff director of a subcommittee and a lobbyist   The House Ways and Means Committee argued in a court filing that U S  District Judge Paul Gardephe in New York should deny the Securities and Exchange Commission s attempt to subpoena documents from the committee and its healthcare subcommittee staff director Brian Sutter   The SEC went to court June 20 to enforce subpoenas it issued as it sought information related to a probe into whether Sutter leaked material nonpublic information about Medicare reimbursement rates to Mark Hayes  a lobbyist at Greenberg Traurig LLP   The committee s filing called the SEC subpoena  a remarkable fishing expedition for congressional records   It said the U S  Constitution shields the panel and Sutter from being compelled to testify or produce documents   A request for comment from the SEC was not immediately returned   The dispute between the House committee and the regulator could test the boundary of the SEC s powers to compel the legislative branch of government to cooperate with its enforcement of the federal securities laws   In previous court filings  the SEC said Hayes spoke with Sutter the same day that the Centers for Medicare and Medicaid Services announced reimbursement rates for the Medicare Advantage program   The regulator said Hayes then emailed the brokerage firm Height Securities  which shortly afterward sent its clients a  flash alert  suggesting the deal could help insurance companies such as Humana Inc  N HUM  and Health Net Inc  N HNT    Share prices of both companies jumped after the report was issued   
The SEC will have until July 11 to respond to the committee s opposing arguments   The case is SEC v  Committee on Ways and Means of the U S  House of Representatives et al  U S  District Court  Southern District of New York  No  14 mc 00193     Reporting by Luciana Lopez in New York and Nate Raymond and Sarah Lynch in Washington  Editing by David Gregorio ",2014-07-04,Reuters,https://www.investing.com/news/world-news/house-panel-opposes-giving-sec-documents-for-insider-trading-probe-293242,293242
142270,363785,HUM,Obamacare rescue ruled out by some states  others weigh options,news,"By David Morgan WASHINGTON  Reuters    Five Republican state governors say they will not rescue a crucial part of Obamacare if it is struck down by the Supreme Court  underlining the prospect for a chaotic aftermath to a ruling that could force millions of Americans to pay much more for coverage or lose their health insurance  The Supreme Court is due to hear opening arguments in the case known as King v  Burwell on March 4  marking the second major challenge to President Barack Obama s Affordable Care Act  ACA  after the justices ruled in 2012 against a claim that it was unconstitutional  The latest case tests the tax credit subsidies at the core of Obamacare  In its ruling expected by June  the high court could bar the federally run insurance marketplace from providing the subsidies in at least 34 states  That could throw the insurance system into turmoil as states respond in starkly different ways  In response to Reuters  queries  spokespeople for the Republican governors of Louisiana  Mississippi  Nebraska  South Carolina and Wisconsin said the states were not willing to create a local exchange to keep subsidies flowing  Republicans argue that Obamacare is unacceptable government intervention that raises costs for consumers and businesses   State exchanges are the federal government s way of sticking states with the cost and responsibility of a massive new bureaucratic program   said Chaney Adams  a spokeswoman for South Carolina Governor Nikki Haley    The right decision was made for South Carolina  and Governor Haley would make it again today       State government officials in Georgia  Missouri  Montana and Tennessee   a mix of Republicans and Democrats   said that opposition by majority Republican state legislators could make it all but impossible to set up a new exchange   Those nine states combined are home to 1 4 million people who have signed up for subsidized coverage in 2015  according to government data  The fate of 5 1 million residents in the remaining 25 states that have signed up for subsidized benefits on the HealthCare gov exchange is also unclear   Six states   Delaware  Maine  Ohio  Pennsylvania  South Dakota and Virginia   are discussing contingency plans to keep the subsidies but each faces substantial logistical or political barriers  according to officials   Ten states did not respond to Reuters queries  while three others had no comment  Iowa  Wyoming  Oklahoma and West Virginia said they were not currently considering setting up exchanges  Alaska said it has not ruled it out  and Arkansas said it was moving toward creating a state exchange in 2017   Republicans are opposed to Obamacare  but such a ruling could have a political cost in their states if hundreds of thousands of low to middle income people are priced out of health coverage  Even if states say they don t plan to set up exchanges  that could change closer to the ruling or afterwards as they come under pressure to avert spiraling insurance costs   We can say with some confidence that the insurance markets are likely to melt down  because only the sick people will stay in them and the others will find it unaffordable   said Drew Altman  who heads the non partisan Kaiser Family Foundation  STATES WEIGH WORKAROUNDS     The plaintiffs in King v  Burwell contend that the Affordable Care Act allows subsidies to be distributed only through state based exchanges  Thirteen states and the District of Columbia set up their own exchanges from October 2013   The remainder of states either opposed the law or could not find ways to make their own exchanges work  so the federal government stepped in  Insurers includ  NYSE AE  NYSE AET T ing Aetna Inc  Cigna Corp a  NYSE HU  NYSE HUM M nd Humana Inc are major players in the HealthCare gov markets  About 87 percent of enrollees in those states qualify for Obamacare subsidies  which can reduce a family s healthcare bill by thousands of dollars annually  A Milwaukee family of four earning the median U S  household income of  53 000  for example  could receive  7 800 a year in subsidies  according to the Kaiser Family Foundation  A ruling against Obamacare would raise their monthly premium payments by at least  652  Congress could respond to a negative ruling with legislation to keep subsidies in place  But partisan gridlock would make any action a challenge   Health policy experts say the most likely fix to a ruling against the administration would involve a new type of partnership with the federal government or between states         Maine and Delaware have considered a model in which the state creates the exchange in name but still relies on the federal government s technology systems to run it  Marketplaces for Nevada  New Mexico and Oregon have operated in that fashion   But experts say this model could be rejected by the Supreme Court  because the ACA does not list the federal government as an entity with which states can By David Morgan WASHINGTON  Reuters    Five Republican state governors say they will not rescue a crucial part of Obamacare if it is struck down by the Supreme Court  underlining the prospect for a chaotic aftermath to a ruling that could force millions of Americans to pay much more for coverage or lose their health insurance  The Supreme Court is due to hear opening arguments in the case known as King v  Burwell on March 4  marking the second major challenge to President Barack Obama s Affordable Care Act  ACA  after the justices ruled in 2012 against a claim that it was unconstitutional  The latest case tests the tax credit subsidies at the core of Obamacare  In its ruling expected by June  the high court could bar the federally run insurance marketplace from providing the subsidies in at least 34 states  That could throw the insurance system into turmoil as states respond in starkly different ways  In response to Reuters  queries  spokespeople for the Republican governors of Louisiana  Mississippi  Nebraska  South Carolina and Wisconsin said the states were not willing to create a local exchange to keep subsidies flowing  Republicans argue that Obamacare is unacceptable government intervention that raises costs for consumers and businesses   State exchanges are the federal government s way of sticking states with the cost and responsibility of a massive new bureaucratic program   said Chaney Adams  a spokeswoman for South Carolina Governor Nikki Haley    The right decision was made for South Carolina  and Governor Haley would make it again today       State government officials in Georgia  Missouri  Montana and Tennessee   a mix of Republicans and Democrats   said that opposition by majority Republican state legislators could make it all but impossible to set up a new exchange   Those nine states combined are home to 1 4 million people who have signed up for subsidized coverage in 2015  according to government data  The fate of 5 1 million residents in the remaining 25 states that have signed up for subsidized benefits on the HealthCare gov exchange is also unclear   Six states   Delaware  Maine  Ohio  Pennsylvania  South Dakota and Virginia   are discussing contingency plans to keep the subsidies but each faces substantial logistical or political barriers  according to officials   Ten states did not respond to Reuters queries  while three others had no comment  Iowa  Wyoming  Oklahoma and West Virginia said they were not currently considering setting up exchanges  Alaska said it has not ruled it out  and Arkansas said it was moving toward creating a state exchange in 2017   Republicans are opposed to Obamacare  but such a ruling could have a political cost in their states if hundreds of thousands of low to middle income people are priced out of health coverage  Even if states say they don t plan to set up exchanges  that could change closer to the ruling or afterwards as they come under pressure to avert spiraling insurance costs   We can say with some confidence that the insurance markets are likely to melt down  because only the sick people will stay in them and the others will find it unaffordable   said Drew Altman  who heads the non partisan Kaiser Family Foundation  STATES WEIGH WORKAROUNDS     The plaintiffs in King v  Burwell contend that the Affordable Care Act allows subsidies to be distributed only through state based exchanges  Thirteen states and the District of Columbia set up their own exchanges from October 2013   The remainder of states either opposed the law or could not find ways to make their own exchanges work  so the federal government stepped in  Insurers including Aetna Inc  Cigna Corp and Humana Inc are major players in the HealthCare gov markets  About 87 percent of enrollees in those states qualify for Obamacare subsidies  which can reduce a family s healthcare bill by thousands of dollars annually  A Milwaukee family of four earning the median U S  household income of  53 000  for example  could receive  7 800 a year in subsidies  according to the Kaiser Family Foundation  A ruling against Obamacare would raise their monthly premium payments by at least  652  Congress could respond to a negative ruling with legislation to keep subsidies in place  But partisan gridlock would make any action a challenge   Health policy experts say the most likely fix to a ruling against the administration would involve a new type of partnership with the federal government or between states         Maine and Delaware have considered a model in which the state creates the exchange in name but still relies on the federal government s technology systems to run it  Marketplaces for Nevada  New Mexico and Oregon have operated in that fashion   But experts say this model could be rejected by the Supreme Court  because the ACA does not list the federal government as an entity with which states can contract for exchange services       Other workarounds that have been discussed include setting up regional exchanges that cover multiple states  or keeping the HealthCare gov website operating as a place to sign up for insurance but allowing states to disburse the federal subsidies      At the very least  states that are open to setting up their own exchange hope the Supreme Court allows for a transition period if it rules against the administration   
     A state based exchange from scratch in six months is probably not doable  We re trying to see what other states are doing and what may work and may not work   said Eric Cioppa  Maine s leading insurance official ",2015-02-17,Reuters,"https://www.investing.com/news/politics-news/obamacare-rescue-ruled-out-by-some-states,-others-weigh-options-328336",328336
142279,363794,HUM,Aetna  AET  Tops Q2 Earnings  Revenues  Raises 2017 Guidance,opinion,Health insurer Aetna Inc  s   NYSE AET   second quarter 2017 earnings of  3 42 per share surpassed the Zacks Consensus Estimate of  2 34 by 46  and also grew 55  year over year  Aetna s bottom line displayed improvement due to higher net income as well as lower transaction and integration related costs Operational UpdateTotal revenue of  15 5 billion surpassed the Zacks Consensus Estimate of  15 30 billion by approximately 1 3   Revenues  however  declined 2 5  year over year due to lower premiums in Aetna s Health Care segment Adjusted expense ratioimproved 60 basis points  bps  to 16 5  from the prior year quarter  This was primarily due to the temporary suspension of the HIF in 2017 and the execution of Aetna s expense management initiatives  partially offset by targeted investment spending on its growth strategies Total expense ratioimproved 110 bps from the year ago quarter to 16 4  in the second quarter  primarily due to lower transaction and integration related costs Second quarter after tax net income margin was 7 7    up 270 bps year over year   Adjusted pre tax marginwas 11 7   up 280 bps from the prior year quarter  The upside was primarily driven by strong performance in Aetna s Health Care segment  partially offset by the negative impact of the temporary suspension of the HIF in 2017Medical membership totaled 22 1 million on Jun 30  2017  down 1 6  year over year Segmental Performance UpdateHealth Care segmentAetna s Health Care segment recorded both total revenue and adjusted revenues of  14 8 billion  down 2 6  year over year  The downside primarily stemmed from lower membership in Aetna s ACA compliant individual and small group products and temporary suspension of the HIF in 2017  This was somewhat offset by higher premium yields in the company s Commercial and Government businesses and membership growth in its Medicare products Pre tax adjusted earnings were  1 8 billion  up 38 5  year over year primarily due to continued strong performance across its core Health Care businesses  The increase also reflects Aetna s updated estimates of risk adjustment payables for the prior year for individual and small group ACA compliant products Group InsuranceTotal revenue of  642 million declined 0 8  from the prior year quarter  Adjusted revenuesof  627 million dropped 0 5  from the last year quarter Pre tax adjusted earningswere  42  down 26 3  from second quarter 2016 due to lower revenues Large Case PensionsTotal revenue of  81 million dropped 1 2  from second quarter 2016  Adjusted revenuesremained flat at  78 million year over year Pre tax adjusted earningsalso remained flat at  3 million year over year Aetna Inc  Price  Consensus and EPS Surprise   Financial PositionTotal assets were  56 7 billion as of Jun 30  2016  down 18  from the prior year quarter Total debt to consolidated capitalization ratiowas 37 3  as of Jun 30  2017  down 1630 bps from 53 6  at year end 2016  This reflects the repayment of approximately  11 6 billion aggregate principal amount of Aetna s senior notes during 2017 GuidanceThe company expects 2017 operating earnings to be in the range of  9 45  9 55  up from the previously guided range of  8 80 to  9 00 Zacks Rank   Performance of Other InsurersAetna currently carries a Zacks Rank  2  Buy   You can see  Among the other firms in the medical sector that have reported second quarter earnings so far  the bottom lines of Anthem Inc    NYSE ANTM    Humana Inc    NYSE HUM   and UnitedHealth Group Inc    NYSE UNH   beat their respective Zacks Consensus Estimate More Stock News  Tech Opportunity Worth  386 Billion inFrom driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity   Most importantly  it reveals 4 stocks with massive profit potential ,2017-08-03,Zacks Investment Research,https://www.investing.com/analysis/aetna-aet-tops-q2-earnings-revenues-raises-2017-guidance-200205051,200205051
142280,363795,HUM,Cigna  CI  Earnings Beat In Q2  Guidance Raised  Shares Gain,opinion,Cigna Corp    NYSE CI   reported second quarter 2017 operating net earnings of  2 91 per share  comfortably beating the Zacks Consensus Estimate of  2 48 and increasing 47  year over year The earnings beat reflected strong contribution from each of the company s business segments Strong earnings performance led the shares to gain 0 4  in pre market trading Other DetailsCigna posted revenues of  10 3 billion  which surpassed the Zacks Consensus Estimate of  9 98 billion   Revenues grew 4  year over year Total benefits and expenses of  9 2 billion remained almost unchanged year over year Operating expense ratio of 19 9  improved 100 basis points year over year The company s medical enrollment grew to 15 7 million from 15 1 million in the year ago quarter  driven by organic growth in all of its commercial market segments Quarterly Review by SegmentGlobal Health Care  Premiums and fees from the segment increased 3  year over year to  7 18 billion  The improvement was driven by customer growth and specialty contributions in the company sCommercial employer group  However  the upside was partially offset by reductions in Government customers Adjusted operating earnings were  591 million  up 21 6  year over year on strong medical and specialty results  and continued effective medical cost Global Supplemental Benefits  Premiums and fees from this segment climbed 14  year over year to  914 million on the back of continued business growth Adjusted operating income increased 26 5  year over year to  105 million  reflecting business growth and strong operating expense management Global Disability and Life  Premiums and fees also increased 1  year over year to  1 02 billion  primarily driven by consistent business growth across disability and life products The segment reported adjusted operating income of  83 million against a loss of  12 million in the year ago quarter  reflecting continued stable life results and further improvement in disability performance Financial PositionCash and marketable investments were  2 2 billion at Jun 30  2017 and  2 8 billion at year end 2016 Cigna s long term debt of  4 6 billion as of Jun 30  2017 declined from  4 8 billion as of Dec 31  2016 Year to date  the company has repurchased 7 7 million shares of common stock for approximately  1 25 billion Cigna Corporation Price  Consensus and EPS Surprise   2017 GuidanceCigna pulled up its 2017 earnings guidance after strong results  It expects adjusted income from operations between  2 50 billion to  2 58 billion  previous estimate was  2 41 billion to  2 53 billion   or  9 75 to  10 05 per share   9 25  9 75  It  however  maintained the guidance for revenue growth rate at 3  to 4   and the global medical customer growth range of 0 5 million to 0 6 million Our TakeCigna s results reflect broad based growth across its business segments  The company is poised for long term growth on the back of its robust Global Supplemental business  growing government business and increasing membership  A strong capital position and resumption of share buyback are the other positives  The company has also been successful in maintaining its medical cost ratio at low levels Zacks Rank and Performance of Other InsurersCurrently  Cigna carries a Zacks Rank  2  Buy   You can see  Among the other firms in the health care sector that have reported their second quarter earnings so far  the bottom line at Aetna Inc    NYSE AET    Humana Inc    NYSE HUM   and UnitedHealth Group Inc    NYSE UNH   beat their respective Zacks Consensus Estimate Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-08-04,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-earnings-beat-in-q2-guidance-raised-shares-gain-200205342,200205342
142281,363796,HUM,Select Medical  SEM  Q2 Earnings Top Estimates  Revises View,opinion,Select Medical Holdings Corp    NYSE SEM   reported second quarter 2017 earnings of 32 cents per share  which surpassed the Zacks Consensus Estimate by 28   Also  earnings improved year over year by 39 1    Notably  shares of the company have rallied 12 7  in the last two trading sessions reflecting the bullish results Second quarter results benefited from solid performance across all the segments  Both revenues and margins exhibited improvement Select Medical Holdings Corporation Price  Consensus and EPS Surprise    Operational UpdateOperating revenues of Select Medical grossed  1 12 billion during the quarter  up 2 1  year over year  Higher Outpatient Rehabilitation revenues  Specialty and Concentra revenues led to the upside  The top line missed the Zacks Consensus Estimate by 1 3  Total operating expenses amounted to  1 billion  up 0 8  year over year  Increase of 0 4  in cost of services  5 9  higher depreciation and amortization expenses  9 3  in general and administrative expenses and 3 8  in bad debt expenses led to the overall rise in expenses Income from operations improved 14 5  year over year to  0 1 billion on the back of higher revenues Adjusted EBITDA rose 12 2  year over year to  158 7 million Segment UpdateSpecialty Hospitals  operating revenues rose 2 6  year over year to  601 million Adjusted EBITDA was  98 1 million  up 18 7  year over year  with margins expanding 220 basis points  bps  to 16 3  Operating revenues from Outpatient Rehabilitation were up 0 5  year over year to  258 1 million  mainly due to higher revenue per visit  increased 1    which was offset by a lower number of visits  decreased 0 7   Adjusted EBITDA rose 9 9  year over year to  41 9 million  while margin expanded 140 bps year over year to 16 2  Concentra segment reported net operating revenues of  261 5 million  up 2 6  from the prior year quarter  Adjusted EBITDA increased 0 05  year over year to  43 million Adjusted EBITDA margin declined 40 bps to 16 5  Financial UpdateSelect Medical exited the quarter with cash of  73 7 million  up from  99 million at year end 2016 As of Jun 30  2017  long term debt  net of current portion  increased to  2 7 billion from  2 6 billion at the end of 2016 Cash flow from operations was  96 2 million  up from  67 1 million in the year ago quarter 2017 GuidanceSelect Medical estimates earnings per share to be between 78 and 96 cents on revenues of  4 4 billion to  4 6 billion  Net income per share is estimated between 69 and 87 cents Adjusted EBITDA is projected between  540 and  580 million Zacks RankSelect Medical presently carries a Zacks Rank  2  Buy   You can see  Performance of Other Health Maintenance Organization StocksAmong other stocks from the health maintenance organization industry that have reported their second quarter earnings  the bottom lines of Humana Inc    NYSE HUM    Aetna Inc    NYSE AET   and UnitedHealth Group Incorporated   NYSE UNH   have topped their respective Zacks Consensus Estimate Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-08-07,Zacks Investment Research,https://www.investing.com/analysis/select-medical-sem-q2-earnings-top-estimates-revises-view-200205977,200205977
142282,363797,HUM,Envision Healthcare  EVHC  Q2 Earnings Beat   17 View Cut,opinion,"Envision Healthcare Corp    NYSE EVHC   reported second quarter earnings of 79 cents per share  surpassing the Zacks Consensus Estimate by 5 33   but declining from  1 01 reported in the year ago quarter The company reported net revenue of  1 95 billion  which missed the Zacks Consensus Estimate by 0 5  but increased from  758 5 million in the year ago quarter      Total operating expenses of  1 75 billion increased from  600 million in the year ago quarter Segment UpdateNet revenues from the Physician Services segment were  1 63 billion in the second quarter of 2017  reflecting an increase of 9 3  year over year  The revenue growth was driven by 10 6  contribution from acquisitions and 2 5  from same contracts Net revenues from Ambulatory Services were  318 5 million  reflecting a decline of 0 4  year over year  Same center revenues increased 0 6   comprising a 0 5  increase in net revenue and a 0 1  increase in procedure volume Financial UpdateEnvision Healthcare had cash and cash equivalents of  441 3 million  up from  316 9 million as of Dec 31  2016 Total long term debt increased to  6 3 billion as of Jun 30  2017 from  5 8 billion as of Dec 31  2016 The company s ratio of total net debt at Jun 30  2017 to trailing 12 month EBITDA as calculated under the company s credit agreement was 4 5 times Envision Healthcare Corporation Price  Consensus and EPS Surprise   Guidance UpdateFor 2017  the company lowered its revenue guidance to  7 75  8 00 billion  from the previous guidance of  7 80 billion to  8 05 billion   adjusted EBIDTA to  1 02 billion to  1 04 billion  from  1 038 billion to  1 066 billion  and adjusted EPS to  3 35 to  3 45  from  3 38 to  3 52  It  however  kept intact  the same contract revenue growth guidance of 3  to 4  in the physician services segment and 0  to 1  in ambulatory services For the third quarter  the company expects adjusted EBIDTA of  266 million to  278 million and adjusted EPS of 87 cents to 93 cents   Zacks Rank   Other Releases
Envision Healthcare carries a Zacks Rank  4  Sell  
You can see  Among the other stocks in the healthcare space  the bottom lines at UnitedHealth Group Inc    NYSE UNH    Aetna Inc    NYSE AET   and Humana Inc    NYSE HUM   beat their respective second quarter estimates 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-08-07,Zacks Investment Research,https://www.investing.com/analysis/envision-healthcare-evhc-q2-earnings-beat-17-view-cut-200205963,200205963
142283,363798,HUM,Wellcare Health s  WCG  Inorganic Growth Boosts Revenues,opinion,WellCare Health Plans  Inc  s   NYSE WCG   growth strategies continue to help it retain its leading position in the industry  It has been strengthening its revenue base consistently over the last 10 years  The Affordable Care Act  ACA  implemented by the former U S  President Barrack Obama also contributed significantly to the company s top line growth  Nevertheless  a lot many hassles around  Repealing and Replacing  the ACA under the Trump administration might lead to volatility in Medicaid programs enrolment However  despite the regulatory uncertainty  WellCare Health remains an attractive pick for investors  Let s delve deeper to find out why WellCare Health has been witnessing consistent revenue growth supported by strategic acquisitions  partnerships and alliances since 2011  These initiatives not only bolstered the company s presence in existing markets but also expanded its operations geographically  In the first half of 2017  revenues of  8 2 billion increased 15 6  year over year due to strong organic growth across all its three lines of business and the company s acquisition of Care1st Arizona The company s substantial cash inflow has helped it increase shareholders  value through several capital deployment initiatives  In the first half of 2017  net cash from operating activities was  335 million versus net cash used for operating activities of  60 million in the prior year quarter  The improvement was primarily driven by the advanced timing of Medicare related receipts   This high level of financial liquidity is expected to support the company s inorganic growth initiatives and further drive top line growth The company delivered positive earnings surprises in the last four quarters with an average beat of 47 37   In the second quarter  its earnings surpassed the Zacks Consensus Estimate and grew year over year on higher revenues  Pursuant to the earnings beat  the company also raised its earnings and revenue guidance for 2017 that boosted shareholder optimism in the stock  Over past seven days  the Zacks Consensus Estimate for 2017 and 2018 has also been revised upward significantly Stocks to ConsiderInvestors interested in the same space can consider stocks like Humana Inc   NYSE HUM    Aetna Inc   NYSE AET   and Anthem Inc   NYSE ANTM   Humana  a leading managed care company  topped estimates in all of the last four quarters with an average beat of 6 63  Aetna surpassed expectations in each of the last four quarters with an average positive surprise of 18 97 Anthem delivered positive surprises in three of the last four quarters with an average beat of 8 58  Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ,2017-08-14,Zacks Investment Research,https://www.investing.com/analysis/wellcare-healths-wcg-inorganic-growth-boosts-revenues-200207313,200207313
142284,363799,HUM,Humana  HUM  Hits 52 Week High On Solid Q2  Raised Outlook ,opinion,On Aug 29  Humana Inc    NYSE HUM   hits a 52 week high of  255 91  The improvement is believed to have been driven by strong second quarter results  guidance raise and the recent completion of accelerated share buyback Notably  the stock has surged 43  in the last year  almost in line with the  s rally of 42  but significantly outperforming the S P 500 index s rise of 12 2  In fact  investors are optimistic on this Zacks Rank  3  Hold  company s strong second quarter earnings that topped Zacks Consensus Estimate by 13 3   This uptick was owing to solid performance by both the Medicare Advantage business segment and Retail segment The company s raised guidance  for the second time this year  is also encouraging  Humana now expects 2017 adjusted earnings per share of  11 50  to be up from the previous guidance of at least  11 10 per share  The latest guidance also reflects 20  increase in earnings compared with 2016  Operating cash flow increased by approximately  200 million  primarily owing to a better financial performance Interestingly  an upbeat guidance instills confidence in the company s ability to perform well in a highly regulated and competitive industry Consequently  the company announced a strong outlook for its Medicare business  one of its most significant growth drivers  It expects approximately 74  of its Medicare members to be in 4 Star or higher plans  for the year 2018  which compares favorably to its previous forecast of 37  Going forward  Humana s anticipates to book 2017 pre tax earnings of approximately  85 million in its Indiividual Commercial segment compared with the previous expectation of a full year loss of approximately  45 million  The reversal in this segment is expected to be driven by lower than anticipated medics cost for the exchange enrollees   Investors also viewed favorably the timely completion of  1 5 billion of accelerated share buyback plan announced in the first quarter In fact  another leading health insurer UnitedHealth Group Inc    NYSE UNH   also touched a 52 week high on the same day  followed by the announcement that The Advisory Board Company s   NASDAQ ABCO   health care business will join Optum  which is the company s health services unit A better ranked stock in the same space include Aetna Inc    NYSE AET   holding a Zacks Rank  2  Buy   You can see Aetna is one of the largest health benefits companies that topped estimates in each of the last four quarters with an average positive surprise of 19  4 Surprising Tech Stocks to Keep an Eye OnTech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really take off ,2017-08-29,Zacks Investment Research,https://www.investing.com/analysis/humana-hum-hits-52week-high-on-solid-q2-raised-outlook-200210529,200210529
142292,363807,HUM,US STOCKS Corporate outlooks  bonds sale lift Wall St,news,"  Texas Instruments  P G boost outlooks
   Monsanto tumbles as 2010 forecast below Street views
   Dow  S P up 0 5 pct  Nasdaq up 0 6 pct
  Updates to early afternoon  changes byline 
 By Chuck Mikolajczak
 NEW YORK  Sept 10  Reuters    U S  stocks rose on Thursday
as a brighter outlook from consumer product company Procter  
Gamble and a successful Treasury debt auction put Wall Street
on pace for a fifth straight session of gains 
 Procter   Gamble was the Dow s biggest lift  climbing 3 7
percent to  55 77  after it affirmed its earnings forecast for
the current quarter and said sales would improve in the next
quarter 
 A third straight strong Treasury auction relieved concerns
about the U S  government s ability to fund its deficit 
 The sale of  12 billion of 30 year bonds  shows the U S 
ability to finance the deficit and its budget in light of the
supply and     the weak dollar  That is why stocks are trading
up   said Peter Boockvar  managing director and equity
strategist at Miller Tabak   Co 
 The potential for rising retail sales was encouraging for
investors  who view consumer spending as a critical component
to an economic recovery 
 Optimism was contained  however  by a 5 6 percent drop to
 78 79 for Monsanto after the world s biggest seed company
forecast fiscal 2010 earnings below Wall Street s estimates 
The S P materials index  shed 0 1 percent 
  This is just kind of a holding pattern   said Kevin
Kruszenski  head of listed trading at KeyBanc Capital Markets
in Cleveland   We ve had an advance  we ve drifted higher 
volume in August was very light  so it s hard to put too much
credence into the move 
 The Dow Jones industrial average gained 46 78 points  or
0 49 percent  to 9 594 00  The Standard   Poor s 500 Index   
 rose 4 85 points  or 0 47 percent  to 1 038 22  The Nasdaq
Composite Index  climbed 11 70 points  or 0 57 percent  to
2 072 09 
 Chip companies Texas Instruments and ASMLboth boosted their
sales outlooks in a signal consumers are spending cash on
personal technology and helped lift the PHLX semiconductor
index 1 percent 
  Now you are going to have to see a follow through in not
only economic data  but in companies  earnings and commentary
along those lines   Kruszenski said 
 If the market maintains its gains  it would mark five
consecutive advances and push the S P 500 index to its highest
level in nearly a year 
 Health insurance stocks rose 2 5 percent after analysts
said President Barack Obama s speech urging Congress to act on
health care reform contained nothing unexpected and indicated a
government run insurance option opposed by the industry was
less likely to pass 
 Cigna Corp rose 4 4 percent to  30 70 and Humana Inc gained
3 1 percent at  39 23 
 Yahoo Inc added 3 9 percent to  15 35 after Banc of America
Securities Merrill Lynch Research upgraded the company  saying
growth in user traffic continues to outpace growth in the
Internet as a whole 
 U S  traded shares of ASML rose 1 4 percent although Texas
Instruments shares slipped 0 3 percent to  25 06 
 Airlines stocks added 6 percent after J P  Morgan said
fundamentals for the U S  airlines sector are on the mend  and
upgraded UAL Corp and U S  Airways Group Inc 
 United airlines parent UAL Corp shares jumped 12 6 percent
to  4 03 while U S  Airways shares surged 17 5 percent to
 7 58 
  Editing by Kenneth Barry ",2009-09-10,Reuters,"https://www.investing.com/news/equities-news/us-stocks-corporate-outlooks,-bonds-sale-lift-wall-st-85658",85658
142297,363812,HUM,American Express  AXP  Q2 Earnings Set To Beat  Here s Why,opinion,"We expect American Express Co    NYSE AXP   to beat expectations when it reports second quarter results on Apr 19  before market opens Why a Likely Positive Surprise Our proven model shows that American Express has the right combination of the two key ingredients to beat earnings estimates Zacks ESP     which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  2 04   This is because the Most Accurate estimate of  1 50 is pegged higher than the Zacks Consensus Estimate of  1 47  The positive ESP is a meaningful indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  American Express carries a Zacks Rank  3  Hold   Note that stocks with a Zacks Rank of  1  2 or 3 have a significantly higher chance of beating on earnings Sell rated stocks   4 or 5  should never be considered going into an earnings announcement   What is Driving the Better Than Expected Earnings We expect American Express  second quarter results to showcase the benefits of its cost reduction efforts over the last couple of years Continued return of significant capital to shareholders through its dividend and share buyback programs will aid bottom lineThe company s Global Commercial Services segment is expected to give a muted performance as travel and entertainment spending by large corporations remains at low levels We expect to see higher net card fees driven by continued strength in its premium U S  portfolios including Platinum  Gold and Delta  as well as growth in key international markets like Japan and Australia Second quarter results will likely reflect an increase in loan lending  Also  focus on existing card members and increased use of digital channels is expected to drive new card issuance Nevertheless  card spending volumes at another of the company s segments   Global Network and Merchant Services   is expected to be under pressure due to the changing regulatory environment specifically in the European Union  Australia and China We also expect to see higher reward expense  which will weigh on margins  as the company has made enhancements to its U S  platinum products to woo and retain its customers American Express Company Price and EPS Surprise

   Other Stocks That Warrant a LookHere are some companies that you may also consider as our model shows that these have the right combination of elements to post an earnings beat this quarter   Humana Inc    NYSE HUM   is expected to report second quarter 2017 earnings results on Aug 2  The company has an Earnings ESP of  0 98  and a Zacks Rank  2  Buy   You can see  Cigna Corp    NYSE CI   has an Earnings ESP of  0 81  and a Zacks Rank  2  The company is expected to report second quarter earnings results on Aug 4 Comerica Inc    NYSE CMA   has an Earnings ESP of  4 67  and a Zacks Rank  2  The company is expected to report second quarter earnings results on Jul 18 
Today s Stocks from Zacks  Hottest Strategies 
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
 And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-07-16,Zacks Investment Research,https://www.investing.com/analysis/american-express-(axp)-q2-earnings-set-to-beat:-here's-why-200201510,200201510
142298,363813,HUM,Visa  V  Gearing Up For Q3 Earnings  Is A Surprise In Store ,opinion,"Visa Inc    NYSE V   is scheduled to report third quarter fiscal 2017 results on Jul 20  after market close Last quarter  Visa surpassed the Zacks Consensus Estimate by 8 86  Let s see how things are shaping up for this announcement Q3 FlashbackWe expect fiscal third quarter earnings to gain traction from the company s digital initiatives  Visa Checkout  a digital payment platform  is sustaining tremendous growth  reaching more than 20 million enrolled accounts  Its other digital initiatives Visa Direct and mVisa are continuing to expand globally The company will likely report an increase in U S  payments  volumes driven by the gain of USAA and Costco  NASDAQ COST  clients The company s Service Revenue is likely to increase on higher global U S  debit as well as credit card payment volumes Also  growth in processed transaction is likely to push up Data Processing fees The company s disciplined capital allocation plan by way of share buyback and dividend payments should add to its bottom line Fiscal third quarter earnings are also likely to be benefited by a lower adjusted tax rate driven by the reorganization of Visa Europe and other subsidiaries   Nevertheless  higher operating cost and forex headwinds will be the dampeners Earnings WhispersOur proven model does not conclusively show that Visa is likely to beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank of  1  2 or 3 for this to happen  That is not the case here as you will see below Zacks ESP  Visa has an Earnings ESP of 0 00   This is because the Most Accurate estimate stands at 81 cents per share  in line with the Zacks Consensus Estimate  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Visa carries a Zacks Rank  2  Buy   which increases the predictive power of ESP  However  an Earnings ESP of 0 00  makes surprise prediction difficult We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Visa Inc  Price and EPS Surprise

   Stocks That Warrant a LookHere are some companies that you may consider as our model shows that these have the right combination of elements to post an earnings beat this quarter   Humana Inc    NYSE HUM   is expected to report second quarter 2017 earnings results on Aug 2  The company has an Earnings ESP of  0 98  and a Zacks Rank  2  You can see  Cigna Corp    NYSE CI   has an Earnings ESP of  0 81  and a Zacks Rank  2  The company is expected to report second quarter earnings results on Aug 4 Comerica Inc    NYSE CMA   has an Earnings ESP of  4 67  and a Zacks Rank  2  The company is expected to report second quarter earnings results on Jul 18 Today s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-07-16,Zacks Investment Research,https://www.investing.com/analysis/visa-(v)-gearing-up-for-q3-earnings:-is-a-surprise-in-store-200201491,200201491
142299,363814,HUM,UnitedHealth  UNH  Beats On Q2 Earnings  Guides Up For 2017,opinion,"UnitedHealth Group Inc    NYSE UNH   reported second quarter net operating earnings per share of  2 46  comfortably beating the Zacks Consensus Estimate of  2 38 and increasing 25 5  year over year Higher revenues  strength in both its segments   UnitedHealthcare and Optum   and membership growth prompted the outperformance UnitedHealth has a tradition of guiding conservatively and then beating its own estimates to surprise investors  The company has surpassed expectations in 25 out of 28 reported quarters and the trend continued in the quarter under review 
The stock gained 1 8  in the pre market trading session and we expect continued outperformance to drive the stock higher UnitedHealth Group Incorporated Price  Consensus and EPS Surprise   Behind the HeadlinesUnitedHealth posted net revenue of  50 1 billion  in line with the Zacks Consensus Estimate  Revenues were up 7 7  year over year The company reported medical care ratio of 82 2   up 20 basis points year over year Operating cost ratio of 14 6  was flat year over year Segment PerformanceIn the reported quarter  UnitedHealth s health benefits segment   UnitedHealthcare   reported revenues of  40 8 billion  up 8 6  year over year  Earnings from operations increased 13 9  year over year to  2 2 billion Revenues from Optum improved 9 9  year over year to  22 7 billion  reflecting strong contribution from the subsegments OptumHealth and OptumInsight as well as OptumRx  Earnings from operations surged 20 5  year over year to  1 5 billion  Continued focus on accelerating growth as well as improving margins and productivity through enhanced integration and business alignment led to the overall improvement of this segment Membership EnrollmentThe company s medical enrollment grew to 49 5 million from 48 million in the year ago quarter Capital PositionCash and short term investments at quarter end were  17 9 billion  up 35  from the 2016 end level Debt to total capital ratio decreased 650 basis points year over year to 41 3  at Jun 30  2017 Cash flows from operations were  2 2 billion  up 29  year over year Share Repurchase and Dividend UpdateDuring the quarter  the company hiked its quarterly dividend by 20  to 75 cents The company repurchased 2 2 million shares during the quarter Guidance UpdateEncouraged by its strong earnings performance in the first half of 2017  the company raised its outlook for 2017 GAAP net earnings to a range of  9 20 to  9 35 per share  previous guidance  9 10 to  9 30  and adjusted net earnings to a range of  9 75 to  9 90 per share  versus previous guidance of  9 65  9 85  Other Stocks That Warrant a LookUnitedHealth with a Zacks Rank  2  Buy  has got this reporting cycle off to a flying start  While the other players in the space are lined up to report their financial results  below are three that are poised to beat on earnings as per our model Humana Inc    NYSE HUM   is expected to report second quarter earnings results on Aug 2  The company has an Earnings ESP of  10 98  and a Zacks Rank  3  Hold   You can see  Cigna Corp    NYSE CI   has an Earnings ESP of  0 81  and a Zacks Rank  2  It is expected to report second quarter earnings results on Aug 4 Select Medical Holdings Corp    NYSE SEM   has an Earnings ESP of  4 00  and a Zacks Rank  3  The company is expected to report second quarter earnings results on Aug 3 
5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-07-17,Zacks Investment Research,"https://www.investing.com/analysis/unitedhealth-(unh)-beats-on-q2-earnings,-guides-up-for-2017-200201901",200201901
142317,363832,HUM,Anthem Quits 2 More Exchanges Amid Regulatory Uncertainty,opinion,Anthem Inc    NYSE ANTM   is quitting public exchange markets in the states of Wisconsin and Indiana for 2018 Anthem offers plans in 14 states as a Blue Cross Blue Shield insurer for the many Affordable Care Act  ACA  marketplaces  It is among the largest insurers offering plans on ACA exchanges Earlier this the month the company called it quits in the Ohio market Anthem has joined the suite of other players like UnitedHealth Group Inc    NYSE UNH   and Aetna Inc    NYSE AET    who after having stubbed their toes with unprofitable public exchanges  have substantially rolled back their participation on it  Another major player  Humana Inc    NYSE HUM    is planning to stop offering individual ACA plans entirely for 2018 The downsizing of exchange participation was anticipated since Anthem recently gave enough hints of folding its public exchange business  Management had confirmed   While the direction in Washington has been positive  we still need certainty about short term fixes in order to determine the extent of our participation in the individual market in 2018   We will be watching developments closely in the first half of 2017 as we evaluate our longer term strategy for the health insurance exchanges  Anthem has incurred loss on its public exchange business led by huge claims from customers enrolled on public exchanges  The number of healthy and young individuals who enrolled on these exchanges was far less than aged customers and those with pre existing diseases lacking coverage earlier  This mix of customer population led to a rise in claims as sicker patients went on to utilize medical care under insurance coverage   Anthem intends to continue its participation on exchanges  only if necessary changes are made to improve its profitability and viability  This calls for a substantial premium increase for 2018 In the past one year  the stock of Anthem has surged roughly 49 3   while the Zacks categorized  industry has rallied 31 4  The struggles of the top players have to a great extent made it clear that the exchanges put in place by former president Obama to provide subsidized health insurance coverage have not fared well with insurers  They are also concerned about high uncertainty relating to the funding of subsidies that have helped people with low income to buy insurance on these exchanges  Republicans have threatened to do away with these subsidies  which will drive away customers  making insurers feel jittery Anthem carries a Zacks Rank  2  Buy   You can see  Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ,2017-06-21,Zacks Investment Research,https://www.investing.com/analysis/anthem-quits-2-more-exchanges-amid-regulatory-uncertainty-200196883,200196883
142318,363833,HUM,Aetna Inks New Deal To Improve Healthcare In North Carolina,opinion,Aetna  Inc    NYSE AET   recently inked a deal with Community Care Physician Network  LLC aimed at developing several innovative ways to transform the health care experience in North Carolina  It targets customers residing outside the urban areas of the state Per the deal  Aetna s expertise in alternative value based delivery models will be combined with Community Care Physician s independent and advanced medical homes which are operated in association with the care management expertise of Community Care of North Carolina  Inc  Aetna s Medicare Advantage members in rural areas of North Carolina are likely to be offered a premium level of healthcare through this collaboration Aetna has a long history of working with several provider groups  It always intended to create improved health care experience and outcomes for its members  The company continues to work toward transforming the Health Care System via Accountable Care Organizations  These initiatives have helped the company grow its revenues and margin According to Aetna  this agreement perfectly considers the changing environment of the health care industry both nationally and globally  While the other HMO players like Humana Inc   NYSE HUM    Anthem Inc   NYSE ANTM    Centene Corp   NYSE CNC   are taking active part in this transformation  Aetna looks forward to working with Community Care Physician to develop a health care delivery to bring sustainable improvements for Aetna s members in 2018 Management of Community Care Physician considers this agreement as an opportunity to demonstrate the effectiveness of a high performing primary care network with Aetna s Medicare Advantage membership  Community Care Physician also thinks that the alliance with Aetna would facilitate it to make an eventual move to Medicaid managed care in the future The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1   Strong Buys   free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5   Strong Sells    Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ,2017-06-25,Zacks Investment Research,https://www.investing.com/analysis/aetna-inks-new-deal-to-improve-healthcare-in-north-carolina-200197519,200197519
142329,363844,HUM,The NASDAQ Adds On,opinion,"Remember  the latest episode of the Zacks Ultimate Strategy Session will be available for viewing this Wednesday  July 12th  Steve Reitmeister  Kevin Cook  Sheraz Mian  Tracey Ryniec and Brian Bolan will cover the investment landscape from most every angle in this  must see TV  event  Don t miss your chance to hear   Tracey and Brian Agree to Disagree on Value versus Growth
  Steve s answers to your questions in Reity s Mailbag
  Tips for improving your portfolio
  And much more So be sure to mark your calendar then log on to Zacks com and bookmark this page  The NASDAQ hasn t gotten many breaks recently  Every time it makes some headway of late  it seems to give the gains back in the following session  But today it was finally able to add onto Friday s more than 1  surge  The index was the best performer of the big 3 on Monday with an increase of 0 38  to 6176 4  It would certainly be a load off the market s mind if tech could get back to its winning ways in the days leading up to earnings season  Another strong bounce day for the NASDAQ is giving any one with bearish thoughts about Tech a good lesson   said Kevin Cook in TAZR Trader  Meanwhile  the S P climbed 0 09  to 2427 4  but the Dow slipped 0 03  to 21408 5  The editors can t wait for earnings season  which promises to be the next  best opportunity for stocks to get back to making new highs   The game plan now is to try to remain patient until the market moves  where we will adjust as needed   said Jeremy in Counterstrike   I m hoping for markets to make their move soon  but I have a feeling we won t get much action until earnings season has arrived   Today  the portfolios included some double digit winners for Stocks Under  10 and Momentum Trader  the latter portfolio also added a new position  Meanwhile  the Black Box Trader swapped out half of its ten stocks  Read more about these moves  and learn why the Heartland may be a good place to invest in this week s Zacks Confidential Today s Portfolio Highlights Stocks Under  10  Everi Holdings  EVRI  has been a  super solid  position for Brian since adding it back in March  It s been so solid  in fact  that the editor wants to protect his profits in the company  so he sold it today for a 64 4  return  Basically  EVRI hasn t been advancing with other financial stocks even after a competitor in the space was recently being bought out  Looking forward  the portfolio only has 17 names now  so be ready for a new name tomorrow Momentum Trader  With tech under pressure and Micron  MU  butting up against its 50 day moving average  Dave thought it was best to take some profit and sell half the position for a nice return of 13 9   Meanwhile  the editor also bought a 12 5  allocation in Carolina Financial  CARO   which is breaking out through new highs  This Zacks Rank  1 is enjoying  huge  revenue and EPS growth  The complete commentary has more on today s moves  including a breakdown of CARO s chart Black Box Trader  The portfolio replaced five names in this week s adjustment  The stocks that were sold included   Humana Inc   NYSE HUM   1 6  
  Hartford Financial Services  HIG 
  Best Buy  BBY 
  Thor Industries  THO 
  Calpine Corp  CPN  The new buys that replaced these names are    Cigna Corp  NYSE CI 
  Deere   Co  DE 
  Delek US Holdings  DK 
  CBRE Corp  CBG 
  XPO Logistics  XPO  Read the Black Box Trader s Guide to learn more about this computer driven service designed to take the emotion out of investing  Zacks Confidential  A recent family trip to Branson  Missouri opened Jeremy Mullin s eyes to a section of the country that investors don t think much about the Heartland  The coasts get most of the attention  but Middle America is looking to make a comeback  In this week s Zacks Confidential  Steve hands the keys over to Jeremy  who will let you know which industries are prospering in between California and New York  Read his detailed analysis and get three stock recommendations by clicking  Profits from the Heartland  Surprise Trader   After some struggles to start the quarter  the tech sector appears to be on track now  This is especially true in the semiconductor market  as this area easily beat out broad market indexes once again  Still  we saw broad gains across the tech space even beyond the semis  so it was good to see this market leader regain its position in front yet again    The recent performance from tech is definitely encouraging  but I don t think the area is out of the woods just yet  I d like to see the space retest old highs and surpass them before assuming the recent run of underperformance is over for now      Eric Dutram All the Best 
Jim Giaquinto
Recommendations from Zacks  Private Portfolios   Believe it or not  this article is not available on the Zacks com website  The commentary is a partial overview of the daily activity from Zacks  private recommendation services  If you would like to follow our Buy and Sell signals in real time  we ve made a special arrangement for readers of this website  Starting today you can see all the recommendations from all of Zacks  portfolios absolutely free for 7 days  Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises  which we ve predicted with an astonishing 80   accuracy  ",2017-07-10,Zacks Investment Research,https://www.investing.com/analysis/the-nasdaq-adds-on-200200182,200200182
142339,363854,HUM,Zacks Industry Outlook Highlights  Anthem  Cigna  Aetna  Humana And Molina Healthcare,opinion,"For Immediate Release

	Chicago  IL   June 06  2017   Today  Zacks Equity Research discusses the Industry  Health Insurance  Part 2  including Anthem Inc   NYSE        Cigna Corp   NYSE         Aetna Inc  NYSE AET    NYSE         Humana Inc  NYSE HUM    NYSE        and Molina Healthcare Inc   NYSE        

	Industry  Health Insurance  Part 2

	Link  

	Though the health insurance industry has always faced regulations  the Affordable Care Act  ACA  or Obamacare   enacted in 2010  was so heavy on regulatory oversight that it made health insurance almost synonymous with regulations  The reform  with its numerous provisions  took away working flexibility from insurers who were at ease before it was enacted 

	The industry did eventually adjust to the new regulatory regime  but they likely have to go through that process all over again as the GOP comes through on its  repeal   replace  mandate  The new law  called American Health Care Act  or AHCA  has been passed by the House of Representatives already and is currently in the Senate 

	A lot is still up in the air at this stage  but the overall expectation is that the new regulatory framework will provide for a relatively lighter regulatory touch and will be friendlier to the industry  That said  the expected change would have some negative effects on the industry as well 

	The year so far has been an eventful one for the industry  which saw two mega mergers   Anthem Inc   NYSE        with Cigna Corp   NYSE        and Aetna Inc   NYSE        with Humana Inc   NYSE          being blocked by regulators on antitrust concerns  The industry has also been receiving jolts from executive orders and the initial bill drafted by President Trump s aides in March 

Key AHCA Changes

	The new proposed law  AHCA  is a major departure from the existing statute  with some of its provisions potentially net negatives for the industry 


			AHCA gets rid of the individual mandate that required everyone to have health insurance 



			The new law changes the way Medicaid gets funded   from an open ended program to one with block grants or fixed amounts  Please note that Medicaid expansion was the primary avenue through which ACA expanded health coverage 



			Cutting down subsidies that were provided under the ACA to people enabling them to subsidized policies  The AHCA aim to replace these subsidies with tax credits  which is dependent on the age of the customer 


	Changes to the way Medicaid get funded represent the biggest change that the proposed law makes in the country s healthcare system  Changing Medicaid from an open ended entitlement to a fixed annual amount could potentially force states to become creative in how they administer this system  though most non partisan analysts expect the move to reduce the number of insured 

	A report from PwC estimates that insurers likely would lose most of the  1 9 trillion in federal ACA related subsidies slated to be doled out over the next 10 years  The Congressional Budget Office  CBO  estimates that 23 million people would lose health coverage by 2026 

	Per the CBO  AHCA would cause 14 million more people to be uninsured in 2018  The number is expected to reach 19 million in 2020 and 23 million in 2026  In 2026  about 51 million people under the age of 65 would be uninsured compared with 28 million who would lack insurance that year under Obamacare  This is a potentially negative development for companies with Medicaid centric businesses such as Molina Healthcare Inc   NYSE        

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  

	This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-06-05,Zacks Investment Research,"https://www.investing.com/analysis/zacks-industry-outlook-highlights:-anthem,-cigna,-aetna,-humana-and-molina-healthcare-200193461",200193461
142340,363855,HUM,4 Reasons To Stay Away From Mednax  MD  Now,opinion,"Mednax  Inc    NYSE MD   is a healthcare services company that focuses on physician services for newborn  maternal fetal  pediatric subspecialty and anesthesia care  The company has been growing both organically as well as inorganically  The acquisition of physician practice groups  complementary service businesses and expanding geographic coverage has accrued to the company s top line Nevertheless  over the past one year  Mednax with a Zacks Rank   4  Sell  has lost 21 6   faring miserably against 8 5  loss sustained by the Zacks categorized  industry Let s take a look at the factors that make the stock look unattractive at this point Earnings miss and downward revision in estimates   The company disappointed investors with an earnings miss in the last reported quarter  Its earnings of 70 cents missed the estimates by 14   Also  earnings missed in three of the last four reported quarters with an average negative surprise of 4 91   Following lackluster first quarter earnings  the company has witnessed a downward revision in earnings estimate by 16  to  3 37 per share for 2017 over the past 60 days  The same for 2018 has also gone down by 14 5  to  3 78 per share Lackluster earnings guidance   The company expects earnings per share for the three months ending Jun 30  2017 to be in the range of 68 cents to 72 cents  down from 89 cents reported in the year ago quarter  Adjusted EPS will likely be in the range of 85 cents to 89 cents  down from  1 03 per share reported in the year ago quarter  The range for its second quarter guidance assumes anticipated same unit revenue of negative 2  to flat year over year  For the second quarter of 2017  the company expect that EBITDA to decline by 8  to 12  year over year Fundamental headwinds   Recently  the company s results have suffered due to huge investments made in diversification  The investments might create volatility in its quarter over quarter performance  before reaping long term growth The company is also suffering from a subdued pace of birth across the country  which has slowed growth of one of its core businesses  neonatology  which has in turn stressed revenue growth Mednax is seen a dent in its bottom line led by a spike in its interest expense by almost 160  in 2014 as well as in 2015 and again by 173  in 2016  The same continued in the first quarter of 2017 which saw interest expense rise 22   This has led to a faster increase in expenses than revenue growth  It is to be noted that the company s operating expenses have increased more than revenue growth since 2011  While revenues have witnessed a CAGR of 15 02  from 2011 2015  operating expenses have risen at a rate of 15 87  over the same time frame Valuation Looks StretchedThe company has a trailing 12 month PE ratio of 15  This level compares unfavorably with the industry s PE  TTM  of 14 7 Also  its PEG ratio of 1 40 is higher than 1 37 for the industry The stock s valuation looks a bit expensive when compared with the industry Stocks to ConsiderSome better ranked stocks from the medical sector include Humana Inc    NYSE HUM    Anthem Inc    NYSE ANTM   and UnitedHealth Inc    NYSE UNH    Each of these stocks carry a Zacks Rank  2  Buy   You can see  Anthem surpassed earnings estimates in three of the trailing four quarters with an average positive surprise of 8 36  UnitedHealth delivered positive earnings surprises in each the last four quarters with an average beat of 4  Humana beat earnings estimates in each of the last four quarters with an average positive surprise of 3 75  
3 Stocks to Ride a 588  Revenue Explosion 
At Zacks  we re mostly focused on short term profit cycles  but the hottest of all technology mega trends is starting to take hold   
By last year  it was already generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for those who make the right trades early ",2017-06-06,Zacks Investment Research,https://www.investing.com/analysis/4-reasons-to-stay-away-from-mednax-(md)-now-200193740,200193740
142341,363856,HUM,UnitedHealth  UNH  Announces 20  Dividend Hike  Stock Gains ,opinion,UnitedHealth Group Inc    NYSE UNH   has once again cheered its investors by instituting a quarterly dividend hike of 20   The new dividend of 75 cents per share will be paid in the ongoing quarter This increases the yield  measured as annual divided by the price per share  to 1 6  from 1 4  based on the closing price on Jun 7  This increased dividend payout is higher than the current yields offered by other players in the same industry   Humana Inc    NYSE HUM    Cigna Corp    NYSE CI    Aetna Inc    NYSE AET   The dividend hike comes on the back of UnitedHealth s strong balance sheet and its ability to generate significant cash flows  Following the news  the stock gained 1 32  in yesterday s trading session  The stock also hit a new 52 week high of  183 47 Over the past one year the stock has gained 30 3  outperforming the Zacks categorized  industry which gained 29 3  UnitedHealth has regularly been paying dividends for the past several years   This dividend hike once again affirms the U S  health insurer s commitment to return more value to its shareholders The insurer s five year average dividend yield of 1 48  is higher than the industry average yield of 1 2   Also  the five year dividend growth rate of 19 7  for the industry is lower than the insurer s 31  over the same period Around same time last year  the health insurer announced a hike of 25  in its quarterly dividend to 62 5 cents per share The recent dividend action further cements investors  confidence in the health insurer  The company was successful in keeping aside investor worries about losses accruing in its individual insurance business on public exchanges by exiting a number of unprofitable exchanges  This has helped the company to axe its losses related to this business that would have pulled down overall earnings  Moreover  the company raised its earnings estimates for 2017 on the back of growth in its health services and health benefits  segments UnitedHealth  the leader in the health insurance industry  is also sought after in the investing community since it offers the best of both worlds  dividend income plus earnings growth UnitedHealth carries a Zacks Rank  2  Buy   You can see  3 Top Picks to Ride the Hottest Tech TrendZacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ,2017-06-07,Zacks Investment Research,"https://www.investing.com/analysis/unitedhealth-(unh)-announces-20-dividend-hike,-stock-gains-200194011",200194011
142343,363858,HUM,3 Value Stocks In Health Insurance Promising Solid Returns ,opinion,"The health insurance industry is continuing its steady ride despite significant pullbacks  Players in the industry remain poised to grow on ever increasing demand for government plans  including Medicare and Medicaid  from baby boomers  Companies specializing in these plans like UnitedHealth Group Inc    NYSE UNH   and Humana Inc    NYSE HUM   have seen their revenues get a boost from the government business 
The HMO industry has gained from a decline in uninsured population  which consequently added to membership enrollment  thanks to the individual mandate of the Affordable Care Act  ACA   A recent survey by Gallup stated that the uninsured rate for health insurance in the U S  was 10 9  in the fourth quarter of 2016  The rate was as high as 6 2  in the fourth quarter of 2013 
Increasing business diversification  with ancillary services and products forming a growing portion of insurers  revenues  is also shielding insurersrom stiff regulations  mostly outside of the purview of the ACA   Credit also goes to growing international operations that have brought in geographical diversification  Despite these positives  health insurers continue to suffer from underperforming public exchanges  Business underwritten on these exchanges resulted in significant losses for most of the players  consequently leading to a downsizing of this business 
Increasing operating cost to comply with regulations  investments in information technology  levy of fees and taxes have exerted pressure on margins 
The industry also continues to reel under regulatory uncertainty  with the proposed repeal and replacement of the old law with Donald Trump s American Health Care Act  The bill  which is currently awaiting approval in the Senate  has some provisions favoring the players  However  with some other provisions seeming unacceptable  a lot is still up in the air 
Despite the ambiguity and chaos in the sector  there are some companies with strong business fundamental that make up for attractive bets 
How to Pick the Right Stock
Value investing is always considered wise and is one of the best investing practices that can lead to long term gains  Value investing calls for betting on bargain stocks which are trading at prices below their inherent value  stocks that are cheap   but have strong businesses  These stocks take no time to jump when the markets goes up  thus giving investors a chance to gain from value appreciation of their holdings  The trick to successful long term investing is in picking value stocks 
But how do we find a value stock 
There are certain parameters that can gauge a value stock  These stocks may have low valuation meaning low price to book ratio  low price to earnings ratio or a low price to sales ratio  They may also have a high dividend yield  While it can be a daunting task to specifically look at each parameter and hunt for a value stock our search can be made simpler by the use of the new   designed by Zacks 
The attractiveness of a stock as an investment option is confirmed by its Value Style Score of  A  or  B   Our research shows that stocks with Style Scores of  A  or  B  when combined with a Zacks Rank  1  Strong Buy  or  2  Buy  offer the best investing opportunities  Further  we have selected value stocks that have estimated earnings per share growth rate of 10  or more this fiscal year 
Three Picks  
WellCare Health Plans  Inc    NYSE WCG    providing managed care services targeted exclusively at government sponsored healthcare programs  has a long term earnings growth rate of 13 2   and a Value and Growth Score of  A  each  The company surpassed earnings estimates in each of the last four quarters  with an average positive surprise of 59 23  
In the last one year  this Zacks Rank  1 stock has returned an impressive 62 2   while the Zacks categorized  industry has gained 32 4   The company has an estimated earnings per share growth rate of 18 4  for 2017   You can see  
Anthem Inc    NYSE ANTM    a healthcare company providing medical products  has a long term earnings growth rate of 10 3   and a Value Score and Growth Score of  A   The company beat earnings estimates in three out of the last four quarters  with an average positive surprise of 8 36  
In the past one year  this Zacks Rank  2 stock has enjoyed a bullish run and surged roughly 49 2   while the Zacks categorized Medical HMO industry has rallied 32 4   Anthem has an estimated earnings per share growth rate of 8 18  for 2017 
Cigna Corp    NYSE CI    providing health care services and products  has a long term earnings growth rate of 13 2   and a Value Score and Growth Score of  B   The company delivered a positive earnings surprise in three of the last four quarters  with an average beat of 1 35  
In the past one year  this Zacks Rank  2 stock has gained 32 5   almost in line with the Zacks categorized Medical HMO industry s rise of 32 4   The company has an estimated earnings per share growth rate of 20 3  for 2017 
Bottom Line
Despite the volatility in the healthcare sector  we suggest these stocks with positive attributes  a strong estimate revision trend and solid earnings growth forecast  These could be good bets for investors 
Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them    
Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-06-21,Zacks Investment Research,https://www.investing.com/analysis/3-value-stocks-in-health-insurance-promising-solid-returns-200196709,200196709
142375,363890,HUM,UnitedHealth s  UNH  Business Unit Collaborates With Merck,opinion,UnitedHealth Group  Inc  s   NYSE UNH   information and technology enabled health services business  Optum  recently announced its collaboration with Merck   Co  Inc   NYSE MRK    The companies have primarily joined forces to develop and simulate the performance of contractual reimbursement models in which payment for prescription drugs is closely related to patient health outcomes Optum has carved a niche in terms of its expertise in pharmaceutical contracting  health economics and outcomes research  actuarial analytics  and health policy and regulation  Merck  on the other hand  boasts data science and outcomes research expertise  and a deep understanding of the pharmaceuticals marketplace  In addition  Merck s vast experience of working with large private and public customers to create flexible pricing models across multiple therapy areas should help Optum cater to the needs of its customers more efficiently We note that Optum regularly upgrades its products and services through several partnerships and collaborations  which have resulted in UnitedHealth s technological advancement on every front  Shareholders  optimism about UnitedHealth s digitalizing initiatives is clearly reflected in the company s share price movement  In the last one year  the stock has gained 33   slightly underperforming the Zacks categorized Health Maintenance Organization  HMO  Through a shared  Learning Laboratory   the companies are expected to study value based and pay for performance models or Outcomes Based Risk Sharing Agreements   OBRSA    These models are mainly focused on payers reimbursing drug manufacturers on the basis of clinical outcomes achieved  Depending on the success and failure of the drugs  prices of them can fall or rise  The companies plan to publicly share analytic insights  findings and recommendations that would help in understanding the use OBRSAs in the health care system Optum s real data assets will facilitate assess to OBRSA models across different patient populations  clinical settings  and therapeutic areas aligned with Merck s product portfolio Zacks Rank and Stocks to ConsiderUnited Health has a Zacks Rank  2  Buy  You can see  Other top ranked medical sector stocks include Inogen Inc    NASDAQ INGN    WellCare Health Plans  Inc    NYSE WCG   and Humana Inc    NYSE HUM    While Inogen and WellCare sport a Zacks Rank  1  Strong Buy   Humana holds a Zacks Rank  2  Buy  Inogen is a medical instruments seller that delivered positive surprises in all of the last four quarters with an average beat of 82 42  WellCare  the leading Health Maintenance Organization  HMO  in the United States  topped estimates in all of the last four quarters with an average beat of 59 23  Humana  another HMO behemoth  surpassed expectations in all of the last four quarters with an average beat of 3 75 Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ,2017-05-25,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth's-(unh)-business-unit-collaborates-with-merck-200191698,200191698
142376,363891,HUM,The Zacks Analyst Blog Highlights  Eli Lilly  HSBC  Marriott  American Airlines And Humana,opinion,"For Immediate Release

	Chicago  IL   June 01  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Eli Lilly        HSBC        Marriott        American Airlines       and Humana       

	Today  Zacks is promoting its   Buy   stock recommendations    

Here are highlights from Wednesday s Analyst Blog  

Top Stock Reports for Today  LLY  HSBC  MAR   More 

	Today s Research Daily features new research reports on 16 major stocks  including Eli Lilly          HSBC       and Marriott        You can see    

	Pharmaceutical stocks have been under pressure since last year on pricing and regulatory concerns and Eli Lilly shares have been no different  That said  the stock has done modestly better than the peer group  it is up  5 7  over the last 12 months vs   1 7  gain for the Zacks Pharma industry and  0 7  decline for the Zacks Medical sector as a whole  Lilly s recent high profile pipeline setbacks are a concern for investors  But the Zacks analyst is encouraged by the fact that Lilly expects to launch 20 new products in a 10 year time frame ranging from 2014 to 2023 and could launch at least 2 new indications line extensions on average every year  Moreover  Lilly returned to annual dividend hikes in Dec 2016 and plans to return excess cash through share buybacks   You  can  

	Shares of Buy rated HSBC outperformed the Zacks Foreign Banks industry over the last three months  gaining  7 3  vs  1 7   The Zacks analyst likes its extensive global network  strong capital position and a solid asset growth  Moreover  continued disposal of unprofitable non core operations has enhanced its efficiency  as operating costs remain manageable  Further  the company remains on track to achieve its 2017 cost savings target  However  operating uncertainty in the post Brexit Europe remains a major cloud on the bank as are recent muted trends in loan demand   You can   

Marriott  s shares have outperformed the Zacks Hotels industry in the year to date period  the stock is up  28 9  vs   3 9  gain for the industry   With the purchase of Starwood  Buy rated Marriott became the world s largest hotel company that provides it with increased scale and a robust development pipeline  The Zacks analyst likes Marriott s rising North American business and large international exposure and thinks they should continue to drive growth  Further  investments in technology for hotel bookings are likely to improve guest experience and thus boost occupancy  Yet  political uncertainties in key international markets and currency headwinds remain causes of concern   You can   

	Other noteworthy reports we are featuring today include American Airlines         and Humana        

Now See All Our Private Trades

	While today s Zacks Rank  1 new additions are being shared with the public  other trades are hidden from everyone but selected members  Would you like to peek behind the curtain and view them  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum       from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors    

	Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  









 

	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-05-31,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-eli-lilly,-hsbc,-marriott,-american-airlines-and-humana-200192704",200192704
142377,363892,HUM,Health Insurance Industry Outlook   June 2017,opinion,"The health insurance industry has been embroiled in a regulatory web since the Affordable Care Act  ACA  or Obamacare  was passed in 2010  Even though industry players eventually warmed up to the law over the following years by adjusting their operations to the changed environment  they may have to go through the process all over again as the Trump administration attempts to replace ACA with its own version   
Many in the market doubt Congress s ability to repeal and replace ACA  but the U S  House of Representatives has already passed the American Health Care Act  ACHA  that would replace Obamacare  The bill is now in front of the Senate  though many suspect that the upper chamber plans to come up with a version of its own instead of starting out with the House version 
In the meantime  the Congressional Budget Office  CBO  has estimated that while the proposed legislation will bring down the deficit and cut government spending  it will also cause the loss of insurance for 23 million people over the following 10 years  The CBO projections have likely made it difficult for a number of GOP senators to easily stand behind the House version 
The health insurance industry s strong performance this year reflects the market s understanding that these healthcare operators remain well placed  irrespective of the legislation s fate  Many other operators in the healthcare space  like hospital operators and drug companies  are not in that category 
The Zacks HMO industry is currently up  14  in the year to date period  outperforming the S P 500 index s  8 1  gain 
Why Health Insurance Stocks Still Have Some Upside Left
While the industry has outperformed the broader market lately  but valuations are far from stretched and leave room for further upside going forward 
The Zacks HMO industry is currently trading at 16 7X forward 12 month consensus EPS estimates  which compares to 18 2X for the S P 500 index as a whole  Over the last 5 years  the industry has traded in a range of 8 6X to 18X  with a median of 14 3X  Please note that the low valuation point  8 6X multiple  was in mid 2012 when there was all around uncertainty about the impact of ACA on the industry s business 
What this shows is that while HMO stocks aren t cheap  they are not nose bleed expensive either 
Zacks Industry Rank
Within the Zacks Industry classification  health insurers are broadly grouped in the Medical sector  one of the 16 Zacks sectors  
We rank 265 industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry  We put our industries into two groups  the top half  industries with the best average Zacks Rank  and the bottom half  the industries with the worst average Zacks Rank   Over the last 10 years  using a one week rebalance  the top half beat the bottom half by more than twice as much  The Zacks Industry Rank is  74  top 28    The ranking is available on the  
Please note that the Zacks Rank for stocks  which is the core of our Industry Outlook  has an impressive track record    verified by outside auditors    of foretelling stock prices  particularly over the short term  1 to 3 months   The rank  along with   helps in predicting the probability of earnings surprises 
Stocks Worth Considering
Investors can consider the following HMO stocks that have solid fundamentals along with a favorable Zacks Rank 
WellCare Health Plans  Inc   WCG  provides managed care services for government sponsored health care programs  It operates through three segments  Medicaid Health Plans  Medicare Health Plans  and Medicare PDPs  The stock currently has a Zacks Rank  1  Strong Buy  and surpassed earnings estimates in each of the trailing four quarters  with an average beat of 59   It company has a long term expected growth rate of 13   
UnitedHealth Group Inc   UNH  is a diversified health and well being company in the United States  The company offers consumer oriented health benefit plans and services  health care coverage  and health and well being services to individuals aged 50 and older  The stock currently has a Zacks Rank  2  Buy  and surpassed earnings estimates in each of  the trailing four quarters  with an average beat of 4 7   It company has a long term expected growth rate of 13 4  
Nobilis Health Corp   HLTH  own and manage ambulatory and acute care facilities for healthcare services  In addition  it owns and manages ambulatory surgery centers  acute care hospitals  imaging centers and urgent care clinics  The company operates primarily in Houston  Dallas and Scottsdale  Arizona  Nobilis is headquartered in Houston  Texas  The stock currently has a Zacks Rank  1 and surpassed earnings estimates two of the last four reported quarters  with an average beat of 100 21    It company has a long term expected growth rate of 20  
Anthem Inc   ANTM  provides medical products through its subsidiaries  It operates through Commercial  Consumer and Other segments  The company offers managed care plans to the large and small employer  individual  Medicaid and senior markets  The stock currently has a Zacks Rank  2 and surpassed earnings estimates in three of the last four reported quarters  with an average beat of 8 36    The company has a long term expected growth rate of 10 3  
Humana Inc  NYSE HUM    HUM  is a health services company that facilitates the delivery of health care services through networks of providers to its medical members  The company s products are marketed primarily through health maintenance organizations and preferred provider organizations that encourage or require the use of contracted providers  The stock currently has a Zacks Rank  2 and surpassed earnings estimates in each of the last four reported quarters  with an average beat of 3 75   The company has a long term expected growth rate of 13 3  ",2017-06-01,Zacks Investment Research,https://www.investing.com/analysis/health-insurance-industry-outlook---june-2017-200192746,200192746
142378,363893,HUM,Zacks Industry Outlook Highlights  WellCare Health Plans  UnitedHealth Group  Nobilis Health  Anthem And Humana,opinion,"For Immediate Release

	Chicago  IL   June 02  2017   Today  Zacks Equity Research discusses the Industry  Health Insurance  Part 1  including WellCare Health Plans  Inc   NYSE          UnitedHealth Group Inc   NYSE          Nobilis Health Corp   NYSEMKT          Anthem Inc   NYSE         and Humana Inc  NYSE HUM    NYSE         

Industry  Health Insurance  Part 1

	Link  

	The health insurance industry has been embroiled in a regulatory web since the Affordable Care Act  ACA  or Obamacare  was passed in 2010  Even though industry players eventually warmed up to the law over the following years by adjusting their operations to the changed environment  they may have to go through the process all over again as the Trump administration attempts to replace ACA with its own version 

	Many in the market doubt Congress s ability to repeal and replace ACA  but the U S  House of Representatives has already passed the American Health Care Act  ACHA  that would replace Obamacare  The bill is now in front of the Senate  though many suspect that the upper chamber plans to come up with a version of its own instead of starting out with the House version 

	In the meantime  the Congressional Budget Office  CBO  has estimated that while the proposed legislation will bring down the deficit and cut government spending  it will also cause the loss of insurance for 23 million people over the following 10 years  The CBO projections have likely made it difficult for a number of GOP senators to easily stand behind the House version 

	The health insurance industry s strong performance this year reflects the market s understanding that these healthcare operators remain well placed  irrespective of the legislation s fate  Many other operators in the healthcare space  like hospital operators and drug companies  are not in that category 

	The Zacks HMO industry is currently up  14  in the year to date period  outperforming the S P 500 index s  8 1  gain 

Why Health Insurance Stocks Still Have Some Upside Left

	While the industry has outperformed the broader market lately  but valuations are far from stretched and leave room for further upside going forward 

	The Zacks HMO industry is currently trading at 16 7X forward 12 month consensus EPS estimates  which compares to 18 2X for the S P 500 index as a whole  Over the last 5 years  the industry has traded in a range of 8 6X to 18X  with a median of 14 3X  Please note that the low valuation point  8 6X multiple  was in mid 2012 when there was all around uncertainty about the impact of ACA on the industry s business 

	What this shows is that while HMO stocks aren t cheap  they are not nose bleed expensive either 

Zacks Industry Rank

	Within the Zacks Industry classification  health insurers are broadly grouped in the Medical sector  one of the 16 Zacks sectors  

	We rank 265 industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry  We put our industries into two groups  the top half  industries with the best average Zacks Rank  and the bottom half  the industries with the worst average Zacks Rank   Over the last 10 years  using a one week rebalance  the top half beat the bottom half by more than twice as much  The Zacks Industry Rank is  74  top 28    The ranking is available on the  

	Please note that the Zacks Rank for stocks  which is the core of our Industry Outlook  has an impressive track record    verified by outside auditors    of foretelling stock prices  particularly over the short term  1 to 3 months   The rank  along with   helps in predicting the probability of earnings surprises 

Stocks Worth Considering

	Investors can consider the following HMO stocks that have solid fundamentals along with a favorable Zacks Rank 

	WellCare Health Plans  Inc   NYSE         provides managed care services for government sponsored health care programs  It operates through three segments  Medicaid Health Plans  Medicare Health Plans  and Medicare PDPs  The stock currently has a Zacks Rank  1  Strong Buy  and surpassed earnings estimates in each of the trailing four quarters  with an average beat of 59   It company has a long term expected growth rate of 13   

	UnitedHealth Group Inc   NYSE         is a diversified health and well being company in the United States  The company offers consumer oriented health benefit plans and services  health care coverage  and health and well being services to individuals aged 50 and older  The stock currently has a Zacks Rank  2  Buy  and surpassed earnings estimates in each of the trailing four quarters  with an average beat of 4 7   It company has a long term expected growth rate of 13 4  

	Nobilis Health Corp   NYSEMKT         own and manage ambulatory and acute care facilities for healthcare services  In addition  it owns and manages ambulatory surgery centers  acute care hospitals  imaging centers and urgent care clinics  The company operates primarily in Houston  Dallas and Scottsdale  Arizona  Nobilis is headquartered in Houston  Texas  The stock currently has a Zacks Rank  1 and surpassed earnings estimates two of the last four reported quarters  with an average beat of 100 21   It company has a long term expected growth rate of 20  

	Anthem Inc   NYSE         provides medical products through its subsidiaries  It operates through Commercial  Consumer and Other segments  The company offers managed care plans to the large and small employer  individual  Medicaid and senior markets  The stock currently has a Zacks Rank  2 and surpassed earnings estimates in three of the last four reported quarters  with an average beat of 8 36   The company has a long term expected growth rate of 10 3  

	Humana Inc   NYSE         is a health services company that facilitates the delivery of health care services through networks of providers to its medical members  The company s products are marketed primarily through health maintenance organizations and preferred provider organizations that encourage or require the use of contracted providers  The stock currently has a Zacks Rank  2 and surpassed earnings estimates in each of the last four reported quarters  with an average beat of 3 75   The company has a long term expected growth rate of 13 3  

Zacks Industry Rank

	Within the Zacks Industry classification  health insurers are broadly grouped in the Medical sector  one of the 16 Zacks sectors  

	We rank 265 industries into 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry  We put our X industries into two groups  the top half  industries with the best average Zacks Rank  and the bottom half  the industries with the worst average Zacks Rank  

	Over the last 10 years  using a one week rebalance  the top half beat the bottom half by more than twice as much  The Zacks Industry Rank is  177  bottom 34    The ranking is available on the  

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  

	This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-06-01,Zacks Investment Research,"https://www.investing.com/analysis/zacks-industry-outlook-highlights:-wellcare-health-plans,-unitedhealth-group,-nobilis-health,-anthem-and-humana-200192882",200192882
142379,363894,HUM,Will Health Insurers Have To Rework Under ACHA ,opinion,"Though the health insurance industry has always faced regulations  the Affordable Care Act  ACA  or Obamacare   enacted in 2010  was so heavy on regulatory oversight that it made health insurance almost synonymous with regulations  The reform  with its numerous provisions  took away working flexibility from insurers who were at ease before it was enacted 
The industry did eventually adjust to the new regulatory regime  but they likely have to go through that process all over again as the GOP comes through on its  repeal   replace  mandate  The new law  called American Health Care Act  or AHCA  has been passed by the House of Representatives already and is currently in the Senate 
A lot is still up in the air at this stage  but the overall expectation is that the new regulatory framework will provide for a relatively lighter regulatory touch and will be friendlier to the industry  That said  the expected change would have some negative effects on the industry as well 
The year so far has been an eventful one for the industry  which saw two mega mergers  Anthem Inc   ANTM  with Cigna Corp   CI  and Aetna Inc  NYSE AET    AET  with Humana Inc  NYSE HUM    HUM    being blocked by regulators on antitrust concerns  The industry has also been receiving jolts from executive orders and the initial bill drafted by President Trump s aides in March 
Key AHCA Changes
The new proposed law  AHCA  is a major departure from the existing statute  with some of its provisions potentially net negatives for the industry AHCA gets rid of the individual mandate that required everyone to have health insurance The new law changes the way Medicaid gets funded   from an open ended program to one with block grants or fixed amounts  Please note that Medicaid expansion was the primary avenue through which ACA expanded health coverage Cutting down subsidies that were provided under the ACA to people enabling them to subsidized policies  The AHCA aim to replace these subsidies with tax credits  which is dependent on the age of the customer Changes to the way Medicaid get funded represent the biggest change that the proposed law makes in the country s healthcare system  Changing Medicaid from an open ended entitlement to a fixed annual amount could potentially force states to become creative in how they administer this system  though most non partisan analysts expect the move to reduce the number of insured 
A report from PwC estimates that insurers likely would lose most of the  1 9 trillion in federal ACA related subsidies slated to be doled out over the next 10 years  The Congressional Budget Office  CBO  estimates that 23 million people would lose health coverage by 2026 
Per the CBO  AHCA would cause 14 million more people to be uninsured in 2018  The number is expected to reach 19 million in 2020 and 23 million in 2026  In 2026  about 51 million people under the age of 65 would be uninsured compared with 28 million who would lack insurance that year under Obamacare  This is a potentially negative development for companies with Medicaid centric businesses such as Molina Healthcare Inc   MOH   Centene Corp   CNC  and WellCare Health Plans  Inc   WCG  
While the AHCA has yet to reach its final shape  let s look at the challenges facing the industry players  particularly with reference to ACA related issues 
Public Exchanges Woes
Public Exchanges made their debut in Oct 2013  and were considered one of the signature achievements of Obamacare  aimed at providing subsidized insurance to millions  The insurers were also sanguine about the exchanges  hoping to make big business out of them  but are struggling now 
These insurers are saddling high medical expenses of individuals who bought the subsidized policies under the health care law  The public exchanges attracted a disproportionate number of unhealthy individuals compared to healthy ones  A higher percentage of unhealthy patients led to higher claims for the insurers  thus leading to losses from the policies sold to these groups of people 
Big players like UnitedHealth Group Inc   UNH  and Aetna have significantly reduced their presence on these exchanges  Other players are also considering doing this  as well 
Margins Under Pressure
Health insurer margins have been under pressure lately  a trend that will likely continue til ACA related issues get addressed  A host of factors    including compliance costs related to health care reform regulation  increased fees and taxes  pricing pressure  stiff competition and rising medical costs    have been exerting pressure on the bottom line 
A general shift in patient mix from commercial insurance to government  Medicare  Medicaid and State subsidized marketplace or exchange  has also affected profitability to a large extent  Premiums for Medicare  Medicaid and state subsidized policies tend to be higher due to serious health issues for many enrollees  however  they carry smaller profitability margins compared to commercial insurance 
High Regulatory Cost
Regulatory reform sweeping through the sector has hit insurers with high compliance costs  Expenditures involved in redoing the internal systems has led to increased expenses  There has been huge spending on health information technology  HIT  following the implementation of The American Recovery and Reinvestment Act of 2009  or Recovery Act  which contains the Health Information Technology for Economic and Clinical Health Act  or the HITECH Act  Notably  HIT includes electronic health records or EHRs  health information exchanges or HIEs and other initiatives 
The federal government s emphasis on the use of health IT  which helps providers communicate better with each other about patient care  reduces medical errors  paperwork and needless duplicate screenings and tests  leading to better coordinated patient care and lower health care costs  These have increased health care information technology spending  Financial incentives offered by regulators to providers and hospitals for the implementation of the meaningful use of health care IT products are primarily driving IT spending 
Global Economic Woes and Regulatory ChallengesA fragile global economy presents a headwind for insurers looking to expand their international operations  One of the largest insurers  UnitedHealth Group  made an acquisition to reap benefits from the Brazil market but is now facing slowing growth rates in that country In the case of India  which remains one of the most profitable opportunities for insurers  the regulatory environment is still somewhat challenging  China    which merits the highest risk adjusted opportunity ranking  largely because of its immense scale    poses significant investment restrictions to foreign insurers entering and operating there 
HMO Stocks to Avoid for the Time Being
We presently recommend investors to stay away from the following HMO stocks  given their unfavorable Zacks Rank  The other metrics also indicate that they are not profitable investment options at present 
Select Medical Holdings Corp   SEM  through its subsidiaries  operates specialty hospitals and outpatient rehabilitation clinics  The company s Specialty Hospital segment offers long term acute care hospital services and inpatient acute rehabilitative hospital care services   The stockcurrently has a Zacks Rank  4  Sell  and missed earnings estimates in two of the last four reported quarters  with an average negative surprise of 11   
The Joint Corp   JYNT  is a healthcare franchisor of chiropractic clinics  The company s plans include  Single Visit  Premium Wellness Plan and Wellness Plan  It also provides a family wellness plan  The Company also provides removal of subluxations  The stock currently has a Zacks Rank  4  Sell  and missed earnings estimates in two of the last four reported quarters  with an average negative surprise of 10  
Triple S Management Corp   GTS  is an independent licensee of the Blue Cross Blue Shield Association  It is the largest managed care company in Puerto Rico  serving approximately one million members across all regions  The stock currently has a Zacks Rank  5  Strong Sell   It missed earnings estimates in each of the last four reported quarters  with an average negative surprise of 142 2  ",2017-06-05,Zacks Investment Research,https://www.investing.com/analysis/will-health-insurers-have-to-rework-under-acha-200193350,200193350
142380,363895,HUM,Was This A Three Day Weekend Too  ,opinion,"Remember  the latest episode of the Zacks Ultimate Strategy Session will be available for viewing this Wednesday  June 7th  Steve Reitmeister  Kevin Matras  Sheraz Mian  Tracey Ryniec and Eric Dutram will cover the investment landscape from most every angle in this  must see TV  event 
Don t miss your chance to hear 
  Tracey and Eric Agree to Disagree on Moody s credit downgrade on China
  Steve s answers to your questions in Reity s Mailbag
  Tips for improving your portfolio
  And much more
So be sure to mark your calendar then log on to Zacks com and bookmark this page 
A lot of investors were probably looking at their calendars on Monday and wondering if it was another market holiday  After rallying in the final two sessions last week to give the major indices their second straight week of gains  stocks couldn t get it together today 
Despite a solid ISM Services report  the market had no momentum on Monday  The S P was down 0 12  to 2436 1  the Dow was off 0 10  to 21 184 and the NASDAQ slipped 0 16  to 6295 7  Nevertheless  the indices are still one moderately good day away from putting together another round of all time highs  With 2 400 in the S P now behind us  the next target is 2 480  let s round it up to 2 500 since the market likes its round numbers   I think that should come relatively quickly   said Kevin in today s Options Trader 
Stocks weren t alone in taking a breather today  so too did the editors  Activity in the portfolios really picked up along with the market last week  but it didn t carry over to today  The only moves came from the weekly realignment for Black Box Trader  However  the highlights section below offers some analysis from the portfolios and this week s Zacks Confidential Today s Portfolio Highlights Black Box Trader  Only one swap in this week s adjustment  The portfolio got out of Humana  NYSE HUM  with a 1 9  profit  and then replaced the name by buying The Chemours Co   CC   Read the Black Box Trader s Guide to learn more about this computer driven service designed to take the emotion out of investing Zacks Confidential  EVERYONE knows that tech is one of the hottest spaces in the market right now  But there s another industry that may be even hotter and practically NOBODY is paying attention  In this week s Zacks Confidential  Steve hands the keys over to Tracey Ryniec  who explains why the housing market provides one of the best buying opportunities out there  The space has recovered from the collapse nearly 10 years ago  so read her detailed article and get three recommendations by clicking  What s Hotter Than Tech  The Housing Market Reitmeister Trading Alert   Stocks closed above 2400 for the 7th straight session  That leaves very little doubt that a breakout is under way with likely more gains ahead   On Monday  the indices stalled out for the session  This is more about taking a breather than anything that is truly negative  In fact  the economic positives continued to roll in as ISM Services put up its 3rd best reading since the start of 2016   This is another in a string of strong economic reports which explains why GDP is looking like  3  in Q2 and explains why stocks should be heading higher in the days ahead      Steve ReitmeisterMomentum Trader   Stocks couldn t keep last week s momentum going on Monday  This week is setting up to be a bit of a snoozer with the FOMC next week  Until then it s likely to be  Thin to win  for equity markets   The market peaked around lunch time then faded off into the end of the session  The selling wasn t anything extraordinary but rather a slow trickle south   In terms of earnings and economic data it should be a slow week  Next week is the main event  That s when we ll get the Fed s decision on interest rates  Odds are they go ahead and hike for the second time this year  Until then  I expect more slow accumulation across the major market averages      Dave Bartosiak
All the Best 
Jim Giaquinto
Recommendations from Zacks  Private Portfolios   Believe it or not  this article is not available on the Zacks com website  The commentary is a partial overview of the daily activity from Zacks  private recommendation services  If you would like to follow our Buy and Sell signals in real time  we ve made a special arrangement for readers of this website  Starting today you can see all the recommendations from all of Zacks  portfolios absolutely free for 7 days  Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises  which we ve predicted with an astonishing 80   accuracy  ",2017-06-05,Zacks Investment Research,https://www.investing.com/analysis/was-this-a-three-day-weekend-too-200193347,200193347
142406,363921,HUM,Zacks Investment Ideas Feature Highlights  TrimTabs Float Shrink ETF  Deckers  BestBuy  Humana And Kroger,opinion,"For Immediate Release

	Chicago  IL   May 10  2017   Today  Zacks Investment Ideas feature highlights Features  TrimTabs Float Shrink ETF  BATS            Deckers  NYSE           BestBuy  NYSE           Humana  NYSE          and Kroger  NYSE          

Free Cash Flow  An Overlooked Metric for Finding Stocks 

	Since the presidential election in 2016  U S  stocks are posting a pretty solid performance including a roughly 13  gain for SPY  NYSE SPY   But while this double digit percentage performance is quite impressive  there are plenty of funds that have easily beaten out this gain 

	One that you might not be too familiar with  but has posted a 15  gain since the election  is the TrimTabs Float Shrink ETF  BATS            This fund focuses on companies that are reducing their share count but are also generating free cash flow 

	To get more information on this approach  I recently spoke with Ted Theodore  the Vice Chairman and CIO of TrimTabs  for some insights  In particular  we take a closer look at free cash flow and why focusing on this metric could be a good strategy for investors seeking quality stocks going forward  also read     

	What follows is the Q A we had on the topic  which should hopefully give investors some insights into this process 

Eric Dutram  What is  free cash flow  and why should investors put importance on this metric  

	Ted Theodore  Free cash flow is derived in several steps  Changes in working capital are subtracted from operating earnings in order to focus on actual changes in cash balances of the company  Then the amounts shown as depreciation and amortization expense are added back because no cash was utilized for those items during the period 

	The cash outlay for the items needing depreciation and or amortization were actually incurred prior to the current period  These calculations result in  cash flow   The amount the company spent on capital expenditures in the period is also subtracted  This final number is called  free cash flow  as it means the company s cash balances reflect not only changes in cash from operations  but also takes into account the necessity of the company to provide for its future growth through capital investments 

	In all regards  shareholder value is enhanced  Clearly  investors will have the sense of a much stronger  higher quality company where free cash flow is strong  Companies that generate strong free cash flows also can be potential takeover or merger candidates  In fact  one of our holdings   Swift Transportation   just announced a merger with another trucking company and the stock rose considerably after the announcement 

	Investors should care about this because companies that can string together years of free cash flow growth are able to outpace the S P 500  Unfortunately  those companies that have periods of sustained free cash flow declines see their stocks underperform the market 

Eric  What kinds of activities can companies engage in when they have strong free cash flows   Ted  The excess over free cash flow itself is available for any number of uses  Some of this amount can stay in the company and contribute to improving its fundamental balance between assets and liabilities  Some of the excess free cash flow can be used to acquire other companies and some of it can be returned to investors in the form of increased dividends 

Eric  Do you have any examples of companies with  strong  or  weak  free cash flow right now  

	Ted  Two companies we own that have strong free cash flow are Deckers  NYSE         and BestBuy  NYSE          Interestingly they are both in the consumer sector that has been under pressure from online shopping  Each company however has been able to steadily increase their presence in that channel as well as provide stronger merchandising than their competitors 

	At the other end of the spectrum  Humana  NYSE          and Kroger  NYSE         are struggling with competitors as well  but the challenges are even more daunting  In the case of Humana  regulatory uncertainties are contributing to having to cover more contingencies than the company is likely to desire  Kroger competes in an environment of both declining food and staples prices as well as brand new kinds of competition even from the likes of Amazon  NASDAQ AMZN  and Walmart  NYSE WMT  

Eric  Are certain sectors industries more  or less  prone to companies with strong free cash flows  Is a good free cash flow in one industry a poor one in another  

	Ted  As it turns out  banks have historically chosen a particularly wide variety of ways to provide the basic accounting building blocks for calculating cash flow  While bank managers have been granted perfectly acceptable discretion to report in these different manners by their auditors  most other industries share common approaches to these values 

	On the other hand  and except for banks  we have not found much industry bias in the calculation of free cash flow to either accept or eliminate them from consideration  For that reason  free cash flow is a particularly useful metric to separate good and bad performers within and between industries 

	The actual portfolios are designed to equally weight each security at the time of purchase  Additionally  on average we invest in 100 companies  The resulting sector allocations just reflect these three guiding factors  rather than a top down sector preference  As we use an equal weighting process with a large number of stocks  it is clear we want the benefits of diversification  But recognizing the chance that this approach could result in a truly unbalanced portfolio from a sector perspective  we actively monitor that bet  Yet  as implied here  it is a secondary consideration 

Eric  How might investors utilize this strategy in today s uncertain market environment  

	Ted  While very few companies are completely isolated from the impact of the general environment for the economy  companies that have exhibited strong free cash flow have built something of a cushion should times become uncertain  These are companies likely to be relatively the last to feel an overall downturn 

Eric  How does a product like TTAC fit into an investor s portfolio  

	Ted  Over the years our process implies the portfolios will likely have about the same risk as the market  And given the large number of stocks in the portfolio and the fact that they are not weighted by market capitalization  we tend to create returns which have similar risk to the overall market  So  we consider our strategy to fit into the  core  category rather than one of the satellite kind  But even with market risk  our emphasis on strong long term fundamentals  implemented with quantitative disciplines  gives the chance to outperform the broad market 

	Be sure to follow me on 

	Want more articles from this author  Go to Zacks com on this article and click the FOLLOW AUTHOR button to get an email each time a new article is published 

	Brian Bolan is a Stock Strategist for Zacks com 

	He runs Stocks Under  10 Investor service where he looks for low priced stocks that are seeing positive earnings estimate revisions  This popular service has seen some strong early returns and offers a free trial via the Zacks Ultimate service 

	Brian also runs the brand new Zacks Game Changers where he looks for stocks that are disrupting their industries and reaping big gains 

Looking for Ideas with Even Greater Upside 

	Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more  











	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-05-09,Zacks Investment Research,"https://www.investing.com/analysis/zacks-investment-ideas-feature-highlights:-trimtabs-float-shrink-etf,-deckers,-bestbuy,-humana-and-kroger-200188291",200188291
142407,363922,HUM,Aetna  AET  Calls It Quits On Unsustainable Public Exchanges,opinion,"In the wake of continued loss incurred by its public exchange business  health insurer Aetna Inc    NYSE AET   has announced to pull back its presence in all the remaining states where it is operates now The company will now make an exit from the public exchanges in the states of Delaware and Nebraska  Last month  the company called it quits on Iowa and Virginia  With the exits  the company will now be virtually absent from the public exchange business Losses to the tune of  700 million from 2014 2016 from the public exchange business drained the company s bottomline  Despite having curbed its exposure  the company still anticipates a loss of  200 million in 2017 These losses and other headwinds such as merger led uncertainty have led shares to gain 31 7  over the past one year  However  this compares favorably with the  Zacks categorized  industry which has gained 34 4  Aetna joins other players  with UnitedHealth Group Inc    NYSE UNH   being the frontrunners  in folding up the public exchange business  It was the first health insurer in the industry to cut its exposure to the painful public exchange business  It was present in only three states in 2017  down substantially from 34 states last year  Other insurers like Humana Inc    NYSE HUM   and Anthem Inc    NYSE ANTM   are also cautious of this business Individual Public Exchange  a signature achievement of Obamacare was created to provide insurance to individuals and offer subsidies based on income levels  Insurers were hopeful of making gains out of the provision that was anticipated to provide steep membership growth between 2015 and 2019  But it did not turn out as expected  Soon the public exchange business started losing sheen as it attracted a greater number of old and sick population in comparison with the young and healthy ones  which increased the overall risk profile of the members insured on public exchanges  It therefore led to higher than expected claim cost and consequent losses Public exchanges are now detested all the more as this provision has come under the critical eye of Donald Trump  who via his repeal and replace plans has created significant uncertainty related to its future  The GOP s plan calls for the elimination of Obamacare subsidies  which are refundable tax credits based on a person s income and cost of coverage in their area  The subsidies made it easy to buy insurance on exchanges  The scrapping of these subsidies will drive them away from the exchanges 
Aetna carries a Zacks Rank  3  Hold   You can see  
The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1   Strong Buys   free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5   Strong Sells    Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ",2017-05-10,Zacks Investment Research,https://www.investing.com/analysis/aetna-(aet)-calls-it-quits-on-unsustainable-public-exchanges-200188603,200188603
142408,363923,HUM,Anthem Finally Walks Away From Cigna Merger  Seeks Charges,opinion,"Anthem Inc    NYSE ANTM   has officially terminated its merger with Cigna Corp    NYSE CI    This development came after the Delaware Chancery Judge refused Anthem s request last week to hold back Cigna for another 60 days In January  Anthem postponed the merger date to April end to buy time  The company had hopes of the merger materializing under the Trump administration and planned to seek a quick appeal of the court decision that blocked it In February  Cigna filed a suit in Delaware Chancery Court asking to be freed from the deal and sought  1 85 billion of termination fee and  13 billion in other charges There was always a friction between the companies  with each blaming the other for the deal breakup  The fight has now reached a stage where the focus is on the breakup fee Anthem and Cigna were already in a rough patch  Since the very beginning  Anthem continued its pursuit of Cigna by creating pressure on its board members despite the latter s repeated rejection of the takeover proposal Anthem was also ready to go public with its proposal offer if Cigna did not give consent to the deal  With time  the differences between the two companies have broadened and now the fight is in the open Since the announcement of the merger  shares of both Anthem and Cigna have underperformed the Zacks categorized    industry by generating returns of 17 6  and 24   respectively  compared with the sector s gain of 31 8   The share price performance of each of the players reflects the pessimism that surrounded their stocks following the merger related uncertainty and investor perception that they may finally be blocked Anthem also charged Cigna for its coldness toward the merger and has alleged that its ways were aimed at sabotaging the deal  Anthem pointed out that Cigna s conduct at each stage of the merger  right from its integration efforts to the appeals  reflected its reluctance to pursue and seal the deal Anthem blamed the company of improper use of its rights to terminate the merger  Therefore  per Anthem  Cigna is not entitled to a termination fee  Anthem on the other hand will charge Cigna of the massive damages it has suffered because of the non completion of the deal Recently  another mega merger of Aetna Inc    NYSE AET   with Humana Inc    NYSE HUM   was also terminated and the termination fee was duly paid to the concerned party Both Cigna and Anthem carry a Zacks Rank  2  Buy   You can see 
5 Trades Could Profit   Big League   from Trump Policies
If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course 
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-05-14,Zacks Investment Research,"https://www.investing.com/analysis/anthem-finally-walks-away-from-cigna-merger,-seeks-charges-200189241",200189241
142409,363924,HUM,The Zacks Analyst Blog Highlights  Merck  3M  United Technologies  Ford Motor And Humana,opinion,"For Immediate Release

	Chicago  IL   May 26  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Merck   Co   Inc   NYSE           3M Co  NYSE           United Technologies Corporation  NYSE UTX   NYSE           Ford Motor Company  NYSE F   NYSE          and Humana Inc  NYSE HUM   NYSE          

	Today  Zacks is promoting its   Buy   stock recommendations     

Here are highlights from Thursday s Analyst Blog  

New Stock Research Reports for Merck  3M   United Technologies  

	Today s Research Daily features new research reports on 16 major stocks  including Merck   Co   Inc   NYSE           3M Co  NYSE         and United Technologies Corporation  NYSE           You can see   

Merck shares have outperformed the Large Cap Pharmaceuticals industry over the last one year  gaining  15 1  versus the industry s  3 4  increase  This momentum reflects the progress it has made with product pipeline and strong recent results  the company beat estimates in Q1 and raised guidance  While generic competition for several drugs and pricing pressures as are material in the Merck story as they are for many of its peers  the Zacks analyst points out that the company s new products like Keytruda and Zepatier hold great potential  The analyst discusses all of these issues in the updated research report issued today   You can     

3M  shares are up  11 4  in the year to date period  outperforming the S P 500 index  up  7 7   and the Zacks Conglomerates sector  up  1    Driving this momentum has been the company s successful efforts to align its portfolio to customer relevance  productivity and speed through a leaner operating structure  3M is also standardizing its business processes through a new  global ERP system and expects  500  700 million in annual operational savings by 2020  The impact of these showed up in the latest quarterly release when it guided higher  On the flip side  high pension expenses and exposure to commodity price risks remain significant headwinds   You can     

United Technologies  shares have outperformed the Zacks Conglomerates sector as well as the S P 500 index in the year to date period  the stock is up  11 6 vs   1 1  gain for the sector  on the back of a revamped aerospace unit and improved growth outlook through strategic acquisition opportunities  While questions remain about the new administration s ability to ramp up defense spending  this favorable expectation is nevertheless a positive for the company  The improving outlook for the global economy is another macro tailwind for UTX  The company remains in excellent financial health and pays a stable dividend  currently yielding 2 2    but value oriented investors will likely have issues with the stock s current elevated valuation   You can     

	Other noteworthy reports we are featuring today include Ford Motor Company  NYSE         and Humana Inc  NYSE          

Will You Make a Fortune on the Shift to Electric Cars  

	Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 

	With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 

	It s not the one you think 

 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  

	This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-05-25,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-merck,-3m,-united-technologies,-ford-motor-and-humana-200191632",200191632
142440,363955,HUM,Stocks To Watch Ahead Of GOP Healthcare Vote,opinion,"After seven long years of promising to repeal President Obama s landmark Affordable Care Act  House Republicans finally think that they have enough votes to pass their replacement bill  Representatives are scheduled to vote on the new American Health Care Act on Thursday following several last minute changes that convinced key moderates and conservatives to support it 
The House vote will likely come down to the wire  and it s even more likely that the Senate makes key revisions to the bill  but getting the law out of this chamber of Congress would be a clear political victory for Republican leadership and the Trump administration 
Although some pundits expected the GOP to delay its healthcare reform after the original version of the AHCA was canned  the current iteration of the bill garnered centrist and right wing support relatively quickly 
The GOP s new plan would eliminate Obamacare subsidies which are based on income and cost of coverage in their area and replace them with refundable tax credits based mainly on age  The credits would be worth around  2 000 for those in their 20s to  4 000 for those in their 60s  Credits for people making more than  75 000 would begin to taper our  while people making more than  215 000 would not be eligible for the credits at all 
The AHCA would also do away with the individual and employer mandates  two staples of Obamacare  The individual mandate requires that people have a health insurance plan or face a tax  and the employer mandate requires companies with more than 50 employees to offer an affordable plan to their full time workers 
These mandates would be replaced by continuous coverage requirements  which levy surcharges on the premiums of those who let their coverage lapse for a certain amount of time  An amendment to the bill now allows states to seek waivers that would replace these requirements with one that allows insurance companies to charge people who had a coverage lapse based on their health 
Critics of the new law claim that the state waiver process weakens coverage for those with pre existing conditions  While Obamacare absolutely bars any insurer from denying coverage based on a pre existing condition  the new law allows states to seek waivers that could allow insurance companies to set premiums based on one s medical background  States would also be able to apply for waivers that would allow insurers to sell plans that don t include benefits mandated by Obamacare 
Another point of controversy is the plan s overhaul of Medicaid  The law includes several major changes to Medicaid  including a general shift in responsibility from the federal government to the states  This would likely result in less overall funding for the program  which could result in coverage rollbacks 
A Congressional Budget Office study projects that the AHCA would cut the federal government s Medicaid spending by 25  by 2026  The CBO also said that the new law would result in 24 million more uninsured people by that year 
So how should investors approach today s monumental vote  Well  like with anything that brings uncertainty into play  it s best to approach with caution 
Of course  the most important stocks to watch will be the massive insurance companies  including UnitedHealth   NYSE UNH    Anthem   NYSE ANTM    Humana   NYSE HUM    Aetna   NYSE AET    and Cigna   NYSE CI   
If you glance back at their historical prices  these stocks didn t have a massive immediate reaction to the passage of Obamacare in March 2010  but they have all been climbing higher since  In fact  insurers are hitting new highs despite their struggles to profit on Obamacare enrollees 
Investors should also keep an eye on the major health related ETFs  Those that could see an effect from today s vote include the iShares U S  Healthcare Providers ETF   iShares U S  Medical Devices ETF   MT IHI    iShares Nasdaq Biotechnology ETF   SPDR S P Biotech  MX XBI  ETF   and the Health Care Select Sector SPDR Fund  
All of these industries will be impacted  as the GOP plan has wide ranging repercussions for overall access to care  as well as taxes imposed on companies and consumers  However  the same could be said about Obamacare  and historical price data shows that these tickers were all relatively flat during the week that the law passed 
Investors will likely display some sort of initial reaction  but the market could be hesitant regardless of whether the vote passes or not  As mentioned  the Senate will likely make changes  and there seems to be a certain lingering uncertainty about how the AHCA will look in practice as there also was with Obamacare 
Want more stock market analysis from this author  Make sure to follow   on Twitter 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ",2017-05-04,Zacks Investment Research,https://www.investing.com/analysis/stocks-to-watch-ahead-of-gop-healthcare-vote-200187206,200187206
142441,363956,HUM,No Fear   but No Rally Yet Either,opinion,"The election of Emmanuel Macron as France s new President this weekend was only the latest bit of reassuring news that the market has enjoyed in recent days  Last week  we received a strong jobs report following an alarmingly weak one in the previous month  and the House showed that it can still do something when it passed a healthcare bill  All of this comes amid a solid earnings season and mostly encouraging economic data 
And yet the major indices couldn t get a rally going on Monday  The S P was up only 0 09 of a point  or 0   to 2399 4  The Dow and NASDAQ could each climb only 0 03  to 21 012 3 and 6102 7  respectively 
However  it is important to know that the VIX  a k a   the fear gauge   is at its lowest point in more than 20 years   The VIX is our biggest clue to determining if last night was some kind of top   said Jeremy in Counterstrike   Falling well under 10 and the lowest close since  93  the VIX tells us there is absolutely no fear out there and it s only a matter of time before we grind higher  
Speaking of Counterstrike  the portfolio added a company on Monday that moved lower after a triple digit earnings surprise  Jeremy knows it s the work of high frequency traders  and he plans to ride this stock back up when they re done  Meanwhile  Black Box Trader replaced six names this week  and one of the sells was a double digit winner  Take a look at the highlights section below 
Today s Portfolio Highlights 
Zacks Counterstrike  When a company reports a 188  positive surprise and then dips by double digits shortly thereafter  there s a good chance that the high frequency traders are playing some games  Such was the case with Boise Cascade  BCC   a Zacks Rank  1 wood products manufacturer and building products distributor  Jeremy sees a great opportunity here  so he added BCC to the portfolio on Monday with a 13  allocation  The full write up has more on this company s earnings and a look at its chart 
Black Box Trader  The portfolio replaced six positions in this week s adjustment  and four of the sells were profitable 
  Best Buy  BBY   13 5  
  DXC Tech  DXC   3 9  
  Centene  CNC   1 8  
  Masco  MAS   0 3  
  BWA and CAT were also sold
The six new additions replacing these names are 
  Pilgrim s Pride  PPC 
  Fiat Chrysler  FCAU 
  Humana  NYSE HUM 
  Live Nation Entertainment  LYV 
  Sprouts Farmers Markets  SFM 
  Weight Watchers  WTW 
Read the Black Box Trader s Guide to learn more about this computer driven service designed to take the emotion out of investing 
Zacks Confidential  The earnings recession is over  which means Sheraz Mian s quarterly scorecard is a lot less depressing than it used to be  But that doesn t mean every industry is knocking it out of the park  In this week s Zacks Confidential  Steve cleared the way for Sheraz s usual  extremely in depth analysis of the first quarter  Find out which industries are hot and get a couple recommendations by clicking  Q1 Earnings Scorecard 
Reitmeister Trading Alert   Small caps are losing again this year  Just like 2014  Just like 2015  Just like most of 2016 
 This is very odd for a bull market since small caps generally lead the charge  The only time in recent memory they have been in the lead is right after the election through the end of 2016 when small caps beat large caps by 3 to 1 spread  Since then large caps have flipped the script leading by nearly 4 to 1 
 Yes  one could look at this information and say the momentum is on the side of large caps  But the value oriented contrarian in me sees the exact opposite  That large caps are getting played out and small caps are about ready to shine  I would even bet that once the market finally breaks above 2400 is exactly when small caps take the lead      Steve Reitmeister
All the Best 
Jim Giaquinto
Before You Go   
Remember  the third episode of the Zacks Ultimate Strategy Session will be available for viewing this Wednesday  May 10th  Steve Reitmeister  Sheraz Mian  Dr  John Blank and David Bartosiak will cover the investment landscape from most every angle in this  must see TV  event 
Don t miss your chance to hear 
  Sheraz and John Agree to Disagree on Risk and Earnings Growth
  Steve s answers to your questions in Reity s Mailbag
  Tips for improving your portfolio
  And much more
So be sure to mark your calendar then log on to Zacks com and bookmark this page 
Recommendations from Zacks  Private Portfolios   Believe it or not  this article is not available on the Zacks com website  The commentary is a partial overview of the daily activity from Zacks  private recommendation services  If you would like to follow our Buy and Sell signals in real time  we ve made a special arrangement for readers of this website  Starting today you can see all the recommendations from all of Zacks  portfolios absolutely free for 7 days  Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises  which we ve predicted with an astonishing 80   accuracy  ",2017-05-08,Zacks Investment Research,https://www.investing.com/analysis/no-fear...but-no-rally-yet-either-200187888,200187888
142482,363997,HUM,Dark Clouds On Humana s Horizon,opinion,"It was a nice run  but Humana s upside potential is limited from now on
The last eight years must have been great for Humana Inc  NYSE HUM   investors  From its March 2009 bottom at  18 57  the stock has gained over  200 a share or roughly 1077   That is 36 2  compounded annually  which is a great return in anybody s book  Humana closed slightly below its all time high yesterday  which is a strong indication that investors are felling as if the uptrend is going to last forever  But is it  Of course not and our job is to try to determine what is left of it by applying the  to Humana s weekly price chart given below 
The chart above shows the stock s entire rally since 2009  According to the theory  a five wave  is what every trend is made of  Humana seems to be confirming that by drawing a clear impulsive pattern  whose wave V is still developing  Unfortunately  every five wave sequence is followed by a three wave correction of similar magnitude in the opposite direction  This means that once wave V exceeds the top of wave III  a major bearish reversal would be likely  In our opinion  investors should not get too carried away by Humana s impressive performance in the last eight years  The  of wave IV near  150 a share is a reasonable target of the anticipated decline  It looks like the bull party is approaching to its end and in the stock market  latecomers always suffer the most ",2017-03-14,EWM Interactive,https://www.investing.com/analysis/dark-clouds-on-humanas-horizon-200178843,200178843
142483,363998,HUM,Aetna  AET  Hurt By Exchange Business  High Medical Costs,opinion,"Shares of health insurer Aetna Inc    NYSE AET   underperformed over the past one year  While the stock returned 17 7   the Zacks categorized  industry gained 24 3  
The underperformance is likely to have resulted from a number of issues bothering the company of late  Its merger with Humana Inc    NYSE HUM   was ripped apart recently on regulatory concerns  The deal would have positioned Aetna as a major Medicare provider   a market coveted by all other players in the industry 
Aetna has been troubled by its public exchange business  After incurring loss on public exchanges in 2015  Aetna bore a pre tax operating losses of  450 in 2016  Lackluster results from this line of business prompted the company to substantially reduce its risk exposure to these products for 2017  Based on its current view of open enrollment  the company projects that its first quarter Individual Commercial membership will decline to 240 000 from approximately 965 000 at year end 2016  The company also projects losses on its Individual Commercial ACA compliant products in 2017 
Aetna s membership has also been under pressure  The company ended 2016 with medical membership of 23 1 million  down from 23 49 million in 2015  It is witnessing continued pressure in membership growth in the middle market and small group businesses due to its previous pricing actions to improve margins  The company  expects 22 2 to 22 3 million medical members in the first quarter of 2017 
Aetna is also facedwith an increase in medical benefit ratio  MBR   which measures medical cost as a percentage of premium revenues  Total MBR for full year 2016 was 81 8   up from 80 8  in 2015  The increase was driven by an unfavorable performance in individual Commercial products and lower favorable development of prior period healthcare cost estimates for Government business  The company projects full year 2017 total Health Care Medical Benefit Ratio in the range of 84  to 85   representing an increase of 270 basis points year over year at the midpoint of the range 
Despite these challenges  we believe the company will achieve long term growth on the back of its strongly performing government business  cost control measures  growing accountable care organization initiative  expanding international markets and a strong capital position 
Aetna carries a Zacks Rank  3  Hold   Some better ranked stocks from the medical space are UnitedHealth Group  Inc    NYSE UNH   and Inogen Inc    NASDAQ INGN    While Inogen sports a Zacks Rank  1  Strong Buy   UnitedHealth holds a Zacks Rank  2  Buy   You can see  Inogen beat earnings estimates in three of the last four quarters with an average positive surprise of 49 08  UnitedHealth beat earnings estimates in each of the last four quarters with an average positive surprise of 3 80  
The Best   Worst of Zacks
Today you are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5  Strong Sells   Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ",2017-04-13,Zacks Investment Research,"https://www.investing.com/analysis/aetna-(aet)-hurt-by-exchange-business,-high-medical-costs-200182891",200182891
142485,364000,HUM,Aetna  AET  Up 6 9  Since Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for Aetna Inc    NYSE AET    Shares have added about 6 9  in that time frame  outperforming the market 
Will the recent positive trend continue leading up to the stock s next earnings release  or is it due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts Aetna Earnings Beat Estimates in Q4  Revenues MissAetna reported fourth quarter 2016 earnings of  1 63 per share  surpassing the Zacks Consensus Estimate of  1 45 and improving 19  year over year  The earnings upside was primarily driven by higher fees and other revenue in Aetna s Health Care segment Better than expected earnings drove up the share price by 1 92  in pre market trading Aetna posted operating revenues of  15 72 billion  a tad below our consensus estimate of  15 9 billion  but up 4  year over year Revenue growth was primarily led by higher premiums in Aetna s Health Care segment Total operating expenses were  3 6 billion  12 8  higher year over year  due to increased health care cost  and higher selling expense  and general and administrative expense Adjusted operating expense ratio was 19 8   down from 20 5  in the year ago quarter  The reduction in operating expense ratio was due to the increase in revenue coupled with the company s focus on expense management that paid off Fourth quarter pre tax operating margin was 6 4   up 40 basis points year over year Medical membership at Dec 31  2016 remained flat sequentially at 23 1 million Full year 2016 earnings per share of  8 23 increased 7  year over year  while revenues of  63 05 billion were up 5  year over year Segmental PerformanceAetna s Health Care segment recorded operating revenues of  15 billion  up 4 2  year over year  The revenue increase was primarily due to higher premium yields and membership growth in Aetna s Government business  This was somewhat offset by membership loss in Aetna s Commercial insurance business Operating earnings increased 18 3  from the year ago quarter to  582 million Aetna s Group Insurance operating revenues were up by just 0 3  year over year to  621 million  Operating earnings  however  increased 50  year over year to  33 million  due toimproved underwriting margins in Aetna s long term care products  partially offset by lower underwriting margins in life products At Large Case Pensions  operating revenues were down 4 5  year over year to  64 million  Operating earnings were up 25  year over year to  5 million Financial PositionTotal assets were  39 2 billion as of Dec 31  2016 compared with  53 5 billion as on Dec 31  2015 Total debt to consolidated capitalization ratiowas 53 6  at Dec 31  2016 compared with 32 6  at Dec 31  2015  due to the issuance of  13 billion of senior notes to partially fund the proposed acquisition of Humana  NYSE HUM  Days claims payablewere 54 at Dec 31  2016  down 3 days sequentially 2017 GuidanceThe company expects 2017 operating earnings of  at least  8 55  per share 
How Have Estimates Been Moving Since Then 
Following the release  investors have witnessed an upward trend in fresh estimates  There has been one upward revision for the current quarter Aetna Inc  Price and Consensus
    VGM Scores
At this time  Aetna s stock has a subpar Growth Score of  D   however its momentum is doing a lot better with an  B   Following the exact same course  the stock was allocated a grade of  A  on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of  B   If you aren t focused on one strategy  this score is the one you should be interested in 
Zacks  style scores indicate that the stock is suitable for value and momentum investors 
Outlook
Estimates have been broadly trending upward for the stock  The magnitude of these revisions also looks promising  Interestingly  the stock has a Zacks Rank  3  Hold   We are expecting an inline return from the stock in the next few months ",2017-04-19,Zacks Investment Research,https://www.investing.com/analysis/aetna-(aet)-up-6.9-since-earnings-report:-can-it-continue-200183641,200183641
142488,364003,HUM,What s In The Cards For Centene  CNC  This Earnings Season ,opinion,"Centene Corporation   NYSE CNC   will release first quarter 2017 results on Apr 25  before the market opens  Last quarter  the company posted a positive earnings surprise of 6 25   Let s see how things are shaping up for this announcement Factors to be Considered this QuarterCentene s acquisition of Health Net in the last reported quarter is expected to have boosted its top line this time around The company s new Medicaid contracts are likely have boosted the membership  in turn  bolstering revenue growth in the to be reported quarter The company also started Medicare Advantage plans in four new states in Jan 2017  which is likely to have contributed to revenue growth The company also remains committed toward enhancing shareholders  value  To this end  it undertook share repurchases  which should impact the bottom line positively by reducing the outstanding share count However  the company s merger with Health Net resulted  in incurring substantial costs  which are likely to put pressure on the bottom line Health Net s high Selling General and Administrative expenses are also expected to have increased its overallexpenses  limiting bottom line growth Increasing costs related to extinguishment of debt  reserves for settlements  legal judgments and lawsuits  impairments of long lived assets are anticipated to have affected earnings Centene Corporation Price and EPS Surprise
    Earnings WhispersOur proven model does not conclusively show that Centene is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Centene has an Earnings ESP of  1 89   This is because the Most Accurate estimate is pegged at  1 04  while the Zacks Consensus Estimate stands at  1 06  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Centene carries a Zacks Rank  3  Though the company has a favorable Zacks Rank  its negative Earnings ESP complicates surprise prediction We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some other companies from the medical sector that you may want to consider as these have the right combination of elements to post an earnings beat this quarter Amgen  Inc    NASDAQ AMGN    which is set to report first quarter earnings on Apr 26  has an Earnings ESP of  1 99  and a Zacks Rank  3  You can see  Anthem  Inc   NYSE ANTM   has an Earnings ESP of  7 79  and a Zacks Rank  2  The company is set to report first quarter earnings on Apr 26 Humana  Inc    NYSE HUM   has an Earnings ESP of  2 06  and a Zacks Rank  2 The company is set to report first quarter earnings on May 3 Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-04-19,Zacks Investment Research,https://www.investing.com/analysis/what's-in-the-cards-for-centene-(cnc)-this-earnings-season-200184007,200184007
142511,364026,HUM,Will Health Insurers Suffer From Trump Presidency ,opinion,"One of the biggest campaign promises made by President elect Donald Trump was the dismantling and replacing of Obamacare  officially known as the Affordable Care Act  or ACA   the signature legislation passed through Congress and enacted during President Obama s two terms in office  Health insurance companies provided a major overhaul of their business plans to comply  and now they look to be put on a new road forward 
So yesterday  in lieu of an actual replacement policy being made public as of yet  healthcare insurance companies have put forward a list of ACA benefits they do not want to see removed  if when Obamacare is officially taken apart  First is a commitment to offset some healthcare costs for low income Americans  They also consider young people signing up for health insurance is crucial to keeping costs low for the companies 
Already tough sledding for insurers to provide appropriate care for its customers  without these provisions made by the incoming administration   and Trump and his team have been mum on this issue to this point   insurers will be abandoning the system en masse  and complete failure of the ACA would eventually amount to more than 22 million Americans currently insured for healthcare thrown out into the cold 
Healthcare insurers   including the Zacks Rank  2  Buy  Humana  NYSE HUM    The Joint Corp  and WellCare    do not want this to happen  But America s Health Insurance Plans  a leading industry trade group  and presumably the Blue Cross Blue Shield Association  which has not yet issued a public statement on this matter  are concerned about dire consequences in the industry should the ACA be removed without a suitable replacement  At very least  the organizations would like three years to re set the table for their businesses and their shareholders 
With tens of millions of new customers on the rolls  health insurers are in no mood to go back to the way things were  Yet what course the new law   assuming there is one   takes going forward will have major consequences on the  4 2 trillion Health Care industry ",2016-12-06,Zacks Investment Research,https://www.investing.com/analysis/will-health-insurers-suffer-from-trump-presidency-200168711,200168711
142512,364027,HUM,Humana  FullWell To Enhance Value Based Care In Colorado,opinion,Humana Inc    NYSE HUM   recently announced that it has entered in to a value based agreement with population health leader  FullWell  The main objective of the agreement is to deliver a more proactive and wellness focused health care experience to Humana s Medicare Advantage  MA  members in Colorado  This alliance also aims to financially reward doctors for providing high quality care Humana forms these value based relationships to strategically transform healthcare through more proactive and patient centric high quality medical assistance  Humana s ability to control costs alongside enhancing its members  well being has cemented the confidence of its shareholders on the stock  Over the last three months  the shares of Humana have gained 15 01  compared with 14 14  gained by the Zacks categorized Health Maintenance Organization industry PRICE CHARTThis new alliance would enable the MA members of Humana to access more than 150 FullWell primary care providers in the Denver metro area  Through this new value based agreement  both companies took a step toward the common goal of offering improved healthcare to Humana s MA members who fall under the coverage of FullWell s Colorado Health Neighborhoods Network Value based health care is basically a transition from fee for service  which prioritized expensive treatments instead of preventive measures  Under the original fee for service model  payments of physicians were not based on the health outcomes but on the number of services provided  The shift to the value based payment models not only ensures overall prevention from diseases  but also reimburses the physicians on the basis of the recovery of the patients they treat Along with other medical sector stocks like UnitedJHealth Group Inc    NYSE UNH    Molina Healthcare Inc    NYSE MOH   and WellCare Health Plans Inc    NYSE WCG   to name a few  Humana has been an early adopter of this value based healthcare model  As a result  the company managed to  lower costs by 20  in 2015 compared with those who still operate with the conventional fee for service healthcare model As of the third quarter  Humana has 1 8 million individual MA members and 0 2 million commercial members  who are cared for by 49 600 primary care providers in more than 900 value based relationships across 43 states and Puerto Rico Notably  almost 63  of Humana s individual MA members were treated under the value based model  The company aims to have 75  of individual MA members in its value based payment models by the end of 2017 Under the terms of this value based agreement  both FullWell and Humana are supposed to frame strategies to improve the quality of healthcare at a low cost for the Humana members in Colorado  Together  the companies are striving to find the gaps in care  manage medication adherence  follow up on patients needing PCP visits  and identify high Emergency Room  ER  seekers and at risk patients to provide them proper treatment before their condition turns severe  Continuous screening and monitoring of chronic conditions like diabetes and heart diseases are also expected help patients Humana presently caries Zacks Rank  2  Buy   You can see  Zacks  Best Private Investment IdeasIn addition to the recommendations that are available to the public on our website  how would you like to follow all Zacks  private buys and sells in real time Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors  Starting today  for the next month  you can have unrestricted access ,2016-12-07,Zacks Investment Research,"https://www.investing.com/analysis/humana,-fullwell-to-enhance-value-based-care-in-colorado-200168938",200168938
142513,364028,HUM,Stock Exchange  Diverse Ideas  But A Presidential Veto ,opinion,"Last week s  illustrated how human traders could call upon models as  consultants   effectively creating their own trading room  If you missed the post  please check it out  This week the gang is short on fresh ideas   and I vetoed one of them  We never reach for new trades  and that itself is a good tale 

My crew varies widely in reading skills  Felix reads everything   and very carefully  Oscar reads the sports section  Holmes is a dog  Athena does not read since she already knows everything  It is my job to keep up with relevant world events  and our modeling guru s  Vince  to create and monitor systems  One way that we judge our team is by comparing our approach to the recommendations of Brett Steenbarger  He is the world class leader when you want to combine the theoretical and the practical  This  why trading methods need a deep foundation 


  S uccessful traders must be able to innovate at two levels  First  they must find new ideas and fresh opportunities  Second  they must cultivate new sources of ideas and opportunity  The first involves exploiting the edges we already possess  the second involves identifying additional edges  The successful trader is never static  never dependent on one type of market condition to make a living  Just as research and development is the lifeblood of technology and pharmaceutical companies  it is the source of long term success for traders 
When successful traders aren t trading  they are researching  developing  and innovating  When unsuccessful traders aren t trading  they re staring at screens and forcing trades  There is nothing better for trading psychology than being at the cutting edge of a growing business 


This is great advice  Traders who sit staring at a screen when nothing is happening are simply wasting time  It also illustrates the usefulness of having teammates to provide other ideas and spark the thought processes  Let s take a look at this week s ideas  As usual  I will conclude with a brief observation 

Getting Updates

We have a new  free  service to subscribers to our Felix Oscar update list  You can suggest three favorite stocks and sectors  We report regularly on the  favorite fifteen  in each category  stocks and sectors as determined by readers  Sign up with email to  etf at newarc dot com   Suggestions and comments are welcome  In the tables below  green is a  buy   yellow a  hold   and red a  sell   Each category represents about 1 3 of the underlying universe  Please remember that these are responses to reader requests  not necessarily stocks and sectors that we own  Sign up now to vote your favorite stock or sector onto the list 

This Week When to Reject a Trading Idea

Holmes

This week I m buying Fomento Economico Mexicano  NYSE FMX   a distributor of soft drinks  owner of small format stores  and investments in the Heineken Group 

For the last year this stock has  until Nov 7th  bounced between the mid 80s and mid 90s piquing my interest in a trade  Then  and fortunately  before I had the chance to pull the trigger  it swooned down to 75 and has been basing there for the last 2 months  I don t really understand why it dropped so quickly and so precipitously  but now that it s basing I don t care 

So  I m buying here with tight stop  72  and looking for a move back into the mid 80s  It is a nice risk reward setup 




J  You said that you are buying  Did you come into some money 

H  Uhh   I meant that I am recommending to our clients 

J  It is an interesting idea  but we are not making the trade 

H  Why not  It fits my criteria very nicely 

J  On rare occasions  we humans override decisions from the trading models 

H  Why would you ever do that 

J  Because we know the criteria you use and monitor facts that you might not be seeing 

H  I see the stock price  volume and other technical indicators  What more do I need to know 

J  Sometimes there are dips that do not really provide a near term rebound potential  In this case  our new President is talking tough on trade with Mexico  The Peso is lower  A time to buy may come  but there are much better opportunities right now 

H  What is a President 

J  That is exactly what I mean 


Athena

I admit it  I have nothing new this week  The current market has not generated fresh  strongly trending stocks 

J  That is fine  As you know  it is a mistake to reach for trades  Stick to those that have significant edge  How about reviewing one of your recent choices 

A   hasn t done much yet  You were skeptical from the beginning  You said that you liked the sector but it had gone too far  too fast  I had originally planned to hang on for a few weeks at most  Part of me feels like it s time to get out of this holding and move on to the next thing 

J  This is another name caught up in the Trump transition speculation  When the expectations for short term interest rates get some clarity  the bank stocks will react  This holding is OK   for now 




Felix

I will once again begin with my responses to reader votes for the favorites list 

My list provides rankings within each zone  as well as the basics about buy  hold  and sell  The list includes the top overall vote getters from our  free  subscription list as well as some new requests I got during the week 

J  The stocks are about the same as last week 

F  The list changes  but only as the reader favorites change  I encourage my fans to submit requests 

J  The order of the ratings has changed  Are you going to resume showing us the week over week comparison 

F  I am thinking about that problem  Some of the stocks were not rated last week  For the moment  readers must follow their favorites each week 

J  Maybe we ll get some good new suggestions  What is your featured stock for this week 

F  You will not like my answer  I have nothing new this week 

J  That is what you said last week  Aren t we still reviewing your request for a raise 

F  Yes  but you should base your decision on my results  not the number of picks  My holding period is longer  As you know I have had the best performance since you added me in September  I have been better than the dog  and a lot better than Oscar 

J  The lawyers say that we cannot discuss performance online   only when we have an investor request  Instead  how about reviewing one of your recent selections 

F  My recent pick of PayPal Holdings Inc  NASDAQ PYPL  is sure to make Athena jealous  Since  on December 29  the price has popped a tasty 3   Of course   short term returns aren t really my thing  I ll probably be holding on here for another few months  at the very least 

J  That has worked out well  I agree that it is consistent with some of your other long term holdings 




Oscar


Here are my ratings for the top reader interests  There are still three open slots  so keep the questions coming 

J  Interesting  What do you have for us this week 

O  I m getting into a new sector this week  Healthcare Services  Just look at the chart for Humana  NYSE HUM   It s ridiculous  I don t think I ve ever seen a 50 day moving average shoot up at a 45 degree angle before  Now you are the public policy guy  not me  so does this really make sense 

J  No one really knows just yet  We know that there will be a  repeal and replace  policy on ObamaCare  The outlines of this are still pretty vague  I have written on this subject several times  I am standing back until there is more clarity 

O  You cannot always sit on the sidelines  This is worth a shot  As far as timeframes are concerned  I almost certainly won t hold onto this for longer than a month  That is  unless someone who reads something other than the sports section can find a reason to do otherwise  BTW  I think there could be some upsets this weekend 

J  Isn t your fantasy football season over 

O  Yes  I am working on becoming an NBA expert while I wait for March Madness 







Background on the Stock Exchange



Each week Felix and Oscar host a poker game for some of their friends  Since they are all traders they love to discuss their best current ideas before the game starts  They like to call this their      Check it out for more background   Their methods are excellent  as you know if you have been following the series  Since the time frames and risk profiles differ  so do the stock ideas  You get to be a fly on the wall from my report  I am the only human present  and the only one using any fundamental analysis 



The result  Several expert ideas each week from traders  and a brief comment on the fundamentals from the human investor  The models are named to make it easy to remember their trading personalities  Each week features a different expert or stock 



Questions



If you want an opinion about a specific stock or sector  even those we did not mention  just ask  Put questions in the comments  Address them to a specific expert if you wish  Each has a specialty  Who is your favorite   You can choose me  although my feelings will not be hurt very much if you prefer one of the models  


Conclusion

Our models provide diverse ideas  but that is only the starting point  Every trader needs a team to provide ideas  but also the capacity to reject suggestions that are off base 

Diversity in Ideas is a Strength  but Be Ready to Veto ",2017-01-20,Jeff Miller,"https://www.investing.com/analysis/stock-exchange:-diverse-ideas,-but-a-presidential-veto!-200173003",200173003
142514,364029,HUM,4 Trade Ideas In Humana  Bonus Idea,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Humana  NYSE HUM   stock price had moved mainly sideways for more than a year into early November  The last 3 months of that was a very tight range consolidation  It started to move higher after the election and continued until the calendar turned to December  It pulled back for 3 days  in a 3 Black Crows candlestick pattern  but quickly found support at the round figure 200  Since then it has been consolidating under resistance at 207  in an expanding triangle  That hit the 100 day SMA last week and quickly rose to the top of the range where it now sits 
A break higher would give a target to 247 on a Measured Move  Momentum indicators back a break higher  The RSI is rising and on the edge of a move back over 60 in the bullish zone  The MACD is crossed up and starting to rise into positive territory  The Bollinger Bands  are running flat though  neither supporting a move higher nor deterring it 
There is resistance above the 207 level at 217  This was also the high in May 2015  Support lower comes at 200 and 197 followed by 192 50 and 180  Short interest is low under 1   The company is expected to report earnings next on May 3rd  It pays a dividend of just over 0 5  and went ex dividend last January 10th  so is not likely to declare another until April  A positive picture in the chart 
The options chains show large open interest this week at the 200 strike and then also on the call side at 220  In March monthly options there is not much open interest built yet but what is there is spread from 190 to 200 on the put side and focused at 210 on the call side  April monthly options show the biggest open interest at the 170 put and then some at the 215 call 
May options  the first beyond the next earnings report  show the biggest open interest below the current price  at the 200 strike  Farther out  the August chain shows a large 185 215 risk reversal or strangle  while the January 2018 expiry has largest open interest at the 240 call strike  A neutral to short term bearish picture and then longer term bullish one in the options 
Humana  Ticker  HUM
Trade Idea 1  Buy the stock on a move over 207 with a stop at 198 
Trade Idea 2  Buy the stock on a move over 207 and add an April 205 190 Put Spread   6 90  for protection while selling an April 215 Call   5 30 credit  
Trade Idea 3  Buy the August 205 215 Call Spread   7 40  and sell the August 185 Put  8 20 credit  
Trade Idea 4  Buy the January 2018 Expiry 210 240 Call Spread   14 90  and sell the 190 Put   15 70 credit  
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which heading into February Options Expiration week sees the equity markets looking strong if not moving towards getting overheated 
Elsewhere look for Gold to continue in its uptrend while Crude Oil churns marking time  The US Dollar Index is looking stronger while US Treasuries consolidate in their downtrend  The Shanghai Composite and Emerging Markets both look strong and ready for more upside 
Volatility looks to remain at extremely low levels keeping the wind at the back of the equity index ETF s SPDR S P 500  NYSE SPY   iShares Russell 2000  NYSE IWM  and PowerShares QQQ Trust Series 1  NASDAQ QQQ   Their charts all look great and ready for more upside in the longer timeframe but the SPY and QQQ are getting a bit hot in the short term and may need a rest  Use this information as you prepare for the coming week and trad em well 
DISCLAIMER  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2017-02-13,Gregory W. Harmon,https://www.investing.com/analysis/4-trade-ideas-in-humana:-bonus-idea-200175536,200175536
142515,364030,HUM,Markets Finish Higher Despite March Rate Hike Hint,opinion,"U S  equities continued their march higher  with financials getting a solid boost from a rise in Treasury yields following Fed Chairwoman Janet Yellen s Congressional testimony  where the prospect of a March rate hike emerged as a possibility  Meanwhile  the U S  dollar  crude oil and gold all gained ground  On the equity front  massive merger terminations in the healthcare space dominated the headlines  while GM and PSA Group disclosed strategic initiative discussions 
The Dow Jones Industrial Average  DJIA  advanced 92 points  0 5   to 20 504  the S P 500 Index gained 9 points  0 4   to 2 338  and the NASDAQ Composite added 19 points  0 3   to 5 783  In moderate volume  813 million shares were traded on the NYSE and 1 9 billion shares changed hands on the NASDAQ  WTI crude oil increased  0 27 to  53 20 per barrel and wholesale gasoline gained  0 01 to  1 55 per gallon  Elsewhere  the Bloomberg gold spot price rose  4 62 to  1 229 88 per ounce  and the dollar index  a comparison of the U S  dollar to six major world currencies  was 0 3  higher at 101 25 
Aetna Inc   NYSE AET  126  and Humana Inc   NYSE HUM  206  announced that they have mutually ended their merger agreement following a ruling from the United States District Court for the District of Columbia granting a United States Department of Justice request to enjoin the merger  AET will pay HUM  1 0 billion as a result of the termination and AET has terminated its previously announced agreement to sell certain Medicare Advantage assets to Molina Healthcare Inc  NYSE MOH  59   AET was higher  while shares of HUM dipped 
In afternoon action  Cigna Corp   NYSE CI  147  announced that it has filed to terminate its merger agreement with Anthem Inc  NYSE ANTM  163   saying that it believes that the transaction would not be able to gain regulatory approval following the Feb 7 order from the U S  District Court for the District of Columbia too enjoin the transaction  CI also has filed suit against ANTH  seeking a reverse termination fee of  1 85 billion observed in the agreement  as well as  13 billion in damages  ANTH responded by saying that CI does not have the right to terminate the agreement and it is still committed to closing the deal  Separately  CI announced its plans to expand its share repurchase program to  3 7 billion  Shares of CI finished higher  while ANTH fell modestly 
Dr Pepper Snapple Group Inc   NYSE DPS  93  reported 4Q earnings per share  EPS  ex items of  1 04  below the  1 06 FactSet estimate  as revenues rose 2 1  y y to  1 6 billion  roughly in line with forecasts  DPS issued 2017 EPS guidance that came in below expectations  Shares were lower 
General Motors Co   NYSE GM  37  got a boost from the confirmation from privately held parent of Peugeot  PSA Group  that it is exploring numerous strategic initiatives with GM including a potential sale of GM s European business Opel to PSA  But PSA stressed that there can be no assurance that an agreement will be reached 
Fed Chief keeps March rate hike on the table
Federal Reserve Chairwoman Janet Yellen delivered the first of her two day semi annual Congressional economic and monetary policy testimony in front of the Senate Banking Committee  Yellen noted that changes in U S  fiscal and other policies are sources of uncertainty  while reiterating that waiting too long to remove accommodation would be unwise  potentially requiring the Federal Open Market Committee  FOMC  to eventually raise rates rapidly  which could risk disrupting financial markets and pushing the economy into recession 
Yellen pointed out that incoming data suggest that labor market conditions continue to strengthen and inflation is moving up to 2 percent  consistent with the FOMC s expectations  Yellen added 

At our upcoming meetings  the Committee will evaluate whether employment and inflation are continuing to evolve in line with these expectations  in which case a further adjustment of the federal funds rate would likely be appropriate 

If economic data continues to surprise on the upside  a March rate hike is likely to be on the table  while there is an additional risk that the Fed may be forced to speed up the tightening process should inflation accelerate from here 
The Producer Price Index  PPI  showed prices at the wholesale level in January were up 0 6  month over month  m m   above the Bloomberg expectation calling for a 0 3  gain and December s downwardly revised 0 2  rise  The core rate  which excludes food and energy  increased 0 4   versus forecasts of a 0 2  advance and December s downwardly revised 0 1  increase  Y Y  the headline rate was 1 6  higher  north of projections of a 1 5  increase  and the core PPI rose 1 2  last month  versus estimates of a 1 1  gain  In December  producer prices were up 1 6  for both the headline and core rates 
The National Federation of Independent Business  NFIB  Small Business Optimism Index for January ticked higher to 105 9 from December s 105 8 level  compared to forecasts calling for a decline to 105 0  This was the highest reading since December 2004 
Treasuries were lower  as the yields on the 2 year and the 10 year notes  as well as the 30 year bond  rose 3 basis points  bps  to 1 23   2 47  and 3 06   respectively 
Stocks remain at record highs  while Treasury yields and the U S  dollar continue to regain some upward momentum in the wake of Yellen s comments  While markets may exhibit increasing volatility  we believe the bull market is being supported by tangible and effective indicators of global growth 
Tomorrow  the U S  economic calendar will ramp up sharply  with the Q A session of Fed Chair Yellen s two day Congressional testimony being accompanied by MBA mortgage applications  the Empire Manufacturing Index  the Consumer Price Index  industrial production and capacity utilization  the NAHB Housing Market Index  and business inventories  However  the headlining report could be the release of January retail sales  given the importance of the consumer on domestic economic output 
The headline figure is projected to show sales ticked 0 1  higher m m  after December s 0 6  increase  Excluding autos  sales are forecasted to rise 0 4  after December s 0 2  gain  while stripping out autos and gas  sales are anticipated to show a 0 3  increase  after being flat in the prior month  The retail sales control group  a figure used in the calculation of GDP  is expected to rise 0 4   doubling December s gain 
The outlook for American consumer spending appears to be improving  with consumer confidence rising and wages ticking higher  However  spending on traditional retail items has been cautious and competition among retailers may limit profitability  resulting in our marketperform rating for the consumer discretionary sector 
Europe mixed amid data and Yellen s testimony  Asia finished lower 
European equity markets finished mixed and the Stoxx Europe 600 Index was little changed after a five session winning streak  Traders digested some equity and economic data  along with today s Congressional testimony from U S  Fed Chief Janet Yellen  where she kept the possibility of a March rate hike on the table  The global markets have rallied as of late as sentiment has shifted to optimism regarding U S  President Donald Trump s reflationary polices from concerns about trade and immigration  Also  the markets have shrugged off festering political uncertainty in the region ahead of some key elections 
Eurozone 4Q GDP growth slightly missed expectations  while UK consumer price inflation fell to weigh on the British pound  The euro was lower as the U S  dollar reversed to the upside on Yellen s comments  while bond yields in the region gained ground 
Stocks in Asia finished lower following the recent global market rally on resurfaced optimism of U S  President Trump s reflationary policies that has taken some of the focus off of exacerbated trade and immigration concerns  The markets were cautious ahead of today s beginning of U S  Fed Chair Yellen s Congressional testimony  Japanese equities fell  with the yen regaining some of yesterday s drop  while stocks in China and Hong Kong both finished flat amid lingering liquidity uncertainty and as traders digested hotter than expected reads on January consumer and wholesale price inflation figures  After the closing bell  China reported mixed lending statistics for last month 
Elsewhere  securities traded in Australia and South Korea declined  while India s market finished little changed in the wake of yesterday s hotter than anticipated wholesale price inflation report  which added credence to last week s decision by the Reserve Bank of India s to move to a neutral monetary policy stance from its previous accommodative position 
Unlike the U S   tomorrow s international economic calendar will be fairly light and include consumer sentiment from Australia  CPI from Spain  employment data from the UK and the Eurozone s trade balance ",2017-02-15,Marvin Clark,https://www.investing.com/analysis/markets-finish-higher-despite-march-rate-hike-hint-200175720,200175720
142542,364057,HUM,Rate Hike Possible,opinion,"Federal Reserve Vice Chair Stanley Fischer spoke in Chile this morning at a central bank conference  in which he said the case for removing accommodation  raising interest rates  is  quite strong   He said he is optimistic a rate hike would be manageable abroad  and that a stronger U S  economy should help other countries 
	Fischer also said that  over time  rates can be expected to plateau at lower levels than normal  Which would mean the vice chair does not expect inflation nor interest rates to run out of control in the months and years ahead 
	These statements come even after we all absorb the initial plans from President elect Trump   borrowing for massive infrastructure spending  which is innately inflationary  That Fischer still looks toward modest growth domestically overall may say something about the larger scope of the U S  economy over the next year or two 
	This would tend to lead to a discussion over expected tariffs with foreign nations the U S  does lots of trading with  Take China  for instance   if goods manufactured there are suddenly faced with big import costs  that country s government may  more than  may   choose to make it harder for Amazon  NASDAQ AMZN   or Facebook  NASDAQ FB   to make inroads there 
	Meaning growth in some sectors like construction and materials looks to essentially be transferred from others like technology  Not to say the U S  economy is a zero sum game   historically  it definitely is not   but that gangbusters growth in all industries for the dawning of the Trump Era is not very realistic 
	After the bell Thursday  Disney  underperformed Q3 earnings estimates on both top and bottom lines  Earnings per share of  1 10 missed the consensus by 5 cents and fell 8  year over year  whereas  13 14 billion in revenues was lower than the  13 47 billion expected  Declining subscriber numbers in the company s ESPN division looks to have played a big part in the miss 
	That said  the entertainment conglomerate is bullish on digital bundle offerings in the future  and CEO Michael Iger said he intends to  look expansively  at  opportunities to create more value  for Disney  What might this mean  Dare we speculate Disney buying Twitter  might help synergies between bolstering ESPN and utilizing the troubled social media company s algorithmic value  Or  keeping the Trump initiatives in mind  would Disney do better investing in raw materials for building a giant wall 
	In other earnings highlights  Humana  NYSE HUM   posted solid Q3 numbers and upwardly revising guidance  hitting a new 52 week high in the process  AstraZeneca  saw sales slow in its Q3  but earnings beat estimates in the quarter  JCPenney  posted another quarterly loss  but narrower than expected ",2016-11-10,Zacks Investment Research,https://www.investing.com/analysis/rate-hike-possible-200164229,200164229
142543,364058,HUM,Humana Partners DaVita Unit To Enhance MA Plans In Florida,opinion,Humana Inc    NYSE HUM   recently joined forces with JSA Medical Group to add one primary care practice to its Florida Medicare Advantage  MA  Plan Networks  JSA Medical Group is a unit of DaVita Inc   DVA   Notably  the companies had teamed up last year as well to provide better healthcare to Humana s MA beneficiaries residing in Florida  Presently  Humana s MA members have access to total three JSA Medical Group practices in Florida  including the new location in Sarasota and the two existing ones in Bradenton The new practice  is operated by JSA Medical Group and accepts certain MA plans administered only by Humana  However  it will now accept traditional Medicare as well JSA Medical Group is renowned for its unique coordinated care approach  The entity brings together primary care providers  specialists and professional staff to provide individualized care to patients and improve their overall health  Hence  teaming up with JSA Medical Group would enable Humana to keep pace with the rapidly changing healthcare needs of customers Humana forms these value based relationships to strategically transform healthcare through more proactive and patient centric high quality medical assistance With the addition of this new practice  Humana is expected to be able to render high quality care  The company also aims to increase patients  ability to manage their own care and understand the requirements for their health and well being  Collectively  Humana and JSA Medical Group aim to provide premium healthcare to patients in Florida Humana boasts a solid Medicare history  In 2015  Humana s MA members served by physicians under value based care arrangements experienced 6  fewer Emergency Room  ER  visits  higher screening rates and healthier outcomes than those served by physicians with MA plans of other providers  At the end of the third quarter of 2016  Humana had 1 8 million individual MA members and 0 2 million commercial members  who were cared for by 0 05 million primary care providers in more than 900 value based relationships across 43 states and Puerto Rico  As of Sep 30  2016  nearly 63  of Humana s individual MA members are in value based payment relationships  The company expects 75  individual MA members to be enrolled in the value based payment models by the end of 2017 HUMANA INC NEW Price    Humana remains committed to help its members achieve optimal health by providing innovative and value added solutions that cater to customers  changing healthcare needs  This is a proactive approach by the company to spread awareness about health amongst its members  This reduces the incidence of severe sickness  which consequently keeps claims cost at bay and supports margin expansion  Humana presently carries a Zacks Rank  2  Buy  However  the company has been witnessing a rise in healthcare costs due to rapid growth of the aging population and increased life expectancy  Year to date  the stock has gained 16 45   which is much lower than 19 18  gained by the Zacks categorized Health Maintenance Organization Industry Other Stocks to ConsiderInvestors can also look at other well ranked medical sector stocks like WellCare Health Plans Inc    NYSE WCG    Magellan Health Inc    NASDAQ MGLN   and UnitedHealth Group Inc    NYSE UNH  WellCare sports a Zacks Rank  1  Strong buy   You can see   The company delivered positive surprise in the last four quarters with an average beat of 40 01 Magellan delivered positive surprise in three of the last four quarters with an average beat of 42 58   It also sports a Zacks Rank  1 UnitedHealth carries a Zacks Rank  2   The company delivered positive surprises in all the last four quarters with an average beat of 3 86  The Best Place to Start Your Stock SearchToday  you are invited to download the full list of 220 Zacks Rank  1  Strong Buy  stocks   absolutely free of charge  Since 1988  Zacks Rank  1 stocks have nearly tripled the market  with average gains of  26  per year  Plus  you can access the list of portfolio killing Zacks Rank  5  Strong Sells  and other private research ,2016-11-28,Zacks Investment Research,https://www.investing.com/analysis/humana-partners-davita-unit-to-enhance-ma-plans-in-florida-200167131,200167131
142544,364059,HUM,Zacks com Featured Highlights  Edgewell Personal Care  Cambrex  Humana  Research Frontiers And Galena Biopharma,opinion,"For Immediate Release

	Chicago  IL   November 29  2016   Stocks in this week s article include Edgewell Personal Care Company  NYSE      Cambrex Corporation  NYSE      Humana Inc  NYSE HUM    NYSE      Research Frontiers Inc   NASDAQ     and Galena Biopharma Inc   NASDAQ      

Screen of the Week of Zacks Investment Research 

Bet on Stocks with Rising P E to Enjoy Growing Gains

	Betting on bargain stocks that have a low price to earnings  P E  ratio is a convenient investment approach  The perception is that the lower the P E  the higher is the value of the stock  This inference is drawn on the simple logic that a stock s current market price does not justify  is not equivalent to  its higher earnings and therefore has room to run 

	But have you ever given it a thought that stocks with a rising P E can also be worth buying  We ll tell you why 

Why Rising P E a Valuable Tool 

	Investors should note that stock price moves in tandem with earnings performance  If earnings come in stronger  the price of a stock shoots up  Solid quarterly earnings and the forward guidance boost earnings forecasts  leading to stronger demand for the stock and an uptrend in its price 

	So  if the price is rising steadily  it means that investors are assured of the stock s fundamental strength and expect some strong positives out of it  Suppose an investor wants to buy a stock with a P E ratio of 30  it means that he is willing to shell out  30 for only  1 worth of earnings  This is because the investor expects earnings of the company to rise at a faster pace in the future on the back of strong fundamentals 

	Also  studies have revealed that stocks have seen their P E ratios jump over 100  from their breakout point in the cycle  So  if you can pick stocks early in their breakout cycle  you can end up seeing considerable gains 

The Winning Strategy

	In order to shortlist stocks that are exhibiting an increasing P E  we chose the following as our primary screening parameters 

EPS growth estimate for the current year is greater than or equal to last year s actual growth

Percentage change in last year EPS should be greater than or equal zero

	 These two criteria point to flat earnings or a growth trend over the years  

Percentage change in price over four weeks greater than the percentage change in price over 12 weeks

Percentage change in price over 12 weeks greater than percentage change in price over 24 weeks

	 These two criteria show that price of the stock is increasing consistently over the said timeframes  

Percentage price change for four weeks relative to the S P 500 greater than the percentage price change for 12 weeks relative to the S P 500 

Percentage price change for 12 weeks relative to the S P 500 greater than the percentage price change for 24 weeks relative to the S P 500 

	 Here  the case for consistent price gains gets even stronger as it displays percentage price changes relative to the S P 500  

Percentage price change for 12 weeks is 20  higher than or equal to the percentage price change for 24 weeks  but it should not exceed 100  

	 A 20  increase in the price of a stock from the breakout point gives cues of an impending uptrend  But a jump of over 100  indicates that there is limited scope for further upside and that the stock might be due for a reversal  

	In addition  we place a few other criteria that lead us to some likely outperformers 

Zacks Rank less than or equal to 2  Only companies with a Zacks Rank  1  Strong Buy  or 2  Buy  rating can get through  You can see     

Average 20 day Volume greater than or equal to 50 000    High trading volume implies that the stocks have adequate liquidity 

	Just these few criteria narrowed down the universe from over 7 700 stocks to just 39 

	Here are five out of the 39 stocks 

Edgewell Personal Care Company   NYSE          This is a personal care products company with aZacks Industry Rank in the top 33   The stock has a Zacks Rank  1 

Cambrex Corporation   NYSE          This is a manufacturer of specialty chemicals presently sporting a Zacks Rank  1  The Zacks Industry Rank is in the top 28  

Humana Inc    NYSE          This health services company carries a Zacks Rank  2  The Zacks Industry Rank is in the top 37  

Research Frontiers Inc    NASDAQ          The Zacks Rank  2 company is into the development of suspended particle technology and devices  The Zacks Industry Rank is in the top 14  

Galena Biopharma Inc    NASDAQ          It is a biopharmaceutical company  It has a Zacks Industry Rank in the top 28   The stock has a Zacks Rank  2 

	You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge 

	The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 

  

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  

Disclosure  Performance information for Zacks  portfolios and strategies are available at     

Zacks Restaurant Recommendations    In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector  

	Sign up now for your free trial today and start picking better stocks immediately  And with the backtesting feature  you can test your ideas to see how you can improve your trading in both up markets and down markets  Don t wait for the market to get better before you decide to do better  Start learning how to be a better trader today  

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material 

About Screen of the Week 

	Zacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine  But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use  Each week  Zacks Profit from the Pros free email newsletter shares a new screening strategy  Learn more about it here 

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

 

 

 

 

 

	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Contact  Jim Giaquinto
	Company  Zacks com
	Phone  312 265 9268
	Email  

	Visit  

	Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer    

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-11-28,Zacks Investment Research,"https://www.investing.com/analysis/zacks.com-featured-highlights:-edgewell-personal-care,-cambrex,-humana,-research-frontiers-and-galena-biopharma-200167117",200167117
142545,364060,HUM,UnitedHealth   CVS Pharmacy Partner To Improve Healthcare,opinion,In keeping with the intention to provide convenient and low healthcare option to customers  UnitedHealth Group Inc  s   NYSE UNH   pharmacy care services business   OptumRx   recently joined forces with CVS Pharmacy This partnership will strengthen the existing relationship between these two as traditional pharmacy network partners  Also  the deal ensures a new pharmacy network solution for employers  Under this new network  eligible OptumRx members can avail 90 day prescriptions at the same price as home delivery co pay levels offered at all CVS locations across the nation or OptumRx home delivery  The involved companies expect the new 90 day pharmacy solution to be available to OptumRx commercial clients opting for the latest 90 day prescription benefit designs  The new solution will be available from Jul 1  2017 With this strategic alliance  both OptumRx and CVS pharmacy will be able to operate on a common pharmacy platform and introduce new pharmacy  health and wellness programs by integrating their capabilities  This partnership is also likely to enhance consumer engagement with better health outcomes for both companies CVS Pharmacy is the retail division of CVS Health  NYSE CVS  Corporation   one of the leading retail pharmacies of the U S with more than 9 600 retail pharmacies nationwide  Hence  the aforesaid partnership will highly benefit OptumRx with CVS Pharmacy s leading in store health and wellness capabilities UNITEDHEALTH GP Price    UnitedHealth remains committed to help its members achieve optimal health by providing innovative and value added solutions that cater to customers  changing healthcare needs  Hence  the deal with CVS Pharmacy will open up immense opportunities for OptumRx and further innovate and modernize its healthcare services UnitedHealth s regular product upgrades and innovations have helped it retain investors  confidence  Year to date  the stock has gained 33 96   which is much higher than 18 44  gained by the Zacks categorized Health Maintenance Organization Industry UnitedHealth presently carries a Zacks Rank  3  Hold  Other Stocks to ConsiderInvestors can also look at other well ranked medical sector stocks like WellCare Health Plans Inc    NYSE WCG    Magellan Health Inc    NASDAQ MGLN   and Humana Inc    NYSE HUM  WellCare sports a Zacks Rank  1  Strong Buy   You can see   The company delivered positive surprise in the last four quarters with an average beat of 40 01 Magellan delivered positive surprise in three of the last four quarters with an average beat of 42 58   It also sports a Zacks Rank  1 Humana carries a Zacks Rank  2   The company delivered positive surprises in three of the last four quarters with an average beat of 1 94  Zacks  Top Investment Ideas for Long Term ProfitHow would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ,2016-11-29,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth---cvs-pharmacy-partner-to-improve-healthcare-200167488,200167488
142546,364061,HUM,Will Trump Era Mean Disaster For Health Insurers ,opinion,Wednesday  December 7  2016One of the biggest campaign promises made by President elect Donald Trump was the dismantling and replacing of Obamacare  officially known as the Affordable Care Act  or ACA   the signature legislation passed through Congress and enacted during President Obama s two terms in office  Health insurance companies provided a major overhaul of their business plans to comply  and now they look to be put on a new road forward So yesterday  in lieu of an actual replacement policy being made public as of yet  healthcare insurance companies have put forward a list of ACA benefits they do not want to see removed  if when Obamacare is officially taken apart  First is a commitment to offset some healthcare costs for low income Americans  They also consider young people signing up for health insurance is crucial to keeping costs low for the companies Already tough sledding for insurers to provide appropriate care for its customers  without these provisions made by the incoming administration   and Trump and his team have been mum on this issue to this point   insurers will be abandoning the system en masse  and complete failure of the ACA would eventually amount to more than 22 million Americans currently insured for healthcare thrown out into the cold Healthcare insurers   including the Zacks Rank  2  Buy  Humana   NYSE HUM    The Joint Corp   NASDAQ JYNT   and WellCare   NYSE WCG     do not want this to happen  But America s Health Insurance Plans  a leading industry trade group  and presumably the Blue Cross Blue Shield Association  which has not yet issued a public statement on this matter  are concerned about dire consequences in the industry should the ACA be removed without a suitable replacement  At very least  the organizations would like three years to re set the table for their businesses and their shareholders With tens of millions of new customers on the rolls  health insurers are in no mood to go back to the way things were  Yet what course the new law   assuming there is one   takes going forward will have major consequences on the  4 2 trillion Health Care industry Mark VickerySenior Editor,2016-12-06,Zacks Investment Research,https://www.investing.com/analysis/will-trump-era-mean-disaster-for-health-insurers-200168715,200168715
142561,364076,HUM,Cigna  CI  Beats Earnings And Revenue Estimates In Q3,opinion,"Cigna Corp    NYSE CI   reported third quarter 2016 operating net earnings of  1 94 per share  which surpassed the Zacks Consensus Estimate of  1 91  However  earnings declined 15  year over year Revenues of  9 81 billion  surpassed the Zacks Consensus Estimate of  9 79 billion and grew 4 5  year over year Premiums of  7 6 billion increased 3 5  year over year  while mail order pharmacy revenues increased 18 5   Total Medical Customers totaled 15 2 million as of Sep 30  2016 Cigna s global medical customers were 15 2 million  up 2 2  from 14 8 million members in the year ago quarter  The improvement was driven by organic growth in Middle Market  Select and International markets Quarterly Review by Segment Premiums and fees from the Global Health Care segment increased 3  year over year to  6 81 billion  Customer growth  specialty contributions  and rate actions in the company s Commercial employer group drove the upside  However  the increase was partially offset by reductions in Medicare Part D and Individual customers  Operating earnings were  416 million  down 13 7  year over year  The company narrowed is adjusted income from operations expectation to the range of  1 84 billion to  1 87 billion from the previous expectation of  1 9 billion to  1 93 billion  Premiums and fees from Cigna s Global Supplemental Benefits climbed 9 5  year over year to  833 million and reflected the value created by affordable and personalized solutions delivered to individual consumers  Operating income increased 30 6  year over year to  81 million  reflecting business growth and strong operating expense discipline  The company expects adjusted income from operations in the range of  275  285 million compared with the previous expectation of  255 million to  275 million The Global Disability and Life segment s premiums and fees also increased 4 5  year over year to  1 02 billion  primarily driven by consistent strong persistency and new sales  The segment posted operating earnings of  53 million compared with  84 million in the year ago quarter  For 2016  adjusted income from operations is expected in the range of  80 110 million compared with the previous expectation of  40  80 million 2016 GuidanceCigna updated its 2016 earnings guidance  It expects earnings per share in the range of  7 80 to  8 05 and mid single digit growth in revenue  The company expects global medical customer growth in a low single digit percentage range CIGNA CORP Price  Consensus and EPS Surprise   Zacks Rank and Performance of Other Insurers Currently  Cigna carries a Zacks Rank  3  Hold   You can see Among the other health insurers that have reported their third quarter earnings so far  the bottom line at UnitedHealth Group Inc    NYSE UNH    Humana Inc    NYSE HUM   and Aetna Inc    NYSE AET   beat their respective Zack Consensus Estimate 
Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-02,Zacks Investment Research,https://www.investing.com/analysis/cigna-(ci)-beats-earnings-and-revenue-estimates-in-q3-200162636,200162636
142562,364077,HUM,Humana  HUM  Earnings  Revenues Beat Estimates In Q3,opinion,"Humana Inc  s   NYSE HUM   third quarter 2016 operating earnings per share of  3 18 beat the Zacks Consensus Estimate of  3 06 roughly by 4   The bottom line also improved 41  year over year on solid performance across all business lines except the individual commercial business 
Operational Update
Revenues inched up 2  year over year to  13 7 billion  The bottom line also surpassed the Zacks Consensus Estimate by 2 2   Growth in higher premiums and services revenues contributed to top line growth Humana s consolidated benefit ratio   the percentage of benefit expenses in premium revenues   was 81 5   This marks an improvement of 240 basis points  bps  year over year  Lower utilization of Humana s Medicare Advantage business as well as favorable comparisons for prior period development primarily drove the upside 
Consolidated operating cost ratio deteriorated 10 bps year over year to 12 8   This was mainly due to higher operating cost ratio in both Retail and Group segments 
Segment ResultsRetail Segment
The segment s reported premiums and services revenues increased 4  year over year to  11 76 billion on higher revenues due to an increase in average membership 
Benefit ratio came in at 83 1   improved 300 bps over the prior year quarter owing to lower year over year Medicare Advantage utilization and favorable comparisons of Prior Period Development Operating cost ratio of 11 1  deteriorated 20 basis points year over year due to the unusually low operating expenses incurred in the last year quarter resulting from the temporary suspension of certain administrative costs and the previously disclosed loss of the large group Medicare Advantage account 
Adjusted pretax income for the segment was  652 million  up 96  year over year  Control on expenses supported the increase Group Segment
Reported premiums and services revenues dipped 2  to  1 79 billion  primarily due to reduced medical membership in average fully insured and ASO commercial group  However  an increase in fully insured group medical per member premiums limited the downside 
Benefit ratio was 82 7   worsen 30 bps year over year due to the greater negative impact of slightly higher utilization in comparison to the same in the last year quarter 
Operating cost ratio was 24 1  in 3Q 2016  deteriorated 70 basis points from the prior year quarter again due to the comparison to unusually low operating expenses in the prior year
Adjusted pretax income for the segment was  12 million  down 71  year over year  due to higher benefit expenses and operating costs 
Healthcare Services
Revenues of  6 35 billion increased 8  year over year  driven by growth in individual Medicare Advantage and stand alone PDP membership  This resulted in increased engagement of members in clinical programs and higher utilization of the Healthcare Services businesses Operating cost ratio was 95 1   worsen 40 bps year over year 
Adjusted pretax income for the segment was  299 million  up 1  year over year 
HUMANA INC NEW Price  Consensus and EPS Surprise
   Financial UpdateAs of Sep 30  2016  cash  cash equivalents and investment securities of Humana were  16 37 billion  up 40  from  11 68 billion as of Dec 31  2015 
Debt to total capitalization as of Sep 30  2016 was 26    down 70 bps on a  sequential basis from 27 3  
Adjusted cash flows from operations as of Sep 30  2016 was  1 50 billion  42  higher than the prior year quarter  Higher earnings and beneficial working capital changes drove the upside Share Repurchase and Dividend UpdateHumana suspended its share repurchase program on Jul 2  2015 due to the pending acquisition by Aetna 
Notably  the company s board of directors approved a new  2 billion share repurchase plan with an expiration date of Dec 31  2016 
Humana presently has approximately  1 04 billion of the current  2 billion repurchase authorization remaining Humana paid cash dividend worth  43 million in the third quarter 2016 Guidance Revised
For 2016  Humana expects adjusted earnings per share to be approximately  9 50 
Consolidated revenues are expected to be approximately  55 billion as against  54 0  54 5 billion guided earlier 
Benefit ratios for Retail segment is now projected within the 84 75  85 25  range compared with the prior guidance of 85 86   The metric for the Group segment is guided within the 79 75 80 25  band as against from prior guidance of 79 5 80 5  Guidance for consolidated operating cost ratio is reiterated at the range of 13 0  to 13 5  Expected net membership growth in individual Medicare Advantage is reiterated in the range of 75000 90000 and the membership in stand alone PDP offerings is expected in the range of 400 000 to 425 000 
Membership in group Medicare Advantage is estimated to be between 125 000 and 130 000 as against the prior guidance of between 120000 and 125000  On the other hand  individual commercial membership is again expected in the range of  200 000 to 300 000 
Guidance for 2017
The company anticipates pretax income for 2017 to be driven primarily by improved operating performance in its individual Medicare Advantage and Healthcare Services businesses  It also expects lower losses in its Individual Commercial business to boost income 
Humana also anticipates a benefit of approximately  2 20 per diluted share due to a lower effective tax rate 
The company projectes net reductions for individual Medicare Advantage of approximately 70 000 members associated with plans no longer offered for 2017 
Humana s Individual Commercial premiums associated with ACA compliant offerings are now projected to be in the range of  1 billion to  1 25 billion in 2017 compared with approximately  3 4 billion in 2016 Zacks RankHumana currently carries a Zacks Rank  2  Buy   You can see  
Among the other firms in the medical sector that have reported their third quarter earnings so far  the bottom line at Aetna Inc    NYSE AET    Molina Healthcare Inc   NYSE MOH   and UnitedHealth Group Inc    NYSE UNH   beat their respective Zacks Consensus Estimates Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-04,Zacks Investment Research,"https://www.investing.com/analysis/humana-(hum)-earnings,-revenues-beat-estimates-in-q3-200162919",200162919
142563,364078,HUM,Humana s  HUM  Q3 Earnings  Revenue Beat Estimates,opinion,Humana Inc    NYSE HUM   is one of the largest health care plan providers in the United States  The company s takeover by Aetna Inc  NYSE AET   is a much awaited and closely watched event in the health insurance space  The acquisition is due in the second half of 2016  The agreement has been unanimously approved by the board of directors of both companies  The combined entity is expected to be the second largest managed care company in the U S At present Humana s core operations include the provision of health insurance benefits under Health Maintenance Organization  HMO   Private Fee For Service  PFFS   and Preferred Provider Organization  PPO  plans  The company also provides other benefits with specialty products including dental  vision  and other supplementary benefits  Humana capitalizes on its established Accountable Care arrangement to provide its Medicare Advantage  MA  members with quality care at an affordable price    Currently  Humana has a Zacks Rank  2  Buy   but that could definitely change following its earnings report which was just released  You can see  We have highlighted some of the key stats from this just revealed announcement below Earnings  Humana surpassed our earnings estimate  Our consensus called for EPS of  3 06  and the company reported EPS of  3 18 HUMANA INC NEW Price and EPS Surprise   Revenue  Revenues also beat our estimates  Our consensus called for revenues of  13 4 billion  and the company reported revenues of  13 7 billion Key Stats to Note Benefit ratio decreased 240 basis points to 81 5  in the quarter  Operating cost ratio increased 10 basis points to 12 8  Cash flows from operations totaled  1 47 billion  which compared favorably to cash flow from operations of  1 billion in the year ago quarter The company raised its 2016 adjusted EPS guidance to at least  9 50 Check back later for our full write up on this HUM earnings report later Confidential from ZacksBeyond this Tale of the Tape  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-04,Zacks Investment Research,"https://www.investing.com/analysis/humana's-(hum)-q3-earnings,-revenue-beat-estimates-200162791",200162791
142564,364079,HUM,Cigna  CI  Poised For Growth Despite Regulatory Hurdles,opinion,"On Nov 7  we updated our research report on CIGNA Corp    NYSE CI    The company s third quarter 2016 consolidated revenue increased 5  year over year to  9 9 billion  It reported adjusted income from operations of  503 million or  1 94 per share  reflecting strong performance in its Commercial Health Care and Global Supplemental Benefits business lines and improving results in its Group Disability and Life segment The company is consistently making investments in value based care programs and incentive payment models to provide quality care at affordable cost  It tries to achieve this via collaborative accountable care  CAC  arrangements  It has 160 such arrangements in place across 29 states  serving over two million customers  Its CAC initiatives have also helped in controlling medical cost Also  the company s Global Health Care and Global Supplemental Benefits businesses are performing strongly with high customer retention levels and solid revenue and earnings growth Cigna has been growing it membership for the past many quarters  The company ended the third quarter with more than 15 2 million medical members  up 2 2  year over year  We expect a rise in membership going forward  driven by organic growth in Cigna s Middle Market  International  Select  and Medicare segments  For 2016  the company expects global medical membership to increase in the low single digit percentage range CIGNA CORP Price and Consensus

   Nevertheless  the company faces a ban on selling private Medicare plans this enrollment season because of an investigation by U S  regulators  The ban was imposed because the company was found guilty of non compliance with rules relating to Medicare policies The company has also been sued by the Justice Department over its acquisition by Anthem Inc    NYSE ANTM   Cigna carries a Zacks Rank  3  Hold   Other health insurers that have reported better than expected third quarter earnings like Cigna include UnitedHealth Group Inc    NYSE UNH   and Humana Inc    NYSE HUM   both with a Zacks Rank  2  Buy   You can see  
Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-07,Zacks Investment Research,https://www.investing.com/analysis/cigna-(ci)-poised-for-growth-despite-regulatory-hurdles-200163275,200163275
142566,364081,HUM,Humana  HUM  Partners With MDLIVE  Improves MA Plans,opinion,Humana Inc    NYSE HUM   recently joined forces with MDLIVE  a renowned telemedicine services and software provider  to improve its Medicare Advantage  MA  plans in Georgia  The alliance mainly aims to provide virtual access to doctors in selected counties across Georgia and South Carolina to the Medicare beneficiaries of Humana  MDLIVE s board certified doctors are already known for catering to patients  needs and hence  the alliance will benefit Humana s MA members  This is the first year of telemedicine benefit offered on Humana s Regional Medicare Advantage PPO plans in the concerned counties This telemedicine benefit will be added to certain MA plans of Humana that are to be offered in 2017  Notably  Humana offered this benefit on a few plans in 2016 as well and received immense appreciation from its members  Members opting for these special plans will gain access to doctors through computers  telephones or mobile devices  The doctors can be contacted for numerous non emergency conditions as well with the appropriate co pay for each visit With this telemedicine benefit  doctors can now be easily reached even beyond their scheduled working hours  People who have difficulties in travelling due to illness can also gain access to doctors by enrolling into these special MA plans However  the telemedicine benefit will not be applicable for emergency situations or chronic conditions like heart disease or diabetes  The telemedicine benefit also does not substitute an in person visit with a primary care physician or other provider  Nonetheless  the restrictions on healthcare and prescription services offered by the telemedicine benefit differ according to the concerned state Humana s clinical data technology ensures that individual health records remain available to the MDLIVE physicians  network  The MDLIVE clinicians  prescribed treatment will also be shared with the members  primary care physicians to maintain transparency at both ends  Existing Medicare members may choose the plans between Oct 15 and Dec 7  2016  the annual Medicare Advantage and Prescription Drug Plan enrollment period  Those that opt for the plan with telemedicine benefit will be eligible to start using the service from Jan 1  2017 Humana remains committed to helping its members achieve optimal health by providing innovative and value added solutions that cater to customers  changing healthcare needs  We note that growing enrollment  drove the company s solid results in third quarter 2016  Humana presently carries Zacks Rank  2  Buy   You can see  HUMANA INC NEW Price    Other Stocks to ConsiderInvestors can also look at other well ranked medical sector stocks like WellCare Health Plans Inc    NYSE WCG    UnitedHealth Group Inc    NYSE UNH   and Infinity Pharmaceuticals Inc    NASDAQ INFI   WellCare sports a Zacks Rank  1  The company delivered positive surprise in the last four quarters with an average beat of 40 01 Another Zacks Rank  1 medical sector stock is Infinity Pharma  The company delivered positive surprises in each of the last four straight quarters with an average beat of 67 62  UnitedHealth carries a Zacks Rank  2   The company delivered positive surprises in all the last four quarters with a average beat of 3 86  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-07,Zacks Investment Research,"https://www.investing.com/analysis/humana-(hum)-partners-with-mdlive,-improves-ma-plans-200163462",200163462
142569,364084,HUM,After Obamacare  How Will TrumpCare Treat Insurers ,opinion,"Now that the presidency of Donald Trump is certain  Obamacare is shrouded in uncertainty  In any case  Trump s intention of repealing this law was clear from the very beginning  The Healthcare Reform Act  which was formed in 2010 by Barack Obama faced constant friction since its inception  This time  it is being opposed by the President elect himself The sense of urgency to replace the law was evident in Trump s comment in the final week of his campaign  He had declared   We will do it  and we will do it very  very quickly  It is a catastrophe  Trump proposed to repeal and replace Obamacare with Health Savings Accounts  HSAs  and a series of offers encouraging free market competition  These include encouraging the sale of insurance policies across state lines  and making individual health insurance premium payments fully tax deductible Trump is however  favoring one key mandate of the law which prohibits insurers from refusing coverage to people with preexisting medical problems or from over charging them  Though some of the changes proposed by Trump will encourage healthy competition among health insurers  the proposal to cover patients with a preexisting condition will be a major hurdle 
Insurers have already said that covering preexisting diseases turns out costly for them unless healthy patients enroll en masse to offset the cost of insuring the sick population  which can only be achieved by an individual mandate  a feature of Healthcare Reform the Trump wants to undo Reaction of InsurersStocks of the insurers had a mixed reaction to the outcome  While insurer Aetna Inc    NYSE AET   and Humana Inc    NYSE HUM   gained on hopes that the new governance will help them through the merger  other players such as Cigna Corp    NYSE CI   UnitedHealth Group Inc    NYSE UNH   carrying a Zacks Rank   2  Buy   Centene Corp    NYSE CNC   and Molina Healthcare Inc    NYSE MOH   suffered  You can see  Medical   HMOs Industry Price Index

Will a Repeal Be Easy Modifying Obamacare will bring its own set of woes  It is likely to raise the number of Americans without insurance by 24 million and increase the deficit by  353 billion over 10 years  according to a report by the Congressional Budget Office How Did Insurers Fare Under Obamacare Obamacare was one of the most sweeping changes experienced by the health care industry  Its numerous provisions put a bridle on the players and changed the face of the industry  After opposing vehemently to the law initially  the players somehow embraced it  This resulted in significant modifications to their business that included new product launches  geographical diversification  growing ancilliary business  and resorting to mergers and acquisitions These business changes led to additional cost of investment  This was offset by an increase in revenues that came on the back of membership growth as a result of individual mandate  which forced the uninsured to get insurance cover Now  after sharing space with Obamacare for six years  insurers will have to start afresh to comply with the sea change that TrumpCare will bring  We wait to see  how they fare under the changed regulation 
Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more     ",2016-11-10,Zacks Investment Research,"https://www.investing.com/analysis/after-obamacare,-how-will-trumpcare-treat-insurers-200163999",200163999
142572,364087,HUM,Humana Hits 52 Week High On Solid Q3 Results  Revised View,opinion,On Nov 10  2016  shares of Humana Inc    NYSE HUM   hit a 52 week high of  194 05 driven by strong third quarter 2016 results  About 3 5 million shares exchanged hands in the last trading session and the stock finally closed at  192 88  down 0 52  The stock price appreciation was fueled by the company s robust quarterly earnings of  3 18per share that surpassed the Zacks Consensus Estimate by 4   The bottom line also improved 41  year over year on solid performance across all business lines except the individual commercial business  Revenues inched up 2  year over year to  13 7 billion primarily driven by higher premiums and services revenues growth  A better control on benefit expenses also resulted in a 240 basis points improvement in Humana s benefit expense ratio The investors were also thrilled by Humana s guidance raise following third quarter earnings outperformance  The company now expects adjusted earnings per share to be approximately  9 50 and consolidated revenues to be approximately  55 billion as against  54 0  54 5 billion guided earlier  For 2017  the company anticipates higher pre tax income  primarily due to improved operating performances by its individual Medicare Advantage and Healthcare Services businesses Investors also view favorably  Humana s Medicare Advantage business which has been delivering strong results for quite some time now  This consistently impressive performance has been supported by operating initiatives that have contributed to better medical claims development and lower current year utilization  As a result  the company has raised its guidance for membership growth in group Medicare Advantage and now estimates it between 125 000 and 130 000 as against the prior guidance of 120000 to 125000 Notably  the company delivered an average positive surprises in three of the last four quarters with an average beat of 1 94   Based on the earnings outperformance  the Zacks Consensus Estimate for 2016 and 2017 has been revised upward by 0 7  and 0 3   respectively  over the last seven days The shares of Humana also must have received a fillip from the new governance featuring the Presidency of Donald Trump  on hope that it will help the company sail through the merger with Aetna Inc    NYSE AET    Along with Humana and Aetna  other medical sector companies like Anthem Inc    NYSE ANTM    UnitedHealth Group Inc    NYSE UNH   to name a few are also counting on a better future under the leadership of the new president HUMANA INC NEW Price and Consensus    Zacks RankHumana presently carries Zacks Rank  2  Buy   You can see  Zacks  Top Investment Ideas for Long Term ProfitHow would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ,2016-11-10,Zacks Investment Research,"https://www.investing.com/analysis/humana-hits-52-week-high-on-solid-q3-results,-revised-view-200164145",200164145
142591,364106,HUM,Health Insurers Seek Growth Via New Business  Cost Control,opinion,"Amid global economic volatility  the U S  health insurance industry provides investors a level of defense thanks to the high degree of its domestic business exposure  Players like Cigna Corp  NYSE CI    CI   UnitedHealth Group Inc  NYSE UNH    UNH   Centene Corp   CNC  and Aetna Inc  NYSE AET    AET  with business in international markets also have limited exposure  accounting for 3   4   1  and 0 5  of revenues  respectively 
The sole factor that has shaken the healthcare industry and changed it wholly is the Health Care Reform or Obamacare  enacted in Mar 2010  Though initially intensively lobbied against by the players  health care reform did not turn out as worse as expected  Despite the share of headwinds that the reform brought  it has helped the companies to grow their top line by increasing membership 
Total revenues of the top eight players  UnitedHealth  Aetna  Cigna  Molina Healthcare  MOH   Centene  WellCare Health Plans  Inc   WCG   Anthem Inc   ANTM  and Humana  Inc   HUM  increased to  437 billion in 2015 from  383 billion in 2014 with medical enrollment rising to 150 million in 2015 from 145 million in the prior year  Along with posting strong operating numbers  most of the players guided strong earnings for 2016  pointing to the fact that despite hurdles  the industry presents enough growth opportunities  
Now  after sharing the space with Obamacare for almost six years  insurers have embraced the law  Most of the players are now looking for newer avenues to expand their business  They are reassessing their business model from the perspective of product  pricing  risk management  distribution and claims to fraud management for a realistic pace of growth Let s discuss some of the opportunities provided by the changing industry landscape Higher Enrollment   Higher Revenues
Thanks to ObamaCare  the nation s uninsured rate has gone down to single digits  Before ACA  around 47 million lacked health coverage  Current data shows that the uninsured rate is around 9   According to an ongoing NHIS CDC study  the current uninsured rate of 9  for 2015 is the lowest in over 50 years The data also shows that Obamacare has led to increased coverage provided by health insurers that would in turn add to their top line  Most health insurers have reported a secular rise in their revenues from membership gains because of the law Baby Boomers Presents Medicare GrowthAccording to the U S  Census data  the population of Medicare beneficiaries will grow by 36  by the end of this decade led by a vast aging baby boomer population  In fact  in the next 25 years  the compounded annual growth rate of the Medicare population is expected to increase to 2 7  from 1 5  at present Revenues from the managed care plans of Medicare Advantage are expected to grow significantly as baby boomers retire  Medicare Advantage is a privately run version of the government s Medicare insurance program for the aged and disabled  Until now  only two public providers    UnitedHealth and Humana    control more than 10  of the market  Carriers in the health insurance sector are in a race to win Medicare Advantage market share and the fastest way of achieving the target is by acquiring a company in the same business International Markets Seems LucrativePressure on profit margins in the U S  market has compelled American health insurers to look to foreign markets for sustained growth and profitability  International markets seem attractive as these are less penetrated and competitive than the U S  Asia and Europe represent the best near term opportunities for the U S  health insurers Cigna and UnitedHealth Group lead the private health insurance industry in terms of international deal activity  They re followed by Aetna and Humana  The deals have either been mergers and acquisitions or joint ventures with local insurance companies Some of the deals made by players in this field echo the emerging trend toward globalization  In Apr 2014  Aetna bought U K  based InterGlobal  which offers private medical insurance to groups and individuals in the Middle East  Asia  Africa and Europe  Prior to that in Feb 2014  Cigna announced its debut in India s underpenetrated health insurance sector  in a joint venture with an Indian conglomerate TTK Group  In 2013  UnitedHealth bought a stake in AmilParticipacoes of Brazil for a nearly  5 billion  It already had a presence in Australia  the Middle East and the U K   Managing Costs via ACOsHealth insurers are trying to clinch accountable care payment contracts following the healthcare reform law s inclusion of Accountable Care Organization  ACO  tests under Medicare  The law s emphasis on providing accurate and efficient health care service rather than volume of service has led to the emergence of ACOs  These are formed when a group of health care providers  physicians  hospitals  non physician providers  and the likes  collectively take responsibility for the financial and quality outcome for a defined population The ACOs are appealing to insurers as these reduce medical cost and improve outcome  Insurers form an essential part of ACO because these track and collect patient data  enabling an evaluation of patient care  Since clinical information and care processes are shared and supported by all providers  it becomes easier to manage care and effectively lower the cost  With Obamacare  health insurers have to be more than just claims payers Under health reform  insurers have lost flexibility in ways that they can cope with rising medical expenses  They can no longer rely on many of their traditional medical underwriting strategies  such as exclusion of pre existing conditions  The most effective approach for insurers now is to rely exclusively on current cost control mechanisms to manage members  medical expenses   Private commercial payers  such as Cigna  Anthem and Aetna are thus supporting ACO formation  CIGNA has one of the most established track records in the group for ACOs 
Developing Ancillary BusinessesInsurers are eyeing growth and expansion opportunities that accompany the critical challenges of modernizing the health care system  They are branching out to the non traditional areas 
Over the last few years  several large insurers have acquired companies that fall outside the realm of traditional health insurance yet complement it  Humana acquired Antiva in 2011 to provide analytics services  Aetna invested in Health IT by acquiring Medicity and UnitedHealth has the broadest approach to and the greatest potential in cross selling synergies via its health benefits business via Optum  The Optum division is the poster child of UnitedHealth s successful diversification 
Healthy Balance Sheet 
Health insurers are also well poised with respect to their balance sheet  The risk based capital ratio of Anthem  Cigna  Aetna and UnitedHealth stands north of 500   substantially higher than the statutory level of 200   A low utilization rate  which has reduced claim payments  has helped to strengthen the balance sheet of these players  Stocks Worth Adding
Investors can consider the following HMO stocks that have solid fundamentals along with a favorable Zacks Rank 
WellCare Health Plans provides managed care services for government sponsored health care programs  It operates through three segments  Medicaid Health Plans  Medicare Health Plans  and Medicare PDPs  The stock currently has a Zacks Rank  1  Strong Buy  and experienced positive estimate revisions over the past three months  It company has a long term expected growth rate of 18   You can see  
Aetna operates as a health care benefits company in the United States  It operates through three segments  Health Care  Group Insurance  and Large Case Pensions  The stock currently has a Zacks Rank  2  Strong Buy  and experienced positive estimate revisions over the past three months  It company has a long term expected growth rate of 10  
UnitedHealth Group Inc  is a diversified health and well being company in the United States  The company offers consumer oriented health benefit plans and services  health care coverage  and health and well being services to individuals aged 50 and older  The stock currently has a Zacks Rank  2  Strong Buy  and experienced positive estimate revisions over the past three months  It company has a long term expected growth rate of 13 4  
Humana Inc  NYSE HUM  together with its subsidiaries  operates as a health and well being company  The company operates through three segments  Retail  Group  and Healthcare Services  The stock currently has a Zacks Rank  2  Strong Buy  and experienced positive estimate revisions over the past three months  It company has a long term expected growth rate of 13 5  
Bottom LineIn a changing industry  which is witnessing the shift of power from insurance players to consumers  the need of the hour is to understand what consumers want and need  and provide quality service at the right time  Only those health players that modify their business strategy in tandem with the changing market will prevail and flourish in a consumer centric health insurance industry 
Confidential from ZacksBeyond this Industry Outlook  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand    ",2016-10-19,Zacks Investment Research,"https://www.investing.com/analysis/health-insurers-seek-growth-via-new-business,-cost-control-200159671",200159671
142592,364107,HUM,Zacks Industry Outlook Highlights  WellCare Health Plans  Aetna  UnitedHealth Group And Humana,opinion,"For Immediate Release

	Chicago  IL   October 20  2016   Today  Zacks Equity Research discusses the Health insurance  Part 3  including WellCare Health Plans  NYSE       Aetna  NYSE AET   NYSE     UnitedHealth Group Inc  NYSE UNH    NYSE     and Humana Inc  NYSE HUM    NYSE      

	Industry  Health insurance  Part 3

	Link  

	Amid global economic volatility  the U S  health insurance industry provides investors a level of defense thanks to the high degree of its domestic business exposure  Players like Cigna  NYSE CI   UnitedHealth Group  Centene and Aetna with business in international markets also have limited exposure  accounting for 3   4   1  and 0 5  of revenues  respectively 

	The sole factor that has shaken the healthcare industry and changed it wholly is the Health Care Reform or Obamacare  enacted in Mar 2010  Though initially intensively lobbied against by the players  health care reform did not turn out as worse as expected  Despite the share of headwinds that the reform brought  it has helped the companies to grow their top line by increasing membership 

	Total revenues of the top eight players  UnitedHealth  Aetna  Cigna  Molina Healthcare  Centene  WellCare Health Plans  Anthem and Humana increased to  437 billion in 2015 from  383 billion in 2014 with medical enrollment rising to 150 million in 2015 from 145 million in the prior year  Along with posting strong operating numbers  most of the players guided strong earnings for 2016  pointing to the fact that despite hurdles  the industry presents enough growth opportunities 

	Now  after sharing the space with Obamacare for almost six years  insurers have embraced the law  Most of the players are now looking for newer avenues to expand their business  They are reassessing their business model from the perspective of product  pricing  risk management  distribution and claims to fraud management for a realistic pace of growth 
	Let s discuss some of the opportunities provided by the changing industry landscape Higher Enrollment   Higher Revenues

	Thanks to ObamaCare  the nation s uninsured rate has gone down to single digits  Before ACA  around 47 million lacked health coverage  Current data shows that the uninsured rate is around 9   According to an ongoing NHIS CDC study  the current uninsured rate of 9  for 2015 is the lowest in over 50 years 
	The data also shows that Obamacare has led to increased coverage provided by health insurers that would in turn add to their top line  Most health insurers have reported a secular rise in their revenues from membership gains because of the law Baby Boomers Presents Medicare Growth
	According to the U S  Census data  the population of Medicare beneficiaries will grow by 36  by the end of this decade led by a vast aging baby boomer population  In fact  in the next 25 years  the compounded annual growth rate of the Medicare population is expected to increase to 2 7  from 1 5  at present 
	Revenues from the managed care plans of Medicare Advantage are expected to grow significantly as baby boomers retire  Medicare Advantage is a privately run version of the government s Medicare insurance program for the aged and disabled  Until now  only two public providers    UnitedHealth and Humana    control more than 10  of the market  Carriers in the health insurance sector are in a race to win Medicare Advantage market share and the fastest way of achieving the target is by acquiring a company in the same business International Markets Seems Lucrative
	Pressure on profit margins in the U S  market has compelled American health insurers to look to foreign markets for sustained growth and profitability  International markets seem attractive as these are less penetrated and competitive than the U S  Asia and Europe represent the best near term opportunities for the U S  health insurers 
	Cigna and UnitedHealth Group lead the private health insurance industry in terms of international deal activity  They re followed by Aetna and Humana  The deals have either been mergers and acquisitions or joint ventures with local insurance companies 
	Some of the deals made by players in this field echo the emerging trend toward globalization  In Apr 2014  Aetna bought U K  based InterGlobal  which offers private medical insurance to groups and individuals in the Middle East  Asia  Africa and Europe  Prior to that in Feb 2014  Cigna announced its debut in India s underpenetrated health insurance sector  in a joint venture with an Indian conglomerate TTK Group  In 2013  UnitedHealth bought a stake in AmilParticipacoes of Brazil for a nearly  5 billion  It already had a presence in Australia  the Middle East and the U K Managing Costs via ACOs

	Health insurers are trying to clinch accountable care payment contracts following the healthcare reform law s inclusion of Accountable Care Organization  ACO  tests under Medicare  The law s emphasis on providing accurate and efficient health care service rather than volume of service has led to the emergence of ACOs  These are formed when a group of health care providers  physicians  hospitals  non physician providers  and the likes  collectively take responsibility for the financial and quality outcome for a defined population 
	The ACOs are appealing to insurers as these reduce medical cost and improve outcome  Insurers form an essential part of ACO because these track and collect patient data  enabling an evaluation of patient care  Since clinical information and care processes are shared and supported by all providers  it becomes easier to manage care and effectively lower the cost  With Obamacare  health insurers have to be more than just claims payers 
	Under health reform  insurers have lost flexibility in ways that they can cope with rising medical expenses  They can no longer rely on many of their traditional medical underwriting strategies  such as exclusion of pre existing conditions  The most effective approach for insurers now is to rely exclusively on current cost control mechanisms to manage members  medical expenses  Private commercial payers  such as Cigna  Anthem and Aetna are thus supporting ACO formation  CIGNA has one of the most established track records in the group for ACOs 

Developing Ancillary Businesses
	Insurers are eyeing growth and expansion opportunities that accompany the critical challenges of modernizing the health care system  They are branching out to the non traditional areas 

	Over the last few years  several large insurers have acquired companies that fall outside the realm of traditional health insurance yet complement it  Humana acquired Antiva in 2011 to provide analytics services  Aetna invested in Health IT by acquiring Medicity and UnitedHealth has the broadest approach to and the greatest potential in cross selling synergies via its health benefits business via Optum  The Optum division is the poster child of UnitedHealth s successful diversification 

Healthy Balance Sheet

	Health insurers are also well poised with respect to their balance sheet  The risk based capital ratio of Anthem  Cigna  Aetna and UnitedHealth stands north of 500   substantially higher than the statutory level of 200   A low utilization rate  which has reduced claim payments  has helped to strengthen the balance sheet of these players Stocks Worth Adding

	Investors can consider the following HMO stocks that have solid fundamentals along with a favorable Zacks Rank 

WellCare Health Plans  NYSE      provides managed care services for government sponsored health care programs  It operates through three segments  Medicaid Health Plans  Medicare Health Plans  and Medicare PDPs  The stock currently has a Zacks Rank  1  Strong Buy  and experienced positive estimate revisions over the past three months  It company has a long term expected growth rate of 18   You can see   

Aetna  NYSE      operates as a health care benefits company in the United States  It operates through three segments  Health Care  Group Insurance  and Large Case Pensions  The stock currently has a Zacks Rank  2  Strong Buy  and experienced positive estimate revisions over the past three months  It company has a long term expected growth rate of 10  

UnitedHealth Group Inc     NYSE        is a diversified health and well being company in the United States  The company offers consumer oriented health benefit plans and services  health care coverage  and health and well being services to individuals aged 50 and older  The stock currently has a Zacks Rank  2  Strong Buy  and experienced positive estimate revisions over the past three months  It company has a long term expected growth rate of 13 4  

Humana Inc     NYSE        together with its subsidiaries  operates as a health and well being company  The company operates through three segments  Retail  Group  and Healthcare Services  The stock currently has a Zacks Rank  2  Strong Buy  and experienced positive estimate revisions over the past three months  It company has a long term expected growth rate of 13 5  

Bottom Line
	In a changing industry  which is witnessing the shift of power from insurance players to consumers  the need of the hour is to understand what consumers want and need  and provide quality service at the right time  Only those health players that modify their business strategy in tandem with the changing market will prevail and flourish in a consumer centric health insurance industry 

Confidential from Zacks  
	Beyond this Industry Outlook  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand     

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  









	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact
	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-10-19,Zacks Investment Research,"https://www.investing.com/analysis/zacks-industry-outlook-highlights:-wellcare-health-plans,-aetna,-unitedhealth-group-and-humana-200159809",200159809
142593,364108,HUM,Aetna  AET  Beats Q3 Earning Estimates On Membership Growth,opinion,"Aetna Inc    NYSE AET   is one of the nation s leading diversified healthcare benefits companies  Aetna with its strong business  a diversified revenue stream should benefit in this changing environment Aetna proposed to acquire Humana Inc  NYSE HUM   last year  The deal would have enabled it to penetrate the fast growing the Medicare space   However  the company has been sued by the U S  Department of Justice and there now remains uncertainty around the closing of the deal Aetna has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 7 31  Currently  Aetna has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  You can see   We have highlighted some of the key stats from this just revealed announcement below The Bottom Line  Aetna beats on earnings  Our consensus called for EPS of  2 02 and the company reported earnings per share of  2 07  Earnings increased 9  on an year over year basis The Top Line  Revenues missed expectations  Aetna posted operating revenues of  15 74 billion  a tad lower than our consensus estimate of  15 76 billion  but was up 5  year over year Key Stats  Total operating expenses were  2 8 billion for the third quarter of 2016 Medical membership increased by 143000 compared with Jun 30  2016  primarily reflecting increases in Aetna s Commercial ASC products AETNA INC NEW Price and EPS Surprise   Check back later for our full write up on this AET earnings report later 
Confidential from ZacksBeyond this Tale of the Tape  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand    ",2016-10-27,Zacks Investment Research,https://www.investing.com/analysis/aetna-(aet)-beats-q3-earning-estimates-on-membership-growth-200161060,200161060
142594,364109,HUM,Anthem  ANTM  Q3 Earnings  Disappointment In The Cards  ,opinion,Anthem Inc    NYSE ANTM   is set to report third quarter 2016 results  before the market opens  on Nov 2 Last quarter  the company posted a positive earnings surprise of 2 78   Let s see how things are shaping up for this announcement Factors to be Considered this QuarterAnthem s Public Exchange business is expected to perform well in the to be reported quarter owing to its competitive edge despite the risks involved in this new market Total membership  including both fully insured and self funded  are likely have been boosted by solid expansion of Affordable Care Act  ACA  However  fully insured membership losses in Commercial business might partially offset the upside Government Business is also expected to have witnessed robust enrollment growth  Medicaid Business is likely to have tapped the huge opportunities available in the market  resulting in an improvement in margin Consequent to membership growth  operating revenues are likely have improved in the third quarter The company s focus on addressing the challenges of rising healthcare costs and the quality of healthcare is expected to have led to the introduction of more customer centric healthcare solutions In addition  a persistent soft interest rate environment is likely to keep net investment income under pressure  Also  benefit expense ratio is expected to increase owing on margin expansion ANTHEM INC Price and EPS Surprise    Earnings WhispersOur proven model does not conclusively show that Anthem is likely to beat earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Anthem has a Earnings ESP of  2 01   This is because the Most Accurate estimate stands at  2 44  while the Zacks Consensus Estimate is pegged at  2 49  Please check our  that enables you to find stocks that are expected to come out with earnings surprises Zacks Rank  Anthem carries a Zacks Rank  4  Sell  We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies from the Medical sector that you may want to consider as these have the right combination of elements to post an earnings beat this quarter WellCare Health Plans Inc   NYSE WCG    which is expected to report third quarter earnings results on Nov 1  has an Earnings ESP of  3 6  and a Zacks Rank  1  Strong Buy   You can see  Humana Inc   NYSE HUM   has an Earnings ESP of  2 94  and a Zacks Rank  2  Buy   The company is expected to report third quarter earnings results on Nov 4 Ariad Pharmaceuticals Inc   NASDAQ ARIA  has an Earnings ESP of  5 26  and a Zacks Rank  2  The company is slated to report third quarter earnings results on Nov 1 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-30,Zacks Investment Research,https://www.investing.com/analysis/anthem-(antm)-q3-earnings:-disappointment-in-the-cards-200161794,200161794
142600,364115,HUM,Cigna  CI  Poised To Beat On Earnings In Q3  Here s Why,opinion,"Health insurer Cigna Corp    NYSE CI   is expected to release third quarter financial results before the market opens on Nov 3 In the last reported quarter  the company missed the earnings estimate by 17 15   Let s see how things are shaping up for this announcement Why a Likely Positive Surprise Our proven model shows that Cigna is likely to beat on earnings as it has the right combination of the two key components  Note that a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy  or  2  Buy  or at least  3  Hold  to have a significantly higher chance of beating estimates Zacks ESP  The Earnings ESP for Cigna is  2 62   This is because the Most Accurate estimate of  1 96 per share is above the Zacks Consensus Estimate of  1 91 per share  Please check our  that enables you find stocks that are expected to come out with earnings surprises Zacks Rank  Cigna s Zacks Rank  3 increases the predictive power of ESP Factors to Drive Q3 ResultsThe poor performance in Disability is a result of modifications made to the disability claim process  in the first quarter this year  where the company is investing additional resources in the upfront medical review of claims to conduct further physical examinations  perform deeper medical history reviews and enhanced documentation These modifications resulted in longer claim cycles  thereby increasing the disability durations and claim inventory which contributed significantly to the unfavorable financial impact experienced in the first half of 2016 for this business Cigna s U S  individual business is likely to have experienced softness similar to the rest of the industry The third quarter results are expected to demonstrate continued strength in the operating performance of the Global Health Care and Global Supplemental benefits  business We expect the company to continue posting favorable results on solid revenue growth in the government business  disciplined expense management and effective medical cost management Favorable medical utilization along with medical cost management is expected to contribute to the bottom line  Moreover  its strong balance sheet which enables share buyback should support the upcoming results  CIGNA CORP Price and EPS Surprise   Other Stocks to ConsiderHere are three stocks from the medical sector which you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter   Humana Inc    NYSE HUM   is expected to report third quarter earnings results on Nov 4  The company has an Earnings ESP of  2 94  and a Zacks Rank  2  You can see  Aerie Pharmaceuticals  Inc    NASDAQ AERI   has an Earnings ESP of  8 57  and a Zacks Rank  3  The company is scheduled to release third quarter results on Nov 2 AMN Healthcare Services Inc    NYSE AMN   has an Earnings ESP of  1 79  and a Zacks Rank  3  The company is scheduled to release third quarter results on Nov 3 
Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-31,Zacks Investment Research,https://www.investing.com/analysis/cigna-(ci)-poised-to-beat-on-earnings-in-q3:-here's-why-200162000,200162000
142601,364116,HUM,Humana  HUM  Likely To Top Q3 Earnings  Stock To Gain ,opinion,We expect  Humana Inc    NYSE HUM   to beat expectations when it reports third quarter results on Nov 4  before the market opens Why a Likely Positive Surprise Our proven model shows that Humana has the right combination of two key ingredients to beat estimates Zacks ESP  of the company  2 94   This is because the Most Accurate estimate is pegged at  3 15  while the Zacks Consensus Estimate stands at  3 06  A positive ESP is a meaningful indicator of a likely positive earnings surprise for the company  Please check our  that enables you to find stocks that are expected to come out with earnings surprises Zacks Rank  Humana carries a Zacks Rank  2  Buy   Note that stocks with a Zacks Rank of  1  Strong Buy   2 or 3  Hold  have a significantly higher chance of beating on earnings Conversely  the Sell rated stocks   4 or 5  should never be considered going into an earnings announcement   What is Driving the Better Than Expected EarningHumana s Individual Medicare Advantage and Healthcare Services businesses likely have delivered solid performances in the to be reported quarter  The Group Medicare Advantage Business is also expected to come out with strong results Humana s Medicare business is expected to drive earnings through growth in stand alone PDP  Prescription Drug Plans  contracts  Management expects continuous increase in the PDP membershipHumana s Individual commercial membership is likely to increase despite management s earlier expectation of membership reduction due to the rise in premiums and benefit redesigns since the beginning of 2016 The persistent underperformance by Humana s public exchange business over the last few quarters might adversely affect margins by limiting the sale of Affordable Care Act  ACA  plans on public exchanges Humana is likely to witness an increase in operating expenses in the third quarter due to higher benefit expenses as well as depreciation and amortization costs  This might put pressure on margin HUMANA INC NEW Price and EPS Surprise   Stocks to ConsiderHere are some companies from the Medical sector that you may want to consider as these have the right combination of elements to post an earnings beat this quarter Aquinox Pharmaceuticals Inc    NASDAQ AQXP   which is expected to report third quarter earnings results on Nov 8  has an Earnings ESP of  3 33  and a Zacks Rank  3  Hold   You can see  AveXis  Inc    NASDAQ AVXS   has an Earnings ESP of  11 43  and a Zacks Rank  2  Buy   The company is expected to report third quarter earnings results on Nov 10 Curis Inc   NASDAQ CRIS   has an Earnings ESP of  10 00  and a Zacks Rank  3  The company is slated to report third quarter earnings results on Nov 3 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-31,Zacks Investment Research,https://www.investing.com/analysis/humana-(hum)-likely-to-top-q3-earnings;-stock-to-gain-200162058,200162058
142602,364117,HUM,Should You Buy Humana Inc   HUM  Ahead Of Earnings ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Humana Inc    NYSE HUM   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Humana Inc  is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings with the most up to date information possible is a pretty good indicator of some favorable trends underneath the surface for HUM in this report In fact  the Most Accurate Estimate for the current quarter is currently at  3 15 per share for HUM  compared to a broader Zacks Consensus Estimate of  3 06 per share  This suggests that analysts have very recently bumped up their estimates for HUM  giving the stock a Zacks Earnings ESP of 2 94  heading into earnings season HUMANA INC NEW Price and EPS Surprise    Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that HUM has a Zacks Rank  2  Buy  and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for Humana Inc   and that a beat might be in the cards for the upcoming report Confidential from ZacksBeyond this Tale of the Tape  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-02,Zacks Investment Research,https://www.investing.com/analysis/should-you-buy-humana-inc.-(hum)-ahead-of-earnings-200162641,200162641
142637,364152,HUM,WellCare Solidifies Arizona Presence  To Add Care1st Arizona,opinion,WellCare Health Plans  Inc    NYSE WCG   recently entered into an agreement to acquire the subsidiaries of Care1st Health Plan  a unit of Blue Shield of California  for about  157 5 million including statutory capital  The health maintenance organization will be buying Care1st Health Plan Arizona  Inc  and ONECare by Care1st Health Plan of Arizona  Inc  collectively known as  Care1st Arizona   This buyout will enable WellCare Health to extend its footprint into Arizona s thriving Medicaid and Medicare markets Shares  however  slipped 0 2  in the last trading session owing to broader market fundamentals Care1st Arizona offers Medicaid and Medicare benefits to about 114 000 beneficiaries in Arizona s largest geographic service areas   Maricopa and Pima counties The transaction is anticipated to be financed with available cash on hand  The acquisition is expected to be completed by the first quarter of 2017 pending closing conditions  WellCare expects the buyout to be accretive to earnings per diluted share in the first year post the completion of the transaction Care1st Arizona is renowned as a superior quality health plan that has met the criteria of government sponsored programs in Arizona for more than 13 years  The health plan s commitment toward community based relationships and combined delivery of medical care and social services is in line with the acquirer s objective of providing enhanced health outcomes for low income families  children  the disabled  seniors and individuals with complex medical needs WellCare has been boosting its inorganic growth profile through strategic acquisitions  The company acquired certain assets of Advicare Corp  s Medicare business on Jun 1  2016  The buyout will allow the health maintenance organization to expand its footprint to South Carolina and strengthen its partnership with the state via the delivery of quality  cost effective health care solutions to benefit low income children and families Currently  WellCare sports a Zacks Rank  1  Strong Buy   You can see  WELLCARE HEALTH Price    Stocks to ConsiderInvestors interested in other stocks from the same space can consider Aetna Inc    NYSE AET    Humana Inc    NYSE HUM   and UnitedHealth Group Incorporated   NYSE UNH    Each of these stocks holds a Zacks Rank  2  Buy  Aetna  a health and maintenance organization  delivered positive surprises in all of the last four quarters  with an average beat of 7 31  Humana  another health and maintenance organization  delivered positive surprises in three of the last four quarters  with an average beat of 1 32  UnitedHealth Group  a health and maintenance organization  delivered positive surprises in all of the last four quarters  with an average beat of 2 93  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-06,Zacks Investment Research,"https://www.investing.com/analysis/wellcare-solidifies-arizona-presence,-to-add-care1st-arizona-200157704",200157704
142638,364153,HUM,5 Trade Ideas For The Week Of October 10  2016,opinion,"Chicago Bridge   Iron Company NV  NYSE CBI 

Chicago Bridge   Iron  CBI  had settled into a consolidation after falling through January  That lasted until August  over 6 months  But instead of breaking consolidation to the upside it broke down  eventually finding a new bottom in September 
Since then it has been moving higher Friday it hit the short term support area from the beginning of September  It has a RSI climbing toward the bullish zone and a MACD crossed up and rising  A push through this resistance is a reason to participate to the upside   
Cemex SAB de CV  NYSE CX 

CEMEX  CX  moved higher off of a bottom in January  It paused in consolidation from April to June before a second move higher that peaked in early August  Another consolidating pullback ended with a touch at the 100 day SMA in mid September and it has been rising since  Last week it pushed back to its 50 day SMA and held there 
The RSI is knocking on the edge of a move into the bullish zone and the MACD is crossed up  rising and positive  Look for a break over the end of September high to participate to the upside   
Foot Locker  NYSE FL 

Foot Locker  FL  fell out of consolidation in April and found support in June  Making a low after the Brexit vote  it has risen ever since  It pulled back to its 20 day SMA from a peak in August and is now back at that level as resistance  The RSI is in the bullish zone and the MACD is flat after falling  and positive  Look for a push higher to participate in the upside   
Humana  NYSE HUM 

Humana  HUM  was slammed lower to start July  and after 2 weeks of settling rose almost as fast  But it never recovered fully  Since mid August it ran lower in a falling channel until reaching its 200 day SMA 
That has held as support and forced price to morph into sideways consolidation  With the Bollinger Bands  squeezing  look for a move over consolidation to participate to the upside   
Infinera Corporation  NASDAQ INFN 

Infinera  INFN  has been trending lower since April  It has vacillated between the 50 day and 100 day SMA as resistance as it heads lower  But since August it has been moving sideways in a channel and ended last week pressing against the top of that channel 
The RSI is rising and on the edge of the bullish zone while the MACD is rising and positive  Look for a push over resistance to participate to the upside   
Up Next  Bonus Idea
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which heading into next week sees the equity index ETF s look like they need a breather in the short term 
Elsewhere look for Gold to continue lower while Crude Oil continues to the upside  The US Dollar Index looks strong but range bound while US Treasuries are biased lower again  The Shanghai Composite is biased to the drift to the downside Emerging Markets look like they will continue to consolidate in the uptrend 
Volatility looks to remain in the lower end of the normal range keeping the bias higher for the equity index ETF s SPDR S P 500  NYSE SPY   iShares Russell 2000  NYSE IWM  and PowerShares QQQ Trust Series 1  NASDAQ QQQ   Their charts all look to continue consolidating in the short run with the QQQ looking the best for upside and the SPY next  with the IWM at risk for a pullback  Use this information as you prepare for the coming week and trad em well 
DISCLAIMER  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer ",2016-10-10,Gregory W. Harmon,"https://www.investing.com/analysis/5-trade-ideas-for-monday-the-week-of-october-10,-2016-200157865",200157865
142639,364154,HUM,Humana  Delaware Valley Renew Deal To Improve Healthcare,opinion,Humana Inc    NYSE HUM   recently announced that it has renewed its value based network agreement with the Delaware Valley Accountable Care Organization   DVACO    The revised agreement will be effective from Jan 1  2017 DVACO serves nearly 9 000 members of Humana Medicare Advantage plan in Greater Philadelphia by providing access to a premium level of healthcare  The company has already facilitated Humana members with its value based care  In fact  these members experienced fewer ER visits  lower hospital readmission rates  higher screening rates  and assistance at the time of medical expense reimbursements We expect the latest deal to result in a more proactive and wellness focused health care experience for the Humana members  Doctors involved in this initiative are also likely to receive financial rewards on providing high quality treatment  Humana members are also offset to gain from numerous wellness programs that include screening and monitoring of chronic conditions like diabetes  heart diseases to name a few Value based healthcare  which has replaced the  Fee for Service  model of conventional healthcare  has mainly shifted the focus from curing the disease to prevention  This proactive approach has also changed the policy of payments to doctors  Physicians  who were earlier paid according to the number of services they provided  are now reimbursed on the basis of patients  health outcomes DVACO is one of the largest Accountable Care Organizations in the United States  Hence  the renewal of the partnership should help Humana provide a cheaper yet smarter medical experience to its members  Under the new agreement  the doctors of DVACO will be held accountable for more than 200 000 Humana members in Greater Philadelphia  This new deal between Humana and DVACO covers nine acute care hospitals  two rehabilitation hospitals and a variety of ancillary health care services Humana will also be largely benefitted through the alignment of DVACO s highly talented physician base with its own expertise in value based healthcare  population health tools and data driven insights  By the end of second quarter  roughly 61  of Humana s Medicare Advantage members were served by value based healthcare providers  With this new deal  Humana targets 75  of its members to be in the same list by the end of 2017 DVACO  on the other hand  will utilize Humana s analytics to better understand patients  needs  The data will be used to provide preventive services to the members in order to avoid serious medical conditions Under the agreement  both the companies are expected to develop strategies in order to provide superior level of wellness treatment at a lower cost  Humana has already witnessed 18  cost reduction in 2014 due to its relentless efforts to transform its historic health care model from a fee for service model to a value based one HUMANA INC NEW Price    When the entire HMO  Health Maintenance Organization  industry is suffering from rising medical costs  players like UnitedHealth Group Inc    NYSE UNH    Molina Healthcare Inc    NYSE MOH    Aetna Inc   NYSE AET    have started to shift their focus on initiatives to bring out low cost solutions  Humana is no exception to this trend as evidenced by its recent moves  All these companies are putting continuous efforts to meet the growing demand of personalized services with less expensive healthcare offerings Humana presently carries a Zacks Rank  2  Buy   You can see Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-11,Zacks Investment Research,"https://www.investing.com/analysis/humana,-delaware-valley-renew-deal-to-improve-healthcare-200158372",200158372
142640,364155,HUM,Humana Raises View For FY16  Medicare Rating Downgraded,opinion,"Humana Inc    NYSE HUM   has recently raised its financial guidance for 2016 and updated its outlook for the third quarter Based on the preliminary results of the to be reported quarter  Humana expects diluted GAAP earnings per common share  EPS  for the full year to be roughly  8 80  Adjusted EPS are projected to be around  9 50  For the third quarter  the company anticipates EPS to be  3 07 on a GAAP basis and  3 15 on an adjusted basis Humana had previously revised the guidance on Jul 21 and reaffirmed the same during its second quarter earnings release in August  The company had then guided adjusted EPS of at least  9 25 The recent increase of 25 cents in the adjusted EPS for the full year was likely driven by strong performance at the Medicare Advantage  Healthcare Service and Individual Commercial segments  Both Medicare Advantage  which comprises the Group and Individual segments  and Healthcare Service have recorded better than expected performance this quarter  The company has even managed to turn around the Individual Commercial business from last quarter s dismal performance However  Humana witnessed a downgrade in the Star quality ratings for the 2018 plan year  as published by the Centers for Medicare and Medicaid Services   CMS    The latest Star quality ratings show that Humana s percentage of membership in 4 star or higher plans as of Jul 31  2016 has declined to 37  from the year ago level of 78   The company is already making strategic operational efforts to lower the negative impact of these star quality ratings  Humana also has a plan to file for the reconsideration of certain ratings under proper administrative process Humana had objected and closed a comprehensive audit program by the CMS  which has resulted into the civil monetary penalty imposed on Dec 29  2015  The penalty led to an automatic downgrade in the Beneficiary Access and Plan Performance  BAPP  Star measure  The rating downgrade was also due to higher threshold levels for certain individual Star measures that were calculated across the sector other than the weighted average membership of each plan Humana believes that the CMS audit has not taken into account its relentless efforts on improvising services  The company has been persistently investing in the integrated care delivery model  operational processes and procedures  clinical engagement  provider engagement  and consumer engagement  With the latest rating downgrade  Humana is now focused on the effective implementation of its operational and strategic initiatives  specially the Medicare initiatives  state based contract strategy  and participation in the new health insurance exchanges  The company is determined to get a better rating experience in the next CMS audit  The company  however  assured that this rating action will not hurt its Medicare membership growth next year 
HUMANA INC NEW Price
 
   On the other hand  Aetna Inc    NYSE AET    which was set to acquire Humana  has received high Medicare Star Quality Ratings for its Medicare Advantage Prescription Drug  MAPD  plans for 2017 from the CMS  This upgrade reflected Aetna s increased member base in plans with a star rating of 4 0 or higher than 91   representing a 4 percentage point increase from last year Zacks Rank   Key PicksHumana presently carries a Zacks Rank  2  Buy   A couple of other favorably placed stocks in the same space include WellCare Health Plans Inc    NYSE WCG   and UnitedHealth Group Inc   NYSE UNH    While Wellcare sports Zacks Rank  1  Strong Buy   UnitedHealth holds Zacks Rank  2 You can seeWellcare has recorded a positive earnings surprise in each of the last four quarters  The Zacks Consensus Estimate for 2016 and 2017 has increased by 1 cent and 14 cents  respectively  over last 30 days UnitedHealth has also delivered a positive earnings surprise in the four trailing quarters  The Zacks Consensus Estimate for 2016 and 2017 has increased by 1 cent and 5 cents  respectively  over last 30 days Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-12,Zacks Investment Research,"https://www.investing.com/analysis/humana-raises-view-for-fy16,-medicare-rating-downgraded-200158598",200158598
142641,364156,HUM,5 Healthcare Players Poised To Beat Q3 Earnings Estimates,opinion,"The third quarter earnings season is round the corner  Let s find out how the health care sector  which includes diversified industries like managed care organizations  clinical  laboratories and diagnostics research  medical equipment  hospitals  and more  is likely to perform this time 

Since the start of this year  the managed care industry or the health maintenance organizations  HMOs   which includes the medical insurance group  has been displaying weakness  Factors like disappointing public exchange business  stringent regulations regarding the proposed mega merger of Anthem Inc   ANTM  with Cigna Corp   NYSE CI   and Aetna Inc   NYSE AET  with Humana Inc   NYSE HUM   increasing medical ratio to name a few  have been the primary reasons behind the bearishness  Also  the different stance of the presidential candidates regarding the ObamaCare and the changes likely to be implemented upon getting elected  added to the uncertainty 
We note that the situation is no different in the third quarter  The Department of Justice has filed suits against the proposed mergers  The mergers  which were scheduled to be completed this year  have now been delayed  In fact  the closure of these deals is now shrouded with uncertainty 
This apart  issues related to the public exchanges business have been adding to the woes  Most insurers incurred losses from this business in the first half of the year and the trend is unlikely to reverse this quarter  Although insurance companies had expected better profitability in 2016 after making meager profits in 2015  the individual exchange business disappointed the firms  Major players incurred losses in this business and are now reducing their participation on the exchanges by exiting unprofitable markets 
However  all is not lost for this sector  In the quarter  HMO industry players are likely to have witnessed an increase in premium from the government businesses   Medicare  Medicare Advantage and Medicaid  A surge in the baby boomer population has led to higher demand for these policies  In 2015  about 55 million people were enrolled in Medicare  This number is expected number to climb to 75 million by 2026  courtesy of the aging of the baby boomers  Humana  Cigna  Aetna  UnitedHealth Group Inc   NYSE UNH  had earlier projected growth in their government business 
In addition  higher number of enrollees in the Medicare  Medicaid and Medicare Advantage businesses is expected to have driven membership growth in the third quarter  However  this upside might have been partly offset by a decline in membership on the public exchange business 
The insurers are also likely to see earnings growth on the back of their international operations  Players like Aetna  Cigna and UnitedHealth Group have extended their business worldwide in the wake of stringent regulations on the home turf  However  a strong U S  dollar will be a drag on the quarterly earnings 
Moreover  strong balance sheets with low leverage and attractive organic cash flow generation  along with excess capital in the form of statutory reserves and parent cash continue to make this sector attractive 

Another healthcare sub sector  which provides clinical services for pets  is poised for growth as the veterinary market continues to strengthen  Also  healthy competition in the lab market continues to drive growth  Higher demand for veterinary services owing to increase in pet population  more knowledge and awareness  better medicines for pets  highly trained doctors  more technology  and improved diagnostics have been catalysts behind earnings growth of this sub sector 

Diagnostic and laboratory research companies are also slated to see earnings improvement owing to a greater health care access  which fuels demand for these services  Growth in the industry is influenced by aging populations and rising demand for preventive care and personalized medical treatments  Small medical labs are competing effectively by providing specialized analyses and establishing their presence in regions with fewer medical facilities 

Owing to these positives  we believe that the health care sector might still be a good bet as there exist some stocks that are likely to deliver positive earnings surprises this earnings season  How to Pick the Attractive Stocks 
Given the large number of industry participants  selecting stocks that have the potential to beat estimates appears to be a daunting task  Nonetheless  our proprietary methodology makes it fairly simple 
One way to narrow down the list of choices this earnings season is by looking at stocks that have the combination of a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  and a positive   Notably  a positive Earnings ESP helps to identify stocks that have high chances of surprising estimates in their next earnings announcement  It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate 
Our research shows that for stocks with this combination  the chance of a positive earnings surprise is as high as 70  
Below are five health care stocks that we believe are best positioned to stand out this earnings season UnitedHealth Group Inc     is a major health insurance company providing health insurance and health benefits services   It has an Earnings ESP of  0 96  and carries a Zacks Rank  2  The company is slated to report third quarter earnings on Oct 18  You can see VCA Inc     operates as an animal healthcare company in the United States and Canada  It operates through two segments   Animal Hospital and Laboratory  It has an Earnings ESP of  13 61  and carries a Zacks Rank  2  The company is slated to report third quarter earnings on Oct 26 Quintiles IMS Holdings  Inc     provides biopharmaceutical development services and commercial outsourcing services in the Americas  Europe  Africa  and the Asia Pacific  It has an Earnings ESP of  1 01  and carries a Zacks Rank  2  The company is slated to report third quarter earnings on Oct 26 ICON Public Limited Company     is a contract research organization that provides outsourced development services to the pharmaceutical  biotechnology  and medical device industries in Ireland  rest of Europe  the United States  and internationally  It has an Earnings ESP of  1 7  and carries a Zacks Rank  2  The company is slated to report third quarter earnings on Oct 20 Aetna Inc     operates as a health care benefits company in the United States  It operates through three segments   Health Care  Group Insurance  and Large Case Pensions  It has an Earnings ESP of  1 49  and carries a Zacks Rank  2  The company is slated to report third quarter earnings on Oct 27 Where Do Zacks  Investment Ideas Come From 
You are welcome to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buy  stocks free of charge  There is no better place to start your own stock search  Plus you can access the full list of must avoid Zacks Rank  5  Strong Sells  and other private research     ",2016-10-13,Zacks Investment Research,https://www.investing.com/analysis/5-healthcare-players-poised-to-beat-q3-earnings-estimates-200158640,200158640
142642,364157,HUM,Anthem Gets High Medicare Star Quality Ratings From CMS,opinion,"Anthem Inc    NYSE ANTM   recently announced that it has received high Medicare Star Quality Ratings from the Centers for Medicare   Medicaid Services   CMS    The ratings have been assigned for the insurer s Medicare Advantage  MA  plans for 2017 
The superior ratings from CMS acknowledge the company s continued investments to strengthen its Medicare program  The ratings take into account that approximately 51  of Anthem s MA members will be enrolled in plans with four stars or higher for 2017 as against 22  members enrolled in such plans in 2016 
Anthem regularly undertakes initiatives to improve the quality and reach of its MA plans  The frequent restructuring of its product portfolio to meet the changing health insurance demands of customers is also notable  Anthem s prioritization on continuous reframing of its MA plans has not only helped it to retain its existing customers but also has paved the way to achieve a bigger market share 
In order to deliver high quality services to its customers  Anthem has been investing in its MA programs   Moreover  the company has working to broaden its product portfolio  expand its services area  increase the number of staffs  involved in practicing the local health plan and strengthen provider and member engagement 
Anthem believes that its efforts have been correctly identified by CMS as is evidenced by the aforesaid star quality ratings  We expect these ratings to further motivate Anthem to continue delivering services to ensure complete customer satisfaction 
ANTHEM INC Price
   CMS  Medicare Star Rating system is based on two parameters   quality and performance of the concerned business segment  Hence  MA plans are rated on the basis of their ability to help members stay healthy  the extent to which they assist members in managing chronic diseases  their ability to ensure positive member experiences and member satisfaction as well as their capability of providing effective customer service 
On the other hand  Medicare Prescription Drug plans are rated on their performance on drug plan customer service  the frequency and extent of member complaints  member experience with drug plan and the safety assured by the drug  A scale of one to five stars  with five being the best  is used for the calculation of star ratings 
Aetna Inc    NYSE AET   too has received high Medicare Star Quality Ratings for its Medicare Advantage Prescription Drug  MAPD  plans for 2017 from the CMS  This upgrade reflected Aetna s increased member base in plans with a star rating of four or higher than 91   representing a 4 percentage point increase from last year 
Humana Inc    NYSE HUM    however  witnessed a downgrade in the CMS star quality ratings for 2018  This is because Humana s membership in four star or higher rated plans as of Jul 31  2016 has declined to 37  from the year ago level of 78  
Cigna Corp    NYSE CI   has also received star quality ratings from CMS as approximately 20  of MA customers were in a four stars or higher rated plan  However  it is unlikely to have any financial impact in 2016 or 2017 as these ratings apply to plans for 2018 
Anthem presently carries a Zacks Rank  4  Sell   You can see 
 
Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-14,Zacks Investment Research,https://www.investing.com/analysis/anthem-gets-high-medicare-star-quality-ratings-from-cms-200158941,200158941
142643,364158,HUM,Health Insurance Industry Outlook   October 2016,opinion,"In the first nine months of the year 2016  the U S  health insurance industry was largely dominated by issues related to the underperforming public exchange business and stringent regulatory intervention relating to the two proposed mega mergers  Notwithstanding these  the companies performed favorably  with most of the players reporting an increase in the top line along with membership growth 
The Department of Justice filed lawsuits against the proposed mergers of Anthem Inc   ANTM  with Cigna Corp  NYSE CI    CI   and Aetna Inc  NYSE AET    AET  with Humana Inc  NYSE HUM    HUM   The mergers  which were scheduled to be completed this year  have now been delayed  In fact  the closure of these deals is now uncertain 
This apart  concerns related to the public exchanges business have been adding to the woes  Most insurers incurred losses from this business in the first half of the year  and the trend is unlikely to reverse anytime soon  Although insurance companies expected improved profitability in 2016 after making meager profits in 2015  the individual exchange business disappointed the firms 
Major players incurred losses in this business and are now reducing their participation on the exchanges by exiting unprofitable markets  For 2017  the players have very little exposure on the public exchanges 
Nevertheless  the companies have managed to record higher revenues on the back of an increase in premium from the government businesses   Medicare  Medicare Advantage and Medicaid  A surge in baby boomer retirees has led to higher demand for these policies  In 2015  about 55 million people were enrolled in Medicare  The number is expected to climb to 75 million by 2026  courtesy aging baby boomers  Humana  Cigna  Aetna  UnitedHealth Group Inc  NYSE UNH    UNH  have expanded their government businesses and are very optimistic about it 
In addition  a higher number of enrollees in the Medicare  Medicaid and Medicare Advantage businesses drove membership growth across the board  However  this upside was partly offset by a decline in membership on the public exchange business 
The insurers are likely to see earnings growth on the back of their international operations  Players like Aetna  Cigna and UnitedHealth Group have extended their business worldwide in the wake of stringent regulations on the home turf  However  a stronger U S  dollar will be a drag on earnings from international operations 
Strong balance sheets with low leverage and attractive organic cash flow generation  along with excess capital in the form of statutory reserves and parent cash continue to make this sector attractive 
Factors that might impact the industry significantly in the coming months are the Presidential election  the Public Exchange Business  and mergers and acquisitions 
The industry has caught the attention of the presidential candidates who are vowing to make major changes to the legislation that gave the industry a complete makeover  Insurers who have strived hard to adapt to the numerous changes brought about by the reforms may have to readjust their businesses if the new president brings in his her desired changes 
Industry Flashback
The industry witnessed a massive overhaul following the Health Care Reform Act which came into effect in Mar 2010  The reform changed the face of the industry  so much so that the once successful strategies and business practices of the players were no longer sustainable 
The players enjoyed no interference from government entities from the early 1980s til 2010  The health insurers were fully autonomous in conducting their business  many a times refusing to grant coverage to people with pre existing diseases and also rejecting genuine claims  But with the implementation of Obamacare  things have changed substantially 
The reform  via its numerous provisions  put a bridle on insurers  Some of the clauses of the law related to the provision of insurance coverage for people with preexisting diseases  a bar on rejecting claims  restrictions on increases in premium and many more have changed the operating environment of the industry  These players are now faced with increased competition  regulatory compliance costs  changing patient mix  pricing pressure  rising consumerism  higher taxes and fees  rising medical costs and a general marketplace uncertainty 
Amid the sea change in the industry  the players are busy remodeling their businesses with innovative  consumer centric products and services  They are also aggressively hunting for new avenues of growth both at home and abroad 
Industry Ranking Overall PositiveWithin the Zacks Industry classification  Health Maintenance Organization is grouped under the Medical sector  one of the 16 Zacks sectors  We rank all the 257 industries in the 16 Zacks sectors based on the earnings outlook of the constituent companies in each industry  The ranking is available on the  page The way to align the ranking and outlook from the complete list of Zacks Industry Rank for the 257 companies is by considering the outlook for the top one third of the list  Zacks Industry Rank of  86 and lower  as positive  the middle one third  Zacks Industry Rank between  86 and  172  as neutral and the bottom one third  Zacks Industry Rank  173 and higher  as negative The HMO industry features in the top 1 3rd range with a Zacks Industry Rank  70  This indicates that the overall outlook is  Positive  Please note that the Zacks Rank for stocks  which is the core of our Industry Outlook  has an impressive track record  verified by outside auditors  to foretell stock prices  particularly over the short term  1 to 3 months   The rank  along with   helps in predicting the probability of earnings surprises Earnings TrendsWith the impending Q3 earnings season  it s time to look at the estimate revision trends  The broader Medical Sector  of which HMOs are part  is currently expected to be up 2 7  from the same period last year on 7 4  higher revenues  This  however  compares unfavorably to 2016 Q2 earnings growth of 4 8  and 9  revenue growth 
For more information about earnings for this sector and others  please read our    report 
Stocks Worth Adding
Investors can consider the following HMO stocks that have solid fundamentals along with a favorable Zacks Rank 
WellCare Health Plans  Inc   WCG  provides managed care services for government sponsored health care programs  It operates through three segments  Medicaid Health Plans  Medicare Health Plans  and Medicare PDPs  The stock currently has a Zacks Rank  1  Strong Buy  and experienced positive estimate revisions over the past three months  It company has a long term expected growth rate of 18   You can see  
Aetna Inc  operates as a health care benefits company in the United States  It operates through three segments  Health Care  Group Insurance  and Large Case Pensions  The stock currently has a Zacks Rank  2  Strong Buy  and experienced positive estimate revisions over the past three months  It company has a long term expected growth rate of 10  
UnitedHealth Group Inc  is a diversified health and well being company in the United States  The company offers consumer oriented health benefit plans and services  health care coverage  and health and well being services to individuals aged 50 and older  The stock currently has a Zacks Rank  2  Strong Buy  and experienced positive estimate revisions over the past three months  It company has a long term expected growth rate of 13 4  
Humana Inc  together with its subsidiaries  operates as a health and well being company  The company operates through three segments  Retail  Group  and Healthcare Services  The stock currently has a Zacks Rank  2  Strong Buy  and experienced positive estimate revisions over the past three months  It company has a long term expected growth rate of 13 5  
Confidential from ZacksBeyond this Industry Outlook  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand    ",2016-10-17,Zacks Investment Research,https://www.investing.com/analysis/health-insurance-industry-outlook---october-2016-200159217,200159217
142644,364159,HUM,Health Insurers Face Regulatory Scrutiny  Exchange Issues,opinion,"Health insurers have called upon themselves the close scrutiny of regulators with Anthem s  ANTM  proposal to acquire Cigna Corp  NYSE CI    CI  and Aetna s  AET  buyout deal with Humana Inc  NYSE HUM    HUM  
Recently  the viability of the proposed merger between Anthem and Cigna  and Humana with Aetna  NYSE AET  was challenged by the Department of Justice  DoJ  on groundsthat the mega deals would curb competition and hurt consumers  The DoJ has therefore sued all the companies involved in either of the mergers  casting uncertainty over the merger consummation 
Moreover  the presidential candidates are looking at ways to fine tune the provisions of the healthcare legislation  which  if implemented  will see insurers reworking their business strategies 
Democratic presidential candidate Hillary Clinton s priority includes a crackdown on insurers to limit out of pocket costs  These include are expenses like deductibles  coinsurance and copayments for covered services  among others  that aren t reimbursed by insurance  Clinton is pitching for three sick visits per year in insurance plans before deductibles kick in  In her campaign  Clinton pointed to a recent Kaiser Family Foundation study that average deductible for an individual has increased seven times faster than a worker s average wage since 2010 
High deductibles are barring some people from visiting a doctor because they cannot pay the first few thousand dollars of the bill before insurance kicks in  Having a deductible so high that one cannot afford to go to a physician is akin to having no insurance at all 
The deductible is part of the medical bill which must be cleared before patients can use their insurance coverage  But thanks to a high deductible  doctor visits are being barred by some thousands of dollars that must be shelled out before patients can avail the insurance 
Also on Hillary Clinton s agenda to provide the Department of Health and Human Services with the ability to block or modify unreasonable rate increases by insurers 
Donald Trump proposes to end Obamacare and replace it with something that would require a lot less money Coming back  the legislation has undoubtedly altered the regulatory landscape in ways that are not always beneficial to a private health insurer s bottom line  But calling it a permanent drag would be an overstatement U S  health plans are expected to operate in a lowered margin environment  Some health plans   especially the smaller ones   may not survive  Pricing pressure  higher taxes and fees  rising medical costs  regulatory compliance costs  increased competition and general marketplace uncertainty are some of the headwinds faced by the players in the industry 
Public Exchanges Woes
Public Exchanges made their debut in Oct 2013  and were considered one of the signature achievements of Obamacare aimed at providing subsidized insurance to millions  The insurers were also sanguine about the exchanges  hoping to make big business out of them  But health insurers are now struggling to profit from the public exchange business 
These insurers are saddling under high medical expenses of individuals who are buying the subsidized policies under the health care law  The public exchanges attracted a disproportionate number of unhealthy individuals compared to healthy ones  A higher percentage of unhealthy patients led to higher claims for the insurers  thus leading to losses from the policies sold to these groups of people 
In Nov 2015  UnitedHealth Group  NYSE UNH   UNH  disclosed concerns about losses incurred on its individual business from the public exchange Compelled by the loss suffered from the individual insurance policies sold on the exchanges  the health insurer announced that it will not entertain such losses and may exit this unprofitable market completely by 2017  The company has already scaled back its marketing efforts for individual insurance policies sold on exchanges 
Another insurer  Aetna  also suffered losses from its public exchange business in 2015 and reduced its operations to 15 states this year from 17 states last year  It is  however  taking measures such as re pricing and product modification to generate profits in 2016  
Yet another player  Humana  is contemplating dropping individual insurance coverage through exchanges in the states of Alabama  Kansas  Wisconsin and Virginia  The company is considering to exit this business which brought in meager profits in this years  first quarter and would likely result in a loss for the full year 
If the players realize that the exchanges are not seeing profitable business opportunities  a mass exodus may happen which may hamper the functionality of the exchanges and cause a failure of the Obamacare exchanges  thus defeating the basic aim of providing coverage to millions of uninsured Americans 
Some of the other challenges faced by the industry are briefed below Margins Under Pressure
Health insurers are expected to witness lowered margin environment  A host of factors including compliance costs related to health care reform regulation  increased fees and taxes  pricing pressure  stiff competition and rising medical costs will squeeze the bottom line 
A general shift in patient mix from Commercial insurance to Government  Medicare  Medicaid and State subsidized marketplace or exchange  will also affect profitability to a large extent  Premiums for Medicare  Medicaid and state subsidized policies tend to be higher due to serious health issues for many enrollees  however  they carry smaller profitability margins compared to commercial insurance 
High Regulatory Cost
Regulatory reform sweeping through the sector has hit insurers with high compliance costs  The expenditures involved in redoing the internal systems can pinch them hard  There has been huge spending on health information technology   HIT    following the implementation of The American Recovery and Reinvestment Act of 2009   ARRA    or  Recovery Act   which contains the Health Information Technology for Economic and Clinical Health Act  or the  HITECH Act   Notably  HIT includes electronic health records or EHRs  health information exchanges or HIEs and other initiatives 
The federal government s emphasis on the use of health IT  which helps providers communicate better with each other about patient care  reduces medical errors  paperwork and needless duplicate screenings and tests  leading to better coordinated patient care and lower health care costs  These have increased health care information technology spending  Financial incentives offered by regulators to providers and hospitals for the implementation of the meaningful use of health care IT products are primarily driving IT spending 
Consumer Has Upper Hand
Rising consumerism is the reality of the health insurance industry  Until the implementation of the ACA  the insurance companies had an upper hand in choosing to whom to provide coverage  and consumers  people receiving health care  had no active role in the decision making process 
But now the trend has changed  Health insurance reform has put consumer power and choice in the hands of the people  and ensures that all Americans receive the health care services that they need  Consumers  increased purchasing power and access to information to take health care decisions are the major threats to insurers Prior to reform  big insurers dominating large markets hardly ever bothered to provide consumers with even basic information  such as the performance of health insurance policies  procedures to claim  the size of the provider network and cancellation processes  Now  customers demand transparency  value and convenience  leaving insurers grappling for innovative ways to satisfy these unmet needs  The new mission  however  will not be easy to execute Global Economic Woes and Regulatory ChallengesA fragile global economy presents a headwind for insurers looking to expand their international operations  One of the largest insurers  UnitedHealth Group made an acquisition to reap benefits from the Brazil market but is now facing slowing growth rates in that country In the case of India  which remains one of the most profitable opportunities for insurers  the regulatory environment still remains somewhat challenging  China    which merits the highest risk adjusted opportunity ranking  largely because of its immense scale    poses significant investment restrictions to foreign insurers entering and operating there 
HMO Stocks to Avoid for the Time Being
We presently recommend investors stay away from the following HMO stocks  as they presently have an unfavorable Zacks Rank  The other metrics also indicate that they are not profitable investment options at present 
Anthem Inc   ANTM  currently has a Zacks Rank  4  Sell   The 2016 earnings estimates have gone down by 0 6  in the last 90 days 
Centene Corp   CNC  currently has a Zacks Rank  4  The 2016 earnings estimates have gone down by 4 8  in the last 60 days 
Magellan Health  Inc   MGLN  carries a Zacks Rank  4  Sell   The 2016 earnings estimates have gone down by 9 8  in the last 90 days  You can see    Bottom LineThe changed regulatory landscape has undoubtedly created hurdles that would weigh on profits and margins of industry operators going forward  But it is hardly the unmitigated disaster that some industry players make it out to be  Beyond the ACA  the investment appeal of the space also reflects its perceived defensive and counter cyclical orientation  which is crucial amid the current uncertainty 
Confidential from ZacksBeyond this Industry Outlook  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand    ",2016-10-18,Zacks Investment Research,"https://www.investing.com/analysis/health-insurers-face-regulatory-scrutiny,-exchange-issues-200159482",200159482
142645,364160,HUM,Zacks Industry Outlook Highlights  UnitedHealth Group  Anthem  Centene And Magellan Health,opinion,"For Immediate Release

	Chicago  IL   October 19  2016   Today  Zacks Equity Research discusses the Health insurance  Part 2  including UnitedHealth Group  NYSE UNH   NYSE     Anthem Inc   NYSE     Centene Corp   NYSE     and Magellan Health  Inc   NASDAQ      

	Industry  Health insurance  Part 2

	Link  

	Health insurers have called upon themselves the close scrutiny of regulators with Anthem s proposal to acquire Cigna Corp  NYSE CI   and Aetna s buyout deal with Humana Inc  NYSE HUM  

	Recently  the viability of the proposed merger between Anthem and Cigna  and Humana with Aetna  NYSE AET  was challenged by the Department of Justice  DoJ  on grounds that the mega deals would curb competition and hurt consumers  The DoJ has therefore sued all the companies involved in either of the mergers  casting uncertainty over the merger consummation 

	Moreover  the presidential candidates are looking at ways to fine tune the provisions of the healthcare legislation  which  if implemented  will see insurers reworking their business strategies 

	Democratic presidential candidate Hillary Clinton s priority includes a crackdown on insurers to limit out of pocket costs  These include are expenses like deductibles  coinsurance and copayments for covered services  among others  that aren t reimbursed by insurance  Clinton is pitching for three sick visits per year in insurance plans before deductibles kick in  In her campaign  Clinton pointed to a recent Kaiser Family Foundation study that average deductible for an individual has increased seven times faster than a worker s average wage since 2010 

	High deductibles are barring some people from visiting a doctor because they cannot pay the first few thousand dollars of the bill before insurance kicks in  Having a deductible so high that one cannot afford to go to a physician is akin to having no insurance at all 

	The deductible is part of the medical bill which must be cleared before patients can use their insurance coverage  But thanks to a high deductible  doctor visits are being barred by some thousands of dollars that must be shelled out before patients can avail the insurance 

	Also on Hillary Clinton s agenda to provide the Department of Health and Human Services with the ability to block or modify unreasonable rate increases by insurers 

	Donald Trump proposes to end Obamacare and replace it with something that would require a lot less money 
	Coming back  the legislation has undoubtedly altered the regulatory landscape in ways that are not always beneficial to a private health insurer s bottom line  But calling it a permanent drag would be an overstatement 
	U S  health plans are expected to operate in a lowered margin environment  Some health plans   especially the smaller ones   may not survive  Pricing pressure  higher taxes and fees  rising medical costs  regulatory compliance costs  increased competition and general marketplace uncertainty are some of the headwinds faced by the players in the industry 

Public Exchanges Woes

	Public Exchanges made their debut in Oct 2013  and were considered one of the signature achievements of Obamacare aimed at providing subsidized insurance to millions  The insurers were also sanguine about the exchanges  hoping to make big business out of them  But health insurers are now struggling to profit from the public exchange business 

	These insurers are saddling under high medical expenses of individuals who are buying the subsidized policies under the health care law  The public exchanges attracted a disproportionate number of unhealthy individuals compared to healthy ones  A higher percentage of unhealthy patients led to higher claims for the insurers  thus leading to losses from the policies sold to these groups of people 

	In Nov 2015  UnitedHealth Group  NYSE      disclosed concerns about losses incurred on its individual business from the public exchange  Compelled by the loss suffered from the individual insurance policies sold on the exchanges  the health insurer announced that it will not entertain such losses and may exit this unprofitable market completely by 2017  The company has already scaled back its marketing efforts for individual insurance policies sold on exchanges 

	Another insurer  Aetna  also suffered losses from its public exchange business in 2015 and reduced its operations to 15 states this year from 17 states last year  It is  however  taking measures such as re pricing and product modification to generate profits in 2016 

	Yet another player  Humana  is contemplating dropping individual insurance coverage through exchanges in the states of Alabama  Kansas  Wisconsin and Virginia  The company is considering to exit this business which brought in meager profits in this years  first quarter and would likely result in a loss for the full year 

	If the players realize that the exchanges are not seeing profitable business opportunities  a mass exodus may happen which may hamper the functionality of the exchanges and cause a failure of the Obamacare exchanges  thus defeating the basic aim of providing coverage to millions of uninsured Americans 

	Some of the other challenges faced by the industry are briefed below Margins Under Pressure

	Health insurers are expected to witness lowered margin environment  A host of factors including compliance costs related to health care reform regulation  increased fees and taxes  pricing pressure  stiff competition and rising medical costs will squeeze the bottom line 

	A general shift in patient mix from Commercial insurance to Government  Medicare  Medicaid and State subsidized marketplace or exchange  will also affect profitability to a large extent  Premiums for Medicare  Medicaid and state subsidized policies tend to be higher due to serious health issues for many enrollees  however  they carry smaller profitability margins compared to commercial insurance 

High Regulatory Cost

	Regulatory reform sweeping through the sector has hit insurers with high compliance costs  The expenditures involved in redoing the internal systems can pinch them hard  There has been huge spending on health information technology   HIT    following the implementation of The American Recovery and Reinvestment Act of 2009   ARRA    or  Recovery Act   which contains the Health Information Technology for Economic and Clinical Health Act  or the  HITECH Act   Notably  HIT includes electronic health records or EHRs  health information exchanges or HIEs and other initiatives 

	The federal government s emphasis on the use of health IT  which helps providers communicate better with each other about patient care  reduces medical errors  paperwork and needless duplicate screenings and tests  leading to better coordinated patient care and lower health care costs  These have increased health care information technology spending  Financial incentives offered by regulators to providers and hospitals for the implementation of the meaningful use of health care IT products are primarily driving IT spending 

Consumer Has Upper Hand

	Rising consumerism is the reality of the health insurance industry  Until the implementation of the ACA  the insurance companies had an upper hand in choosing to whom to provide coverage  and consumers  people receiving health care  had no active role in the decision making process 

	But now the trend has changed  Health insurance reform has put consumer power and choice in the hands of the people  and ensures that all Americans receive the health care services that they need  Consumers  increased purchasing power and access to information to take health care decisions are the major threats to insurers 
	Prior to reform  big insurers dominating large markets hardly ever bothered to provide consumers with even basic information  such as the performance of health insurance policies  procedures to claim  the size of the provider network and cancellation processes  Now  customers demand transparency  value and convenience  leaving insurers grappling for innovative ways to satisfy these unmet needs  The new mission  however  will not be easy to execute Global Economic Woes and Regulatory Challenges
	A fragile global economy presents a headwind for insurers looking to expand their international operations  One of the largest insurers  UnitedHealth Group made an acquisition to reap benefits from the Brazil market but is now facing slowing growth rates in that country 
	In the case of India  which remains one of the most profitable opportunities for insurers  the regulatory environment still remains somewhat challenging  China    which merits the highest risk adjusted opportunity ranking  largely because of its immense scale    poses significant investment restrictions to foreign insurers entering and operating there 

HMO Stocks to Avoid for the Time Being

	We presently recommend investors stay away from the following HMO stocks  as they presently have an unfavorable Zacks Rank  The other metrics also indicate that they are not profitable investment options at present 

Anthem Inc   NYSE      currently has a Zacks Rank  4  Sell   The 2016 earnings estimates have gone down by 0 6  in the last 90 days 

Centene Corp   NYSE      currently has a Zacks Rank  4  The 2016 earnings estimates have gone down by 4 8  in the last 60 days 

Magellan Health  Inc   NASDAQ      carries a Zacks Rank  4  Sell   The 2016 earnings estimates have gone down by 9 8  in the last 90 days  You can see   Bottom Line
	The changed regulatory landscape has undoubtedly created hurdles that would weigh on profits and margins of industry operators going forward  But it is hardly the unmitigated disaster that some industry players make it out to be  Beyond the ACA  the investment appeal of the space also reflects its perceived defensive and counter cyclical orientation  which is crucial amid the current uncertainty 

Confidential from Zacks  
	Beyond this Industry Outlook  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand     

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  









	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact
	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-10-18,Zacks Investment Research,"https://www.investing.com/analysis/zacks-industry-outlook-highlights:-unitedhealth-group,-anthem,-centene-and-magellan-health-200159558",200159558
142646,364161,HUM,Buy UnitedHealth ETFs On Upbeat Q3 Earnings,opinion,The health insurance industry is seeing an upheaval this year on increased regulation  pricing concerns and the sustainability of Obamacare  which is highly dependent on the outcome of the November election  read    Against such a weak backdrop  the largest U S  health insurer UnitedHealth Group  NYSE UNH  came up with robust third quarter 2016 results and raised its outlook for the full year  This has sparked a rally in the industry  infusing an air of confidence in future growth and profitability Q3 Earnings in FocusUnitedHealth Group continued its long streak of earnings beat with earnings per share of  2 17 surpassing the Zacks Consensus Estimate by nine cents and coming in 23  higher than the year ago quarter  Revenues rose 12  year over year to  46 3 billion  edging past the Zacks Consensus Estimate of  45 9 billion  Growth was broad based with a staggering 34  increase in revenues for Optum  the health services segment  read    UnitedHealth lifted its earnings per share guidance for 2016 to  8 from the previous projection of  7 80  7 95  This is well above the Zacks Consensus Estimate of  7 91  During the conference call  Chief Executive Officer Stephen Hemsley signaled strong earnings growth in 2017 as well  According to Hemsley  the company could beat analysts  expectations thanks to strong performance by Optum Following the upbeat results and solid outlook  the stock climbed the most in three years by as much as 7  on the day  This suggests that the health insurer is turning around after Obamacare related losses weighed on its results earlier this year Further  UnitedHealth s financial results  which act as a barometer for the rest of the industry  helped the stocks of the other players to close the day in green  Of these  Aetna  NYSE AET  climbed 2 7   Humana  NYSE HUM  was up 2   Anthem  ANTM  rose 4 1   Cigna  NYSE CI  added 4 2   Molina Healthcare  MOH  gained 3 1  and Centene  CNC  was up 2 8  Attractive FundamentalsUnitedHealth has been clearly outpacing the broad sector and the market  gaining about 21 9  in the year to date time frame against the loss of 2 6  for the S P 500 Health Care Index and gain of 4 7  for the S P 500 index  It is the No  1 stock in IBD s Medical Managed Care group  see    The stock has a Zacks Rank  2  Buy  and boasts a solid Industry rank in the top 37   underscoring its potential to outperform in the weeks ahead  Additionally  it has enticing flavors of Value Style Score of A and Growth Style Score of B Given attractive fundamentals and UNH s potential to lift the entire health insurer sector  many investors may want to buy ETFs having the largest allocation to this giant health insurer  For them  iShares U S  Healthcare Providers ETF  could especially be on radar as UNH takes the top spot in the fund s portfolio with 14 2  share IHF in FocusThis ETF provides exposure to 49 companies that provide health insurance  diagnostics and specialized treatment by tracking the Dow Jones U S  Select Healthcare Providers Index  About 45 6  of the portfolio is dominated by managed care firms while healthcare services and healthcare facilities round off the top three  The fund has amassed  555 5 million in its asset base while volume is moderate at about 88 000 shares per day on average  It charges 44 bps in annual fees and expenses and added 2 9  following the UNH earnings release  The product is down about 1  so far in the year and has a Zacks ETF Rank of 2 or  Buy  rating with a Medium risk outlook  read    Other ETFsOther healthcare ETFs like Health Care Select Sector SPDR Fund  Vanguard Health Care ETF  iShares U S  Healthcare ETF  John Hancock Multifactor Healthcare ETF  and Fidelity MSCI Health Care Index ETF   also have a decent exposure to UnitedHealth in the range of 4 5  Apart from the healthcare space  UNH is among the top 10 holdings in some large cap ETFs such as SPDR Dow Jones Industrial Average ETF   V DIA   WisdomTree LargeCap Value Fund   PowerShares Dynamic Large Cap Growth Portfolio  andFirst Trust Mega Cap AlphaDEX Fund   DE FMK    with 5 1   3 8   3 6  and 3 5  share  respectively Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2016-10-18,Zacks Investment Research,https://www.investing.com/analysis/buy-unitedhealth-etfs-on-upbeat-q3-earnings-200159539,200159539
142670,364185,HUM,Aetna Members To Enjoy World Class Services Of Piedmont ,opinion,"Aetna Inc    NYSE AET   recently signed an agreement with Piedmont Healthcare to provide its members continuous in network access to all the medical facilities of the latter  In addition to this  more than 1 400 Piedmont Clinic physicians will provide medical consultation service to Aetna members According to Aetna s market president for Georgia  Angela Meoli  Aetna and Piedmont have been working in partnership over years to ensure access to high quality care and improving health for members of the Greater Atlanta community  Hence  the latest contract is expected to further boost the long term partnership of the duo The CEO of Piedmont Healthcare  Kevin Brown  believes that the partnership with Aetna  will largely benefit the company s patients  This is because these patients will not only continue have access to Piedmont physicians but also gain from the premium level of health care provided by Aetna s technologically improved advanced services network  Aetna s substantially large international business will also add to Piedmont s strength Piedmont Healthcare is now entitled to participate in Aetna s Institutes of Excellence  a network of high performing hospitals  clinics and health care facilities that offer specialized care  This indicates Piedmont Healthcare s position as a leading health care facility in terms of high quality and cost effective operation for adult liver  kidney and pancreas transplantation On the other hand  Aetna members are likely to be gain significantly from Piedmont Healthcare s world class transplant medical facilities and the assistance of the highly skilled and experienced Piedmont Healthcare physicians  This  in turn  should  boost Aetna s membership base to a great extent Aetna presently carries Zacks Rank  3  Hold AETNA INC NEW Price
    Stocks That Warrant a Look
Investors can also look at some better ranked stocks from the same space like Humana Inc   NYSE HUM    UnitedHealth Group Incorporated   NYSE UNH   and Wellcare Health Plans Inc   NYSE WCG    Among these stocks  Humana sports Zacks Rank  1  Strong Buy  while UnitedHealth and Wellcare Health carry Zacks Rank  2  Buy  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-06,Zacks Investment Research,https://www.investing.com/analysis/aetna-members-to-enjoy-world-class-services-of-piedmont-200152203,200152203
142671,364186,HUM,Humana s New Healthcare Network For Employers In Wisconsin,opinion,"Humana Inc    NYSE HUM   recently announced the launch of a new healthcare network  named Wisconsin Value Network  This new network will present a premium quality health plan solution to employers in Wisconsin at a fairly reduced cost This Wisconsin Value Network will combine four major area healthcare systems    Ascension Wisconsin  Aurora Health Care  Bellin Health and ProHealth Care   into a single platform  This collaborative effort will facilitate Humana in delivering better service to its clients through an integrated healthcare network  Collectively  these four renowned hospitals will also support Humana in continuous delivery of its customized solutions at a much lower cost without compromising with the quality of service provided The employer groups in Wisconsin  which comprise roughly 2999 employees  are expected to be largely benefited by this unique provider network with innovative and cost effective yet simple healthcare solution  Humana plans to begin quoting for Wisconsin Value Network on Oct 1  2016  The coverage is expected to become effective from Jan 1  2017 The Kentucky based  Zacks Rank  2  Buy  health maintenance organization is one of the largest health care plan providers in the United States that remains focused on meeting the changing demands of its customers  Humana s customer centric approach has not only boosted its bottom line and market share  but also paved the way for long term growth through several organic and inorganic strategies HUMANA INC NEW Price
    Stocks to ConsiderInvestors keen on the Health Maintenance Organization industry can also consider stocks like UnitedHealth Group Inc   NYSE UNH    WellCare Health Plans Inc    NYSE WCG   and The Joint Corp   NASDAQ JYNT    Along with Humana  all of these stocks also carry Zacks Rank  2  Buy   You can see Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-13,Zacks Investment Research,https://www.investing.com/analysis/humana's-new-healthcare-network-for-employers-in-wisconsin-200153470,200153470
142672,364187,HUM,Should You Dump Anthem  ANTM  From Your Portfolio Now ,opinion,"On Sep 14  Zacks Investment Research downgraded Anthem Inc    NYSE ANTM   to a Zacks Rank  4  Sell  
Why the Downgrade Anthem witnessed downward estimate revisions over the past 60 days  The stock seems to be bothered by a number of factors working against it such as uncertainty over the Cigna deal  weak public exchange business and low interest rates Anthem s proposed acquisition of Cigna Corp    NYSE CI   has drawn friction from regulators  The Department of Justice  DoJ  has blocked the merger of Cigna over concerns that it could stifle competition in the industry  The merger of Anthem and Cigna would mean more power in the hands of the surviving company   Anthem   which will gain in size and scale 
Though Anthem will challenge the lawsuit filed by the DoJ  it will entangle both parties in months of litigation  dragging the deal that was announced about a year ago  If the merger with Cigna falls apart  the company will have to pay a breakup fee of  1 85 billion ANTHEM INC Price and Consensus

   Anthem is also witnessing losses on its public exchange business like UnitedHealth Group Inc    NYSE UNH    Aetna Inc    NYSE AET   to name a couple  For 2016  the company expects membership declines of approximately 300 000 in its individual business  It also expects to see  mid single digit  margin loss in this business The persistent low interest rate environment has also taken a toll on Anthem s investment income  In 2015  net investment income declined 6 5  year over year to  677 6 million  For 2016  the company projects investment income of approximately  650 million  which translates into a year over year decline of 4  from the actual 2015 level Anthem also expects medical loss ratio in the range of 84 9  plus or minus 30 basis points for the year  reflecting higher than previously expected claims rates in its Individual ACA compliant plans as well as its Medicaid businesses remain at elevated levels  This includes worse than expected results in the newly entered Iowa market The share repurchase suspension in the wake of the Cigna deal has affected the bottom line 
The Zacks Consensus Estimate have moved down by a penny for 2016 and 14 cents for 2017 in the last 60 days  The same is currently pegged at  10 91 and  11 85 for 2016 and 2017  respectively 
Stocks to ConsiderNot all consumer discretionary stocks  however  are performing as poorly as Anthem  Some better ranked stocks in this space are UnitedHealth Group Inc    NYSE UNH   and Humana Inc    NYSE HUM    each carrying a Zacks Rank  2  Buy  You can see  
Confidential from Zacks 
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-14,Zacks Investment Research,https://www.investing.com/analysis/should-you-dump-anthem-(antm)-from-your-portfolio-now-200153582,200153582
142673,364188,HUM,Humana   Oak Street Extend Alliance To Improve Primary Care,opinion,"Humana Inc    NYSE HUM   recently joined forces with Oak Street Health to provide proactive care that is tailored to suit the needs of its Medicare beneficiaries  Under the deal  four primary care practices will be added to Humana s Medicare Advantage Plan networks in Indiana and Michigan  These new primary care practices would ensure better quality of care and help patients to take care of their own health and well being Notably  the four practices are in addition to the two practices that Humana gained from Oak Street in 2015  when the duo teamed up for the first time  These newly added practices include a care team comprising doctors  nurses  medical assistants  and medical records experts to keep notes of developments  It also comprises a care team for maximum face to face time with members to keep track of their health issues  A care manager has been appointed to assist patients in connecting with community resources  The practices also extend the scope of visiting any of the care centers without a prior appointment and receiving consultation on the same day Other than these services  Oak Street Health will offer aesthetically beautiful and spacious community rooms for patients to assemble for daily events and classes  Staff familiarity with the member s Medicare Advantage insurance would be an added advantage Oak Street s primary care practices  when combined with Humana s certain advanced Medicare Advantage plans  would ensure premium quality of health care services for patients  The cases and the issues that emerge during the process would be dealt by the companies on a regular basis to minimize the risk of compromising with the patients  health Management at Oak Street has expressed optimism about the alliance with Humana  The insurer s command on outstanding health care experience is expected to largely benefit the patients Fort Wayne and Detroit and also help Oak Street to expand operations in Indianapolis  On the other hand  Oak Street s assistance ensures added strength to Humana s already solid Medicare history Currently  Humana has 1 7 million individual Medicare Advantage members and 200 000 commercial members treated by 48 200 primary care providers in more than 900 value based relationships across 43 U S  states and Puerto Rico  In addition  roughly 61  of Humana individual Medicare Advantage members are in value based payment relationships  The company further plans to have 75  of individual Medicare Advantage members in value based payment models by the end of 2017 HUMANA INC NEW Price
    Zacks Rank and Stocks To ConsiderHumana presently carries Zacks Rank  2  Buy  Investors interested in the same industry can also consider stocks like UnitedHealth Group Inc   NYSE UNH    WellCare Health Plans Inc    NYSE WCG   and The Joint Corp   NASDAQ JYNT    These stocks also carry a Zacks Rank  2  Buy   You can see Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-14,Zacks Investment Research,https://www.investing.com/analysis/humana---oak-street-extend-alliance-to-improve-primary-care-200153692,200153692
142674,364189,HUM, Insurers  ACO Enthusiasm Continues In Control Cost Zeal,opinion,Health insurers have been trying to clinch Accountable Care Organization  ACO  deals since the passage of the  2010 healthcare reform law The law s emphasis on accurate and efficient healthcare service rather than volume of service has led to the emergence of ACOs  These are formed when a group of healthcare providers  physicians  hospitals  non physician providers  and the likes  collectively take responsibility for the financial and quality outcome for a defined population Given their focus on reducing medical cost and improving outcome  ACOs are appealing to insurers  Insurers form an essential part of ACO because these track and collect patient data  enabling an evaluation of patient care  Since clinical information and care processes are shared and supported by all providers  it becomes easier to manage care and effectively lower the cost  With Obamacare  health insurers have to be more than just a claims payer This network of doctors  hospitals and other healthcare providers that coordinate patient care are eligible for bonuses when they deliver the required care more efficiently  The reimbursement under ACOs are based on the quality of care provided and not the quantity  This improves service and avoids duplication which also helps in reducing overall costs  Medical Sector Price IndexUnder health reform  insurers have lost flexibility in ways that they can cope with rising medical expenses  They can no longer rely on many of their traditional medical underwriting strategies  such as the exclusion of pre existing conditions  The most effective approach for insurers now is to rely exclusively on the current cost control mechanisms to manage members  medical expenses   Private commercial payers  such as Cigna  Anthem and Aetna are thus endorsing ACO formation The companies in the sector are therefore committed to investing in capabilities and creating partnerships to promote cost savings  Humana added eight ACOs in the second quarter bringing the total to over 900 serving 1 7 million Medicare Advantage members and 200 000 commercial members across 43 states  While Humana Inc    NYSE HUM   carrying a Zacks Rank   2  Buy  has the maximum number of ACO relationships  more than 900   UnitedHealth Group Inc    NYSE UNH   ranks second with more than 750 deals  followed by Cigna Corp  s   NYSE CI   156  Anthem Inc  s   NYSE ANTM   142 and Aetna Inc  s   NYSE AET   71  Aetna has a pipeline of 200 ACO deals  You can see  However  many healthcare economists believe that the race to form ACOs could have a significant downside in the form of hospital mergers and provider consolidation  Nevertheless  recent developments attest to the fact that ACOs are gaining prominence rapidly  and are crucial to building a more efficient healthcare system in America Now See Our Private Investment IdeasWhile the above ideas are being shared with the public  other trades are hidden from everyone but selected members  Would you like to peek behind the curtain and view them  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum       from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors     ,2016-09-15,Zacks Investment Research,https://www.investing.com/analysis/insurers'-aco-enthusiasm-continues-in-control-cost-zeal-200154021,200154021
142675,364190,HUM,Humana s Government Business Impresses  High Costs A Drag ,opinion,On Sep 21  2016  we issued an updated research report on Humana Inc    NYSE HUM   The Kentucky based company is one of the largest health care plan providers in the United States  Last year  this internationally renowned insurer made it to the headlines due to its proposed acquisition by Aetna Inc  NYSE AET   The merger  if successful  would have resulted in the formation of the second largest managed care company in the nation  However  the future of the deal remains shrouded in uncertainty given the objection raised by the U S department of Justice  DOJ  Humana has been witnessing strong performances in Individual Medicare Advantage and Healthcare Services businesses over last few quarters  Consequently  it raised its guidance for the full year  Adjusted earnings per share for 2016 are now expected to be at least  9 25  Its Medicare business has also been outperforming over the past few years  primarily due to the operating initiatives that have started bearing fruit through favorable prior period medical claims development and lower current year utilization Humana s financial strength is backed by its solid cash balance  Effective control on debt financing also helped Humana manage its capital  The company s focus on creating shareholders  value through several capital deployment activities helped it cement investors  confidence and drive long term growth Nevertheless  Humana s public exchange business continues to remain weak  This has compelled it to curtail the sale of Affordable Care Act  ACA  plans and halt the expansion of the business  The company s group Medicare Advantage business has also been affected by low revenues and earnings due to its failure in overcoming the loss incurred on a large profitable account at the beginning of this year Moreover  Humana s Individual commercial membership has been adversely impacted by the sudden increases in premiums as well as benefit redesigns effective since the start of this year  As a result  Humana now anticipates membership of this segment to decrease by 200 000 to 300 000 The continuous increase in operating  depreciation and amortization costs that has resulted in higher benefit ratios is another headwind for the company Zacks Rank and Stocks That Warrant a LookHumana currently carries a Zacks Rank  3  Hold  Investors can also look at some better ranked stocks from the same space like WellCare Health Plan Inc   NYSE WCG    UnitedHealth Group Inc   NYSE UNH   and The Joint Corp   NASDAQ JYNT    All of these stocks carry Zacks Rank  2  Buy   You can see Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-09-20,Zacks Investment Research,"https://www.investing.com/analysis/humana's-government-business-impresses,-high-costs-a-drag-200154793",200154793
142676,364191,HUM,Will Rising Medical Costs Limit Molina Healthcare s Growth ,opinion,On Sep 23  2016  we issued an updated research report on Molina Healthcare Inc    NYSE MOH  The California based multi staged managed care organization enjoys a monopoly in government sponsored healthcare programs  The company s strong performance in the recent past is clearly evident from its posting average beat of 2 09  over last four quarters Despite a volatile global economic environment  Molina Healthcare has continued to create value for shareholders by effectively utilizing the existing domestic business exposure Molina Healthcare has been witnessing robust growth in two of the major components of its revenue mix   premiums and service revenues   mainly due to the persistently growing membership  The major contribution of this growing membership was increasing premiums and service revenues substantially  The company presently expects  560 million in service revenues in 2016  which translates into year over year growth of 121 3 Molina Healthcare s inorganic growth was primarily driven by in market or tuck in acquisitions  In fact  the year 2015 was deemed the most active in terms of M A  Mergers   Acquisition   The company acquired Universal American Corp  s   NYSE UAM   Total Care Medicaid plan and agreed to acquire certain Medicare Advantage assets from both Aetna Inc    NYSE AET   and Humana Inc    NYSE HUM   in 2016  Through these strategic acquisitions  the company progresses on its target to better serve the complex needs of patients  We expect this patient centric approach to eventually bolster the top line of Molina Healthcare Molina Healthcare s strong financial position is supported by its improving cash inflow  Molina Healthcare has been prudently managing its capital in order to enhance shareholders  value  Capital deployment initiatives like share buybacks and dividend payouts at regular intervals have cemented investors  confidence on this stock However  rising medical care costs have been putting margins under pressure and hence  remain an area of concern for Molina Healthcare  The increased expenses mainly stemmed from higher utilization factors and were most evident in connection with physician and outpatient costs  Dependence on debt financing is a negative as this leads to an increase in interest expenses Molina Healthcare presently carries Zacks Rank  3  Hold    You can see Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-09-22,Zacks Investment Research,https://www.investing.com/analysis/will-rising-medical-costs-limit-molina-healthcare's-growth-200155184,200155184
142679,364194,HUM,Cigna Partners With American Well To Boost Telehealth Services ,opinion,"Cigna Corporation   NYSE CI   recently announced that Americans enrolled in its administered medical and behavioral health plans for 2017 will now enjoy better access and more choice of affordable telehealth services Cigna started offering telehealth service to clients 10 years back with an objective to integrate convenience with affordability in its premium quality healthcareservices  However  several Americans  particularly those residing in rural areas  face challenges in accessing behavioral health professionals when needed  Cigna intends to mitigate this issue by expanding its behavioral health services Cigna s telehealth benefit unit   MDLIVE   was added in 2013  At present  MDLIVE covers roughly 30  of Cigna s U S  group medical population Cigna now plans to add American Well s telehealth platform AMWELL to MDLIVE in order to meet the growing demand of personalized behavioral healthcare services  American Well has ensured utmost cooperation from its end in order to facilitate Cigna in providing modernized healthcare services to Americans  Also  Cigna will add American Well s medical network Online Care Group to its portfolio  This would not only allow Cigna customers to have greater access telehealth services but also choose where they want to receive the services  Cigna further plans to add telehealth video consultations for its health plan customers by using its contracted behavioral health professionals in Jan 2017 This expanded telehealth service will now cover most of Cigna s employer sponsored group health plans as well as individual health plans on and off public marketplace exchanges  AMWELL and MDLIVE currently operate national networks of board certified doctors for the treatment minor medical conditions like allergies  cold and flu and sinusitis  Hence  these telehealth services will be a major part of Cigna s 2017 healthcare plan Cigna remains focused on developing the most affordable means to cater to the U S customers  Given that healthcare cost is rising continuously  health insurers like Aetna Inc    NYSE AET    Anthem Inc    NYSE ANTM    Humana Inc    NYSE HUM   have been are strategizing to combat the losses  In such a scenario  Cigna s  latest business move is undoubtedly a prudent one  Both MDLIVE and AMWELL are slated to share consult notes with the primary care physicians of the eligible customers in order to deliver better quality and results at a reduced cost CIGNA CORP Price
    Cigna presently carries a Zacks Rank  4  Sell   You can see Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-27,Zacks Investment Research,https://www.investing.com/analysis/cigna-partners-with-american-well-to-boost-telehealth-services-200156078,200156078
142682,364197,HUM,UnitedHealth  UNH  Introduces New Medical Plan For 2017,opinion,"Minnesota based Health Maintenance Organization  HMO   UnitedHealth Group Inc    NYSE UNH   recently introduced its 2017 Medicare Advantage and Part D prescription drug plans  These plans are based on its successful 2016 medical plan  The 2016 medical plan not only reflected the persistently stable Medicare Advantage premiums but also the benefits reaped by customers through low premium prescription drug plans The new medical plan   AARP MedicareRx Walgreens  PDP    primarily focuses on customers looking for peace of mind  The Part D prescription drug plans are slated to serve these customers by providing them the convenience of shopping at their neighborhood from more than 8 000 locations of Walgreens across the nation 
Notably  Walgreens and Duane Reade are the plan s preferred retail pharmacy chains that are included in the Retail Pharmacy USA Division of Walgreens Boots Alliance  Inc    NASDAQ WBA    Apart from convenience  these pharmacies offer a low rate of premium at  22 50 as well as no co pays for tier 1 medications and no deductible for tier 1 and 2 medications purchased  This low cost Part D plans are apt for customers who prefer more affordable care This alliance between UnitedHealth and Walgreens is expected to provide customers with a premium quality healthcare solution that is both convenient and affordable  Like other HMO s such as Humana Inc   NYSE HUM    Aetna Inc   NYSE AET    UnitedHealth s profitability too has been suffering due to high cost of prescription drugs  However  the new initiatives should come as a respite for cost conscious customers  in turn improving the growth prospects of these companies The new plan can easily be combined with other AARP Medicare Rx stand alone Part D plans   AARP MedicareRx Preferred  PDP  and AARP MedicareRx Saver Plus  PDP   Those combined plans are likely to offer more customized prescription drug coverage to meet the specific needs of customers The another component of the 2017 medical plan    Medicare Advantage plans   are expected to offer choice  access to quality care and a superior experience to customers UnitedHealth intends to introduce Medicare Advantage plans in more than 160 counties in 2017  Almost 2 millions of additional beneficiaries will gain access to this opportunity  Like the Part D plans  these Medicare Advantage plans will also combine affordability with convenience and offer greater flexibility  More than 90  of members and over 80  Medicare eligible people in the company s coverage area will be able to avail two or more of these plans in 2017  Moreover  roughly 30 millions of Medicare beneficiaries under the company s coverage area and nearly 90  of its Medicare Advantage members will be able to access this plan with a no premium in 2017 Furthermore  approximately 80  members enrolled in these plans that have received four out of five stars for 2017 in the CMS Star Rating system  The members will also have access to affordable preventive care beyond the annual wellness visit at no co pays for visits with primary care physicians available with many plans  The UnitedHealthcare s HouseCalls program would enable people to receive annual wellness check ups in the comfort of their own home at no additional cost 
More than 2 5 million people enrolled in these plans are likely to be treated by physicians who actively participate in value based  collaborative programs  More than 115 000 of members in Nevada  Illinois  Iowa  Nebraska  Kentucky and Ohio will have the option of virtual telemedicine appointments with primary care doctors by 2017  Access to a 24 7 nurse line for help regarding urgent health issues is another part of this plan The plan also ensures superior experience as most of the enrolled members will enjoy lower to zero premiums  With the help of its customer service advocates who use predictive analytics to understand customers  needs and references  the company expects to schedule 200 000 doctors  appointments for its members by the end of 2016 
In addition  members can enjoy fitness membership at no extra cost for regular exercise and other wellness practices  UnitedHealthcare Medicare Advantage members are further expected to redeem more than 400 000 rewards in 2016 UNITEDHEALTH GP Price

   Apart from its Medicare Advantage and Part D plans  UnitedHealthcare is positioned as the provider of Medicare supplement insurance  The company serves more than 4 2 million beneficiaries through a wide variety of competitively priced plans endorsed by AARP  UnitedHealth presently carries Zacks Rank  2  Buy   You can see 
Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-04,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-(unh)-introduces-new-medical-plan-for-2017-200157067,200157067
142700,364215,HUM,Forget Aetna  AET   Buy These HMO Stocks Instead,opinion,"An underperforming public exchange business and regulatory attacks on the proposed acquisition of Humana are lately hassling health insurer Aetna Inc    NYSE AET   Earlier this week  Aetna voiced its concerns over the public exchange business and is mulling over exiting from this business in 11 of the 15 states in which it is currently present  It will reduce its individual public exchange participation to 242 counties from 778 for the 2017 plan year This development comes after Aetna suffered a pretax loss of  200 million in the second quarter and total pretax loss of more than  430 million since Jan 2014 in its individual products sold via public exchanges Earlier  Aetna had expected to be at breakeven profitability on this business in 2016  but is now reevaluating it  after witnessing huge claims from sicker than expected customers enrolled on public exchanges  The number of healthy and young individuals who enrolled on these exchanges are far less that customers who are aged and had pre existing diseases who lacked coverage earlier  This adverse mix of customer population led to increased claims leading to losses for the insurer  Aetna is now expecting losses  pre tax  north of  300 million on policies sold on public exchanges for 2016 Aetna is being troubled by regulators  with the Department of Justice suing it for its proposed merger with Humana Inc    NYSE HUM    The merger  which would have lifted the rank of Aetna as the major Medicare provider  a market coveted by all the other players in the industry  is now shrouded in uncertainty  Aetna is  however  determined to overcome the challenge and is divesting Medicare Advantage plans that cover 290 000 people in 21 states to Molina Healthcare  Inc   MOH  to gain approval for the deal Aetna s bottom line will also suffer from the suspension of share buyback to lower debt levels to below 40  within 24 months  The company s debt to consolidated capitalization ratio shot up to 53 8  as of Jun 30  2016 from 32 6  on Dec 31  2015  due to the issuance of  13 billion of senior notes to partially fund the acquisition of Humana   Aetna is also witnessing hurdles in growing its membership  The company is experiencing continued membership pressure in the middle market and small group businesses due to its previous pricing actions to improve margins  The company now expects losses in its commercial membership to more than offset growth in government membership over the remainder of 2016  The year 2015 saw medical membership decline by 61 000  Also  the company ended the second quarter with 23 million medical members  essentially flat with the first quarter  The company now projects 2016 membership at around 23 million  down from 23 49 million in 2015  as growth in Government membership over the remainder of the year will be largely offset by declines in Commercial Insured membership  including continued attrition within its individual products AETNA INC NEW Price and Consensus   While Aetna  carrying a Zacks Rank  3  Hold   is trapped in a web of woes  other players worth considering in this space are Humana   United Health Group Inc    NYSE UNH   and WellCare Health Plans  Inc    NYSE WCG   Humana with a Zacks Rank   1  Strong Buy  has strong fundamentals  Its strong performing individual Medicare Advantage and other government sponsored plans remain the highlights  Also  its Healthcare Services business is well poised and will contribute to its growth  Last month  Humana won a contract from the U S  Department of Defense to administer TRICARE benefits to about 6 million people  which nearly doubles the number of military beneficiaries served by Humana However  challenges in its individual commercial medical business are nagging  Also  its merger with Aetna remains uncertain  Nevertheless  the company has reaffirmed its 2016 financial guidance  The company expects earnings of at least  8 56 in 2016 compared with  8 32 predicted before  Humana has also witnessed a 4 9  increase in earnings estimate to  9 28 per share for 2016  over the past 30 days  with all the 10 analysts covering the stock raising their estimates  Its long term EPS growth rate is 13 5  HUMANA INC NEW Price and Consensus   UnitedHealth with a Zacks Rank  2  Buy  is the most diversified health maintenance organization  Though the company also remains troubled by its public exchange business and has exited most of the markets  it remains attractive given the strength in its other business segments  Instead of its heavily regulated Health Benefits business  the company is focusing on investing and growing its health services business branded as Optum 
To this end  the company acquired Catamaran last year  The acquisition has been evidently fruitful thanks to the revenue accretion from it  Optum is becoming an increasingly valuable business and is expected to contribute about 42  of UnitedHealth Group s consolidated operating earnings outlook this year 
Also  the company has also grown membership over the past five years by nearly 13 5 million or 40  well diversified across commercial  government programs and international offerings  The company s membership is further set to grow in Medicare Advantage  Medicaid as well as commercial plans  UnitedHealth also has a strong balance sheet and generates handsome cash flows which allow it to increase dividend payments and make regular share buybacks UnitedHealth also witnessed a 0 4  increase in earnings estimate to  7 91 per share for 2016  over the past 30 days  with eight out of the 13 analysts covering the stock raising their individual estimates  Its long term EPS growth rate is 13 4  UNITEDHEALTH GP Price and Consensus   WellCare Health Plans with a Zacks Rank  2 remains well poised to grow in the Medicaid  Medicare and Medicare Part D business  During the second quarter  it closed the Advicare transaction  gaining greater Medicaid presence in South Carolina  The company taking both organic and inorganic steps to fuel its growth and is trying to double its revenues between 2017 and 2021 
The company also increased its 2016 adjusted earnings per diluted share guidance to a range of  4 95 to  5 05 from its previous guidance range of  4 55 to  4 70 WellCare Health also witnessed a 7 5  increase in earnings estimate to  5 01 per share for 2016  over the past 30 days   with each of the nine analysts covering the stock raising their individual estimates  Its long term EPS growth rate is 17 7  WELLCARE HEALTH Price and Consensus  ",2016-08-17,Zacks Investment Research,"https://www.investing.com/analysis/forget-aetna-(aet),-buy-these-hmo-stocks-instead-200148812",200148812
142701,364216,HUM,Humana Remains On Growth Trajectory  Should You Add ,opinion,On Aug 18  we issued an updated research report on Humana Inc    NYSE HUM   Humana s second quarter 2016 operating earnings per share of  2 30 beat the Zacks Consensus Estimate by 1 8   The bottom line also improved 30  year over year buoyed by benefits from Humana s clinical programs along with lower healthcare costs With respect to the surprise trend  this Zacks Rank  1  Strong Buy  health maintenance organization posted positive surprise in three of the last four quarters  with an average beat of 1 32   Moreover  the Zacks Consensus Estimate has been revised upward over the last 30 days Humana has been benefiting from solid performances in Individual Medicare Advantage and Healthcare Services businesses  Also  the company s Medicare business that comprises Medicare Advantage and Medicare Part D Prescription Drug Plan  PDP  contracts with the federal government has shown excellent performance over the past few years   The Medicare Advantage business has been delivering strongly due to operating initiatives that have resulted in favorable prior period medical claims development and lower current year utilization Humana boasts financial strength backed by its hefty cash balance  Effective control on debt financing also helped Humana manage its capital  The company s relentless focus on creating shareholders  value through capital deployment activities drove long term growth Following strong second quarter earnings  Humana lifted its full year guidance for 2016 adjusted earnings per share at a minimum of  9 25 on  54  54 5 billion revenues  The company also raised its projection for Individual Medicare Advantage membership and stand alone PDP membership  Nonetheless  Humana lowered the same for Group Medicare Advantage membership and Individual commercial membership However  the pending merger with Aetna  NYSE AET  that is grappling with legal issues related to the U S Department of Justice   unprofitable Public Exchanges Business  weak performance by Individual Commercial Business as well as Group Medicare Advantage businesses along with escalating expenses are major drags for Humana Other Stocks that Warrant a LookInvestors interested in the industry can also consider stocks like The Joint Corp    NASDAQ JYNT    UnitedHealth Group Inc    NYSE UNH   and Wellcare Health Plans Inc    NYSE WCG    Each of these stocks holds a Zacks Rank  2  Buy  ,2016-08-17,Zacks Investment Research,https://www.investing.com/analysis/humana-remains-on-growth-trajectory:-should-you-add-200148796,200148796
142702,364217,HUM,Molina Healthcare Eyes Growth Despite Escalating Expenses,opinion,On Aug 23  we issued an updated research report on Molina Healthcare Inc    NYSE MOH   Molina Healthcare s second quarter 2016 bottom line beat the Zacks Consensus Estimate as well as improved year over year  Improvement in Ohio and Texas health plans  which were supported by a substantial decrease in the medical care ratio  primarily drove the upside  With respect to surprise trend  this Zacks Rank  3  Hold  health maintenance organization beat estimates in three of the last four quarters  with an average of 2 09  Molina Healthcare has been witnessing robust growth in two of the major components of its revenue mix   premiums and service revenues mainly due to growing membership  The momentum continued into the second quarter with revenues improving 24  Molina Healthcare has been growing inorganically via in market or tuck in acquisitions that helped the company grow significantly in existing markets  After 2015  which was deemed the most active MA  Mergers   Acquisition  year  the company completed its acquisition of Universal American s   NYSE UAM   Total Care Medicaid plan month and agreed to acquire certain Medicare Advantage assets from both Aetna Inc    NYSE AET   and Humana Inc    NYSE HUM   in 2016  These deals reflect the company s focus on arranging health care services for patients with complex requirements  which in turn  is expected to boost revenues Molina Healthcare also possesses a healthy balance sheet with steadily improving cash flow  Though the company witnessed a decline in operating cash flow in the first quarter of 2016  the metric recovered in the following quarter and generated  139 million  A long term trend of rising operating cash flow has been strengthening the company s cash position and is facilitating efficient capital deployment However  rising medical care costs have been putting margins under pressure and hence  remain an area of concern for Molina Healthcare  The increased expenses mainly stemmed from higher utilization factors and were most evident in connection with physician and outpatient costs  High operating expenses also continue to pose a risk for the company s operating leverage and can weigh heavily on margins  bottom line and cash flows going ahead  The company s dependence on debt financing that resulted in an increase in interest expenses is another negative ,2016-08-22,Zacks Investment Research,https://www.investing.com/analysis/molina-healthcare-eyes-growth-despite-escalating-expenses-200149591,200149591
142705,364220,HUM,After A String Of Obamacare Exits  What s Up For HMO Stocks ,opinion,The health insurance industry has been creating a lot of noise lately with players cribbing about their bad experience in the individual exchange business on public exchanges also popularly called Obamacare While UnitedHealth Group Inc    NYSE UNH   was a the first to disclose its unpleasant experience on public exchanges last year   this year Aetna Inc    NYSE AET    Humana Inc    NYSE HUM    Anthem Inc    NYSE ANTM   and now CIGNA Corp    NYSE CI   have joined the bandwagon UnitedHealth which was present in 34 states in 2016  has already exited public exchanges in more than two dozen markets and will exit more  In2017  it will completely exit the business or at the most be present on only three to four  Aetna has a similar saga to share  After its second quarter earnings  the company announced that it is calling quits in the public exchange business in 11 of the 15 states in which it is currently present Aetna will reduce its individual public exchange participation to 242 counties from 778 for the 2017 plan year  This development comes after Aetna suffered pretax loss of  200 million in the second quarter and total pretax loss of more than  430 million since Jan 2014 in its individual products sold via public exchanges Aetna is now expecting losses  pretax  north of  300 million on policies sold on public exchanges for 2016 Another player Humana Inc   HUM  recently announced it will sell plans through public exchanges in 11 states in 2017  down from 15 states this year because of losses  Anthem Inc   ANTM  also witnessed huge claims in its public exchange business in the second quarter While at the outset it seemed that public exchanges would add to the topline of the players by bringing in more enrollments  it did not turn out that straight  Insurers witnessed an adverse mix of population signing up for insurance on these exchanges  Those who sought insurance were mostly sick who went on to utilize healthservices  therefore causing a spike in claim ratio  In short  the premium paid by these members did not compensate for the care they sought  thus giving rise to losses on these policies Medical Sector Price IndexFriction with RegulatorsUp next  the players might see the axing of the mega mergers of Aetna with Humana and Anthem with Cigna announced last year  These mergers have drawn flak from regulators on concerns that the deals will stifle competition and reduce the number of players in the industry from five to three  The Department of Justice is closely scrutinizing the deal and has sued each of the four parties involved to block the merger The cause of concern for the regulators is that the mergers would mean more power in the hands of the surviving companies Anthem and Aetna as theywill gain in size and scale  It is feared that the companies if equipped with more strength will bother less to serve its customers  It is also being contemplated that these insurers will have lesser incentive to improve the quality of their product and service since there will be fewer and smaller players to compete against them  They might also hike premium and increase out of pocket costs  and in turn harass customers Merger was the most sought after strategy by these players to grow faster in the rapidly changing health insurance industry  The players wanted to gain in scale and size in one shot via these mergers which would have given them an upper hand in negotiating claims with hospitals  Investment in technology from cost savings  expanded reach to care by gaining quick access to new markets were other advantages of the merger cited by them The health insurers are being caught up in a series of events one after another  The presidential election that is coming up is the next major event for the industry What does Presidential Election Hold for Insurers Obamacare has become a political fodder with a contentious election around the corner  Both candidates have spoken length and breadth about the law displaying their varied opinion The presidential candidates are looking at ways to fine tune the provisions of the healthcare legislation  which  if implemented  will upend the business models of insurers     Democratic presidential candidate Hillary Clinton s priority includes a crackdown on insurers to limit out of pocket costs  These costs are expenses like deductibles  coinsurance and copayments for covered services among others that aren t reimbursed by insurance Also on Hillary Clinton s agenda is giving more power to lawmakers to reject undue rate hikes by health insurers Donald Trump on the other hand proposes to repeal the Affordable Care Act and replace it with something that would require a lot less money  He wants to propose a health plan that will return authority to the states and operate under free market principles  Trump s plan will provide choice to buyers  provide individual tax relief for health insurance and keep plans portable and affordable  The plan will break health insurance company monopolies and allow individuals to buy across state lines  Health insurers will have a rough ride if Trump wins the election since he commented that  The insurance companies are getting rich on Obamacare  The insurance companies are getting rich on health care and health services and everything having to do with health  We are going to end that  As it is insurers seem to have no respite from the series of events unfolding one after another  Now  we have to wait and see how these players turn the tide in their favor ,2016-08-22,Zacks Investment Research,"https://www.investing.com/analysis/after-a-string-of-obamacare-exits,-what's-up-for-hmo-stocks-200149557",200149557
142709,364224,HUM,Will Public Exchanges  Regulators Thwart Anthem s Growth ,opinion,On Aug 30  we issued an updated research report on Anthem Inc    NYSE ANTM   Anthem is one of the largest publicly traded managed care organizations in the U S  which serves customers in all the 50 states through its subsidiaries  The company is also the largest BCBS  Blue Cross Blue Shield  plan provider in the U S In order to further grow its size and scale Anthem has been keenly interested to acquire Cigna Corp    NYSE CI    The transaction would have complemented Anthem s Medicaid franchise  Medicare supplement and Medicare advantage business owing to Cigna s strong focus in dental  vision and behavioral health and wellness  However  Anthem has been sued by the Department of Justice over its pending acquisition of Cigna on grounds of several market oriented issues  Objection from the regulatory authorities have tied the company up in months of litigation and the deal  which was scheduled to close by 2016  has been deferred Nonetheless  successful acquisitions  commencement of health insurance exchanges  penetration of national accounts into the commercial segment and Medicaid expansion in the government segment have improved membership base  This has prompted the company to project medical membership for 2016 in the range of 39 6 39 8 million The company s effective capital management is reflected by consistent dividends payouts and stock repurchases  However  Anthem has temporarily suspended share buybacks owing to the pending acquisition of Cigna  Anthem s operational efficiency is reflected by its cash flow projection of more than  3 billion for 2016 However  the public exchange business that has been underperforming of late  This has compelled the company to lower 2016 membership projection by 300 000 in its individual business  Moreover  the sustained low interest rate environment has adversely affected its net investment income over the past few years The continuous deterioration of debt to capital ratio clearly indicates the company s high level of leverage  mainly due to the borrowing made for several acquisitions  The company is undertaking strategic initiatives to de lever its balance sheet as evidenced by the reduction in debt level in the first half of 2016  Zacks Rank   Stocks to ConsiderAnthem presently carries a Zacks Rank  3  Hold  Some better ranked stocks from the Health maintenance Organization industry include Humana Inc    NYSE HUM   and United Health Group Incorporated    NYSE UNH   Both of these stocks sport a Zacks Rank  2  Buy  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-08-30,Zacks Investment Research,"https://www.investing.com/analysis/will-public-exchanges,-regulators-thwart-anthem's-growth-200151045",200151045
142710,364225,HUM,UnitedHealth  UNH  Enhances Its Mobile App Features  ,opinion,In an effort to better serve its customers  leading health insurer UnitedHealth Group Inc    NYSE UNH   has enhanced its mobile app  Health4Me  This mobile app is compatible with iPhone and Android devices  It is aimed at lowering costs by increasing preventative care and reducing time to access care The Health4Me Mobile App was first launched in 2012  It provides millions of UnitedHealthcare employer plan participants 24 7 access to a registered nurse  enabling them to locate a nearby in network physician  hospital or other medical facility  and access to their personal health benefits information  An  Easy Connect  feature allows users to select the type of questions they have about their claims and benefits  Users could also request a callback from a UnitedHealthcare customer service representative UnitedHealth has now added new features to this app  primarily related to preventive services  These alert the customers about their health status early on  which helps them to take necessary measures to prevent actual occurrence of the disease later on  The preventive service therefore saves customers from utilizing costly medical care and ultimately saves the company from paying out claims  thereby aiding its bottom line The mobile app will now offer personalized care notifications  which will automatically alert members about preventive services and recommended medical treatments or tests  While reminding them about their missed medical service  such as immunization of a child or a blood sugar test for a diabetic  it will also help people to look for health care providers and schedule appointments UNITEDHEALTH GP Price   UnitedHealth is providing personalized care notifications to select UnitedHealthcare plan participants nationwide  including Medicaid beneficiaries in 17 states The app will now also enable members to pay medical bills with a credit card  debit card  bank account or health savings account  Access to a nurse or virtual physician visits 24 hours a day  a digital identification card  and wellness related resources such as integration with wearable devices are some of the other features Later during the year UnitedHealth plans to enhance its service by providing clinically focused notifications based on personalized claims data  such as alerts for prenatal care and support programs for people with back pain The introduction of this enhanced mobile service will help UnitedHealth to be a frontrunner in the industry by providing greater service via handheld devices   Also  customers are increasingly demanding such care services  given their ease and flexibility of use According to research firm Forrester  65  of the consumers are interested in using a health plan s website or app to access a physician  and 53  are interested in receiving symptom based treatment suggestions  The company wants to leverage upon this growing demand for technology enabled services UnitedHealth carries a Zacks Rank  2  Buy   Other stocks worth considering include Humana Inc    NYSE HUM    WellCare Health Plans  Inc    NYSE WCG   and Nobilis Health Corp    NYSE HLTH    All these stocks carry the same Zacks Rank as UnitedHealth Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand    ,2016-08-31,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-(unh)-enhances-its-mobile-app-features-200151406,200151406
142711,364226,HUM,Forget Cigna  CI   Buy These HMO Stocks Instead,opinion,"Cigna Corp    NYSE CI   is going through a rough patch with niggling concerns like an underperforming Life and Disability segment  CMS sanctions on the sale of Medicare Advantage policies  a weak public exchange business and uncertainty surrounding the Anthem   NYSE ANTM   merger  These compelled the company to cut its full year 2016 earnings guidance to  7 75  8 10 per share from  8 95  9 35 Cigna has one of the greatest shares in the Disability market  But this business has become increasing unpredictable and volatile in recent years  The segment suffered due to modifications made to the disability claim process  The modification includes upfront medical review of claims to conduct further physical examinations  deeper medical history reviews and enhanced documentation  These modifications resulted in longer claim cycles  thereby increasing disability durations and claim inventory which did not favor its business in the first half of 2016  Investments are being made in this segment to strengthen the operational processes in a manner that will lead to improved customer experience and lower claim volatility  The life subsegment suffered from a spike in claims  Though the company is taking necessary steps to restore profitability of the segment  we would remain cautious until we see it posting favorable earnings Another friction faced by the company is the blockage of the deal to merge with Anthem by the Department of Justice  The deal may now be delayed to 2017  The merger  which would have raised the rank of the company in the industry is now shrouded in uncertainty  Any delay would adversely impact the company and come in the way of its desired operational performance  In fact  in 2015 the company incurred a loss of  57 million in connection with the anticipated merger and  62 million in the first half of 2016  Unfavorable refinancing expenses and unexpected costs associated with the delay can be a matter of concern The company also faces restriction from the Centers for Medicare   Medicaid Services   CMS   regarding the sale of Medicare Advantage policies  Effective Jan 21  2016  the CMS imposed sanctions suspending Cigna s enrollment and marketing activities related to all Cigna Medicare Advantage and standalone prescription drug plan contracts   To date  it remains unclear as to when these might be lifted  The sanctions point directly to failure to comply with coverage determinations  appeals and grievances  and Part D administration which CMS characterized as  systemic  and  longstanding  and unchanged even several years after warning the company  Cigna won t be allowed to market or sell Medicare Advantage policies or Part D drug plans to new clients in the open enrollment season that will start in mid October  If Cigna is unable to address these issues prior to open enrollment  its MA membership will be hit hard and be a drag on its earnings Moreover  Cigna is currently losing money in its public exchange business  It is mulling over discontinuing operations in the Texas market  Though the company said that it has intentions to selectively expand its public exchange presence to a few new geographical regions in 2017  we view this as quite unlikely in the light of similar comments coming from Aetna  NYSE AET  and UnitedHealth just after pulling back from the exchanges citing increasing losses While Cigna  which carries a Zacks Rank   5  Strong Sell  remains mired in its problems  we take this opportunity to look at other health maintenance organization  HMO  stocks in the space providing better investment opportunities  These include Humana Inc    NYSE HUM    United Health Group Inc    NYSE UNH   and WellCare Health Plans  Inc    NYSE WCG    We have picked these three stocks using our style score system  Not only do they have a solid Value Style Score of  A  or  B  and a favorable Zacks Rank  1  Strong Buy  or  2  Buy   they also witnessed a rise in earnings estimates over the past 60 days CIGNA CORP Price and Consensus   The PicksHumana with a Zacks Rank  1 has strong fundamentals  Its strong performing individual Medicare Advantage and other government sponsored plans remain the highlights  Also  its Healthcare Services business is well poised and will contribute to its growth  Last month  Humana won a contract from the U S  Department of Defense to administer TRICARE benefits to about 6 million people  which nearly doubles the number of military beneficiaries served by Humana However  challenges in its individual commercial medical business pose as concerns  Also  its merger with Aetna remains uncertain  Nevertheless  the company raised its 2016 earnings guidance to at least  8 56 from  8 32 predicted before  Humana has also witnessed a 4 3  increase in its Zacks Consensus Estimate to  9 23 per share for 2016  over the past 60 days  with 11 out of 12 analysts covering the stock raising their estimates  Its long term EPS growth rate is 13 5   It has a Value Style score of  B  HUMANA INC NEW Price and Consensus   UnitedHealth  with a Zacks Rank  2  is the most diversified health maintenance organization  Though the company remains troubled by its public exchange business and has exited most of the markets  it  is still attractive given the strength in its other business segments  Instead of its heavily regulated Health Benefits business  the company is focusing on investing and growing its health services business branded as Optum To this end  the company acquired Catamaran last year  The acquisition is evidently fruitful thanks to the revenue accretion from it  Optum is becoming an increasingly valuable business and is expected to contribute about 42  to UnitedHealth Group s consolidated operating earnings this year Also  the company s membership has grown over the past five years by nearly 13 5 million or 40  well diversified across commercial  government programs and international offerings  The company s membership is further set to grow in Medicare Advantage  Medicaid as well as commercial plans  UnitedHealth also has a strong balance sheet and generates handsome cash flows which allow it to increase dividend payments and make regular share buybacks Moreover  UnitedHealth witnessed an increase in the 2016 Zacks Consensus Estimate to  7 90 per share from  7 88  over the past 60 days  with eight out of 14 analysts covering the stock raising their individual estimates  Its long term EPS growth rate is 13 4   It has a Value Style score of  A UNITEDHEALTH GP Price and Consensus   WellCare Health Plans   NYSE WCG   with a Zacks Rank  2 remains well poised to grow in the Medicaid  Medicare and Medicare Part D business  During the second quarter  it closed the Advicare transaction  gaining greater Medicaid presence in South Carolina  The company is taking both organic and inorganic steps to fuel its growth and trying to double its revenues between 2017 and 2021 The company also increased its 2016 adjusted earnings per diluted share guidance to a range of  4 95 to  5 05 from its previous guidance of  4 55 to  4 70 WellCare Health also witnessed a 7 5  increase in the Zacks Consensus Estimate to  5 01 per share for 2016  over the past 60 days  with each of the nine analysts covering the stock raising their individual estimates  Its long term EPS growth rate is 17 7   It has a Value Style score of  A  
WELLCARE HEALTH Price and Consensus   
Confidential  Zacks  Best Investment IdeasWould you like to see a hand picked  all star  selection of investment ideas from the man who heads up Zacks  trading and investing services  Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand     ",2016-09-01,Zacks Investment Research,"https://www.investing.com/analysis/forget-cigna-(ci),-buy-these-hmo-stocks-instead-200151580",200151580
142739,364254,HUM,Blue Chip Stock Earnings Preview  PFE  PG  HUM ,opinion,"This video takes a closer look at three top blue chip companies which may be in focus for investors this earnings season  After all  with recent risks to the market  investors have been focusing more on blue chips and large caps in general  potentially making these  boring  companies exciting ones to watch this week  In particular  we take a look at the following trio of companies 
Pfizer  NYSE PFE  is up first  and this mega cap pharma name has a great history of beats in earnings season  The company reports before the bell on 8 2  and while it has just a Zacks Rank  3  Hold   it does have some decent fundamentals including a  B  VGM score and a great dividend yield which has definitely been attracting investors PFIZER INC Price  Consensus and EPS Surprise   
Humana  NYSE HUM  is another big cap reporting this week  and any commentary about its recent guidance move and the DOJ moving to block its potential merger are likely to weigh on the company s report on Wednesday before the bell  The stock does have a nice history of beating estimates though  while it has a Zacks Rank  2  Buy  a positive earnings ESP which suggests a beat HUMANA INC NEW Price and EPS Surprise   
And last but not least  Procter   Gamble  PG  is also up this week  reporting on the Second before the bell  The company has been in focus thanks to recent investor demand for safe haven stocks and it has been on the move in 2016  This makes expectations for PG s report potentially high  and especially considering we haven t seen any real lift in earnings estimates lately  possibly setting up PG for a rough earnings report PROCTER   GAMBL Price  Consensus and EPS Surprise   
For more in depth analysis of these companies  make sure to watch our short video on the topic  And for additional insights on trading earnings reports  listen to podcast below 
Author is long PFE",2016-08-01,Zacks Investment Research,"https://www.investing.com/analysis/blue-chip-stock-earnings-preview:-pfe,-pg,-hum-200145518",200145518
142740,364255,HUM,Aetna  AET  Beats Q2 Earning Estimates On Revenue Growth,opinion,Aetna Inc    NYSE AET   is one of the nation s leading diversified healthcare benefits companies  serving an estimated 46 3 million people  Aetna is a solid company  with a diversified revenue stream that should be beneficial in this changing environment Aetna proposed to acquire Humana Inc  NYSE HUM   last year  The deal would have enabled it to penetrate the penetrate fast growing the Medicare space   However  the company has been sued by the U S  Department of Justice and there now remains uncertainty around the closing of the deal Aetna has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 8 98  Currently  Aetna has a Zacks Rank  2  Buy   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below The Bottom Line  Aetna beats on earnings  Our consensus called for EPS of  2 11 and the company reported earnings per share of  2 21  Earnings increased 8  on an year over year basis The Top Line  Revenues also came in ahead of expectations  Aetna posted revenues of  15 95 billion  higher than our consensus estimate of  15 74 billion Key Stats  Total operating expenses were  2 8 billion for the second quarter of 2016 Medical membership remained flat at 23 0 million in the second quarter For the full year 2016  Aetna expects earnings in the range of  7 90 to  8 10 per share AETNA INC NEW Price and EPS Surprise   Check back later for our full write up on this AET earnings report later ,2016-08-02,Zacks Investment Research,https://www.investing.com/analysis/aetna-(aet)-beats-q2-earning-estimates-on-revenue-growth-200145667,200145667
142741,364256,HUM,Why Are Health Insurers Ditching Obamacare  ,opinion,"Health insurer Aetna Inc    NYSE AET   announced its second quarter financial data after the bell Tuesday  and despite beating our estimates for both earnings and revenue  the company highlighted some troubling signs about the effectiveness of the Affordable Care Act 
Aetna said that it expects to lose about  300 million dollars on its Obamacare business this year  The company also announced that it is cancelling plans to expand its Obamacare offerings to five new states  and it will reassess its existing business in the 15 states it already covers 
 While we are pleased with our overall results  in light of updated 2016 projections for our individual products and the significant structural challenges facing the public exchanges  we intend to withdraw all of our 2017 public exchange expansion plans  and are undertaking a complete evaluation of future participation in our current 15 state footprint   said Aetna CEO Mark T  Bertolini 
Aetna joins a growing list of health insurance companies that are struggling to make money from the new law  United Healthcare   NYSE UNH    the country s largest insurer  already announced that it will be scaling its Obamacare business down from 1 200 counties in eight states to just 156 counties across 11 states 
Insurance companies are also requesting higher premium hikes for next year  On average  insurers have requested that premiums for the benchmark silver plan  which federal subsidies are based upon  increase by 9   with some requests hitting double digits in several markets  In 2016  premiums for this benchmark plan increased by 2  
A large number more than half of the co op insurers created and funded by Obamacare have also failed  As insurance providers disappear from markets  individuals have limited choices and often must pick from only one or two companies 
 Insurers are saying that premiums are simply too low to cover the new patients  who tend to get sicker and be more costly to cover  People who are covered under Obamacare plans are more prone to serious diseases and  on average  cost 22  more per month to cover than those with employer plans 
As a result  insurance companies need to either raise premiums or cut their own costs  One method that we ve seen insurers look towards to shave costs is consolidation  Two massive mergers have been attempted  with Anthem   NYSE ANTX   looking to purchase Cigna   NYSE CI   for  54 billion and Aetna attempting to buy Humana   NYSE HUM   for  37 billion 
By consolidating their businesses  these companies are looking to increase efficiency and cut down on operating costs  This would  however  reduce the amount of major players in the industry from five to just three 
In an effort to protect competiveness in the market  the Department of Justice recently sued the companies involved in these deals to block the mergers  The DoJ is presumably most concerned with the effects that these new insurance giants would have on smaller companies in the industry  The mergers could also result in more expensive prices as individuals have less options to choose from 
Both Anthem and Aetna have already responded to the DoJ s suits by promising to fight the blockage  As for right now  it looks like these massive mergers and or increased premiums will eventually come as a result of the difficult climate for Obamacare providers ",2016-08-03,Zacks Investment Research,https://www.investing.com/analysis/why-are-health-insurers-ditching-obamacare-200145849,200145849
142742,364257,HUM,Humana  HUM  Q2 Earnings   Revenues Beat  Revises View,opinion,"Humana Inc  s   NYSE HUM   second quarter 2016 operating earnings per share of  2 30 beat the Zacks Consensus Estimate of  2 26 by 1 8   The bottom line also improved 30  year over year 
This upside was mainly driven by the improvement in Humana s clinical programs coupled with lower healthcare cost 
Revenues increased 2  year over year to  14 01 billion  Higher premiums and services revenues contributed to top line growth  Revenues surpassed the Zacks Consensus Estimate by 2 9  Quarterly ReviewHumana s consolidated benefit ratio   the percentage of benefit expenses in premium revenues   was 84 3   This marks an improvement of 90 basis points  bps  year over year  Lower benefit ratios at both the Retail and Group segments attributed to the improvement Consolidated operating cost ratio   the percentage of operating costs in total revenue less investment income   also decreased 90 bps year over year to 12 4  driven by favorable results at both the Retail and Group segments  The sale of Concentra in Jun 2015 which carries a very high operating cost ratio also contributed to the improvement Quarterly Results by SegmentRetail Segment  Reported premiums and services revenues increased 4  year over year to  12 03 billion in the second quarter  The upside primarily reflects an increase in average Medicare Advantage membership and per member premium increases Benefit ratio came in at 86 8  as against 87 1  in the prior year quarter  This was because operating initiatives on businesses within the segment resulted in favorable prior period development and lower current year utilization in pricing Operating cost declined 20 bps year over year at 10 3   Administrative cost efficiencies from medical membership growth and continuous operational efficiency efforts primarily supported cost reduction Group Segment  Reported premiums and services revenues dipped 1  to  1 83 billion  primarily due to decline in average fully insured and Administrative Services Only commercial group medical membership  However  an increase in fully insured group medical per member premiums limited the downside 
Benefit ratio was 78 8   down 260 bps year over year due to favorable current year medical claims development  Moreover  favorable risk adjustment accruals in the second quarter contributed to this increase Healthcare Services  Revenues from this segment increased 6  year over year to  6 24 billion  mainly due to growth in the company s individual Medicare Advantage and stand alone PDP membershipOperating cost ratio was 95 3   down 20 bps year over year 
Financial UpdateAs of Jun 30  2016  cash  cash equivalents and investment securities of Humana were  11 90 billion  up from  11 68 billion as of Dec 31  2015 but down 5  from  12 48 billion as of Mar 31  2016 As of Jun 30  2016  the company had  300 million outstanding under its commercial paper program Share Repurchase and Dividend UpdateHumana suspended its share repurchase program on Jul 2  2015 due to the pending acquisition by Aetna  Notably  the company has  1 04 billion remaining under its authorization Humana paid cash dividend worth  43 million in the second quarter Guidance RevisedHumana now projects 2016 adjusted earnings per share of  at least  9 25   Net membership growth in individual Medicare Advantage is expected in the range of 75000 90000 and net membership growth in stand alone PDP offerings are projected between 400 000 and 425 000  Membership in Group Medicare Advantage is estimated to be down 120 000 to 125 000  while Individual commercial membership is expected to decline 200 000 to 300 000  Revenues are expected to be in the range of  54  54 5 billion  up from at least  53 5 billion  Adjusted earnings per share are estimated to be at least  2 77 for the third quarter of 2016 HUMANA INC NEW Price  Consensus and EPS Surprise
   Zacks RankHumana currently carries a Zacks Rank  2  Buy  
Performance by Other HMOsAmong the other health maintenance organizations  HMOs   UnitedHealth Group Inc    NYSE UNH    Aetna Inc    NYSE AET   and Anthem Inc   NYSE ANTM   surpassed their respective Zacks Consensus Estimate in the second quarter of 2016 ",2016-08-03,Zacks Investment Research,"https://www.investing.com/analysis/humana-(hum)-q2-earnings---revenues-beat,-revises-view-200145847",200145847
142743,364258,HUM,Aetna  AET  To Quit 11 State Exchanges To Check Losses,opinion,Aetna Inc    NYSE AET   is calling it quits in the public exchange business in 11 of the 15 states in which it is currently present  It will  however  maintain its presence in Delaware  Iowa  Nebraska and Virginia  Aetna will reduce its individual public exchange participation to 242 counties from the initial 778 ones for the 2017 plan year This development comes after Aetna suffered a pretax loss of  200 million in the second quarter and total pretax losses of more than  430 million since Jan 2014 in its individual products sold via the public exchanges Earlier  Aetna expected to be at a breakeven in this business in 2016  but now is reevaluating it since it is witnessing huge claims from the sicker than expected customers enrolled at the public exchanges  The number of healthy and young individuals which enrolled at these exchanges are far less than the customers with old age and pre existing diseases who lacked coverage earlier  This adverse mix of customer population led to increased claims  leading to losses for the insurer AETNA INC NEW Price   Last year  UnitedHealth Group Inc    NYSE UNH   was the first among the health insurers to spell out its troubles on the public exchanges  In order to scale back its activity on the exchanges recently UnitedHealth withdrew platinum products  increased prices  eliminated marketing and commissions  intensified clinical engagement and medical management with this membership group and reduced operating cost Another player Humana Inc    NYSE HUM   recently announced it will sell plans through public exchanges in 11 states in 2017  down from 15 states this year because of losses Anthem Inc    NYSE ANTM   also witnessed huge claims in its public exchange business in the second quarter Insurers by and large have had an adverse stint on the public exchanges  which were created under the Affordable Care Act  also known as Obamacare  to provide insurance to more than 9 million individuals  The recent exits on public exchanges by health insurance majors raises questions about the viability of online exchange business which was created to provide subsidized health insurance coverage  Moreover it is most likely that other insurers would also be thinking to exit the exchanges  Most of the players are realizing that exchanges do not provide profitable business opportunity  and that this may cause a mass exodus which may hamper the functionality of the exchanges and cause a failure of the Obamacare program thus defeating the central aim of providing coverage to millions of uninsured Americans Aetna carries a Zacks Rank   3  Hold  ,2016-08-15,Zacks Investment Research,https://www.investing.com/analysis/aetna-(aet)-to-quit-11-state-exchanges-to-check-losses-200148275,200148275
142744,364259,HUM,Aetna  AET  Is Reducing It s Participation In Obamacare Significantly,opinion,"Aetna Inc    NYSE AET   has announced that it will stop offering individual Obamacare plans in 11 of the 15 states where it is participating   Other major insurers who have exited government run markets include UnitedHealth Group   NYSE UNH   and Humana   NYSE HUM    
The reason why each of these insurers is retreating from the public individual on exchange markets is because of the losses incurred which amount to hundreds of millions of dollars annually   The lack of profitability has lead to many insurers exiting the state run exchange market  According to a   insurers offering individual state run health plans have been on a decline  and since 2013  the number of insurers  public individual plans decreased from 395 to 287 
Aetna is lowering its participation in Affordable Care Act  ACA  individual public exchanges in light of a Q2 pretax loss of  200 million from its individual products   55  of individual on exchange memberships are new in 2016  and the company saw individuals who needed high cost care taking up a larger portion of their on exchange population   This has lead to an unbalanced risk pool among policyholders  and Aetna now questions the sustainability of its state run exchanges 
The US Department of Health and Human Services recently announced that it will seek to find ways to modify the risk adjustment programs in the hope that they will be able to work on making a more sustainable public exchange model   Aetna is a proponent of public exchanges as a way to help the uninsured  and CEO Mark Bertolini says that he is encouraged by the Department of Health and Human Services  announcement  
The four states where plans will continue to be sold on state exchanges include Iowa  Delaware  Nebraska  and Virginia   Aetna is reducing its public exchange participation from 778 to 242 counties in the 2017 plan year   For most of the counties where public products were offered in 2016  the company will offer an off exchange individual product option for 2017   Aetna s decision to lower its public on exchange participation will not affect people who are covered by the insurer this year   Pay attention to earnings estimate revisions from analysts and whether they move upwards or downwards over the near term   Aetna stock is currently a Zacks Rank  3  Hold  
Interested in healthcare stocks  Read up on  
The Zacks Rank is a truly marvelous trading tool   Our ranking system has beaten the S P 500  yielding an average return of 25  per year for the last 29 years   Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-16,Zacks Investment Research,https://www.investing.com/analysis/aetna-(aet)-is-reducing-it's-participation-in-obamacare-significantly-200148304,200148304
142757,364272,HUM,UnitedHealth Poised For Growth Despite Increasing Competition,opinion,On Jul 20  2016  we issued an updated research report on UnitedHealth Group Incorporated   NYSE UNH   UnitedHealth s second quarter 2016 earnings per share beat the Zacks Consensus Estimate and improved year over year on higher revenues  Solid performance at health services business Optum  and membership increase also contributed to the outperformance UnitedHealth leverages core competencies in advanced technology based transactional capabilities through its diverse operations in healthcare and well being  Through Optum  its health services business  the company covers almost every aspect of health and wellness management   This business is highly profitable and currently contributes 42  of UnitedHealth s total revenue  Optum is on track to achieve significant growth and meet performance targets for this year UnitedHealth s commendable Medical member base reflects its leading market position across all private health insurance segments of North and South America  The company has grown its membership by 40  over the past five years  Its well diversified operations across commercial  government programs as well as international offerings reflect its competitiveness  In order to mitigate the risks associated with stringent and increasing U S regulations  the company remains focused on expanding its operations worldwide  mostly through overseas acquisitions The Zacks Rank  3  Hold  company boasts a strong balance sheet  This  in turn  helps it to consistently engage in efficient capital deployment through share repurchases  mergers  dividend increases or other similar strategic moves However  the company s weak debt to capital ratio raises concerns  Also  the company remains exposed to stiff competition with the same intensifying pending mergers of medical sector giants like Anthem Inc    NYSE ANTM    Cigna Corp    NYSE CI   and Humana Inc    NYSE HUM    Also  UnitedHealth plans to shut down its exchange business in 2017 as rising forex regulations puts pressure on profitability  The company has already reduced its marketing efforts for individual insurance policies sold on exchanges for 2016 UnitedHealth experienced a low level of medical care over the past couple of years  This resulted in reduced medical claim costs and increasing profits  However  management expects a return to more normalized medical utilization trends soon  which will wipe out the extra earnings benefit that the company had been enjoying so far The commercial business  which accounts for one third of the company s operating margin  has not been as profitable as expected  The shift in Group Employer benefits moved to the subsidized Public and Private Exchanges is likely to have been the primary reason behind the underperformance ,2016-07-20,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-poised-for-growth-despite-increasing-competition-200143335,200143335
142762,364277,HUM,Here s How Presidents And Elections Affect The Stock Market,opinion,"Thursday marks the conclusion of the Republican National Convention  the first of two major party conventions that will see Donald Trump and Hillary Clinton accept their respective nominations  This election year has already been uniquely contested  and there s still several important months ahead of us 
With the media portraying an increasingly polarized country and a Supreme Court spot up for grabs  this year s election also promises to be very important  As nationwide polls continue to come in  it s obviously too early to call the race and it looks like we won t be sure of a winner until Election Day 
So what does this mean for investors  Well  for now  it means uncertainty  We know the market doesn t like uncertainty  but does the winner of the presidential race even matter for us  Today we re going to look at some trends and tendencies to determine what effect  if any  the president has on the stock market 
Historical Trends
Before we ask any sort of  Why   question  it s easier to simply identify the facts  One clear trend involving presidents and share prices is that the stock market tends to have more favorable returns under Democratic presidents  Since 1900  the Dow Jones Industrial average has returned 7 0  annually under Democratic presidents  compared to 3 0  under Republican presidents 
When we break this down further  we also notice a trend between market performance and the year of a president s term  Far and away  the third year of one s presidency tends to be the best year for market returns  while the final year  or  lame duck year   tends to be the worst 
The sluggish performance associated with lame duck years probably has to do with the president s lack of political restraint  Since the lame duck doesn t have an election to win  they can be a bit more unpredictable  It s also important to remember that lame duck years are also election years  which indicates that elections can also signal rocky performance 
Fiscal vs  Economic Policy
We also need to take into consideration what powers the president has to actually affect the economy  Remember  there s no magic gas prices and stocks button in the Oval Office  The president is just one part of an intricate system of checks and balances  and it can be hard to recognize exactly what pieces of their ideology are actually doing something  On that note  let s define fiscal policy and monetary policy 
Fiscal policy is the use of government revenue collection to collect and distribute money in an effort to influence the economy  In other words  it s how the government adjusts spending levels and tax rates to make a specific impact on the economic activity in the country 
The president is able to have a significant impact on fiscal policy  In many elections  you ll see candidates running with specific fiscal policy plans  and once elected  the president can support legislation that defines that policy  Of course  the other key actor in the fiscal policy play is Congress  and any legislation has to go through both the executive and legislative branches 
On the other hand  monetary policy is set by a central bank  in the case of the United States  this is the Federal Reserve s job  The Fed sets interest rates to influence the amount of money that is available to spend in the economy 
Both fiscal and monetary policy affect how much money consumers have in their hands  which affects economic performance  which affects the stock market  Both of these tactics can send stocks up or down 
However  it is probably fair to say that the markets anticipate news from the Fed more  Especially this year  we have seen big reactions to the news that the Fed was delaying its interest rate hike schedule  which created a sense of uncertainty of the state of the economy 
We also have to note that not all presidents see a correlation between the health of the economy and positive stock returns  For example  Besides Nixon  Lyndon B  Johnson saw the worst post WWII market returns  yet gross domestic product was hitting new heights during his presidency  On the other hand  George H W  Bush saw average market returns during a notably sluggish economy 
Case by Case Basis
Perhaps the biggest presidential effects on stocks are seen on a specific case by case basis  For example  we have seen a massive shakeup in the healthcare industry since the passing of the Affordable Care Act under President Obama  Just take a look a returns on stocks like UnitedHealth   NYSE UNH    Humana   NYSE HUM    Aetna   NYSE AET    and Universal Health Services   NYSE UHS   since Obamacare passed in 2010 
Looking forward  we can start to identify the sectors that could move based on the major points of Clinton and Trump s platforms  For example  when Clinton tweeted about reigning in price gouging in the drug market last year  the major biotech ETF  fell nearly 4 5  in a day  and that was before Clinton was even close to locking up the nomination 
Clinton has also shown to be more hawkish on national security than President Obama  and her campaign has received the most donations from the aerospace and defense sector  Take a look at these  
In a surprising twist  Donald Trump s campaign took a left leaning stance on big banks during the convention this week  officially adopting the stance that Glass Steagall should be reinstated  You can check out a  
Bottom Line
This election is an important one  and investors should always be keeping their eyes on something that could have even the tiniest effect on stocks  Although the past indicates that the market favors Democrats  it s much easier to identify specific sectors and stocks that would be affected by the platforms of the winner  A president simply does not have all of the power when it comes to the performance of the entire stock market ",2016-07-21,Zacks Investment Research,https://www.investing.com/analysis/here's-how-presidents-and-elections-affect-the-stock-market-200143344,200143344
142763,364278,HUM,The Zacks Analyst Blog Highlights  UnitedHealth  Humana  Aetna  Universal Health And IShares NASDAQ Biotechnology Index,opinion,"For Immediate Release 

Chicago  IL   July 22  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include UnitedHealth     Humana  NYSE HUM      Aetna  NYSE AET      Universal Health Services    and iShares NASDAQ Biotechnology Index     

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Thursday s Analyst Blog  

Here s How Presidents and Elections Affect the Stock Market

Thursday marked the conclusion of the Republican National Convention  the first of two major party conventions where Donald Trump and Hillary Clinton accept their respective nominations  This election year has already been uniquely contested  and there s still several important months ahead of us 

With the media portraying an increasingly polarized country and a Supreme Court spot up for grabs  this year s election also promises to be very important  As nationwide polls continue to come in  it s obviously too early to call the race and it looks like we won t be sure of a winner until Election Day 

So what does this mean for investors  Well  for now  it means uncertainty  We know the market doesn t like uncertainty  but does the winner of the presidential race even matter for us  Today we re going to look at some trends and tendencies to determine what effect  if any  the president has on the stock market 

Historical Trends

Before we ask any sort of  Why   question  it s easier to simply identify the facts  One clear trend involving presidents and share prices is that the stock market tends to have more favorable returns under Democratic presidents  Since 1900  the Dow Jones Industrial average has returned 7 0  annually under Democratic presidents  compared to 3 0  under Republican presidents 

When we break this down further  we also notice a trend between market performance and the year of a president s term  Far and away  the third year of one s presidency tends to be the best year for market returns  while the final year  or  lame duck year   tends to be the worst 

The sluggish performance associated with lame duck years probably has to do with the president s lack of political restraint  Since the lame duck doesn t have an election to win  they can be a bit more unpredictable  It s also important to remember that lame duck years are also election years  which indicates that elections can also signal rocky performance 

Fiscal vs  Economic Policy

We also need to take into consideration what powers the president has to actually affect the economy  Remember  there s no magic gas prices and stocks button in the Oval Office  The president is just one part of an intricate system of checks and balances  and it can be hard to recognize exactly what pieces of their ideology are actually doing something  On that note  let s define fiscal policy and monetary policy 

Fiscal policy is the use of government revenue collection to collect and distribute money in an effort to influence the economy  In other words  it s how the government adjusts spending levels and tax rates to make a specific impact on the economic activity in the country 

The president is able to have a significant impact on fiscal policy  In many elections  you ll see candidates running with specific fiscal policy plans  and once elected  the president can support legislation that defines that policy  Of course  the other key actor in the fiscal policy play is Congress  and any legislation has to go through both the executive and legislative branches 

On the other hand  monetary policy is set by a central bank  in the case of the United States  this is the Federal Reserve s job  The Fed sets interest rates to influence the amount of money that is available to spend in the economy 

Both fiscal and monetary policy affect how much money consumers have in their hands  which affects economic performance  which affects the stock market  Both of these tactics can send stocks up or down 

However  it is probably fair to say that the markets anticipate news from the Fed more  Especially this year  we have seen big reactions to the news that the Fed was delaying its interest rate hike schedule  which created a sense of uncertainty of the state of the economy 

We also have to note that not all presidents see a correlation between the health of the economy and positive stock returns  For example  Besides Nixon  Lyndon B  Johnson saw the worst post WWII market returns  yet gross domestic product was hitting new heights during his presidency  On the other hand  George H W  Bush saw average market returns during a notably sluggish economy 

Case by Case Basis

Perhaps the biggest presidential effects on stocks are seen on a specific case by case basis  For example  we have seen a massive shakeup in the healthcare industry since the passing of the Affordable Care Act under President Obama  Just take a look a returns on stocks like UnitedHealth      Humana       Aetna     and Universal Health Services    since Obamacare passed in 2010 

Looking forward  we can start to identify the sectors that could move based on the major points of Clinton and Trump s platforms  For example  when Clinton tweeted about reigning in price gouging in the drug market last year  the major biotech ETF     fell nearly 4 5  in a day  and that was before Clinton was even close to locking up the nomination 

Clinton has also shown to be more hawkish on national security than President Obama  and her campaign has received the most donations from the aerospace and defense sector  Take a look at these   

In a surprising twist  Donald Trump s campaign took a left leaning stance on big banks during the convention this week  officially adopting the stance that Glass Steagall should be reinstated  You can check out a   

Bottom Line

This election is an important one  and investors should always be keeping their eyes on something that could have even the tiniest effect on stocks  Although the past indicates that the market favors Democrats  it s much easier to identify specific sectors and stocks that would be affected by the platforms of the winner  A president simply does not have all of the power when it comes to the performance of the entire stock market 

Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days   

Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact
	Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-07-21,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-unitedhealth,-humana,-aetna,-universal-health-and-ishares-nasdaq-biotechnology-index-200143541",200143541
142764,364279,HUM,Anthem  ANTM  Q2 Earnings Beat On Solid Premium Growth ,opinion,Anthem Inc    NYSE ANTM   reported second quarter 2016 adjusted income of  3 33 per share that beat the Zacks Consensus Estimate of  3 24 by 2 8   The bottom line also increased 7 4  year over year as solid membership growth drove premiums higher Operating revenues of  21 27 billion surpassed the Zacks Consensus Estimate of  20 45 billion and also increased 7 7  year over year on higher premiums and increased enrollment in the Medicaid and Commercial self funded businesses Anthem s premium revenues were up 7 7  to  19 9 billion and administrative fees rose 7  to  1 3 billion  both on a year over year basis  Other revenues  however  plunged 14 4  year over year to  10 7 million Total expenses increased 8 4  year over year to  20 billion in the reported quarter  Higher interest expenses and benefit costs resulted in the overall rise in expenses Medical enrollment at Anthem grew 3 2  year over year to 39 8 million as of Jun 30  2016  The upside was primarily driven by enrollment gainsin Commercial   Specialty Business and Medicaid business   Anthem posted a benefit expense ratio  benefit expenses as a percentage of premium revenues  of 84 2  in the reported quarter  This reflects an increase of 210 basis points year over year Segment ResultsCommercial   Specialty BusinessThis segment covers the Local Group  National Accounts  Individual and Specialty businesses  Operating revenues incresead 5 4  year over year to  9 9 billion in the reported quarter Operating gains in the segment increased 17 8  year over year to  1 1 billion  mainly due to changes in the prior and current year risk adjustment estimates in ACA compliant products  Also  a lower SG A  Selling  General and Administrative  ratio due to reduced administrative costs as a result of expense efficiency initiatives undertaken by the company contributed to the improvement Government BusinessThis segment consists of the Medicaid and Medicare business lines  and National Government Services  Operating revenues grew 9 6  year over year to  11 4 billion in the quarter under review Operating gains in the segment decreased 26 1  year over year to  450 5 million on increases in medical cost experience  which exceeded the net impact of annual premium rate adjustments in the Medicaid business  However  the downside was partially offset by a lower SG A ratio supported by reduced administrative costs as a result of expense efficiency initiatives undertaken by Anthem Financial UpdateAs of Jun 30  2016  Anthem had cash and cash equivalents of  1 5 billion  lower than  2 1 billion as of Dec 31  2015 Long term debt of Anthem decreased to  14 2 billion as of Jun 30  2016 from  15 3 billion as of Dec 31  2015  Shareholder equity was  24 2 billion as of Jun 30  2016  higher than  23 0 billion at year end 2015 Operating cash flow was  662 million  The reported figure was 0 8 times the net income in the second quarter Dividend UpdateIn the reported quarter  Anthem declared and paid a quarterly dividend of 65 cents per share  This resulted in payout of  170 9 million  The Audit Committee also declared a third quarter dividend of 65 cents per share payable on Sep26  2016  to shareholders of record on Sep 9  2016 ANTHEM INC Price  Consensus and EPS Surprise   Guidance for 2016Anthem expects adjusted net income of greater than  10 80 per share  Including more than  1 46 per share of net unfavorable items  net income is now expected to be higher than  9 34 per share Medical membership is expected in the range of 39 6 39 8 million  Fully insured membership is anticipated between 14 9 million and 15 million  while self funded membership is estimated to be in the range of 24 6 24 7 million Operating revenues are projected in the  82 5  83 5 billion range as against  81  82 billion guided previously Benefit expense ratio is expected to be around 84 9   while SG A ratio is expected to be around 14 5  Anthem continues to expect operating cash flow in excess of  3 billion in 2016 Zacks Rank and Other HMOsAnthem currently carries a Zacks Rank  3  Hold   Another player  UnitedHealth Group Inc  s   NYSE UNH   second quarter earnings surpassed the Zacks Consensus Estimate  Other health  maintenance organization like Aetna Inc   NYSE AET   and Humana Inc    NYSE HUM   are scheduled to report second quarter results on Aug 2 and Aug 3  respectively ,2016-07-26,Zacks Investment Research,https://www.investing.com/analysis/anthem-(antm)-q2-earnings-beat-on-solid-premium-growth-200144407,200144407
142765,364280,HUM,Molina s  MOH  Q2 Earnings Beat Estimate  Will Stock Gain ,opinion,Molina Healthcare Inc    NYSE MOH   reported second quarter 2016 adjusted net income per share of 67 cents that handily beat the Zacks Consensus Estimate of 52 cents by 29   Earnings also improved 31  year over year Including one time items  net income per diluted share surged 35  year over year to 58 cents Improvement in Ohio and Texas health plans  driven by substantial decrease in the medical care ratio  mainly contributed to the upside Operational UpdateOperating revenues rose 24  year over year to  4 4 billion  mainly due to the increase in premium revenues and investment income  service revenues  premium tax revenues and Health insurer fee revenues  Also  revenues marginally missed the Zacks Consensus Estimate Premium revenues jumped 21  year over year to  4 0 billion due to strong enrolment growth Service revenues soared 187  year on year to  135 million Further  Molina Healthcare s investment income grew 100  year over year to  8 million  Premium tax revenues also increased 14 7  to  109 million in the second quarter Total operating expenses rose 23  year over year to  4 2 billion due to 22 7  higher Medical care costs  251  increase in cost of service revenues  22  rise in general and administrative expenses  14 7  higher premium tax expenses  25  increase in HIF expenses  anad a 36  rise in depreciation and amortization costs  all on a year over year basis Operating income decreased 9 5  year over year to  105 million in the quarter Additionally  Molina Healthcare s interest expenses increased 66 7  year over year to  25 million  Medical care ratio  ratio of medical care costs to premium revenues  was 89 2   up 50 basis points year over year Membership increased 26  year over year Financial UpdateAs of Jun 30  2016  Molina Healthcare s cash and cash equivalents rose 0 7  from that at year end 2015 to  2 3 billion  As of Jun 30  2016  total assets increased 9 5  to  7 2 billion from  6 6 billion at the end of 2015  Molina Healthcare s shareholder equity inched up 2  from year end 2015 to  1 6 billion at the end of the reported quarter Net cash from operating activities amounted to  139 million in the quarter as against  94 million a year ago  primarily due to receivables and prepaid expenses and other assets MOLINA HLTHCR Price  Consensus and EPS Surprise   Zacks Rank and the Performance of Other StocksMolina Healthcare currently carries a Zacks Rank  4  Sell   UnitedHealth Group Inc    NYSE UNH   and Anthem Inc s   NYSE ANTM   second quarter earnings surpassed the Zacks Consensus Estimate  Another health  maintenance organization Humana Inc    NYSE HUM   with Zacks Rank  1 is scheduled to report its second quarter results on Aug 2 ,2016-07-27,Zacks Investment Research,https://www.investing.com/analysis/molina's-(moh)-q2-earnings-beat-estimate:-will-stock-gain-200144776,200144776
142768,364283,HUM,Cigna  CI  To Report Q2  Will It Continue To Beat Estimates ,opinion,Health insurer Cigna Corp    NYSE CI   is expected to release second quarter financial results before the market opens on Jul 29 In the last reported quarter  the company beat the earnings estimate by 6 91   Moreover  the company posted a positive earnings surprise in each of the last four quarters  with an average beat of 5 93   Let s see how things are shaping up for this announcement Why a Likely Positive Surprise Our proven model shows that Cigna is likely to beat on earnings as it has the right combination of the two key components  Note that a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy  or  2  Buy  or at least  3  Hold  to have a significantly higher chance of beating estimates Zacks ESP  The Earnings ESP for Cigna is  1 67   This is because the Most Accurate estimate of  2 44 per share is above the Zacks Consensus Estimate of  2 40 Zacks Rank  Cigna s Zacks Rank  3 increases the predictive power of ESP Factors to Drive Q2 ResultsCigna s upcoming quarter results are expected to demonstrate its continued strength in operating performance We expect the company to continue posting favorable results on solid revenue growth in government business  disciplined expense management and effective medical cost management The company s global supplements business is expected to add to its earnings Moreover  favorable medical utilization along with medical cost management should drive the bottom line A strong balance sheet should also lend support to results CIGNA CORP Price and EPS Surprise   Other Stocks to ConsiderHere are three more stocks from the finance sector that you may want to consider as they also have the right combination of elements to post an earnings beat this quarter   ANI Pharmaceuticals  Inc    NASDAQ ANIP   has an Earnings ESP of  2 63  and a Zacks Rank  1  The company is scheduled to release second quarter earnings results on Aug 2 Humana Inc    NYSE HUM   has an Earnings ESP of  0 44  and a Zacks Rank  1  The company is scheduled to release second quarter earnings results on Aug 3 Aetna Inc    NYSE AET   has an Earnings ESP of  3 32  and a Zacks Rank  2  The company is scheduled to release second quarter earnings results on Aug 2 ,2016-07-28,Zacks Investment Research,https://www.investing.com/analysis/cigna-(ci)-to-report-q2:-will-it-continue-to-beat-estimates-200144609,200144609
142770,364285,HUM,Aetna  AET  Poised To Beat On Earnings In Q2  Here s Why,opinion,Health insurer Aetna Inc    NYSE AET   is scheduled to release second quarter financial results before market open on Aug 2 In the last reported quarter  the company beat the earnings estimate by 3 6   Moreover  the company posted a positive earnings surprise in each of the last four quarters  with an average beat of 8 98   Let s see how things are shaping up for this announcement Why a Likely Positive Surprise Our proven model shows that Aetna is likely to beat on earnings as it has the right combination of the two key components  Note that a stock needs to have both a positive   and a Zacks Rank  1  Strong Buy  or  2  Buy  or at least  3  Hold  to have a significantly higher chance of beating estimates Zacks ESP  The Earnings ESP for Aetna is  3 32   This is because the Most Accurate estimate of  2 18 per share is above the Zacks Consensus Estimate of  2 11 per share Zacks Rank  Aetna s Zacks Rank  2 increases the predictive power of ESP Factors to Drive Q2 ResultsAetna earnings will see an upside from its Government business  which continues to be a key source of growth  Within the Government business  Medicare business is expected to see membership growth  Also  Medicaid is expected to deliver another quarter of solid revenue growth and underwriting margin driven by a combination of new contract wins  county expansion in existing states and ACA related expansion membership We also expect to see favorable prior year reserve development across all of its core products which should lift earnings However  the bottom line might be hurt by the absence of share buyback during the second quarter due to the proposed Humana acquisition AETNA INC NEW Price and EPS Surprise   Other Stocks to ConsiderHere are some other companies you may want to consider as our model shows that these also have the right combination of elements to post an earnings beat this quarter ANI Pharmaceuticals  Inc    NASDAQ ANIP   has an Earnings ESP of  2 63  and a Zacks Rank  1  The company is scheduled to release second quarter results on Aug 2 Humana Inc    NYSE HUM   has an Earnings ESP of  0 44  and a Zacks Rank  2  The company is scheduled to release second quarter results on Aug 3 Galena Biopharma   NASDAQ GALE   has an Earnings ESP of  28 57  and a Zacks Rank  2  The company is scheduled to release second quarter earnings on Aug 9 ,2016-07-28,Zacks Investment Research,https://www.investing.com/analysis/aetna-(aet)-poised-to-beat-on-earnings-in-q2:-here's-why-200145047,200145047
142787,364302,HUM,Zacks Industry Outlook Highlights  Cigna  UnitedHealth Group  Aetna  Anthem And Humana,opinion,"For Immediate Release

Chicago  IL   June 22  2016   Today  Zacks Equity Research discusses Health Insurance  Part 2  including  Cigna Corp  NYSE CI       UnitedHealth Group Inc  NYSE UNH       Aetna Inc  NYSE AET       Anthem Inc      and Humana  NYSE HUM   Inc     

Industry  Health Insurance  Part 2

Link  

In a volatile global economic environment  the U S  health insurance industry provides investors a micro defense thanks to high degree of its domestic business exposure  Players like Cigna Corp      UnitedHealth Group Inc     and Aetna Inc      with business in international markets also have limited exposure  accounting for 3   4   1  and 0 5  of revenues respectively   More importantly  the sector is largely insulated from headwinds   low oil prices  interest rate hikes  strengthening dollar  China s economic slowdown   which have been plaguing other sectors of the economy 
	The sole factor that has shaken the healthcare industry and changed it wholly is the Health Care Reform or Obamacare  enacted in Mar 2010  Though initially intensively lobbied against by the players  health care reform has turned out beneficial  Courtesy of Obamacare  insurers have witnessed meaningful gains in their membership enrollment  which has beefed up their revenues 

Total revenues of the top eight players  UnitedHealth   Aetna  Cigna  Anthem Inc     and Humana  Inc      increased to  437 billion in 2015 from  383 billion in 2014  with medical enrollment rising to 150 million in 2015 from 145 million in the prior year  Along with posting strong operating numbers  most of the players guided strong earnings for 2016  pointing to the fact that despite hurdles  the industry presents enough growth opportunities 

Now  after sharing the space with Obamacare for almost six years  insurers have embraced the law  Most of the players are now looking for newer avenues to expand their business  They are reassessing their business model from the perspective of product  pricing  risk management  distribution and claims to fraud management for a realistic pace of growth 

Let s discuss some of the opportunities provided by the changing industry landscape 

Extensive Consolidation

The Affordable Care Act  ACA  has heightened the drive toward market consolidation  The influx of the previously huge uninsured population into the space has increased overall membership  Now  the players are scrambling to maintain and grow their member enrollment further  and the best way to achieve this is by growing in size  With the health care law emphasizing value based care  it becomes imperative for health insurers to have a large number of patients to dilute risk  and of course ensure premium dollars to cover the expenses of their sick enrollees  thereby improving overall health outcomes 

Moreover  a bigger size would help in leveraging fixed cost and reducing overall administrative cost  increase cost of compliance with the new health care law   A bigger market share will also equip them better to negotiate harder with hospitals   Get big or get out  has therefore become the trend in the industry 

The merger frenzy hit a fever pitch with Anthem agreeing to acquire Cigna  Aetna seeking the Humana buyout and Centene s recent acquisition of Health Net  The market is speculating that consolidation will lead to the  big five  insurers transforming into the  big three   likely comprising Aetna  Anthem and UnitedHealth 

Higher Insured Population   Top Line Growth

Thanks to ObamaCare  the nation s uninsured rate has gone down to single digits  Before ACA  around 47 million lacked health coverage  Current data shows that the uninsured rate is around 9   According to an ongoing NHIS CDC study  the current uninsured rate of 9  for 2015 is the lowest in over 50 years 

The data shows that Obamacare has to a large extent accomplished its purpose which also points to the increased coverage provided by health insurers that would in turn add to their top line  Most health insurers have reported a secular rise in their revenues from membership gains because of the law 

Baby Boomers Present Medicare Growth

According to the U S  Census data  the population of Medicare beneficiaries will grow by 36  by the end of this decade led by a vast aging baby boomer population  In fact  in the next 25 years  the compounded annual growth rate of the Medicare population is expected to increase to 2 7  from 1 5  at present 

Revenues from the managed care plans of Medicare Advantage are expected to grow significantly as baby boomers retire  Medicare Advantage is a privately run version of the government s Medicare insurance program for the aged and disabled  Until now  only two public providers    UnitedHealth and Humana    control more than 10  of the market  Carriers in the health insurance sector are in a race to win Medicare Advantage market share and the fastest way of achieving the target is by acquiring a company in the same business 

Shift to International Markets

Pressure on profit margins in the U S  market has compelled American health insurers to look to foreign markets for sustained growth and profitability  International markets seem attractive as these are less penetrated and competitive than the U S  Asia and Europe represent the best near term opportunities for the U S  health insurers 

Cigna and UnitedHealth Group lead the private health insurance industry in terms of international deal activity  They re followed by Aetna and Humana  The deals have either been mergers and acquisitions or joint ventures with local insurance companies 

Some of the deals made by players in this field echo the emerging trend toward globalization  In Apr 2014  Aetna bought U K  based InterGlobal  which offers private medical insurance to groups and individuals in the Middle East  Asia  Africa and Europe  Prior to that in Feb 2014  Cigna announced its debut in India s underpenetrated health insurance sector  in a joint venture with an Indian conglomerate TTK Group  In 2013  UnitedHealth bought a stake in AmilParticipacoes of Brazil for a nearly  5 billion  It already had a presence in Australia  the Middle East and the U K 

ACOs Gaining Prominence

Health insurers are trying to clinch accountable care payment contracts following the healthcare reform law s inclusion of Accountable Care Organization  ACO  tests under Medicare  The law s emphasis on providing accurate and efficient health care service rather than volume of service has led to the emergence of ACOs  These are formed when a group of health care providers  physicians  hospitals  non physician providers  and the likes  collectively take responsibility for the financial and quality outcome for a defined population 

The ACOs are appealing to insurers as these reduce medical cost and improve outcome  Insurers form an essential part of ACO because these track and collect patient data  enabling an evaluation of patient care  Since clinical information and care processes are shared and supported by all providers  it becomes easier to manage care and effectively lower the cost  With Obamacare  health insurers have to be more than just claims payers 

Under health reform  insurers have lost flexibility in ways that they can cope with rising medical expenses  They can no longer rely on many of their traditional medical underwriting strategies  such as exclusion of pre existing conditions  The most effective approach for insurers now is to rely exclusively on current cost control mechanisms to manage members  medical expenses  Private commercial payers such as Cigna  Anthem and Aetna are thus supporting ACO formation  CIGNA has one of the most established track records in the group for ACOs 

Want the latest recommendations from Zacks Investment Research  Today  you can download7 Best Stocks for the Next 30 Days  

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact

Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-06-21,Zacks Investment Research,"https://www.investing.com/analysis/zacks-industry-outlook-highlights:-cigna,-unitedhealth-group,-aetna,-anthem-and-humana-200137561",200137561
142788,364303,HUM,Health Insurers Suffer On High Costs  Unprofitable Exchanges ,opinion,"Health insurers called upon themselves the close scrutiny of regulators  with Anthem Inc  s  ANTM  proposal to acquire Cigna Corp  NYSE CI    CI  and Aetna Inc  NYSE AET   s  AET  buyout deal with Humana Inc  NYSE HUM    HUM  
Recently  the viability of the proposed merger between Anthem and Cigna was challenged by Insurance Commissioner Dave Jones  who contends that the mega deal worth  48 billion would curb competition and hurt consumers in the state of California 
Moreover  the presidential candidates are looking at ways to fine tune the provisions of healthcare legislation  which  if implemented  will see insurers reworking their business strategies 
Democratic presidential candidate Hillary Clinton s priority includes a crackdown on insurers to limit out of pocket costs  These costs are expenses like deductibles  coinsurance and copayments for covered services among others that aren t reimbursed by insurance Also on Clinton s agenda is giving more power to lawmakers to reject undue rate hikes by health insurers  Under the current healthcare reform  this authority is in the hands of certain select states only Donald Trump said that he would end Obamacare and replace it with something that would require a lot less money Coming back  the legislation has undoubtedly altered the regulatory landscape in ways that are not always beneficial to a private health insurer s bottom line  But calling it a permanent drag would be an overstatement U S  health plans are expected to operate in a lowered margin environment  Some health plans   especially the smaller ones   may not survive  Pricing pressure  higher taxes and fees  rising medical costs  regulatory compliance costs  increased competition and general marketplace uncertainty are some of the headwinds faced by the players in the industry While the aim of this write up is to put the spotlight on the headwinds facing the industry  an earlier write up in this space had the opposite focus 
Public Exchanges Losses
Public Exchanges made their debut in Oct 2013  and were considered one of the signature achievements of Obamacare aimed at providing subsidized insurance to millions  The insurers were also sanguine about the exchanges  hoping to make big business out of them  But health insurers are now struggling to make profits from the public exchange business 
These insurers are saddling high medical expenses of individuals who are buying the subsidized policies under the health care law  The public exchanges attracted a disproportionate number of unhealthy individuals compared to healthy ones  A higher percentage of unhealthy patients led to higher claims for the insurers  thus leading to losses from the policies sold to these groups of people 
In Nov 2015  UnitedHealth Group  NYSE UNH   UNH  disclosed concerns about losses incurred on its individual business from the public exchange Compelled by the loss suffered from the individual insurance policies sold on the exchanges  the health insurer announced that it will not entertain such losses and may exit this unprofitable market completely by 2017  The company has already scaled back its marketing efforts for individual insurance policies sold on exchanges 
Another insurer  Aetna  also suffered losses in its public exchange business in 2015 and reduced its operations to 15 states this year from 17 states last year  It is  however  taking measures such as re pricing and product modification to generate profits in 2016  
Another player Humana is also contemplating to drop individual insurance coverage through exchanges in the states of Alabama  Kansas  Wisconsin and Virginia  The company is considering to exit this business which brought in meager profits in this years  first quarter and would likely result in a loss for the full year 
If the players realize that the exchanges are not seeing profitable business opportunities  a mass exodus may happen which may hamper the functionality of the exchanges and cause a failure of the ObamaCare exchanges  thus defeating the basic aim of providing coverage to millions of uninsured Americans 
Some of the other challenges faced by the industry are briefed below Margins to ShrinkThe health insurers are expected to witness lowered margin environment onward  A host of factors including compliance costs related to health care reform regulation  increased fees and taxes  pricing pressure  stiff competition and rising medical costs will squeeze the bottom line  A general shift in patient mix from Commercial insurance to Government  Medicare  Medicaid and State subsidized marketplace or exchange  will also affect profitability to a large extent  Premiums for Medicare  Medicaid and State subsidized policies tend to be higher due to serious health issues for many enrollees  however  they carry smaller profitability margins compared to commercial insurance 
High Compliance Costs
Regulatory reform sweeping through the sector has hit insurers with high compliance costs  The expenditure involved in redoing the internal systems can pinch the players hard  There has been huge spending on health information technology   HIT    following the implementation of The American Recovery and Reinvestment Act of 2009   ARRA    or  Recovery Act   which contains the Health Information Technology for Economic and Clinical Health Act  or the  HITECH Act   Notably  HIT includes electronic health records  EHRs   health information exchanges  HIEs  and other initiatives 
The federal government s emphasis on the use of health IT  which helps providers communicate better with each other about patient care  reduces medical errors  paperwork and needless duplicate screenings and tests  leading to better coordinated patient care and lower health care costs  These have increased current health care information technology spending  Financial incentives offered by regulators to providers and hospitals for the implementation of the meaningful use of health care IT products are primarily driving IT spending 
Growing ConsumerismRising consumerism has now become the reality of the health insurance industry  Until the implementation of the ACA  the insurance companies had an upper hand in choosing who to provide coverage to and consumers  people receiving health care  had no active role in the decision making process  But now the trend has changed  Health insurance reform has put consumer power and choice in the hands of the Americans  and ensure that all Americans receive the health care services that they need and deserve  Consumers  increased purchasing power and access to information to take health care decisions are the major threats to insurers Prior to reform  big insurers dominating large markets hardly ever bothered to provide consumers with even basic information  such as the performance of health insurance policies  procedures to claim  the size of the provider network and cancellation processes  Now  customers demand transparency  value and convenience  leaving insurers grappling for innovative ways to satisfy these unmet needs  The new mission  however  will not be easy to execute Global Economic Woes and Regulatory ChallengesA fragile global economy presents a headwind for insurers looking to expand their international operations  One of the largest insurers  UnitedHealth Groupmade an acquisition to reap benefits from the Brazil market but is now facing slowing growth rates in that country In case of India  which remains one of the most profitable opportunities for insurers  the regulatory environment still remains somewhat challenging  China    which merits the highest risk adjusted opportunity ranking  largely because of its immense scale    poses significant investment restrictions to foreign insurers entering and operating there Bottom LineThe changed regulatory landscape has undoubtedly created hurdles that would weigh on profits and margins of industry operators going forward  But it is hardly the unmitigated disaster that some industry players make it out to be  Beyond the ACA  the investment appeal of the space also reflects its perceived defensive and counter cyclical orientation  which is crucial amid the current uncertainty ",2016-06-22,Zacks Investment Research,"https://www.investing.com/analysis/health-insurers-suffer-on-high-costs,-unprofitable-exchanges-200137762",200137762
142789,364304,HUM,Zacks Industry Outlook Highlights  Anthem  Cigna  Aetna  Humana And UnitedHealth Group,opinion,"For Immediate Release

Chicago  IL   June 23  2016   Today  Zacks Equity Research discusses Health Insurance  Part 3  including  Anthem Inc      Cigna Corp  NYSE CI       Aetna Inc  NYSE AET       Humana Inc  NYSE HUM       and UnitedHealth Group  NYSE UNH    

Industry  Health Insurance  Part 3

Link 

Health insurers called upon themselves the close scrutiny of regulators  with Anthem Inc  s    proposal to acquire Cigna Corp     and Aetna Inc  s    buyout deal with Humana Inc      

Recently  the viability of the proposed merger between Anthem and Cigna was challenged by Insurance Commissioner Dave Jones  who contends that the mega deal worth  48 billion would curb competition and hurt consumers in the state of California 

Moreover  the presidential candidates are looking at ways to fine tune the provisions of healthcare legislation  which  if implemented  will see insurers reworking their business strategies 

Democratic presidential candidate Hillary Clinton s priority includes a crackdown on insurers to limit out of pocket costs  These costs are expenses like deductibles  coinsurance and copayments for covered services among others that aren t reimbursed by insurance 
	Also on Clinton s agenda is giving more power to lawmakers to reject undue rate hikes by health insurers  Under the current healthcare reform  this authority is in the hands of certain select states only 
	Donald Trump said that he would end Obamacare and replace it with something that would require a lot less money 
	Coming back  the legislation has undoubtedly altered the regulatory landscape in ways that are not always beneficial to a private health insurer s bottom line  But calling it a permanent drag would be an overstatement 
	U S  health plans are expected to operate in a lowered margin environment  Some health plans   especially the smaller ones   may not survive  Pricing pressure  higher taxes and fees  rising medical costs  regulatory compliance costs  increased competition and general marketplace uncertainty are some of the headwinds faced by the players in the industry 
	While the aim of this write up is to put the spotlight on the headwinds facing the industry  an earlier write up in this space had the opposite focus 

Public Exchanges Losses

Public Exchanges made their debut in Oct 2013  and were considered one of the signature achievements of Obamacare aimed at providing subsidized insurance to millions  The insurers were also sanguine about the exchanges  hoping to make big business out of them  But health insurers are now struggling to make profits from the public exchange business 

These insurers are saddling high medical expenses of individuals who are buying the subsidized policies under the health care law  The public exchanges attracted a disproportionate number of unhealthy individuals compared to healthy ones  A higher percentage of unhealthy patients led to higher claims for the insurers  thus leading to losses from the policies sold to these groups of people 

In Nov 2015  UnitedHealth Group    disclosed concerns about losses incurred on its individual business from the public exchange  Compelled by the loss suffered from the individual insurance policies sold on the exchanges  the health insurer announced that it will not entertain such losses and may exit this unprofitable market completely by 2017  The company has already scaled back its marketing efforts for individual insurance policies sold on exchanges 

Another insurer  Aetna  also suffered losses in its public exchange business in 2015 and reduced its operations to 15 states this year from 17 states last year  It is  however  taking measures such as re pricing and product modification to generate profits in 2016 

Another player Humana is also contemplating to drop individual insurance coverage through exchanges in the states of Alabama  Kansas  Wisconsin and Virginia  The company is considering to exit this business which brought in meager profits in this years  first quarter and would likely result in a loss for the full year 

If the players realize that the exchanges are not seeing profitable business opportunities  a mass exodus may happen which may hamper the functionality of the exchanges and cause a failure of the ObamaCare exchanges  thus defeating the basic aim of providing coverage to millions of uninsured Americans 

Some of the other challenges faced by the industry are briefed below Margins to Shrink
	The health insurers are expected to witness lowered margin environment onward  A host of factors including compliance costs related to health care reform regulation  increased fees and taxes  pricing pressure  stiff competition and rising medical costs will squeeze the bottom line  A general shift in patient mix from Commercial insurance to Government  Medicare  Medicaid and State subsidized marketplace or exchange  will also affect profitability to a large extent  Premiums for Medicare  Medicaid and State subsidized policies tend to be higher due to serious health issues for many enrollees  however  they carry smaller profitability margins compared to commercial insurance 

High Compliance Costs

Regulatory reform sweeping through the sector has hit insurers with high compliance costs  The expenditure involved in redoing the internal systems can pinch the players hard  There has been huge spending on health information technology   HIT    following the implementation of The American Recovery and Reinvestment Act of 2009   ARRA    or  Recovery Act   which contains the Health Information Technology for Economic and Clinical Health Act  or the  HITECH Act   Notably  HIT includes electronic health records  EHRs   health information exchanges  HIEs  and other initiatives 

The federal government s emphasis on the use of health IT  which helps providers communicate better with each other about patient care  reduces medical errors  paperwork and needless duplicate screenings and tests  leading to better coordinated patient care and lower health care costs  These have increased current health care information technology spending  Financial incentives offered by regulators to providers and hospitals for the implementation of the meaningful use of health care IT products are primarily driving IT spending 

Growing Consumerism
	Rising consumerism has now become the reality of the health insurance industry  Until the implementation of the ACA  the insurance companies had an upper hand in choosing who to provide coverage to and consumers  people receiving health care  had no active role in the decision making process  But now the trend has changed  Health insurance reform has put consumer power and choice in the hands of the Americans  and ensure that all Americans receive the health care services that they need and deserve  Consumers  increased purchasing power and access to information to take health care decisions are the major threats to insurers 
	Prior to reform  big insurers dominating large markets hardly ever bothered to provide consumers with even basic information  such as the performance of health insurance policies  procedures to claim  the size of the provider network and cancellation processes  Now  customers demand transparency  value and convenience  leaving insurers grappling for innovative ways to satisfy these unmet needs  The new mission  however  will not be easy to execute Global Economic Woes and Regulatory Challenges
	A fragile global economy presents a headwind for insurers looking to expand their international operations  One of the largest insurers  UnitedHealth Groupmade an acquisition to reap benefits from the Brazil market but is now facing slowing growth rates in that country 
	In case of India  which remains one of the most profitable opportunities for insurers  the regulatory environment still remains somewhat challenging  China    which merits the highest risk adjusted opportunity ranking  largely because of its immense scale    poses significant investment restrictions to foreign insurers entering and operating there Bottom Line
	The changed regulatory landscape has undoubtedly created hurdles that would weigh on profits and margins of industry operators going forward  But it is hardly the unmitigated disaster that some industry players make it out to be  Beyond the ACA  the investment appeal of the space also reflects its perceived defensive and counter cyclical orientation  which is crucial amid the current uncertainty 

Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days  

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact

Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-06-22,Zacks Investment Research,"https://www.investing.com/analysis/zacks-industry-outlook-highlights:-anthem,-cigna,-aetna,-humana-and-unitedhealth-group-200137808",200137808
142790,364305,HUM,Aetna  AET  And Units Receive Rating Action From A M  Best,opinion,"Aetna Inc    NYSE AET   and its affiliates recently received rating actions from A M  Best  The health insurer s issuer credit rating  ICR  was lowered to  bbb  from  bbb   and it was removed from under review with negative implications  Concurrently  the credit rating giant reiterated the financial strength ratings  FSR  of A  Excellent  of Aetna Life Insurance Company and other subsidiaries Additionally  issue ratings of the existing debt of Aetna and Coventry Health Care Inc  s senior unsecured notes were revised to  bbb  from  bbb    Another unit   Aetna Insurance Company of Connecticut   saw its FSR lowered to B    Good  from A  Excellent  and ICR downgraded to  bbb  from  a   Both these units were removed from under review with negative implications Notably  the ratings carry stable outlook The rating downgrade on Aetna reflects a surge in financial ratio due to the issuance of  13 billion debt for the Humana Inc    NYSE HUM   buyout  This not only limited the firm s borrowing capacity but also lowered interest coverage ratio  Also  the company remains exposed to integration risks  while its goodwill and intangibles are expected to rise to more than total equity Nevertheless  A M  Best notes Aetna has been delivering sustained solid operating results fueled by low medical cost trends and improved operational efficiencies besides solid cash flows and health insurance and group insurance operations offering a diversified revenue stream AETNA INC NEW Price   Zacks Rank and Stocks to ConsiderAetna carries a Zacks Rank of  3  Hold   Some better ranked stocks in the medical sector are Magellan Health  Inc    NASDAQ MGLN   and AMN Healthcare Services Inc    NYSE AHS    Both these stocks sport Zacks Rank  1  Strong Buy  
Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-06-24,Zacks Investment Research,https://www.investing.com/analysis/aetna-(aet)-and-units-receive-rating-action-from-a.m.-best-200138107,200138107
142795,364310,HUM,Aetna Humana Merger Faces Ire From California Commissioner,opinion,After opposing to the pending merger of Anthem Inc    NYSE ANTM   and Cigna Corp    NYSE CI    the California Insurance Commissioner Dave Jones has now raised his voice against another pending mega merger between Aetna Inc    NYSE AET   and Humana Inc    NYSE HUM    Jones urged national antitrust regulators to block the deal by raising concerns over the viability of the deal  He contends that the mega deal  worth  34 billion  would curb competition and hurt consumers in the state  rather than doing good as professed by the companies involved This resistance from Jones comes after the deal got a green signal from California s other insurance regulators  The approval  however  came with riders like the acquiring company will have to keep premium increases at bay and invest  50 million in communities During the first quarter earnings release  Aetna indicated that its pending acquisition of Humana is progressing well and will be closed in the second half of 2016  So far  the deal has received approvals from almost 14 of the 20 necessary states  while six state approvals are remaining  The company is also working closely with the Justice Department which is conducting its review on the deal AETNA INC NEW Price   HUMANA INC NEW Price   According to Jones  the merger will lead to market consolidation and cause a greater concentration in the health insurance market in the already saturated California  The acquisition would mean the absence of one more insurance company from the market and more power in the hands of the acquiring company  which will gain in size and scale  Greater power might result in mistreatment of customers by the company by way of insufficient handling of grievances or undue hike in premium These concerns are not baseless  Looking back at the pre  Obamacare industry  the prevalence of consolidation and market dominance had resulted in decline in competition  Big insurers  dominating large markets  hardly ever bothered to provide even basic information to consumers  such as the performance of health insurance policies  procedures to claim  the size of the provider network and cancellation procedures The executives of the companies involved however  are defending the deal by saying that the merger will help them to add scale to their businesses and enable unnecessary costs incurred in duplication of services provided to patients  They are also of the opinion that by gaining in size they will be in a better position to negotiate with hospitals for claims and lower their overall administrative costs  Investment in technology from the saved costs  expanded access to care by gaining quick access to new markets are the other advantages of the merger cited by them Though Obamacare reined in the malpractices by the players  it is feared that some of these may occur again with only a handful of players in the market creating an oligopolistic structure Aetna carries a Zacks Rank   3  Hold  ,2016-06-24,Zacks Investment Research,https://www.investing.com/analysis/aetna-humana-merger-faces-ire-from-california-commissioner-200138101,200138101
142796,364311,HUM,Aetna May Divest Parts Of Its Business To Acquire Humana,opinion,"Aetna Inc    NYSE AET   is planning to shed some of its Medicare Advantage business in some markets  as per sources  Aetna hopes the divestures will address federal regulators  concerns regarding its proposed acquisition of Humana Inc    NYSE HUM   
The assets to be sold are worth billions of dollars  But it has become necessary for Aetna to trim these operations to establish that its  37 billion acquisition of Humana will not quell competition in several markets 
The company has not yet finalized the assets to be sold but its advisers are busy identifying Medicare Advantage   MA   business in those markets where operations of both companies overlap significantly AETNA INC NEW Price   Last week  California s insurance commissioner made a desperate attempt to block Aetna s acquisition of Humana  The commissioner said that the deal would curb competition in the state and further shrink the already concentrated health insurance market 
Aetna is considering the sale of some of its MA business in order to get the green signal from regulators so that the deal can be sealed as per schedule  So far  the acquisition has received approval from 14 states of the 20 necessary states  The company is also working closely with the Justice Department  which is reviewing the deal 
Aetna has been bound to divest its MA business  in which Humana also has a strong franchise  With Humana  the combined company will have 47  of its business from Medicare  Together  the companies would lead Medicare Advantage plans by a large margin  This would also lead to greater concentration of the combined company in MA business  which is in huge demand due to the large aging baby boomer population  It is feared that the emergence of a single big MA player can be unfavorable for consumers in the form of high premiums and low quality of service 
The Aetna Humana deal is not the only one being closely scrutinized by the Department of Justice  The proposed acquisition of Cigna Corp    NYSE CI   by Anthem Inc    NYSE ANTM   is also being monitored by the Justice Department as this mega merger will also end up reducing the number of players in the industry 
Aetna carries a Zacks Rank  3  Hold  ",2016-07-03,Zacks Investment Research,https://www.investing.com/analysis/aetna-may-divest-parts-of-its-business-to-acquire-humana-200139812,200139812
142800,364315,HUM,Humana Drops To 52 Week Low On Doubts Over Aetna Merger,opinion,"On Jul 11  2016  shares of Humana Inc    NYSE HUM   dropped to a 52  week low of  152 34 on regulatory concerns over its deal with Aetna Inc    NYSE AET    Over the past one year the stock has declined 16  Regulators have been increasingly scrutinizing the Aetna Humana deal since it will create a company holding the largest market share of the highly coveted Medicare Advantage plan Medicare government will comprise 47  of the combined company s business and account for about 65  of total revenue  They will together be the largest provider of Medicare Advantage  MA  plans by a large margin  This will lead to a greater concentration of the company in MA business which is enjoying huge demand due to the high aging baby boomer population  It is feared that the emergence of a single big MA player can be unfavorable for consumers in the form of high premiums and low service quality 
In an effort to win over regulators  Aetna took steps to sell off its MA assets in markets which had significant business overlap  This move  however  failed to satisfy the regulators and investors are skeptical over the stock as they doubt whether that the deal will at all materialize Investors were happy with the deal with Aetna as it would have elevated Humana from its current fifth position in the market to the second rank  Now that the deal is on tenterhooks  investors are concerned about the Humana stock  HUMANA INC NEW Price and Consensus   Nonetheless  Humana carries a Zacks Rank  2  Buy   Other stocks in the same space that are worth considering include WellCare Health Plans  Inc    NYSE WCG   with a Zacks Rank  1 Strong Buy  and Centene Corp    NYSE CNC   with a Zacks Rank  2 ",2016-07-11,Zacks Investment Research,https://www.investing.com/analysis/humana-drops-to-52-week-low-on-doubts-over-aetna-merger-200141360,200141360
142801,364316,HUM,Research Reports For Amazon  IBM  Cisco   Others,opinion,"Tuesday  July 19  2016
We have hand picked 16 research reports in today s Research Daily  out of the roughly 80 research reports issued by our team of analysts  including the 7 featured below about Amazon com  NASDAQ AMZN   AMZN   Visa  V   Mallinckrodt  NYSE MNK   MNK   IBM  NYSE IBM   IBM   Cisco  CSCO   Spetra Energy  SE  and General Motors  NYSE GM   GM 
Shares of Zacks Rank   2  Buy  rated Amazon are up more than 9  year to date  with estimates steadily going up  The analyst likes Amazon for its efforts to strengthen its leadership position in the ecommerce segment with innovation in delivery and logistics  broadening of its product selection  device strategy  international expansion and the Prime membership program  Additionally  Amazon is the leading provider of cloud infrastructure as a service to enterprise customers through its Amazon Web Services  AWS  business   You can   
The analyst likes the Zacks Rank   2  Buy  rated Visa for the company s growing electronic business  compelling inorganic growth story  solid international business and sound balance sheet are some of its other positives  Additionally  Visa s initiative to accelerate secure mobile payments by adopting the pay Wave software application is encouraging   You can   
Zacks Rank   2 rated Mallinckrodt s shares have been weak lately  but the analyst cites a number of positives in the drug maker s story  Mallinckrodt s strategic acquisitions over the last few years have broadened its portfolio significantly and boosted its growth prospects  The company s Specialty Brands segment is performing well and should help it achieve its raised outlook for fiscal 2016  Inomax and Acthar hold significant potential and the company continues to work on boosting its presence in the hospital segment   You can   
Other noteworthy reports we are featuring today include IBM  IBM   Cisco  CSCO  and General Motors  GM  To see the complete list of the roughly 80 research reports issued by our analyst team   
Sheraz Mian
Director of Research
Note  Sheraz Mian regularly provides earnings analysis on Zacks com and appears frequently in the print and electronic media  His weekly earnings related articles include  and   He also provides weekly commentary to  subscribers and manages the  and  portfolios  
If you want an email notification each time Sheraz publishes a new article  please  
Today s Must Read









Featured Reports

The Zacks Analyst thinks IBM s business model transition to higher growth markets like cloud and mobile  though time consuming  will prove accretive over the long term 


The covering analyst believes the CloudLock buyout and the partnership with IBM will drive Cisco s growth  


Reynolds may witness lower volume in Q2 due to a general shift of preference away from tobacco products  according to the Zacks analyst 


The covering analyst believes L Brands sustained focus on cost containment  inventory management  and speed to market initiatives have kept it afloat in a soft consumer environment  


The Zacks analyst stresses that since Shell is the most gas focused integrated major  the commodity s price slump has affected the group s earnings and cash flows 


The covering analyst believes that Jakafi will continue to drive the company s top line growth  Incyte s efforts to develop its pipeline are also encouraging 


Pricing gains  innovations  powerful marketing programs  strong performance of non carbonated beverages and productivity improvements can boost sales growth in Q2 

New Upgrades

The covering analyst believes that Spectra Energy s fee based businesses offer stable earnings growth alongside a rising dividend which yields 4 37  


The Zacks analyst thinks gradual recovery in the U S  housing market will benefit Weyerhaeuser s businesses  Also  the company remains committed toward rewarding its shareholders handsomely 


While the Humana acquisition will make the company a leading player in the Medicare market  Aetna is mulling to divest its MA business in markets with significant overlap to satisfy regulators 

New Downgrades

The Zacks analyst thinks margins may fall in Q2 due to a higher labor costs  Further  brick and mortar retailers are finding it difficult to compete with online retailers  


The covering analyst believes BlackRock missed estimates due to lower fee based revenues  Further  high dependence on overseas revenue could pose a threat to its overall business activities 


The Zacks analyst thinks declining US sales and new federal ruling regarding defective ignition switches will pose challenges for General Motors ",2016-07-19,Zacks Investment Research,"https://www.investing.com/analysis/research-reports-for-amazon,-ibm,-cisco---others-200142768",200142768
142805,364320,HUM,Aetna And Anthem Insurer Deals To Be Challenged By US DoJ,opinion,"According to   regulators are getting ready to file lawsuits in order to block two major health insurance mergers   About a year ago  Anthem   NYSE ANTM   agreed to purchase Cigna   NYSE CI   for  48 billion  and Humana   NYSE HUM   agreed to be bought out by Aetna   NYSE AET   for  37 billion 
The Justice Department is concerned over the increased consolidation in the health insurance space  and it believes that these mergers stand to negatively affect the competition in the industry   The companies who are set to merge already make up for four of the top five players in the health insurance space  and collectively  the companies generated sales north of  230 billion in 2015  
They represent a large share of the health insurance market  and the deals have been criticized since their inception a year ago   Doctors and consumer groups have been especially critical of the deals  citing the lessening of competition in the space because of fewer options for people to choose from   James King  a professor at the University of California Hastings College of Law  questioned the impact that the mergers have on competition  saying that  instead of going into these areas on their own   the insurers  are attempting to acquire somebody who is already there and successful  
Regulators were previously worried when the deals were announced  but Aetna and Anthem had the opportunity to persuade the Justice Department  and they said that any antitrust issue could be resolved by distributing assets to other competitors   If the Department does end up filing a lawsuit  the insurers will probably fight the antitrust claims in court 
The Zacks Rank is a truly marvelous trading tool   Our ranking system has beaten the S P 500  yielding an average return of 25  per year for the last 29 years   Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-07-19,Zacks Investment Research,https://www.investing.com/analysis/aetna-and-anthem-insurer-deals-to-be-challenged-by-us-doj-200142817,200142817
142814,364329,HUM,UnitedHealth Hits 52 Week High As It Recalibrates Business ,opinion,The largest U S  health insurer UnitedHealth Group Inc    NYSE UNH   touched a 52 week high of  136 15 on Jun 2  2016  The rise in the stock was propelled by continued strength in the company s earnings and its recent exit from a number of exchanges  The exit is aimed at limiting its losses on individual insurance business written via public exchanges that would protect its earnings Over the past one year  the stock gained 17 5  in contrast to 17   12 2  and 8 4  that Anthem Inc    NYSE ANTM    Humana Inc    NYSE HUM   and Cigna Corp    NYSE CI   lost respectively  A gain of 3 2  logged by Aetna Inc    NYSE AET   also looks paltry when compared with the leader UnitedHealth So what makes UnitedHealth stand out in the industry UnitedHealth s already diverse business profile was made stronger by its recent business changes  These include the trimming of business on loss incurring public exchanges  while focusing on segments that generate higher return on equity While this week UnitedHealth exited the California and Wisconsin exchange markets  it has already left or will be leaving the exchange markets in Alabama  Arizona  Arkansas  Colorado  Connecticut  Florida  Georgia  Indiana  Iowa  Kansas  Kentucky  Louisiana  Maryland  Massachusetts  Michigan  Mississippi  Missouri  Nebraska  North Carolina  Oklahoma  Pennsylvania  Rhode Island  South Carolina  Tennessee  Texas and Washington The loss incurred by the public exchange line of business had prompted the company to trim its earnings forecast last year  The company had also commented that if it keeps on insuring individuals via exchanges it will continue to suffer huge claims which would mar its profitability The recent exit from unprofitable markets will put a bridle on the losses that the company has incurred from the individual exchange business  These moves have restored investors  confidence in the company s profitability UnitedHealth won investors  favor by virtue of its strong earnings generation capability  The first quarter of 2016 maintained this trend with earnings of  1 81 per share surpassing the Zacks Consensus Estimate by 9 cents and improving 17  year over year  The improvement was backed by broad based growth and a 54  increase in revenues from Optum  the health services business Increase in earnings estimates for 2016 also drew investors  attention to the stock  UnitedHealth expects earnings of  7 75  7 90 per share for 2016 instead of  7 60 to  7 80 projected earlier  The company expects revenues of approximately  182 billion for 2016 that translates into 16  year over year growth UnitedHealth carries a Zacks Rank   2  Buy  ,2016-06-02,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-hits-52-week-high-as-it-recalibrates-business-200133875,200133875
142818,364333,HUM,Stock Market News For June 03  2016,opinion,"Benchmarks finished in the green on Thursday following encouraging U S  private sector jobs data and gains in healthcare stocks  Moreover  late rebound in oil prices following a decline in crude inventories also boosted investor sentiment  All the three key U S  indexes ended in positive territory with the S P 500 settled at its highest level since Nov 3  2015 and the Nasdaq registered seven straight session rise For a look at the issues currently facing the markets  make sure to read today s  article

The Dow Jones Industrial Average  DJI  increased 0 3   to close at 17 838 56  The S P 500 also rose 0 3  to close at 2 105 26  The tech laden Nasdaq Composite Index closed at 4 971 36  gaining 0 4   The fear gauge CBOE Volatility Index  VIX  decreased 4  to settle at 13 63  A total of around 6 4 billion shares were traded on Thursday  lower than the last 20 session average of 7 billion shares  Advancers outpaced declining stocks on the NYSE  For 63  stocks that advanced  34  declined 

Yesterday  a report from Automatic Data Processing  Inc     revealed that private sector employers added 173 000 jobs in May  which was higher than April s readings  Also  job additions for April were revised up by 10 000 to 166 000 

The U S Department of Labor reported that seasonally adjusted initial claims decreased 1 000 to 267 000 in the week ending May 28  posting third straight weekly fall  Initial claims were also less than the consensus estimate of 268 000 

Initial claims remained below 300 000 for 65 consecutive weeks  its longest stretch since 1973  Also  the 4 week moving average came in at 276 750 last week  lower than 278 500 reported for the week ending May 21  Rise in number of jobs in the private sector and decline in initial claims highlighted economic growth  which in turn had a positive impact on investor sentiment 

In company news  Johnson   Johnson s    shares increased 1 5  after the company said that it will buy Vogue International LLC for  3 3 billion cash  Moreover  shares of Humana Inc  NYSE HUM      and Aetna Inc  NYSE AET      jumped 5 6  and 4 1   respectively  on news that the latter have sold  13 billion bonds to help its  34 billion deal to acquire Humana  Gains in Johnson   Johnson  NYSE JNJ   Humana and Aetna led the Health Care Select Sector SPDR ETF  NYSE XLV  to increase 1 3   becoming the biggest gainer among the S P 500 sectors 

Key stocks from the healthcare sector including AbbVie Inc  NYSE ABBV       Medtronic  NYSE MDT  plc      Bristol Myers Squibb Company  NYSE BMY      Allergan  NYSE AGN pa  plc    and Amgen Inc  NASDAQ AMGN      increased 3 6   3 1   1 6   2  and 1 2   respectively  Dow components Merck  NYSE MRK    Co  Inc      Pfizer Inc   NYSE PFE     and UnitedHealth Group Incorporated  NYSE UNH     rose 0 9   0 4  and 1 1   respectively 

Gains in healthcare stocks offset losses in energy stocks  Earlier on the day  oil prices declined after OPEC members failed to come to any agreement regarding crude production freeze in yesterday s meeting in Vienna  which weighed on energy sector 

However  oil prices made a late recovery to end in positive territory after the U S  Energy Information Administration  EIA  reported that the U S  commercial crude oil inventories fell 1 4 million barrels to 535 7 million for the week ended May 27  It was in contrast to an increase of 2 4 million barrels reported by the American Petroleum Institute  API  a day earlier 

Moreover  total motor gasoline inventories declined by 1 5 million barrels last week  Fall in oil and gasoline inventories had a positive impact on oil prices  Both the WTI and Brent crude increased 0 3  and 0 6  to  49 17 per barrel and  50 04 a barrel  respectively ",2016-06-02,Zacks Investment Research,"https://www.investing.com/analysis/stock-market-news-for-june-03,-2016-200133855",200133855
142821,364336,HUM,UnitedHealth  UNH  Hikes Dividend By 25   Stock Climbs,opinion,"UnitedHealth Group Inc    NYSE UNH   has once again cheered its investors by instituting a quarterly dividend hike of 25   The new dividend of 62 5 cents per share will be paid on Jun 28  to shareholders of record as of Jun 17  2016 This increases the yield  measured as annual divided by the price per share  to 1 8  from 1 4  based on the closing price on Jun 8  This increased dividend payout is higher than the current yields offered by the company s biggest competitors   Humana Inc    NYSE HUM    Cigna Corp    NYSE CI    Aetna Inc    NYSE AET   The dividend hike comes on the back of UnitedHealth s strong balance sheet with moderate leverage and its ability to generate significant cash flows  The last concluded quarter saw a cash flow of  2 3 billion  up 2 2  year over year UnitedHealth has regularly been paying dividends over the past several years   This dividend hike once again affirms the U S  health insurer s commitment to return more value to its shareholders The insurer s five year average dividend yield of 1 44  is higher than the industry average yield of 1 2   Also  the five year dividend growth rate of 26  for the industry is lower than the insurer s 36  over the same period In Jun 2015  the health insurer announced a hike of 33  in its quarterly dividend to 50 cents per share This dividend action further cements investor s confidence in the health insurer  The company was successful in keeping aside investor worries about losses accruing in its individual insurance business on public exchanges by exiting a number of unprofitable exchanges  This has helped the company to axe its losses related to this business that would have pulled down the overall earnings  Moreover  the company raised its earnings estimates for 2016 on the back of growth in its health services and health benefits  segments 
UnitedHealth  the leader in the health insurance industry  also remains sought after in the investing community since it offers the best of both worlds  dividend income plus earnings growth This news of dividend hike led the stock to gain 2 53  in yesterday s trading session  The stock also hit a new 52 week high of  140 89 UnitedHealth currently carries a Zacks Rank   2  Buy  ",2016-06-08,Zacks Investment Research,"https://www.investing.com/analysis/unitedhealth-(unh)-hikes-dividend-by-25,-stock-climbs-200135065",200135065
142822,364337,HUM, Anthem s Pending Cigna Acquisition Under Fire In California,opinion,"Clouds of uncertainty were cast over the pending merger between Anthem Inc    NYSE ANTM   and Cigna Corp    NYSE CI   after concerns was raised by California Insurance Commissioner Dave Jones regarding the viability of the deal  Jones argued that the mega deal worth  48 billion would curb competition and hurt consumers in the state The acquisition will lead to market consolidation and greater concentration in the already saturated health insurance market in California  According to Jones  office  in case the acquisition materializes  the new Anthem would control more than 50  of the market in 28 of the state s counties and over 40  of the market in 38 counties  This would mean more power in the hands of the company  which will gain in size and scale Will Anthem Flex its Muscles Post Merger It is feared that the company  which already has a history of rejecting claims and insufficiently addressing consumer grievances  will bother even less to service its customers with more power in hand   It is also being contemplated that the insurer will have lesser incentive to improve the quality of its products and services  since it will vie against fewer and smaller players  The company may also hike premium and increase out of pocket costs  which will come directly from the pockets of its customers These concerns are not baseless  A  415 000 fine was imposed on Anthem by state health officials in May as the company failed to identify  timely process and resolve enrollees  grievances  Naturally  this instills a fear that the company may repeat its high handedness in the future Moreover  the executives at Anthem did not give a clear reply when asked whether the company will pass on to its customers a portion of the  2 billion efficiencies flowing from the acquisition  in the form of lower prices The executives of the companies involved in the deal  however  have been defending their case from the very beginning by saying that the acquisition will help them to add scale to their business and eliminate unnecessary cost incurred in duplication of services provided to patients  They are also of the opinion that by gaining in size  they will be in a better position to negotiate with hospitals for claims and lower their overall administrative costs  Investment in technology from cost savings and expanded care by gaining quick access to new markets were the other advantages of the merger cited by them Past Consolidations by InsurersThe health insurance market in the United States has always been highly concentrated  Since 1996  the industry has witnessed acquisitions worth approximately  90 billion  resulting in dominance by just a few players  During 1990 2000  the industry witnessed approximately 400 big and small mergers and acquisitions  M A   Consolidation and market dominance consequently led to a decline in competition 
Big insurers that dominated large markets  hardly ever bothered to provide even basic information to consumers  such as the performance of health insurance policies  procedures to claim  the size of the provider network and cancellation procedures  Moreover  in the absence of any reason to lower policy holder costs  insurance companies went on raking in more profits year after year  Data from HealthReform gov showed that the profits of the 10 largest insurance companies increased 250  between 2000 and 2009  10 times faster than inflation  Consolidation among healthcare companies is leaving consumers with fewer choices and therefore more problems Another similar pending acquisition of Aetna Inc    NYSE AET   with Humana Inc    NYSE HUM   worth  34 billion is also being very closely scrutinized by federal regulators Other parties   The American Medical Association and the American Hospital Association    have also contested the Anthem Cigna merger  They have written to the antitrust division of the Justice Department asking to stop the merger Though the deal was approved by the shareholders of both companies back in Dec 2015  it will hit a rough patch with the antitrust regulators  with opposition flaring up now ",2016-06-16,Zacks Investment Research,https://www.investing.com/analysis/anthem's-pending-cigna-acquisition-under-fire-in-california-200136639,200136639
142824,364339,HUM,Health Insurance Industry Outlook   June 2016,opinion,"The health insurance industry is largely immune to recent market worries like Brexit  a slowdown in China  indecisiveness of the Fed over interest rates and weak overall global growth that are hampering other sectors  The overriding issues for the health insurance industry pertain to the regulatory  financial and competitive challenges brought about by the Health Care Reform Act  more popularly known as Obamacare 
The massive overhaul following the reform which came into effect in March 2010 has changed the face of the industry  so much so that once successful strategies and business practices of the players are no longer sustainable 
Having faced limited government interference in their operations prior to 2010  health insurers were totally autonomous in dealing with questions of coverage  pre existing conditions and handling of claims  But all of that has changed following Obamacare 
The legislation has put major restrictions on insurers  Some of the clauses of the law relating to the provision of insurance coverage to people with pre existing diseases  a bar on rejecting claims  restrictions on undue increases in premium  etc  have changed the environment of this business  These players are now faced with increased competition  regulatory compliance costs  changing patient mix  pricing pressures  rising consumerism  higher taxes and fees  rising medical costs and general marketplace uncertainty 
Amid the sea change that the industry is undergoing  players are busy remodeling their businesses with innovative  consumer centric products and services  They are also aggressively hunting for new avenues of growth both at home and abroad 
How Q1 2016 Transpired for the Industry
Most of the health insurers came up with impressive results and surpassed earnings expectations in the first quarter of 2016  The list of those that surpassed estimates  include most of the industry leaders like UnitedHealth Group Inc  NYSE UNH    UNH   Aetna Inc  NYSE AET    AET   Cigna Corp  NYSE CI    CI   Humana Inc  NYSE HUM    HUM   Anthem Inc   ANTM  and WellCare Health Plans  Inc   WCG   Moreover  when judged on revenue and membership growth  these players tell positive a story 
Total revenue as well as enrollment of most of the top players increased year over year in the first quarter  This brings home the fact that the industry players trended strongly in the first quarter after a solid ending to 2015  which was the second year of full implementation of most of the major provisions of the Affordable Care Act  ACA   Along with strong operating numbers  most of the players guided strong earnings for 2016  which again pointed at opportunities latent in the industry despite many hurdles on its growth path  
What to Look Forward for the Rest of 2016 
The major catalysts that might shake up the industry in the coming months are the Presidential elections  Public Exchange Business  and the merger and acquisition environment 
The industry has caught the attention of presidential candidates vowing to make major changes to the legislation that gave the industry a complete makeover  Insurers who strived hard to adapt to the numerous changes brought about by the reform may have to readjust their business if the new president brings in his her desired changes 
Also  most big players in the industry have been vocal about the troubles faced by their individual exchange business on the public exchanges  The setting up of the public exchanges was one of the main features of the act  aimed at providing subsidized insurance  UnitedHealth  Aetna  Humana and others have reported a loss in their exchange business 
These players will watch the viability of this business in 2016 and will decide on their course of action  In case the business remains unprofitable and the players decide to fold it  the central theme of the health care reform act to bring insurance to the millions of uninsured Americans will be defeated 
Another major event to watch in the industry will be its merger and acquisition environment  The industry is due to witness two major mega mergers   Anthem with Cigna and Humana with Aetna  Apart from these two  another acquisition recently completed was that of Centene Corp   CNC  taking over Health Net  These mergers will reduce the number of players  thereby saturating the already concentrated industry  eventually leading to a reshuffling of the ranks of the players that exist 
Industry Ranking  Overall PositiveWithin the Zacks Industry classification  Health Insurance is grouped under the Finance sector  one of the 16 Zacks sectors  We rank all the 257 industries in the 16 Zacks sectors based on the earnings outlook of the constituent companies in each industry  The ranking is available on the  page The way to align the ranking and outlook from the complete list of Zacks Industry Rank for the 257 companies is by considering the outlook for the top one third of the list  Zacks Industry Rank of  86 and lower  as positive  the middle one third  Zacks Industry Rank between  86 and  172  as neutral and the bottom one third  Zacks Industry Rank  173 and higher  as negative The health insurance industry features in the top 1 3rd range with a Zacks Industry Rank  7  This indicates that the overall outlook is  Positive  Please note that the Zacks Rank for stocks  which is the core of our Industry Outlook  has an impressive track record  verified by outside auditors  to foretell stock prices  particularly over the short term  1 to 3 months   The rank  along with   helps in predicting the probability of earnings surprises Earnings TrendsFinally  with Q1 earnings season behind us  it is apparent that overall growth remained stressed  The broader Finance sector  of which the health insurance is a part  experienced a 7 0  decline in earnings from the same period last year on 2 7  higher revenues  with 59 1  beating EPS estimates and 53 4  coming ahead of top line estimates 
For the second quarter of 2016  earnings for the finance sector is expected to decline 5  year over year and while revenues are expected to go down by 0 3  
For more information about earnings for this sector and others  please read our Trends  report ",2016-06-20,Zacks Investment Research,https://www.investing.com/analysis/health-insurance-industry-outlook---june-2016-200137204,200137204
142827,364342,HUM,Zacks Industry Outlook Highlights  UnitedHealth Group  Aetna  Cigna  Humana And Anthem,opinion,"For Immediate Release

Chicago  IL   June 21  2016   Today  Zacks Equity Research discusses Health Insurance  Part 1  including  UnitedHealth Group Inc  NYSE UNH       Aetna Inc  NYSE AET       Cigna Corp  NYSE CI       Humana Inc  NYSE HUM       and Anthem Inc     

Industry  Health Insurance  Part 1

Link  

The health insurance industry is largely immune to recent market worries like Brexit  a slowdown in China  indecisiveness of the Fed over interest rates and weak overall global growth that are hampering other sectors  The overriding issues for the health insurance industry pertain to the regulatory  financial and competitive challenges brought about by the Health Care Reform Act  more popularly known as Obamacare 

The massive overhaul following the reform which came into effect in March 2010 has changed the face of the industry  so much so that once successful strategies and business practices of the players are no longer sustainable 

Having faced limited government interference in their operations prior to 2010  health insurers were totally autonomous in dealing with questions of coverage  pre existing conditions and handling of claims  But all of that has changed following Obamacare 

The legislation has put major restrictions on insurers  Some of the clauses of the law relating to the provision of insurance coverage to people with pre existing diseases  a bar on rejecting claims  restrictions on undue increases in premium  etc  have changed the environment of this business  These players are now faced with increased competition  regulatory compliance costs  changing patient mix  pricing pressures  rising consumerism  higher taxes and fees  rising medical costs and general marketplace uncertainty 

Amid the sea change that the industry is undergoing  players are busy remodeling their businesses with innovative  consumer centric products and services  They are also aggressively hunting for new avenues of growth both at home and abroad 

How Q1 2016 Transpired for the Industry

Most of the health insurers came up with impressive results and surpassed earnings expectations in the first quarter of 2016  The list of those that surpassed estimates include most of the industry leaders like UnitedHealth Group Inc      Aetna Inc      Cigna Corp      Humana Inc     and Anthem Inc       Moreover  when judged on revenue and membership growth  these players tell positive a story 

Total revenue as well as enrollment of most of the top players increased year over year in the first quarter  This brings home the fact that the industry players trended strongly in the first quarter after a solid ending to 2015  which was the second year of full implementation of most of the major provisions of the Affordable Care Act  ACA   Along with strong operating numbers  most of the players guided strong earnings for 2016  which again pointed at opportunities latent in the industry despite many hurdles on its growth path 

What to Look Forward for the Rest of 2016 

The major catalysts that might shake up the industry in the coming months are the Presidential elections  Public Exchange Business  and the merger and acquisition environment 

The industry has caught the attention of presidential candidates vowing to make major changes to the legislation that gave the industry a complete makeover  Insurers who strived hard to adapt to the numerous changes brought about by the reform may have to readjust their business if the new president brings in his her desired changes 

Also  most big players in the industry have been vocal about the troubles faced by their individual exchange business on the public exchanges  The setting up of the public exchanges was one of the main features of the act  aimed at providing subsidized insurance  UnitedHealth  Aetna  Humana and others have reported a loss in their exchange business 

These players will watch the viability of this business in 2016 and will decide on their course of action  In case the business remains unprofitable and the players decide to fold it  the central theme of the health care reform act to bring insurance to the millions of uninsured Americans will be defeated 

Another major event to watch in the industry will be its merger and acquisition environment  The industry is due to witness two major mega mergers   Anthem with Cigna and Humana with Aetna  These mergers will reduce the number of players  thereby saturating the already concentrated industry  eventually leading to a reshuffling of the ranks of the players that exist 

Industry Ranking  Overall Positive
	Within the Zacks Industry classification  Health Insurance is grouped under the Finance sector  one of the 16 Zacks sectors  
	We rank all the 257 industries in the 16 Zacks sectors based on the earnings outlook of the constituent companies in each industry  The ranking is available on the  page 
	The way to align the ranking and outlook from the complete list of Zacks Industry Rank for the 257 companies is by considering the outlook for the top one third of the list  Zacks Industry Rank of  86 and lower  as positive  the middle one third  Zacks Industry Rank between  86 and  172  as neutral and the bottom one third  Zacks Industry Rank  173 and higher  as negative 
	The health insurance industry features in the top 1 3rd range with a Zacks Industry Rank  7  This indicates that the overall outlook is  Positive  
	Please note that the Zacks Rank for stocks  which is the core of our Industry Outlook  has an impressive track record  verified by outside auditors  to foretell stock prices  particularly over the short term  1 to 3 months   The rank  along with   helps in predicting the probability of earnings surprises Earnings Trends
	Finally  with Q1 earnings season behind us  it is apparent that overall growth remained stressed  The broader Finance sector  of which the health insurance is a part  experienced a 7 0  decline in earnings from the same period last year on 2 7  higher revenues  with 59 1  beating EPS estimates and 53 4  coming ahead of top line estimates 

For the second quarter of 2016  earnings for the finance sector is expected to decline 5  year over year and while revenues are expected to go down by 0 3  

Want the latest recommendations from Zacks Investment Research  Today  you can download7 Best Stocks for the Next 30 Days  

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact

Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-06-20,Zacks Investment Research,"https://www.investing.com/analysis/zacks-industry-outlook-highlights:-unitedhealth-group,-aetna,-cigna,-humana-and-anthem-200137279",200137279
142829,364344,HUM,UnitedHealth Maintains Profitability  Exits Public Exchange,opinion,"On Jun 21  we issued an update research report on the health insurer UnitedHealth Group Inc    NYSE UNH   UnitedHealth  is a leader in the health insurance industry and is incurring losses on the individual exchange business that is conducted via the public exchange  To protect its profitability  the company has exited public exchanges in more than a dozen states  This has saved the company from the loss that this business would have brought if it was continued Rather UnitedHealth is focusing on investing and growing its health services business branded as Optum  To this end  the company acquired Catamaran last year  The acquisition has been fruitful as evident from the revenue accretion from it   Optum is becoming an increasingly valuable business and is expected to account for about 42  of UnitedHealth Group s consolidated operating earnings this year 
 UNITEDHEALTH GP Price and Consensus   Over the past five years  UnitedHealth has also grown membership by nearly 13 5 million  or 40   well diversified across commercial  government programs and international offerings  The company s membership is further set to grow in the Medicare Advantage  Medicaid as well as commercial plans UnitedHealth also carries a strong balance sheet and generates handsome cash flows which allows it to increase dividend payments and make regular share buyback The company will nevertheless face stiff competition with the entry of new entities formed by the pending mergers of Anthem Inc    NYSE ANTM   with Cigna Corp    NYSE CI   and Aetna Inc    NYSE AET   with Humana Inc    NYSE HUM    The combined company formed by the Anthem Cigna merger is expected to cover 53 million lives  surpassing UnitedHealth  which covers 49 million as the nation s largest health insurer by membership at present  The Aetna Humana merger would enable the new entity to cover 33 million people and give stiff competition to UnitedHealth UnitedHealth carries a Zacks Rank  3  Hold  ",2016-06-21,Zacks Investment Research,"https://www.investing.com/analysis/unitedhealth-maintains-profitability,-exits-public-exchange-200137379",200137379
142830,364345,HUM,U S  Health Insurers Offer Safety Amid Volatility,opinion,"In a volatile global economic environment  the U S  health insurance industry provides investors a micro defense thanks to high degree of its domestic business exposure  Players like Cigna Corp  NYSE CI    CI   UnitedHealth Group Inc  NYSE UNH    UNH   Centene Corp   CNC  and Aetna Inc  NYSE AET    AET  with business in international markets also have limited exposure  accounting for 3   4   1  and 0 5  of revenues respectively   More importantly  the sector is largely insulated from headwinds   low oil prices  interest rate hikes  strengthening dollar  China s economic slowdown   which have been plaguing other sectors of the economy The sole factor that has shaken the healthcare industry and changed it wholly is the Health Care Reform or Obamacare  enacted in Mar 2010  Though initially intensively lobbied against by the players  health care reform has turned out beneficial  Courtesy of Obamacare  insurers have witnessed meaningful gains in their membership enrollment  which has beefed up their revenues 
Total revenues of the top eight players  UnitedHealth   Aetna  Cigna  Molina Healthcare  MOH   Centene  WellCare Health Plans  Inc   WCG   Anthem Inc   ANTM  and Humana  NYSE HUM   Inc   HUM  increased to  437 billion in 2015 from  383 billion in 2014  with medical enrollment rising to 150 million in 2015 from 145 million in the prior year  Along with posting strong operating numbers  most of the players guided strong earnings for 2016  pointing to the fact that despite hurdles  the industry presents enough growth opportunities   
Now  after sharing the space with Obamacare for almost six years  insurers have embraced the law  Most of the players are now looking for newer avenues to expand their business  They are reassessing their business model from the perspective of product  pricing  risk management  distribution and claims to fraud management for a realistic pace of growth 
Let s discuss some of the opportunities provided by the changing industry landscape 
Extensive Consolidation
The Affordable Care Act  ACA  has heightened the drive toward market consolidation  The influx of the previously huge uninsured population into the space has increased overall membership  Now  the players are scrambling to maintain and grow their member enrollment further  and the best way to achieve this is by growing in size  With the health care law emphasizing value based care  it becomes imperative for health insurers to have a large number of patients to dilute risk  and of course ensure premium dollars to cover the expenses of their sick enrollees  thereby improving overall health outcomes 
Moreover  a bigger size would help in leveraging fixed cost and reducing overall administrative cost  increase cost of compliance with the new health care law   A bigger market share will also equip them better to negotiate harder with hospitals   Get big or get out  has therefore become the trend in the industry 
The merger frenzy hit a fever pitch with Anthem agreeing to acquire Cigna  Aetna seeking the Humana buyout and Centene s recent acquisition of Health Net  The market is speculating that consolidation will lead to the  big five  insurers transforming into the  big three   likely comprising Aetna  Anthem and UnitedHealth 
Higher Insured Population   Top Line Growth
Thanks to ObamaCare  the nation s uninsured rate has gone down to single digits  Before ACA  around 47 million lacked health coverage  Current data shows that the uninsured rate is around 9   According to an ongoing NHIS CDC study  the current uninsured rate of 9  for 2015 is the lowest in over 50 years 
The data shows that Obamacare has to a large extent accomplished its purpose which also points to the increased coverage provided by health insurers that would in turn add to their top line  Most health insurers have reported a secular rise in their revenues from membership gains because of the law 
Baby Boomers Present Medicare Growth
According to the U S  Census data  the population of Medicare beneficiaries will grow by 36  by the end of this decade led by a vast aging baby boomer population  In fact  in the next 25 years  the compounded annual growth rate of the Medicare population is expected to increase to 2 7  from 1 5  at present 
Revenues from the managed care plans of Medicare Advantage are expected to grow significantly as baby boomers retire  Medicare Advantage is a privately run version of the government s Medicare insurance program for the aged and disabled  Until now  only two public providers    UnitedHealth and Humana    control more than 10  of the market  Carriers in the health insurance sector are in a race to win Medicare Advantage market share and the fastest way of achieving the target is by acquiring a company in the same business 
Shift to International Markets
Pressure on profit margins in the U S  market has compelled American health insurers to look to foreign markets for sustained growth and profitability  International markets seem attractive as these are less penetrated and competitive than the U S  Asia and Europe represent the best near term opportunities for the U S  health insurers 
Cigna and UnitedHealth Group lead the private health insurance industry in terms of international deal activity  They re followed by Aetna and Humana  The deals have either been mergers and acquisitions or joint ventures with local insurance companies 
Some of the deals made by players in this field echo the emerging trend toward globalization  In Apr 2014  Aetna bought U K  based InterGlobal  which offers private medical insurance to groups and individuals in the Middle East  Asia  Africa and Europe  Prior to that in Feb 2014  Cigna announced its debut in India s underpenetrated health insurance sector  in a joint venture with an Indian conglomerate TTK Group  In 2013  UnitedHealth bought a stake in AmilParticipacoes of Brazil for a nearly  5 billion  It already had a presence in Australia  the Middle East and the U K 
ACOs Gaining Prominence
Health insurers are trying to clinch accountable care payment contracts following the healthcare reform law s inclusion of Accountable Care Organization  ACO  tests under Medicare  The law s emphasis on providing accurate and efficient health care service rather than volume of service has led to the emergence of ACOs  These are formed when a group of health care providers  physicians  hospitals  non physician providers  and the likes  collectively take responsibility for the financial and quality outcome for a defined population 
The ACOs are appealing to insurers as these reduce medical cost and improve outcome  Insurers form an essential part of ACO because these track and collect patient data  enabling an evaluation of patient care  Since clinical information and care processes are shared and supported by all providers  it becomes easier to manage care and effectively lower the cost  With Obamacare  health insurers have to be more than just claims payers 
Under health reform  insurers have lost flexibility in ways that they can cope with rising medical expenses  They can no longer rely on many of their traditional medical underwriting strategies  such as exclusion of pre existing conditions  The most effective approach for insurers now is to rely exclusively on current cost control mechanisms to manage members  medical expenses   Private commercial payers such as Cigna  Anthem and Aetna are thus supporting ACO formation  CIGNA has one of the most established track records in the group for ACOs 
Developing Ancillary Businesses
Insurers are eyeing growth and expansion opportunities that accompany the critical challenges of modernizing the health care system  They are branching out to the non traditional areas  Over the last few years  several large insurers have acquired companies that fall outside the realm of traditional health insurance yet complement it  Humana acquired Antiva in 2011 to provide analytics services  Aetna invested in Health IT by acquiring Medicity and UnitedHealth has the broadest approach to and the greatest potential in cross selling synergies via its health benefits business via Optum  The Optum division is the poster child of UnitedHealth boasting successful diversification Healthy Balance SheetHealth insurers are also well poised with respect to their balance sheet  The risk based capital ratio of Anthem  Cigna  Aetna and UnitedHealth stands north of 500   substantially higher than the statutory level of 200   A low utilization rate  which has reduced claim payments  has helped to strengthen the balance sheet of these players 
Bottom Line
In a changing industry  which is witnessing the shift of power from insurance players to consumers  the need of the hour is to understand what consumers want and need  and provide quality service at the right time  Only those health players that modify their business strategy in tandem with the changing market will prevail and flourish in a consumer centric health insurance industry ",2016-06-21,Zacks Investment Research,https://www.investing.com/analysis/u.s.-health-insurers-offer-safety-amid-volatility-200137414,200137414
142852,364367,HUM,Humana  HUM  Q1 Earnings Beat Estimates  Guidance Intact,opinion,Humana Inc  s   NYSE HUM   first quarter 2016 operating earnings came in at  1 86 per share  beating the Zacks Consensus Estimate by 2 8   Results  however  declined 28  year over year The decline was due to lower operating results at the Retail segment  partially offset by slightly higher operating results in the Group and Healthcare Services segments Revenues at Humana slipped about 1  year over year to  13 80 billion  Lower premiums and services revenues resulted in the top line decline  Revenues marginally missed the Zacks Consensus Estimate of  13 77 billion Quarterly ReviewHumana s consolidated benefit ratio  which reflects the percentage of benefit expenses in premium revenues  was 84 8   This marks a deterioration of 170 basis points  bps  year over year due to a rise in benefit ratios in the Retail segment Consolidated operating cost ratio  which reflects the percentage of operating costs in total revenue less investment income  improved 150 bps year over year to 12 7   The improvement was primarily driven by cost management initiatives across all lines of business as well as the sale of Concentra in Jun 2015  which carried a higher operating cost ratio Quarterly Results by SegmentRetail Segment  Reported premiums and services revenues increased 2  year over year to  11 84 billion in the first quarter  The upside primarily reflects an increase in average Medicare Advantage membership and per member premium increases The benefit ratio came in at 87 7   deteriorating from 85 8  in the prior year quarter due to unfavorable leap year seasonality  lower seasonal policy reserve releases related to the legacy individual commercial business  adjustments to receivables associated with the 3Rs  and the seasonal impact of the Premium deficiency reserve Operating cost remained flat year over year at 10 8   Administrative cost efficiencies associated with medical membership growth were offset by the loss of the large group Medicare Advantage account Group Segment  Reported premiums and services revenues decreased 2  to  1 81 billion  primarily reflecting declines in average fully insured and Administrative Services Only commercial group medical membership  However  an increase in fully insured commercial medical per member premiums limited the downside Benefit ratio was 74 8   up 90 bps year over year  reflecting unfavorable current year medical claims development as well as unfavorable leap year seasonality Healthcare Services  Revenues from this segment increased 6  year over year to  6 18 billion  mainly on higher Medicare membership and stand alone Prescription Drug Plan membership Operating cost ratio was 95 7   up 40 bps owing to lower profitability in the provider services business Financial UpdateAs of Mar 31  2016  cash  cash equivalents and investment securities of Humana were  12 48 billion  up from  11 68 billion as of Dec 31  2015 The debt to capital ratio of Humana as of Mar 31  2016 was 28 0   down 30 bps from Dec 31  2015 As of Mar 31  2016  the company had  300 million outstanding under its commercial paper program Share Repurchase UpdateHumana suspended its share repurchase program on Jul 2  2015 due to the pending acquisition by Aetna  However  the company has  1 04 billion remaining under its authorization Dividend UpdateHumana paid cash dividend worth  47 million in the quarter In Apr 2016  the company s board of directors announced a cash dividend of 29 cents per share  The dividend will be paid on Jul 29  2016 to stockholders of record on Jun 30 GuidanceHumana reaffirmed 2016 adjusted earnings per share of  at least  8 85   projected net membership growth in individual Medicare Advantage of 100 000 to 120 000 and net membership growth in stand alone PDP offerings of 300 000 to 330 000  Membership in Group Medicare Advantage is estimated to be down 120 000 to 125 000 while the same at Individual commercial is expected to decline 200 000 to 300 000  Revenues are expected to be at least  53 5 billion Adjusted earnings per share are estimated to be at least  2 15 for the second quarter of 2016 Performance by Other HMOsAmong the other health maintenance organizations  HMOs   UnitedHealth Group Inc    NYSE UNH    Aetna Inc    NYSE AET   and Anthem Inc   NYSE ANTM   surpassed their respective Zacks Consensus Estimate in the first quarter of 2016 Zacks RankHumana currently carries a Zacks Rank  4  Sell  ,2016-05-03,Zacks Investment Research,"https://www.investing.com/analysis/humana-(hum)-q1-earnings-beat-estimates,-guidance-intact-200127978",200127978
142853,364368,HUM,Select Medical  SEM  Tops Q1 Earnings On Higher Revenues,opinion,"Select Medical Holdings Corp   NYSE SEM   reported first quarter 2016 earnings of 23 cents a share which surpassed the Zacks Consensus Estimate of 21 cents by 9 5   Earnings declined 18 5  from the year ago level Though revenues improved  an increase in expenses weighed on the bottom line 
Including gains from the sale of its contract therapy business  equity impairment loss  early debt retirement loss  Physiotherapy Associates Holdings  Inc    Physiotherapy   acquisition costs and other line items  Select Medical delivered net income of 42 cents per share on net operating revenues of  1 1 billion Operational ActivitiesOperating revenues of Select Medical grossed  1 1 billion during the quarter  up 36 8  year over year  on higher Outpatient Rehabilitation revenues and Concentra revenues  The top line also beat the Zacks Consensus Estimate of  1 billion by 4  Total operating expenses amounted to  1 billion  up 39  year over year  Increase of 99  in depreciation and amortization expenses  38 8  in cost of services  30 4  in general and administrative expenses  and 29 4  in bad debt expenses led to the overall rise in expenses Income from operations amounted to  86 8 million  up 9 6  year over year on higher revenues Business UpdateSelect Medical completed the acquisition of Physiotherapy  a national provider of outpatient physical rehabilitation care  The insurer also purchased 100  of the issued and outstanding equity securities of the acquired entity  Physiotherapy s financial results have been consolidated with those of Select Medical from Mar 4  2016 Select Medical made a pre tax gain of  30 4 million through the sale of its contract therapy business on Mar 31  2016  Results from this segment have been included in the quarterly results  Segment UpdateSpecialty Hospitals  operating revenues remained flat year over year at  599 million Adjusted EBITDA was  86 8 million  down 10  year over year  with margins contracting 160 basis points  bps  to 14 5   The decline was due to start up losses of  3 8 million along with 4 1  lower patient days and 3 7  lower number of admissions Operating revenues from Outpatient Rehabilitation surged 21 2  year over year to  238 1 million mainly due to the inclusion of Physiotherapy revenues worth  26 2 million acquired by the company and higher number of visits by patients Number of visits to clinics increased 27 5  year over year Adjusted EBITDA soared 30 5  year over year to  28 9 million  while margin expanded by 80 bps to 12 1  year over year Concentra segment reported net operating revenues of  250 9 million for the quarter  while adjusted EBITDA was  34 2 million  Adjusted EBITDA margin was 13 6  for the reported quarter Share Repurchase UpdateThe company did not repurchase shares this quarter under its authorized  500 million stock repurchase program  It bought back a total of 35 9 million shares at a cost of  314 7 million or  8 76 per share since inception of the program to Mar 31  2016 Financial UpdateSelect Medical exited the first quarter with cash of  85 million  increasing more than six fold from  14 4 million at year end 2015 As of Mar 31  2016  long term debt  net of current portion  increased 28 3  to  2 8 billion from  2 2 billion at the end of 2015  Cash flow from operations increased 196  year over year to  111 1 million in the quarter 2016 GuidanceSelect Medical updated its full year 2016 operating earnings outlook to account for the acquisition of Physiotherapy   The sale of its contract therapy business along with refinancing completed during the first quarter has also been included in the revised guidance The company expects diluted income per share to be between 87 cents and  1 06 per share on operating revenue of  4 15  4 35 billion  Adjusted EBITDA is expected between  500 million and  540 million   Zacks RankSelect Medical presently carries a Zacks Rank  2  Buy  Performance of Other Healthcare StocksThe bottom line at Humana   NYSE HUM   and Anthem Inc    NYSE ANTM   outperformed their respective Zacks Consensus Estimate  while Molina Healthcare   NYSE MOH   missed the same for the first quarter ",2016-05-05,Zacks Investment Research,https://www.investing.com/analysis/select-medical-(sem)-tops-q1-earnings-on-higher-revenues-200128553,200128553
142855,364370,HUM,Will Humana  HUM  Grow In Spite Of Segmental Weakness ,opinion,On May 18  2016  we issued an updated research report on Humana Inc    NYSE HUM   Humana s first quarter 2016 earnings surpassed the Zacks Consensus Estimate but declined year over year due to lower operating results at the Retail segment  However  slightly better operating results in the Group and Healthcare Services segments partially offset the downside Humana is set to be acquired by Aetna Inc    NYSE AET   to form a combined company by the second half of 2016  The combination of the two healthcare industry majors will create the second largest managed care company in the U S  Moreover  the company remains optimistic about this transaction as the deal is expected to further enhance the high quality healthcare experience of its members Moreover  Humana s Medicare business  which covers Medicare Advantage and Medicare Part D Prescription Drug Plan  PDP  contracts with the federal government  accounts for the majority of its premiums and services revenues  The company remains optimistic about the consistent performance of this business and expects PDP net membership growth of 300 000 330 000 in 2016 Further  the company has maintained a strong cash and short term investment position over the past several years  while efficiently deploying excess capital  However  the company suspended its share repurchase program on Jul 2  2015 owing to its pending acquisition by Aetna  Presently  the company has  1 04 billion remaining under its authorization In addition  the company has been able to retain the confidence of the ratings agencies on the back of solid earnings as well as strong capitalization However  Humana continues to face weakness in its Group Medicare Advantage Business  Also  the company s Individual commercial membership business displayed persistent underperformance  Moreover  the company s outlook for this business in the near term is dismal Stocks to ConsiderCurrently Humana carries a Zacks Rank  3  Hold   Some better ranked stocks are Magellan Health  Inc    NASDAQ MGLN   and UnitedHealth Group Incorporated   NYSE UNH    Both of these stocks hold a Zacks Rank  2  Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-05-18,Zacks Investment Research,https://www.investing.com/analysis/will-humana-(hum)-grow-in-spite-of-segmental-weakness-200130954,200130954
142882,364397,HUM,Preparing For The Grexit,opinion," If you owe your bank manager a thousand pounds  you are at his mercy  If you owe him a million pounds  he is at your mercy    John Maynard Keynes The day of dawning is upon us  at least  that is  for the financial future of Greece  In looking at the situation  the IMF and ECB are keeping the Greek Central Bank alive  and further down the food chain  the four largest Greek Banks  The banks assets are predominantly in Greek government bonds and deferred tax assets  so there continues to be very little tangible equity to support their customer bases  On the last two days of the week  depositers took  1 billion per day out of these financial institutions  As such  the Greek leaders may not have much alternative to cut a deal  but after six years of this mess  trying to predict their response is a waste of time  The country which has the most to consider  besides Greece  is Germany  Mrs  Merkel wants them in  and an ominous precedent would be set for the long term viability of the European Union if Greece says so long  As the world becomes more aware of by the day  Keynes prescient quote about banking remains pertinent  With a global world connected in every crevice and corner by fiberoptic cables  powerful satellites  and other forms of technology  every financial instrument is potentially linked in some way  As such  the idea a Greek default is going to be contained may have merit  but certainly  prudent people might want to start thinking about the possibilities if the Drachma becomes a reality   The most similar situation would be the financial crisis of 2008  which involved huge publicly traded companies needing billions of dollars of government capital  On a country basis  maybe the Mexican debt crisis could be a circumstance of equal comparison  From my point of view  in thinking about what happened in 2008  the first lesson learned was the eventual bottoming process took about nine months time  Lehman went bye bye in September of 2008  but markets did not bottom until March of 2009  Looking back  it turns out that by opportunistically buying during any of these months  you had a very good outcome  Still  if you purchased a little bit later  your price point was probably lower  so when the market came back  well  you get my drift  We have no idea what will unfold over the next few months  Anyone who thinks they do is far too confident  in my judgment  If you have extra cash available  it is a valuable asset which could be very productive if circumstances work in your favor  You have time to clearly consider where you want to have exposure  Next week will probably be very interesting and markets are going to react  or maybe they won t  which is part of the fun  In many cases  the eventual outcome is far different than what the general consensus believes  In sum  I personally don t believe this is anything close to what we experienced with Lehman  but you never know  so stay calm and keep your eye on your target  Financial markets have been relatively news free over the last week  The Fed decided to keep interest rates in place and considering the events transpiring in Europe  chances are  lower for longer  remains spot on  In corporate news  Federal Express and Oracle reported earnings last week and while strong  both guided expectations down for the rest of the year  In the IPO market  FitBit and Fogo De Chao jumped well over 20  each as public investors decided to mix good eating and exercise  The SEC rules on crowdfunding went into effect and it will be interesting to see how small companies are able to raise capital  Just as important  and more of a priority from where I sit  is whether the returns available prove worthy of the risk  Elsewhere in the government  the Treasury announced Alexander Hamilton will be replaced on the  10 bill  Alex deserves better   In the merger and acquisition arena  it seems the large health insurance entities  United  Cigna  NYSE CI   Aetna  NYSE AET   Humana  NYSE HUM   have all been rumored as buyers and sellers 
Next week  twelve enterprises will debut as freshly minted public companies  including credit reporting giant TransUnion  Y H   C Investments  Yale Bock  and the family of Yale Bock own positions in securities mentioned in the blog post  Investing in stocks can lead to the complete loss of your capital  As always  on any company mentioned here  past performance is not a guarantee of future returns  Investing involves risk of losses on invested capital  One should research any investment and make sure it is suitable with your objectives  risk tolerance  risk profile liquidity considerations  tax situation  and anything else pertinent to your financial situation  Also  the CFA credential in no way implies investment returns will be superior for any charter holder ",2015-06-21,Yale Bock,https://www.investing.com/analysis/preparing-for-the-grexit-255723,255723
142883,364398,HUM,Financial Review  US Reaction To Greek  No  Muted,opinion,"DOW   46   17 683SPX   8   2068NAS   17   499110 YR YLD    11   2 29 OIL   4 40   52 53GOLD   4 10   1170 80SILV    06   15 85
Perhaps you have heard about the big vote in Greece over the weekend  Greeks voted to pay off all of their debt  they put the money in a big wooden horse  They left the horse on the doorstep of the European Central Bank in Brussels  Problem solved 
Actually  Greeks voted  No  in a referendum asking them to accept an international creditor proposal that would have included more austerity reforms  The final tally showed 61  voted  no   so it was a bit of a landslide  Both the Greek people and their government want to remain within the euro  and it isn t clear that there is a legal mechanism to kick Greece out of the Eurozone  at least not any time soon  Of course  a Greek exit might not be so bad  If you are an unemployed Greek worker  it really doesn t matter if you are not being paid in euros or drachmas  Actually  the idea of printing their own currency  even if it is greatly devalued  is probably easier to swallow than the boot to the throat that is austerity  The question is whether the Greeks must leave the euro to have their own currency  or if they can run a parallel currency and still remain in the Eurozone  Don t put it past the Greeks to fight a form of financial guerilla warfare 
Greek Prime Minister Alexis Tsipras spoke last night  saying that democracy cannot be blackmailed   Greeks have made a brave choice and I m convinced that the mandate is not to clash with Europe   adding that the question of Greece s place in Europe should be  off the table completely  
Depends on whose table  A couple of emergency meetings are now in the works  including an ECB gathering to discuss emergency liquidity assistance and a meeting between Angela Merkel and Francois Hollande that will review the Eurozone s response to the vote  Merkel is demanding Greece present a proposal for creditors  she says time is running out  Apparently  the proposal the Greeks sent on June 30th is not on the table anymore  Meanwhile  Finance Minister Yanis Varoufakis will not be at the table  he is stepping down from his post due to heavy pressure from Greece s European partners 
The ECB is leaving little doubt about their approach  the beatings will continue until the Greeks collapse  Greek banks will not be getting any more help from the European Central Bank  In an  on Monday afternoon  the ECB said it would keep its Emergency Liquidity Assistance  or ELA  to Greece unchanged at levels announced last Monday  That level is believed to be around  89 billion euro  The problem for Greek banks  as it stands  is that it looks like they are quickly running out of cash  and unless the ECB releases more money to them  the banks will not be able to reopen this week  and the ATMs may run out of cash  Also of note is that the ECB said that it will adjust the haircuts on collateral accepted by the Bank of Greece as part of the ELA  This means  basically  that if the ECB increases the haircuts on collateral accepted by the Bank of Greece  the size of the ELA effectively decreases  If the adjustment is the other way  the ELA is effectively increased in size 
What the rest of Europe doesn t yet realize is that the entire Eurozone is only as strong as its weakest link  and efforts to punish the Greeks will only backfire on the whole of the Euro Union 
In an interview with German newspaper Die Zeit  French economist Thomas Piketty  the author of  Capitalism in the Twenty First Century   said Germany didn t repay its external debt after World War I nor did it repay debts after World War II and  has no standing to lecture other nations   Piketty said Germany s economic miracle after the end of the war is based in part on debt relief  noting that the London Debt Agreement of 1953 forgave 60  of German foreign debt and restructured its internal debts  Piketty says similar steps should be taken now with Greece 
The reaction in the US was muted  Stocks were down initially  then rallied to breakeven  then drifted lower 
The real elephant in the room might be China  Chinese stocks have dropped by 31 percent over the past month  losing more than  3 2 trillion in valuation  That is six times Greece s entire foreign debt  or 11 years of Greek economic output  Leveraged bets on Chinese stocks have increased to a record versus the size of the market  as prices fall faster than margin traders cut positions  Over the weekend  the Securities Association of China announced that 21 of the country s largest brokerages had agreed to pledge the equivalent of 15 percent of their net assets  or no less than  26 billion in total  to invest in blue chip investment stocks  The move represents a massive flow of liquidity into the market that will ultimately find its way to investors so they can undertake a buying binge  In addition to just throwing money at the problem  the Chinese government canned all new stock market floats  This follows from recent moves to cut interest rates and ease lenders  capital settings  The trouble is  despite using its well stocked toolbox  the Chinese government may not necessarily succeed in stabilizing its equity market 
Even after falls of 25 percent in the past couple of weeks  the Shanghai exchange is still boasting a one year return of more than 86 percent  The earnings of Chinese listed companies have not risen 86 percent this year   thus nor has their real value  Instead  the growth in the Chinese economy has been easing at the same time the stock market was experiencing these gains  Whether the Chinese government s move represents little more than a padded Band Aid remains to be seen 
China s Shanghai Composite finished higher by 2 4  amid a volatile session  The index opened with a gain of more than 8 5  before sliding  Elsewhere  Hong Kong s Hang Seng dropped 3 2   as trade entered a technical correction  now 11  off the April high 
Key elements of a nuclear accord between Iran and six world powers fell further into place on Sunday  U S  Secretary of State John Kerry warned there were more sticking points that may scuttle the deal  and he was prepared to walk away from negotiations if the problems were not resolved by Tuesday  Should sanctions be lifted  Iran would double its oil exports to 2 3 million barrels a day 
Oil production from the Organization of the Petroleum Exporting Countries climbed to its highest monthly level since Aug  2012  OPEC production in June rose by 170 000 barrels per day from a month earlier  to 31 28 million barrels per day  OPEC is now pumping nearly 1 3 million barrels above its production ceiling of 30 million barrels a day  So  between Greece and China representing possible economic slowdown  plus the prospect of Iran pumping extra supplies  plus the reality of Saudi Arabia actually pumping extra supplies of oil  the price of oil was down almost 8  today  and that should result in savings of 2 cents per gallon in about 6 weeks  maybe 
We don t know if oil prices will continue to fall but there is a side bet on oil  and that is the Canadian dollar  or the loonie  Hedge funds and other fast money pushed net bets against the loonie to almost record levels ahead of crude oil s collapse last year  After the currency and crude oil s surprising resilience over the past few months beat them back  those positions are starting to grow again 
U S  service companies and other non manufacturing companies reported that growth picked up slightly in June  The Institute for Supply Management services index rose to 56  in June  compared with May s reading at 55 7   Readings over 50  indicate overall expansion 
After weeks of health insurer merger talks  Aetna  NYSE AET  has agreed to buy Humana  NYSE HUM  for about  37 billion  or about  230 per share  The deal will see Humana shareholders receive  125 in cash plus Aetna shares for each share held  representing a premium of 23  from July 2nd s close  Following the merger  Aetna shareholders will own about 74  of the combined company  And the Aetna Humana deal could pressure other health insurers to merge  Cigna  NYSE CI  rejected offers from Anthem  NYSE ANTM  for as much as  184 a share in cash and stock  citing concerns about governance and management 
Ant Financial  the financial services affiliate of Alibaba  NYSE BABA   has closed a private placement of shares that values it at more than  50 billion  The so called Series A round of financing was led by the National Social Security Fund of China  one of the country s biggest state funds  While a timetable has not yet been revealed for the company s public listing  Jack Ma has suggested that any IPO would most likely take place in China s capital markets 
Investors pulled another  3 billion in assets from the Pimco Total Return Fund  NYSE BOND  in June  compared with  2 7 billion the previous month  in another sign the fund is still bleeding since the departure of Bill Gross last fall  On top of cash withdrawals of  5 6 billion in April and  7 3 billion in March  total assets in the fund have now plunged to  102 billion from a peak of  293 billion in April 2013 
Chicago was once home to one of the largest trading pits in the world  Since 1848  the trading pits were the very symbol of the markets  In 1997  there were close to 10 000 traders on the floor in Chicago  It was physical  It was loud  It was total mayhem  as traders yelled out their buy and sell orders  The open outcry trading pits are now a relic  replaced by computers  The Chicago Mercantile Exchange closed the pits today  About a dozen traders donned multi colored jackets and traded soybeans  more for the show than anything  Then the bell rang  and that was it  The robots win another round ",2015-07-07,Marvin Clark,https://www.investing.com/analysis/financial-review-no-257417,257417
142884,364399,HUM,Dollar Rises After Greece Referendum,opinion,"US stocks fell sharply at the open on Monday  but pared losses during the day after Greek voters rejected the bailout proposal terms in referendum on Sunday  The S P 500 fell 0 4  to 2068 79  US Treasury prices rose  and yields fell to a two week low  as the increased risk of Greek exit from the eurozone sparked a flight to haven assets such as Treasuries and other government bonds  The dollar strengthened  with the ICE dollar index up 0 1  at 96 22  Shares of Aetna Inc  NYSE AET  fell 6 4   after the health insurer announced on Friday it would buy Humana Inc  NYSE HUM  for  37 billion  Energy shares were hit hard as oil prices fell on Monday  oil companies National Oilwell Varco Inc  NYSE NOV  and Transocean Ltd  NYSE RIG  fell 5  and 4 3  respectively  Today at 13 30 CET  May Trade Balance will be released in the US  The tentative outlook is negative  At 15 00 CET  June Job Openings and Labor Turnover Summary will be released by the Labor Department  The tentative outlook is negative for the dollar  At 20 00 CET  July Consumer Credit will be released  The tentative outlook is negative 
European stocks tumbled on Monday after Greek voters overwhelmingly rejected austerity measures demanded by creditors  Most of the regional indexes recorded losses of more than 1  after more than 61  of Greeks voted against the reform plans demanded by eurozone  European Central Bank and International Monetary Fund in return for extending the bailout  The Stoxx Europe 600 fell 1 2   with bank stocks leading the losses  Germany s DAX 30 fell 1 5   The euro fell 0 4  against the dollar  The ECB on Monday left unchanged the level of emergency liquidity assistance available to Greek banks  Instead  it raised requirements for collateral quality  which means Greek banks will have to pledge more collateral than before for emergency funding  Greek Prime Minister Alexis Tsipras promised German Chancellor Angela Merkel that Greece would bring a new proposal  Today at 12 00 CET  eurozone leaders will meet in Brussels  Yanis Varoufakis on Monday resigned as Greece s finance minister  and bank holidays and capital controls were extended through Wednesday  In economic data today  May industrial production was weaker than expected in Germany  At 9 30 CET  May Manufacturing and Industrial Production will be released in the UK  The tentative outlook is positive for the pound 
Nikkei today gained 1 3  after tumbling 2 1  on Monday  Tomorrow at 00 50 CET  May trade balance  current account  June bank lending will be released in Japan  The tentative outlook is positive  At 6 00  Eco watchers survey will be released  The tentative outlook is negative 
Chinese stocks fell today after stabilizing on Monday  despite the fact that China s major insurance firms bought tens of billions of yuans worth shares of blue chip exchange traded funds and large caps on Monday  and measures by authorities to curb new share issues and promises by brokerages and fund managers to buy at least 120 billion yuan of stocks  The Shanghai Composite Index has plunged 12 1  last week  Commodities are falling  as the falling stock market doesn t bode well for the prospect of China s economy 
Oil prices are edging up today  after falling to lowest settlement in nearly three months on Monday over Greece s rejection of bailout terms and China s falling stock market 
Gold prices snapped a three session losing streak and settled higher on Monday  helped by haven related demand ",2015-07-07,IFC Markets,https://www.investing.com/analysis/dollar-is-rising-after-the-greece-referendum-257504,257504
142885,364400,HUM,Swing Trading Watch List  TSO  MDLZ  HUM  CBI  ETE,opinion,"Here s today s swing trading watch list 

Long  Tesoro Petroleum  NYSE TSO 



Long  Mondelez International  NASDAQ MDLZ 



Long  Humana  NYSE HUM 



Short  Chicago Bridge   Iron  NYSE CBI 



Short  Energy Transfer  NYSE ETE ",2015-07-09,Ryan Mallory,"https://www.investing.com/analysis/swing-trading-watch-list:-tso,-mdlz,-hum,-cbi,-ete-257742",257742
142886,364401,HUM,US Dollar Up As Fed Expected To Confirm Rate Hike This Year,opinion,"US stocks rose sharply on Tuesday  as the Chinese stock market stabilized and corporate reports beat expectations  The US dollar edged higher  with the ICE US dollar index  a measure of dollar s strength against a basket of six currencies  adding 0 1   S P 500 index rose 1 1  to 2091  with the energy sector adding 3  and leading the gains  Today Mastercard Inc   NYSE MA   Facebook Inc   NASDAQ FB   Altria Group Inc   NYSE MO  and Humana Inc   NYSE HUM  will report quarterly earnings  The Federal Reserve will release the interest rate statement at the close of two day meeting today at 19 00 CET  While no change in interest rates is expected today  markets are waiting for clues on rate hike timing  and are divided on whether the central bank will raise the rates in September or December for the first time since 2006  Fed Chair Janet Yellen had stated in her July 15 testimony that the central bank will raise interest rates some time later in the year as the economy continues to evolve  the decision being dependent on incoming economic data  Since then  the economy has not moved much toward the 2  inflation target  and though the labor market has improved  the economy is not at full employment yet  as Yellen said in her testimony  We believe that the Fed will reaffirm the plans for hiking rates this year  leaving September hike a possibility  but given also the weakness in global economy  as evidenced by recent turmoil in Chinese markets  December rate hike is more likely  Today at 12 00 CET  Mortgage Applications will be released by the Mortgage Bankers  Associations in US  At 15 00 CET  June Pending Home Sales will be released  The tentative outlook is positive  At 15 30 CET  US Crude Oil Inventories will be released by Energy Information Administration 
European stocks rebounded on Tuesday amid strong earnings reports and rising merger and acquisition activity  as concerns over sell off in China s markets subsided  The euro weakened against the dollar  The Stoxx Europe 600 gained 1 1  after Monday s 2 2  drop  Germany s DAX 30 rose 1 1   France s CAC 40 added 1   Today  no important economic data are expected in eurozone  Tomorrow at 8 55 CET  July employment change and unemployment rate will be released in Germany  The tentative outlook is positive  At 9 00 CET  ECB will publish the July economic bulletin  Today at 09 30 CET  Net Consumer Credit  Mortgage Lending and Mortgage Approvals will be released in UK  The tentative outlook is positive 
Nikkei fell 0 1  today  as yen edged higher against the dollar and Fanuc Corp  TOKYO 6954  and Tokyo Electron Ltd  OTC TOELY  plunged more than 10  after they cut their forecast for the year 
Chinese stocks are edging lower today  showing signs of stabilization after the central bank injected more liquidity into the system  pledging it would take additional monetary easing measures to halt the stock selloff that resulted in more than 8  plunge on Monday 
Oil prices are falling today on oversupply concerns  as data showed OPEC production was around 3 million barrels per day more than daily demand in the second quarter 
Gold prices are edging higher after ending lower near  1100 an ounce on Tuesday  as investors awaited the Federal Reserve interest rate decision for clues when the rate hike will happen  A survey from metal consultancy GFMS indicated that demand for gold in the second quarter fell to its lowest level since 2009  as Chinese demand for the precious metal fell ",2015-07-29,IFC Markets,https://www.investing.com/analysis/us-dollar-up-as-fed-expected-to-confirm-rate-hike-this-year-259896,259896
142887,364402,HUM,Winners From The Anthem Cigna Mega Deal,opinion,"Almost a year in the making  healthcare insurance giants Anthem  NYSE ANTM  and Cigna  NYSE CI  have finally struck a deal 
And what a deal  too  Anthem will acquire Cigna for a whopping  48 billion  And with a combined 53 million insured people  the Anthem Cigna alliance would be the largest health insurer in the United States  second in revenue   behind UnitedHealth Group  NYSE UNH  and ahead of the proposed combination of Aetna  NYSE AET  and Humana  NYSE HUM  
In fact  if both the Cigna and Humana acquisitions are approved  the healthcare insurance industry will quickly consolidate into three giant insurers  which will insure over 40  of all Americans 
So what s driving this bout of consolidation 
Quite simply  you are  You and Obamacare 
The Real Beneficiaries of Obamacare
When Congress passed the Affordable Care Act  ACA  in 2010  critics immediately dubbed it  Obamacare   But supporters of the law have since adopted that term  And since the Supreme Court has now twice agreed with the Obama administration that the law means exactly the opposite of what Congress wrote  it s more than fair to call it Obamacare 
The primary beneficiaries of Obamacare aren t actually the American people   it s the big insurance companies  Need proof  Anthem  Cigna  UnitedHealth  Aetna  and Humana have all at least doubled over the past five years  And that s compared to an impressive 64  return for the Dow Jones Industrial Average 

The bottom line is that while the number of insured people has risen significantly   generally a good thing   many of these newly insured aren t actually using their insurance because the deductibles are so high 
You see  these people were required by law to purchase insurance   insurance that had to cover just about anything  even if the customer didn t want or need certain kinds of coverage  But to keep prices down  even after government subsidies  insurance companies were allowed to market plans with very high deductibles 
So many of these people never expect to use the coverage they were forced to buy unless they have a catastrophic illness or injury  even though the plans  cover  a variety of conditions  That s a pretty high profit proposition for the companies providing such  coverage  
On the other side of the equation  many who were previously denied coverage because of pre existing conditions finally received coverage under Obamacare  This is undeniably a good thing 
But the costs those patients incur are passed on to the rest of the insured population  making those high deductible plans an even better deal for insurance companies   and worse for customers 
Another big outcome of Obamacare is the acceleration of a trend that was already happening in healthcare  squeezing healthcare providers 
The Medicare  Advantage 
In theory  this trend should lower costs  even if it pains some doctors and hospitals  But by focusing on unit pricing instead of outcome based pricing  doctors are forced to work harder to keep the same incomes  but patient outcomes and overall costs don t improve 
Further industry consolidation will speed up this trend  After all  if just three companies are paying the bill for 40  or more of your customers  you pretty much have to do what they say 
This impacts Medicare  too   specifically  Medicare Advantage 
This is the government s plan to get seniors into  private  healthcare systems by paying the premiums  Rather than paying for services  Medicare Advantage pays the insurance company a monthly fee  just like companies and individuals do with their health insurers 
This is a high profit outcome for insurers  Indeed  the reason why UnitedHealth has larger revenue than the proposed Anthem Cigna combination is that United has more Medicare Advantage customers  Plenty of the recent merger activity among healthcare insurers has centered on acquiring these customers and being positioned to grab even more of them in the future 
Low Competition  High Control  Consistent Profits
Either way you slice Obamacare  most of the benefits end up going towards either large health insurance companies or large pharmaceutical companies 
But in the wake of increased consolidation among healthcare insurers  the market is asking whether these proposed mergers will go through  Or will they be killed due to antitrust issues  just like the Comcast  NASDAQ CMCSA  Time Warner  NYSE TWX  deal was scrubbed 
The answer is  no   Lowering competition is a goal of the current administration  no matter what it says to the contrary  In fact  the big goal that you still hear from more honest Democrats is  single payer   And for some  the big dream is that the single payer will be the government 
However  cannier policymakers who believe in single payer systems know that it s actually easier to assert control over private companies than it is the bureaucracy laden federal government  So for them  the goal is a very small number of private companies that are highly regulated  in exchange for modest  but nearly guaranteed  profits  Utilities  basically 
So with this in mind  you can expect antitrust regulators to approve the mergers with some amount of token rhetoric that will make big headlines  but which won t overly influence the general direction of the health insurance industry toward just a few giants 
And it certainly won t hurt that one of the Obama administration s biggest champions   someone who ran the Centers for Medicare and Medicare Service and was partially responsible for the disastrous initial rollout of healthcare gov   recently agreed to take a job as the chief executive of the health insurance s lobbying group 
So what will this mean for consumers 
Why Big Government Loves Big Healthcare Mergers
In the near term  not much  There are rumblings of big increases coming for private plans in many states  but with Obamacare having already taken away so many ways for health insurance companies to compete  any increases would be equally likely with a lot of companies as with a few 
The long run is more complicated   and more consolidation like the Anthem Cigna deal is what the government wants  Fewer companies generally mean less competition and higher prices  But again  there isn t much room for real competition in the Obamacare environment  As I mentioned  the government s goal in encouraging mergers is to increase the high control it already has over the industry 
There s a danger here  though  Those politicians rely on votes  and if the climate gets too bad  those voters will make their voices heard  This could be a case where the health insurance industry scoops big benefits early on  but in the long run  it ends up regretting that it got what it wished for ",2015-07-30,Wall Street Daily,https://www.investing.com/analysis/the-winners-from-the-anthem-cigna-mega-deal-260031,260031
142915,364430,HUM,Insider Trading In Washington  Here We Go Again,opinion,If transparency is the great disinfectant  then the stench emanating from Washington not only remains strong but just got a whole lot stronger  How so  Recall that the STOCK Act  that is the legislation passed a year ago to outlaw insider trading in Washington  only came into being after a 60 Minutes expose embarrassed Congress to address this racket  Prior to that the legislation sat bottled up in committee for many years  Well  if you had any real confidence that the STOCK Act would really clean out the insider trading stables in Washington  think again  With both old holes and recent new holes in this smelly piece of legislation  this act should be renamed the Molded Swiss Cheese Act  Thanks to the regular reader who brought  to my attention  Let s navigate  While almost no one was looking  a law making it easier for congressional and top executive branch staffers to engage in corrupt trading was signed into law Monday  The law is a modification of the Stop Trading on Congressional Knowledge  STOCK  Act  The modification was passed by unanimous consent by the House and the Senate last week with no debate or even discussion  The STOCK Act  which became law just a year ago  was designed to discourage insider trading by members of Congress and top government officials  In addition to outlawing trading based on non public information gleaned by government officials during the course of their public duties  the law required extensive disclosure of financial holdings by Congressional staffers and 28 000 senior executive branch employees  The financial disclosures of these officials were to be posted in an online database open to the public  The disclosure requirements were an important part of the law  They would have allowed researchers to detect abnormally successful trading activity by unelected senior government staffers just as similar disclosure requirements for Congressmen and Senators had allowed scholars to produce evidence that suggested members of Congress were benefiting from non public information  Currently  although the reports of staff financial positions are officially part of the public record  they aren t readily available  Often they have to be requested from individual agencies using the names of the individuals about whom information is sought  The result is that the public is effectively blocked from learning the information disclosed in the reports  As if the stench attached to that  keep  em in the dark  amendment were not enough to highlight that the crowd in Washington still does not  get it   check out the smell associated with this   A key source for a private report that sent health care stocks on a tear earlier this month is a former top congressional aide who is now a health industry lobbyist  according to emails reviewed by The Wall Street Journal  Mark Hayes is currently an outside lobbyist for health insurance giant Humana Inc  His email to Washington investment research firm Height Securities  alerting it to a government decision that will save the industry billions of dollars  was a final piece of confirmation Height received before blasting a news alert to its clients  according to emails and people familiar with the matter  In this case  on April 1 Height sent a report to clients 18 minutes before the end of trading that predicted correctly  it turned out a government agency would drop planned cuts in funding for insurers that offered Medicare Advantage plans  The report snagged the attention of big hedge fund firms that placed profitable trades  according to people familiar with the trading activity  Shares in several health care companies  including Humana  climbed sharply before the market close and again when trading opened the next day  This specific trade and activity of this sort falls under the heading of trading based on  political intelligence  emanating from Washington  The STOCK Act  heretofore known as The MOLDED SWISS CHEESE Act  does not directly address this stench  In fact  the  and concluded that  There are no laws or ethics rules that specifically govern the sale of information by a political intelligence firm  The allure of the cronyism and dirty money is just too much for those in Washington to resist  Financial reform  Yeah  right   Thank you again to the reader who brought these developments to my attention ,2013-04-19,Larry Doyle,https://www.investing.com/analysis/insider-trading-in-washington:-here-we-go-again-163578,163578
142916,364431,HUM,Market Primer  Thursday  May 2,opinion,Futures Higher On Central Banks U S  equity futures rose slightly in early pre market trade following the FOMC saying that it is prepared to increase or decrease asset purchases depending on the state of the economy  Today  the European Central Bank is set to release its interest rate decision and is expected to cut rates by 25 basis points to 0 5 percent   Top News In other news around the markets  The FOMC said that it was prepared to increase or decrease asset purchases depending on the economy and that inflation is running below the long term objective  Also  the FOMC said that fiscal policy is restraining growth and that labor markets are improving but the unemployment rate is still elevated Japan s monetary base expanded at a 23 1 percent annualized rate in April  much faster than March s rate of 19 8 percent  showing that the new BoJ policies are already having an effect The Chinese HSBC Manufacturing PMI slipped to 50 4 in April from 50 6 in March on expectations of a reading of 50 5  confirming the official PMI released Wednesday which showed a very modest downtrend in growth in April form March  Also  the Eurozone Manufacturing Index rose to 46 7 in April from 46 5 in March on expectations of a flat reading S P 500 futures rose 2 2 points to 1 579 50 The EUR USD was lower at 1 3166 Spanish 10 year government bond yields fell 1 basis point to 4 13 percent Italian 10 year government bond yields fell 1 basis point to 3 9 percent Gold rose 0 56 percent to  1 454 30 per ounce Asian Markets Asian shares were lower overnight following the weaker than expected Chinese manufacturing data as well as reports from the Chinese Securities Journal saying that inflation could increase in the second quarter  leading to tightening of monetary policy   Also  unconfirmed rumors were circulating that China will downgrade its official growth forecast to closer to 7 percent growth  The Japanese Nikkei Index fell 0 76 percent and the Shanghai Composite Index fell 0 17 percent and the Hang Seng Index dropped 0 3 percent  Also  the Korean Kospi lost 0 34 percent while Australian shares fell 0 7 percent   European Markets European shares were mixed ahead of the ECB decision despite the better than expected manufacturing data  The Spanish Ibex Index rose 0 39 percent while the Italian FTSE MIB Index fell 0 35 percent  Meanwhile  the German DAX rose 0 15 percent while the French CAC 40 fell 0 25 percent and U K  shares slipped 0 28 percent   Commodities Commodities were mostly higher overnight following hopes that the Fed will not halt purchases as soon as originally thought and could even increase the rate of purchases  WTI Crude futures rose 0 15 percent to  91 17 per barrel and Brent Crude futures rose 0 46 percent to  100 41 per barrel  Copper futures bounced from new 2013 lows by 0 97 percent to  311 00 per pound  Gold was higher and silver futures rose 0 95 percent to  23 57 per ounce   Currencies Currency markets were rather quiet overnight except for the Australian dollar which saw massive weakness against many trading partners  The EUR USD was lower at 1 3166 and the dollar fell against the yen to 97 27  Overall  the Dollar Index rose 0 26 percent on strength against the euro and the Swiss franc  Notably  the Australian dollar lost 0 54 percent against the greenback to 1 0223 and fell 0 65 percent against the yen while losing 0 35 percent against the euro   Earnings Reported Yesterday Key companies that reported earnings Wednesday include  Facebook  FB  reported first quarter EPS of  0 12 vs   0 13 expected on revenue of  1 46 billion vs   1 44 billion expected CVS Caremark  CVS  reported first quarter EPS of  0 83 vs   0 79 on revenue of  30 76 billion vs   30 36 billion expected Humana  HUM  reported first quarter EPS of  2 95 vs   1 81 on revenue of  10 49 billion vs   10 25 billion expected MasterCard  MA  reported first quarter EPS of  6 23 vs   6 17 on revenue of  1 9 billion vs   1 93 billion expected Visa  V  reported second quarter EPS of  1 92 vs   1 81 on revenue of  2 96 billion vs   2 85 billion Pre Market Movers Stocks moving in the pre market included  Facebook  FB  shares rose 1 17 percent pre market after releasing first quarter results Visa  V  shares rose 2 13 percent pre market following its strong second quarter results Earnings Notable companies expected to report earnings Thursday include  Fortress Investment Group  FIG  is expected to report first quarter EPS of  0 15 vs   0 11 a year ago American International Group  AIG  is expected to report first quarter EPS of  0 87 vs   1 65 a year ago Gilead Pharmaceuticals  GILD  is expected to report first quarter EPS of  0 50 vs   0 46 a year ago General Motors  GM  is expected to report first quarter EPS of  0 54 vs   0 93 a year ago Kraft Foods  KRFT  is expected to report first quarter EPS of  0 64 LinkedIn  LNKD  is expected to report first quarter EPS of  0 31 vs   0 15 a year ago Teva Pharmaceuticals  TEVA  is expected to report first quarter EPS of  1 10 vs   1 47 a year ago Economics On the economics calendar Thursday  the European Central Bank decision is due out at 7 45 am eastern  Also  the Challenger Job Cut Report is expected as well as initial jobless claims  international trade data  and productivity and costs data  Overnight  the Chinese Non Manufacturing PMI is set to be released as well as the British Services PMI BY Matthew Kanterman,2013-05-02,Benzinga ,"https://www.investing.com/analysis/market-primer:-thursday,-may-2-165424",165424
142917,364432,HUM,Is This The Right Time To Invest In Health Insurance Stocks ,opinion,"The insurance industry is on the threshold of stability and growth  despite clear signs of stress  Most players are reassessing their business model from product  pricing  risk management  distribution  claims and fraud management to a realistic pace of growth  The industry is also witnessing consolidation 
For decades  the industry has sought private sector engagement in meeting ever increasing national healthcare needs  These include the foundation of Medicare Advantage  the launch of Medicare Part D drug benefits  the formation of accountable care organizations  ACOs   steady migration of Medicaid to managed care  the expansion of benefit coverage to the uninsured under online exchanges  expanded Medicaid programs and the improvement in healthcare gov and many state based exchanges  Let s discuss some of the opportunities offered by the changing industry landscape  A bigger pool of people coming into the insurance system because of the ACA rule that every individual must have access to insurance  The Congressional Budget Office  CBO  has estimated that by 2020  approximately 24 million people will purchase coverage through the new federal and state health insurance exchanges established by the ACA    a substantial addition to the market  As per research by The Urban Institute s Health Reform Monitoring Survey  HRMS   7 3 million adults gained coverage in the first open enrollment period which ended on Mar 31  2014  WellPoint Inc   NYSE WLP   a publicly traded insurer which recorded the maximum enrollment in the new health care market  raised its 2014 earnings guidance after having benefited from the overhaul  Another insurer UnitedHealth Group Inc   NYSE UNH  stated that it will expand its Obamacare exchanges to two dozen in 2015 from five this year  A number of insurers have shown interest in increasing participation in exchanges and are submitting plans for approval for the second enrollment season  starting Nov 15  The expansion of the Medicaid program in 2014 presents an opportunity for large insurers participating in it  The ACA expanded Medicaid eligibility in 2014 to nearly everyone under the age of 65 with income up to 138  of federal poverty levels  According to the Congressional Budget Office  CBO  the expansion of Medicaid will increase the insurance coverage by 8 million in 2014  UnitedHealth Group Inc  and WellPoint Inc  are among the largest Medicaid providers  Other companies that traditionally focused on employer based coverage may seek to enlarge their Medicaid plans  The rising senior population presents growth in the Medicare segment  According to the U S  Census data  the population of Medicare beneficiaries will grow by 36  by the end of this decade led by a vast  aging baby boomer population  In fact  in the next 25 years  the compounded annual growth rate of the Medicare population is expected to increase to 2 7  from 1 5  at present 
Revenues from managed care plans of Medicare Advantage are expected to grow significantly as baby boomers retire  Medicare Advantage is a privately run version of the government s Medicare insurance program for the aged and disabled  Until now  only two public providers    UnitedHealth and Humana  NYSE HUM     control more than 10  of the market  However  we expect sharp consolidation in this market  Carriers in the health insurance sector are in a race to win Medicare Advantage market share and the fastest way of achieving the target is to acquire a company in the same business 
Global Opportunities
A sluggish economic growth  uncertainties in the newly enacted health care legislation and pressure on profit margins in general have led American health insurers to look to foreign markets for continued high rates of growth and profitability  Asia and Europe represent the best near term opportunities for U S  health insurers  Companies like Cigna Corp   NYSE CI  and Aetna Inc   NYSE AET   with a wide overseas presence  view their international business as a positive differentiator and key driver of higher than peer growth rates  Both companies intend to penetrate deeper into the emerging economies of Asia and the Middle East  In Apr 2014  Aetna bought U K  based InterGlobal  which offers private medical insurance to groups and individuals in the Middle East  Asia  Africa and Europe  UnitedHealth is also following the same growth path  The company has expanded its reach from Australia  the Middle East and U K  to Brazil with its buyout of AmilParticipacoes  We expect to see more international deals going forward 
Alternative Care Delivery Models
Several new models    including ACO  patient centered medical homes  PCMH  and a wide variety of evidence based and pay for performance theories    are being tested for their ability to decrease total cost of care while maintaining or improving quality  ACO formation is rampant in the industry  ACOs are appealing to insurers as these provide a way to reduce medical cost and improve outcome  Insurers form an essential part of ACOs because these track and collect patient data  enabling the system to evaluate patient care   Since clinical information and care processes are shared and supported by all providers  it becomes easier to manage care and effectively lower the cost  With Obamacare  health insurers have to be more than just an insurer or claims payer  Under health reform  insurers have lost flexibility in ways that they can cope with rising medical expenses  They can no longer rely on traditional medical underwriting strategies  such as exclusion of pre existing conditions  The most effective approach for insurers now is to rely exclusively on cost control mechanisms to manage members  medical expenses  Under ACO  fees to physicians are paid on performance rather than on service  An ACO helps insurers to accomplish these objectives  In June 2013  the country s largest insurer  UnitedHealth Group  said it targeted spending about  50 billion under accountable care contracts by 2017  compared with the then  20 billion  In June 2014  Cigna successfully reached its 100 ACO goal announced in 2012 
Developing Ancillary Businesses
Insurers are eying growth and expansion opportunities accompanying the critical challenges of modernizing the health care system  They are branching out into non traditional areas  Over the last few years  several large insurers have acquired companies that fall outside the realm of traditional health insurance yet still complement it  Humana acquired Antiva in 2011 to provide analytics services while Aetna invested in Health IT by acquiring Medicity  UnitedHealth has the broadest approach and the greatest potential for cross selling synergies through its health benefits business via Optum  UnitedHealth Group s Optum division is the poster child for successful diversification  The unit includes OptumInsight  a health care analytics company  OptumHealth  which provides health management and wellness services  and OptumRx  a pharmacy benefit manager  Management at UnitedHealth is considering the expansion of its health service business to 35 40  of operating income over the long term 
Acquisitions and Strategic Partnerships
Many health insurance carriers are regularly carrying out acquisitions both domestic and international to expand their existing customer base and product lines into new markets  Not discounting the copious mergers and acquisitions over several years  the Health Care Reform has set the stage right for further consolidation  With small insurers turning inefficient  following their inability to achieve the required level of profitability  big ticket acquisitions are the name of the game since 2011  WellPoint bought Amerigroup to expand its supplement lines business  UnitedHealth acquired AmilParticipacoes and XL Health for a wider base and new product lines  Other significant examples are Humana buying Metropolitan Health Networks  Inc   Cigna s buyout of Healthspring and Aetna s acquisition of Coventry Health Care Inc  Health Insurance Innovations Inc   NASDAQ HIIQ  buyout of privately held  Silicon Valley based HealthPocket  Inc  is also prominent in this regard Bottom Line The health insurance industry has been in flux recently  with many regulatory changes clouding the industry s outlook  But most of those issues are now behind us  which is helping reduce the level of uncertainty about the industry  This makes it an attractive opportunity for investors ",2014-10-30,Zacks Investment Research,https://www.investing.com/analysis/is-this-the-right-time-to-invest-in-health-insurance-stocks-230747,230747
142932,364447,HUM,Humana Needs A Doctor,opinion,This morning  leading health care provider Humana Inc  NYSE HUM  is trading sharply lower after lowering its full year guidance  Today  HUM stock is trading lower by  6 92 to  63 63 a share  The leading health care insurer is oversold at the moment  however  the better support levels are still lower  Short term traders should watch for intra day support around the  57 64 level Some other leading healthcare stocks that are trading lower in sympathy to Humana Inc include UnitedHealth Group Inc  NYSE UNH   WellPoint  Inc  NYSE WLP   and CIGNA Corporation  NYSE CI   All of these stocks would likely bounce higher when HUM stock catches a bid  Obviously  HUM stock is leading the sector today ,2012-08-01,Nicholas Santiago,https://www.investing.com/analysis/humana-needs-a-doctor-131538,131538
142940,364455,HUM,Humana  Vol Breaches Annual High  Buckle Up For News Pre Earnings,opinion,Humana Inc   HUM  is a health care company  Humana operates in three segments  Retail  Employer Group  and Health and Well Being Services    I found this stock using a real time custom scan that hunts for calendar spreads between the front two monthly expiries  The interesting thing here is that HUM has earnings due out in the back month   or that s my projection  meaning that the earnings can be owned for less than the front  Further  the stock has breached an annual high in IV30  today   making this a wildly compelling phenomenon  Whatever the news that s coming  the option market reflects not only greater risk to it than earnings  but greater risk now than at any time in the last year   Custom Scan Details Stock Price GTE  5  Sigma1   Sigma2   7 IV30  GTE 30 Average Option Volume GTE 1 200  The goal with this scan is to identify back months that are cheaper than the front by at least 10 vol points  I m also looking for a reasonable amount of liquidity in the options  thus the minimum average option volume  and enough strikes to spread and thus a minimum stock price  I also require a minimum vol level in order to avoid any boring ETFs  or whatever    Let s start with the Skew Tab to examine the month to month and line by line vols We can see quite clearly how elevated Apr is to May  red curve is above the yellow curve   For the last two years HUM has had earnings on 5 2 2011  4 30 212   both of which are outside of Apr expiry  I see the same timing pattern this year   that is  I project the same pattern based on the last earnings date of 2 4 2013 The one year HUM Charts Tab is included  below   The top portion is the stock price the bottom is the vol  IV30    red vs HV20    blue vs HV180    pink  Y O Y it has not been a pretty picture for HUM with the stock dropping from  91 85 to now in the  70 range  Also  if you look at the last four earnings reports  the blue  E  icon  you can see quite substantial moves off of the news  So  in English  earnings reports are volatility events for HUM  yet whatever is coming before the earnings date appears to be an even greater volatility event Let s turn to the one year IV30  chart in isolation  below We can see that with the pop in the implied today  HUM has breached an annual high in IV30   So whatever the news that s coming  the option market reflects not only greater risk to it than earnings  but greater risk now than at any period in the last year Finally  let s look to the Options Tab  below  Across the top we can see that Apr is priced to 52 23 and May  with earnings  is priced to 41 87   Something is coming for HUM   buckle up  Then re  adjust  and buckle up for earnings again Disclosure  This is trade analysis  not a recommendation Images provided by Livevol ,2013-04-02,Ophir Gottlieb,https://www.investing.com/analysis/humana:-vol-breaches-annual-high;-buckle-up-for-news-pre-earnings-161217,161217
142952,364467,HUM,Humana Inc   Supreme Court Decision Looms  Industry On Hold  Vol Pops,opinion,Humana Inc   HUM  is a health care company  Humana operates in three segments  Retail  Employer Group  and Health and Well Being Services  The Company offers a range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well being This is a vol note surrounding the increasingly contentious and interesting pending Supreme Court Ruling on President Obama s healthcare bill  Here s a news snippet that focuses on the impact to health insurers  If you haven t read up on the bill and pending ruling yet  I highly recommend checking that out as well It can be difficult to read the tea leaves after a Supreme Court debate  but the arguments over the law this week appear to point to a favorable situation for health insurers  Bernstein Research analyst Ana Gupta argues Based on commentary from the justices  it looks like the law s requirement that individuals purchase health insurance will be shot down  Gupte argues  But in that case  the court will also probably invalidate the portion of the law that makes insurers price policies the same whether you are sick or healthy  the part that allows people with pre existing conditions like cancer to get access to affordable coverage   That would be a net positive for insurers  Gupte says The court does not look  particularly  likely to strike down the entire law  a scenario that the insurance industry would be against  That might be somewhat  positive  for insurers  but could create uncertainty  Gupte argues Gupte sees the managed care sector rallying after the decision in the case is handed down in June     Source  Barron s via Yahoo  Finance    written by Avi SalzmanEither way it sounds like a vol event is embedded in these companies and a potential move may be coming  Let s turn to the Charts Tab  six months   below  The top portion is the stock price  the bottom is the vol  IV30    red vs HV20    blue vs HV180    pink  On the stock side  we can see a nearly 50  rise from six months ago  But  it s the vol that caught my attention  The pop today is rather expected   but check out the level relative to its past The 52 wk range is  20 72   51 00    putting the current level in the 10th percentile  Odd given the potential for an abrupt reaction off of the news  Then there s the issue of earnings  which are due out on 4 30 2012  Hmmm Let s turn to the Skew Tab  below We can see a rather noticeable  normalcy  to the skew shape across all of the front expiries  In other words  the option market doesn t reflect any kind of bias  I do note that May is elevated to the other two expiries because of earnings  but that vol diff is relatively muted To understand what option skew is and why it exists you can read this post  Understanding Option Skew    What it is and Why it ExistsLet s turn to the Options Tab for some more detail I wrote about this one for TheStreet com  OptionsProfits   so no specific trade analysis here  Across the top  we can see that while Apr is priced to 23 68   May is priced to 27 24   and Aug is 26 75    That 27 24  level would be in the 24th percentile   so still depressed relative to its own history In English  the May vol which has both this industry wide event and a company specific earnings release  is priced in the bottom quartile  annual  of vol  relative to its own history   One huge note here  this is an event stock as long as the decision isn t released  which means back month vega can be very risky   all of the premium can be lost in a heart beat  That premium is at high risk in a very short period of time This is trade analysis  not a recommendation ,2012-03-30,Ophir Gottlieb,"https://www.investing.com/analysis/humana-inc.:-supreme-court-decision-looms;-industry-on-hold,-vol-pops-118696",118696
